Calcium

Evidence-based effects and studies

← Back to Supplements
Effects
2403
Total evidences
2896

Effects and Evidences

Detailed analysis of research findings

Postoperative PTH (day 1) median

1 evidences

Comparison of para‑tracheal versus conventional capsular dissection in bilateral thyroidectomy (n=142) reporting better preservation of parathyroid function and fewer transient hypoparathyroidism cases with the para‑tracheal technique.

Trust comment: Human surgical comparative study directly relevant to calcium homeostasis (parathyroid/PTH outcomes); moderate quality (reasonable N) though some design details are retrospective/unclear.

Study Details

PMID:40720432
Participants:142
Impact:Para‑tracheal 2.26 pmol/L vs conventional 2.00 pmol/L (P=0.04)
Trust score:3/5

Proportion with low PTH on POD1

1 evidences

Comparison of para‑tracheal versus conventional capsular dissection in bilateral thyroidectomy (n=142) reporting better preservation of parathyroid function and fewer transient hypoparathyroidism cases with the para‑tracheal technique.

Trust comment: Human surgical comparative study directly relevant to calcium homeostasis (parathyroid/PTH outcomes); moderate quality (reasonable N) though some design details are retrospective/unclear.

Study Details

PMID:40720432
Participants:142
Impact:Para‑tracheal 27.6% (21/76) vs conventional 43.9% (29/66)
Trust score:3/5

Transient hypoparathyroidism (follow‑up)

1 evidences

Comparison of para‑tracheal versus conventional capsular dissection in bilateral thyroidectomy (n=142) reporting better preservation of parathyroid function and fewer transient hypoparathyroidism cases with the para‑tracheal technique.

Trust comment: Human surgical comparative study directly relevant to calcium homeostasis (parathyroid/PTH outcomes); moderate quality (reasonable N) though some design details are retrospective/unclear.

Study Details

PMID:40720432
Participants:142
Impact:Para‑tracheal 0/76 vs conventional 4/66 (P=0.04)
Trust score:3/5

supragingival plaque index

1 evidences

In orthodontic patients, photodynamic therapy, chlorhexidine varnish and a tricalcium phosphate (TCP‑5% NaF) varnish were compared for effects on plaque, bacteria and gum inflammation over 18 weeks.

Trust comment: Randomized controlled trial on humans with 48 randomized and 40 analyzed; single‑blind and appropriate outcomes though sample moderate in size.

Study Details

PMID:41091662
Participants:40
Impact:decreased vs control at T2 and T3 (statistically significant, P≤0.005–0.002)
Trust score:4/5

total supragingival bacteria count

1 evidences

In orthodontic patients, photodynamic therapy, chlorhexidine varnish and a tricalcium phosphate (TCP‑5% NaF) varnish were compared for effects on plaque, bacteria and gum inflammation over 18 weeks.

Trust comment: Randomized controlled trial on humans with 48 randomized and 40 analyzed; single‑blind and appropriate outcomes though sample moderate in size.

Study Details

PMID:41091662
Participants:40
Impact:decreased during study in PDT, CHX, and TCP‑5% NaF groups (statistically significant, P=0.023 to <0.001)
Trust score:4/5

gingival index

1 evidences

In orthodontic patients, photodynamic therapy, chlorhexidine varnish and a tricalcium phosphate (TCP‑5% NaF) varnish were compared for effects on plaque, bacteria and gum inflammation over 18 weeks.

Trust comment: Randomized controlled trial on humans with 48 randomized and 40 analyzed; single‑blind and appropriate outcomes though sample moderate in size.

Study Details

PMID:41091662
Participants:40
Impact:decrease in PDT group between T1 and T2 (P=0.016)
Trust score:4/5

postoperative pain (VAS)

6 evidences

Patients undergoing single‑visit endodontic retreatment received one of three root canal sealers (calcium hydroxide‑based, calcium silicate‑based, or epoxy resin‑based); postoperative pain and analgesic use were recorded for 7 days.

Trust comment: Single‑center randomized clinical trial with sample size calculated and 80 patients analyzed; good methodology and clear outcomes.

Study Details

PMID:41068727
Participants:80
Impact:no significant difference between sealer types at any time point (P>0.05)
Trust score:4/5

In single-visit root canal treatment of symptomatic lower molars, calcium silicate and calcium hydroxide sealers produced similar postoperative pain and analgesic use.

Trust comment: Randomized clinical trial in 60 patients with objective pain scales but modest sample size and single-visit design.

Study Details

PMID:37683888
Participants:60
Impact:No significant difference between calcium silicate and calcium hydroxide sealers at all timepoints (6, 12, 24, 48 h; 3, 5, 7 days)
Trust score:3/5

After PKP surgery, patients given calcium plus calcitriol showed improved short-term pain and function and increased BMD versus preoperative; adding calcitonin and exercise improved longer-term outcomes.

Trust comment: Randomized study (138 randomized, 114 completers) with clinical and BMD outcomes reported; limited methodological detail in excerpt but plausible internal validity.

Study Details

PMID:26255474
Participants:114
Impact:decreased at 3 days, 2 weeks and 1 month vs preoperative
Trust score:3/5

Randomized clinical study in previously treated teeth with periapical lesions comparing intracanal Ca(OH)2 alone or with ibuprofen or ciprofloxacin: all Ca(OH)2-based pastes significantly lowered periapical PGE2; Ca(OH)2 + ciprofloxacin produced the largest PGE2 reduction vs Ca(OH)2 alone; no differences in postoperative pain among groups.

Trust comment: Randomized clinical study with a modest sample (n=66); biochemical outcome (PGE2) showed clear differences though clinical pain outcomes did not differ.

Study Details

PMID:33383182
Participants:66
Impact:No significant difference among groups at 24–72 h and 1 week
Trust score:3/5

In retreatment root canal patients, calcium hydroxide, chlorhexidine gel, or their mixture produced similar postoperative pain and flare-up rates over one week.

Trust comment: Randomized, stratified clinical trial with clearly reported methods and outcomes, moderate sample (n=108) and appropriate analyses.

Study Details

PMID:38849655
Participants:108
Impact:no significant difference between Ca(OH)2, CHX gel, and Ca(OH)2+CHX (p>0.05)
Trust score:4/5

Using calcium alginate nasal packing after sinus surgery reduced swelling and adhesions versus carboxymethyl cellulose but did not change pain or discharge-related discomfort.

Trust comment: Randomized, within-patient controlled single-blind trial with appropriate outcome measures but small sample size (27 patients).

Study Details

PMID:26212693
Participants:27
Impact:no significant change
Trust score:4/5

analgesic intake

3 evidences

Patients undergoing single‑visit endodontic retreatment received one of three root canal sealers (calcium hydroxide‑based, calcium silicate‑based, or epoxy resin‑based); postoperative pain and analgesic use were recorded for 7 days.

Trust comment: Single‑center randomized clinical trial with sample size calculated and 80 patients analyzed; good methodology and clear outcomes.

Study Details

PMID:41068727
Participants:80
Impact:no significant difference between sealer types at any time point (P>0.05)
Trust score:4/5

Compared two calcium-silicate sealers and one epoxy-resin sealer after single-visit root canal treatment; postoperative pain and analgesic use were similar across sealers.

Trust comment: Randomized human RCT (n=90) directly compares calcium-silicate-containing vs non-calcium sealers; moderate quality but modest sample size.

Study Details

PMID:32929721
Participants:90
Impact:Analgesic intake decreased significantly after 12 h in all groups, with no between-group differences
Trust score:3/5

In single-visit root canal treatment of symptomatic lower molars, calcium silicate and calcium hydroxide sealers produced similar postoperative pain and analgesic use.

Trust comment: Randomized clinical trial in 60 patients with objective pain scales but modest sample size and single-visit design.

Study Details

PMID:37683888
Participants:60
Impact:No significant difference between groups at any evaluated interval
Trust score:3/5

correlation: pain vs analgesic intake

1 evidences

Patients undergoing single‑visit endodontic retreatment received one of three root canal sealers (calcium hydroxide‑based, calcium silicate‑based, or epoxy resin‑based); postoperative pain and analgesic use were recorded for 7 days.

Trust comment: Single‑center randomized clinical trial with sample size calculated and 80 patients analyzed; good methodology and clear outcomes.

Study Details

PMID:41068727
Participants:80
Impact:strong positive correlation at 48 h and 96 h (statistically significant)
Trust score:4/5

serum calcium

72 evidences

Three‑month randomized, placebo‑controlled pilot in children with celiac disease: prebiotic (Synergy 1) increased vitamin D and E levels but did not change serum mineral concentrations overall.

Trust comment: Randomized, double‑blind placebo‑controlled pilot with 30 completers but small sample size limits precision.

Study Details

PMID:30445682
Participants:30
Impact:No significant change overall; among 5 children with baseline hypocalcaemia, 4 normalized after Synergy 1 (no change in urinary mineral excretion)
Trust score:3/5

Overweight people with low dietary calcium were randomized to energy reduction and/or calcium (400 mg + 125 IU vitamin D3 daily) for 2 years; calcium increased serum calcium and 25(OH)D3 but alone produced limited glycemic benefits, while energy reduction plus calcium produced the greatest improvements in fasting glucose and peripheral insulin sensitivity.

Trust comment: Large, long (2-year) randomized trial with clear biochemical and clinical outcomes reported; some attrition and complex interventions but overall high-quality.

Study Details

PMID:33589569
Participants:1021
Impact:+0.07 mmol/L in calcium supplementation group vs −0.02 mmol/L in non-calcium group (CSG vs NCSG; P<0.001)
Trust score:4/5

Six months of supervised intradialytic exercise in hemodialysis patients increased serum calcium, reduced serum phosphorus and substantially lowered PTH and ALP.

Trust comment: Randomized controlled trial in HD patients with objective lab endpoints and blinded outcome assessment; moderate sample and open‑label delivery.

Study Details

PMID:37730530
Participants:39
Impact:+1.1 mg/dL (8.1 → 9.2; p<0.001)
Trust score:4/5

In 60 women with gestational diabetes, 6 weeks of magnesium-zinc-calcium-vitamin D reduced inflammation and oxidative stress markers and modestly lowered fasting glucose.

Trust comment: Randomized, double-blind, placebo-controlled trial with adequate sample (n=60) but short duration (6 weeks) and multi-nutrient intervention.

Study Details

PMID:30922259
Participants:60
Impact:+0.3 mg/dL change in intervention (vs +0.1 mg/dL placebo), p=0.001
Trust score:4/5

Oral calcidiol (25‑OH vitamin D) quickly raised serum 25(OH)D above 30 ng/ml without altering serum calcium or other mineral metabolism markers over 3 months.

Trust comment: Randomized pharmacokinetic trial in postmenopausal women with clear biochemical endpoints and safety monitoring; directly relevant to mineral metabolism but not calcium supplementation per se.

Study Details

PMID:28815282
Participants:87
Impact:no significant change (safety)
Trust score:4/5

Older adults received calcium plus two doses of vitamin D; vitamin D forms correlated with some BMD changes but free/bioavailable forms were not clearly superior to total 25(OH)D.

Trust comment: 1-year double-blind RCT with 221 completers; well-powered for bone outcomes though calcium given to all arms and vitamin D was the randomized factor.

Study Details

PMID:33280041
Participants:221
Impact:No association with vitamin D variables
Trust score:4/5

Peritoneal dialysis patients randomized to icodextrin versus glucose solutions showed improved nighttime ultrafiltration and several biochemical and clinical changes over 4 months.

Trust comment: Multicenter randomized controlled trial (n=40) showing biochemical effects including higher serum calcium; moderate sample size but randomized design.

Study Details

PMID:41027653
Participants:40
Impact:higher serum calcium in icodextrin group at 4 months (statistically significant, P<0.05)
Trust score:4/5

Double-blind RCT of a multivitamin/mineral vs placebo in older adults on certain medications; MVMS increased folate and vitamin C status but did not significantly change serum calcium.

Trust comment: Double-blind placebo-controlled RCT in humans with small sample size and baseline nutrient status within normal ranges; directly measured calcium status but found no effect.

Study Details

PMID:33078646
Participants:54
Impact:no significant change
Trust score:3/5

In patients with lung cancer and bone metastases, adding zoledronic acid to treatment reduced serum calcium, pain, inflammation and improved quality-of-life and immune markers compared with control.

Trust comment: Randomized single-center study (n=104) reporting significant clinical and biochemical improvements including reduced serum calcium; methods are described but limited detail reduces confidence to moderate.

Study Details

PMID:34938354
Participants:104
Impact:Decreased significantly at 1 and 6 weeks (research group) vs baseline
Trust score:3/5

180 thyroid cancer patients randomized to mitoxantrone tracer, nanocarbon tracer, or no tracer; mitoxantrone tracer improved surgical field clarity and reduced collateral parathyroid/recurrent laryngeal nerve injury, with higher early postoperative serum calcium and PTH.

Trust comment: Prospective randomized controlled study with substantial sample (n=180) and clinically relevant endpoints, though full numerical details not shown in excerpt.

Study Details

PMID:39472118
Participants:180
Impact:MHI group had higher serum calcium on postoperative day 1 and day 5 vs nanocarbon and control (exact means not provided)
Trust score:4/5

An imaging method helped surgeons identify and preserve parathyroid glands, resulting in higher postoperative PTH and calcium and fewer cases of low parathyroid function.

Trust comment: Randomized study with clear clinical endpoints and 100 elderly patients; methods and outcomes reported but full methodological details (e.g., blinding, multicenter) limited in abstract.

Study Details

PMID:39807041
Participants:100
Impact:higher (at postoperative days 1, 3 and 6 months)
Trust score:4/5

In vitamin D–sufficient Indian children with low dietary calcium, vitamin D–calcium supplementation paradoxically raised PTH without changing other bone biochemistry.

Trust comment: Follow-up of an RCT with moderate sample size and clear biochemical measures but limited by baseline vitamin D sufficiency and dietary factors.

Study Details

PMID:31704050
Participants:178
Impact:no meaningful increase (low-normal at follow-up)
Trust score:3/5

In hospitalized diabetic foot patients, lower blood calcium and albumin and higher neutrophil-to-lymphocyte ratio were associated with worse 6-month outcomes (minor/major amputation or death).

Trust comment: Single-center retrospective analysis of hospitalized patients with clear biomarker measurements and ROC/correlation analyses but possible selection bias and limited generalizability.

Study Details

PMID:36366862
Participants:156
Impact:-0.3427 mmol/L (2.2760 → 1.9333 from healing to death; −15.1% vs healing)
Trust score:3/5

Oral calcium polystyrene sulfonate lowered serum potassium over 7 days; higher dose (30 g/day) had greater effect and was well tolerated.

Trust comment: Prospective randomized trial with adequate sample size for short-term efficacy, single-center and open-label design reduce generalizability.

Study Details

PMID:37063062
Participants:96
Impact:no significant change reported
Trust score:4/5

Intradialytic exercise for 6 months improved 12-month survival and led to increases in serum calcium, physical function, and nutritional markers.

Trust comment: Randomized controlled trial with blinded end-points and balanced groups, but single-center and modest sample size limits precision.

Study Details

PMID:37069527
Participants:74
Impact:+1.2 mg/dL (7.9 → 9.1 mg/dL over 6 months)
Trust score:4/5

7-day randomized crossover trial in hemodialysis patients: therapeutic diet rapidly improved mineral markers (lower phosphate/PTH/FGF23) and increased serum calcium.

Trust comment: Randomized crossover design but small short-term study (n=33) with biochemical endpoints; limited duration for clinical outcomes.

Study Details

PMID:37120127
Participants:33
Impact:increase (P = 0.01)
Trust score:3/5

Multicenter randomized trial of vitamin D3 in PCOS; dietary calcium citrate (2×200 mg/day) was provided to participants with low intake — calcium alone for 12 weeks produced minimal changes but yielded partial ovarian‑morphology improvement in a subset.

Trust comment: High‑quality multicenter double‑blind RCT (ITT n=84); calcium was co‑supplemented (calcium citrate) during lead‑in but calcium‑specific effects were limited and mostly non‑significant.

Study Details

PMID:40219003
Participants:84
Impact:no significant change during calcium-only lead‑in
Trust score:4/5

In non-dialysis CKD-MBD patients, Ronghuang granule improved symptoms and markers of calcium/phosphorus metabolism compared with control.

Trust comment: Randomized trial with 65 completers showing biochemical improvements in calcium/phosphorus metabolism, but single-center and traditional-medicine context limit generalizability.

Study Details

PMID:30613009
Participants:65
Impact:improved/normalized in treatment group (significant at 4, 8, 12 weeks; treatment>control, P<0.05)
Trust score:3/5

Compared two oral rehydration salts in children with neurally mediated syncope; electrolytes including serum calcium showed no meaningful change and clinical efficacy was similar between salts.

Trust comment: Randomized pediatric trial measuring electrolytes including calcium but small sample and some unclear reporting of electrolyte p-values; relevant but not focused on calcium supplementation specifically.

Study Details

PMID:29886470
Participants:76
Impact:no significant change pre- vs post-treatment
Trust score:3/5

Measured calciotropic hormones, IGF-1, body composition and bone mass across puberty in adolescents; bone mass rose with Tanner stage while serum calcium did not change.

Trust comment: Moderate–high quality: reasonably large, well-characterized cohort and appropriate analyses (post hoc from RCT dataset).

Study Details

PMID:27676398
Participants:335
Impact:no significant variation by Tanner stage
Trust score:4/5

In CKD patients, paricalcitol improved endothelial function but raised phosphate and slightly increased calcium.

Trust comment: Randomized controlled trial secondary analysis in 88 CKD patients with objective vascular and biochemical measures; moderate-high quality.

Study Details

PMID:27113290
Participants:88
Impact:+3% (PCT; P=0.01)
Trust score:4/5

In 48-week randomized treatment completers, both calcium carbonate and sevelamer groups showed decreased serum fetuin-A; calcium carbonate produced a larger serum calcium increase and fetuin-A decreases correlated with calcium increase and changes in iPTH and albumin.

Trust comment: Randomized, controlled trial with a 48-week per-protocol post-hoc analysis but small number of completers (n=50) and open-label design limit generalizability.

Study Details

PMID:27007989
Participants:50
Impact:Increased by +0.80 ± 0.93 mg/dL with calcium carbonate (p<0.05)
Trust score:3/5

Secondary analysis of a multi‑center SCI trial found multiple race-associated differences in serological markers across the first year, including consistently higher serum calcium in Black versus White participants.

Trust comment: Moderate-sized secondary analysis of an RCT dataset with careful modeling; however data are historical (samples from 1992–1997) and retrospective selection limits current generalizability.

Study Details

PMID:38961159
Participants:316
Impact:Main effect of race: White < Black across timepoints (reported difference range in text: 0.16–33 mg/dL)
Trust score:3/5

Serum copper, iron, and calcium levels were lower during pulmonary exacerbation and rose by 3 months after recovery in adults with cystic fibrosis.

Trust comment: Small ancillary study with clear repeated measures showing significant changes, but limited sample size and context (ancillary to vitamin D trial).

Study Details

PMID:26078287
Participants:24
Impact:+1.1 mg/dL (9.7 ± 0.8 → 10.8 ± 2.0 mg/dL; P = .024) (~+11.3%)
Trust score:3/5

Randomized children/adolescents to three vitamin D regimens; regimens with loading doses raised 25(OH)D and had small, variable effects on serum calcium and PTH.

Trust comment: Large randomized trial with objective biochemical outcomes; direct intervention was vitamin D (calcium measured as safety/biomarker), good sample size and follow-up though single-region pediatric population.

Study Details

PMID:27927221
Participants:637
Impact:initial→4 months median % change: Group1 −3.97%, Group2 +1.23%, Group3 −4.21% (statistically different between groups)
Trust score:4/5

In preterm infants, higher vitamin D dose (1000 IU/day) increased serum calcium and vitamin D and improved bone mineralization and growth.

Trust comment: Randomized double-blind human RCT with clear biochemical and clinical outcomes, but the intervention was vitamin D (not calcium supplementation) so relevance to calcium-supplement effects is indirect.

Study Details

PMID:27325795
Participants:50
Impact:increase (significant, p<0.001)
Trust score:3/5

In dialysis patients with refractory SHPT, total parathyroidectomy alone suppressed PTH more effectively and showed no recurrences over 3 years compared with total parathyroidectomy plus autotransplantation; serum calcium was similar between groups.

Trust comment: Prospective randomized pilot trial with limited sample size and nonconfirmatory design; provides useful but preliminary human data.

Study Details

PMID:27741007
Participants:100
Impact:similar between groups (≈2.1 mmol/L)
Trust score:3/5

In edentulous women given dentures, a daily multi-nutrient supplement (containing 150 mg calcium per serving) led to modest within-group improvements and a significant between-group increase in bone mineral density, but most between-group nutritional outcomes were not different.

Trust comment: Randomized controlled design with objective BMD measures but some reporting inconsistencies and relatively short follow-up limit confidence.

Study Details

PMID:37861611
Participants:121
Impact:serum calcium increased within supplement group (p=0.01 within-group); no significant difference between groups
Trust score:3/5

Extended-release calcifediol normalized 25-hydroxyvitamin D and progressively reduced PTH with minimal effect on serum calcium in CKD patients.

Trust comment: Large multicenter randomized double-blind placebo-controlled trials with high completion rates; high-quality evidence for CKD population.

Study Details

PMID:27676085
Participants:429
Impact:no consequential change (minimal impact)
Trust score:5/5

Subcutaneous PTH fragments were rapidly absorbed and caused dose-dependent increases in serum calcium and suppression of endogenous PTH in healthy postmenopausal women.

Trust comment: Randomized, double-blind dose-escalation study in humans but small sample and short duration.

Study Details

PMID:27487342
Participants:33
Impact:increased (dose-dependent)
Trust score:3/5

Not giving routine oral calcium and calcitriol after thyroid surgery in patients with at least one well-perfused parathyroid gland did not change calcium or PTH levels.

Trust comment: Randomized noninferiority RCT with clear outcome measurements and 56 randomized patients; methods and endpoints appropriate.

Study Details

PMID:33471739
Participants:56
Impact:no statistically significant difference between groups (POD1 and POD30)
Trust score:4/5

Six-month treadmill exercise in obese asthmatics on long-term corticosteroids increased bone mineral density and serum calcium and reduced PTH and inflammatory cytokines compared with controls.

Trust comment: Controlled intervention with modest sample size; demonstrates changes in calcium-related biomarkers but exercise (not calcium supplementation) was the intervention and randomization/details unclear.

Study Details

PMID:27917214
Participants:80
Impact:significant increase in serum calcium in exercise group (exact values not provided)
Trust score:3/5

Using carbon nanoparticles in endoscopic thyroid surgery reduced accidental removal of parathyroids and sped recovery of parathyroid hormone; serum calcium was slightly higher but not significantly different.

Trust comment: Randomized human surgical trial with clear outcomes but small sample size limits precision.

Study Details

PMID:25761552
Participants:55
Impact:higher in CN group during follow-up (not statistically significant)
Trust score:4/5

Higher soy isoflavone exposure was associated with a small increase in serum calcium and a decrease in serum chloride in premenopausal women.

Trust comment: Well-conducted 2-year double-blind RCT in humans but findings depend on adherent subgroup (associations not seen in full intention-to-treat), lowering certainty slightly.

Study Details

PMID:29183775
Participants:166
Impact:+0.24 mg/dL (mean change associated with higher isoflavone excretion)
Trust score:4/5

In 373 older adults randomized to 400, 4,000, or 10,000 IU/day vitamin D, higher doses raised urine calcium excretion and caused rare mild transient hypercalcemia, while serum calcium and safety events were otherwise similar.

Trust comment: Large, double‑blind RCT with prespecified secondary analyses measuring calcium outcomes and clinically relevant endpoints.

Study Details

PMID:31746327
Participants:373
Impact:No significant difference between dose groups
Trust score:4/5

In hemodialysis patients, adding cinacalcet to paricalcitol led to lower serum phosphorus and higher serum calcium over 6–12 months compared with paricalcitol alone.

Trust comment: Randomized 140-patient trial with objective laboratory endpoints; good sample size though blinding and single-center details are limited.

Study Details

PMID:37814913
Participants:140
Impact:increased (significantly vs paricalcitol alone, P<0.05)
Trust score:4/5

Secondary analysis of a 2-year RCT in adults with type 2 diabetes comparing very low‑carb vs high‑carb diets found micronutrient biomarkers (including calcium) remained within normal ranges with no differences between diets.

Trust comment: Well-conducted 2-year randomized trial with biochemical endpoints and measured completed participants, suitable for assessing dietary calcium status.

Study Details

PMID:33058957
Participants:61
Impact:No significant change or differential response between diet groups over 2 years (no deficiency reported; time×diet interaction P≥0.17)
Trust score:4/5

In 1,277 patients after lumbar fusion, a nomogram including serum calcium predicted surgical site infection risk; lower serum calcium was independently associated with higher SSI risk.

Trust comment: Large retrospective cohort with internal validation and clear multivariable analysis; observational design limits causal inference but findings on serum calcium as predictor are plausible.

Study Details

PMID:37625933
Participants:1277
Impact:Lower serum calcium independently associated with higher SSI risk (OR 0.93, 95% CI 0.89–0.96; p<0.001)
Trust score:4/5

After parathyroidectomy patients received standard postoperative calcium; auricular plaster plus calcium improved quality of life more than calcium carbonate alone.

Trust comment: Small randomized study (n=34) using calcium supplementation as standard care; limited sample size and incomplete quantitative reporting reduce confidence.

Study Details

PMID:29354913
Participants:34
Impact:improved to some degree (no clear significant change reported)
Trust score:3/5

Vitamin D supplementation for 3 months reduced body size measures and produced significant changes in calcium-related labs.

Trust comment: Double-blind randomized controlled trial (n=66) with reported significant outcomes; direct intervention was vitamin D not calcium supplement but calcium-related labs were measured.

Study Details

PMID:29615318
Participants:66
Impact:significant change (direction not specified)
Trust score:4/5

Structured sunlight exposure increased 25(OH)D levels and led to increases in calcium and albumin in elderly nursing-home residents.

Trust comment: Randomized experimental design but small sample (n=40) and short intervention (4 weeks); objective lab measures reported.

Study Details

PMID:33888407
Participants:40
Impact:increase observed in intervention group (magnitude not specified)
Trust score:3/5

Twelve weeks of 4000 IU/day vitamin D3 increased serum 25(OH)D, raised serum and seminal calcium, and significantly improved total and progressive sperm motility in men with asthenozoospermia.

Trust comment: Randomized, triple-blind, placebo-controlled trial with clear numeric reporting of calcium and semen outcomes.

Study Details

PMID:34225767
Participants:86
Impact:mean change +0.03 mg/dl in VD3 group vs −0.02 mg/dl in placebo (p=0.009)
Trust score:4/5

A new human milk fortifier (higher protein:energy, includes similar mineral/calcium content) increased weight gain in preterm infants; small changes in blood and urine calcium but no change in bone mineral density.

Trust comment: Multicenter, double-blind randomized trial with objective growth and biochemical measures; moderate sample size and early stopping for efficacy.

Study Details

PMID:28727654
Participants:153
Impact:minimally higher in new fortifier at D21 (+1.9%, 95% CI +0.3% to +3.5%)
Trust score:4/5

In 30 maintenance hemodialysis patients, HFR caused greater acute reductions in several micronutrients compared with HDF, including serum calcium.

Trust comment: Randomized crossover trial in 30 humans with clear within-subject measurements—small sample but direct measurements of serum calcium make findings credible.

Study Details

PMID:40914150
Participants:30
Impact:decrease (greater post-treatment reduction with HFR vs HDF; p<0.05)
Trust score:4/5

Forty adults with low vitamin D were randomized to daily or monthly cholecalciferol; vitamin D levels rose and serum calcium increased modestly, with decreased PTH and reduced bone turnover on longer monthly treatment.

Trust comment: Randomized study with complete follow-up but small sample limits generalizability; findings are indirect for calcium (via vitamin D effects).

Study Details

PMID:30563215
Participants:40
Impact:increased (significant in both daily and monthly groups at 6 months)
Trust score:3/5

Weekly ergocalciferol in hemodialysis patients increased 25-hydroxyvitamin D levels without changing serum calcium or parathyroid hormone.

Trust comment: Small randomized trial with 35 completers showing clear vitamin D rises but no changes in calcium or PTH; sample size modest and short duration.

Study Details

PMID:30595565
Participants:35
Impact:no significant change
Trust score:3/5

Fish oil plus wheat germ oil increased mean serum calcium in hemodialysis patients, with no significant changes in other mineral-bone or inflammatory markers.

Trust comment: Randomized double-blind trial showing a significant rise in serum Ca, but the supplement was fish oil + wheat germ oil (not calcium), and sample size was small.

Study Details

PMID:28667579
Participants:46
Impact:increased in supplemented group (p=0.0016; vs placebo p=0.0418)
Trust score:3/5

Pilot randomized double-blind trial in adolescents showing probiotics increased blood biomarkers including vitamins and calcium over 10 weeks versus placebo.

Trust comment: Small pilot randomized double-blinded study; positive signals for serum biomarkers but preliminary and requires replication.

Study Details

PMID:31646599
Participants:40
Impact:increase (higher vs placebo from baseline to 10 weeks)
Trust score:3/5

In 466 hospitalized patients randomized to rosuvastatin or atorvastatin, rosuvastatin increased QTc interval; higher serum calcium was associated with reduced risk of QT prolongation.

Trust comment: Large randomized clinical trial with 466 analyzed patients and multivariate analyses; calcium association is observational within the trial but statistically reported.

Study Details

PMID:40890448
Participants:466
Impact:inverse association with QT prolongation (each 0.1 mmol/L increase associated with ~28% reduced risk; multivariate OR 0.72, p=0.042)
Trust score:4/5

Randomized trial in severe acute pancreatitis where combination therapy improved clinical outcomes and raised serum calcium compared with conventional care.

Trust comment: Prospective randomized controlled trial (n=100) with clear pre/post biochemical and clinical endpoints; calcium measured and reported.

Study Details

PMID:31662003
Participants:100
Impact:+0.7 mmol/L (combination group: 1.6 → 2.3 mmol/L)
Trust score:4/5

Long BPL RYGB led to faster and greater weight loss and better diabetes/dyslipidaemia control; it produced lower serum calcium and hemoglobin and higher PTH compared with standard RYGB, but values remained within normal range.

Trust comment: Randomized prospective trial with 150 randomized and 121 completers; outcomes and nutritional labs reported, though some nutritional differences were small and within normal ranges.

Study Details

PMID:34981324
Participants:121
Impact:Lower serum calcium in L-RYGB vs S-RYGB (reduced but within normal range)
Trust score:4/5

Large randomized trial measuring vitamin D, calcium and iPTH; vitamin D raised 25(OH)D while calcium stayed stable and iPTH decreased.

Trust comment: Large randomized, placebo-controlled trial with robust measurements; calcium reported as a secondary biomarker and appears reliable.

Study Details

PMID:31669447
Participants:15804
Impact:no change
Trust score:4/5

In severely obese adults over 12 weeks, a traditional Brazilian diet increased spine and hip BMD and lowered PTH, while extra virgin olive oil supplementation increased serum calcium.

Trust comment: Well-conducted randomized trial with DXA-measured BMD and biochemical outcomes, though short duration (12 weeks) and mostly female sample limit generalizability.

Study Details

PMID:32032997
Participants:97
Impact:significant increase in olive oil group (P=0.007); PTH decreased in DieTBra group (P=0.047)
Trust score:4/5

Postmenopausal women receiving Caltrate D (a calcium/vitamin D product) plus exercise had greater lumbar and femoral neck BMD, higher serum calcium and quality-of-life scores, and lower serum phosphorus, ALP and PMOP recurrence versus Caltrate D alone.

Trust comment: Randomized allocation reported and moderate sample size, but limited methodological details (blinding, effect sizes) and single-centre design reduce confidence.

Study Details

PMID:40089924
Participants:110
Impact:Increased (group with added exercise higher than Caltrate D alone; reported significant)
Trust score:3/5

Intensive neurorehabilitation improved mood and function in poststroke patients; vitamin D supplementation showed additional biochemical and some clinical changes.

Trust comment: Randomized controlled design but small final sample and some reporting inconsistencies limit confidence in attributing effects solely to vitamin D vs rehabilitation.

Study Details

PMID:34766589
Participants:29
Impact:+0.32 (from 8.81 to 9.13; T0→T1 in vitamin D group)
Trust score:3/5

Patients with sialolithiasis had lower serum calcium and higher saliva fetuin-A, saliva phosphorus, and saliva total protein compared with controls, suggesting local biochemical differences in stone formers.

Trust comment: Small case-control study with 20 patients and 20 controls; direct measurements of serum/saliva electrolytes including calcium but limited sample size.

Study Details

PMID:28457217
Participants:40
Impact:lower in sialolithiasis patients vs controls (P = 0.04)
Trust score:3/5

Pregnant women randomized to 1000 vs 2000 IU/day vitamin D: 2000 IU improved maternal 25(OH)D more, but glycemic, lipid and oxidative stress markers were similar; small decreases in maternal serum calcium occurred in both groups.

Trust comment: Randomized clinical trial in pregnant women with measured biochemical outcomes and good completion rate (73), high internal validity for reported endpoints.

Study Details

PMID:33054794
Participants:73
Impact:Small decrease in maternal serum calcium in both groups: −0.50±0.41 mg/dL (1000 IU) and −0.43±0.45 mg/dL (2000 IU); time P<0.001; between-group NS
Trust score:4/5

In 648 acute pancreatitis patients, lower serum calcium was associated with development of severe acute pancreatitis and serum calcium was among the important predictors in the random forest model.

Trust comment: Large retrospective cohort with robust modeling and internal validation; observational design limits causal inference about calcium effects.

Study Details

PMID:35755843
Participants:648
Impact:lower in SAP (median 1.9 mmol/L in SAP vs 2.2 mmol/L in no-SAP; −0.3 mmol/L)
Trust score:3/5

Older adults given calcifediol or vitamin D3 had faster and larger increases in blood vitamin D without causing high blood calcium.

Trust comment: Randomized, double-blind RCT in older adults with appropriate metabolite measures; moderate sample size but well-conducted.

Study Details

PMID:28433267
Participants:59
Impact:No cases of hypercalcemia during the 24-week intervention
Trust score:4/5

Retrospective MIMIC-IV analysis produced a nomogram to predict 30-day sepsis in ICU TBI patients; lower serum calcium was an independent predictor of higher sepsis risk.

Trust comment: Large retrospective database study with internal validation using MIMIC-IV; robust for hypothesis generation though causal claims are limited by observational design.

Study Details

PMID:37596695
Participants:1167
Impact:Lower serum calcium associated with increased sepsis risk (reported as an independent predictor in multivariable analysis; OR reported in text)
Trust score:4/5

Chicory inulin (oligofructose-enriched) for 2 months raised serum calcium and improved glucose and some liver enzyme measures in female T2DM patients.

Trust comment: Randomized controlled trial but small, short duration, and limited to female patients, limiting generalizability.

Study Details

PMID:26872721
Participants:46
Impact:+significant increase (P=0.014)
Trust score:3/5

100 male type 2 diabetic patients assigned to aerobic or resistance training for 6 months; both exercise types increased serum calcium and handgrip strength and decreased PTH.

Trust comment: Intervention study with 6-month follow-up and clear biochemical/functional outcomes, but allocation method and blinding not fully described in abstract.

Study Details

PMID:26957979
Participants:100
Impact:significant increase in both groups after 6 months
Trust score:3/5

In CKD patients, paricalcitol (VDR activator) produced a small rise in serum calcium and phosphate but did not change insulin resistance indices over 12 weeks.

Trust comment: Post-hoc analysis of a randomized placebo-controlled trial in CKD (moderate size); intervention raised calcium slightly but no IR effect detected.

Study Details

PMID:29307660
Participants:88
Impact:+0.07 mmol/L (P=0.01)
Trust score:3/5

In women with anorexia nervosa, a 4-week protein‑fortified dairy product slightly raised IGF‑I and produced a small increase in serum calcium; no change in bone turnover markers.

Trust comment: Multicenter randomized double‑blind placebo‑controlled trial (good design) but calcium change was small and secondary to a protein/dairy intervention.

Study Details

PMID:26602423
Participants:62
Impact:Slight increase during intervention in higher-protein group (P=0.02)
Trust score:4/5

Cinacalcet in healthy volunteers produced expected pharmacokinetic behavior and lowered plasma PTH and serum calcium after single and multiple doses.

Trust comment: Well-described randomized PK/PD study in healthy volunteers with clear measurements; small sample size but methods appropriate.

Study Details

PMID:26804640
Participants:41
Impact:decreased after cinacalcet administration
Trust score:4/5

In 34 healthy adults, a liposomal multivitamin altered how some minerals and vitamins appeared in blood; serum calcium rose at 2 h after the liposomal MVM and some calcium PK markers (Tmax, absorption rate) differed; no side effects reported.

Trust comment: Randomized, double-blind, crossover human trial with detailed PK analysis but small completed sample (n=34).

Study Details

PMID:37447400
Participants:34
Impact:+6.2% at 2 h with liposomal MVM vs baseline (non-liposomal +1.6%)
Trust score:4/5

Education and the mobile app increased bone-health knowledge and were associated with changes in some blood markers including calcium.

Trust comment: Randomized controlled trial in 82 women with measured biochemical outcomes, but small sample and reported changes lack detailed effect sizes in the provided text.

Study Details

PMID:28388981
Participants:82
Impact:changed vs control (direction/magnitude not specified in text)
Trust score:3/5

8-week randomized trial in vitamin D–deficient overweight/obese women with PCOS tested calcium, vitamin D, both, or placebo; co-supplementation improved some insulin and triglyceride measures.

Trust comment: Randomized double-blind placebo-controlled RCT with clear reported outcomes and adequate sample size per arm (n=26 groups), supporting moderate–high trust.

Study Details

PMID:25300649
Participants:104
Impact:increased (P=0.002)
Trust score:4/5

In dialysis patients ferric citrate achieved similar phosphorus control and produced similar changes in serum calcium and PTH compared with sevelamer and/or calcium acetate over 52 weeks.

Trust comment: Large randomized phase 3 trial in dialysis patients with relevant biochemical outcomes; open-label design and mixed active control (including calcium acetate) are limitations.

Study Details

PMID:25958079
Participants:441
Impact:increase: ferric citrate +0.22 ± 0.90 mg/dL vs active control +0.31 ± 0.95 mg/dL (similar)
Trust score:4/5

Double-blind randomized crossover (29 analysed) in people with type 2 diabetes: 6 weeks of inulin-type fructans (16 g/day) did not change serum calcium, magnesium, vitamin D, or bone turnover markers.

Trust comment: Randomized, double-blind crossover with accredited assays but small sample and short duration limit power for bone outcomes.

Study Details

PMID:40471453
Participants:29
Impact:No significant change after 6 weeks (prebiotics vs control)
Trust score:4/5

8-week randomized double-blind dietary study: EPG altered some fat‑soluble vitamins but did not change serum calcium or other measured minerals.

Trust comment: Well-powered double‑blind randomized study (n=139) with comprehensive nutrient measures; EPG (not calcium) was the intervention and calcium was a measured endpoint.

Study Details

PMID:25497998
Participants:139
Impact:No significant change after 8 weeks of dietary EPG
Trust score:4/5

Oral cancer patients randomized to professional nutritional support (including individualized micronutrient supplements such as calcium tablets when indicated) lost less weight and had more stable lab values including calcium compared with standard care.

Trust comment: Randomized trial with clear clinical endpoints but small sample (n=46), some measures only in intervention group, and potential allocation bias by weekday.

Study Details

PMID:35987809
Participants:46
Impact:more stable/improved calcium values in intervention group at 3 months (T3; significant)
Trust score:3/5

Clinical success rate

5 evidences

In primary molar pulpotomies, choice of base material (including calcium hydroxide) did not change clinical or radiographic success rates over 2 years.

Trust comment: Two-year randomized controlled dental trial with clear clinical and radiographic endpoints and adequate follow-up; moderate sample (by teeth).

Study Details

PMID:35726548
Participants:105
Impact:97.1%, 94.2%, 97.1% (Groups 1–3; zinc oxide-eugenol, calcium hydroxide, MTA) — no significant difference
Trust score:4/5

Primary molar pulpotomies were treated using either mineral trioxide aggregate (MTA; a calcium‑containing material) or grape seed extract and followed clinically and radiographically up to 6 months.

Trust comment: Small prospective randomized split‑mouth trial (32 teeth); relevant calcium‑containing material but small sample and limited follow‑up (6 months).

Study Details

PMID:41029033
Participants:32
Impact:high in both groups; MTA 100% at 1 and 3 months, 93.75% at 6 months; GSE 100% at 1 month and 93.75% at 3 and 6 months
Trust score:3/5

Tested a new tricalcium silicate dental cement vs standard MTA in children's primary molar pulpotomies; both showed high success but the new cement avoided tooth discoloration.

Trust comment: Small randomized clinical dental trial in children with clear outcomes but limited sample size (33 patients) and 12-month follow-up.

Study Details

PMID:32876119
Participants:33
Impact:100% (both groups at 12 months; no difference)
Trust score:3/5

Split‑mouth RCT in children compared silver diamine fluoride (SDF) and biodentine (a calcium silicate material) for indirect pulp therapy; clinical, radiographic and histological outcomes were assessed.

Trust comment: Randomized split‑mouth trial with 68 children and both clinical and histological endpoints; solid design though follow‑up limited to 9 months for reported outcomes.

Study Details

PMID:41026563
Participants:68
Impact:Biodentine superior: 85.3% (Group 2) vs 77.9% (SDF) at 9 months (P=0.035)
Trust score:4/5

Children received diode laser pulpotomy with pulp capping by MTA, calcium hydroxide (CH), or calcium‑enriched mixture (CEM); clinical success similar, radiographic outcomes better with MTA/CEM than CH.

Trust comment: Randomized split‑mouth RCT with 36‑month follow‑up in 30 children; limited by small sample but robust follow-up and relevant clinical/radiographic endpoints.

Study Details

PMID:38035897
Participants:30
Impact:no significant difference among MTA, CH, and CEM (p>0.05)
Trust score:4/5

radiographic success rate

7 evidences

In children with infected primary molars, both calcium-enriched mixture cement pulpotomy and pulpectomy gave high success rates with no clear difference.

Trust comment: Multicentre randomized trial in children with clear participant numbers and objective outcomes; appropriate design though sample size moderate.

Study Details

PMID:38488954
Participants:94
Impact:First/second follow-up PCEM 98.6%/96.4% vs PM 96.4%/91.1% (no significant difference)
Trust score:4/5

Children received diode laser pulpotomy with pulp capping by MTA, calcium hydroxide (CH), or calcium‑enriched mixture (CEM); clinical success similar, radiographic outcomes better with MTA/CEM than CH.

Trust comment: Randomized split‑mouth RCT with 36‑month follow‑up in 30 children; limited by small sample but robust follow-up and relevant clinical/radiographic endpoints.

Study Details

PMID:38035897
Participants:30
Impact:MTA and CEM superior to calcium hydroxide at 12–36 months (significant, p<0.05)
Trust score:4/5

Primary molar pulpotomies were treated using either mineral trioxide aggregate (MTA; a calcium‑containing material) or grape seed extract and followed clinically and radiographically up to 6 months.

Trust comment: Small prospective randomized split‑mouth trial (32 teeth); relevant calcium‑containing material but small sample and limited follow‑up (6 months).

Study Details

PMID:41029033
Participants:32
Impact:MTA 100% at 3 months and 93.75% at 6 months; GSE 100% at 3 months and 87.5% at 6 months (no significant difference overall, P>0.05)
Trust score:3/5

Split‑mouth RCT in children compared silver diamine fluoride (SDF) and biodentine (a calcium silicate material) for indirect pulp therapy; clinical, radiographic and histological outcomes were assessed.

Trust comment: Randomized split‑mouth trial with 68 children and both clinical and histological endpoints; solid design though follow‑up limited to 9 months for reported outcomes.

Study Details

PMID:41026563
Participants:68
Impact:Biodentine superior: 83.8% vs 70.6% at 9 months (P=0.01)
Trust score:4/5

Tested a new tricalcium silicate dental cement vs standard MTA in children's primary molar pulpotomies; both showed high success but the new cement avoided tooth discoloration.

Trust comment: Small randomized clinical dental trial in children with clear outcomes but limited sample size (33 patients) and 12-month follow-up.

Study Details

PMID:32876119
Participants:33
Impact:100% (both groups at 12 months; no difference)
Trust score:3/5

In children receiving pulpotomy, using calcium hydroxide paste produced clinical and radiographic success rates similar to zinc oxide–eugenol over 12 months.

Trust comment: Randomized clinical trial but small sample (29 children) and outcomes reported per tooth limit precision of estimates.

Study Details

PMID:30837416
Participants:29
Impact:78.9–88.9% across groups; no significant difference (P=0.968)
Trust score:3/5

In primary molar pulpotomies, choice of base material (including calcium hydroxide) did not change clinical or radiographic success rates over 2 years.

Trust comment: Two-year randomized controlled dental trial with clear clinical and radiographic endpoints and adequate follow-up; moderate sample (by teeth).

Study Details

PMID:35726548
Participants:105
Impact:65.7%, 65.7%, 77.1% (Groups 1–3) — no significant difference
Trust score:4/5

inflammatory reaction

1 evidences

Primary molar pulpotomies were treated using either mineral trioxide aggregate (MTA; a calcium‑containing material) or grape seed extract and followed clinically and radiographically up to 6 months.

Trust comment: Small prospective randomized split‑mouth trial (32 teeth); relevant calcium‑containing material but small sample and limited follow‑up (6 months).

Study Details

PMID:41029033
Participants:32
Impact:MTA associated with reduced inflammatory reactions (qualitative statement from authors)
Trust score:3/5

nighttime net ultrafiltration

1 evidences

Peritoneal dialysis patients randomized to icodextrin versus glucose solutions showed improved nighttime ultrafiltration and several biochemical and clinical changes over 4 months.

Trust comment: Multicenter randomized controlled trial (n=40) showing biochemical effects including higher serum calcium; moderate sample size but randomized design.

Study Details

PMID:41027653
Participants:40
Impact:greater in icodextrin group vs glucose group (P<0.05)
Trust score:4/5

albumin and QoL

1 evidences

Peritoneal dialysis patients randomized to icodextrin versus glucose solutions showed improved nighttime ultrafiltration and several biochemical and clinical changes over 4 months.

Trust comment: Multicenter randomized controlled trial (n=40) showing biochemical effects including higher serum calcium; moderate sample size but randomized design.

Study Details

PMID:41027653
Participants:40
Impact:higher albumin and improved SF‑36 scores in icodextrin group at 4 months (P<0.05)
Trust score:4/5

histological outcome

1 evidences

Split‑mouth RCT in children compared silver diamine fluoride (SDF) and biodentine (a calcium silicate material) for indirect pulp therapy; clinical, radiographic and histological outcomes were assessed.

Trust comment: Randomized split‑mouth trial with 68 children and both clinical and histological endpoints; solid design though follow‑up limited to 9 months for reported outcomes.

Study Details

PMID:41026563
Participants:68
Impact:histology favored biodentine for dentin bridge formation and pulpal health (qualitative/statistically significant per authors)
Trust score:4/5

periapical healing rate

1 evidences

Randomized trial comparing calcium hydroxide mixed with saline, local anesthetic, or 2% chlorhexidine as intracanal medicaments; periapical healing was followed over time.

Trust comment: Randomized, triple‑blind trial with pre‑specified sample size (n=75) and clinically relevant endpoints; good methodology though single‑center and modest size.

Study Details

PMID:40995720
Participants:75
Impact:CH+CHX showed higher healing rate and faster time to healthy PAI (mean time ~8.10±3.28 months) compared with CH+LA or CH+NS (statistically significant)
Trust score:4/5

clinical outcome

1 evidences

Randomized trial comparing calcium hydroxide mixed with saline, local anesthetic, or 2% chlorhexidine as intracanal medicaments; periapical healing was followed over time.

Trust comment: Randomized, triple‑blind trial with pre‑specified sample size (n=75) and clinically relevant endpoints; good methodology though single‑center and modest size.

Study Details

PMID:40995720
Participants:75
Impact:choice of vehicle influenced long‑term healing; CH+CHX superior (P<0.05)
Trust score:4/5

radiographic improvement (PAI)

1 evidences

Randomized trial comparing calcium hydroxide mixed with saline, local anesthetic, or 2% chlorhexidine as intracanal medicaments; periapical healing was followed over time.

Trust comment: Randomized, triple‑blind trial with pre‑specified sample size (n=75) and clinically relevant endpoints; good methodology though single‑center and modest size.

Study Details

PMID:40995720
Participants:75
Impact:faster reduction to PAI ≤2 in CH+CHX group (Kaplan‑Meier and log‑rank tests significant)
Trust score:4/5

spontaneous pain prevalence

1 evidences

In children with nonvital immature permanent incisors, both Well-Root PT (premixed bioceramic putty) and MTA improved clinical signs; Well-Root PT produced greater reduction in periapical radiolucency and higher periapical bone radiodensity at 12 months.

Trust comment: Randomized, double-blind controlled clinical trial with objective radiographic measures and complete 12-month follow-up but moderate sample size.

Study Details

PMID:40691703
Participants:38
Impact:MTA: 80% → 4% at 12 months (−76 percentage points); Well-Root PT: 84% → 0% at 12 months (−84 percentage points)
Trust score:4/5

periapical radiolucency area (PAR)

1 evidences

In children with nonvital immature permanent incisors, both Well-Root PT (premixed bioceramic putty) and MTA improved clinical signs; Well-Root PT produced greater reduction in periapical radiolucency and higher periapical bone radiodensity at 12 months.

Trust comment: Randomized, double-blind controlled clinical trial with objective radiographic measures and complete 12-month follow-up but moderate sample size.

Study Details

PMID:40691703
Participants:38
Impact:MTA: mean 20.34 → 2.3 mm^2 at 12 months (−18.04 absolute; −88.7%); Well-Root PT: mean 20.9 → 0.14 mm^2 at 12 months (−20.76 absolute; −99.3%)
Trust score:4/5

periapical bone radiodensity

1 evidences

In children with nonvital immature permanent incisors, both Well-Root PT (premixed bioceramic putty) and MTA improved clinical signs; Well-Root PT produced greater reduction in periapical radiolucency and higher periapical bone radiodensity at 12 months.

Trust comment: Randomized, double-blind controlled clinical trial with objective radiographic measures and complete 12-month follow-up but moderate sample size.

Study Details

PMID:40691703
Participants:38
Impact:MTA: mean 118.4 → 164.8 gray value at 12 months (+46.4; +39.2%); Well-Root PT: mean 118.6 → 178.2 at 12 months (+59.6; +50.2%)
Trust score:4/5

seminal fluid phosphate concentration

1 evidences

In infertile men seminal fluid phosphate is very high and associated with poorer sperm motility and morphology; high-dose cholecalciferol plus 500 mg calcium daily did not change seminal fluid phosphate.

Trust comment: Large, double-blind randomized clinical trial with clear predefined endpoints and robust sample size.

Study Details

PMID:40690555
Participants:307
Impact:Placebo median 21.4 mmol/L (IQR 15.9–28.4) vs treatment median 21.1 mmol/L (IQR 14.5–29.8); no change with vitamin D + 500 mg calcium supplementation
Trust score:5/5

sperm motility (progressive + non-progressive)

1 evidences

In infertile men seminal fluid phosphate is very high and associated with poorer sperm motility and morphology; high-dose cholecalciferol plus 500 mg calcium daily did not change seminal fluid phosphate.

Trust comment: Large, double-blind randomized clinical trial with clear predefined endpoints and robust sample size.

Study Details

PMID:40690555
Participants:307
Impact:Men with SF phosphate ≥29 mmol/L had lower motility: median 27% vs 37% (P = 0.007)
Trust score:5/5

sperm morphology (% normal)

1 evidences

In infertile men seminal fluid phosphate is very high and associated with poorer sperm motility and morphology; high-dose cholecalciferol plus 500 mg calcium daily did not change seminal fluid phosphate.

Trust comment: Large, double-blind randomized clinical trial with clear predefined endpoints and robust sample size.

Study Details

PMID:40690555
Participants:307
Impact:Men with SF phosphate ≥29 mmol/L had lower normal morphology: median 1.9% vs 2.5% (P = 0.014)
Trust score:5/5

radiographic treatment success (PAI)

1 evidences

In adult patients undergoing nonsurgical root canal treatment, calcium-silicate-sealer based obturation (SBO) produced similar clinical and radiographic success to warm vertical compaction (WVC) but required significantly less obturation time.

Trust comment: Randomized controlled trial with substantial sample and 12–22 month follow-up and objective imaging endpoints; moderate loss to follow-up.

Study Details

PMID:40653155
Participants:167
Impact:SBO success 76.6% vs WVC 80.5% (PAI); no significant difference
Trust score:4/5

CBCT-assessed success (CBCT-PAI)

1 evidences

In adult patients undergoing nonsurgical root canal treatment, calcium-silicate-sealer based obturation (SBO) produced similar clinical and radiographic success to warm vertical compaction (WVC) but required significantly less obturation time.

Trust comment: Randomized controlled trial with substantial sample and 12–22 month follow-up and objective imaging endpoints; moderate loss to follow-up.

Study Details

PMID:40653155
Participants:167
Impact:SBO 71.3% vs WVC 65.5%; no significant difference
Trust score:4/5

obturation time

1 evidences

In adult patients undergoing nonsurgical root canal treatment, calcium-silicate-sealer based obturation (SBO) produced similar clinical and radiographic success to warm vertical compaction (WVC) but required significantly less obturation time.

Trust comment: Randomized controlled trial with substantial sample and 12–22 month follow-up and objective imaging endpoints; moderate loss to follow-up.

Study Details

PMID:40653155
Participants:167
Impact:SBO 85.4 ± 44.0 s vs WVC 159.7 ± 71.0 s (SBO faster; P < .001)
Trust score:4/5

serum 25(OH)D3

1 evidences

Overweight people with low dietary calcium were randomized to energy reduction and/or calcium (400 mg + 125 IU vitamin D3 daily) for 2 years; calcium increased serum calcium and 25(OH)D3 but alone produced limited glycemic benefits, while energy reduction plus calcium produced the greatest improvements in fasting glucose and peripheral insulin sensitivity.

Trust comment: Large, long (2-year) randomized trial with clear biochemical and clinical outcomes reported; some attrition and complex interventions but overall high-quality.

Study Details

PMID:33589569
Participants:1021
Impact:+5.58 ng/mL in calcium group vs 1.76 ng/mL in non-calcium group (P<0.001)
Trust score:4/5

parathyroid hormone (PTH)

41 evidences

Older adults received calcium plus two doses of vitamin D; vitamin D forms correlated with some BMD changes but free/bioavailable forms were not clearly superior to total 25(OH)D.

Trust comment: 1-year double-blind RCT with 221 completers; well-powered for bone outcomes though calcium given to all arms and vitamin D was the randomized factor.

Study Details

PMID:33280041
Participants:221
Impact:Negative correlation with vitamin D variables (r = -0.22 to -0.25)
Trust score:4/5

In hemodialysis patients, L-carnitine supplementation increased plasma calcium and phosphate but did not change PTH or FGF23 over one year.

Trust comment: Multicentre double-blind randomized trial (n=92, 1 year) with appropriate design; some assay limits noted for Klotho measurements but overall moderate–high quality.

Study Details

PMID:30408788
Participants:92
Impact:no detectable change
Trust score:4/5

In CKD patients, paricalcitol lowered PTH substantially and increased circulating FGF23 over 12 weeks.

Trust comment: Randomized 12-week trial with complete measurements and clear biochemical endpoints in CKD patients.

Study Details

PMID:31863599
Participants:88
Impact:decrease −75.1 pg/mL (95% CI −90.4 to −59.8); P<0.001
Trust score:4/5

In kidney transplant recipients all given calcium and vitamin D, addition of pamidronate did not change bone mineral density over 6 months compared with control; calcium + vitamin D may have mitigated early bone loss.

Trust comment: Small randomized trial (n=40) with short (6-month) follow-up; all subjects received calcium + vitamin D so calcium effects are confounded but clinically relevant.

Study Details

PMID:25599737
Participants:40
Impact:normalized in both groups at 6 months
Trust score:3/5

In a randomized crossover study of healthy women, strenuous load-carriage exercise lowered ionized calcium, raised PTH, increased fractional calcium absorption, and produced a more positive calcium balance.

Trust comment: Randomized crossover human study with dual stable Ca isotopes and direct kinetic measures; rigorous methods but small sample size (n=21).

Study Details

PMID:38630876
Participants:21
Impact:increased during exercise (P<0.05)
Trust score:4/5

Double-blind RCT in healthy young adults (33 enrolled, 30 completed) randomized to 600, 4000 or 10,000 IU/day vitamin D3 for 24 weeks assessing serum 25(OH)D, PTH, calcium and genome-wide gene expression in white blood cells.

Trust comment: Well-controlled double-blind trial with clear biochemical and genomic outcomes but limited by small sample size.

Study Details

PMID:31776371
Participants:30
Impact:Decreases of ~17.5% (4000 IU/d) and ~33.3% (10,000 IU/d) at 16 weeks (p=0.04)
Trust score:4/5

In this Macau population survey, taking calcium supplements was modestly associated with slightly higher vitamin D levels and slightly lower PTH.

Trust comment: Well‑characterized cross‑sectional household survey with adjusted analyses; observational design limits causal inference.

Study Details

PMID:25636721
Participants:566
Impact:Negative association with calcium supplement intake (β=−0.06; adjusted for 25OHD)
Trust score:3/5

In post-RYGB patients given 1200 mg elemental calcium daily, calcium citrate and calcium carbonate produced similar small changes in PTH, but citrate produced larger reductions in bone turnover markers.

Trust comment: Double-blind randomized trial directly comparing two calcium formulations in humans; small sample limits precision but design is strong.

Study Details

PMID:30107042
Participants:39
Impact:−1.9% (citrate) vs +0.9% (carbonate); no significant difference, P=0.68
Trust score:4/5

1000 IU/day vitamin D3 for one month increased 25(OH)D and lowered PTH but did not improve measured physical performance.

Trust comment: Randomized trial with objective biochemical and performance measures and good completion (n=117); short duration (1 month) and lack of placebo reduce strength of conclusions.

Study Details

PMID:37735799
Participants:117
Impact:−3.77 pg/mL (45.76 → 41.99; p<0.05)
Trust score:4/5

Pilot randomized trial of four weekly whole‑body UV sessions in vitamin D‑deficient adults; UV exposure raised vitamin D and altered calcium‑phosphorus metabolism without causing systemic inflammation.

Trust comment: Randomized pilot trial with comprehensive biomarker measurements but small sample size limits precision and generalizability.

Study Details

PMID:40595199
Participants:24
Impact:decreased after 4 exposures (significant, p<0.05) (paired with decreased phosphorus)
Trust score:4/5

Six months of supervised intradialytic exercise in hemodialysis patients increased serum calcium, reduced serum phosphorus and substantially lowered PTH and ALP.

Trust comment: Randomized controlled trial in HD patients with objective lab endpoints and blinded outcome assessment; moderate sample and open‑label delivery.

Study Details

PMID:37730530
Participants:39
Impact:−210.4 pg/mL (459 → 248.6; p<0.001)
Trust score:4/5

Single 1000 mg calcium dose from milk or calcium carbonate acutely reduced bone resorption (CTX-1) and lowered PTH in postmenopausal women regardless of visceral fat.

Trust comment: Randomized three-period crossover with objective biochemical endpoints and frequent sampling; moderate sample size and open-label design.

Study Details

PMID:36967157
Participants:77
Impact:-47% (calcium carbonate); -22% (milk)
Trust score:4/5

Switching dialysis acid from acetate to citrate lowered pre-dialysis ionic calcium and increased PTH, reduced hypotension, and increased lean mass index over 16 weeks.

Trust comment: Prospective multicenter randomized crossover trial in humans with objective biochemical and clinical endpoints, moderate sample size.

Study Details

PMID:36210622
Participants:56
Impact:increase (significant)
Trust score:4/5

Intervention (pilot n=12) and RCT (98 randomized, 98 included) evaluated single‑dose denosumab (60 mg) in infertile men: denosumab caused a transient fall in serum calcium with compensatory PTH rise and associated changes in phosphate and bone turnover markers; most changes normalized over months.

Trust comment: Well‑designed single‑dose RCT with supporting pilot data and detailed biochemical monitoring; moderate‑large sample and appropriate analyses support good reliability.

Study Details

PMID:40055742
Participants:110
Impact:+35% higher PTH in denosumab group vs placebo at day 80 (p<0.0001)
Trust score:4/5

Small randomized study in postmenopausal women showing 12 weeks of moderate aerobic exercise increased PTH and vitamin D and altered ECG P-R interval; calcium changes not reported as significant.

Trust comment: Small randomized study with objective measures but limited sample size and reporting; no calcium supplementation tested.

Study Details

PMID:32208176
Participants:31
Impact:increase (P = 0.001) after 12 weeks exercise
Trust score:3/5

In vitamin D–sufficient Indian children with low dietary calcium, vitamin D–calcium supplementation paradoxically raised PTH without changing other bone biochemistry.

Trust comment: Follow-up of an RCT with moderate sample size and clear biochemical measures but limited by baseline vitamin D sufficiency and dietary factors.

Study Details

PMID:31704050
Participants:178
Impact:increased (paradoxical significant rise after supplementation)
Trust score:3/5

Taking 1000 mg calcium 60 min before prolonged load carriage kept blood calcium higher, lowered PTH, and reduced markers of bone breakdown versus no supplement.

Trust comment: Randomized crossover trial with frequent timed biochemical sampling and relevant biomarkers in 48 women, providing high internal validity for acute metabolic effects.

Study Details

PMID:39804018
Participants:48
Impact:decreased with supplement (versus increased in control)
Trust score:5/5

RCT (n=50) comparing low vs high dialysate calcium over 12 months: low dialysate calcium lowered pre-dialysis ionised calcium and raised PTH but did not change vascular calcification, PWV, LVMI, or BMD.

Trust comment: Randomized controlled trial directly manipulating dialysate calcium with objective outcomes; moderate sample size.

Study Details

PMID:27364375
Participants:50
Impact:+16 pmol/L (LC group; p=0.01)
Trust score:4/5

A 13-week vitamin D, calcium and leucine-enriched whey protein supplement increased 25(OH)D, suppressed PTH and produced small but positive increases in total-body BMD.

Trust comment: Multicenter, randomized, double-blind controlled trial with adequate sample size, but relatively short duration (13 weeks) for bone outcomes.

Study Details

PMID:31338563
Participants:380
Impact:decreased (suppressed; significant vs control)
Trust score:4/5

In bariatric surgery patients ~9–10 months post‑op, calcium citrate produced greater calcium bioavailability than calcium carbonate: higher serum AUC and Cmax, greater urinary calcium excretion, and larger PTH suppression.

Trust comment: Large (n=150), double‑blind randomized crossover with direct pharmacokinetic and biochemical measurements; strong design and relevant endpoints.

Study Details

PMID:39603923
Participants:150
Impact:Greater PTH reduction with citrate between 3–6 h postdose (significant)
Trust score:5/5

In middle-aged men, dietary calcium intake was not associated with baseline bone mineral density or bone loss over 2 years, though higher calcium intake correlated with slightly lower PTH.

Trust comment: Cohort analysis with reasonable sample size and measured biomarkers, but limited to men and observational associations; moderate quality.

Study Details

PMID:28606219
Participants:323
Impact:inverse correlation with dietary calcium (r = -0.19)
Trust score:3/5

In vitamin D–deficient community adults, vitamin D with or without calcium showed no clear clinical benefit over placebo at 6 months, though combined vitamin D+calcium reduced PTH and increased urine Ca/Cr in adherent subjects.

Trust comment: Randomized double-blind trial but substantial loss to follow-up and modest adherence limit confidence in null clinical findings.

Study Details

PMID:35505326
Participants:277
Impact:decreased from 29 to 22 pg/mL in vitamin D + calcium group (−7 pg/mL at 6 months)
Trust score:3/5

Small double-blind RCT in heart failure patients testing high-dose vitamin D3 vs placebo; vitamin D levels rose markedly and some hormonal (PTH), BNP and QOL measures improved.

Trust comment: Randomized, double-blind human trial with appropriate measures and clear biochemical effects (large 25(OH)D change); small sample limits precision and generalizability.

Study Details

PMID:29084522
Participants:36
Impact:decreased ~−20 ±20 pg/ml in treatment vs +7 ±53 pg/ml in placebo (p=0.002 unadjusted; attenuated after adjustment)
Trust score:4/5

Not giving routine oral calcium and calcitriol after thyroid surgery in patients with at least one well-perfused parathyroid gland did not change calcium or PTH levels.

Trust comment: Randomized noninferiority RCT with clear outcome measurements and 56 randomized patients; methods and endpoints appropriate.

Study Details

PMID:33471739
Participants:56
Impact:no statistically significant difference between groups (POD1 and POD30)
Trust score:4/5

In 36 pediatric ALL patients, daily vitamin D (4000 IU) plus calcium (1000 mg) with or without omega‑3 for 6 weeks increased 25(OH)D, lowered PTH, and the omega‑3 group showed reduced ICTP (a bone resorption marker) at 12 weeks.

Trust comment: Randomized supplement trial in 36 pediatric patients with well‑described assays and per‑protocol analyses; small sample but direct biochemical outcomes reported.

Study Details

PMID:40806109
Participants:36
Impact:decrease (ω‑3VDCa 77.4 → 48.5 pg/mL at 6 weeks; p=0.009)
Trust score:4/5

In recurrent calcium stone formers with vitamin D deficiency, two vitamin D repletion protocols raised serum 25(OH)D, lowered PTH, and increased 24‑h urinary calcium without changing stone supersaturation.

Trust comment: Randomized clinical trial with pre-specified outcomes, dietary control and multivariable adjustment; moderate sample size and no placebo arm limit generalizability.

Study Details

PMID:37481570
Participants:62
Impact:−7.16 pg/mL (decrease over time, p<0.001)
Trust score:4/5

A high-calcium dairy breakfast before cycling kept blood ionized calcium steadier and reduced markers of bone resorption compared with a low-calcium meal.

Trust comment: Randomized crossover trial in 32 elite female cyclists with appropriate biomarkers and analysis; unblinded meal and short-term outcomes limit some generalizability.

Study Details

PMID:25970439
Participants:32
Impact:attenuated exercise-induced rise (smaller fold-increase with calcium; e.g., 1.42x vs 1.66x from pre- to post-exercise)
Trust score:4/5

Twelve-week randomized study: calcium- and vitamin D–fortified milk (higher calcium + vitamin D + FOS-inulin) reduced bone resorption markers and PTH more than regular milk, especially in postmenopausal women.

Trust comment: Large randomized study with clear biochemical outcomes showing biologically plausible benefits of calcium/vitamin D–fortified milk; 12-week duration and marker-based endpoints are appropriate but not long-term bone outcomes.

Study Details

PMID:26264387
Participants:257
Impact:PTH decreased in most groups over time; postmenopausal control showed an increase at 12 weeks while fortified groups showed reductions
Trust score:4/5

100 male type 2 diabetic patients assigned to aerobic or resistance training for 6 months; both exercise types increased serum calcium and handgrip strength and decreased PTH.

Trust comment: Intervention study with 6-month follow-up and clear biochemical/functional outcomes, but allocation method and blinding not fully described in abstract.

Study Details

PMID:26957979
Participants:100
Impact:significant decrease in both groups after 6 months
Trust score:3/5

In dialysis patients with refractory SHPT, total parathyroidectomy alone suppressed PTH more effectively and showed no recurrences over 3 years compared with total parathyroidectomy plus autotransplantation; serum calcium was similar between groups.

Trust comment: Prospective randomized pilot trial with limited sample size and nonconfirmatory design; provides useful but preliminary human data.

Study Details

PMID:27741007
Participants:100
Impact:lower at end of follow-up in TPTX vs TPTX+AT (31.7 ± 43.6 vs 98.2 ± 156.8)
Trust score:3/5

Six-month treadmill exercise in obese asthmatics on long-term corticosteroids increased bone mineral density and serum calcium and reduced PTH and inflammatory cytokines compared with controls.

Trust comment: Controlled intervention with modest sample size; demonstrates changes in calcium-related biomarkers but exercise (not calcium supplementation) was the intervention and randomization/details unclear.

Study Details

PMID:27917214
Participants:80
Impact:significant reduction in PTH in exercise group
Trust score:3/5

Randomized children/adolescents to three vitamin D regimens; regimens with loading doses raised 25(OH)D and had small, variable effects on serum calcium and PTH.

Trust comment: Large randomized trial with objective biochemical outcomes; direct intervention was vitamin D (calcium measured as safety/biomarker), good sample size and follow-up though single-region pediatric population.

Study Details

PMID:27927221
Participants:637
Impact:after 4 months mean PTH higher in groups 1 and 3 versus group2 (group2 mean ~36.18 pg/ml vs group1 76.8 and group3 74.5); significant between-group differences (p<0.001)
Trust score:4/5

Single-center randomized trial (68 per arm) comparing percutaneous ethanol ablation (PEA) to parathyroidectomy (PTx) for solitary parathyroid adenoma; both treatments substantially reduced PTH, serum-adjusted calcium and adenoma size with similar efficacy at 6 months.

Trust comment: Well-powered randomized trial with ITT analysis and detailed laboratory follow-up; high trust for reported effects on serum calcium and PTH (though not a calcium-supplement study).

Study Details

PMID:39849501
Participants:136
Impact:Significant continuous reduction in PTH in both groups over follow-up (both groups, p<0.001); no significant intergroup difference
Trust score:4/5

In pediatric ESRD patients, substituting some hemodialysis sessions with online hemodiafiltration improved biochemical markers including calcium/phosphorus/PTH and reduced inflammation over follow-up.

Trust comment: Prospective clinical study with measured calcium/phosphate/PTH outcomes in children; moderate sample size and single‑center design limit generalizability.

Study Details

PMID:32723294
Participants:31
Impact:-20.19% (3–9 months) and -51.97% (3–18 months) in HDF group (significant)
Trust score:3/5

In adolescents, milk powder fortified with calcium (300–900 mg/day) plus vitamin D for 1.5 years did not produce greater bone density gains versus control, but altered PTH and IGF-1.

Trust comment: Randomized, cluster-assigned controlled trial with long follow-up and objective measures (DXA, biomarkers); limitations include modest vitamin D dose and some loss to follow-up.

Study Details

PMID:31375874
Participants:181
Impact:Decreased in intervention groups; Ca6D group showed significant decrease (−31.2% vs baseline, p<0.0001) and significant treatment effect vs other groups
Trust score:4/5

In dialysis patients with secondary hyperparathyroidism, IV etelcalcetide over 1 year reduced PTH and lowered blood calcium and phosphate; hypocalcemia occurred in some patients.

Trust comment: Large multicenter human trial with central lab measurements but single-arm open-label extension limits causal inference.

Study Details

PMID:30859218
Participants:682
Impact:−26.1% (mean percent change, EAP)
Trust score:4/5

Weekly ergocalciferol in hemodialysis patients increased 25-hydroxyvitamin D levels without changing serum calcium or parathyroid hormone.

Trust comment: Small randomized trial with 35 completers showing clear vitamin D rises but no changes in calcium or PTH; sample size modest and short duration.

Study Details

PMID:30595565
Participants:35
Impact:no significant change
Trust score:3/5

In obese adults with vitamin D deficiency, adding high-dose weekly vitamin D to a weight-loss diet raised vitamin D levels and reduced PTH, inflammatory markers, and fat mass.

Trust comment: Double-blind randomized controlled trial but small sample (n=44); endpoints and statistical significance are clearly reported.

Study Details

PMID:30246883
Participants:44
Impact:significant decrease (P<0.001)
Trust score:3/5

35-day randomized, double-blind, placebo-controlled trial in 64 healthy college students comparing 400 mg/day calcium supplement vs placebo with identical controlled diet: no significant differences in serum/urine metabolites, calcium-related hormones, or biochemical indicators.

Trust comment: Randomized, double-blind, placebo-controlled dietary RCT with strict intake control; short duration and young healthy sample limit generalizability.

Study Details

PMID:34445834
Participants:64
Impact:no significant change (P>0.05)
Trust score:4/5

In an 8-week controlled feeding trial, the DASH diet modestly lowered active vitamin D (calcitriol) but did not change PTH or blood ionized calcium.

Trust comment: Randomized, multicenter controlled feeding trial with centralized assays and good adherence; moderate sample size and prespecified mineral metabolism outcomes.

Study Details

PMID:29562597
Participants:334
Impact:no significant change
Trust score:4/5

After stroke only serum calcium showed clear circadian rhythm; naturalistic light was associated with lower PTH at discharge.

Trust comment: Secondary exploratory analysis of an RCT with small sample (n=45); measures of calcium metabolism reported but study is small and exploratory.

Study Details

PMID:39912742
Participants:45
Impact:lower in naturalistic light unit at discharge (PTH decreased vs control)
Trust score:3/5

Serum phosphate (CA group)

1 evidences

Randomized comparison of sevelamer versus calcium acetate in dialysis patients with high phosphate; calcium acetate lowered phosphate but increased serum calcium and was associated with greater coronary calcification progression than sevelamer.

Trust comment: Randomized controlled clinical study with adequate sample size and relevant biochemical and imaging outcomes, but likely single-center and not clearly blinded, so moderate confidence.

Study Details

PMID:40964123
Participants:92
Impact:-0.43 mmol/L
Trust score:3/5

Serum calcium (CA group)

1 evidences

Randomized comparison of sevelamer versus calcium acetate in dialysis patients with high phosphate; calcium acetate lowered phosphate but increased serum calcium and was associated with greater coronary calcification progression than sevelamer.

Trust comment: Randomized controlled clinical study with adequate sample size and relevant biochemical and imaging outcomes, but likely single-center and not clearly blinded, so moderate confidence.

Study Details

PMID:40964123
Participants:92
Impact:+0.10 mmol/L
Trust score:3/5

Calcium‑phosphate product (CA group)

1 evidences

Randomized comparison of sevelamer versus calcium acetate in dialysis patients with high phosphate; calcium acetate lowered phosphate but increased serum calcium and was associated with greater coronary calcification progression than sevelamer.

Trust comment: Randomized controlled clinical study with adequate sample size and relevant biochemical and imaging outcomes, but likely single-center and not clearly blinded, so moderate confidence.

Study Details

PMID:40964123
Participants:92
Impact:-0.44 (mmol^2/L^2)
Trust score:3/5

Intact PTH (iPTH, CA group)

1 evidences

Randomized comparison of sevelamer versus calcium acetate in dialysis patients with high phosphate; calcium acetate lowered phosphate but increased serum calcium and was associated with greater coronary calcification progression than sevelamer.

Trust comment: Randomized controlled clinical study with adequate sample size and relevant biochemical and imaging outcomes, but likely single-center and not clearly blinded, so moderate confidence.

Study Details

PMID:40964123
Participants:92
Impact:-75 pg/mL
Trust score:3/5

Coronary artery calcification score (CACs, CA group)

1 evidences

Randomized comparison of sevelamer versus calcium acetate in dialysis patients with high phosphate; calcium acetate lowered phosphate but increased serum calcium and was associated with greater coronary calcification progression than sevelamer.

Trust comment: Randomized controlled clinical study with adequate sample size and relevant biochemical and imaging outcomes, but likely single-center and not clearly blinded, so moderate confidence.

Study Details

PMID:40964123
Participants:92
Impact:+26.62 (Agatston units)
Trust score:3/5

vitamin D3 (25‑OH D3)

1 evidences

In 30 maintenance hemodialysis patients, HFR caused greater acute reductions in several micronutrients compared with HDF, including serum calcium.

Trust comment: Randomized crossover trial in 30 humans with clear within-subject measurements—small sample but direct measurements of serum calcium make findings credible.

Study Details

PMID:40914150
Participants:30
Impact:decrease (greater reduction with HFR vs HDF; p<0.05)
Trust score:4/5

selenium

1 evidences

In 30 maintenance hemodialysis patients, HFR caused greater acute reductions in several micronutrients compared with HDF, including serum calcium.

Trust comment: Randomized crossover trial in 30 humans with clear within-subject measurements—small sample but direct measurements of serum calcium make findings credible.

Study Details

PMID:40914150
Participants:30
Impact:decrease (greater reduction with HFR vs HDF; p<0.05)
Trust score:4/5

vitamin B3 (niacin)

1 evidences

In 30 maintenance hemodialysis patients, HFR caused greater acute reductions in several micronutrients compared with HDF, including serum calcium.

Trust comment: Randomized crossover trial in 30 humans with clear within-subject measurements—small sample but direct measurements of serum calcium make findings credible.

Study Details

PMID:40914150
Participants:30
Impact:increase (higher post-treatment after HFR; p=0.047)
Trust score:4/5

QTc interval

2 evidences

In 466 hospitalized patients randomized to rosuvastatin or atorvastatin, rosuvastatin increased QTc interval; higher serum calcium was associated with reduced risk of QT prolongation.

Trust comment: Large randomized clinical trial with 466 analyzed patients and multivariate analyses; calcium association is observational within the trial but statistically reported.

Study Details

PMID:40890448
Participants:466
Impact:increase (rosuvastatin change +6.57±20.32 ms vs atorvastatin −0.83±22.07 ms; p<0.001)
Trust score:4/5

In women with primary hyperparathyroidism, parathyroidectomy (which corrects hypercalcemia) reduced premature heart beats and normalized QTc on 24-h ECG.

Trust comment: Randomized human study with objective ECG endpoints but small sample size (n=52).

Study Details

PMID:29875287
Participants:52
Impact:Shorter QTc at baseline vs controls; normalized (lengthened) after parathyroidectomy
Trust score:4/5

newly emerged QT prolongation

1 evidences

In 466 hospitalized patients randomized to rosuvastatin or atorvastatin, rosuvastatin increased QTc interval; higher serum calcium was associated with reduced risk of QT prolongation.

Trust comment: Large randomized clinical trial with 466 analyzed patients and multivariate analyses; calcium association is observational within the trial but statistically reported.

Study Details

PMID:40890448
Participants:466
Impact:higher incidence with rosuvastatin (9.2% vs 4.2%; rosuvastatin increased risk by ~42%, adjusted OR 2.57, p=0.025)
Trust score:4/5

remineralization (DIAGNOdent change)

1 evidences

In 32 children (100 teeth), in‑office application followed by home use of remineralizing agents improved enamel remineralization and color of white‑spot lesions; nano‑hydroxyapatite (NHA) produced the largest remineralization effect.

Trust comment: Randomized, assessor‑blinded clinical trial in children with objective measures (DIAGNOdent, spectrophotometer); moderate sample size but robust outcome measures.

Study Details

PMID:40830200
Participants:32
Impact:NHA +65.68% at 1 month vs control 0.00%; MI (CPP‑ACP) +48.57%; MI+ (CPP‑ACP+F) +42.68%; Fluoride +40.58% (all p<0.001 vs control)
Trust score:4/5

color change (ΔE)

3 evidences

Randomized trial (5 groups) testing violet LED with/without peroxide gels for tooth whitening; LED+HP gave largest color change, LED alone least; tooth sensitivity varied by protocol; enamel Ca/P ratio did not decrease after treatments.

Trust comment: Well-conducted randomized, controlled trial with blinding of evaluators and sample size calculation; moderate sample size per group.

Study Details

PMID:32428059
Participants:90
Impact:LED/HP highest (ΔE1 12.9±2.6; ΔE2 14.4±2.2); HP 8.8±3.0 & 10.0±4.1; LED lowest (ΔE1 3.4±1.3; ΔE2 3.7±1.4)
Trust score:4/5

In 32 children (100 teeth), in‑office application followed by home use of remineralizing agents improved enamel remineralization and color of white‑spot lesions; nano‑hydroxyapatite (NHA) produced the largest remineralization effect.

Trust comment: Randomized, assessor‑blinded clinical trial in children with objective measures (DIAGNOdent, spectrophotometer); moderate sample size but robust outcome measures.

Study Details

PMID:40830200
Participants:32
Impact:MI+ largest ΔE at 1 month (9.03); NHA ΔE 5.39; Control ΔE 3.61 (statistically significant group differences, p<0.001)
Trust score:4/5

After tooth bleaching, CPP-ACPF reduced immediate post-operative sensitivity (notably after the first session) vs control; NovaMin showed only short-term reduction and neither agent affected bleaching color change.

Trust comment: Randomized, double-blind clinical trial in humans with objective color measures; moderate sample size (51 completers) supports findings though groups were small.

Study Details

PMID:28678953
Participants:51
Impact:No difference in ΔE between control, NovaMin and CPP-ACPF groups (bleaching unaffected)
Trust score:4/5

25(OH)D concentration

2 evidences

In 36 pediatric ALL patients, daily vitamin D (4000 IU) plus calcium (1000 mg) with or without omega‑3 for 6 weeks increased 25(OH)D, lowered PTH, and the omega‑3 group showed reduced ICTP (a bone resorption marker) at 12 weeks.

Trust comment: Randomized supplement trial in 36 pediatric patients with well‑described assays and per‑protocol analyses; small sample but direct biochemical outcomes reported.

Study Details

PMID:40806109
Participants:36
Impact:increase (ω‑3VDCa: 19.4 → 44.0 ng/mL at 6 weeks; VDCa: 15.3 → 42.8 ng/mL at 6 weeks; both p<0.05)
Trust score:4/5

100 adults ≥50 y in a randomized cross-over trial: monthly vitamin D alone produced higher compliance than daily vitamin D+calcium, with similar changes in 25(OH)D.

Trust comment: Randomized cross-over human study with objective compliance and biochemical endpoints; appropriate design and sample size for compliance outcome.

Study Details

PMID:26100413
Participants:100
Impact:increase with both regimens (VD: 29.1→35.7 ng/mL; VDCa: 27.9→31.8 ng/mL) with no significant difference (p=0.16)
Trust score:4/5

ICTP (bone resorption marker)

1 evidences

In 36 pediatric ALL patients, daily vitamin D (4000 IU) plus calcium (1000 mg) with or without omega‑3 for 6 weeks increased 25(OH)D, lowered PTH, and the omega‑3 group showed reduced ICTP (a bone resorption marker) at 12 weeks.

Trust comment: Randomized supplement trial in 36 pediatric patients with well‑described assays and per‑protocol analyses; small sample but direct biochemical outcomes reported.

Study Details

PMID:40806109
Participants:36
Impact:lower at 12 weeks in ω‑3VDCa vs VDCa (0.74 vs 1.05 ng/mL; p=0.024)
Trust score:4/5

urinary Ca/Cr ratio

1 evidences

In 36 pediatric ALL patients, daily vitamin D (4000 IU) plus calcium (1000 mg) with or without omega‑3 for 6 weeks increased 25(OH)D, lowered PTH, and the omega‑3 group showed reduced ICTP (a bone resorption marker) at 12 weeks.

Trust comment: Randomized supplement trial in 36 pediatric patients with well‑described assays and per‑protocol analyses; small sample but direct biochemical outcomes reported.

Study Details

PMID:40806109
Participants:36
Impact:increase at 6 weeks (0.01 → 0.06 mg/dL; p=0.014) then decreased at 12 weeks
Trust score:4/5

treatment success (≥50% VAS reduction)

1 evidences

Randomized, double-blind, placebo-controlled trial in pediatric IBS (active: calcium butyrate 500 mg + zinc + vitamin D once daily for 8 weeks) showing large, clinically meaningful reductions in abdominal pain and overall GI symptoms and associated microbiome/metabolome changes.

Trust comment: Randomized double-blind placebo-controlled pediatric trial with clear large effects on primary outcome but modest sample size and limited fecal sample availability for multiomics, so moderately high trust.

Study Details

PMID:40635319
Participants:50
Impact:+69.2 percentage points (73% active vs 3.8% placebo, ITT)
Trust score:4/5

abdominal pain (VAS) reduction at end of treatment

1 evidences

Randomized, double-blind, placebo-controlled trial in pediatric IBS (active: calcium butyrate 500 mg + zinc + vitamin D once daily for 8 weeks) showing large, clinically meaningful reductions in abdominal pain and overall GI symptoms and associated microbiome/metabolome changes.

Trust comment: Randomized double-blind placebo-controlled pediatric trial with clear large effects on primary outcome but modest sample size and limited fecal sample availability for multiomics, so moderately high trust.

Study Details

PMID:40635319
Participants:50
Impact:−66.3% (active) vs −3.2% (placebo) at end of treatment
Trust score:4/5

GI symptom score (GSRS) reduction

1 evidences

Randomized, double-blind, placebo-controlled trial in pediatric IBS (active: calcium butyrate 500 mg + zinc + vitamin D once daily for 8 weeks) showing large, clinically meaningful reductions in abdominal pain and overall GI symptoms and associated microbiome/metabolome changes.

Trust comment: Randomized double-blind placebo-controlled pediatric trial with clear large effects on primary outcome but modest sample size and limited fecal sample availability for multiomics, so moderately high trust.

Study Details

PMID:40635319
Participants:50
Impact:−51.1% (active) vs −9.2% (placebo) at end of treatment
Trust score:4/5

oral mucositis symptom frequency

1 evidences

Crossover randomized trial in children compared a calcium-phosphate mouth rinse (Caphosol) versus saline; Caphosol cycles were associated with fewer severe oral symptoms and modest microbiome differences.

Trust comment: Randomized, double‑blind crossover trial with microbiome sequencing and appropriate analyses but modest sample size and some dropout.

Study Details

PMID:40604730
Participants:32
Impact:-16 percentage points (29% saline → 13% Caphosol; patient‑reported severe oral symptoms)
Trust score:4/5

oral microbiome alpha diversity

1 evidences

Crossover randomized trial in children compared a calcium-phosphate mouth rinse (Caphosol) versus saline; Caphosol cycles were associated with fewer severe oral symptoms and modest microbiome differences.

Trust comment: Randomized, double‑blind crossover trial with microbiome sequencing and appropriate analyses but modest sample size and some dropout.

Study Details

PMID:40604730
Participants:32
Impact:no significant change
Trust score:4/5

Burkholderia‑Caballeronia‑Paraburkholderia abundance

1 evidences

Crossover randomized trial in children compared a calcium-phosphate mouth rinse (Caphosol) versus saline; Caphosol cycles were associated with fewer severe oral symptoms and modest microbiome differences.

Trust comment: Randomized, double‑blind crossover trial with microbiome sequencing and appropriate analyses but modest sample size and some dropout.

Study Details

PMID:40604730
Participants:32
Impact:increased in Caphosol group (significant, p=0.013)
Trust score:4/5

Serum 25(OH)D concentration

3 evidences

24-week RCT testing vitamin D and/or calcium in people with prediabetes; vitamin D+calcium improved PSQI vs baseline and calcium alone improved sleep in prespecified subgroups.

Trust comment: Randomized controlled trial with moderate sample size; post-hoc analysis for sleep reduces primary outcome strength but methods and sample are adequate.

Study Details

PMID:38366270
Participants:212
Impact:increased in intervention groups (P<0.05)
Trust score:4/5

Pilot randomized trial of four weekly whole‑body UV sessions in vitamin D‑deficient adults; UV exposure raised vitamin D and altered calcium‑phosphorus metabolism without causing systemic inflammation.

Trust comment: Randomized pilot trial with comprehensive biomarker measurements but small sample size limits precision and generalizability.

Study Details

PMID:40595199
Participants:24
Impact:+6 ng/mL after 2 exposures; +13 ng/mL after 4 exposures (approx. 12 → 18 → 25 ng/mL)
Trust score:4/5

Daily supplementation with 1000 IU vitamin D plus 500 mg calcium for six months increased serum 25(OH)D in schoolchildren; children with lower baseline levels benefited most.

Trust comment: Single-arm pre-post supplementation study (n=106) with objective vitamin D measurement but no randomized control group; moderate quality.

Study Details

PMID:29247782
Participants:106
Impact:+20.1 nmol/L mean increase (from 59.7 ±11.2 to 79.8 ±23.3 nmol/L)
Trust score:3/5

serum calcium level

3 evidences

A multimodal nutrition protocol around knee replacement reduced albumin transfusions, electrolyte disorders including low calcium on day 1, and shortened hospital stay.

Trust comment: Randomized controlled trial with 162 patients and significant p-values; calcium-related outcomes were secondary but directly measured.

Study Details

PMID:28697860
Participants:162
Impact:higher on postoperative day 1 (P<0.05)
Trust score:4/5

Randomized trial with >10-year follow-up (analyzed n=151) comparing total thyroidectomy alone vs with prophylactic central compartment lymph node dissection: no differences in oncologic outcomes or rates of permanent hypocalcemia or serum calcium at long-term follow-up.

Trust comment: Long-term randomized trial with substantial follow-up; analysis based on 151 patients and provides reliable clinical outcome data including calcium-related safety endpoints.

Study Details

PMID:39983243
Participants:151
Impact:No significant difference between groups at follow-up (P=0.181)
Trust score:4/5

Pilot randomized trial of four weekly whole‑body UV sessions in vitamin D‑deficient adults; UV exposure raised vitamin D and altered calcium‑phosphorus metabolism without causing systemic inflammation.

Trust comment: Randomized pilot trial with comprehensive biomarker measurements but small sample size limits precision and generalizability.

Study Details

PMID:40595199
Participants:24
Impact:decreased ≈2 mg/dL after 4 exposures (approx. 14 mg/dL → 12 mg/dL; p<0.05)
Trust score:4/5

bone formation marker (P1NP)

5 evidences

12-week randomized dietary supplement trial in adults with abdominal obesity; whey protein increased urinary calcium but did not change bone turnover markers or BMD.

Trust comment: Randomized controlled trial with objective biochemical measures but a post-hoc analysis and limited sample size for bone endpoints, reducing power for those outcomes.

Study Details

PMID:35422766
Participants:64
Impact:No change (adjusted change ≈0 μg/L; protein p≈0.93)
Trust score:4/5

Prospective randomized study in postmenopausal women given calcium + vitamin D with or without genistein; vitamin D increases associated with reductions in bone turnover markers, and genistein added no consistent additional benefit.

Trust comment: Randomized supplementation study with pharmacogenomic subanalysis; moderate sample size and clear null effect of genistein adjunct.

Study Details

PMID:29151102
Participants:102
Impact:P1NP decreased in association with vitamin D increase; genistein provided no additional effect
Trust score:4/5

Randomized double-blind trial in 150 postmenopausal women testing placebo, calcium+vitamin D, and calcium+vitamin D+genistein for 12 weeks; vitamin D rose in all groups and adding genistein produced no additional changes in vitamin D, calcium metabolism, or bone remodeling markers.

Trust comment: Well-conducted double-blind RCT (n=150) measuring relevant biomarkers, although seasonal increases in vitamin D limit attribution to supplementation.

Study Details

PMID:36919425
Participants:150
Impact:No additional change with genistein added to calcium+vitamin D
Trust score:4/5

In older men doing home-based resistance exercise, obesity/metabolic risk reduced anabolic response; a higher-quality multi-ingredient supplement (which included calcium) produced better lean-mass, strength and bone marker outcomes than a lower-quality supplement.

Trust comment: Original study was a randomized, double-blind trial; current report is a retrospective analysis on a modest sample (n=32) and includes a multi-ingredient supplement so calcium-specific effects are not isolated.

Study Details

PMID:39771028
Participants:32
Impact:increased in M5 group only (indicative of improved bone formation)
Trust score:4/5

Longitudinal study of 467 pregnant Gambian women showing small increases in peripheral bone density and marked biochemical changes between early second and third trimesters despite low habitual calcium intake.

Trust comment: Large longitudinal human cohort with objective pQCT and biochemical endpoints; well-powered and directly relevant to calcium economy in pregnancy.

Study Details

PMID:33784438
Participants:467
Impact:-32.4% (95% CI -37.19, -28.17)
Trust score:4/5

Nasal calcium concentration

4 evidences

Randomized, blinded, controlled trial testing intranasal 1% disodium orthophosphate vs saline for chronic post-COVID-19 smell loss.

Trust comment: Randomized, blinded controlled clinical trial with objective olfactory testing and ionic measurement but moderate sample size; directly measures and modifies local calcium levels.

Study Details

PMID:40538165
Participants:52
Impact:reduction vs sodium chloride (decreased nasal Ca2+ in mucus)
Trust score:4/5

Intranasal sodium gluconate (a calcium-chelating agent) reduced nasal calcium and was associated with improved sense of smell one month after treatment in post‑COVID patients.

Trust comment: Prospective randomized blinded controlled trial (n=50) directly testing an agent that lowers local calcium; small sample and short follow-up.

Study Details

PMID:35942688
Participants:50
Impact:Marked decrease after sodium gluconate versus saline (quantitative decrease reported vs control)
Trust score:3/5

Intranasal NTA reduced nasal mucus calcium and markedly improved sense of smell in COVID-19 patients.

Trust comment: Randomized, double-blind controlled trial with objective measures (Sniffin’ Sticks, ion-selective electrode) but single-center and modest sample size.

Study Details

PMID:35567630
Participants:58
Impact:-25.75 mM (from 37.25 to 11.50 in NTA group)
Trust score:4/5

Topical intranasal DTPA significantly reduced nasal mucus calcium and improved smell scores in patients with post-COVID-19 anosmia.

Trust comment: Randomized, blinded trial with objective olfactory testing and biochemical measures, moderate sample size supports reliability.

Study Details

PMID:37018923
Participants:66
Impact:−13.15 mM (37.54 → 24.39 mM after 1 month)
Trust score:4/5

Olfactory function (TDI score classification)

1 evidences

Randomized, blinded, controlled trial testing intranasal 1% disodium orthophosphate vs saline for chronic post-COVID-19 smell loss.

Trust comment: Randomized, blinded controlled clinical trial with objective olfactory testing and ionic measurement but moderate sample size; directly measures and modifies local calcium levels.

Study Details

PMID:40538165
Participants:52
Impact:clinical improvement in 81% of treated patients (shift from anosmia to hyposmia)
Trust score:4/5

serum phosphorus

10 evidences

Randomized study in hemodialysis patients (105 completers) showing that adding rhubarb to medicinal activated carbon reduced serum phosphorus, calcium-phosphorus product, and PTH over 8 weeks.

Trust comment: Randomized trial with a reasonable completer number but limited reporting clarity and potential methodological concerns.

Study Details

PMID:30634204
Participants:105
Impact:decreased (rhubarb + activated carbon vs control)
Trust score:3/5

Six months of supervised intradialytic exercise in hemodialysis patients increased serum calcium, reduced serum phosphorus and substantially lowered PTH and ALP.

Trust comment: Randomized controlled trial in HD patients with objective lab endpoints and blinded outcome assessment; moderate sample and open‑label delivery.

Study Details

PMID:37730530
Participants:39
Impact:−1.7 meq/L (5.8 → 4.1; p<0.01)
Trust score:4/5

In dialysis patients ferric citrate achieved similar phosphorus control and produced similar changes in serum calcium and PTH compared with sevelamer and/or calcium acetate over 52 weeks.

Trust comment: Large randomized phase 3 trial in dialysis patients with relevant biochemical outcomes; open-label design and mixed active control (including calcium acetate) are limitations.

Study Details

PMID:25958079
Participants:441
Impact:decrease: ferric citrate −2.04 ± 1.99 mg/dL vs active control −2.18 ± 2.25 mg/dL (similar)
Trust score:4/5

In 60 postmenopausal women with CKD stage 5, raloxifene increased lumbar spine BMD (~+2%) but did not differ from placebo in reducing intact PTH.

Trust comment: Randomized study but small sample and mixed dialysis status limits generalizability.

Study Details

PMID:25362221
Participants:60
Impact:decreased ~1.8% in both groups
Trust score:3/5

In patients with type 2 diabetes, 500 mg/day resveratrol for 6 months modestly improved whole-body bone density and content and altered phosphorus and vitamin D markers compared to placebo.

Trust comment: Large, double-blind randomized placebo-controlled trial with centralized DXA and biochemical measures; high internal validity for measured endpoints.

Study Details

PMID:30237505
Participants:179
Impact:increase in Resv500 vs placebo +0.13 mmol/L (95% CI 0.05–0.21), P=0.002
Trust score:4/5

Adding systematic diet education and multidisciplinary nursing improved nutrition, lowered serum phosphorus and Ca×P product, and reduced anxiety in DKD patients on alogliptin.

Trust comment: Randomized allocation with clear biochemical outcomes in 90 patients, but single-center design and short follow-up limit generalizability.

Study Details

PMID:35340239
Participants:90
Impact:decreased (P<0.001)
Trust score:3/5

In dialysis patients, non-calcium phosphate binders reduced serum phosphorus and markedly lowered FGF-23 over 1 year; iPTH fell initially then returned near baseline.

Trust comment: Large randomized Phase 3 completer analysis with central lab measures; post‑hoc pooled analysis and completer-only set limit some generalizability.

Study Details

PMID:29846719
Participants:549
Impact:-30% (reduction from baseline maintained over 52 weeks)
Trust score:4/5

Adding nicotinamide to calcium-based phosphate binders lowered serum phosphorus and improved lipid parameters in pediatric hemodialysis patients.

Trust comment: Randomized 6-month trial in 60 children with clear biochemical endpoints and reported adverse events; moderate sample size but appropriate design.

Study Details

PMID:26420678
Participants:60
Impact:significant decline versus control (p=0.0001)
Trust score:4/5

Ferric citrate was non-inferior to sevelamer at lowering serum phosphorus in hemodialysis patients; corrected serum calcium and intact-PTH changes were similar, while ferric citrate improved iron indices and had more mild GI adverse events.

Trust comment: Phase III multicenter randomized trial with high completion rate; open-label design may introduce some bias but endpoints are objective.

Study Details

PMID:37812931
Participants:217
Impact:decreased to 0.59 ± 0.54 mmol/L (ferric citrate) vs 0.56 ± 0.62 mmol/L (sevelamer); no significant difference between groups
Trust score:4/5

In hemodialysis patients, adding cinacalcet to paricalcitol led to lower serum phosphorus and higher serum calcium over 6–12 months compared with paricalcitol alone.

Trust comment: Randomized 140-patient trial with objective laboratory endpoints; good sample size though blinding and single-center details are limited.

Study Details

PMID:37814913
Participants:140
Impact:decreased (significantly vs paricalcitol alone, P<0.05)
Trust score:4/5

Serum 25(OH)D

10 evidences

Giving 60 g/day formula milk (rich in calcium and vitamin D) to 4–6 y children for 12 months increased forearm bone mass and caused short-term biomarker changes.

Trust comment: Cluster randomized controlled trial with objective bone measurements, adequate sample and high adherence though not double-blinded (minor limitation).

Study Details

PMID:37111231
Participants:174
Impact:+5.54% (6 months)
Trust score:5/5

Randomized open-label trial in Thai youth on TDF/FTC PrEP: vitamin D (200 IU) plus calcium (600 mg) supplementation twice daily led to greater lumbar spine BMD gains at 6 months versus no supplementation.

Trust comment: Randomized clinical trial with objective DXA outcomes and clear effect on lumbar spine BMD at 6 months; moderate follow-up losses but appropriate analyses.

Study Details

PMID:33040465
Participants:79
Impact:Maintained/increased in supplemented group (arm A median change +8.1 ng/mL in adherent subgroup) vs decreased in non-supplemented group (arm B −2.05 ng/mL); between-group p=0.02
Trust score:4/5

Pregnant women randomized to 1000 vs 2000 IU/day vitamin D: 2000 IU improved maternal 25(OH)D more, but glycemic, lipid and oxidative stress markers were similar; small decreases in maternal serum calcium occurred in both groups.

Trust comment: Randomized clinical trial in pregnant women with measured biochemical outcomes and good completion rate (73), high internal validity for reported endpoints.

Study Details

PMID:33054794
Participants:73
Impact:Increase greater with 2000 IU/d vs 1000 IU/d (+46.7±30.6 nmol/L change difference; time P<0.001; interaction P=0.004)
Trust score:4/5

A 24‑week RCT of fortified milk (providing ~1008 mg Ca/day) plus exercise improved vitamin B‑12 and 25(OH)D levels and reduced bone turnover markers versus control.

Trust comment: Well‑conducted 24‑week RCT with good sample size and compliance; combined nutrition+exercise limits attribution to Calcium alone.

Study Details

PMID:32588047
Participants:163
Impact:+25.4 nmol/L (mean: 54.7 → 80.1 nmol/L at 24 wk)
Trust score:4/5

Personalized vitamin D3 loading followed by 2000 IU/day raised 25(OH)D to sufficiency in CRC patients; no cases of hypervitaminosis D or hypercalcemia occurred, though transient hypercalciuria was observed in some patients after loading dose.

Trust comment: Randomized, double-blind, placebo-controlled interim analysis with clear biochemical endpoints and safety monitoring; sample size for safety endpoints limited by interim nature.

Study Details

PMID:36364809
Participants:74
Impact:+45.0 nmol/L (mean increase from baseline to visit 2 in verum group)
Trust score:4/5

Daily 1200 IU vitamin D prevented wintertime vitamin D deficiency but did not change hand grip strength or major hormone levels in young male conscripts.

Trust comment: Triple-blinded randomized placebo-controlled trial (analyzed n=53) with robust biochemical measures but limited power for secondary outcomes.

Study Details

PMID:35875694
Participants:53
Impact:Intervention delta +12.5 nmol/L vs placebo delta −13.4 nmol/L at Dec (p<0.001); sustained higher 25(OH)D and fewer critically low values (p<0.001 at follow-ups)
Trust score:4/5

1000 IU/day vitamin D3 for one month increased 25(OH)D and lowered PTH but did not improve measured physical performance.

Trust comment: Randomized trial with objective biochemical and performance measures and good completion (n=117); short duration (1 month) and lack of placebo reduce strength of conclusions.

Study Details

PMID:37735799
Participants:117
Impact:+8.14 ng/mL (18.85 → 26.98; ≈+43%)
Trust score:4/5

Randomized placebo-controlled 16-week trial in vitamin D-deficient overweight/obese adults: cholecalciferol raised 25(OH)D and lowered iPTH but did not change serum calcium, phosphate, iFGF-23, or whole-body BMD.

Trust comment: Randomized placebo-controlled trial with objective biochemical and BMD endpoints; moderate sample size and 16-week duration limits long-term inference.

Study Details

PMID:30367939
Participants:54
Impact:increased with cholecalciferol
Trust score:4/5

Double-blind RCT in healthy young adults (33 enrolled, 30 completed) randomized to 600, 4000 or 10,000 IU/day vitamin D3 for 24 weeks assessing serum 25(OH)D, PTH, calcium and genome-wide gene expression in white blood cells.

Trust comment: Well-controlled double-blind trial with clear biochemical and genomic outcomes but limited by small sample size.

Study Details

PMID:31776371
Participants:30
Impact:+7 ng/mL (600 IU/d), +18 ng/mL (4000 IU/d), +61 ng/mL (10,000 IU/d) over 24 weeks
Trust score:4/5

In osteoporosis patients given denosumab plus vitamin D and calcium supplements, supplementation raised 25(OH)D to sufficiency and denosumab increased BMD and reduced vertebral fracture risk versus placebo irrespective of baseline vitamin D status.

Trust comment: Large randomized, double-blind, placebo-controlled trial (prespecified subanalysis); high-quality evidence though subanalysis limits full certainty.

Study Details

PMID:32671481
Participants:956
Impact:Increased to >30 ng/mL (sufficient) at 24 months with supplementation
Trust score:4/5

serum klotho level

1 evidences

In older adults in a 3-year randomized trial (Ca + vitamin D vs placebo), serum klotho was inversely related to waist circumference in women but Ca+D treatment did not change klotho levels or musculoskeletal outcomes.

Trust comment: Randomized, double-blind placebo-controlled trial with good sample size and well-described measures, though this is a secondary analysis of archived samples.

Study Details

PMID:40592050
Participants:387
Impact:no significant difference (Ca + vitamin D vs placebo)
Trust score:4/5

waist circumference (women)

1 evidences

In older adults in a 3-year randomized trial (Ca + vitamin D vs placebo), serum klotho was inversely related to waist circumference in women but Ca+D treatment did not change klotho levels or musculoskeletal outcomes.

Trust comment: Randomized, double-blind placebo-controlled trial with good sample size and well-described measures, though this is a secondary analysis of archived samples.

Study Details

PMID:40592050
Participants:387
Impact:inverse association with serum klotho (β = −0.006847, p = 0.01)
Trust score:4/5

falls incidence / musculoskeletal measures

1 evidences

In older adults in a 3-year randomized trial (Ca + vitamin D vs placebo), serum klotho was inversely related to waist circumference in women but Ca+D treatment did not change klotho levels or musculoskeletal outcomes.

Trust comment: Randomized, double-blind placebo-controlled trial with good sample size and well-described measures, though this is a secondary analysis of archived samples.

Study Details

PMID:40592050
Participants:387
Impact:no significant association with serum klotho
Trust score:4/5

liver steatosis (CAP)

1 evidences

In a randomized trial comparing sodium butyrate and calcium butyrate for MASLD, calcium butyrate did not change liver steatosis overall but significantly reduced fecal calprotectin (marker of gut inflammation); sodium butyrate reduced TMAO.

Trust comment: Randomized clinical trial with microbiome and biomarker analyses and clear reporting, though treatment duration was relatively short (12 weeks) for steatosis outcomes.

Study Details

PMID:40565024
Participants:177
Impact:no significant change (calcium butyrate vs baseline)
Trust score:4/5

fecal calprotectin

1 evidences

In a randomized trial comparing sodium butyrate and calcium butyrate for MASLD, calcium butyrate did not change liver steatosis overall but significantly reduced fecal calprotectin (marker of gut inflammation); sodium butyrate reduced TMAO.

Trust comment: Randomized clinical trial with microbiome and biomarker analyses and clear reporting, though treatment duration was relatively short (12 weeks) for steatosis outcomes.

Study Details

PMID:40565024
Participants:177
Impact:decreased (calcium butyrate; significant interaction p = 0.031)
Trust score:4/5

dentin hypersensitivity pain (Biomin F)

1 evidences

In a 6-month double-blind RCT comparing NaF varnish, two toothpastes (one containing bioactive glass/calcium-phosphate) and a metal-containing product, all reduced dentin hypersensitivity and improved oral health–related quality of life; Ca-containing bioactive glass toothpaste (Biomin F) was effective over time.

Trust comment: Double-blind randomized clinical trial with objective and patient-reported outcomes, though sample size is modest.

Study Details

PMID:40550352
Participants:51
Impact:reduced over time (effective at 3–6 months)
Trust score:4/5

oral health-related quality of life

1 evidences

In a 6-month double-blind RCT comparing NaF varnish, two toothpastes (one containing bioactive glass/calcium-phosphate) and a metal-containing product, all reduced dentin hypersensitivity and improved oral health–related quality of life; Ca-containing bioactive glass toothpaste (Biomin F) was effective over time.

Trust comment: Double-blind randomized clinical trial with objective and patient-reported outcomes, though sample size is modest.

Study Details

PMID:40550352
Participants:51
Impact:improved (all products; low magnitude)
Trust score:4/5

uterine tone (verbal numeric rating)

1 evidences

Randomized, placebo-controlled trial in cesarean deliveries: IV calcium gluconate (1 g) did not improve obstetrician-assessed uterine tone but reduced blood loss and need for additional uterotonics.

Trust comment: Large, randomized, placebo-controlled, blinded trial with registered protocol and clinically relevant endpoints.

Study Details

PMID:40493979
Participants:367
Impact:no significant improvement (mean change P=0.11)
Trust score:5/5

postpartum blood loss

1 evidences

Randomized, placebo-controlled trial in cesarean deliveries: IV calcium gluconate (1 g) did not improve obstetrician-assessed uterine tone but reduced blood loss and need for additional uterotonics.

Trust comment: Large, randomized, placebo-controlled, blinded trial with registered protocol and clinically relevant endpoints.

Study Details

PMID:40493979
Participants:367
Impact:-55.6 mL (526.0 ±155.2 vs 581.5 ±148.9 mL; P=0.001)
Trust score:5/5

additional uterotonic administration

1 evidences

Randomized, placebo-controlled trial in cesarean deliveries: IV calcium gluconate (1 g) did not improve obstetrician-assessed uterine tone but reduced blood loss and need for additional uterotonics.

Trust comment: Large, randomized, placebo-controlled, blinded trial with registered protocol and clinically relevant endpoints.

Study Details

PMID:40493979
Participants:367
Impact:reduced (21.7% vs 42.39%; RR 0.51; P=0.001)
Trust score:5/5

adverse events

3 evidences

Randomized double-blind trial in 217 adults with AF/AFL found IV calcium chloride pretreatment (90 or 180 mg) prevented diltiazem-induced hypotension, raising SBP at 5–15 min without increasing adverse events.

Trust comment: Randomized, double-blind, placebo‑controlled trial (n=217) directly testing IV calcium intervention with clinically relevant endpoints and safety assessment.

Study Details

PMID:39577214
Participants:217
Impact:no significant increase in adverse events with calcium pretreatment
Trust score:5/5

Pre-bleaching application of a calcium phosphate–based desensitizer markedly reduced bleaching-associated sensitivity during treatment and up to one week, without affecting whitening.

Trust comment: Randomized, double-blind, placebo-controlled crossover trial (n=50) with clear clinical outcomes and low risk of bias.

Study Details

PMID:29520944
Participants:50
Impact:no adverse effects reported related to desensitizer
Trust score:4/5

Hydroxyapatite deposition by PJD reduced dentin hypersensitivity similarly to a calcium‑phosphate desensitizer over 12 weeks; non‑inferiority was not statistically demonstrated.

Trust comment: Randomized, split‑mouth RCT with blinded evaluators but small sample (n=34) and single‑blind design limits power.

Study Details

PMID:37759198
Participants:34
Impact:4 patients had mild AEs (stomatitis/gingivitis); no severe AEs or device malfunctions reported
Trust score:3/5

preeclampsia incidence

2 evidences

Two large randomized trials (India and Tanzania) compared 500 mg vs 1500 mg daily calcium in pregnancy; 500 mg was noninferior to 1500 mg for preeclampsia overall.

Trust comment: Two large, double-blind, randomized, well-powered trials with high adherence and low loss to follow-up support high trustworthiness.

Study Details

PMID:38197817
Participants:22000
Impact:India: 3.0% (500 mg) vs 3.6% (1500 mg) (−0.6 percentage points); Tanzania: 3.0% vs 2.7% (+0.3 percentage points); overall no material difference (500 mg noninferior)
Trust score:5/5

In pregnant women with pre‑existing diabetes, an adapted DASH diet vs standard diet produced no difference in preeclampsia incidence; both groups improved glycated hemoglobin and some oxidative markers improved with DASH; calcium supplements (500 mg/day) were prescribed to women with low intake but not analyzed separately.

Trust comment: Randomized controlled dietary trial in humans with clear reporting; calcium carbonate was given to deficient participants but calcium-specific effects were not isolated in analyses.

Study Details

PMID:37457679
Participants:68
Impact:No significant difference between groups (overall incidence 17.7%; SDG 22.9% vs DDG 12.1%, p=0.25)
Trust score:3/5

serum magnesium

1 evidences

Double-blind randomized crossover (29 analysed) in people with type 2 diabetes: 6 weeks of inulin-type fructans (16 g/day) did not change serum calcium, magnesium, vitamin D, or bone turnover markers.

Trust comment: Randomized, double-blind crossover with accredited assays but small sample and short duration limit power for bone outcomes.

Study Details

PMID:40471453
Participants:29
Impact:No significant change after 6 weeks (prebiotics vs control)
Trust score:4/5

Bone turnover markers (P1NP, CTX-1)

1 evidences

Double-blind randomized crossover (29 analysed) in people with type 2 diabetes: 6 weeks of inulin-type fructans (16 g/day) did not change serum calcium, magnesium, vitamin D, or bone turnover markers.

Trust comment: Randomized, double-blind crossover with accredited assays but small sample and short duration limit power for bone outcomes.

Study Details

PMID:40471453
Participants:29
Impact:No significant change after 6 weeks
Trust score:4/5

Postoperative pain intensity

4 evidences

Triple-blind RCT in 60 patients with symptomatic apical periodontitis: Jasminum-based TiO2 nano-reinforced calcium hydroxide intracanal medicament produced greater and faster reduction in postoperative pain over 96 hours than conventional calcium hydroxide.

Trust comment: Triple-blind randomized trial with 60 patients testing a calcium-containing dental medicament; modest sample but randomized and blinded.

Study Details

PMID:40466913
Participants:60
Impact:Nano-reinforced Ca(OH)2 group reported consistently lower pain scores and greater reductions at all assessed time points (up to 96 h) vs conventional Ca(OH)2
Trust score:4/5

Partial pulpotomy using two calcium‑silicate materials (MTA Angelus vs Total Fill BC) showed similar long‑term success; Total Fill BC was associated with higher postoperative pain intensity.

Trust comment: Double‑blind randomized trial with median 2‑year follow-up and multivariable analyses; directly evaluates calcium‑containing silicate dental materials.

Study Details

PMID:37452640
Participants:123
Impact:Higher odds of greater postoperative pain with Total Fill BC vs MTA Angelus (adjusted OR 4.73, 95% CI 2.31–9.66, p<0.001)
Trust score:4/5

Randomized trial in single-rooted premolars found no difference in postoperative pain between epoxy-resin and calcium silicate sealers or with/without sonic activation; low overall pain.

Trust comment: Well-powered randomized clinical trial with sample size calculation and blinded patients; appropriate methods and reporting.

Study Details

PMID:39443924
Participants:72
Impact:No significant difference between sealers or activation methods (p>0.05); low mean VAS at 24h ~1.1–1.8 across groups
Trust score:4/5

Randomized single-blind trial comparing two calcium‑silicate dental pulp capping materials (TheraCal LC vs iRoot BP Plus) in pulpitis permanent teeth; both achieved similar 1‑year success but TheraCal LC had shorter procedure time and less early postoperative pain.

Trust comment: Well‑conducted randomized clinical trial with 1‑year follow‑up and objective outcomes, moderate sample size; single‑blind and some operator unblinding are limitations.

Study Details

PMID:38701294
Participants:104
Impact:TheraCal LC −1.1 points on 0–9 scale (1.5→0.4) vs iRoot BP Plus
Trust score:4/5

olfactory threshold (T)

1 evidences

Double-blind placebo-controlled trial (n=66) of topical glutamate diacetate (calcium chelator) vs saline in post-COVID chronic olfactory dysfunction: GLD reduced nasal calcium and produced small improvements in olfactory test scores, though changes did not reach clinical significance.

Trust comment: Double-blind RCT directly modulating nasal calcium with objective olfactory testing, but effects were small and judged not clinically significant.

Study Details

PMID:40462619
Participants:66
Impact:+0.78 ± 0.15 (month 6) in GLD group vs smaller gain in saline
Trust score:3/5

olfactory discrimination (D)

1 evidences

Double-blind placebo-controlled trial (n=66) of topical glutamate diacetate (calcium chelator) vs saline in post-COVID chronic olfactory dysfunction: GLD reduced nasal calcium and produced small improvements in olfactory test scores, though changes did not reach clinical significance.

Trust comment: Double-blind RCT directly modulating nasal calcium with objective olfactory testing, but effects were small and judged not clinically significant.

Study Details

PMID:40462619
Participants:66
Impact:+0.72 ± 0.15 (month 6) in GLD group vs smaller gain in saline
Trust score:3/5

nasal calcium level

1 evidences

Double-blind placebo-controlled trial (n=66) of topical glutamate diacetate (calcium chelator) vs saline in post-COVID chronic olfactory dysfunction: GLD reduced nasal calcium and produced small improvements in olfactory test scores, though changes did not reach clinical significance.

Trust comment: Double-blind RCT directly modulating nasal calcium with objective olfactory testing, but effects were small and judged not clinically significant.

Study Details

PMID:40462619
Participants:66
Impact:Significant reduction with GLD (reported post-treatment values: GLD 7.36 ± 1.21 mM vs saline 2.49 ± 0.51 mM; authors note reduction associated with olfactory improvement)
Trust score:3/5

pulp fibrosis (histology score)

1 evidences

Randomized clinical/histological trial in 40 children (80 treated primary molars) comparing ACTIVA BioACTIVE vs MTA for pulpotomy: ACTIVA induced milder vascular changes, stronger fibrotic response, greater fibronectin and osteopontin expression, and more pulp-stone formation at 15–30 days.

Trust comment: Randomized clinical histologic study with objective immunohistochemistry, moderate sample of teeth/patients but short follow-up limits clinical outcome inference.

Study Details

PMID:40457274
Participants:40
Impact:ACTIVA mean 2.30 vs MTA mean 1.50 (p < 0.001); greater fibrosis with ACTIVA at 30 days
Trust score:4/5

fibronectin expression

1 evidences

Randomized clinical/histological trial in 40 children (80 treated primary molars) comparing ACTIVA BioACTIVE vs MTA for pulpotomy: ACTIVA induced milder vascular changes, stronger fibrotic response, greater fibronectin and osteopontin expression, and more pulp-stone formation at 15–30 days.

Trust comment: Randomized clinical histologic study with objective immunohistochemistry, moderate sample of teeth/patients but short follow-up limits clinical outcome inference.

Study Details

PMID:40457274
Participants:40
Impact:ACTIVA % change 26.01% vs MTA 9.11% (15→30 days); significant between groups (P≤0.03)
Trust score:4/5

osteopontin (OPN) expression

1 evidences

Randomized clinical/histological trial in 40 children (80 treated primary molars) comparing ACTIVA BioACTIVE vs MTA for pulpotomy: ACTIVA induced milder vascular changes, stronger fibrotic response, greater fibronectin and osteopontin expression, and more pulp-stone formation at 15–30 days.

Trust comment: Randomized clinical histologic study with objective immunohistochemistry, moderate sample of teeth/patients but short follow-up limits clinical outcome inference.

Study Details

PMID:40457274
Participants:40
Impact:ACTIVA increased OPN from 50.42 → 92.56 (15→30 days); % change 83.58% vs MTA 18.57% (significant)
Trust score:4/5

Morphometric vertebral fracture (physical frailty)

1 evidences

In older women with frailty, sequential teriparatide→alendronate reduced vertebral fracture risk in physically frail patients; higher serum calcium was associated with lower rates of stopping treatment.

Trust comment: Large randomized trial subgroup analysis with robust methods; calcium appears as an observational predictor rather than an assigned intervention.

Study Details

PMID:40425867
Participants:718
Impact:Rate ratio 0.50 (TPTD vs ALN); 50% relative reduction (95% CI 0.37–0.68; P<0.01)
Trust score:4/5

Adherence-related treatment discontinuation associated with serum calcium

1 evidences

In older women with frailty, sequential teriparatide→alendronate reduced vertebral fracture risk in physically frail patients; higher serum calcium was associated with lower rates of stopping treatment.

Trust comment: Large randomized trial subgroup analysis with robust methods; calcium appears as an observational predictor rather than an assigned intervention.

Study Details

PMID:40425867
Participants:718
Impact:Higher serum Ca associated with lower discontinuation (OR 0.54 per 1 mg/dL increase; 95% CI 0.30–0.96; P=0.03)
Trust score:4/5

Dentin bridge formation

5 evidences

Selective removal to soft dentin (with or without calcium silicate) had higher 5-year tooth vitality success than selective removal to firm dentin; calcium silicate improved dentin bridge formation in deeper cavities.

Trust comment: Randomized controlled trial with 5-year follow-up; well-defined clinical outcomes though sample groups uneven and some subgroup analyses.

Study Details

PMID:39702606
Participants:134
Impact:improved with calcium silicate in deeper cavities (increased healing)
Trust score:4/5

In children needing indirect pulp therapy, calcium hydroxide performed similarly to other agents for clinical and radiographic success at 12 months, with moderate dentin bridge formation.

Trust comment: Randomized controlled trial but small sample (45 children, 60 teeth); outcomes clinically meaningful though limited by sample size and single follow-up duration.

Study Details

PMID:39798105
Participants:45
Impact:mean 0.50 mm in Ca(OH)2 group
Trust score:3/5

Combining Er:YAG laser with a calcium-silicate material (Biodentine) improved dentin bridge formation and reduced postoperative sensitivity compared with other approaches.

Trust comment: Small randomized trial (n=42) evaluating a calcium-containing dental material (Biodentine); limited sample but randomized with 12-month follow-up.

Study Details

PMID:40407835
Participants:42
Impact:Increased with Er:YAG + Biodentine (statistically significant, P=0.01)
Trust score:3/5

In a split-mouth randomized trial in children, WMTA mixed with 2.25% NaOCl gel improved short‑term odontoblastic integrity but showed less complete dentin bridge formation and more early pulp calcification compared with WMTA mixed with distilled water.

Trust comment: Triple‑blinded, randomized split‑mouth histologic trial with clearly reported outcomes but limited by small sample size and relatively short follow-up.

Study Details

PMID:39733128
Participants:24
Impact:more complete dentin bridge formation with WMTA + distilled water vs WMTA + NaOCl gel at 90 days (control favored)
Trust score:4/5

In 7–9-year-old children with pulp exposures, Biodentine and MTA showed 100% clinical and radiographic success at 6 and 12 months and similar dentin bridge formation.

Trust comment: Split-mouth clinical study with objective outcomes but small sample size and short follow-up, limiting generalizability.

Study Details

PMID:28216271
Participants:29
Impact:evident at 6 and 12 months for both groups (no difference)
Trust score:3/5

postoperative sensitivity

1 evidences

Combining Er:YAG laser with a calcium-silicate material (Biodentine) improved dentin bridge formation and reduced postoperative sensitivity compared with other approaches.

Trust comment: Small randomized trial (n=42) evaluating a calcium-containing dental material (Biodentine); limited sample but randomized with 12-month follow-up.

Study Details

PMID:40407835
Participants:42
Impact:Reduced with Er:YAG + Biodentine (statistically significant, P=0.03)
Trust score:3/5

Overall clinical/radiographic success

1 evidences

Combining Er:YAG laser with a calcium-silicate material (Biodentine) improved dentin bridge formation and reduced postoperative sensitivity compared with other approaches.

Trust comment: Small randomized trial (n=42) evaluating a calcium-containing dental material (Biodentine); limited sample but randomized with 12-month follow-up.

Study Details

PMID:40407835
Participants:42
Impact:Higher success rate for Er:YAG + Biodentine (statistically significant vs some comparators)
Trust score:3/5

New bone fraction (6 months)

1 evidences

Adding rhBMP-2 to a biphasic calcium phosphate graft markedly increased new bone formation and accelerated graft replacement in extraction sockets.

Trust comment: Randomized controlled histological trial (n=30) directly testing a calcium-phosphate graft material; small sample but randomized with objective histomorphometry outcomes.

Study Details

PMID:40388262
Participants:30
Impact:67.42% (rhBMP-2+BCP) vs 16.55% (BCP alone); ≈+50.9 percentage points (P<0.05)
Trust score:4/5

New bone fraction (9 months)

1 evidences

Adding rhBMP-2 to a biphasic calcium phosphate graft markedly increased new bone formation and accelerated graft replacement in extraction sockets.

Trust comment: Randomized controlled histological trial (n=30) directly testing a calcium-phosphate graft material; small sample but randomized with objective histomorphometry outcomes.

Study Details

PMID:40388262
Participants:30
Impact:93.6% (rhBMP-2+BCP) vs 23.35% (BCP alone); ≈+70.3 percentage points (P<0.05)
Trust score:4/5

Residual graft fraction (3 months)

1 evidences

Adding rhBMP-2 to a biphasic calcium phosphate graft markedly increased new bone formation and accelerated graft replacement in extraction sockets.

Trust comment: Randomized controlled histological trial (n=30) directly testing a calcium-phosphate graft material; small sample but randomized with objective histomorphometry outcomes.

Study Details

PMID:40388262
Participants:30
Impact:3.8% (rhBMP-2) vs 37.85% (control); markedly reduced residual graft with rhBMP-2
Trust score:4/5

clinical/radiographic success

1 evidences

76 primary molar perforations repaired with MTA or premixed bioceramic; premixed bioceramic showed a trend to better sealing and superior clinical/radiographic performance at 6 and 12 months.

Trust comment: Randomized clinical component with moderate sample size (76 teeth); results show trends and some statistically significant longer‑term differences.

Study Details

PMID:33483869
Participants:76
Impact:premixed bioceramic > MTA at 6 and 12 months (inequivalent success rates)
Trust score:3/5

mineral loss (ΔF average / ΔF max)

1 evidences

Split-mouth RCT: two-step high-concentration ammonium fluoride + nano-CaF2 (contains calcium fluoride) produced superior remineralization and higher lesion regression vs single-step ammonium fluoride varnish over 12 months.

Trust comment: Human randomized split-mouth trial testing a remineralization product that includes nano calcium fluoride; randomized design but modest sample size (21 participants, 56 lesions evaluable).

Study Details

PMID:40335196
Participants:21
Impact:significant decrease in test group at 6 and 12 months vs baseline (P=0.001); greater reduction vs control at 6 months (intergroup P=0.05)
Trust score:4/5

lesion size and volume (WS area, ΔQ)

1 evidences

Split-mouth RCT: two-step high-concentration ammonium fluoride + nano-CaF2 (contains calcium fluoride) produced superior remineralization and higher lesion regression vs single-step ammonium fluoride varnish over 12 months.

Trust comment: Human randomized split-mouth trial testing a remineralization product that includes nano calcium fluoride; randomized design but modest sample size (21 participants, 56 lesions evaluable).

Study Details

PMID:40335196
Participants:21
Impact:significant reduction in test group at 6 and 12 months vs baseline (P=0.001); no significant change in control group
Trust score:4/5

qualitative lesion regression rate

1 evidences

Split-mouth RCT: two-step high-concentration ammonium fluoride + nano-CaF2 (contains calcium fluoride) produced superior remineralization and higher lesion regression vs single-step ammonium fluoride varnish over 12 months.

Trust comment: Human randomized split-mouth trial testing a remineralization product that includes nano calcium fluoride; randomized design but modest sample size (21 participants, 56 lesions evaluable).

Study Details

PMID:40335196
Participants:21
Impact:higher regression odds in test group vs control at 6 and 12 months (P<0.05)
Trust score:4/5

Calcium intake (mg/day)

1 evidences

An 8-week education program based on Pender’s model increased pregnant women's calcium-rich food consumption and improved related knowledge and self-efficacy.

Trust comment: Randomized, semi-experimental study with validated questionnaires but small sample, self-reported dietary records, and short follow-up limit certainty.

Study Details

PMID:40297037
Participants:70
Impact:Post-intervention means: intervention 422.5 vs control 224.7 mg/day; adjusted difference +197.8 mg/day (p<0.001)
Trust score:3/5

Knowledge score

1 evidences

An 8-week education program based on Pender’s model increased pregnant women's calcium-rich food consumption and improved related knowledge and self-efficacy.

Trust comment: Randomized, semi-experimental study with validated questionnaires but small sample, self-reported dietary records, and short follow-up limit certainty.

Study Details

PMID:40297037
Participants:70
Impact:Intervention increased from 2.6 to 4.08 (+1.48 points; p=0.001)
Trust score:3/5

Perceived self-efficacy

1 evidences

An 8-week education program based on Pender’s model increased pregnant women's calcium-rich food consumption and improved related knowledge and self-efficacy.

Trust comment: Randomized, semi-experimental study with validated questionnaires but small sample, self-reported dietary records, and short follow-up limit certainty.

Study Details

PMID:40297037
Participants:70
Impact:Intervention increased from 13.2 to 16.9 (+3.7 points; p=0.001)
Trust score:3/5

Total clinical efficacy rate

1 evidences

Use of an advanced hemodialysis system in elderly CKD patients improved inflammatory markers, renal function metrics, and calcium–phosphorus homeostasis compared with standard therapy.

Trust comment: Randomized study in humans but excerpt lacks detailed numeric reporting of calcium-related changes and full methods.

Study Details

PMID:40296765
Participants:84
Impact:Intervention 85.71% vs control 64.29%
Trust score:3/5

inflammatory biomarkers

1 evidences

Use of an advanced hemodialysis system in elderly CKD patients improved inflammatory markers, renal function metrics, and calcium–phosphorus homeostasis compared with standard therapy.

Trust comment: Randomized study in humans but excerpt lacks detailed numeric reporting of calcium-related changes and full methods.

Study Details

PMID:40296765
Participants:84
Impact:Reported reductions in TNF-α, IL-6, IL-1, hs-CRP in the intervention group (no absolute magnitudes provided)
Trust score:3/5

Calcium–phosphorus homeostasis

1 evidences

Use of an advanced hemodialysis system in elderly CKD patients improved inflammatory markers, renal function metrics, and calcium–phosphorus homeostasis compared with standard therapy.

Trust comment: Randomized study in humans but excerpt lacks detailed numeric reporting of calcium-related changes and full methods.

Study Details

PMID:40296765
Participants:84
Impact:Reported improvement in serum calcium, phosphorus and Ca×P balance (no magnitudes provided)
Trust score:3/5

clinical/radiographic success rate

2 evidences

Randomized comparison of acemannan vs calcium hydroxide for direct pulp capping in primary molars (6-month outcomes): similar clinical/radiographic success but acemannan showed better histology.

Trust comment: Randomized clinical study in children with modest sample size and short-term follow-up; relevant because calcium hydroxide (a calcium compound) was the comparator but not a nutrient intervention.

Study Details

PMID:26264630
Participants:37
Impact:Acemannan 72.73% vs calcium hydroxide 70.0% at 6 months (similar success rates)
Trust score:3/5

Partial pulpotomy in immature permanent molars using Biodentine, MTA, or calcium hydroxide had high overall success (87%); Biodentine and MTA showed higher (but not statistically significant) success than calcium hydroxide; root lengths increased at 6 months.

Trust comment: Randomized trial on 50 patients with clear clinical/radiographic endpoints but modest sample size limits precision.

Study Details

PMID:34657018
Participants:50
Impact:Overall success 87% across groups
Trust score:3/5

ovarian morphology improvement

1 evidences

Multicenter randomized trial of vitamin D3 in PCOS; dietary calcium citrate (2×200 mg/day) was provided to participants with low intake — calcium alone for 12 weeks produced minimal changes but yielded partial ovarian‑morphology improvement in a subset.

Trust comment: High‑quality multicenter double‑blind RCT (ITT n=84); calcium was co‑supplemented (calcium citrate) during lead‑in but calcium‑specific effects were limited and mostly non‑significant.

Study Details

PMID:40219003
Participants:84
Impact:partial improvement in 18.2% after 12 weeks of calcium-only lead‑in
Trust score:4/5

cycle length

1 evidences

Multicenter randomized trial of vitamin D3 in PCOS; dietary calcium citrate (2×200 mg/day) was provided to participants with low intake — calcium alone for 12 weeks produced minimal changes but yielded partial ovarian‑morphology improvement in a subset.

Trust comment: High‑quality multicenter double‑blind RCT (ITT n=84); calcium was co‑supplemented (calcium citrate) during lead‑in but calcium‑specific effects were limited and mostly non‑significant.

Study Details

PMID:40219003
Participants:84
Impact:no significant change during calcium-only lead‑in
Trust score:4/5

Total serum calcium (T-Calcium)

1 evidences

120 premenopausal women with osteoporosis did 16 weeks of HIIT, vitamin D, both, or control; bone density, vitamin D, and bone markers were measured.

Trust comment: Well-conducted 4-arm randomized trial (n=120) with objective DEXA and serum measures; calcium reported as a measured biomarker though calcium supplementation was not the intervention.

Study Details

PMID:40259289
Participants:120
Impact:HITT MD -15.7 (SD 0.915); VD MD -6.4 (SD 0.895); HIIT+VD MD -24.4 (SD 0.932); p=0.001 (Table 3)
Trust score:4/5

25‑hydroxyvitamin D (25OHD)

1 evidences

120 premenopausal women with osteoporosis did 16 weeks of HIIT, vitamin D, both, or control; bone density, vitamin D, and bone markers were measured.

Trust comment: Well-conducted 4-arm randomized trial (n=120) with objective DEXA and serum measures; calcium reported as a measured biomarker though calcium supplementation was not the intervention.

Study Details

PMID:40259289
Participants:120
Impact:HITT MD -13.8 (SD 2.95) p=0.010; VD MD -16.9 (SD 3.42) p=0.010; HIIT+VD MD -3.1 (SD 3.24) p=0.001 (Table 2)
Trust score:4/5

Hip and lumbar spine BMD (T‑score)

1 evidences

120 premenopausal women with osteoporosis did 16 weeks of HIIT, vitamin D, both, or control; bone density, vitamin D, and bone markers were measured.

Trust comment: Well-conducted 4-arm randomized trial (n=120) with objective DEXA and serum measures; calcium reported as a measured biomarker though calcium supplementation was not the intervention.

Study Details

PMID:40259289
Participants:120
Impact:Right hip: HITT MD -0.340 (SD 0.085) p=0.010; VD MD -0.330 (SD 0.075) p=0.010; HIIT+VD MD -0.010 (SD 0.064) p=0.001 (Table 2)
Trust score:4/5

Tactile pain reduction

1 evidences

Triple-blind randomized trial comparing PRG Barrier Coat, Embrace varnish (xylitol‑coated calcium/phosphate), and Duraphat varnish for dentin hypersensitivity and tubule occlusion.

Trust comment: Triple‑blind randomized clinical trial with objective SEM quantification and consistent clinical pain measures; directly assesses calcium-containing varnish effects (Embrace/Duraphat) on dentin occlusion.

Study Details

PMID:40251520
Participants:63
Impact:+94.9% mean reduction (±6.1%) for PRG Barrier Coat (highest) vs Embrace 64.3% (±8.1%) and Duraphat 45.4% (±6.6%) (Table 8)
Trust score:5/5

Thermal pain reduction

1 evidences

Triple-blind randomized trial comparing PRG Barrier Coat, Embrace varnish (xylitol‑coated calcium/phosphate), and Duraphat varnish for dentin hypersensitivity and tubule occlusion.

Trust comment: Triple‑blind randomized clinical trial with objective SEM quantification and consistent clinical pain measures; directly assesses calcium-containing varnish effects (Embrace/Duraphat) on dentin occlusion.

Study Details

PMID:40251520
Participants:63
Impact:+93.5% mean reduction (±5.9%) for PRG vs Embrace 60.4% (±6.4%) and Duraphat 40.3% (±5.0%) (Table 8)
Trust score:5/5

Patent dentinal tubule surface area

1 evidences

Triple-blind randomized trial comparing PRG Barrier Coat, Embrace varnish (xylitol‑coated calcium/phosphate), and Duraphat varnish for dentin hypersensitivity and tubule occlusion.

Trust comment: Triple‑blind randomized clinical trial with objective SEM quantification and consistent clinical pain measures; directly assesses calcium-containing varnish effects (Embrace/Duraphat) on dentin occlusion.

Study Details

PMID:40251520
Participants:63
Impact:PRG reduced mean patent area from 21.0% (±2.7) to 0.6% (±0.5) — mean change 96.9% (±2.5); Embrace 26.2%→8.0% (change 69.7%±5.7); Duraphat 23.2%→11.9% (change 48.3%±7.6) (Table 9–10)
Trust score:5/5

Clinical success rate (12 months)

2 evidences

Randomized trial (n=108) comparing direct pulp capping with MTA alone versus PRF placed before MTA; clinical and CBCT radiographic outcomes at 6 and 12 months.

Trust comment: Large randomized clinical trial (n=108) with blinded assessment and CBCT confirmation; investigates calcium‑containing MTA material's clinical/radiographic effects (indirect calcium relevance).

Study Details

PMID:40234535
Participants:108
Impact:Both groups 92.59% success at 12 months (50/54 cases in each group), p=1.0
Trust score:4/5

Randomized trial in children comparing three cavity liners (calcium hydroxide, MTA, Portland cement) after selective caries removal; all liners performed similarly over 12 months.

Trust comment: Randomized clinical trial but small sample size (n=36 molars, 34 with 12-month follow-up), limiting precision and generalisability.

Study Details

PMID:31166415
Participants:34
Impact:Overall 94.11%, no significant differences between CHC, MTA, PCZ groups
Trust score:3/5

Dentin bridge formation (CBCT, 12 months)

1 evidences

Randomized trial (n=108) comparing direct pulp capping with MTA alone versus PRF placed before MTA; clinical and CBCT radiographic outcomes at 6 and 12 months.

Trust comment: Large randomized clinical trial (n=108) with blinded assessment and CBCT confirmation; investigates calcium‑containing MTA material's clinical/radiographic effects (indirect calcium relevance).

Study Details

PMID:40234535
Participants:108
Impact:PRF+MTA: 92.59% (50/54) vs MTA alone: 48.15% (26/54); p<0.001
Trust score:4/5

Serum calcium (hospital day 2)

1 evidences

Multicenter randomized pilot trial (n=105) testing IV calcium and magnesium correction vs placebo in acute ICH to assess safety, serum level correction, hematoma expansion, and 30‑day outcome.

Trust comment: Randomized multicenter pilot (n=105) with blinded volumetric CT endpoints and daily serum monitoring; underpowered pilot but demonstrates safe correction of serum calcium/mag with no clear effect on hematoma expansion.

Study Details

PMID:40228559
Participants:105
Impact:Study group 9.29±0.61 mg/dL vs control 8.25±0.67 mg/dL, p<0.001 (Table 4)
Trust score:4/5

Serum magnesium (hospital day 2)

1 evidences

Multicenter randomized pilot trial (n=105) testing IV calcium and magnesium correction vs placebo in acute ICH to assess safety, serum level correction, hematoma expansion, and 30‑day outcome.

Trust comment: Randomized multicenter pilot (n=105) with blinded volumetric CT endpoints and daily serum monitoring; underpowered pilot but demonstrates safe correction of serum calcium/mag with no clear effect on hematoma expansion.

Study Details

PMID:40228559
Participants:105
Impact:Study group 2.20±0.37 mg/dL vs control 1.93±0.31 mg/dL, p<0.001 (Table 4)
Trust score:4/5

ICH hematoma volume (days 2–3)

1 evidences

Multicenter randomized pilot trial (n=105) testing IV calcium and magnesium correction vs placebo in acute ICH to assess safety, serum level correction, hematoma expansion, and 30‑day outcome.

Trust comment: Randomized multicenter pilot (n=105) with blinded volumetric CT endpoints and daily serum monitoring; underpowered pilot but demonstrates safe correction of serum calcium/mag with no clear effect on hematoma expansion.

Study Details

PMID:40228559
Participants:105
Impact:No significant difference in ICH volume: HD2 24.8±15.5 vs 23.4±12.5 cc (p=0.613); HD3 23.9±13.2 vs 25.0±14.3 cc (p=0.671) (Table 2)
Trust score:4/5

Mini Nutritional Assessment (MNA) score

1 evidences

RCT (n=70 allocated, 68 completed) of tailored progressive dietary advice plus new complete dentures vs standard care in edentulous elders, assessing nutritional status (MNA) and nutrient intake at 3 months.

Trust comment: Randomized, single‑blind RCT with validated nutritional measures (MNA) and ANCOVA adjustment; modest sample and short (3‑month) follow-up but clinically relevant improvements reported.

Study Details

PMID:40227937
Participants:68
Impact:Intervention mean change +1.08 (SD 1.15); ANCOVA F(1,65)=25.99, p<0.001, partial η²=0.286 (Table 2 & 3)
Trust score:4/5

Body mass index (BMI)

3 evidences

Adding 50 g/day Kashk (high‑protein, calcium‑enriched probiotic yogurt) to a low‑energy diet for 8 weeks improved lipids and reduced body weight and waist in overweight/obese women.

Trust comment: Randomized controlled trial with moderate sample size and short duration; reported significant between-group changes but study is small and authors note need for further trials.

Study Details

PMID:31987116
Participants:70
Impact:Greater reduction vs control (between-group, P=0.018)
Trust score:3/5

RCT (n=70 allocated, 68 completed) of tailored progressive dietary advice plus new complete dentures vs standard care in edentulous elders, assessing nutritional status (MNA) and nutrient intake at 3 months.

Trust comment: Randomized, single‑blind RCT with validated nutritional measures (MNA) and ANCOVA adjustment; modest sample and short (3‑month) follow-up but clinically relevant improvements reported.

Study Details

PMID:40227937
Participants:68
Impact:Intervention group change reported −0.55 (SD 1.01) (paired p=0.003); ANCOVA group effect F(1,65)=4.952, p=0.030, partial η²=0.071 (Table 2 & 3)
Trust score:4/5

In vitamin D–insufficient adults with type 2 diabetes, 8 weeks of calcium plus vitamin D reduced BMI, hip circumference, and systolic blood pressure versus placebo.

Trust comment: Randomized placebo-controlled trial with moderate sample size but short (8-week) duration.

Study Details

PMID:25738212
Participants:118
Impact:Greater reduction in calcium+vitamin D group vs others (p = 0.03)
Trust score:4/5

energy intake

4 evidences

Twelve weeks of a nutrient-dense drink (contains 250 mg calcium/serving) increased energy and micronutrient intake and improved body weight and some muscle mass in older outpatients at risk of malnutrition.

Trust comment: Well-conducted randomized controlled trial with objective measures and good compliance, though industry produced the supplement and the product contained multiple nutrients (not calcium alone).

Study Details

PMID:40154078
Participants:101
Impact:+370 kcal/day (intervention delta) ; between-group difference +336 kcal/d, p<0.001
Trust score:4/5

In this cohort, pregnant women frequently did not meet recommended micronutrient intakes, including calcium, across trimesters.

Trust comment: Multicenter longitudinal FFQ-based analysis with 176 women using validated methods, but relies on self-reported intake and has typical FFQ limitations.

Study Details

PMID:35565911
Participants:176
Impact:below recommended levels across trimesters
Trust score:4/5

Crossover RCT: eating two calcium-fortified cereal bars daily for 3 weeks significantly increased women's dietary calcium intake (~+360 mg/day) without increasing energy intake or body weight.

Trust comment: Checklist: 1) Confirm relevance to Calcium (dietary calcium intervention); 2) extract main outcomes (calcium intake, energy, weight); 3) record participants (completed n=35); 4) rate trust — randomized crossover RCT with good compliance and appropriate dietary assessment but small sample and short duration.

Study Details

PMID:25941810
Participants:35
Impact:no significant change during intervention (no weight gain)
Trust score:4/5

Oral nutritional supplements plus dietary counseling increased energy and micronutrient intakes (including calcium), and improved appetite versus counseling alone in picky-eating children over 90 days.

Trust comment: Randomized, multi-center, double-blind trial with robust dietary assessment and high compliance—relevant indirect evidence about increasing calcium intake via supplements.

Study Details

PMID:37299491
Participants:321
Impact:Mean increase +281.9 kcal (ONS1+DC) and +277.6 kcal (ONS2+DC) vs +130.6 kcal (DC-only) at Day 90
Trust score:4/5

protein intake

5 evidences

Adding walnuts to the diet increased intake of calcium and several fats and raised calories when intake was not calorie-controlled.

Trust comment: Well-powered randomized crossover trial (n=112) with controlled dietary assessment, though not primarily a calcium intervention.

Study Details

PMID:30068215
Participants:112
Impact:increase from baseline +20.0 ± 8.8 g; P < .05
Trust score:4/5

An 8-week protein-rich home meal service increased protein and calcium intake and improved sit-to-stand performance in older adults compared with control.

Trust comment: Randomized controlled trial but small sample (n=67 completers) limits precision; objective nutrient measures and functional test strengthen findings.

Study Details

PMID:33684023
Participants:67
Impact:increase +0.11 g/kg aBW/d (≈+9.4 g/d)
Trust score:3/5

Twelve weeks of a nutrient-dense drink (contains 250 mg calcium/serving) increased energy and micronutrient intake and improved body weight and some muscle mass in older outpatients at risk of malnutrition.

Trust comment: Well-conducted randomized controlled trial with objective measures and good compliance, though industry produced the supplement and the product contained multiple nutrients (not calcium alone).

Study Details

PMID:40154078
Participants:101
Impact:+25.6 g/day (intervention delta); between-group difference +23.9 g/day, p<0.001
Trust score:4/5

Dietary recalls in 12-month-old infants showed generally low nutrient intakes and inadequacy for multiple micronutrients including calcium, with protein intake slightly higher in the intervention arm.

Trust comment: Sub-sample of a cluster randomized trial with validated dietary recall methods (n=282); single 24-h recall limits individual-level precision but group comparisons are robust.

Study Details

PMID:39796565
Participants:282
Impact:+1.6 g/day (intervention vs standard of care; p=0.03)
Trust score:4/5

Post-hoc analysis of an RCT comparing fasting + plant-based diet vs guideline diet in RA patients; both groups had dietary calcium below recommendations, with the guideline (DGE) group having higher calcium intake than the PBD group.

Trust comment: Randomized parent trial but this is a post-hoc nutritional analysis with modest sample size and self-reported food records, limiting certainty of absolute intake estimates.

Study Details

PMID:36839208
Participants:50
Impact:higher in DGE than PBD at week 4 (71.5 vs 50.9 g/day, p=0.003)
Trust score:3/5

calcium intake

7 evidences

Twelve weeks of a nutrient-dense drink (contains 250 mg calcium/serving) increased energy and micronutrient intake and improved body weight and some muscle mass in older outpatients at risk of malnutrition.

Trust comment: Well-conducted randomized controlled trial with objective measures and good compliance, though industry produced the supplement and the product contained multiple nutrients (not calcium alone).

Study Details

PMID:40154078
Participants:101
Impact:+379.7 mg/day (intervention delta), p<0.001
Trust score:4/5

An 8-week online program improved older adults' calcium intake, knowledge, and confidence about bone-health behaviors.

Trust comment: Large randomized trial with behavioral outcomes, though reliance on self-report may limit objective measurement.

Study Details

PMID:26675352
Participants:866
Impact:increased vs control
Trust score:4/5

In this small pilot secondary analysis, patients who reduced sodium intake ≥25% had larger decreases in dietary calcium intake but no adverse changes in overall nutritional status.

Trust comment: Small (n=38), secondary analysis of a pilot trial with measured dietary intakes—provides limited but direct data on calcium intake changes.

Study Details

PMID:28531423
Participants:38
Impact:median change −262 (25th–75th: −585, −9) in ≥25% sodium‑reduction group vs +91 (−114, 210) in <25% group; p=0.01 between groups
Trust score:3/5

Compared diets of 20 HPP patients and 20 matched controls and related calcium/phosphorus intake to symptom frequency.

Trust comment: Cross-sectional matched study with small sample (40) and clear statistical associations but limited causal inference.

Study Details

PMID:32502243
Participants:40
Impact:median intake significantly lower in HPP patients vs controls
Trust score:3/5

Nutrition counseling (medical nutrition therapy) led people living with HIV to increase intake of calcium, vitamin D and other nutrients and to increase exercise over the intervention period.

Trust comment: Randomized trial with moderate sample size showing significant behavioral/nutrient intake changes, but convenience sampling and limited reporting of effect sizes reduce robustness.

Study Details

PMID:33027800
Participants:130
Impact:Increased (statistically significant vs baseline and vs control)
Trust score:3/5

An 8-week protein-rich home meal service increased protein and calcium intake and improved sit-to-stand performance in older adults compared with control.

Trust comment: Randomized controlled trial but small sample (n=67 completers) limits precision; objective nutrient measures and functional test strengthen findings.

Study Details

PMID:33684023
Participants:67
Impact:increase +169.9 mg/d
Trust score:3/5

Adding walnuts to the diet increased intake of calcium and several fats and raised calories when intake was not calorie-controlled.

Trust comment: Well-powered randomized crossover trial (n=112) with controlled dietary assessment, though not primarily a calcium intervention.

Study Details

PMID:30068215
Participants:112
Impact:+230.7 ± 114.2 mg (walnut-included) vs -95.2 ± 117.4 mg (walnut-excluded); P = .05
Trust score:4/5

Body weight

5 evidences

One-year RCT in habitual snackers comparing daily almonds vs biscuits: diet quality improved with almonds but body weight did not change.

Trust comment: Registered 1-year randomized controlled trial (n=136) with objective measures and multiple follow-ups; well conducted though modest sample size.

Study Details

PMID:37156442
Participants:136
Impact:no significant change
Trust score:4/5

12-week randomized trial in Chinese adults at risk of malnutrition: daily oral nutrition supplement increased weight, anthropometric measures, and multiple nutrient intakes.

Trust comment: Randomized controlled trial with adequate power and objective outcomes, but open-label, unblinded, and lacking body-composition measures.

Study Details

PMID:36141627
Participants:82
Impact:+1.381 kg (estimated mean group difference; intervention mean +1.78 kg vs control +0.30 kg, p < 0.001)
Trust score:4/5

Randomized study in obese vitamin‑D‑deficient women: combined high‑dose cholecalciferol plus calcium with a weight‑loss diet produced larger decreases in weight, BMI, waist circumference, body fat, glycemia, PTH and lipids vs controls.

Trust comment: Randomized intervention with reported large effects but small sample (45) and limited methodological detail; risk of bias and confounding possible.

Study Details

PMID:30442233
Participants:45
Impact:Diet + vitamin D3 + calcium group: −10.49 kg vs control (3‑month change)
Trust score:3/5

Twelve weeks of a nutrient-dense drink (contains 250 mg calcium/serving) increased energy and micronutrient intake and improved body weight and some muscle mass in older outpatients at risk of malnutrition.

Trust comment: Well-conducted randomized controlled trial with objective measures and good compliance, though industry produced the supplement and the product contained multiple nutrients (not calcium alone).

Study Details

PMID:40154078
Participants:101
Impact:+1.1 kg (intervention delta); between-group difference 0.9 kg, p=0.021
Trust score:4/5

Among overweight adults on a 24-week calorie-restricted diet, high-dairy (higher calcium) intake did not increase fecal fat excretion or accelerate weight/fat loss versus low-dairy.

Trust comment: Randomized controlled trial with clear endpoints and reported group differences; moderate sample size.

Study Details

PMID:28829923
Participants:80
Impact:HD: -6.6 ± 1.3 kg vs LD: -7.9 ± 1.5 kg (P = 0.73)
Trust score:4/5

Skeletal muscle mass (women)

1 evidences

Twelve weeks of a nutrient-dense drink (contains 250 mg calcium/serving) increased energy and micronutrient intake and improved body weight and some muscle mass in older outpatients at risk of malnutrition.

Trust comment: Well-conducted randomized controlled trial with objective measures and good compliance, though industry produced the supplement and the product contained multiple nutrients (not calcium alone).

Study Details

PMID:40154078
Participants:101
Impact:+3.3 kg in women after 12 weeks, p=0.023 (sex-stratified)
Trust score:4/5

Total bacterial load (Eubacteria) reduction

1 evidences

In regenerative endodontic treatment of traumatized immature teeth, both calcium hydroxide (CH) and 2% chlorhexidine (CHD) dressings reduced bacterial loads; greater reductions were associated with successful clinical outcomes and presence of E. faecalis after treatment associated with failure.

Trust comment: Randomized clinical trial with long follow-up and molecular quantification (qPCR); moderate sample size (n=41) limits power for some species-level comparisons.

Study Details

PMID:40150951
Participants:41
Impact:CH: significant reductions after S2 and S3 in successful cases; CHD: significant reduction after S3 in successful cases (p≤0.01 for key comparisons)
Trust score:4/5

Actinomycetota load

1 evidences

In regenerative endodontic treatment of traumatized immature teeth, both calcium hydroxide (CH) and 2% chlorhexidine (CHD) dressings reduced bacterial loads; greater reductions were associated with successful clinical outcomes and presence of E. faecalis after treatment associated with failure.

Trust comment: Randomized clinical trial with long follow-up and molecular quantification (qPCR); moderate sample size (n=41) limits power for some species-level comparisons.

Study Details

PMID:40150951
Participants:41
Impact:Significant decrease S1→S2 in CH success group (p=0.01); no consistent association with outcome in CHD group
Trust score:4/5

Presence of Enterococcus faecalis

1 evidences

In regenerative endodontic treatment of traumatized immature teeth, both calcium hydroxide (CH) and 2% chlorhexidine (CHD) dressings reduced bacterial loads; greater reductions were associated with successful clinical outcomes and presence of E. faecalis after treatment associated with failure.

Trust comment: Randomized clinical trial with long follow-up and molecular quantification (qPCR); moderate sample size (n=41) limits power for some species-level comparisons.

Study Details

PMID:40150951
Participants:41
Impact:Presence after intracanal dressing associated with higher odds of RET failure (OR≈9.78, p=0.0432)
Trust score:4/5

Calcium attachment to stent

1 evidences

After 4 weeks indwelling, stents with Hydroplus coating (Percuflex) accumulated more calcium and magnesium and caused worse urinary symptoms compared with Percushield (Tria) and pHreeCoat (InLay Optima) coated stents.

Trust comment: Randomized single-blind trial with objective biochemical measures and clinically relevant endpoints; single-center and modest sample size but statistically significant biomineral findings.

Study Details

PMID:40148554
Participants:61
Impact:Higher in Percuflex group: median 5.42 mg/dL vs Tria 1.92 and InLay 1.98 mg/dL (p=0.02)
Trust score:4/5

Magnesium attachment to stent

1 evidences

After 4 weeks indwelling, stents with Hydroplus coating (Percuflex) accumulated more calcium and magnesium and caused worse urinary symptoms compared with Percushield (Tria) and pHreeCoat (InLay Optima) coated stents.

Trust comment: Randomized single-blind trial with objective biochemical measures and clinically relevant endpoints; single-center and modest sample size but statistically significant biomineral findings.

Study Details

PMID:40148554
Participants:61
Impact:Higher in Percuflex: median 0.20 mg/dL vs Tria 0.07 and InLay 0.05 mg/dL (p<0.01)
Trust score:4/5

Bacterial adherence (counts/µL)

1 evidences

After 4 weeks indwelling, stents with Hydroplus coating (Percuflex) accumulated more calcium and magnesium and caused worse urinary symptoms compared with Percushield (Tria) and pHreeCoat (InLay Optima) coated stents.

Trust comment: Randomized single-blind trial with objective biochemical measures and clinically relevant endpoints; single-center and modest sample size but statistically significant biomineral findings.

Study Details

PMID:40148554
Participants:61
Impact:Numerically higher in Percuflex (45.92) vs Tria (17.80) and InLay (11.90) but difference not statistically significant (p=0.17)
Trust score:4/5

Alveolar ridge width reduction (1 mm, 3 mm, 5 mm below crest)

1 evidences

β-TCP coated bovine deproteinized bone performed similarly to Bio-Oss® for alveolar ridge preservation over 6 months; changes in ridge width and height did not differ significantly between materials.

Trust comment: Prospective randomized controlled clinical trial with substantial completion (n=123) and objective CBCT measurements; β-TCP is a calcium-phosphate bone substitute so findings are directly relevant to calcium-containing biomaterials.

Study Details

PMID:40116954
Participants:123
Impact:β-TCP/PBDB: 1.27±1.32, 0.89±1.31, 0.63±1.37 mm vs Bio-Oss: 1.12±1.65, 0.55±1.41, 0.56±1.32 mm; no significant differences (p>0.05)
Trust score:4/5

Alveolar ridge height reduction (buccal/lingual)

1 evidences

β-TCP coated bovine deproteinized bone performed similarly to Bio-Oss® for alveolar ridge preservation over 6 months; changes in ridge width and height did not differ significantly between materials.

Trust comment: Prospective randomized controlled clinical trial with substantial completion (n=123) and objective CBCT measurements; β-TCP is a calcium-phosphate bone substitute so findings are directly relevant to calcium-containing biomaterials.

Study Details

PMID:40116954
Participants:123
Impact:β-TCP/PBDB buccal 0.75±1.96 mm and lingual 0.95±1.96 mm vs Bio-Oss buccal 1.01±2.44 mm and lingual 0.99±2.13 mm; no significant differences (p>0.05)
Trust score:4/5

Safety and healing

1 evidences

β-TCP coated bovine deproteinized bone performed similarly to Bio-Oss® for alveolar ridge preservation over 6 months; changes in ridge width and height did not differ significantly between materials.

Trust comment: Prospective randomized controlled clinical trial with substantial completion (n=123) and objective CBCT measurements; β-TCP is a calcium-phosphate bone substitute so findings are directly relevant to calcium-containing biomaterials.

Study Details

PMID:40116954
Participants:123
Impact:All sockets and soft tissues healed well; β-TCP/PBDB considered safe and comparable to Bio-Oss
Trust score:4/5

S. mutans count

1 evidences

Intensive applications of three remineralizing agents in preschool children reduced S. mutans counts and plaque; CPP-ACPF (which contains calcium phosphate) produced the largest reduction at 3 months.

Trust comment: Randomized triple-arm clinical trial with objective microbiological outcomes and intention-to-treat analysis; modest sample size and 3-month follow-up limit longer-term inference.

Study Details

PMID:40106002
Participants:66
Impact:Decreased in all groups to 3 months; CPP-ACPF ~−56% total count (baseline→3mo), P11-4 ~−33%, NaF ~−26% (per group total counts)
Trust score:4/5

Plaque index

2 evidences

Intensive applications of three remineralizing agents in preschool children reduced S. mutans counts and plaque; CPP-ACPF (which contains calcium phosphate) produced the largest reduction at 3 months.

Trust comment: Randomized triple-arm clinical trial with objective microbiological outcomes and intention-to-treat analysis; modest sample size and 3-month follow-up limit longer-term inference.

Study Details

PMID:40106002
Participants:66
Impact:Decreased in all groups at 1 and 3 months (~0.24–0.28 point absolute reduction, ≈15–18%)
Trust score:4/5

Randomized trial in children comparing a zinc hydroxyapatite toothpaste vs a calcium sodium phosphosilicate toothpaste; both reduced dental sensitivity and improved periodontal indices over 6 months.

Trust comment: Randomized clinical trial but small sample and limited outcome reporting; dental endpoints directly relevant to calcium-containing formulation.

Study Details

PMID:38357755
Participants:40
Impact:reduced (significant) over 6 months
Trust score:3/5

lumbar BMD

1 evidences

Postmenopausal women receiving Caltrate D (a calcium/vitamin D product) plus exercise had greater lumbar and femoral neck BMD, higher serum calcium and quality-of-life scores, and lower serum phosphorus, ALP and PMOP recurrence versus Caltrate D alone.

Trust comment: Randomized allocation reported and moderate sample size, but limited methodological details (blinding, effect sizes) and single-centre design reduce confidence.

Study Details

PMID:40089924
Participants:110
Impact:Increased (combined therapy > Caltrate D alone) (reported as significantly higher post-treatment)
Trust score:3/5

femoral neck BMD

6 evidences

Nutrition education and dietary intervention increased dietary calcium intake and improved lumbar spine and femoral neck BMD versus control over 6 months.

Trust comment: Randomized dietary intervention with significant BMD changes but potential for performance and measurement bias from non-blinding; moderate trust.

Study Details

PMID:27301220
Participants:90
Impact:Increased vs control (P<0.05)
Trust score:3/5

Postmenopausal women receiving Caltrate D (a calcium/vitamin D product) plus exercise had greater lumbar and femoral neck BMD, higher serum calcium and quality-of-life scores, and lower serum phosphorus, ALP and PMOP recurrence versus Caltrate D alone.

Trust comment: Randomized allocation reported and moderate sample size, but limited methodological details (blinding, effect sizes) and single-centre design reduce confidence.

Study Details

PMID:40089924
Participants:110
Impact:Increased (combined therapy > Caltrate D alone) (reported as significantly higher post-treatment)
Trust score:3/5

In Chinese postmenopausal women, daily fortified milk (1200 mg calcium + vitamin D + FOS-inulin) for 52 weeks increased 25(OH)D, suppressed bone turnover markers and preserved femoral neck BMD compared with regular milk.

Trust comment: Randomized 1-year trial directly testing calcium+vitamin D fortified milk with clear biochemical and DXA outcomes; moderate sample size and clinically relevant endpoints.

Study Details

PMID:28975432
Participants:121
Impact:preserved in intervention vs decreased in control (borderline treatment effect p=0.07)
Trust score:4/5

Randomized multicenter trial comparing ALN+eldecalcitol versus ALN+vitamin D+calcium found both increased BMD; ALN+eldecalcitol produced significantly greater femoral neck BMD gain and larger reductions in bone turnover markers.

Trust comment: Large randomized multicenter trial with central DXA reading and clinically relevant endpoints; unblinded design is a limitation but results are robust for BMD and BTMs.

Study Details

PMID:25592133
Participants:219
Impact:increase: ALN+ELD +2.70% vs ALN+VitD+Ca +1.18% (intergroup difference significant, p=0.011)
Trust score:4/5

Randomized trial in people ≥80 years with osteopenia comparing calcium+alfacalcidol ± alendronate over 18 months; assessed BMD, fractures, falls and biomarkers.

Trust comment: Randomized controlled trial with reasonable sample size and objective endpoints (DXA, fracture) though some baseline imbalances and borderline fracture significance.

Study Details

PMID:32495521
Participants:123
Impact:left femoral neck +3.43% and right femoral neck +2.86% in experiment group vs minimal/negative changes in control (intergroup P<0.01/P<0.05)
Trust score:4/5

In kidney transplant recipients all given calcium and vitamin D, addition of pamidronate did not change bone mineral density over 6 months compared with control; calcium + vitamin D may have mitigated early bone loss.

Trust comment: Small randomized trial (n=40) with short (6-month) follow-up; all subjects received calcium + vitamin D so calcium effects are confounded but clinically relevant.

Study Details

PMID:25599737
Participants:40
Impact:no significant change between groups at 6 months
Trust score:3/5

KOOS-pain

1 evidences

Cross-sectional analysis found no significant association between CT-detected intraarticular calcium crystal deposits and knee pain or MRI-detected joint inflammation in people with overweight and knee OA.

Trust comment: Well-characterized cohort with CT and advanced MRI measures but exploratory cross-sectional design and small number with calcium deposits limit power.

Study Details

PMID:40082322
Participants:158
Impact:No significant difference (OA with CaC mean 65.9 vs OA without CaC 63.7; mean difference −2.2 points, p=0.603)
Trust score:3/5

MRI inflammation (DCE-MRI variables)

1 evidences

Cross-sectional analysis found no significant association between CT-detected intraarticular calcium crystal deposits and knee pain or MRI-detected joint inflammation in people with overweight and knee OA.

Trust comment: Well-characterized cohort with CT and advanced MRI measures but exploratory cross-sectional design and small number with calcium deposits limit power.

Study Details

PMID:40082322
Participants:158
Impact:No significant association between presence of calcium crystals and DCE-MRI perfusion/inflammation measures (IRE, ME, Nvoxel; p>0.10)
Trust score:3/5

Calcium supplement adequacy (daily use)

1 evidences

An mHealth app versus face-to-face counseling was tested in pregnant women to improve intake of folic acid, iron, calcium, and vitamin D; more women improved supplement use with the app, notably vitamin D, but the control group had greater calcium adequacy and biochemical calcium did not improve.

Trust comment: - Checklist: confirm human RCT; identify main outcomes (calcium use, serum calcium, CSUS); extract participant count from completers; assess study quality and biochemical subset; report exact changes when available. This is a randomized, single-center RCT in pregnant women with objective biochemical measures on a subset, good sample size but unblinded and with notable loss to follow-up, so moderate-high trust.

Study Details

PMID:40203301
Participants:232
Impact:Intervention: +35.7 percentage points (30.7% → 66.4%); Nonintervention: +83.7 percentage points (5.9% → 89.6%)
Trust score:4/5

Hypocalcemia prevalence (serum calcium <8.6 mg/dL)

1 evidences

An mHealth app versus face-to-face counseling was tested in pregnant women to improve intake of folic acid, iron, calcium, and vitamin D; more women improved supplement use with the app, notably vitamin D, but the control group had greater calcium adequacy and biochemical calcium did not improve.

Trust comment: - Checklist: confirm human RCT; identify main outcomes (calcium use, serum calcium, CSUS); extract participant count from completers; assess study quality and biochemical subset; report exact changes when available. This is a randomized, single-center RCT in pregnant women with objective biochemical measures on a subset, good sample size but unblinded and with notable loss to follow-up, so moderate-high trust.

Study Details

PMID:40203301
Participants:232
Impact:Intervention: 0 pp change (12.5% → 12.5%); Nonintervention: +42 pp (16% → 58%)
Trust score:4/5

Cumulative supplement use score (CSUS)

1 evidences

An mHealth app versus face-to-face counseling was tested in pregnant women to improve intake of folic acid, iron, calcium, and vitamin D; more women improved supplement use with the app, notably vitamin D, but the control group had greater calcium adequacy and biochemical calcium did not improve.

Trust comment: - Checklist: confirm human RCT; identify main outcomes (calcium use, serum calcium, CSUS); extract participant count from completers; assess study quality and biochemical subset; report exact changes when available. This is a randomized, single-center RCT in pregnant women with objective biochemical measures on a subset, good sample size but unblinded and with notable loss to follow-up, so moderate-high trust.

Study Details

PMID:40203301
Participants:232
Impact:Intervention: −76.7% (mean CSUS 7.72 → 1.79); Nonintervention: −67.7% (mean 7.87 → 2.54)
Trust score:4/5

Postpartum blood loss (2 h and 24 h)

1 evidences

Double-blind randomized trial in women with uterine atony compared calcium gluconate alone versus calcium gluconate plus ergometrine maleate; the combination reduced postpartum blood loss, shortened labor stages and hemostasis time, and improved hemoglobin, RBC count and several coagulation and inflammatory markers.

Trust comment: - Checklist: confirm human randomized double-blind trial; identify main outcomes (blood loss, hemostasis time, coagulation parameters); confirm participant count from methods. This randomized double-blind study (n=96) directly tests calcium gluconate (with/without ergometrine) and reports statistically significant clinical benefits, though detailed numeric effect sizes are not provided in the excerpt; overall moderate-high trust.

Study Details

PMID:40159712
Participants:96
Impact:Decreased (study group vs control, p<0.05)
Trust score:4/5

hemostasis time

1 evidences

Double-blind randomized trial in women with uterine atony compared calcium gluconate alone versus calcium gluconate plus ergometrine maleate; the combination reduced postpartum blood loss, shortened labor stages and hemostasis time, and improved hemoglobin, RBC count and several coagulation and inflammatory markers.

Trust comment: - Checklist: confirm human randomized double-blind trial; identify main outcomes (blood loss, hemostasis time, coagulation parameters); confirm participant count from methods. This randomized double-blind study (n=96) directly tests calcium gluconate (with/without ergometrine) and reports statistically significant clinical benefits, though detailed numeric effect sizes are not provided in the excerpt; overall moderate-high trust.

Study Details

PMID:40159712
Participants:96
Impact:Shorter (study group vs control, p<0.05)
Trust score:4/5

Hemoglobin and RBC count at 24 h

1 evidences

Double-blind randomized trial in women with uterine atony compared calcium gluconate alone versus calcium gluconate plus ergometrine maleate; the combination reduced postpartum blood loss, shortened labor stages and hemostasis time, and improved hemoglobin, RBC count and several coagulation and inflammatory markers.

Trust comment: - Checklist: confirm human randomized double-blind trial; identify main outcomes (blood loss, hemostasis time, coagulation parameters); confirm participant count from methods. This randomized double-blind study (n=96) directly tests calcium gluconate (with/without ergometrine) and reports statistically significant clinical benefits, though detailed numeric effect sizes are not provided in the excerpt; overall moderate-high trust.

Study Details

PMID:40159712
Participants:96
Impact:Higher in combination group (p<0.05)
Trust score:4/5

RANKL:OPG ratio

2 evidences

Randomized single-blind clinical trial in patients needing endodontic retreatment compared tricalcium silicate-based dressing versus calcium hydroxide dressing; both reduced inflammatory mediators and markers of bone resorption, with calcium hydroxide showing greater percentage reductions in several mediators.

Trust comment: - Checklist: confirm human randomized trial; identify main outcomes (RANKL/OPG, TNF-α, TGF-β); extract sample size and percent changes. This randomized clinical trial (n=60) directly compares two calcium-based intracanal medicaments with measurable mediator changes and reports quantitative percentage changes, supporting moderate-high trust.

Study Details

PMID:40155539
Participants:60
Impact:Calcium silicate: mean change +15.66% ±19.45; Calcium hydroxide: +48.38% ±15.28 (greater reduction with calcium hydroxide, p<0.001)
Trust score:4/5

Randomized clinical study testing calcium hydroxide (with or without ibuprofen or ciprofloxacin) on RANKL and OPG levels in periapical lesions.

Trust comment: Randomized controlled clinical study in humans with clear biochemical outcomes, but limited by sample size and single outcome measures.

Study Details

PMID:31706622
Participants:66
Impact:no significant pre/post change within groups and no differences between groups
Trust score:3/5

TGF-β

1 evidences

Randomized single-blind clinical trial in patients needing endodontic retreatment compared tricalcium silicate-based dressing versus calcium hydroxide dressing; both reduced inflammatory mediators and markers of bone resorption, with calcium hydroxide showing greater percentage reductions in several mediators.

Trust comment: - Checklist: confirm human randomized trial; identify main outcomes (RANKL/OPG, TNF-α, TGF-β); extract sample size and percent changes. This randomized clinical trial (n=60) directly compares two calcium-based intracanal medicaments with measurable mediator changes and reports quantitative percentage changes, supporting moderate-high trust.

Study Details

PMID:40155539
Participants:60
Impact:Calcium silicate: mean change +18.03% ±21.24; Calcium hydroxide: +51.80% ±9.32 (greater reduction with calcium hydroxide, p<0.001)
Trust score:4/5

TNF-α

2 evidences

Randomized single-blind clinical trial in patients needing endodontic retreatment compared tricalcium silicate-based dressing versus calcium hydroxide dressing; both reduced inflammatory mediators and markers of bone resorption, with calcium hydroxide showing greater percentage reductions in several mediators.

Trust comment: - Checklist: confirm human randomized trial; identify main outcomes (RANKL/OPG, TNF-α, TGF-β); extract sample size and percent changes. This randomized clinical trial (n=60) directly compares two calcium-based intracanal medicaments with measurable mediator changes and reports quantitative percentage changes, supporting moderate-high trust.

Study Details

PMID:40155539
Participants:60
Impact:Calcium silicate: mean change +11.37% ±12.58; Calcium hydroxide: +19.32% ±12.86 (greater reduction with calcium hydroxide, p=0.002)
Trust score:4/5

Sarcopenic older adults received combined exercise plus nutritional support (included BCAA and daily Caltrate: 600 mg calcium + 800 IU vitamin D3); after 12 weeks inflammatory cytokines decreased and muscle strength/mass improved.

Trust comment: Human RCT per‑protocol analysis (n=57) showing reductions in inflammatory markers and improved strength, but calcium was given as part of a multi‑component nutrition + exercise program so effects cannot be attributed to calcium alone.

Study Details

PMID:38032288
Participants:57
Impact:−48.84 pg/mL (mean change), p=0.003
Trust score:3/5

KOOS overall score improvement (scaffold vs control)

1 evidences

A multicentre RCT found that implantation of an aragonite (calcium carbonate) scaffold produced superior clinical (KOOS) and MRI defect-fill outcomes and lower failure rates versus debridement/microfracture at 48 months, with comparable results in females and males.

Trust comment: Large, multi-centre FDA‑approved randomized trial with 48‑month follow-up and objective MRI endpoints, though sex imbalance and some subgroup sample‑size limitations exist.

Study Details

PMID:40080289
Participants:247
Impact:+24 to +33 points (greater improvement with scaffold vs control, depending on subgroup/stratum)
Trust score:4/5

MRI defect fill (≥75% at 24 months)

1 evidences

A multicentre RCT found that implantation of an aragonite (calcium carbonate) scaffold produced superior clinical (KOOS) and MRI defect-fill outcomes and lower failure rates versus debridement/microfracture at 48 months, with comparable results in females and males.

Trust comment: Large, multi-centre FDA‑approved randomized trial with 48‑month follow-up and objective MRI endpoints, though sex imbalance and some subgroup sample‑size limitations exist.

Study Details

PMID:40080289
Participants:247
Impact:Scaffold: males 86.2% / females 92.6% vs control: males 32.6% / females 28.0% (large absolute increase with scaffold)
Trust score:4/5

Failure rate (scaffold vs control)

1 evidences

A multicentre RCT found that implantation of an aragonite (calcium carbonate) scaffold produced superior clinical (KOOS) and MRI defect-fill outcomes and lower failure rates versus debridement/microfracture at 48 months, with comparable results in females and males.

Trust comment: Large, multi-centre FDA‑approved randomized trial with 48‑month follow-up and objective MRI endpoints, though sex imbalance and some subgroup sample‑size limitations exist.

Study Details

PMID:40080289
Participants:247
Impact:Females: 6.7% vs 39.4%; Males: 14% vs 31.4% (≈−25 to −32 percentage points lower with scaffold)
Trust score:4/5

Pain (VAS) over time

1 evidences

Randomized clinical trial comparing RMGIC versus TheraCal LC (light‑curable tricalcium silicate) for indirect pulp capping in deep caries; both reduced pain over time and maintained pulp vitality, with RMGIC showing a somewhat higher final vitality rate.

Trust comment: Small randomized trial (n=46) with repeated clinical/radiographic follow-up to 6 months; limited sample and medium follow-up duration moderate confidence.

Study Details

PMID:40079993
Participants:46
Impact:VAS decreased to 0 by 6 months in both groups; no significant between‑group difference (p>0.05)
Trust score:3/5

Pulp vitality rate at 6 months

1 evidences

Randomized clinical trial comparing RMGIC versus TheraCal LC (light‑curable tricalcium silicate) for indirect pulp capping in deep caries; both reduced pain over time and maintained pulp vitality, with RMGIC showing a somewhat higher final vitality rate.

Trust comment: Small randomized trial (n=46) with repeated clinical/radiographic follow-up to 6 months; limited sample and medium follow-up duration moderate confidence.

Study Details

PMID:40079993
Participants:46
Impact:RMGIC 100% vs TheraCal LC 81% (≈+19 percentage points for RMGIC)
Trust score:3/5

1‑year clinical/radiographic success rate

1 evidences

Randomized clinical study of full pulpotomy in molars using two calcium‑silicate materials (MTA+ vs Well‑Root PT); overall 1‑year clinical/radiographic success was high and similar between materials, and higher TNF‑α and MMP‑9 levels correlated with poorer outcomes.

Trust comment: Randomized clinical study with 1‑year follow‑up and molecular correlations but moderate sample size (n=60) limits precision.

Study Details

PMID:40058408
Participants:60
Impact:Overall success 88.3% at 12 months
Trust score:3/5

Material comparison (MTA+ vs Well‑Root PT)

1 evidences

Randomized clinical study of full pulpotomy in molars using two calcium‑silicate materials (MTA+ vs Well‑Root PT); overall 1‑year clinical/radiographic success was high and similar between materials, and higher TNF‑α and MMP‑9 levels correlated with poorer outcomes.

Trust comment: Randomized clinical study with 1‑year follow‑up and molecular correlations but moderate sample size (n=60) limits precision.

Study Details

PMID:40058408
Participants:60
Impact:No significant difference in success rates between materials across class I/II cavities (similar performance)
Trust score:3/5

Biomarker correlation (TNF‑α, MMP‑9)

1 evidences

Randomized clinical study of full pulpotomy in molars using two calcium‑silicate materials (MTA+ vs Well‑Root PT); overall 1‑year clinical/radiographic success was high and similar between materials, and higher TNF‑α and MMP‑9 levels correlated with poorer outcomes.

Trust comment: Randomized clinical study with 1‑year follow‑up and molecular correlations but moderate sample size (n=60) limits precision.

Study Details

PMID:40058408
Participants:60
Impact:Higher TNF‑α and MMP‑9 levels correlated significantly with pulpotomy failure/outcome
Trust score:3/5

ionized calcium

3 evidences

Intervention (pilot n=12) and RCT (98 randomized, 98 included) evaluated single‑dose denosumab (60 mg) in infertile men: denosumab caused a transient fall in serum calcium with compensatory PTH rise and associated changes in phosphate and bone turnover markers; most changes normalized over months.

Trust comment: Well‑designed single‑dose RCT with supporting pilot data and detailed biochemical monitoring; moderate‑large sample and appropriate analyses support good reliability.

Study Details

PMID:40055742
Participants:110
Impact:Transient decrease (e.g., 1.21 → 1.17 mmol/L at day 14; ≈−3%), returning to baseline by ~day 180
Trust score:4/5

In burned critically ill patients, Plasmalyte produced similar base excess to Ringer lactate but led to higher gluconate accumulation and significantly lower ionized calcium levels.

Trust comment: Randomized trial in a small but well-defined critical care population with direct biochemical measurements; limited sample size reduces precision.

Study Details

PMID:32027547
Participants:28
Impact:significantly lower ionized calcium levels with Plasmalyte
Trust score:4/5

In an 8-week controlled feeding trial, the DASH diet modestly lowered active vitamin D (calcitriol) but did not change PTH or blood ionized calcium.

Trust comment: Randomized, multicenter controlled feeding trial with centralized assays and good adherence; moderate sample size and prespecified mineral metabolism outcomes.

Study Details

PMID:29562597
Participants:334
Impact:no significant change
Trust score:4/5

alkaline phosphatase

1 evidences

Intervention (pilot n=12) and RCT (98 randomized, 98 included) evaluated single‑dose denosumab (60 mg) in infertile men: denosumab caused a transient fall in serum calcium with compensatory PTH rise and associated changes in phosphate and bone turnover markers; most changes normalized over months.

Trust comment: Well‑designed single‑dose RCT with supporting pilot data and detailed biochemical monitoring; moderate‑large sample and appropriate analyses support good reliability.

Study Details

PMID:40055742
Participants:110
Impact:≈−28% lower alkaline phosphatase in denosumab group vs placebo at day 80 (p<0.0001)
Trust score:4/5

IGF-1

1 evidences

In adolescents, milk powder fortified with calcium (300–900 mg/day) plus vitamin D for 1.5 years did not produce greater bone density gains versus control, but altered PTH and IGF-1.

Trust comment: Randomized, cluster-assigned controlled trial with long follow-up and objective measures (DXA, biomarkers); limitations include modest vitamin D dose and some loss to follow-up.

Study Details

PMID:31375874
Participants:181
Impact:Increased in all intervention groups (Ca3D +18.5%, Ca6D +22.6%, Ca9D +22.8%) while control decreased (−16.2%)
Trust score:4/5

plasma intact parathyroid hormone (iPTH)

1 evidences

Per-protocol analysis of randomized patients with ND-CKD on extended‑release calcifediol: adding adjunct active vitamin D reduced iPTH further but raised serum calcium, phosphorus, FGF23 and accelerated eGFR decline over the treatment period.

Trust comment: Randomized, controlled design with measured biochemical outcomes; per‑protocol N=78 limits power and duration was relatively short but results are robust for safety signals.

Study Details

PMID:39987904
Participants:78
Impact:Further reduced with adjunct AVD (additional ≈35% reduction vs ERC alone; P<0.001)
Trust score:4/5

corrected serum calcium

8 evidences

Per-protocol analysis of randomized patients with ND-CKD on extended‑release calcifediol: adding adjunct active vitamin D reduced iPTH further but raised serum calcium, phosphorus, FGF23 and accelerated eGFR decline over the treatment period.

Trust comment: Randomized, controlled design with measured biochemical outcomes; per‑protocol N=78 limits power and duration was relatively short but results are robust for safety signals.

Study Details

PMID:39987904
Participants:78
Impact:Increased by 0.40 mg/dL with adjunct AVD (P<0.001)
Trust score:4/5

Atorvastatin 20 mg/day modestly reduced corrected serum calcium at 12 weeks in lithium users compared to placebo.

Trust comment: Double-blind randomized placebo-controlled human trial with objective lab measurements, moderate size though small absolute calcium change.

Study Details

PMID:36153583
Participants:56
Impact:decrease of -0.03 mmol/L vs placebo (β = -0.03; 95% CI -0.07, -0.0035; p≈0.0336)
Trust score:4/5

One week of cinacalcet (30 mg/day) lowered blood calcium and PTH but did not significantly change arterial stiffness or heart function in hemodialysis patients.

Trust comment: Randomized double-blind crossover RCT with rigorous measures but small sample and some missing echocardiography data, likely underpowered for arterial stiffness endpoints.

Study Details

PMID:28538380
Participants:21
Impact:-0.12 mmol/L (2.25 → 2.13 mmol/L), P<0.001
Trust score:4/5

Extended-hours haemodialysis lowered serum phosphate, produced a small increase in serum calcium, and did not change PTH over 12 months.

Trust comment: Large randomized multicentre trial with blinded endpoint assessment; outcomes and adjustments reported clearly.

Study Details

PMID:31299919
Participants:200
Impact:+0.05 mmol/L (mean difference)
Trust score:4/5

In hemodialysis patients with adynamic bone disease, the calcium-based binder (calcium carbonate) was associated with higher blood calcium, greater progression of coronary artery calcification and lower bone mineral density compared with lanthanum carbonate over 12 months.

Trust comment: Randomized, objective imaging (CT, DXA) outcomes in 92 patients support reliability, but single-center and open-label design limit blinding.

Study Details

PMID:29137107
Participants:92
Impact:increased with calcium carbonate vs lanthanum carbonate (significant, P<0.001)
Trust score:4/5

Ferric citrate was non-inferior to sevelamer at lowering serum phosphorus in hemodialysis patients; corrected serum calcium and intact-PTH changes were similar, while ferric citrate improved iron indices and had more mild GI adverse events.

Trust comment: Phase III multicenter randomized trial with high completion rate; open-label design may introduce some bias but endpoints are objective.

Study Details

PMID:37812931
Participants:217
Impact:no significant change vs comparator by end of treatment (p>0.05)
Trust score:4/5

In Japanese osteoporosis patients receiving teriparatide (with daily calcium/vitamin D), PINP rose rapidly but corrected serum calcium stayed within normal range and calcium-related AEs were rare.

Trust comment: Phase III randomized double‑blind study and systematic lab monitoring support reliability; post hoc analysis limits causal inference.

Study Details

PMID:26185429
Participants:180
Impact:remained within normal range at all measured time points; 2 cases transient hypercalcemia (recovered)
Trust score:4/5

In hemodialysis patients, dialysate calcium 2.5 vs 3.0 mEq/L did not significantly change cardiovascular events or mortality; alfacalcidol produced a short-term rise in serum calcium and a short-term fall in PTH.

Trust comment: Post-hoc analysis of a randomized trial with long follow-up and serial labs but limited statistical power; results are plausible though not definitive.

Study Details

PMID:36070301
Participants:976
Impact:Transient increase with alfacalcidol (returned to baseline)
Trust score:4/5

estimated glomerular filtration rate (eGFR)

2 evidences

Six months of a vitamin D + calcium + leucine‑enriched whey protein drink (up to 2 servings/day) did not impair kidney function or cause vitamin D/calcium toxicity in sarcopenic older adults.

Trust comment: Large multicenter randomized trial with objective lab endpoints and 6‑month follow-up supporting safety of the calcium‑containing product.

Study Details

PMID:32162241
Participants:379
Impact:Median increase ≈ +1.0 mL/min/1.73 m2 at 13 weeks in test group (small, nonpathologic change)
Trust score:4/5

Per-protocol analysis of randomized patients with ND-CKD on extended‑release calcifediol: adding adjunct active vitamin D reduced iPTH further but raised serum calcium, phosphorus, FGF23 and accelerated eGFR decline over the treatment period.

Trust comment: Randomized, controlled design with measured biochemical outcomes; per‑protocol N=78 limits power and duration was relatively short but results are robust for safety signals.

Study Details

PMID:39987904
Participants:78
Impact:Greater decline with adjunct AVD: −3.09 mL/min/1.73m2 (−11.8%) vs ERC alone −0.66 mL/min/1.73m2 (−3.0%); between-group difference significant (P<0.05)
Trust score:4/5

Permanent hypocalcemia

2 evidences

Near-infrared ICG angiography during total thyroidectomy improved parathyroid detection and was associated with lower early postoperative hypocalcemia rates compared with standard surgery.

Trust comment: Randomized surgical trial with objective calcium outcomes but single-center and modest sample size.

Study Details

PMID:34248023
Participants:58
Impact:1 case in standard group vs 0 cases in ICG group at 3 months
Trust score:3/5

Randomized trial with >10-year follow-up (analyzed n=151) comparing total thyroidectomy alone vs with prophylactic central compartment lymph node dissection: no differences in oncologic outcomes or rates of permanent hypocalcemia or serum calcium at long-term follow-up.

Trust comment: Long-term randomized trial with substantial follow-up; analysis based on 151 patients and provides reliable clinical outcome data including calcium-related safety endpoints.

Study Details

PMID:39983243
Participants:151
Impact:No significant difference between groups (P=0.238)
Trust score:4/5

Oncologic outcomes (thyroglobulin, further surgery, radioactive iodine)

1 evidences

Randomized trial with >10-year follow-up (analyzed n=151) comparing total thyroidectomy alone vs with prophylactic central compartment lymph node dissection: no differences in oncologic outcomes or rates of permanent hypocalcemia or serum calcium at long-term follow-up.

Trust comment: Long-term randomized trial with substantial follow-up; analysis based on 151 patients and provides reliable clinical outcome data including calcium-related safety endpoints.

Study Details

PMID:39983243
Participants:151
Impact:No significant differences after ~13 years follow-up
Trust score:4/5

total cholesterol

6 evidences

Parathyroidectomy lowered total cholesterol and, in patients with higher baseline ionized calcium, reduced arterial stiffness (PWV); ambulatory diastolic BP increased.

Trust comment: Randomized clinical trial with modest sample size and clear reported P values for main outcomes.

Study Details

PMID:30860588
Participants:69
Impact:Total cholesterol decreased significantly after parathyroidectomy vs control (P = 0.04)
Trust score:4/5

In overweight middle-aged adults, 6 weeks of melted cheese increased total cholesterol and triglycerides compared to unmelted cheese.

Trust comment: Randomized parallel trial with clear interventions and measured lipid outcomes, though short duration (6 weeks).

Study Details

PMID:39017657
Participants:162
Impact:+0.20 ± 0.15 mmol/L (melted vs unmelted)
Trust score:4/5

Eating whole cheese lowered total and LDL cholesterol compared to a deconstructed cheese product; men and women responded differently.

Trust comment: Secondary analysis of pooled randomized controlled trials (n=197) with clear cholesterol outcomes but effect magnitudes not fully specified for all comparisons.

Study Details

PMID:39923541
Participants:197
Impact:decrease (cheese vs deconstructed cheese)
Trust score:4/5

In overweight pregnant women, higher calcium intake was associated with higher total cholesterol; legumes intake associated with lower total cholesterol and LDL.

Trust comment: Cross-sectional analysis of baseline data (n=239) showing a small statistical association; observational design limits causal inference.

Study Details

PMID:37354652
Participants:239
Impact:β = +0.02 (direct association with calcium intake; 95% CI 0.002–0.41; P = 0.03)
Trust score:3/5

Daily calcium-rich supplement (with or without scFOS) lowered LDL and total cholesterol versus placebo after 24 months in postmenopausal women.

Trust comment: 24-month double-blind RCT with 300 participants showing lipid changes, though analysis is secondary.

Study Details

PMID:26669430
Participants:300
Impact:lower vs control at 24 months
Trust score:4/5

In this randomized double-blind crossover RCT, calcium-caseinate (calcium-containing protein) did not reduce ambulatory blood pressure but did modestly improve endothelial function and lowered total cholesterol compared with control.

Trust comment: Well-designed randomized, double-blind, 3-way crossover RCT with objective ambulatory BP and vascular measures but modest sample size (38 completers) for subgroup comparisons.

Study Details

PMID:27797709
Participants:38
Impact:−0.12 mmol/L (Δ) reduced vs control
Trust score:4/5

LDL cholesterol

9 evidences

Atorvastatin 20 mg/day modestly reduced corrected serum calcium at 12 weeks in lithium users compared to placebo.

Trust comment: Double-blind randomized placebo-controlled human trial with objective lab measurements, moderate size though small absolute calcium change.

Study Details

PMID:36153583
Participants:56
Impact:decrease (β = -1.07 mmol/L; p < 1e-8)
Trust score:4/5

Adding 50 g/day Kashk (high‑protein, calcium‑enriched probiotic yogurt) to a low‑energy diet for 8 weeks improved lipids and reduced body weight and waist in overweight/obese women.

Trust comment: Randomized controlled trial with moderate sample size and short duration; reported significant between-group changes but study is small and authors note need for further trials.

Study Details

PMID:31987116
Participants:70
Impact:Decreased vs control (between-group, P=0.049)
Trust score:3/5

Randomized dietary trial comparing isolipidic diets with different fat sources (including milk fat with added calcium) on LDL and other cardiovascular markers.

Trust comment: Large randomized double-blind dietary trial; appropriate design though some subgroup findings need confirmation.

Study Details

PMID:31712768
Participants:172
Impact:no significant difference between diets
Trust score:4/5

Daily calcium-rich supplement (with or without scFOS) lowered LDL and total cholesterol versus placebo after 24 months in postmenopausal women.

Trust comment: 24-month double-blind RCT with 300 participants showing lipid changes, though analysis is secondary.

Study Details

PMID:26669430
Participants:300
Impact:lower vs control at 24 months
Trust score:4/5

In dialysis patients, epicardial fat increased more with calcium-based phosphate binders than with sevelamer, and sevelamer reduced LDL cholesterol.

Trust comment: Post-hoc substudy of an RCT with modest sample size; findings relevant to calcium-based binder use but limited by sample and non-significant between-group EAT difference.

Study Details

PMID:27102490
Participants:109
Impact:SVL median -16.4% vs CPiB median +12.1% (between-group p<0.001)
Trust score:3/5

Crossover RCT (64 completers) where 1 L/day of mineral water (bicarbonated vs low-mineral) for 8 weeks reduced LDL and fasting glucose; bicarbonated water increased urine pH and decreased urinary calcium/creatinine ratio.

Trust comment: Randomized, crossover design with objective biochemical measures; modest sample size but well-conducted.

Study Details

PMID:27367723
Participants:64
Impact:-5.8% (bicarbonated water), -3.2% (control water)
Trust score:4/5

WHI subsample RCT assessed Ca+D (1,000 mg Ca carbonate + 400 IU vit D3) effects on LDL-C and other cardiovascular risk factors over years; Ca+D alone had minimal LDL change.

Trust comment: Large, randomized, double-blind trial with objective lipid measures and adequate sample (subsample n=1521); high-quality evidence for small/no LDL change from Ca+D alone.

Study Details

PMID:27926633
Participants:1521
Impact:Calcium+vitamin D alone: −1.6 mg/dL (95% CI −5.5 to 2.2) vs placebo; hormone therapy alone −9.0 mg/dL; combination −13.8 mg/dL
Trust score:5/5

Eating whole cheese lowered total and LDL cholesterol compared to a deconstructed cheese product; men and women responded differently.

Trust comment: Secondary analysis of pooled randomized controlled trials (n=197) with clear cholesterol outcomes but effect magnitudes not fully specified for all comparisons.

Study Details

PMID:39923541
Participants:197
Impact:decrease (cheese vs deconstructed cheese)
Trust score:4/5

In advanced pre-dialysis CKD patients, sevelamer reduced serum p-cresyl sulfate and LDL-cholesterol versus calcium carbonate over 24 weeks; indoxyl sulfate did not change.

Trust comment: Randomized controlled single‑center trial with valid assays but small sample and many advanced CKD patients limit generalizability.

Study Details

PMID:34678981
Participants:33
Impact:Sevelamer reduced LDL by −26.2 mg/dL versus calcium carbonate (p=0.04)
Trust score:3/5

urinary magnesium

1 evidences

Randomized trial in calcium oxalate stone formers showing bicarbonate-rich mineral water increased urine volume, magnesium, citrate and urine pH versus plain water over 12 weeks, but did not change urinary oxalate or Tiselius index.

Trust comment: Prospective randomized controlled study with repeated 24‑h urine measures and clear effect sizes, though open‑label design is a limitation.

Study Details

PMID:35781772
Participants:51
Impact:Increased by 1.894 mmol/24 h (95% CI 1.006 to 2.782) vs plain water
Trust score:4/5

urinary citrate

2 evidences

Both potassium citrate and hydrochlorothiazide reduced 24-h urinary calcium; potassium citrate increased urinary citrate more and had similar short-term stone recurrence.

Trust comment: Prospective randomized study (80 patients) with objective urine measures and 12-month imaging; moderate sample size.

Study Details

PMID:33904027
Participants:80
Impact:increased significantly in both groups; increase greater with potassium citrate
Trust score:4/5

Over 24 weeks, higher dairy intake (~1200 mg calcium/day) versus low dairy changed urinary metabolites linked to energy, protein and gut microbial metabolism in overweight women on calorie restriction.

Trust comment: Randomized 24-week intervention with targeted metabolomics but small sample (n=38) and exploratory outcomes limit generalizability.

Study Details

PMID:26907339
Participants:38
Impact:increased (HD vs LD)
Trust score:3/5

Serum calcium circadian rhythmicity

1 evidences

After stroke only serum calcium showed clear circadian rhythm; naturalistic light was associated with lower PTH at discharge.

Trust comment: Secondary exploratory analysis of an RCT with small sample (n=45); measures of calcium metabolism reported but study is small and exploratory.

Study Details

PMID:39912742
Participants:45
Impact:significant rhythmicity at inclusion and discharge
Trust score:3/5

Safety/tolerability

1 evidences

Calcium hydroxyapatite (CaHA-CMC+) injections produced clinically meaningful, long-lasting jawline contour improvements up to 60 weeks and were generally well tolerated.

Trust comment: Randomized, multicenter, rater-blinded trial with 175 treated patients and long follow-up provides moderate-high confidence in efficacy and safety for this CaHA product.

Study Details

PMID:38934231
Participants:175
Impact:Procedure- or product-related adverse events were mostly mild and resolved
Trust score:4/5

Enamel remineralization (integrated reflectivity)

1 evidences

Fluoridated toothpaste alone or supplemented with CPP-ACPF (a calcium phosphate product) or fluoride varnish promoted enamel remineralization over 12 months.

Trust comment: Randomized clinical trial (26 analyzed) with objective OCT outcome measures; small sample limits power to detect between-group differences.

Study Details

PMID:39907699
Participants:26
Impact:reduced IR over time; remineralization up to 250 μm depth at 12 months
Trust score:3/5

Fluoride varnish vs CPP-ACPF

1 evidences

Fluoridated toothpaste alone or supplemented with CPP-ACPF (a calcium phosphate product) or fluoride varnish promoted enamel remineralization over 12 months.

Trust comment: Randomized clinical trial (26 analyzed) with objective OCT outcome measures; small sample limits power to detect between-group differences.

Study Details

PMID:39907699
Participants:26
Impact:FV had lowest IR at 12 months but differences between groups not statistically significant
Trust score:3/5

lumbar spine BMD

9 evidences

In postmenopausal women (all given calcium 1000 mg and vitamin D3 800 IU), strontium ranelate plus alfacalcidol improved BMD, functional tests, and bone markers more than strontium alone or calcium/vitamin D alone.

Trust comment: Randomized study but open‑label and small (n=48); all groups received calcium/vitamin D so calcium effects cannot be isolated.

Study Details

PMID:25480348
Participants:48
Impact:↑ 8.18% (SrRan+alfacalcidol) vs ↑4.65% (SrRan) and ↑0.24% control; P<0.001 vs control
Trust score:3/5

In a double-blind RCT of 208 older adults, daily whey protein for 18 months increased lean mass but did not change lumbar spine bone mineral density.

Trust comment: Well-designed double-blind RCT with adequate sample size; study addresses calcium metabolism indirectly (protein effect on Ca absorption) but does not assess calcium supplementation.

Study Details

PMID:25844619
Participants:208
Impact:no significant change between protein and placebo groups
Trust score:3/5

Nutrition education and dietary intervention increased dietary calcium intake and improved lumbar spine and femoral neck BMD versus control over 6 months.

Trust comment: Randomized dietary intervention with significant BMD changes but potential for performance and measurement bias from non-blinding; moderate trust.

Study Details

PMID:27301220
Participants:90
Impact:Increased vs control (P<0.05)
Trust score:3/5

In people with HIV, ART type and vitamin D status associate with bone mineral density; higher serum calcium was associated with lower lumbar spine BMD.

Trust comment: Observational analyses from a randomized ART simplification trial baseline (n=160); associative findings subject to confounding but biologically plausible.

Study Details

PMID:26659069
Participants:160
Impact:Higher serum calcium associated with lower lumbar spine BMD (magnitude not provided)
Trust score:3/5

Motivational interviewing increased dairy intake; in female adolescents who consumed ≥4 dairy servings/day for 12 months, total hip BMD increased more than controls, whereas males showed no DXA bone benefits.

Trust comment: Randomized trial with measured dietary (dairy/calcium) intake and DXA outcomes; moderate sample and 80.9% 12-month completion give reasonable confidence for female-specific effect.

Study Details

PMID:35015862
Participants:76
Impact:No significant change vs control
Trust score:4/5

Randomized multicenter trial comparing ALN+eldecalcitol versus ALN+vitamin D+calcium found both increased BMD; ALN+eldecalcitol produced significantly greater femoral neck BMD gain and larger reductions in bone turnover markers.

Trust comment: Large randomized multicenter trial with central DXA reading and clinically relevant endpoints; unblinded design is a limitation but results are robust for BMD and BTMs.

Study Details

PMID:25592133
Participants:219
Impact:increase: ALN+ELD +7.30% vs ALN+VitD+Ca +6.52% (intergroup difference not statistically significant)
Trust score:4/5

In kidney transplant recipients all given calcium and vitamin D, addition of pamidronate did not change bone mineral density over 6 months compared with control; calcium + vitamin D may have mitigated early bone loss.

Trust comment: Small randomized trial (n=40) with short (6-month) follow-up; all subjects received calcium + vitamin D so calcium effects are confounded but clinically relevant.

Study Details

PMID:25599737
Participants:40
Impact:no significant change between pamidronate and control at 6 months
Trust score:3/5

Two-year RCT of dried beancurd (contains isoflavones, calcium, protein) vs rice cake showing improved lumbar spine BMD in postmenopausal women.

Trust comment: Large randomized 2-year trial with clear BMD and biomarker outcomes; moderate-high quality though dried beancurd is a multi-component food rather than isolated calcium.

Study Details

PMID:31489467
Participants:300
Impact:Significant increase (2-year dried beancurd group vs control)
Trust score:4/5

Daily vitamin D3 plus calcium reduced the amount of bone loss over 48 weeks after starting antiretroviral therapy compared with placebo.

Trust comment: Randomized, double-blind, placebo-controlled multicenter trial with adequate sample size and clear clinically relevant outcomes.

Study Details

PMID:26075752
Participants:165
Impact:attenuated decline (similar direction to hip; statistically significant)
Trust score:5/5

Vascular perfusion (peak systolic velocity)

1 evidences

Pilot randomized clinical study comparing intracanal calcium hydroxide paste alone vs with adjunctive Nd:YAG photobiomodulation; PBMT increased perfusion and showed greater lesion shrinkage and hard-tissue development.

Trust comment: Prospective randomized pilot with objective ultrasound measures but small sample and limited statistical power.

Study Details

PMID:39969589
Participants:24
Impact:Significant increase from baseline to 3 and 6 months with PBMT (p<0.05)
Trust score:3/5

Periapical lesion size/volume/area

1 evidences

Pilot randomized clinical study comparing intracanal calcium hydroxide paste alone vs with adjunctive Nd:YAG photobiomodulation; PBMT increased perfusion and showed greater lesion shrinkage and hard-tissue development.

Trust comment: Prospective randomized pilot with objective ultrasound measures but small sample and limited statistical power.

Study Details

PMID:39969589
Participants:24
Impact:Greater mean reduction in PBMT group vs calcium hydroxide alone (difference not statistically significant)
Trust score:3/5

Echogenicity / hard tissue development

1 evidences

Pilot randomized clinical study comparing intracanal calcium hydroxide paste alone vs with adjunctive Nd:YAG photobiomodulation; PBMT increased perfusion and showed greater lesion shrinkage and hard-tissue development.

Trust comment: Prospective randomized pilot with objective ultrasound measures but small sample and limited statistical power.

Study Details

PMID:39969589
Participants:24
Impact:PBMT group showed improvement from hypoechoic to predominantly hyperechoic indicating more hard-tissue formation
Trust score:3/5

Calcium intake vs dietary climate impact

1 evidences

12-week RCT of diets with varying animal/plant protein proportions; dietary calcium intake correlated positively with diet climate impact and with markers of bone turnover.

Trust comment: Well-conducted randomized dietary trial with objective biomarkers, but correlations are cross-sectional at endpoint and not causal.

Study Details

PMID:39964546
Participants:136
Impact:Positive correlation r=0.37 [0.22, 0.51] (higher calcium intake associated with higher climate impact)
Trust score:4/5

PINP/CTX ratio (bone formation/resorption) vs climate impact

1 evidences

12-week RCT of diets with varying animal/plant protein proportions; dietary calcium intake correlated positively with diet climate impact and with markers of bone turnover.

Trust comment: Well-conducted randomized dietary trial with objective biomarkers, but correlations are cross-sectional at endpoint and not causal.

Study Details

PMID:39964546
Participants:136
Impact:Positive correlations: r=0.31 [0.15,0.46] (diet as such) and r=0.34 [0.18,0.48] (per 2,000 kcal)
Trust score:4/5

Cocoa extract — total clinical fracture

1 evidences

Large factorial RCT testing cocoa extract and a multivitamin (which included 220 mg calcium/day); cocoa extract had no effect on fractures, while daily MVM showed a small borderline increase in fracture risk.

Trust comment: Large, double-blind randomized trial with long follow-up and high compliance; fracture outcomes self-reported but robust trial design.

Study Details

PMID:39964350
Participants:21442
Impact:No significant effect: HR 1.03 (0.95–1.12); p=0.49
Trust score:5/5

Multivitamin (contains calcium 220 mg/day) — total clinical fracture

1 evidences

Large factorial RCT testing cocoa extract and a multivitamin (which included 220 mg calcium/day); cocoa extract had no effect on fractures, while daily MVM showed a small borderline increase in fracture risk.

Trust comment: Large, double-blind randomized trial with long follow-up and high compliance; fracture outcomes self-reported but robust trial design.

Study Details

PMID:39964350
Participants:21442
Impact:Adjusted HR 1.09 (1.00–1.19) — borderline increased risk
Trust score:5/5

Multivitamin — nonvertebral fracture

1 evidences

Large factorial RCT testing cocoa extract and a multivitamin (which included 220 mg calcium/day); cocoa extract had no effect on fractures, while daily MVM showed a small borderline increase in fracture risk.

Trust comment: Large, double-blind randomized trial with long follow-up and high compliance; fracture outcomes self-reported but robust trial design.

Study Details

PMID:39964350
Participants:21442
Impact:Adjusted HR 1.10 (1.00–1.20) — borderline increased risk
Trust score:5/5

5-year clinical/radiographic success rate

1 evidences

Five-year follow-up of RCT comparing calcium silicate-based sealer (calcium-containing) obturation to conventional technique: both had similar long-term clinical and radiographic success.

Trust comment: Randomized long-term follow-up but modest sample size with substantial loss to follow-up (recall rate 64.5%), limiting precision.

Study Details

PMID:39923930
Participants:56
Impact:No significant difference: loose criteria success SBO 87.0% vs CWC 81.8%; strict criteria SBO 78.3% vs CWC 75.8%; overall success ~83.9%
Trust score:3/5

Bone mineral density (lumbar spine, femoral neck, hip)

1 evidences

Adding zoledronic acid to calcium + calcitriol in elderly patients improved bone density, altered bone markers, and increased clinical efficacy with fewer adverse reactions.

Trust comment: Randomized clinical trial in humans with 1-year follow-up and clear bone-related endpoints, but modest sample size limits precision.

Study Details

PMID:40042722
Participants:78
Impact:Increased in zoledronic acid + calcium/calcitriol group vs calcium/calcitriol alone (P<0.05)
Trust score:4/5

bone turnover markers

7 evidences

Adding zoledronic acid to calcium + calcitriol in elderly patients improved bone density, altered bone markers, and increased clinical efficacy with fewer adverse reactions.

Trust comment: Randomized clinical trial in humans with 1-year follow-up and clear bone-related endpoints, but modest sample size limits precision.

Study Details

PMID:40042722
Participants:78
Impact:Decreased BSAP, CTX, P1NP and increased osteocalcin vs control (P<0.05)
Trust score:4/5

Denosumab reduced bone erosion and increased BMD; patients received calcium ≥600 mg/day and vitamin D and some denosumab regimens showed mild decreases in albumin‑adjusted serum calcium within normal range.

Trust comment: Large randomized double‑blind phase II trial with robust radiographic and biochemical endpoints, though calcium effects were secondary and values stayed within normal limits.

Study Details

PMID:26585988
Participants:340
Impact:Marked decreases in CTX‑I and PINP vs placebo (p<0.0001)
Trust score:4/5

In hemodialysis patients with osteoporosis, initial elemental calcium plus calcitriol mitigated early denosumab-induced drops in serum calcium, and both denosumab and alendronate increased lumbar spine BMD at 12 months.

Trust comment: Randomized controlled trial in humans; calcium+calcitriol was used as adjunct and shown to prevent early hypocalcemia, but the study was small and not primarily designed to test calcium alone.

Study Details

PMID:30690785
Participants:48
Impact:both treatments markedly decreased serum bone turnover markers at 12 months
Trust score:3/5

6-month pilot RCT in osteopenic breast cancer survivors found no added bone or performance benefit from adding home exercise to calcium + vitamin D supplements.

Trust comment: Pilot randomized controlled trial in 43 participants; randomized design but small sample limits power.

Study Details

PMID:25730596
Participants:43
Impact:no significant difference
Trust score:3/5

Adding collagen peptides to calcium + vitamin D for 12 months increased trabecular bone mass and vBMD at the tibia, prevented spine aBMD decline, and reduced bone turnover versus calcium + vitamin D alone.

Trust comment: Randomized 12-month study in postmenopausal women with clear imaging and marker endpoints; modest sample size but appropriate measures and statistical reporting.

Study Details

PMID:34980546
Participants:51
Impact:Decreased bone turnover markers in Group A vs Group B
Trust score:4/5

Overweight elderly participants all received 1000 mg elemental calcium/day plus either low or high vitamin D for 1 year; serum 25OHD rose more with high-dose vitamin D but there was little additional benefit on BMD or bone markers overall.

Trust comment: Large double-blind RCT (257 randomized, 222 completed) with objective endpoints; well-conducted but limited generalizability to overweight elderly.

Study Details

PMID:28276596
Participants:222
Impact:little or no additional improvement with high-dose vitamin D
Trust score:4/5

In women with anorexia nervosa, a 4-week protein‑fortified dairy product slightly raised IGF‑I and produced a small increase in serum calcium; no change in bone turnover markers.

Trust comment: Multicenter randomized double‑blind placebo‑controlled trial (good design) but calcium change was small and secondary to a protein/dairy intervention.

Study Details

PMID:26602423
Participants:62
Impact:No between-group change
Trust score:4/5

clinical effective rate

1 evidences

Adding zoledronic acid to calcium + calcitriol in elderly patients improved bone density, altered bone markers, and increased clinical efficacy with fewer adverse reactions.

Trust comment: Randomized clinical trial in humans with 1-year follow-up and clear bone-related endpoints, but modest sample size limits precision.

Study Details

PMID:40042722
Participants:78
Impact:92.31% (CCZ) vs 76.93% (CC); adverse reaction rate 12.82% vs 23.08% (P<0.05)
Trust score:4/5

Serum Ca2+ and phosphorus/Ca×P product

1 evidences

Different dialysis modalities combined with low-calcium dialysate improved mineral metabolism markers, reduced inflammation, and lowered vascular calcification rates, with HD+HP showing the largest effects.

Trust comment: Randomized allocation and multiple objective biochemical and imaging outcomes support moderate trust, but full numeric effect sizes and methodology details are limited in the summary.

Study Details

PMID:40033811
Participants:192
Impact:Decreased after treatment across groups (greatest reduction in HD+HP group)
Trust score:3/5

Inflammatory markers (IL-6, hs-CRP, TNF-α)

1 evidences

Different dialysis modalities combined with low-calcium dialysate improved mineral metabolism markers, reduced inflammation, and lowered vascular calcification rates, with HD+HP showing the largest effects.

Trust comment: Randomized allocation and multiple objective biochemical and imaging outcomes support moderate trust, but full numeric effect sizes and methodology details are limited in the summary.

Study Details

PMID:40033811
Participants:192
Impact:Decreased after treatment (largest decreases in HD+HP, then HDF/HFHD, then HD)
Trust score:3/5

Vascular calcification rate

1 evidences

Different dialysis modalities combined with low-calcium dialysate improved mineral metabolism markers, reduced inflammation, and lowered vascular calcification rates, with HD+HP showing the largest effects.

Trust comment: Randomized allocation and multiple objective biochemical and imaging outcomes support moderate trust, but full numeric effect sizes and methodology details are limited in the summary.

Study Details

PMID:40033811
Participants:192
Impact:Lower in HDF, HFHD, and HD+HP vs HD; lowest in HD+HP
Trust score:3/5

serum calcium and PTH

1 evidences

Over 5 years, parathyroidectomy for mild PHPT normalized calcium/PTH and increased bone mineral density compared with observation.

Trust comment: Randomized controlled multicenter trial with 5‑year follow‑up; some loss to follow‑up but strong design for clinical outcomes.

Study Details

PMID:25636048
Participants:145
Impact:Normalized after parathyroidectomy (sustained); no deterioration with observation
Trust score:4/5

serum albumin

1 evidences

In hospitalized diabetic foot patients, lower blood calcium and albumin and higher neutrophil-to-lymphocyte ratio were associated with worse 6-month outcomes (minor/major amputation or death).

Trust comment: Single-center retrospective analysis of hospitalized patients with clear biomarker measurements and ROC/correlation analyses but possible selection bias and limited generalizability.

Study Details

PMID:36366862
Participants:156
Impact:-11.6357 g/L (39.1857 → 27.5500 from healing to death; −29.7% vs healing)
Trust score:3/5

TDI (olfactory composite) score

1 evidences

Chitosan nasal gel modestly improved olfactory discrimination/identification and significantly reduced calcium levels in nasal mucus compared with saline, though total TDI improvement did not reach clinical significance.

Trust comment: Large randomized, double-blind human trial with objective olfactory testing and calcium measurements, but benefits were modest and clinical relevance borderline.

Study Details

PMID:40007172
Participants:195
Impact:Increased by 4.55 points with chitosan gel (improvement did not reach clinical significance threshold of 5.5 points)
Trust score:3/5

Olfactory discrimination and identification

1 evidences

Chitosan nasal gel modestly improved olfactory discrimination/identification and significantly reduced calcium levels in nasal mucus compared with saline, though total TDI improvement did not reach clinical significance.

Trust comment: Large randomized, double-blind human trial with objective olfactory testing and calcium measurements, but benefits were modest and clinical relevance borderline.

Study Details

PMID:40007172
Participants:195
Impact:Improved with chitosan gel; threshold score unchanged
Trust score:3/5

Nasal mucus calcium level

2 evidences

Chitosan nasal gel modestly improved olfactory discrimination/identification and significantly reduced calcium levels in nasal mucus compared with saline, though total TDI improvement did not reach clinical significance.

Trust comment: Large randomized, double-blind human trial with objective olfactory testing and calcium measurements, but benefits were modest and clinical relevance borderline.

Study Details

PMID:40007172
Participants:195
Impact:Significantly reduced with chitosan gel vs control
Trust score:3/5

Randomized controlled trial testing intranasal 1% sodium phytate vs saline in post-COVID olfactory dysfunction; sodium phytate reduced nasal mucus calcium and produced significant olfactory improvement compared with saline.

Trust comment: Randomized, double-controlled trial showing biomarker and clinical changes, but small sample size limits precision and generalizability.

Study Details

PMID:38105576
Participants:52
Impact:Decreased after treatment with sodium phytate (statistically significant)
Trust score:3/5

treatment success rate (per-protocol)

1 evidences

In immature permanent teeth with complicated crown fractures, iRoot BP Plus had similar clinical success to calcium hydroxide over 3 years; root development was preserved.

Trust comment: Prospective randomized controlled trial with 3-year follow-up; clinically relevant outcomes though some loss to follow-up and modest sample size.

Study Details

PMID:39690774
Participants:89
Impact:iRoot 87% vs calcium hydroxide 80% (no significant difference)
Trust score:4/5

dentin depth increase (mesial/middle/distal)

1 evidences

Double-blind RCT comparing Biodentine® versus calcium hydroxide for indirect pulp capping; both promoted dentin bridge formation, with Biodentine showing greater dentin increase at 9 months.

Trust comment: Double-blind randomized clinical trial with clear numeric outcomes and 50 subjects supports moderate-to-high trust for dental effects of calcium-containing material (Ca(OH)2).

Study Details

PMID:39862396
Participants:50
Impact:Biodentine ~0.66–0.67±0.07 mm vs Ca(OH)2 ~0.52–0.55±0.07 mm at 9 months (Biodentine greater, p=0.001)
Trust score:4/5

dentin bridge formation (overall)

1 evidences

Double-blind RCT comparing Biodentine® versus calcium hydroxide for indirect pulp capping; both promoted dentin bridge formation, with Biodentine showing greater dentin increase at 9 months.

Trust comment: Double-blind randomized clinical trial with clear numeric outcomes and 50 subjects supports moderate-to-high trust for dental effects of calcium-containing material (Ca(OH)2).

Study Details

PMID:39862396
Participants:50
Impact:Both materials efficacious; Biodentine produced significantly greater mean dentin increase at 9 months
Trust score:4/5

calcaneal bone density (YAM)

1 evidences

24‑week double-blind RCT of calcium maltobionate tablets vs placebo in Japanese women; calcium maltobionate mitigated declines and in some sites increased bone density and reduced a bone resorption marker, especially in post‑menopausal women.

Trust comment: Randomized, double-blind, placebo-controlled trial with pre-specified outcomes and per-protocol analysis (48 completers); moderate-to-high trust for effect of a specific calcium salt (calcium maltobionate).

Study Details

PMID:39861392
Participants:48
Impact:Significantly higher YAM change in test vs placebo in post‑menopausal participants (maintained/increased vs decline)
Trust score:4/5

facial bone density (CT Hounsfield units)

1 evidences

24‑week double-blind RCT of calcium maltobionate tablets vs placebo in Japanese women; calcium maltobionate mitigated declines and in some sites increased bone density and reduced a bone resorption marker, especially in post‑menopausal women.

Trust comment: Randomized, double-blind, placebo-controlled trial with pre-specified outcomes and per-protocol analysis (48 completers); moderate-to-high trust for effect of a specific calcium salt (calcium maltobionate).

Study Details

PMID:39861392
Participants:48
Impact:Significant increases/greater percent change in HU values at multiple facial bone sites in test vs placebo (pre- and post‑menopausal analyses)
Trust score:4/5

urinary DPD (bone resorption marker)

1 evidences

24‑week double-blind RCT of calcium maltobionate tablets vs placebo in Japanese women; calcium maltobionate mitigated declines and in some sites increased bone density and reduced a bone resorption marker, especially in post‑menopausal women.

Trust comment: Randomized, double-blind, placebo-controlled trial with pre-specified outcomes and per-protocol analysis (48 completers); moderate-to-high trust for effect of a specific calcium salt (calcium maltobionate).

Study Details

PMID:39861392
Participants:48
Impact:Significantly lower change/percent change in DPD in test vs placebo in post‑menopausal participants (reduced bone resorption marker)
Trust score:4/5

clinical attachment gain

1 evidences

Adding a biphasic calcium phosphate bone graft to enamel matrix derivative did not improve periodontal healing versus enamel matrix alone over 3 years.

Trust comment: Randomized, multicenter, 36-month follow-up but small sample (n=30) limits precision.

Study Details

PMID:26174080
Participants:30
Impact:EMD+SBG: +4.1 mm vs EMD: +3.8 mm; no significant difference
Trust score:4/5

serum-adjusted calcium

1 evidences

Single-center randomized trial (68 per arm) comparing percutaneous ethanol ablation (PEA) to parathyroidectomy (PTx) for solitary parathyroid adenoma; both treatments substantially reduced PTH, serum-adjusted calcium and adenoma size with similar efficacy at 6 months.

Trust comment: Well-powered randomized trial with ITT analysis and detailed laboratory follow-up; high trust for reported effects on serum calcium and PTH (though not a calcium-supplement study).

Study Details

PMID:39849501
Participants:136
Impact:Significant reduction after both interventions (PEA ~10.5→8.8 mg/dL at 6 months; PTx similar); no significant difference between groups
Trust score:4/5

adenoma size/volume

1 evidences

Single-center randomized trial (68 per arm) comparing percutaneous ethanol ablation (PEA) to parathyroidectomy (PTx) for solitary parathyroid adenoma; both treatments substantially reduced PTH, serum-adjusted calcium and adenoma size with similar efficacy at 6 months.

Trust comment: Well-powered randomized trial with ITT analysis and detailed laboratory follow-up; high trust for reported effects on serum calcium and PTH (though not a calcium-supplement study).

Study Details

PMID:39849501
Participants:136
Impact:Adenoma diameter and volume reduced after interventions; outcomes influenced recurrence risk (larger adenomas more likely to persist after PEA)
Trust score:4/5

postoperative atrial fibrillation (POAF) — mitral valve (CAP-AF2)

1 evidences

Two randomized, double-blind, sham-controlled trials testing intraprocedural injections of 5% CaCl2 vs saline into atrial ganglionated plexi to prevent postoperative atrial fibrillation (POAF); results varied by surgery type—worse POAF with CaCl2 in mitral valve surgery and no benefit in aortic valve surgery.

Trust comment: Large, randomized, double-blind sham-controlled trials with clear safety signal in one trial (CAP-AF2); high methodological quality for assessing effects of local calcium chloride injection on cardiac outcomes.

Study Details

PMID:39846931
Participants:399
Impact:Higher POAF incidence with CaCl2: 55.13% vs 37.80% (NaCl), p=0.028 (trial stopped for safety)
Trust score:4/5

postoperative atrial fibrillation (POAF) — aortic valve (CAP-AF3)

1 evidences

Two randomized, double-blind, sham-controlled trials testing intraprocedural injections of 5% CaCl2 vs saline into atrial ganglionated plexi to prevent postoperative atrial fibrillation (POAF); results varied by surgery type—worse POAF with CaCl2 in mitral valve surgery and no benefit in aortic valve surgery.

Trust comment: Large, randomized, double-blind sham-controlled trials with clear safety signal in one trial (CAP-AF2); high methodological quality for assessing effects of local calcium chloride injection on cardiac outcomes.

Study Details

PMID:39846931
Participants:399
Impact:No significant difference: 35.59% (CaCl2) vs 39.67% (NaCl), p=0.516
Trust score:4/5

secondary outcomes (hospital stay, AF burden, antiarrhythmic therapy)

1 evidences

Two randomized, double-blind, sham-controlled trials testing intraprocedural injections of 5% CaCl2 vs saline into atrial ganglionated plexi to prevent postoperative atrial fibrillation (POAF); results varied by surgery type—worse POAF with CaCl2 in mitral valve surgery and no benefit in aortic valve surgery.

Trust comment: Large, randomized, double-blind sham-controlled trials with clear safety signal in one trial (CAP-AF2); high methodological quality for assessing effects of local calcium chloride injection on cardiac outcomes.

Study Details

PMID:39846931
Participants:399
Impact:No significant differences between CaCl2 and control in both trials
Trust score:4/5

parathyroid gland identification

1 evidences

An imaging method helped surgeons identify and preserve parathyroid glands, resulting in higher postoperative PTH and calcium and fewer cases of low parathyroid function.

Trust comment: Randomized study with clear clinical endpoints and 100 elderly patients; methods and outcomes reported but full methodological details (e.g., blinding, multicenter) limited in abstract.

Study Details

PMID:39807041
Participants:100
Impact:increased (more glands identified during surgery)
Trust score:4/5

postoperative PTH

1 evidences

An imaging method helped surgeons identify and preserve parathyroid glands, resulting in higher postoperative PTH and calcium and fewer cases of low parathyroid function.

Trust comment: Randomized study with clear clinical endpoints and 100 elderly patients; methods and outcomes reported but full methodological details (e.g., blinding, multicenter) limited in abstract.

Study Details

PMID:39807041
Participants:100
Impact:higher (at postoperative days 1, 3 and 6 months)
Trust score:4/5

postoperative hypoparathyroidism incidence

1 evidences

An imaging method helped surgeons identify and preserve parathyroid glands, resulting in higher postoperative PTH and calcium and fewer cases of low parathyroid function.

Trust comment: Randomized study with clear clinical endpoints and 100 elderly patients; methods and outcomes reported but full methodological details (e.g., blinding, multicenter) limited in abstract.

Study Details

PMID:39807041
Participants:100
Impact:decreased (lower incidence in observation group)
Trust score:4/5

ionized calcium (iCa)

2 evidences

Taking 1000 mg calcium 60 min before prolonged load carriage kept blood calcium higher, lowered PTH, and reduced markers of bone breakdown versus no supplement.

Trust comment: Randomized crossover trial with frequent timed biochemical sampling and relevant biomarkers in 48 women, providing high internal validity for acute metabolic effects.

Study Details

PMID:39804018
Participants:48
Impact:higher throughout exercise with 1000 mg supplement
Trust score:5/5

In a randomized crossover study of healthy women, strenuous load-carriage exercise lowered ionized calcium, raised PTH, increased fractional calcium absorption, and produced a more positive calcium balance.

Trust comment: Randomized crossover human study with dual stable Ca isotopes and direct kinetic measures; rigorous methods but small sample size (n=21).

Study Details

PMID:38630876
Participants:21
Impact:decreased during exercise (rapid reduction observed)
Trust score:4/5

bone resorption (CTX)

3 evidences

Taking 1000 mg calcium 60 min before prolonged load carriage kept blood calcium higher, lowered PTH, and reduced markers of bone breakdown versus no supplement.

Trust comment: Randomized crossover trial with frequent timed biochemical sampling and relevant biomarkers in 48 women, providing high internal validity for acute metabolic effects.

Study Details

PMID:39804018
Participants:48
Impact:decreased with supplement (lower than control from 20 to +90 min)
Trust score:5/5

Pregnant women in an individualized high-dairy-protein diet plus walking program had higher dietary calcium and protein intakes which was associated with reduced bone resorption and preserved bone formation during pregnancy and postpartum.

Trust comment: Randomized controlled trial with objective bone biomarkers and good completion rate, but calcium was increased together with protein/exercise so the calcium-specific effect is not isolated.

Study Details

PMID:35759368
Participants:187
Impact:decreased (minimized vs control)
Trust score:4/5

Five days of low energy availability increased bone resorption and decreased bone formation in women but not in men.

Trust comment: Randomized crossover with objective biomarkers but small short-term sample limits generalizability.

Study Details

PMID:28847532
Participants:22
Impact:β-CTX AUC increased in women (P=0.03); no significant change in men
Trust score:3/5

clinical/radiographic success (IPT)

1 evidences

In children needing indirect pulp therapy, calcium hydroxide performed similarly to other agents for clinical and radiographic success at 12 months, with moderate dentin bridge formation.

Trust comment: Randomized controlled trial but small sample (45 children, 60 teeth); outcomes clinically meaningful though limited by sample size and single follow-up duration.

Study Details

PMID:39798105
Participants:45
Impact:Ca(OH)2 success 88.2% at 12 months (comparable to other materials)
Trust score:3/5

MACE risk (CAC ≥300 vs 0)

1 evidences

Higher coronary artery calcium scores identified individuals without diabetes who had substantially higher risks of cardiovascular events, heart failure, CKD, and death, suggesting CAC can target semaglutide allocation.

Trust comment: Large, well-characterized cohort (MESA) with standardized CAC measurement and robust event ascertainment; observational associations limit causal inference but are strong and clinically relevant.

Study Details

PMID:39797878
Participants:3129
Impact:+116% risk (HR 2.16)
Trust score:4/5

heart failure risk

1 evidences

Higher coronary artery calcium scores identified individuals without diabetes who had substantially higher risks of cardiovascular events, heart failure, CKD, and death, suggesting CAC can target semaglutide allocation.

Trust comment: Large, well-characterized cohort (MESA) with standardized CAC measurement and robust event ascertainment; observational associations limit causal inference but are strong and clinically relevant.

Study Details

PMID:39797878
Participants:3129
Impact:+180% risk (HR 2.80)
Trust score:4/5

CKD risk

1 evidences

Higher coronary artery calcium scores identified individuals without diabetes who had substantially higher risks of cardiovascular events, heart failure, CKD, and death, suggesting CAC can target semaglutide allocation.

Trust comment: Large, well-characterized cohort (MESA) with standardized CAC measurement and robust event ascertainment; observational associations limit causal inference but are strong and clinically relevant.

Study Details

PMID:39797878
Participants:3129
Impact:+59% risk (HR 1.59)
Trust score:4/5

all-cause mortality

6 evidences

Large prospective cohort showing calcium channel blocker (CCB) use was associated with higher long-term all-cause and CVD mortality; associations were attenuated in patients receiving B-vitamin treatment.

Trust comment: Large, well-characterized observational cohort (n=3991) with long follow-up and multivariable adjustment; residual confounding and confounding by indication remain possible.

Study Details

PMID:37121550
Participants:3991
Impact:increased with CCB use (adjusted HR ≈1.34; ~+34%); association attenuated/absent in patients treated with B-vitamins
Trust score:4/5

Higher coronary artery calcium scores identified individuals without diabetes who had substantially higher risks of cardiovascular events, heart failure, CKD, and death, suggesting CAC can target semaglutide allocation.

Trust comment: Large, well-characterized cohort (MESA) with standardized CAC measurement and robust event ascertainment; observational associations limit causal inference but are strong and clinically relevant.

Study Details

PMID:39797878
Participants:3129
Impact:+35% risk (HR 1.35)
Trust score:4/5

Long-term follow-up of postmenopausal women randomized to calcium plus vitamin D showed reduced cancer mortality but a small increase in cardiovascular mortality, with no effect on all-cause mortality.

Trust comment: Very large randomized trial with long follow-up and clinically important outcomes; post-hoc analyses limit causal detail but overall high-quality evidence.

Study Details

PMID:38467003
Participants:36282
Impact:No effect (HR 1.00, 95% CI 0.97–1.03)
Trust score:5/5

Intradialytic exercise for 6 months improved 12-month survival and led to increases in serum calcium, physical function, and nutritional markers.

Trust comment: Randomized controlled trial with blinded end-points and balanced groups, but single-center and modest sample size limits precision.

Study Details

PMID:37069527
Participants:74
Impact:−21 percentage points (6% intervention vs 27% control); HR 0.17
Trust score:4/5

Post-hoc analysis of a large hemodialysis RCT: low-dose oral alfacalcidol did not significantly change cardiovascular events or mortality and ALP did not modify effects.

Trust comment: Large randomized trial with blinded event adjudication and long follow-up; this is a post-hoc subgroup analysis which reduces power for interaction testing.

Study Details

PMID:36104443
Participants:959
Impact:No significant between-group difference and no significant modification by ALP (P for interaction = 0.74)
Trust score:4/5

78 patients were randomized and 58 completed 12 months; Algisyl (injectable calcium alginate hydrogel) plus standard therapy improved exercise capacity and symptoms at 12 months but was associated with higher mortality in the treated group.

Trust comment: Randomized multicenter trial with modest sample size and open-label design; objective exercise outcomes improved but mortality signal raises safety concerns.

Study Details

PMID:26555602
Participants:58
Impact:Algisyl: 9 (22.5%) vs control: 4 (10.5%), higher deaths in treatment arm
Trust score:3/5

calcium intake/adequacy

6 evidences

78 adults with IBS-D followed a low-FODMAP or mNICE diet for 4 weeks; fewer people in the mNICE group met the calcium dietary reference intake after the diet.

Trust comment: Post-hoc analysis of an RCT with 3-day food diaries and modest sample size; dietary intake self-reported which limits precision.

Study Details

PMID:31103370
Participants:78
Impact:decreased (fewer met DRI post-intervention in mNICE group)
Trust score:3/5

In celiac patients on a gluten-free diet, adding a 3-week low-FODMAP restriction did not worsen micronutrient adequacy; calcium intake remained below RDA in both groups.

Trust comment: Randomized controlled short-term trial with small sample (21 vs 25) and dietary monitoring; limited duration reduces inference about long-term calcium status.

Study Details

PMID:31540014
Participants:46
Impact:below RDA in both R-GFD and LF-GFD groups; low-FODMAP restriction did not significantly change calcium adequacy over 21 days
Trust score:3/5

Baseline cross-sectional analysis of 6646 adults with metabolic syndrome found many had suboptimal nutrient intakes, including calcium.

Trust comment: Large cross-sectional sample with validated FFQ assessing nutrient intakes, suitable for estimating prevalence though not causal effects.

Study Details

PMID:31101439
Participants:6646
Impact:high prevalence of inadequate intake (considerable proportion deficient)
Trust score:4/5

Oral nutritional supplements plus dietary counseling increased energy and micronutrient intakes (including calcium), and improved appetite versus counseling alone in picky-eating children over 90 days.

Trust comment: Randomized, multi-center, double-blind trial with robust dietary assessment and high compliance—relevant indirect evidence about increasing calcium intake via supplements.

Study Details

PMID:37299491
Participants:321
Impact:Calcium intake rose to >100% of EAR by Day 90 in both supplemented groups (control: 40.2% → 48.5% meeting EAR); supplemented groups showed significant increases versus control (p<.05)
Trust score:4/5

A prenatal meal-replacement program increased micronutrient intake and reduced inadequate intakes in pregnant women with overweight/obesity.

Trust comment: Randomized controlled trial with blinded assessors and objective dietary recalls, moderate-to-high internal validity.

Study Details

PMID:31091748
Participants:211
Impact:reduced odds of inadequate intake by 66% (OR=0.34, p=0.007)
Trust score:4/5

Dietary recalls in 12-month-old infants showed generally low nutrient intakes and inadequacy for multiple micronutrients including calcium, with protein intake slightly higher in the intervention arm.

Trust comment: Sub-sample of a cluster randomized trial with validated dietary recall methods (n=282); single 24-h recall limits individual-level precision but group comparisons are robust.

Study Details

PMID:39796565
Participants:282
Impact:generally below RNI across sample; no difference between arms; seasonal variation significant
Trust score:4/5

Nutrient adequacy (overall)

1 evidences

Dietary recalls in 12-month-old infants showed generally low nutrient intakes and inadequacy for multiple micronutrients including calcium, with protein intake slightly higher in the intervention arm.

Trust comment: Sub-sample of a cluster randomized trial with validated dietary recall methods (n=282); single 24-h recall limits individual-level precision but group comparisons are robust.

Study Details

PMID:39796565
Participants:282
Impact:most macro- and micronutrients below RNI in this population
Trust score:4/5

coronary artery calcium score

1 evidences

In a CT-imaged cohort, people with diabetes had more calcified coronary plaque and higher heart attack risk over ~9 years.

Trust comment: Large, well-characterized imaging cohort with long follow-up; observational subgroup analysis limits causal inference.

Study Details

PMID:39788814
Participants:1769
Impact:median 71 vs 17 Agatston units (diabetes vs no diabetes); p < 0.001
Trust score:4/5

calcified plaque burden

1 evidences

In a CT-imaged cohort, people with diabetes had more calcified coronary plaque and higher heart attack risk over ~9 years.

Trust comment: Large, well-characterized imaging cohort with long follow-up; observational subgroup analysis limits causal inference.

Study Details

PMID:39788814
Participants:1769
Impact:increased in diabetes; independent predictor (p = 0.009)
Trust score:4/5

myocardial infarction risk

1 evidences

In a CT-imaged cohort, people with diabetes had more calcified coronary plaque and higher heart attack risk over ~9 years.

Trust comment: Large, well-characterized imaging cohort with long follow-up; observational subgroup analysis limits causal inference.

Study Details

PMID:39788814
Participants:1769
Impact:hazard ratio 1.85 (95% CI 1.09–3.17); +85% risk; p = 0.024
Trust score:4/5

lean mass (total and appendicular)

1 evidences

In older men doing home-based resistance exercise, obesity/metabolic risk reduced anabolic response; a higher-quality multi-ingredient supplement (which included calcium) produced better lean-mass, strength and bone marker outcomes than a lower-quality supplement.

Trust comment: Original study was a randomized, double-blind trial; current report is a retrospective analysis on a modest sample (n=32) and includes a multi-ingredient supplement so calcium-specific effects are not isolated.

Study Details

PMID:39771028
Participants:32
Impact:greater Δ gains with higher-quality MIS (M5) vs lower-quality PLA (significant between-group differences)
Trust score:4/5

strength (grip, leg press)

1 evidences

In older men doing home-based resistance exercise, obesity/metabolic risk reduced anabolic response; a higher-quality multi-ingredient supplement (which included calcium) produced better lean-mass, strength and bone marker outcomes than a lower-quality supplement.

Trust comment: Original study was a randomized, double-blind trial; current report is a retrospective analysis on a modest sample (n=32) and includes a multi-ingredient supplement so calcium-specific effects are not isolated.

Study Details

PMID:39771028
Participants:32
Impact:significant pre-to-post improvements in M5 group vs PLA (grip and leg press improved; P < 0.05)
Trust score:4/5

extracellular matrix / regenerative gene expression (PLLA)

1 evidences

In facial injection biopsies, poly-L-lactic acid stimulated regenerative extracellular-matrix pathways, whereas calcium hydroxylapatite induced stronger pro-inflammatory gene responses.

Trust comment: Randomized single-center biopsy study with small n and molecular endpoints; findings are biologically plausible but limited by sample size and short follow-up.

Study Details

PMID:39761144
Participants:21
Impact:upregulated ECM and regenerative pathways (translating to regenerative signature vs CaHA)
Trust score:3/5

pro-inflammatory gene expression (CaHA)

1 evidences

In facial injection biopsies, poly-L-lactic acid stimulated regenerative extracellular-matrix pathways, whereas calcium hydroxylapatite induced stronger pro-inflammatory gene responses.

Trust comment: Randomized single-center biopsy study with small n and molecular endpoints; findings are biologically plausible but limited by sample size and short follow-up.

Study Details

PMID:39761144
Participants:21
Impact:upregulated more pro-inflammatory pathway genes compared with PLLA
Trust score:3/5

maternal calcium level

1 evidences

Personalized nutritional guidance during pregnancy increased maternal nutrient levels (including calcium) and was associated with better pregnancy and neonatal outcomes versus routine guidance.

Trust comment: Randomized two-arm study with adequate sample size (n=200) but limited methodological detail reported here (unclear blinding, single center) and outcomes reported without detailed effect sizes.

Study Details

PMID:39760216
Participants:200
Impact:higher in intervention group vs control (exact values not reported)
Trust score:3/5

adverse birth outcomes

1 evidences

Personalized nutritional guidance during pregnancy increased maternal nutrient levels (including calcium) and was associated with better pregnancy and neonatal outcomes versus routine guidance.

Trust comment: Randomized two-arm study with adequate sample size (n=200) but limited methodological detail reported here (unclear blinding, single center) and outcomes reported without detailed effect sizes.

Study Details

PMID:39760216
Participants:200
Impact:lower incidence in intervention group vs control (exact risk reduction not reported)
Trust score:3/5

fetal birth weight and Apgar score

1 evidences

Personalized nutritional guidance during pregnancy increased maternal nutrient levels (including calcium) and was associated with better pregnancy and neonatal outcomes versus routine guidance.

Trust comment: Randomized two-arm study with adequate sample size (n=200) but limited methodological detail reported here (unclear blinding, single center) and outcomes reported without detailed effect sizes.

Study Details

PMID:39760216
Participants:200
Impact:higher fetal body weight and higher Apgar scores in intervention group (no numeric values provided)
Trust score:3/5

urine RSR CaP (brushite/carbonate apatite supersaturation) in calcium stone formers

1 evidences

In nondiabetic kidney stone formers, empagliflozin significantly improved urine supersaturation measures linked to stone risk: it reduced CaP supersaturation in calcium stone formers and reduced uric-acid supersaturation in UA stone formers.

Trust comment: Randomized, double-blind, placebo-controlled crossover phase 2 trial with objective biochemical primary endpoints and prespecified analysis.

Study Details

PMID:39747681
Participants:53
Impact:reduced by 36% with empagliflozin vs placebo (95% CI −48% to −21%); P < 0.001
Trust score:5/5

urine RSR UA in uric-acid stone formers

1 evidences

In nondiabetic kidney stone formers, empagliflozin significantly improved urine supersaturation measures linked to stone risk: it reduced CaP supersaturation in calcium stone formers and reduced uric-acid supersaturation in UA stone formers.

Trust comment: Randomized, double-blind, placebo-controlled crossover phase 2 trial with objective biochemical primary endpoints and prespecified analysis.

Study Details

PMID:39747681
Participants:53
Impact:reduced by 30% with empagliflozin vs placebo (95% CI −44% to −12%); P = 0.002
Trust score:5/5

urine citrate excretion (calcium stone group)

1 evidences

In nondiabetic kidney stone formers, empagliflozin significantly improved urine supersaturation measures linked to stone risk: it reduced CaP supersaturation in calcium stone formers and reduced uric-acid supersaturation in UA stone formers.

Trust comment: Randomized, double-blind, placebo-controlled crossover phase 2 trial with objective biochemical primary endpoints and prespecified analysis.

Study Details

PMID:39747681
Participants:53
Impact:increased by ~60% with empagliflozin vs placebo (95% CI 39%–85%)
Trust score:5/5

odontoblastic integrity

1 evidences

In a split-mouth randomized trial in children, WMTA mixed with 2.25% NaOCl gel improved short‑term odontoblastic integrity but showed less complete dentin bridge formation and more early pulp calcification compared with WMTA mixed with distilled water.

Trust comment: Triple‑blinded, randomized split‑mouth histologic trial with clearly reported outcomes but limited by small sample size and relatively short follow-up.

Study Details

PMID:39733128
Participants:24
Impact:better with WMTA + NaOCl gel at 7, 30, and 90 days (e.g., 100% normal morphology at 90 days in NaOCl group)
Trust score:4/5

pulp calcification

1 evidences

In a split-mouth randomized trial in children, WMTA mixed with 2.25% NaOCl gel improved short‑term odontoblastic integrity but showed less complete dentin bridge formation and more early pulp calcification compared with WMTA mixed with distilled water.

Trust comment: Triple‑blinded, randomized split‑mouth histologic trial with clearly reported outcomes but limited by small sample size and relatively short follow-up.

Study Details

PMID:39733128
Participants:24
Impact:greater early pulp calcification observed with WMTA + NaOCl gel vs control (significant differences at multiple timepoints)
Trust score:4/5

Systolic blood pressure

5 evidences

Acute calcium supplementation modestly attenuated the diurnal fall in blood pressure and increased some measures of blood coagulability.

Trust comment: Randomized controlled trial with 100 participants and objective hemodynamic and coagulation measures; subgroup TEG limited to 40 participants.

Study Details

PMID:26420590
Participants:100
Impact:reduction smaller in calcium group by >5 mmHg between 2–6 h (P≤0.02)
Trust score:4/5

Daily low-fat milk fortified with 1000 mg calcium + 800 IU vitamin D3, alone or with exercise, did not improve blood pressure or blood lipids over 18 months in middle-aged and older men.

Trust comment: 18-month randomized factorial trial with 180 participants; direct evaluation of dietary calcium fortification—well-conducted secondary analysis.

Study Details

PMID:32666313
Participants:180
Impact:No effect of fortified milk vs control; observed reductions from baseline to 18 months across groups: −5 to −8 mmHg
Trust score:4/5

Sub-study of a randomized trial in women with prior pre-eclampsia and low dietary calcium intake: 500 mg/day calcium vs placebo for up to 12 weeks pre-pregnancy; calcium modestly lowered systolic and mean arterial pressure at 12 weeks.

Trust comment: Large, multicentre randomized double-blind trial sub-study with standardized BP measurement and intention-to-treat analysis; moderate–high trust in blood-pressure findings.

Study Details

PMID:33302116
Participants:791
Impact:−3.1 mmHg (mean difference vs placebo; 95% CI 0.8 to 5.4; p=0.009)
Trust score:4/5

In vitamin D–insufficient adults with type 2 diabetes, 8 weeks of calcium plus vitamin D reduced BMI, hip circumference, and systolic blood pressure versus placebo.

Trust comment: Randomized placebo-controlled trial with moderate sample size but short (8-week) duration.

Study Details

PMID:25738212
Participants:118
Impact:-7.3 ± 8.7 mmHg (calcium+vitamin D) vs +0.5 ± 8.2 mmHg (placebo); p = 0.001
Trust score:4/5

In a repeated-measures cohort, higher ambient temperature lowered blood pressure mainly via a direct effect; urinary calcium contributed a very small indirect (mediated) increase in BP per 5°C rise.

Trust comment: Large repeated-measures study with 24-hour urine measures and causal mediation analysis, well-adjusted models and sensitivity analyses.

Study Details

PMID:39705978
Participants:1175
Impact:direct effect −1.42 mmHg per 5°C increase; urine calcium-mediated indirect effect +0.06 mmHg per 5°C
Trust score:5/5

Diastolic blood pressure

6 evidences

In a repeated-measures cohort, higher ambient temperature lowered blood pressure mainly via a direct effect; urinary calcium contributed a very small indirect (mediated) increase in BP per 5°C rise.

Trust comment: Large repeated-measures study with 24-hour urine measures and causal mediation analysis, well-adjusted models and sensitivity analyses.

Study Details

PMID:39705978
Participants:1175
Impact:direct effect −1.33 mmHg per 5°C increase; urine calcium-mediated indirect effect +0.08 mmHg per 5°C
Trust score:5/5

Sub-study of a randomized trial in women with prior pre-eclampsia and low dietary calcium intake: 500 mg/day calcium vs placebo for up to 12 weeks pre-pregnancy; calcium modestly lowered systolic and mean arterial pressure at 12 weeks.

Trust comment: Large, multicentre randomized double-blind trial sub-study with standardized BP measurement and intention-to-treat analysis; moderate–high trust in blood-pressure findings.

Study Details

PMID:33302116
Participants:791
Impact:−1.4 mmHg (mean difference vs placebo; 95% CI −0.5 to 3.3; not statistically significant)
Trust score:4/5

Daily low-fat milk fortified with 1000 mg calcium + 800 IU vitamin D3, alone or with exercise, did not improve blood pressure or blood lipids over 18 months in middle-aged and older men.

Trust comment: 18-month randomized factorial trial with 180 participants; direct evaluation of dietary calcium fortification—well-conducted secondary analysis.

Study Details

PMID:32666313
Participants:180
Impact:No effect of fortified milk vs control; observed reductions from baseline to 18 months: −4 to −6 mmHg
Trust score:4/5

Acute calcium supplementation modestly attenuated the diurnal fall in blood pressure and increased some measures of blood coagulability.

Trust comment: Randomized controlled trial with 100 participants and objective hemodynamic and coagulation measures; subgroup TEG limited to 40 participants.

Study Details

PMID:26420590
Participants:100
Impact:reduction smaller in calcium group by 4.5 mmHg at 2 h (P=0.004)
Trust score:4/5

In premenopausal women, urinary isoflavone excretion modified the relationship between serum calcium and blood pressure — isoflavone exposure tended to normalize systolic BP responses to varying calcium levels and reduced diastolic BP modestly.

Trust comment: Randomized double-blind placebo-controlled trial with ~197 participants; reported effects rely on per-protocol/excretion-based analyses rather than primary intention-to-treat results.

Study Details

PMID:31535213
Participants:197
Impact:approximate decrease ~2.6 mmHg (per-protocol analysis) associated with isoflavone excretion
Trust score:4/5

In 97 CKD patients with hyperkalemia, both calcium and sodium polystyrene resins lowered potassium; calcium resin had fewer side effects.

Trust comment: Randomized controlled trial but single-center with modest sample size; moderate overall quality.

Study Details

PMID:25672163
Participants:97
Impact:increase observed in SPS group (p=0.004)
Trust score:3/5

tooth vitality (success rate)

1 evidences

Selective removal to soft dentin (with or without calcium silicate) had higher 5-year tooth vitality success than selective removal to firm dentin; calcium silicate improved dentin bridge formation in deeper cavities.

Trust comment: Randomized controlled trial with 5-year follow-up; well-defined clinical outcomes though sample groups uneven and some subgroup analyses.

Study Details

PMID:39702606
Participants:134
Impact:SRSD ± calcium silicate 94.1–100% vs SRFD 75.8% (higher success for SRSD)
Trust score:4/5

root canal wall thickness (upper 1/3)

1 evidences

In immature permanent teeth with complicated crown fractures, iRoot BP Plus had similar clinical success to calcium hydroxide over 3 years; root development was preserved.

Trust comment: Prospective randomized controlled trial with 3-year follow-up; clinically relevant outcomes though some loss to follow-up and modest sample size.

Study Details

PMID:39690774
Participants:89
Impact:iRoot group slightly thinner (1.82 mm vs 1.91 mm; P=0.047)
Trust score:4/5

cumulative clinical success rate

1 evidences

In children with deep caries, pulpotomy using three bioceramic calcium silicate cements showed high clinical and radiographic success over 24 months with no significant differences between materials.

Trust comment: Prospective randomized clinical trial with 24‑month follow-up and moderate sample (117 treated molars); well‑reported but outcome unit is treated teeth rather than number of children.

Study Details

PMID:39641370
Participants:117
Impact:NeoPUTTY 92%; NeoMTA Plus 97%; Biodentine 95%
Trust score:4/5

cumulative radiographic success rate

1 evidences

In children with deep caries, pulpotomy using three bioceramic calcium silicate cements showed high clinical and radiographic success over 24 months with no significant differences between materials.

Trust comment: Prospective randomized clinical trial with 24‑month follow-up and moderate sample (117 treated molars); well‑reported but outcome unit is treated teeth rather than number of children.

Study Details

PMID:39641370
Participants:117
Impact:NeoPUTTY 92%; NeoMTA Plus 97%; Biodentine 89%
Trust score:4/5

serum calcium AUC (0–8 h)

1 evidences

In bariatric surgery patients ~9–10 months post‑op, calcium citrate produced greater calcium bioavailability than calcium carbonate: higher serum AUC and Cmax, greater urinary calcium excretion, and larger PTH suppression.

Trust comment: Large (n=150), double‑blind randomized crossover with direct pharmacokinetic and biochemical measurements; strong design and relevant endpoints.

Study Details

PMID:39603923
Participants:150
Impact:Citrate 76.1 vs Carbonate 74.7 mg/dL·h (P = 0.001)
Trust score:5/5

serum calcium Cmax

1 evidences

In bariatric surgery patients ~9–10 months post‑op, calcium citrate produced greater calcium bioavailability than calcium carbonate: higher serum AUC and Cmax, greater urinary calcium excretion, and larger PTH suppression.

Trust comment: Large (n=150), double‑blind randomized crossover with direct pharmacokinetic and biochemical measurements; strong design and relevant endpoints.

Study Details

PMID:39603923
Participants:150
Impact:Citrate 9.8 vs Carbonate 9.5 mg/dL (P < 0.001)
Trust score:5/5

urinary calcium excretion (9 h)

1 evidences

In bariatric surgery patients ~9–10 months post‑op, calcium citrate produced greater calcium bioavailability than calcium carbonate: higher serum AUC and Cmax, greater urinary calcium excretion, and larger PTH suppression.

Trust comment: Large (n=150), double‑blind randomized crossover with direct pharmacokinetic and biochemical measurements; strong design and relevant endpoints.

Study Details

PMID:39603923
Participants:150
Impact:Citrate 83.7 mg vs Carbonate 68.6 mg (P < 0.001)
Trust score:5/5

Plasma phosphate

2 evidences

Extended-release niacin slightly lowered serum phosphate over 3 years but did not change calcium or other mineral markers.

Trust comment: Large randomized double-blind placebo-controlled trial (n=352) with clear numeric phosphate result; calcium-related markers showed null effects.

Study Details

PMID:29208626
Participants:352
Impact:decreased by 0.08 mg/dL per year vs placebo (p=0.03)
Trust score:4/5

In a controlled crossover trial, potassium supplementation lowered FGF23 and fractional calcium excretion and increased plasma phosphate/TmP-GFR; sodium supplementation also lowered FGF23 but increased urinary (and fractional) calcium excretion.

Trust comment: Well-controlled, double-blind randomized placebo-controlled crossover with dietary control (n=36); post-hoc analysis but robust biochemical measures.

Study Details

PMID:32506135
Participants:36
Impact:increased ≈+5.5% with potassium (P=0.004); decreased ≈−3.4% with sodium (P=0.03)
Trust score:4/5

24 h urinary calcium excretion

1 evidences

Randomized controlled trial showing that advising and achieving adequate dietary calcium intake (1,000–1,200 mg/day) in hypoparathyroidism patients non-adherent to supplements corrected hypocalcemia in most patients (87.5% reached target Ca) without short-term safety issues.

Trust comment: Prospective randomized controlled clinical trial with clear biochemical endpoints and good adherence in the intervention arm; sample modest but results clinically meaningful.

Study Details

PMID:37909613
Participants:67
Impact:increased in study group (mean to 229.6 mg/24h) but remained below safety thresholds
Trust score:4/5

fat mass

2 evidences

In 56 completers, a 12-week dairy-based high-protein breakfast increased calcium intake and BMC but did not change body weight or fat mass versus a low-protein breakfast.

Trust comment: Randomised controlled trial with reasonable sample of completers (n=56) and objective DXA measures; moderate dropout but analyses pre-specified.

Study Details

PMID:39587799
Participants:56
Impact:no significant change
Trust score:4/5

In women doing a 4-month exercise program, adding a protein- and micronutrient-fortified milk (contains calcium) did not improve the primary stair-climb power but produced small gains in lean mass and reductions in fat.

Trust comment: High-quality double-blind, placebo-controlled RCT with adequate sample size and objective measures; findings on calcium-specific effects are secondary within a multinutrient product.

Study Details

PMID:32469393
Participants:216
Impact:-0.6 kg net difference (P=0.004)
Trust score:5/5

body mass (weight)

1 evidences

In 56 completers, a 12-week dairy-based high-protein breakfast increased calcium intake and BMC but did not change body weight or fat mass versus a low-protein breakfast.

Trust comment: Randomised controlled trial with reasonable sample of completers (n=56) and objective DXA measures; moderate dropout but analyses pre-specified.

Study Details

PMID:39587799
Participants:56
Impact:no significant change
Trust score:4/5

bone mineral content (BMC)

2 evidences

In 56 completers, a 12-week dairy-based high-protein breakfast increased calcium intake and BMC but did not change body weight or fat mass versus a low-protein breakfast.

Trust comment: Randomised controlled trial with reasonable sample of completers (n=56) and objective DXA measures; moderate dropout but analyses pre-specified.

Study Details

PMID:39587799
Participants:56
Impact:+20 g between-groups (P=0.01)
Trust score:4/5

Early higher enteral mineral intake did not improve growth or bone density at term age; higher calcium intake was associated with lower bone mineral content in regression analysis.

Trust comment: Randomized multi-center trial (109 randomized; 93 surviving included in growth analyses) but stopped early and underpowered with small DXA subset.

Study Details

PMID:29207479
Participants:93
Impact:no group differences; each mmol/kg Ca over first 10 days associated with −1.21 g BMC (p=0.001)
Trust score:4/5

≥2 falls (recurrent falls)

1 evidences

Planned secondary analysis of a calcium/vitamin D trial in 2,303 postmenopausal women found no association of standardized 25(OH)D up to 60 ng/mL with ≥1 fall, but s25D ≥60 ng/mL was linked to higher odds of ≥2 falls.

Trust comment: Large randomized supplementation trial with annual standardized 25(OH)D and diary-recorded falls; secondary analysis but robust dataset.

Study Details

PMID:39585370
Participants:2303
Impact:OR 1.99 (95% CI 1.2–3.3) for s25D ≥60 ng/mL vs 30–<40 ng/mL
Trust score:4/5

≥1 fall (any fall)

1 evidences

Planned secondary analysis of a calcium/vitamin D trial in 2,303 postmenopausal women found no association of standardized 25(OH)D up to 60 ng/mL with ≥1 fall, but s25D ≥60 ng/mL was linked to higher odds of ≥2 falls.

Trust comment: Large randomized supplementation trial with annual standardized 25(OH)D and diary-recorded falls; secondary analysis but robust dataset.

Study Details

PMID:39585370
Participants:2303
Impact:no significant association
Trust score:4/5

total 25‑hydroxyvitamin D (total 25OHD)

1 evidences

In 307 infertile men randomized to high-dose cholecalciferol or placebo, supplementation raised total 25OHD but did not change free 25OHD%; baseline higher free25OHD% associated with better metabolic markers and lower PTH.

Trust comment: Double-blind, placebo-controlled randomized trial (n=307) with clear biochemical outcomes; applicable to calcium-related physiology via vitamin D effects.

Study Details

PMID:39577708
Participants:307
Impact:increased after cholecalciferol supplementation (150 days)
Trust score:4/5

Free 25OHD

1 evidences

In 307 infertile men randomized to high-dose cholecalciferol or placebo, supplementation raised total 25OHD but did not change free 25OHD%; baseline higher free25OHD% associated with better metabolic markers and lower PTH.

Trust comment: Double-blind, placebo-controlled randomized trial (n=307) with clear biochemical outcomes; applicable to calcium-related physiology via vitamin D effects.

Study Details

PMID:39577708
Participants:307
Impact:no change with supplementation
Trust score:4/5

baseline metabolic markers associated with free25OHD%

1 evidences

In 307 infertile men randomized to high-dose cholecalciferol or placebo, supplementation raised total 25OHD but did not change free 25OHD%; baseline higher free25OHD% associated with better metabolic markers and lower PTH.

Trust comment: Double-blind, placebo-controlled randomized trial (n=307) with clear biochemical outcomes; applicable to calcium-related physiology via vitamin D effects.

Study Details

PMID:39577708
Participants:307
Impact:higher free25OHD% associated with lower TG (0.8 vs 1.0 mmol/L), lower LDL (2.7 vs 3.1 mmol/L), lower fasting glucose (4.9 vs 5.2 mmol/L) and lower PTH (3.8 vs 4.6 pmol/L)
Trust score:4/5

systolic blood pressure (SBP) after diltiazem

1 evidences

Randomized double-blind trial in 217 adults with AF/AFL found IV calcium chloride pretreatment (90 or 180 mg) prevented diltiazem-induced hypotension, raising SBP at 5–15 min without increasing adverse events.

Trust comment: Randomized, double-blind, placebo‑controlled trial (n=217) directly testing IV calcium intervention with clinically relevant endpoints and safety assessment.

Study Details

PMID:39577214
Participants:217
Impact:higher SBP at 5, 10 and 15 min with IV calcium pretreatment vs placebo
Trust score:5/5

heart rate control

1 evidences

Randomized double-blind trial in 217 adults with AF/AFL found IV calcium chloride pretreatment (90 or 180 mg) prevented diltiazem-induced hypotension, raising SBP at 5–15 min without increasing adverse events.

Trust comment: Randomized, double-blind, placebo‑controlled trial (n=217) directly testing IV calcium intervention with clinically relevant endpoints and safety assessment.

Study Details

PMID:39577214
Participants:217
Impact:all groups achieved rate control; HR lower at 10 and 15 min in placebo and low‑dose calcium vs high‑dose group (no compromise of rate control with calcium)
Trust score:5/5

Serum 25‑OH‑D3

1 evidences

In 110 children with bronchial asthma, adding vitamin D to inhaled fluticasone improved symptoms, lung function, immune markers and increased serum 25‑OH‑D and blood calcium and phosphorus compared with fluticasone alone.

Trust comment: Randomized assignment among 110 pediatric patients with multiple clinical and biochemical endpoints reported; positive results but limited detail on blinding and potential confounders.

Study Details

PMID:39560193
Participants:110
Impact:increased with combined fluticasone+vitamin D therapy
Trust score:3/5

blood calcium and phosphorus

1 evidences

In 110 children with bronchial asthma, adding vitamin D to inhaled fluticasone improved symptoms, lung function, immune markers and increased serum 25‑OH‑D and blood calcium and phosphorus compared with fluticasone alone.

Trust comment: Randomized assignment among 110 pediatric patients with multiple clinical and biochemical endpoints reported; positive results but limited detail on blinding and potential confounders.

Study Details

PMID:39560193
Participants:110
Impact:increased in the vitamin D combination group (P<0.05)
Trust score:3/5

lung function and clinical outcomes

1 evidences

In 110 children with bronchial asthma, adding vitamin D to inhaled fluticasone improved symptoms, lung function, immune markers and increased serum 25‑OH‑D and blood calcium and phosphorus compared with fluticasone alone.

Trust comment: Randomized assignment among 110 pediatric patients with multiple clinical and biochemical endpoints reported; positive results but limited detail on blinding and potential confounders.

Study Details

PMID:39560193
Participants:110
Impact:improved FEV1, FVC, PEF and faster symptom resolution; higher treatment effectiveness (96.36% vs 83.64%)
Trust score:3/5

intact parathyroid hormone (iPTH)

9 evidences

In 60 postmenopausal women with CKD stage 5, raloxifene increased lumbar spine BMD (~+2%) but did not differ from placebo in reducing intact PTH.

Trust comment: Randomized study but small sample and mixed dialysis status limits generalizability.

Study Details

PMID:25362221
Participants:60
Impact:decreased in both raloxifene and placebo groups (no between-group difference)
Trust score:3/5

Large randomized trial measuring vitamin D, calcium and iPTH; vitamin D raised 25(OH)D while calcium stayed stable and iPTH decreased.

Trust comment: Large randomized, placebo-controlled trial with robust measurements; calcium reported as a secondary biomarker and appears reliable.

Study Details

PMID:31669447
Participants:15804
Impact:decrease
Trust score:4/5

In dialysis patients, non-calcium phosphate binders reduced serum phosphorus and markedly lowered FGF-23 over 1 year; iPTH fell initially then returned near baseline.

Trust comment: Large randomized Phase 3 completer analysis with central lab measures; post‑hoc pooled analysis and completer-only set limit some generalizability.

Study Details

PMID:29846719
Participants:549
Impact:transient decrease to Week 24 then return to near baseline by Week 52
Trust score:4/5

Single IV doses of the calcimimetic SHR6508 in healthy adults produced dose-dependent reductions in intact PTH and serum-corrected calcium with an acceptable safety profile in 22 completers.

Trust comment: Phase I randomized, double‑blind trial with clear PK/PD and methodology but small sample (22 completers) limits generalizability.

Study Details

PMID:39680101
Participants:22
Impact:Dose‑dependent decrease; nadir ~−35.5% (0.5 mg), −65.9% (2.5 mg), −66.9% (5 mg) vs baseline
Trust score:4/5

Oral paricalcitol reduced intact PTH in children with CKD (stages 3–5) with an acceptable safety profile, though some hypercalcemia occurred in stage 5 patients.

Trust comment: Phase 3 multicenter randomized placebo-controlled trial (children 10–16 y) with clear biochemical endpoints and prespecified analyses, high reliability.

Study Details

PMID:28332096
Participants:61
Impact:greater reduction with paricalcitol; between-group change −72.4 pg/mL; 27.8% achieved ≥30% reduction vs 0% placebo in double-blind phase
Trust score:5/5

4-week study of patiromer in hyperkalemic patients showing no change in serum calcium but reductions in urine phosphate and decreases in intact PTH and 1,25-dihydroxyvitamin D.

Trust comment: Human randomized study with relevant mineral metabolism markers, but short duration and exploratory/post-hoc analyses limit strength for calcium-specific conclusions.

Study Details

PMID:30381412
Participants:112
Impact:median −13 pg/mL
Trust score:3/5

Etelcalcetide given thrice-weekly reduced parathyroid hormone and maintained corrected serum calcium in hemodialysis patients.

Trust comment: Phase I randomized, double-blind trial with clear PK and safety endpoints but small sample typical for phase I.

Study Details

PMID:34774334
Participants:33
Impact:max mean decrease −35.13% from baseline (day 27)
Trust score:4/5

In 90 adults with type 2 diabetes, 12 weeks of daily yogurt fortified with 1000 IU vitamin D3 ± 500 mg calcium modestly improved vitamin D status and produced a modest decrease in intact PTH in the vitamin D+calcium group, especially in participants with baseline vitamin D deficiency/insufficiency; osteocalcin did not change.

Trust comment: Randomized, double‑blind trial in 90 diabetic adults with direct calcium-containing intervention but modest effects and limited duration.

Study Details

PMID:26780278
Participants:90
Impact:CDD (vitamin D + 500 mg Ca) subgroup with baseline deficiency: iPTH change −9.0 ± 21.2 pg/mL vs PD control 8.6 ± 21.8 pg/mL (between-group p=0.042); overall modest decrease in iPTH in DD and CDD
Trust score:3/5

In non-dialysis CKD-MBD patients, Ronghuang granule improved symptoms and markers of calcium/phosphorus metabolism compared with control.

Trust comment: Randomized trial with 65 completers showing biochemical improvements in calcium/phosphorus metabolism, but single-center and traditional-medicine context limit generalizability.

Study Details

PMID:30613009
Participants:65
Impact:reduced/improved in treatment group (significant at 4, 8, 12 weeks; P<0.05)
Trust score:3/5

serum-corrected calcium

2 evidences

Switching elderly hemodialysis patients to lower dialysate calcium (1.25 mmol/L) lowered serum calcium and Ca×P, raised iPTH, and improved vascular calcification indices over 12 months.

Trust comment: Randomized 12-month study (n=82) addressing relevant clinical endpoints, but limited methodological detail and likely single-center reduce certainty.

Study Details

PMID:26905433
Participants:82
Impact:decreased after 1 month and stabilized by 6 months
Trust score:3/5

Single IV doses of the calcimimetic SHR6508 in healthy adults produced dose-dependent reductions in intact PTH and serum-corrected calcium with an acceptable safety profile in 22 completers.

Trust comment: Phase I randomized, double‑blind trial with clear PK/PD and methodology but small sample (22 completers) limits generalizability.

Study Details

PMID:39680101
Participants:22
Impact:Dose‑dependent decrease: −1.5% (0.5 mg), −7.1% (2.5 mg), −7.5% (5 mg) vs baseline
Trust score:4/5

FGF23 concentration

2 evidences

24-week RCT in chronic hemodialysis patients: lanthanum reduced FGF23 and showed a trend to lower hepcidin, whereas calcium carbonate did not produce those reductions.

Trust comment: Randomized multicenter RCT but small (46 recruited, 25 completers) limiting precision; findings on calcium carbonate reported but underpowered.

Study Details

PMID:27928636
Participants:25
Impact:No significant change with calcium carbonate (no decrease observed; lanthanum group decreased from 8677.5 to 4692.8 pg/mL)
Trust score:3/5

Single IV doses of the calcimimetic SHR6508 in healthy adults produced dose-dependent reductions in intact PTH and serum-corrected calcium with an acceptable safety profile in 22 completers.

Trust comment: Phase I randomized, double‑blind trial with clear PK/PD and methodology but small sample (22 completers) limits generalizability.

Study Details

PMID:39680101
Participants:22
Impact:Decreased after dosing (min reductions reported ≈ −17% to −28%), not clearly dose‑dependent
Trust score:4/5

urine pH

1 evidences

Healthy men given 200 g/day fructose for two weeks had higher serum uric acid, a small drop in ionized calcium with higher PTH, lower urine pH, higher urinary oxalate and lower urine magnesium—changes that raise kidney-stone risk.

Trust comment: Within-subject pre–post study in 33 men with robust lab measures; single-arm reporting and high fructose dose limit generalizability.

Study Details

PMID:30409184
Participants:33
Impact:decreased −0.26 ±0.61 (p=0.019)
Trust score:3/5

treatment success rate (loose criteria, 4 years)

1 evidences

Randomized clinical trial with 4‑year follow-up found similar medium/long‑term success for single‑cone obturation with a calcium silicate‑based sealer versus warm vertical compaction with a ZOE sealer.

Trust comment: Randomized clinical trial with 4‑year follow‑up and blinded radiographic assessment; moderate sample and some loss to follow‑up but robust methodology for clinical dental outcomes.

Study Details

PMID:39655615
Participants:45
Impact:Overall success ≈89.6% (no significant difference between CSBS and ZOE groups)
Trust score:4/5

treatment success rate (strict criteria, 4 years)

1 evidences

Randomized clinical trial with 4‑year follow-up found similar medium/long‑term success for single‑cone obturation with a calcium silicate‑based sealer versus warm vertical compaction with a ZOE sealer.

Trust comment: Randomized clinical trial with 4‑year follow‑up and blinded radiographic assessment; moderate sample and some loss to follow‑up but robust methodology for clinical dental outcomes.

Study Details

PMID:39655615
Participants:45
Impact:Overall success ≈83.3% (no significant difference between groups)
Trust score:4/5

periapical index (PAI) score

1 evidences

Randomized clinical trial with 4‑year follow-up found similar medium/long‑term success for single‑cone obturation with a calcium silicate‑based sealer versus warm vertical compaction with a ZOE sealer.

Trust comment: Randomized clinical trial with 4‑year follow‑up and blinded radiographic assessment; moderate sample and some loss to follow‑up but robust methodology for clinical dental outcomes.

Study Details

PMID:39655615
Participants:45
Impact:PAI score decreased significantly over time in both groups (p < 0.001); similar patterns between groups
Trust score:4/5

breast milk volume

1 evidences

Randomized trial in mothers of preterm infants found reflexology produced a non‑significant trend toward increased breast milk volume and small nonsignificant increases in total protein and calcium; calcium changes were not statistically significant between groups.

Trust comment: Randomized single‑center trial with adequate sample (74 analyzed) and biochemical measures, but single site, limited blinding and some baseline/measurement limitations reduce confidence.

Study Details

PMID:39643879
Participants:74
Impact:Within reflexology group +23.51 ml (day1→day7); between‑group net +11.08 ml favoring reflexology (95% CI −2.79 to 24.95), ANCOVA adjusted p≈0.065 (not statistically significant)
Trust score:3/5

breast milk calcium concentration

2 evidences

Randomized trial in mothers of preterm infants found reflexology produced a non‑significant trend toward increased breast milk volume and small nonsignificant increases in total protein and calcium; calcium changes were not statistically significant between groups.

Trust comment: Randomized single‑center trial with adequate sample (74 analyzed) and biochemical measures, but single site, limited blinding and some baseline/measurement limitations reduce confidence.

Study Details

PMID:39643879
Participants:74
Impact:Between‑group net +1.70 mg/dL (95% CI −1.66 to 5.07), not statistically significant; control showed a significant within‑group decrease (−3.54 mg/dL), reflexology within‑group change −1.83 mg/dL (NS)
Trust score:3/5

In this pilot RCT, synbiotic supplementation in lactating mothers prevented declines in breast milk minerals including calcium and was associated with slight improvements in infant weight-for-age Z-score.

Trust comment: Randomized, double-blind pilot trial in humans but small sample size limits confidence.

Study Details

PMID:25744506
Participants:57
Impact:synbiotic: 189±25.3 → 189.9±21.7 mg/L (small increase); placebo: significant decrease; between-group change significant (P<0.05)
Trust score:3/5

total protein in breast milk

1 evidences

Randomized trial in mothers of preterm infants found reflexology produced a non‑significant trend toward increased breast milk volume and small nonsignificant increases in total protein and calcium; calcium changes were not statistically significant between groups.

Trust comment: Randomized single‑center trial with adequate sample (74 analyzed) and biochemical measures, but single site, limited blinding and some baseline/measurement limitations reduce confidence.

Study Details

PMID:39643879
Participants:74
Impact:Small within‑group increase in reflexology group (+4.59 mg/dL) but between‑group difference not significant
Trust score:3/5

HbA1c

2 evidences

Randomized study comparing sevelamer to calcium carbonate in T2DM with DKD found sevelamer reduced circulating and intracellular AGEs and increased antioxidant markers; calcium carbonate did not lower AGEs overall.

Trust comment: Randomized open-label trial with 117 patients; adequate size but open-label design and subgroup findings reduce certainty regarding calcium comparator effects.

Study Details

PMID:25710801
Participants:117
Impact:no overall change between groups; decreased with sevelamer in women (subgroup)
Trust score:3/5

Population-based 10-year longitudinal study in non-diabetic adults assessing supplement intakes (including calcium) and changes in HbA1c; no significant association found for calcium supplementation and HbA1c change.

Trust comment: Large, population-based longitudinal study with long follow-up and thorough supplement assessment, but observational design limits causal inference and residual confounding is possible.

Study Details

PMID:26473975
Participants:2774
Impact:no significant longitudinal association with calcium supplement intake; fully adjusted βx for highest calcium tertile ≈ -0.04% (95% CI -0.16 to 0.08)
Trust score:3/5

HOMA-IR (insulin resistance)

4 evidences

Daily vitamin D plus 500 mg calcium for 150 days lowered fasting insulin and insulin resistance and raised HDL cholesterol in infertile men.

Trust comment: Large double-blind randomized trial with 307 men, but intervention combined vitamin D and calcium so effects cannot be attributed to calcium alone.

Study Details

PMID:34508607
Participants:307
Impact:-19% (2.2 vs 2.7 vs placebo)
Trust score:4/5

24-week randomized multicenter trial: telmisartan+rosuvastatin preserved beta-cell function, lowered fasting glucose and reduced new-onset diabetes risk versus amlodipine+rosuvastatin, without significant HOMA-IR difference.

Trust comment: Randomized multicenter trial with clear metabolic endpoints, but open-label and relatively short follow-up (24 weeks) limits longer-term inference.

Study Details

PMID:36086748
Participants:99
Impact:No significant between-group difference at 24 weeks (telmisartan vs amlodipine, p = 0.809)
Trust score:4/5

Vitamin D-deficient women with PCOS given combined calcium+D+K for 8 weeks had improved insulin sensitivity markers and lower triglycerides/VLDL versus placebo.

Trust comment: Double-blind, placebo-controlled RCT with reported numeric effects but modest sample size (n=55) and limited to vitamin D-deficient PCOS women.

Study Details

PMID:28407660
Participants:55
Impact:-0.4 ±0.7 (supplement) vs +0.4 ±1.4 (placebo); significant decrease vs placebo
Trust score:4/5

In hyperinsulinemic adults, a 6-week high-dairy diet (increasing dietary calcium) did not change blood pressure or arterial stiffness but was associated with increases in body fat, fasting insulin and HOMA-IR.

Trust comment: Randomized cross-over human trial directly relevant to dietary calcium via dairy but small sample size limits power.

Study Details

PMID:37939366
Participants:27
Impact:increased after high dairy intake (direction reported)
Trust score:3/5

Hip geometry parameters (cross-sectional area, CSMI, section modulus)

1 evidences

In Brazilian adolescent mothers, maternal calcium+vitamin D during pregnancy did not affect postpartum hip geometry trajectories over one year.

Trust comment: Randomized controlled supplementation trial with repeated DXA assessments; post-hoc/secondary analysis and modest sample size limit generalizability but design is robust.

Study Details

PMID:39506322
Participants:56
Impact:No significant effect of calcium+vitamin D vs placebo
Trust score:4/5

Time-dependent changes in hip geometry

1 evidences

In Brazilian adolescent mothers, maternal calcium+vitamin D during pregnancy did not affect postpartum hip geometry trajectories over one year.

Trust comment: Randomized controlled supplementation trial with repeated DXA assessments; post-hoc/secondary analysis and modest sample size limit generalizability but design is robust.

Study Details

PMID:39506322
Participants:56
Impact:Decrease from 5 to 20 weeks with recovery by 56 weeks (time effect, P<0.05)
Trust score:4/5

osteoporosis knowledge

1 evidences

An education and counseling program increased osteoporosis knowledge, self-efficacy, weekly exercise and daily calcium intake in at-risk women.

Trust comment: Randomized controlled behavioral trial but small sample (n=73); reports significant increases in reported calcium intake and related behaviors.

Study Details

PMID:28688497
Participants:73
Impact:increased (P<0.001)
Trust score:3/5

adipocyte-regeneration gene expression

1 evidences

Injections for nasolabial folds showed PLLA (not CaHA) upregulated adipocyte-regeneration genes, suggesting a unique adipocyte-mediated regenerative signature absent with calcium hydroxylapatite.

Trust comment: Randomized small study (n=21) with RNA-seq and biopsies; relevant to biological effects of calcium hydroxylapatite but limited by sample size and short follow-up.

Study Details

PMID:39480040
Participants:21
Impact:No upregulation with CaHA (CaHA lacked adipocyte-mediated regenerative signature)
Trust score:3/5

new bone volume density

1 evidences

40 patients had tooth-extraction sockets filled with a calcium-phosphate bone substitute (ErhBMP-2/BioCaP/β-TCP) showing faster early bone healing and similar safety to controls.

Trust comment: Randomized, partially double-blind RCT with pre-specified outcomes and clear reporting; moderate sample size (n=40) limits long-term conclusions.

Study Details

PMID:39478364
Participants:40
Impact:ErhBMP 7.72% vs β‑TCP 2.96% (difference +4.76 percentage points); natural healing 8.37% (similar to ErhBMP)
Trust score:4/5

residual material volume density

1 evidences

40 patients had tooth-extraction sockets filled with a calcium-phosphate bone substitute (ErhBMP-2/BioCaP/β-TCP) showing faster early bone healing and similar safety to controls.

Trust comment: Randomized, partially double-blind RCT with pre-specified outcomes and clear reporting; moderate sample size (n=40) limits long-term conclusions.

Study Details

PMID:39478364
Participants:40
Impact:ErhBMP 10.90% vs β‑TCP 15.73% (ErhBMP lower by −4.83 percentage points)
Trust score:4/5

horizontal alveolar bone width resorption at 1 mm

1 evidences

40 patients had tooth-extraction sockets filled with a calcium-phosphate bone substitute (ErhBMP-2/BioCaP/β-TCP) showing faster early bone healing and similar safety to controls.

Trust comment: Randomized, partially double-blind RCT with pre-specified outcomes and clear reporting; moderate sample size (n=40) limits long-term conclusions.

Study Details

PMID:39478364
Participants:40
Impact:ErhBMP showed significantly less resorption at 1 mm vs natural healing (statistically significant, exact mean differences reported in text)
Trust score:4/5

pain degree

1 evidences

88 patients after vertebroplasty received salmon calcitonin plus baseline calcium carbonate + vitamin D3; study reported reduced pain and improved bone metabolism and function vs calcium+D3 alone.

Trust comment: Prospective randomized controlled design with reasonable sample size, but the report lacks detailed numeric outcome data and statistical specifics in the provided excerpt.

Study Details

PMID:39477477
Participants:88
Impact:Pain reduced in salmon calcitonin group at 3 months vs control (reported p<0.05; magnitude not specified)
Trust score:3/5

bone metabolism markers

1 evidences

88 patients after vertebroplasty received salmon calcitonin plus baseline calcium carbonate + vitamin D3; study reported reduced pain and improved bone metabolism and function vs calcium+D3 alone.

Trust comment: Prospective randomized controlled design with reasonable sample size, but the report lacks detailed numeric outcome data and statistical specifics in the provided excerpt.

Study Details

PMID:39477477
Participants:88
Impact:Improved bone metabolism and matrix metalloproteinase levels in salmon calcitonin group (no numeric values provided)
Trust score:3/5

lumbar function / activities of daily living

1 evidences

88 patients after vertebroplasty received salmon calcitonin plus baseline calcium carbonate + vitamin D3; study reported reduced pain and improved bone metabolism and function vs calcium+D3 alone.

Trust comment: Prospective randomized controlled design with reasonable sample size, but the report lacks detailed numeric outcome data and statistical specifics in the provided excerpt.

Study Details

PMID:39477477
Participants:88
Impact:Improved lumbar function and daily living ability in salmon calcitonin group (no numeric values provided)
Trust score:3/5

type II fiber cross-sectional area (fCSA)

1 evidences

26 participants in a 10-week resistance training study; a multi-ingredient supplement (including calcium citrate) increased type II muscle fiber size more than collagen, with similar satellite cell content.

Trust comment: Randomized supplement trial but small sample (n=26) limits precision; outcomes reported with effect sizes but some effects were trends not significant.

Study Details

PMID:39475860
Participants:26
Impact:MIS induced greater increase in type II fCSA after 10 weeks (effect size ES = 0.89)
Trust score:3/5

satellite cell activation

1 evidences

26 participants in a 10-week resistance training study; a multi-ingredient supplement (including calcium citrate) increased type II muscle fiber size more than collagen, with similar satellite cell content.

Trust comment: Randomized supplement trial but small sample (n=26) limits precision; outcomes reported with effect sizes but some effects were trends not significant.

Study Details

PMID:39475860
Participants:26
Impact:Trend toward greater SC activation with MIS after training/damage (ES = 0.70), but not statistically conclusive
Trust score:3/5

myonuclear accretion / SC content

1 evidences

26 participants in a 10-week resistance training study; a multi-ingredient supplement (including calcium citrate) increased type II muscle fiber size more than collagen, with similar satellite cell content.

Trust comment: Randomized supplement trial but small sample (n=26) limits precision; outcomes reported with effect sizes but some effects were trends not significant.

Study Details

PMID:39475860
Participants:26
Impact:No significant change in myonuclear accretion or SC content between groups
Trust score:3/5

periapical lesion healing

1 evidences

36 enrolled (31 completed) patients received regenerative endodontic treatment with Biodentine or MTA; both materials showed similar healing of lesions and recovery of tooth sensibility at 18 months.

Trust comment: Double-blind randomized clinical trial with registered protocol, but small sample and some dropouts reduce power.

Study Details

PMID:39475095
Participants:31
Impact:Overall 21/31 (67.7%) healed at 18 months; no significant difference between Biodentine and MTA
Trust score:4/5

tooth sensibility (EPT positive)

1 evidences

36 enrolled (31 completed) patients received regenerative endodontic treatment with Biodentine or MTA; both materials showed similar healing of lesions and recovery of tooth sensibility at 18 months.

Trust comment: Double-blind randomized clinical trial with registered protocol, but small sample and some dropouts reduce power.

Study Details

PMID:39475095
Participants:31
Impact:22/31 (71%) regained EPT response by 18 months; no significant difference between groups
Trust score:4/5

radiographic lesion size reduction

1 evidences

36 enrolled (31 completed) patients received regenerative endodontic treatment with Biodentine or MTA; both materials showed similar healing of lesions and recovery of tooth sensibility at 18 months.

Trust comment: Double-blind randomized clinical trial with registered protocol, but small sample and some dropouts reduce power.

Study Details

PMID:39475095
Participants:31
Impact:Both groups showed lesion size reduction at follow-up; no group difference (detailed scores in text)
Trust score:4/5

parathyroid hormone (PTH) levels

1 evidences

180 thyroid cancer patients randomized to mitoxantrone tracer, nanocarbon tracer, or no tracer; mitoxantrone tracer improved surgical field clarity and reduced collateral parathyroid/recurrent laryngeal nerve injury, with higher early postoperative serum calcium and PTH.

Trust comment: Prospective randomized controlled study with substantial sample (n=180) and clinically relevant endpoints, though full numerical details not shown in excerpt.

Study Details

PMID:39472118
Participants:180
Impact:MHI group had higher PTH on postoperative day 1 and day 5 vs other groups (exact means not provided)
Trust score:4/5

parathyroid identification rate / inadvertent excision

1 evidences

180 thyroid cancer patients randomized to mitoxantrone tracer, nanocarbon tracer, or no tracer; mitoxantrone tracer improved surgical field clarity and reduced collateral parathyroid/recurrent laryngeal nerve injury, with higher early postoperative serum calcium and PTH.

Trust comment: Prospective randomized controlled study with substantial sample (n=180) and clinically relevant endpoints, though full numerical details not shown in excerpt.

Study Details

PMID:39472118
Participants:180
Impact:MHI showed higher parathyroid identification rate and lower inadvertent excision rate vs nanocarbon and control (statistically significant, values in text)
Trust score:4/5

intracanal voids (%)

1 evidences

Teeth from 24 volunteer patients were obturated with hydraulic calcium-silicate sealers under different canal dryness/technique protocols; partial drying before single-cone obturation produced more intracanal voids and interfacial gaps.

Trust comment: Randomized, registered clinical trial with objective micro-CT and SEM/EDX outcomes though sample size (teeth n=24) is small.

Study Details

PMID:39463194
Participants:24
Impact:Control (AH Plus/CLC): 0.95% ± 0.11; CLC-ES-SD: 2.22% ± 0.22; SC-ES-SD: 2.26% ± 0.36; SC-ES-PD (partial dryness): 13.14% ± 1.75 (SC-ES-PD significantly higher, p<0.001)
Trust score:4/5

interfacial gaps prevalence (%)

1 evidences

Teeth from 24 volunteer patients were obturated with hydraulic calcium-silicate sealers under different canal dryness/technique protocols; partial drying before single-cone obturation produced more intracanal voids and interfacial gaps.

Trust comment: Randomized, registered clinical trial with objective micro-CT and SEM/EDX outcomes though sample size (teeth n=24) is small.

Study Details

PMID:39463194
Participants:24
Impact:CLC-AHP: 53.1% gaps; CLC-ES-SD: 67.0%; SC-ES-SD: 69.1%; SC-ES-PD: 82.0% (SC-ES-PD highest, p<0.001)
Trust score:4/5

sealer hydration products at dentin interface

1 evidences

Teeth from 24 volunteer patients were obturated with hydraulic calcium-silicate sealers under different canal dryness/technique protocols; partial drying before single-cone obturation produced more intracanal voids and interfacial gaps.

Trust comment: Randomized, registered clinical trial with objective micro-CT and SEM/EDX outcomes though sample size (teeth n=24) is small.

Study Details

PMID:39463194
Participants:24
Impact:Phosphate- and calcium-rich hydration products observed at sealer-dentin interface (presence greater with partial dryness) (qualitative SEM/EDX findings)
Trust score:4/5

adverse event incidence

1 evidences

Randomized trial in patients with bone defects: porous hydroxyapatite/collagen implant produced superior radiographic bone regeneration versus porous β-TCP by 18–24 weeks, with more (non-serious) adverse events.

Trust comment: Randomized controlled trial in humans with clear radiographic endpoints and adequate sample analyzed (59 vs 60); follow-up 24 weeks; adverse events increased but non-serious.

Study Details

PMID:26961287
Participants:119
Impact:Higher incidence with HAp/Col vs β-TCP, but no serious adverse events or trial dropouts
Trust score:4/5

analgesic use (first 24h)

1 evidences

Randomized trial in single-rooted premolars found no difference in postoperative pain between epoxy-resin and calcium silicate sealers or with/without sonic activation; low overall pain.

Trust comment: Well-powered randomized clinical trial with sample size calculation and blinded patients; appropriate methods and reporting.

Study Details

PMID:39443924
Participants:72
Impact:Very low—three patients used analgesics in first 24h (one in three different groups)
Trust score:4/5

sealer extrusion incidence

1 evidences

Randomized trial in single-rooted premolars found no difference in postoperative pain between epoxy-resin and calcium silicate sealers or with/without sonic activation; low overall pain.

Trust comment: Well-powered randomized clinical trial with sample size calculation and blinded patients; appropriate methods and reporting.

Study Details

PMID:39443924
Participants:72
Impact:More frequent with sonic activation (11 with activation vs 4 without); weak positive correlation with activation (r=0.36)
Trust score:4/5

mean operating time

1 evidences

Randomized trial (66 per arm) showed near-infrared autofluorescence did not reduce operating time, change number of glands identified/resected, or alter cure/complication rates versus standard surgery.

Trust comment: Randomized monocentric trial with a moderate sample size and clear outcomes; performed by experienced surgeons but single-center limits generalizability.

Study Details

PMID:39443204
Participants:132
Impact:No significant difference (46.9 ±15.3 min control vs 51.2 ±22.9 min autofluorescence; p=0.21)
Trust score:4/5

cure rate

1 evidences

Randomized trial (66 per arm) showed near-infrared autofluorescence did not reduce operating time, change number of glands identified/resected, or alter cure/complication rates versus standard surgery.

Trust comment: Randomized monocentric trial with a moderate sample size and clear outcomes; performed by experienced surgeons but single-center limits generalizability.

Study Details

PMID:39443204
Participants:132
Impact:Similar cure rates (92.2% control vs 94.8% autofluorescence; p=0.72)
Trust score:4/5

number of visualized/resected glands

1 evidences

Randomized trial (66 per arm) showed near-infrared autofluorescence did not reduce operating time, change number of glands identified/resected, or alter cure/complication rates versus standard surgery.

Trust comment: Randomized monocentric trial with a moderate sample size and clear outcomes; performed by experienced surgeons but single-center limits generalizability.

Study Details

PMID:39443204
Participants:132
Impact:No significant difference between groups
Trust score:4/5

R0 resection rate

1 evidences

Single-center randomized trial found mFOLFOX6 with cetuximab yielded similar R0 resection, pCR, and downstaging rates as mFOLFOX6 with radiotherapy; adverse events comparable.

Trust comment: Prospective randomized design but single-center and modest sample size; results promising but need multicenter confirmation.

Study Details

PMID:39443085
Participants:80
Impact:No difference (96.7% mFOLFOX6-RT vs 96.9% mFOLFOX6-Cet; p=1.000)
Trust score:3/5

pathologic complete response (pCR) rate

1 evidences

Single-center randomized trial found mFOLFOX6 with cetuximab yielded similar R0 resection, pCR, and downstaging rates as mFOLFOX6 with radiotherapy; adverse events comparable.

Trust comment: Prospective randomized design but single-center and modest sample size; results promising but need multicenter confirmation.

Study Details

PMID:39443085
Participants:80
Impact:No difference (23.3% vs 21.9%; p=0.891)
Trust score:3/5

downstaging rate (ypStage 0–1)

1 evidences

Single-center randomized trial found mFOLFOX6 with cetuximab yielded similar R0 resection, pCR, and downstaging rates as mFOLFOX6 with radiotherapy; adverse events comparable.

Trust comment: Prospective randomized design but single-center and modest sample size; results promising but need multicenter confirmation.

Study Details

PMID:39443085
Participants:80
Impact:No difference (53.3% vs 53.1%; p=1.000)
Trust score:3/5

pulp survival (12 months)

1 evidences

Randomized double-blind trial found higher pulp survival after total caries removal (TCR) versus selective removal (SCR) at 6 and 12 months; SCR associated with higher failure odds.

Trust comment: Double-blind randomized clinical trial with adequate sample and clear outcomes; credible results for dental practice.

Study Details

PMID:39442480
Participants:124
Impact:Higher with total caries removal: 98.4% (TCR) vs 82.5% (SCR); p=0.003
Trust score:4/5

pulp survival (6 months)

1 evidences

Randomized double-blind trial found higher pulp survival after total caries removal (TCR) versus selective removal (SCR) at 6 and 12 months; SCR associated with higher failure odds.

Trust comment: Double-blind randomized clinical trial with adequate sample and clear outcomes; credible results for dental practice.

Study Details

PMID:39442480
Participants:124
Impact:100% (TCR) vs 93.65% (SCR); p=0.04
Trust score:4/5

risk of failure (SCR vs TCR)

1 evidences

Randomized double-blind trial found higher pulp survival after total caries removal (TCR) versus selective removal (SCR) at 6 and 12 months; SCR associated with higher failure odds.

Trust comment: Double-blind randomized clinical trial with adequate sample and clear outcomes; credible results for dental practice.

Study Details

PMID:39442480
Participants:124
Impact:SCR associated with higher odds of failure (OR 27.6; 95% CI 3.6–212.4; p=0.001)
Trust score:4/5

serum occludin (24 h)

1 evidences

Randomized study (NBO + EVT vs EVT alone) showed NBO reduced serum BBB and brain-injury biomarkers and lowered intracranial contrast extravasation; 7-day occludin predicted 90-day poor outcome.

Trust comment: Randomized controlled study nested in OPENS-1 with biomarker and imaging endpoints; moderate sample size but biologically coherent and statistically significant effects.

Study Details

PMID:39424403
Participants:86
Impact:Lower with NBO (4.27 vs 5.11 ng/mL at 24h; p=0.026)
Trust score:4/5

intracranial contrast agent extravasation incidence

1 evidences

Randomized study (NBO + EVT vs EVT alone) showed NBO reduced serum BBB and brain-injury biomarkers and lowered intracranial contrast extravasation; 7-day occludin predicted 90-day poor outcome.

Trust comment: Randomized controlled study nested in OPENS-1 with biomarker and imaging endpoints; moderate sample size but biologically coherent and statistically significant effects.

Study Details

PMID:39424403
Participants:86
Impact:Reduced with NBO: 35.9% vs 60.5% (aOR 0.28; p=0.031)
Trust score:4/5

serum NSE/S100B (24 h and 7 days)

1 evidences

Randomized study (NBO + EVT vs EVT alone) showed NBO reduced serum BBB and brain-injury biomarkers and lowered intracranial contrast extravasation; 7-day occludin predicted 90-day poor outcome.

Trust comment: Randomized controlled study nested in OPENS-1 with biomarker and imaging endpoints; moderate sample size but biologically coherent and statistically significant effects.

Study Details

PMID:39424403
Participants:86
Impact:Lower NSE and S100B at 24h (NSE 4.38 vs 5.64 ng/mL p=0.043; S100b 0.56 vs 1.28 ng/mL p=0.008); NSE remained lower at 7 days (p=0.014)
Trust score:4/5

plasma/leukocyte vitamin C pharmacokinetics (ASC/DHA/total)

1 evidences

Compared calcium ascorbate (CA) vs ascorbic acid (AA) in crossover trials: 250 mg showed no differences; 500 mg CA altered vitamin C kinetics and increased neutrophil phagocytosis and certain NK cells.

Trust comment: Randomized, double-blind, crossover pharmacokinetic trial with objective immune and PK endpoints; moderate sample and acute dosing limit generalizability.

Study Details

PMID:39408325
Participants:93
Impact:500 mg CA increased plasma DHA AUC and altered ASC↔DHA conversion versus AA (significant treatment×time effects)
Trust score:4/5

neutrophil phagocytosis

1 evidences

Compared calcium ascorbate (CA) vs ascorbic acid (AA) in crossover trials: 250 mg showed no differences; 500 mg CA altered vitamin C kinetics and increased neutrophil phagocytosis and certain NK cells.

Trust comment: Randomized, double-blind, crossover pharmacokinetic trial with objective immune and PK endpoints; moderate sample and acute dosing limit generalizability.

Study Details

PMID:39408325
Participants:93
Impact:500 mg CA increased neutrophil phagocytosis from baseline (+6.78% at 24 h; p=0.027)
Trust score:4/5

natural killer cells (CD16+ & CD56+)

1 evidences

Compared calcium ascorbate (CA) vs ascorbic acid (AA) in crossover trials: 250 mg showed no differences; 500 mg CA altered vitamin C kinetics and increased neutrophil phagocytosis and certain NK cells.

Trust comment: Randomized, double-blind, crossover pharmacokinetic trial with objective immune and PK endpoints; moderate sample and acute dosing limit generalizability.

Study Details

PMID:39408325
Participants:93
Impact:increased +12.2% at 24 h post-500 mg CA (p=0.012)
Trust score:4/5

serum potassium

2 evidences

In 97 CKD patients with hyperkalemia, both calcium and sodium polystyrene resins lowered potassium; calcium resin had fewer side effects.

Trust comment: Randomized controlled trial but single-center with modest sample size; moderate overall quality.

Study Details

PMID:25672163
Participants:97
Impact:CPS: 5.8 → 4.8 (pre → post); SPS: 5.8 → 4.3 (pre → post)
Trust score:3/5

In 58 hemodialysis patients with hyperkalemia, 3 weeks of calcium‑polystyrene sulfonate reduced serum potassium and phosphorus without causing volume overload or electrolyte imbalance.

Trust comment: Prospective randomized crossover trial (n=58) directly tests a calcium‑containing potassium binder with clear primary outcome improvement and assessment of safety.

Study Details

PMID:30109784
Participants:58
Impact:Significant reduction with Ca‑PS vs control (P<0.01); proportion with K<5.5 mmol/L increased from 32% to 61%
Trust score:4/5

Clinical/radiographic success rate (indirect pulp capping)

1 evidences

In children with reversible pulpitis, three bioactive cements performed similarly; the novel portland cement (fluoride-releasing) showed 100% success at 1 year.

Trust comment: Randomized clinical trial in humans with clear reporting; investigates calcium-containing dental cements (indirectly relevant to calcium materials).

Study Details

PMID:39384060
Participants:86
Impact:Pure tricalcium silicate 88%; resin-modified silicate glass 88.5%; novel portland cement 100% (differences not statistically significant)
Trust score:3/5

Restoration integrity (USPHS criteria)

1 evidences

In children with reversible pulpitis, three bioactive cements performed similarly; the novel portland cement (fluoride-releasing) showed 100% success at 1 year.

Trust comment: Randomized clinical trial in humans with clear reporting; investigates calcium-containing dental cements (indirectly relevant to calcium materials).

Study Details

PMID:39384060
Participants:86
Impact:No significant difference among groups
Trust score:3/5

Multicomponent efficacy endpoint (normocalcemia + independence from conventional therapy)

1 evidences

TransCon PTH restored physiological PTH effects: maintained normal serum calcium while enabling most participants to stop active vitamin D and therapeutic calcium by week 52.

Trust comment: Phase 3 randomized trial with robust design and clinically relevant calcium-related endpoints (high trustworthiness).

Study Details

PMID:39376010
Participants:78
Impact:81% responders at week 52 (63/78)
Trust score:5/5

Independence from therapeutic elemental calcium

1 evidences

TransCon PTH restored physiological PTH effects: maintained normal serum calcium while enabling most participants to stop active vitamin D and therapeutic calcium by week 52.

Trust comment: Phase 3 randomized trial with robust design and clinically relevant calcium-related endpoints (high trustworthiness).

Study Details

PMID:39376010
Participants:78
Impact:95% independent from therapeutic calcium (74/78) at week 52
Trust score:5/5

Albumin-adjusted serum calcium

3 evidences

TransCon PTH restored physiological PTH effects: maintained normal serum calcium while enabling most participants to stop active vitamin D and therapeutic calcium by week 52.

Trust comment: Phase 3 randomized trial with robust design and clinically relevant calcium-related endpoints (high trustworthiness).

Study Details

PMID:39376010
Participants:78
Impact:Maintained within normal range (mean ≈8.9 mg/dL at week 52)
Trust score:5/5

Six months of a vitamin D + calcium + leucine‑enriched whey protein drink (up to 2 servings/day) did not impair kidney function or cause vitamin D/calcium toxicity in sarcopenic older adults.

Trust comment: Large multicenter randomized trial with objective lab endpoints and 6‑month follow-up supporting safety of the calcium‑containing product.

Study Details

PMID:32162241
Participants:379
Impact:Mean increase from 2.29 to 2.33 mmol/L (≈ +0.04 mmol/L) during RCT; no signal of clinical toxicity
Trust score:4/5

Denosumab reduced bone erosion and increased BMD; patients received calcium ≥600 mg/day and vitamin D and some denosumab regimens showed mild decreases in albumin‑adjusted serum calcium within normal range.

Trust comment: Large randomized double‑blind phase II trial with robust radiographic and biochemical endpoints, though calcium effects were secondary and values stayed within normal limits.

Study Details

PMID:26585988
Participants:340
Impact:Decreased in denosumab groups (one asymptomatic mild decrease reported; Q2M/Q3M showed sustained lower levels but remained within normal range)
Trust score:4/5

bone mineral density (BMD)

6 evidences

Overweight elderly participants all received 1000 mg elemental calcium/day plus either low or high vitamin D for 1 year; serum 25OHD rose more with high-dose vitamin D but there was little additional benefit on BMD or bone markers overall.

Trust comment: Large double-blind RCT (257 randomized, 222 completed) with objective endpoints; well-conducted but limited generalizability to overweight elderly.

Study Details

PMID:28276596
Participants:222
Impact:no meaningful additional benefit overall; small hip benefit in subgroup with baseline PTH >76 pg/mL
Trust score:4/5

Randomized double‑blind trial in 160 perimenopausal women comparing placebo, soy isoflavone, calcium, and soy+calcium; soy, calcium, and the combination attenuated BMD loss, with the combination producing greater improvements than either alone.

Trust comment: Well‑designed double‑blind RCT with adequate sample size and clear reported group differences over 6 months, though numeric effect sizes were not provided in the summary.

Study Details

PMID:31583921
Participants:160
Impact:Increase/attenuation of BMD loss with calcium, isoflavone, and greater improvement with isoflavone+calcium (statistically significant vs control)
Trust score:4/5

In edentulous women given dentures, a daily multi-nutrient supplement (containing 150 mg calcium per serving) led to modest within-group improvements and a significant between-group increase in bone mineral density, but most between-group nutritional outcomes were not different.

Trust comment: Randomized controlled design with objective BMD measures but some reporting inconsistencies and relatively short follow-up limit confidence.

Study Details

PMID:37861611
Participants:121
Impact:BMD increased in supplement group (statistically significant, p<0.01 between groups)
Trust score:3/5

Early higher enteral mineral intake did not improve growth or bone density at term age; higher calcium intake was associated with lower bone mineral content in regression analysis.

Trust comment: Randomized multi-center trial (109 randomized; 93 surviving included in growth analyses) but stopped early and underpowered with small DXA subset.

Study Details

PMID:29207479
Participants:93
Impact:no significant group differences; small positive Ca×P interaction on BMD (β=0.0003)
Trust score:4/5

After PKP surgery, patients given calcium plus calcitriol showed improved short-term pain and function and increased BMD versus preoperative; adding calcitonin and exercise improved longer-term outcomes.

Trust comment: Randomized study (138 randomized, 114 completers) with clinical and BMD outcomes reported; limited methodological detail in excerpt but plausible internal validity.

Study Details

PMID:26255474
Participants:114
Impact:increased at 12 months vs preoperative (greater increase in comprehensive group)
Trust score:3/5

In osteoporosis patients given denosumab plus vitamin D and calcium supplements, supplementation raised 25(OH)D to sufficiency and denosumab increased BMD and reduced vertebral fracture risk versus placebo irrespective of baseline vitamin D status.

Trust comment: Large randomized, double-blind, placebo-controlled trial (prespecified subanalysis); high-quality evidence though subanalysis limits full certainty.

Study Details

PMID:32671481
Participants:956
Impact:Greater BMD increase with denosumab vs placebo across all baseline vitamin D groups
Trust score:4/5

intracanal bacterial load (CFUs) reduction S1→S2

1 evidences

Compared three intracanal medicaments (including calcium hydroxide) in infected root canals; glycyrrhizin and Ledermix reduced bacteria more than calcium hydroxide.

Trust comment: Randomized clinical trial but small sample (n=36) and focused on dental intracanal medicaments; moderate quality.

Study Details

PMID:39364820
Participants:36
Impact:significant reduction for all ICMs from S1 to S2
Trust score:3/5

CFUs at S2: Glycyrrhizin vs Ca(OH)2

1 evidences

Compared three intracanal medicaments (including calcium hydroxide) in infected root canals; glycyrrhizin and Ledermix reduced bacteria more than calcium hydroxide.

Trust comment: Randomized clinical trial but small sample (n=36) and focused on dental intracanal medicaments; moderate quality.

Study Details

PMID:39364820
Participants:36
Impact:Glycyrrhizin and Ledermix had significantly lower CFUs than Ca(OH)2 (S2)
Trust score:3/5

dose ratio (calcium gluconate : calcium chloride)

1 evidences

Characterized pharmacokinetics and bioequivalence of intravenous calcium formulations in parturients, defining dose ratio and early serum ionized calcium time-course.

Trust comment: Well-conducted PK/bioequivalence study with reasonable sample for PK (70 parturients); results precise and clinically informative.

Study Details

PMID:39361822
Participants:70
Impact:3.11 (95% CI 2.77–3.48)
Trust score:4/5

peak increase in serum ionized calcium after 1 g CaCl2 infusion

1 evidences

Characterized pharmacokinetics and bioequivalence of intravenous calcium formulations in parturients, defining dose ratio and early serum ionized calcium time-course.

Trust comment: Well-conducted PK/bioequivalence study with reasonable sample for PK (70 parturients); results precise and clinically informative.

Study Details

PMID:39361822
Participants:70
Impact:+0.39 mM peak (decreased by half in ~29 min)
Trust score:4/5

post-exercise serum total calcium (tCa)

1 evidences

In healthy trained men, short-course risedronate reduced post-exercise increases in blood calcium and markers of bone resorption but did not reduce exercise-related nausea/vomiting.

Trust comment: Double-blind RCT with ~100 participants and clear biochemical and clinical outcomes; high internal validity.

Study Details

PMID:39341930
Participants:97
Impact:risedronate 9.7 mg/dL vs placebo 9.9 mg/dL (mean difference ≈−0.2 mg/dL; p<0.05)
Trust score:5/5

incidence of exercise-induced hypercalcemia

1 evidences

In healthy trained men, short-course risedronate reduced post-exercise increases in blood calcium and markers of bone resorption but did not reduce exercise-related nausea/vomiting.

Trust comment: Double-blind RCT with ~100 participants and clear biochemical and clinical outcomes; high internal validity.

Study Details

PMID:39341930
Participants:97
Impact:placebo 78% vs risedronate 58.5% (reduced; p<0.05)
Trust score:5/5

nausea/vomiting incidence

1 evidences

In healthy trained men, short-course risedronate reduced post-exercise increases in blood calcium and markers of bone resorption but did not reduce exercise-related nausea/vomiting.

Trust comment: Double-blind RCT with ~100 participants and clear biochemical and clinical outcomes; high internal validity.

Study Details

PMID:39341930
Participants:97
Impact:no significant difference (~58% placebo vs ~60% risedronate)
Trust score:5/5

serum phosphate

8 evidences

Titrating calcium carbonate in hemodialysis patients achieved and maintained lower serum phosphate over 26 weeks without increased adverse events.

Trust comment: Pilot randomized trial in dialysis patients with modest sample size; findings are feasible but limited by size and duration.

Study Details

PMID:28550080
Participants:104
Impact:Mean 26-week phosphate 4.53 mg/dl (intensive) vs 6.05 mg/dl (liberalized); intensive group declined by 1.24 mg/dl vs liberalized
Trust score:3/5

In hypoparathyroid patients, rhPTH(1-84) reduced serum phosphate and calcium–phosphate product and allowed large reductions in active vitamin D dosing while maintaining serum calcium.

Trust comment: Randomized, double-blind, placebo-controlled phase III trial with prespecified endpoints and robust analyses.

Study Details

PMID:27734257
Participants:124
Impact:-0.2 mmol/L (least-squares mean change from baseline in rhPTH group vs ≈0.0 in placebo; significant, P < 0.001)
Trust score:5/5

In CKD patients, paricalcitol (VDR activator) produced a small rise in serum calcium and phosphate but did not change insulin resistance indices over 12 weeks.

Trust comment: Post-hoc analysis of a randomized placebo-controlled trial in CKD (moderate size); intervention raised calcium slightly but no IR effect detected.

Study Details

PMID:29307660
Participants:88
Impact:+0.08 mmol/L (P=0.034)
Trust score:3/5

In CKD patients, paricalcitol improved endothelial function but raised phosphate and slightly increased calcium.

Trust comment: Randomized controlled trial secondary analysis in 88 CKD patients with objective vascular and biochemical measures; moderate-high quality.

Study Details

PMID:27113290
Participants:88
Impact:+11% (PCT; P=0.039)
Trust score:4/5

7-day randomized crossover trial in hemodialysis patients: therapeutic diet rapidly improved mineral markers (lower phosphate/PTH/FGF23) and increased serum calcium.

Trust comment: Randomized crossover design but small short-term study (n=33) with biochemical endpoints; limited duration for clinical outcomes.

Study Details

PMID:37120127
Participants:33
Impact:decrease (P < 0.001)
Trust score:3/5

In vitamin D–sufficient Indian children with low dietary calcium, vitamin D–calcium supplementation paradoxically raised PTH without changing other bone biochemistry.

Trust comment: Follow-up of an RCT with moderate sample size and clear biochemical measures but limited by baseline vitamin D sufficiency and dietary factors.

Study Details

PMID:31704050
Participants:178
Impact:high-normal (no clear improvement)
Trust score:3/5

Analysis of TPTD-treated patients (with all participants receiving daily calcium 610 mg + vitamin D 400 IU) showing that phosphate handling is linked to lumbar BMD response to teriparatide.

Trust comment: Randomized trial data with central lab measurements and clear results linking phosphate handling to BMD, though calcium supplementation was given to all and the study focuses on teriparatide; some limitations (no endogenous PTH or 25-OH vitamin D measurements).

Study Details

PMID:26478225
Participants:290
Impact:decreased with TPTD (significant at weeks 4, 24, 48, 72)
Trust score:4/5

Extended-hours haemodialysis lowered serum phosphate, produced a small increase in serum calcium, and did not change PTH over 12 months.

Trust comment: Large randomized multicentre trial with blinded endpoint assessment; outcomes and adjustments reported clearly.

Study Details

PMID:31299919
Participants:200
Impact:−0.25 mmol/L (mean difference vs standard)
Trust score:4/5

parathyroid hormone (PTH) suppression

1 evidences

Single doses of 1000 mg calcium from milk or calcium carbonate acutely suppressed bone resorption (CTX-1) and lowered PTH in postmenopausal women, regardless of visceral fat.

Trust comment: Well-powered randomized crossover with frequent sampling and clear biochemical endpoints; results robust for acute effects on bone turnover and PTH.

Study Details

PMID:34751787
Participants:77
Impact:−47% with calcium carbonate; −22% with milk (timing: carbonate faster at 1 h, milk at 2 h)
Trust score:4/5

Disease resolution (implant)

1 evidences

40 patients with peri-implant mucositis received debridement ± a spermidine + calcium chloride gel; clinical parameters improved in both groups and the test group had higher disease resolution (non-significant), with fewer bleeding sites.

Trust comment: Double-blind RCT but small sample and adjunct combined spermidine + calcium chloride makes isolation of calcium effect uncertain.

Study Details

PMID:39304548
Participants:40
Impact:+15 percentage points (85% test vs 70% control at 3 months)
Trust score:3/5

Bleeding on probing (BOP) sites

1 evidences

40 patients with peri-implant mucositis received debridement ± a spermidine + calcium chloride gel; clinical parameters improved in both groups and the test group had higher disease resolution (non-significant), with fewer bleeding sites.

Trust comment: Double-blind RCT but small sample and adjunct combined spermidine + calcium chloride makes isolation of calcium effect uncertain.

Study Details

PMID:39304548
Participants:40
Impact:Fewer BOP-positive sites in test vs control (p<0.05)
Trust score:3/5

Probing depth (PD) and FMPS/FMBS

1 evidences

40 patients with peri-implant mucositis received debridement ± a spermidine + calcium chloride gel; clinical parameters improved in both groups and the test group had higher disease resolution (non-significant), with fewer bleeding sites.

Trust comment: Double-blind RCT but small sample and adjunct combined spermidine + calcium chloride makes isolation of calcium effect uncertain.

Study Details

PMID:39304548
Participants:40
Impact:Improved in both groups at 3 months (p<0.05)
Trust score:3/5

Overall OHSS incidence

1 evidences

192 IVF patients randomized to cabergoline ± IV calcium gluconate; the calcium group had fewer OHSS events but differences were not statistically significant.

Trust comment: Randomized clinical trial with moderate sample size but reported differences were not statistically significant.

Study Details

PMID:39293587
Participants:192
Impact:-10.5 percentage points (26.2% control → 15.7% calcium; p=0.401)
Trust score:3/5

Severe OHSS incidence

1 evidences

192 IVF patients randomized to cabergoline ± IV calcium gluconate; the calcium group had fewer OHSS events but differences were not statistically significant.

Trust comment: Randomized clinical trial with moderate sample size but reported differences were not statistically significant.

Study Details

PMID:39293587
Participants:192
Impact:-3.5 percentage points (7.1% control → 3.6% calcium)
Trust score:3/5

Triglycerides

6 evidences

In overweight middle-aged adults, 6 weeks of melted cheese increased total cholesterol and triglycerides compared to unmelted cheese.

Trust comment: Randomized parallel trial with clear interventions and measured lipid outcomes, though short duration (6 weeks).

Study Details

PMID:39017657
Participants:162
Impact:+0.17 ± 0.08 mmol/L (melted vs unmelted)
Trust score:4/5

A 20-week randomized double-blind trial in older men: twice-daily multi-ingredient supplement (whey protein, creatine, 400 mg calcium, vitamin D, n-3 PUFA) increased lean mass and strength and improved some metabolic markers compared with control.

Trust comment: - Checklist: (1) Confirm supplement contains calcium (400 mg per drink) as part of multi-ingredient formula; (2) Identify main outcomes (lean mass, strength, metabolic markers); (3) Use completers (38) for participant count and extract numerical changes. Randomized, double-blind, placebo-controlled trial with modest sample (n=49 randomized, 38 completers); multi-ingredient design prevents attribution to calcium alone but results robust for the combined product—rated 4 for quality.

Study Details

PMID:28719669
Participants:38
Impact:-35% (SUPP reduction after Phase 1)
Trust score:4/5

Six weeks of magnesium-zinc-calcium-vitamin D co-supplementation in gestational diabetes improved fasting glucose, insulin-related markers and some lipid markers versus placebo.

Trust comment: Randomized, double-blind, placebo-controlled trial with clear quantitative outcomes but relatively small sample (n=60).

Study Details

PMID:29316405
Participants:60
Impact:-0.25 ±0.10 mmol/L vs +0.34 ±0.10 mmol/L (P=0.001)
Trust score:4/5

Secondary analysis of a multi‑center SCI trial found multiple race-associated differences in serological markers across the first year, including consistently higher serum calcium in Black versus White participants.

Trust comment: Moderate-sized secondary analysis of an RCT dataset with careful modeling; however data are historical (samples from 1992–1997) and retrospective selection limits current generalizability.

Study Details

PMID:38961159
Participants:316
Impact:Race-time interaction with White > Black; at one year White higher by ~44.4 mg/dL
Trust score:3/5

Vitamin D-deficient women with PCOS given combined calcium+D+K for 8 weeks had improved insulin sensitivity markers and lower triglycerides/VLDL versus placebo.

Trust comment: Double-blind, placebo-controlled RCT with reported numeric effects but modest sample size (n=55) and limited to vitamin D-deficient PCOS women.

Study Details

PMID:28407660
Participants:55
Impact:-23.4 ±71.3 mg/dL (supplement) vs +9.9 ±39.5 mg/dL (placebo); significant decrease vs placebo
Trust score:4/5

Adding 50 g/day Kashk (high‑protein, calcium‑enriched probiotic yogurt) to a low‑energy diet for 8 weeks improved lipids and reduced body weight and waist in overweight/obese women.

Trust comment: Randomized controlled trial with moderate sample size and short duration; reported significant between-group changes but study is small and authors note need for further trials.

Study Details

PMID:31987116
Participants:70
Impact:Decreased vs control (between-group, P=0.013)
Trust score:3/5

WSRS improvement rate (investigator)

1 evidences

Injectable calcium hydroxylapatite filler improved nasolabial fold appearance similarly to Restylane, with common injection-site swelling and pain.

Trust comment: Well-designed multicenter randomized double‑blind non‑inferiority trial with large sample and relevant endpoints; results focus on a calcium‑containing filler rather than systemic calcium.

Study Details

PMID:39331081
Participants:188
Impact:84.04% (Aphranel) vs 78.72% (Restylane) at 24 weeks; Aphranel non-inferior (P>0.05)
Trust score:4/5

WSRS improvement rate (IRC)

1 evidences

Injectable calcium hydroxylapatite filler improved nasolabial fold appearance similarly to Restylane, with common injection-site swelling and pain.

Trust comment: Well-designed multicenter randomized double‑blind non‑inferiority trial with large sample and relevant endpoints; results focus on a calcium‑containing filler rather than systemic calcium.

Study Details

PMID:39331081
Participants:188
Impact:72.34% (Aphranel) vs 70.21% (Restylane) at 24 weeks
Trust score:4/5

Adverse events — injection site swelling/procedural pain

1 evidences

Injectable calcium hydroxylapatite filler improved nasolabial fold appearance similarly to Restylane, with common injection-site swelling and pain.

Trust comment: Well-designed multicenter randomized double‑blind non‑inferiority trial with large sample and relevant endpoints; results focus on a calcium‑containing filler rather than systemic calcium.

Study Details

PMID:39331081
Participants:188
Impact:Most frequently reported AEs in both groups
Trust score:4/5

Lesion depth (ΔF)

1 evidences

CPP‑ACP (a calcium‑phosphate complex) and fluoride varnish both reduced lesion depth over 6 months; infiltrating resin gave faster area/volume reductions and greater hardness recovery in vitro but cost more.

Trust comment: Registered randomized in‑vivo study with paired in‑vitro experiments and reasonable sample for clinical teeth (33 participants); methods and outcomes well reported though longer follow‑up would strengthen evidence.

Study Details

PMID:39316130
Participants:33
Impact:ΔF decreased significantly with CPP‑ACP and fluoride varnish (in vitro and by 6 months in vivo); CPP‑ACP showed slower early (3‑month) change vs resin
Trust score:4/5

Lesion volume/area (ΔQ, A)

1 evidences

CPP‑ACP (a calcium‑phosphate complex) and fluoride varnish both reduced lesion depth over 6 months; infiltrating resin gave faster area/volume reductions and greater hardness recovery in vitro but cost more.

Trust comment: Registered randomized in‑vivo study with paired in‑vitro experiments and reasonable sample for clinical teeth (33 participants); methods and outcomes well reported though longer follow‑up would strengthen evidence.

Study Details

PMID:39316130
Participants:33
Impact:Infiltrating resin produced larger reductions in ΔQ and area at 3 months; by 6 months inter‑group differences were no longer significant
Trust score:4/5

Surface micro‑hardness

1 evidences

CPP‑ACP (a calcium‑phosphate complex) and fluoride varnish both reduced lesion depth over 6 months; infiltrating resin gave faster area/volume reductions and greater hardness recovery in vitro but cost more.

Trust comment: Registered randomized in‑vivo study with paired in‑vitro experiments and reasonable sample for clinical teeth (33 participants); methods and outcomes well reported though longer follow‑up would strengthen evidence.

Study Details

PMID:39316130
Participants:33
Impact:In vitro, infiltrating resin restored surface hardness more than fluoride varnish or CPP‑ACP (significant recovery)
Trust score:4/5

total 25(OH)D3

1 evidences

Randomized double-blind trial in older vitamin D–deficient women: large single oral cholecalciferol boluses produced dose-dependent rises in total and free vitamin D metabolites with minimal effects on calcium and physical function.

Trust comment: Well-conducted double-blind RCT with robust assays but small sample size limits generalizability.

Study Details

PMID:39275206
Participants:60
Impact:Large dose-dependent increases (500,000 IU vs 50,000 IU at week1: +226% vs 50k)
Trust score:4/5

Free 25(OH)D

1 evidences

Randomized double-blind trial in older vitamin D–deficient women: large single oral cholecalciferol boluses produced dose-dependent rises in total and free vitamin D metabolites with minimal effects on calcium and physical function.

Trust comment: Well-conducted double-blind RCT with robust assays but small sample size limits generalizability.

Study Details

PMID:39275206
Participants:60
Impact:Dose-dependent increases (500,000 IU vs 50,000 IU at week1: +274% vs 50k)
Trust score:4/5

Bone turnover markers (PINP, CTX)

1 evidences

Randomized double-blind trial in older vitamin D–deficient women: large single oral cholecalciferol boluses produced dose-dependent rises in total and free vitamin D metabolites with minimal effects on calcium and physical function.

Trust comment: Well-conducted double-blind RCT with robust assays but small sample size limits generalizability.

Study Details

PMID:39275206
Participants:60
Impact:Transient increase at week1 in 500,000 IU group, returned to baseline by week12
Trust score:4/5

postoperative pain

5 evidences

In 36 patients receiving two-visit root canal treatment, calcium hydroxide intracanal paste produced postoperative pain outcomes similar to double antibiotic paste over 48 hours.

Trust comment: Small, double-blinded randomized trial with objective pain measurements but limited sample size reducing certainty.

Study Details

PMID:30728951
Participants:36
Impact:No significant difference vs double antibiotic paste; median pain at 24h CH=1 vs DAP=1 (no statistical significance)
Trust score:3/5

One-visit RCT with final 2% CHX rinse produced similar postoperative pain and radiographic healing to two-visit treatment with calcium hydroxide dressing.

Trust comment: Prospective comparative clinical study (90 teeth) with 24-month follow-up and clinically relevant outcomes; good applicability though outcomes are procedure-specific.

Study Details

PMID:29603299
Participants:90
Impact:no significant difference between one-visit CHX and two-visit CH groups at 24 and 48 h
Trust score:4/5

Local intra-canal calcium hydroxide reduced post‑root‑canal preparation pain but was less effective than triple‑antibiotic paste.

Trust comment: Single‑center randomized single‑blind RCT with 80 patients and appropriate statistical tests; moderate quality though single‑blind and limited to single‑rooted teeth.

Study Details

PMID:36833788
Participants:80
Impact:reduced — Ca(OH)2 group had second‑lowest pain scores vs other groups; less reduction than triple‑antibiotic paste (TAP)
Trust score:4/5

Compared two calcium-silicate sealers and one epoxy-resin sealer after single-visit root canal treatment; postoperative pain and analgesic use were similar across sealers.

Trust comment: Randomized human RCT (n=90) directly compares calcium-silicate-containing vs non-calcium sealers; moderate quality but modest sample size.

Study Details

PMID:32929721
Participants:90
Impact:No significant difference among groups at any assessed time point (6 h to 7 days)
Trust score:3/5

Randomized trial in adults comparing MTA vs calcium hydroxide pulp capping: at 36 months MTA had higher pulp survival than calcium hydroxide.

Trust comment: Randomized multicentre trial with 36-month follow-up; modest sample size (n=70) but clear outcome and statistically significant primary result.

Study Details

PMID:27891629
Participants:70
Impact:No significant difference between materials
Trust score:4/5

serum calcium regulation

1 evidences

Randomized education intervention in hemodialysis patients: teaching food processing methods improved serum calcium control and stabilized PTH over 1 year.

Trust comment: Randomized study with modest sample size and clinically relevant endpoints but single-center and small numbers limit certainty.

Study Details

PMID:39266931
Participants:47
Impact:Improved regulation in intervention vs control (p=0.013)
Trust score:3/5

Serum PTH

3 evidences

Vitamin D supplementation for 3 months reduced body size measures and produced significant changes in calcium-related labs.

Trust comment: Double-blind randomized controlled trial (n=66) with reported significant outcomes; direct intervention was vitamin D not calcium supplement but calcium-related labs were measured.

Study Details

PMID:29615318
Participants:66
Impact:significant change (direction not specified)
Trust score:4/5

Randomized education intervention in hemodialysis patients: teaching food processing methods improved serum calcium control and stabilized PTH over 1 year.

Trust comment: Randomized study with modest sample size and clinically relevant endpoints but single-center and small numbers limit certainty.

Study Details

PMID:39266931
Participants:47
Impact:Remained stable in intervention group (no significant change, p=0.110)
Trust score:3/5

Randomized double-blind trial in women >60: yogurt fortified with vitamin D3 (400 IU) and additional calcium increased 25OHD and decreased PTH and bone resorption markers over 12 weeks.

Trust comment: Randomized double-blind trial with good adherence and clear biochemical endpoints, moderate sample size.

Study Details

PMID:25923487
Participants:48
Impact:−16.7 ng/L (D84-D0) in fortified group vs −2.8 ng/L in control
Trust score:4/5

vitamin D analog therapy dosage

1 evidences

Randomized education intervention in hemodialysis patients: teaching food processing methods improved serum calcium control and stabilized PTH over 1 year.

Trust comment: Randomized study with modest sample size and clinically relevant endpoints but single-center and small numbers limit certainty.

Study Details

PMID:39266931
Participants:47
Impact:No baseline difference; monitored but no reported between-group change
Trust score:3/5

E. faecalis microbial count reduction

1 evidences

Randomized in vivo comparison in adolescents: probiotics, triple antibiotic paste, and calcium hydroxide all reduced intracanal bacteria; probiotics performed better than calcium hydroxide and similar to TAP.

Trust comment: Small randomized clinical study in a specific dental population; randomized but limited sample size.

Study Details

PMID:39250204
Participants:30
Impact:Probiotics > calcium hydroxide; probiotics ≈ triple antibiotic paste
Trust score:3/5

intracanal disinfection efficacy

1 evidences

Randomized in vivo comparison in adolescents: probiotics, triple antibiotic paste, and calcium hydroxide all reduced intracanal bacteria; probiotics performed better than calcium hydroxide and similar to TAP.

Trust comment: Small randomized clinical study in a specific dental population; randomized but limited sample size.

Study Details

PMID:39250204
Participants:30
Impact:All three medicaments reduced microbial counts after 7 days
Trust score:3/5

MMP-2 expression (reversible vs irreversible pulpitis)

1 evidences

Randomized controlled trial in children comparing MTA and Biodentine (calcium-silicate cements) for pulpotomy in primary molars; MMP-2 and -9 were higher in irreversible pulpitis and both materials showed similar clinical success at 18 months.

Trust comment: Single-center randomized controlled trial with explicit clinical and molecular outcomes in children; moderate sample size (57 participants) and 18-month follow-up.

Study Details

PMID:39215293
Participants:57
Impact:Higher in irreversible vs reversible (means 33.03 vs 25.88; difference +7.15)
Trust score:4/5

MMP-9 expression (reversible vs irreversible pulpitis)

1 evidences

Randomized controlled trial in children comparing MTA and Biodentine (calcium-silicate cements) for pulpotomy in primary molars; MMP-2 and -9 were higher in irreversible pulpitis and both materials showed similar clinical success at 18 months.

Trust comment: Single-center randomized controlled trial with explicit clinical and molecular outcomes in children; moderate sample size (57 participants) and 18-month follow-up.

Study Details

PMID:39215293
Participants:57
Impact:Higher in irreversible vs reversible (means 38.55 vs 32.17; difference +6.38)
Trust score:4/5

18-month clinical success (MTA vs Biodentine)

1 evidences

Randomized controlled trial in children comparing MTA and Biodentine (calcium-silicate cements) for pulpotomy in primary molars; MMP-2 and -9 were higher in irreversible pulpitis and both materials showed similar clinical success at 18 months.

Trust comment: Single-center randomized controlled trial with explicit clinical and molecular outcomes in children; moderate sample size (57 participants) and 18-month follow-up.

Study Details

PMID:39215293
Participants:57
Impact:Similar clinical success (MTA 95% vs Biodentine 94.4%); radiographic success higher for MTA (95% vs 83.3%) but not statistically significant overall
Trust score:4/5

forehead aesthetic improvement (GAIS at 180 days)

1 evidences

Double-blind RCT found that mixing CaHA with HA for supraperiosteal forehead filling produced better 180-day aesthetic improvement and fewer irregularities/nodules than CaHA alone.

Trust comment: Well-designed double-blind RCT with complete follow-up (n=132) and clear aesthetic endpoints; single-center cosmetic study limits broader generalizability.

Study Details

PMID:39099032
Participants:132
Impact:greater improvement with CaHA+HA vs CaHA alone (P<0.01)
Trust score:4/5

presence of irregularities

1 evidences

Double-blind RCT found that mixing CaHA with HA for supraperiosteal forehead filling produced better 180-day aesthetic improvement and fewer irregularities/nodules than CaHA alone.

Trust comment: Well-designed double-blind RCT with complete follow-up (n=132) and clear aesthetic endpoints; single-center cosmetic study limits broader generalizability.

Study Details

PMID:39099032
Participants:132
Impact:reduced more with CaHA+HA (P<0.04)
Trust score:4/5

nodule incidence

1 evidences

Double-blind RCT found that mixing CaHA with HA for supraperiosteal forehead filling produced better 180-day aesthetic improvement and fewer irregularities/nodules than CaHA alone.

Trust comment: Well-designed double-blind RCT with complete follow-up (n=132) and clear aesthetic endpoints; single-center cosmetic study limits broader generalizability.

Study Details

PMID:39099032
Participants:132
Impact:low overall (4 in CaHA alone vs 1 in CaHA+HA); difference not statistically significant (P=0.36)
Trust score:4/5

1,25-(OH)2D3

1 evidences

35-day randomized, double-blind, placebo-controlled trial in 64 healthy college students comparing 400 mg/day calcium supplement vs placebo with identical controlled diet: no significant differences in serum/urine metabolites, calcium-related hormones, or biochemical indicators.

Trust comment: Randomized, double-blind, placebo-controlled dietary RCT with strict intake control; short duration and young healthy sample limit generalizability.

Study Details

PMID:34445834
Participants:64
Impact:no significant change (P>0.05)
Trust score:4/5

Total bone mineral density (BMD)

1 evidences

In older hemodialysis patients, 24 weeks of resistance training (traditional or cluster-set) improved bone density and bone-related biomarkers; cluster-set RT showed more responders on several markers including calcium.

Trust comment: Randomized pilot RCT in humans with clear measurements but limited sample size and pilot scope.

Study Details

PMID:39182595
Participants:78
Impact:Improved (pre vs post) in RT and RT-CS groups
Trust score:3/5

femur BMD

1 evidences

In older hemodialysis patients, 24 weeks of resistance training (traditional or cluster-set) improved bone density and bone-related biomarkers; cluster-set RT showed more responders on several markers including calcium.

Trust comment: Randomized pilot RCT in humans with clear measurements but limited sample size and pilot scope.

Study Details

PMID:39182595
Participants:78
Impact:Improved (pre vs post) in RT and RT-CS; femur BMD differed versus control
Trust score:3/5

Serum calcium (responders, MCID)

1 evidences

In older hemodialysis patients, 24 weeks of resistance training (traditional or cluster-set) improved bone density and bone-related biomarkers; cluster-set RT showed more responders on several markers including calcium.

Trust comment: Randomized pilot RCT in humans with clear measurements but limited sample size and pilot scope.

Study Details

PMID:39182595
Participants:78
Impact:More MCID responders in RT-CS group (cluster-set) versus other groups
Trust score:3/5

Live birth (female vitamin D sufficiency)

1 evidences

Secondary analysis of couples seeking infertility care found higher preconception 25(OH)D (vitamin D) status associated with higher live birth probability; calcium biomarker did not show similar associations.

Trust comment: Large, well-powered observational trial-emulation with adjusted models, but secondary analysis of a supplementation trial.

Study Details

PMID:39173703
Participants:2370
Impact:Higher likelihood of live birth: +28% (aRR 1.28; 95% CI 1.05–1.56) for sufficient vs deficient females
Trust score:4/5

Live birth (both partners sufficient)

1 evidences

Secondary analysis of couples seeking infertility care found higher preconception 25(OH)D (vitamin D) status associated with higher live birth probability; calcium biomarker did not show similar associations.

Trust comment: Large, well-powered observational trial-emulation with adjusted models, but secondary analysis of a supplementation trial.

Study Details

PMID:39173703
Participants:2370
Impact:Increased likelihood when both partners not deficient: aRR 1.26 (95% CI 1.00–1.58)
Trust score:4/5

Calcium (biomarker)

1 evidences

Secondary analysis of couples seeking infertility care found higher preconception 25(OH)D (vitamin D) status associated with higher live birth probability; calcium biomarker did not show similar associations.

Trust comment: Large, well-powered observational trial-emulation with adjusted models, but secondary analysis of a supplementation trial.

Study Details

PMID:39173703
Participants:2370
Impact:No similar association observed (calcium was the exception among biomarkers)
Trust score:4/5

Venous port coagulation grade

1 evidences

Randomized trial comparing segmented citrate infusion (prefilter + low-rate venous port infusion) versus conventional prefiler-only citrate during CRRT: segmented approach reduced venous-port clotting and significantly extended extracorporeal circuit lifespan while maintaining safe systemic ionized calcium.

Trust comment: Prospective randomized controlled design with clinically meaningful endpoints and adequate sample for ICU setting.

Study Details

PMID:39152492
Participants:80
Impact:Significantly lower coagulation grades in experimental (segmented) group (P = 0.022)
Trust score:4/5

Extracorporeal circuit lifespan

1 evidences

Randomized trial comparing segmented citrate infusion (prefilter + low-rate venous port infusion) versus conventional prefiler-only citrate during CRRT: segmented approach reduced venous-port clotting and significantly extended extracorporeal circuit lifespan while maintaining safe systemic ionized calcium.

Trust comment: Prospective randomized controlled design with clinically meaningful endpoints and adequate sample for ICU setting.

Study Details

PMID:39152492
Participants:80
Impact:Longer in segmented group: 69.43 ± 1.49 h vs 49.39 ± 2.44 h (P = 0.001)
Trust score:4/5

Peripheral ionized calcium / calcium infusion rate

1 evidences

Randomized trial comparing segmented citrate infusion (prefilter + low-rate venous port infusion) versus conventional prefiler-only citrate during CRRT: segmented approach reduced venous-port clotting and significantly extended extracorporeal circuit lifespan while maintaining safe systemic ionized calcium.

Trust comment: Prospective randomized controlled design with clinically meaningful endpoints and adequate sample for ICU setting.

Study Details

PMID:39152492
Participants:80
Impact:Peripheral iCa maintained within safe range; calcium infusion rates similar (3.9 ± 0.5 vs 4.1 ± 0.4 ml/h; P > 0.05)
Trust score:4/5

Serum calcium (TPTD-ALN group)

1 evidences

Sub-analysis of an RCT in older Japanese women found that lower baseline serum calcium was associated with greater likelihood of treatment discontinuation in the teriparatide→alendronate group; cognitive impairment (lower MMSE) predicted discontinuation in the alendronate group.

Trust comment: Large randomized trial dataset with comprehensive covariate adjustment; associations are observational within trial data.

Study Details

PMID:39141119
Participants:966
Impact:Higher calcium associated with lower odds of compliance-related discontinuation (OR 0.41 per 1 mg/dL increase, 95% CI 0.21–0.78, p = 0.01) and any-reason discontinuation (OR 0.44, 95% CI 0.28–0.69, p < 0.01)
Trust score:4/5

MMSE (cognitive function, ALN group)

1 evidences

Sub-analysis of an RCT in older Japanese women found that lower baseline serum calcium was associated with greater likelihood of treatment discontinuation in the teriparatide→alendronate group; cognitive impairment (lower MMSE) predicted discontinuation in the alendronate group.

Trust comment: Large randomized trial dataset with comprehensive covariate adjustment; associations are observational within trial data.

Study Details

PMID:39141119
Participants:966
Impact:Higher MMSE associated with lower odds of compliance-related discontinuation (OR 0.92 per point, 95% CI 0.87–0.97, p < 0.01)
Trust score:4/5

left forearm bone mineral density (BMD)

1 evidences

Daily milk for 12 months improved children's forearm (and calcaneus) bone measures compared to control.

Trust comment: Cluster-RCT with moderate sample size and objective BMD/BMC measures over 12 months, though some attrition occurred.

Study Details

PMID:39043915
Participants:278
Impact:+4.05% (6 months); +7.31% (12 months) vs control
Trust score:4/5

left forearm bone mineral content (BMC)

1 evidences

Daily milk for 12 months improved children's forearm (and calcaneus) bone measures compared to control.

Trust comment: Cluster-RCT with moderate sample size and objective BMD/BMC measures over 12 months, though some attrition occurred.

Study Details

PMID:39043915
Participants:278
Impact:+4.69% (6 months); +7.34% (12 months) vs control
Trust score:4/5

calcaneus bone acquisition

1 evidences

Daily milk for 12 months improved children's forearm (and calcaneus) bone measures compared to control.

Trust comment: Cluster-RCT with moderate sample size and objective BMD/BMC measures over 12 months, though some attrition occurred.

Study Details

PMID:39043915
Participants:278
Impact:significant increase vs control (P < 0.05)
Trust score:4/5

weight / glycaemic markers

1 evidences

In overweight middle-aged adults, 6 weeks of melted cheese increased total cholesterol and triglycerides compared to unmelted cheese.

Trust comment: Randomized parallel trial with clear interventions and measured lipid outcomes, though short duration (6 weeks).

Study Details

PMID:39017657
Participants:162
Impact:no change vs control
Trust score:4/5

calcium supplementation adherence

1 evidences

Behavioral trial found calcium-supplementation adherence was highest when morning-types used morning plans.

Trust comment: Randomized behavioral trial with objective adherence measures (Fitbit/MEMS) and a large sample of volunteers.

Study Details

PMID:39014034
Participants:317
Impact:greatest for morning-types in the morning-cue planning condition
Trust score:4/5

exercise adherence (comparison)

1 evidences

Behavioral trial found calcium-supplementation adherence was highest when morning-types used morning plans.

Trust comment: Randomized behavioral trial with objective adherence measures (Fitbit/MEMS) and a large sample of volunteers.

Study Details

PMID:39014034
Participants:317
Impact:matched diurnal preference (morning-types with morning cues, evening-types with evening cues) improved exercise engagement
Trust score:4/5

eltrombopag systemic exposure (AUC/Cmax)

1 evidences

Eltrombopag formulations were bioequivalent; administering with a high-fat, low-calcium meal reduced systemic exposure by ~40%.

Trust comment: Well-controlled crossover pharmacokinetic study in healthy volunteers with clear PK outcomes; relevant meal calcium context.

Study Details

PMID:39011900
Participants:96
Impact:reduced by ~40% when given with a high-fat, low-calcium meal
Trust score:4/5

bioequivalence (fasted and fed)

1 evidences

Eltrombopag formulations were bioequivalent; administering with a high-fat, low-calcium meal reduced systemic exposure by ~40%.

Trust comment: Well-controlled crossover pharmacokinetic study in healthy volunteers with clear PK outcomes; relevant meal calcium context.

Study Details

PMID:39011900
Participants:96
Impact:GMRs for Cmax and AUC within 80–125% acceptance limits
Trust score:4/5

serum lipid panel (TC/HDL-C, LDL-C, non-HDL-C, TGs)

1 evidences

Increasing dairy (milk, yoghurt, cheese) to recommended levels in aged-care residents did not worsen serum lipid profiles at 12 months.

Trust comment: Cluster-randomized 2-year trial with dietary intake assessment and fasting lipids in a vulnerable older population; results likely generalizable within setting.

Study Details

PMID:39003129
Participants:245
Impact:no significant differences at 12 months vs control
Trust score:4/5

ApoB/ApoA-1 ratio

1 evidences

Increasing dairy (milk, yoghurt, cheese) to recommended levels in aged-care residents did not worsen serum lipid profiles at 12 months.

Trust comment: Cluster-randomized 2-year trial with dietary intake assessment and fasting lipids in a vulnerable older population; results likely generalizable within setting.

Study Details

PMID:39003129
Participants:245
Impact:no significant difference at 12 months vs control
Trust score:4/5

25-hydroxyvitamin D (25(OH)D)

3 evidences

Small double-blind RCT in heart failure patients testing high-dose vitamin D3 vs placebo; vitamin D levels rose markedly and some hormonal (PTH), BNP and QOL measures improved.

Trust comment: Randomized, double-blind human trial with appropriate measures and clear biochemical effects (large 25(OH)D change); small sample limits precision and generalizability.

Study Details

PMID:29084522
Participants:36
Impact:increased in treatment group by ~+51 ±32 ng/ml (p<0.001)
Trust score:4/5

In vitamin D–deficient community adults, vitamin D with or without calcium showed no clear clinical benefit over placebo at 6 months, though combined vitamin D+calcium reduced PTH and increased urine Ca/Cr in adherent subjects.

Trust comment: Randomized double-blind trial but substantial loss to follow-up and modest adherence limit confidence in null clinical findings.

Study Details

PMID:35505326
Participants:277
Impact:marginal/non-significant increase with vitamin D groups (between-group p=0.12)
Trust score:3/5

Large randomized trial measuring vitamin D, calcium and iPTH; vitamin D raised 25(OH)D while calcium stayed stable and iPTH decreased.

Trust comment: Large randomized, placebo-controlled trial with robust measurements; calcium reported as a secondary biomarker and appears reliable.

Study Details

PMID:31669447
Participants:15804
Impact:+11.9 ng/mL (active group at 1 year; placebo −0.7 ng/mL)
Trust score:4/5

Premature filter coagulation

1 evidences

In patients at high bleeding risk, regional anticoagulation using calcium‑free dialysate with calcium reinjection (CFD) resulted in fewer premature dialysis terminations and less filter coagulation than heparin‑coated membranes.

Trust comment: Multicentre randomized crossover trial in humans with clear, clinically relevant endpoints and moderate sample size; pragmatic design supports trustworthiness.

Study Details

PMID:38977911
Participants:94
Impact:HCM: 19 sessions (20.9%) vs CFD: 3 sessions (3.2%) (reduction ≈17.7 percentage points with CFD)
Trust score:4/5

Completion of dialysis sessions (≥240 min)

1 evidences

In patients at high bleeding risk, regional anticoagulation using calcium‑free dialysate with calcium reinjection (CFD) resulted in fewer premature dialysis terminations and less filter coagulation than heparin‑coated membranes.

Trust comment: Multicentre randomized crossover trial in humans with clear, clinically relevant endpoints and moderate sample size; pragmatic design supports trustworthiness.

Study Details

PMID:38977911
Participants:94
Impact:More sessions completed with CFD; number who completed CFD but failed HCM = 17 vs completed HCM but failed CFD = 1 (P < .001)
Trust score:4/5

platelet count

1 evidences

Secondary analysis of a multi‑center SCI trial found multiple race-associated differences in serological markers across the first year, including consistently higher serum calcium in Black versus White participants.

Trust comment: Moderate-sized secondary analysis of an RCT dataset with careful modeling; however data are historical (samples from 1992–1997) and retrospective selection limits current generalizability.

Study Details

PMID:38961159
Participants:316
Impact:Main effect of race: Black > White (≈12% higher at one year)
Trust score:3/5

Tertiary dentin thickness

1 evidences

In children needing indirect pulp capping, TheraCal LC (a resin‑modified calcium silicate material) produced more tertiary dentin than MTA and calcium hydroxide (Dycal) over 6 months.

Trust comment: Randomized allocation in a clinical in vivo pediatric study with moderate sample size and objective radiographic measurement, but short follow-up (6 months) and single‑center limitations.

Study Details

PMID:38956853
Participants:75
Impact:TheraCal LC > MTA > Dycal (greater dentin deposition with TheraCal LC)
Trust score:3/5

Dentin thickness change over time

1 evidences

In children needing indirect pulp capping, TheraCal LC (a resin‑modified calcium silicate material) produced more tertiary dentin than MTA and calcium hydroxide (Dycal) over 6 months.

Trust comment: Randomized allocation in a clinical in vivo pediatric study with moderate sample size and objective radiographic measurement, but short follow-up (6 months) and single‑center limitations.

Study Details

PMID:38956853
Participants:75
Impact:Significant increase in dentin thickness in first 3 months vs 6-month follow-up (greater early deposition)
Trust score:3/5

intraoperative PTH drop (5 min)

1 evidences

Randomized clinical trial (N=96) comparing endoscopic vs focused single-gland parathyroidectomy in primary hyperparathyroidism; endoscopic approach achieved faster intraoperative PTH decline, higher early success rate and higher postoperative calcium levels, with better cosmetic satisfaction.

Trust comment: Randomized clinical trial directly addressing parathyroid surgery and calcium homeostasis with reasonable sample size and clinically relevant endpoints.

Study Details

PMID:38907761
Participants:96
Impact:greater drop in endoscopic group (significantly lower ioPTH at 5 min; p=0.005)
Trust score:4/5

early surgical success rate (5 min)

1 evidences

Randomized clinical trial (N=96) comparing endoscopic vs focused single-gland parathyroidectomy in primary hyperparathyroidism; endoscopic approach achieved faster intraoperative PTH decline, higher early success rate and higher postoperative calcium levels, with better cosmetic satisfaction.

Trust comment: Randomized clinical trial directly addressing parathyroid surgery and calcium homeostasis with reasonable sample size and clinically relevant endpoints.

Study Details

PMID:38907761
Participants:96
Impact:endoscopic 95.3% vs focused 77.1% success at 5 min (p=0.013)
Trust score:4/5

postoperative serum calcium

3 evidences

Randomized clinical trial (N=96) comparing endoscopic vs focused single-gland parathyroidectomy in primary hyperparathyroidism; endoscopic approach achieved faster intraoperative PTH decline, higher early success rate and higher postoperative calcium levels, with better cosmetic satisfaction.

Trust comment: Randomized clinical trial directly addressing parathyroid surgery and calcium homeostasis with reasonable sample size and clinically relevant endpoints.

Study Details

PMID:38907761
Participants:96
Impact:postoperative calcium lower in focused method vs endoscopic (difference significant, p=0.042)
Trust score:4/5

Preoperative calcitriol given for 1 week before thyroidectomy did not change postoperative serum calcium or hypocalcemia incidence versus placebo; one case of Grade 3 hypercalcemia occurred.

Trust comment: Randomized double-blind placebo-controlled Phase II trial with small sample focused on calcium outcomes; results showed no benefit and one adverse hypercalcemia event.

Study Details

PMID:34076308
Participants:47
Impact:no difference over time (p=0.22)
Trust score:4/5

A perioperative multimodal nutrition protocol improved postoperative labs and recovery: higher albumin and electrolyte levels, fewer electrolyte disorders, and shorter hospital stay.

Trust comment: Randomized controlled trial with 187 patients and clinically relevant postoperative biochemical and recovery endpoints; results report differences in electrolytes including calcium.

Study Details

PMID:30817733
Participants:187
Impact:Higher postoperative calcium levels in MNM group vs control
Trust score:4/5

incidence of new caries (2 years)

1 evidences

Double-blind RCT in 582 high-risk preschool children comparing 5% NaF varnish alone vs NaF with TCP vs NaF with CPP-ACP applied quarterly for 24 months; varnishes containing calcium/phosphate additives showed no superior efficacy to standard NaF varnish.

Trust comment: Large, double-blind randomized trial directly testing fluoride varnishes that include calcium/phosphate additives; high sample size and 2-year follow-up support moderate-high trust.

Study Details

PMID:38901821
Participants:582
Impact:MI Varnish (CPP‑ACP) 59.2% vs Clinpro (TCP) 65.1% vs Duraphat (NaF) 66.1% (p=0.466; no significant difference)
Trust score:4/5

cavitated lesion increment

1 evidences

Double-blind RCT in 582 high-risk preschool children comparing 5% NaF varnish alone vs NaF with TCP vs NaF with CPP-ACP applied quarterly for 24 months; varnishes containing calcium/phosphate additives showed no superior efficacy to standard NaF varnish.

Trust comment: Large, double-blind randomized trial directly testing fluoride varnishes that include calcium/phosphate additives; high sample size and 2-year follow-up support moderate-high trust.

Study Details

PMID:38901821
Participants:582
Impact:no significant difference among groups (p=0.714)
Trust score:4/5

non-cavitated lesion increment

1 evidences

Double-blind RCT in 582 high-risk preschool children comparing 5% NaF varnish alone vs NaF with TCP vs NaF with CPP-ACP applied quarterly for 24 months; varnishes containing calcium/phosphate additives showed no superior efficacy to standard NaF varnish.

Trust comment: Large, double-blind randomized trial directly testing fluoride varnishes that include calcium/phosphate additives; high sample size and 2-year follow-up support moderate-high trust.

Study Details

PMID:38901821
Participants:582
Impact:no significant difference among groups (p=0.223)
Trust score:4/5

normocalcemia at 1 month after first-line imaging‑guided MIP

1 evidences

Multicenter randomized phase 3 trial (57 patients imaged first-line) comparing first-line F18‑choline PET/CT vs Tc99m‑MIBI SPECT/CT for localization in PHPT: FCH PET/CT guided more successful minimally invasive parathyroidectomies leading to normocalcemia at 1 month.

Trust comment: Randomized multicenter diagnostic trial linking imaging modality to surgical outcome (normocalcemia); directly relevant to calcium homeostasis in PHPT with clear primary endpoint.

Study Details

PMID:38900416
Participants:57
Impact:FCH1 85% (23/27) vs MIBI1 56% (14/25); difference 29% (95% CI 4%–51%)
Trust score:4/5

sensitivity (lesion-based)

1 evidences

Multicenter randomized phase 3 trial (57 patients imaged first-line) comparing first-line F18‑choline PET/CT vs Tc99m‑MIBI SPECT/CT for localization in PHPT: FCH PET/CT guided more successful minimally invasive parathyroidectomies leading to normocalcemia at 1 month.

Trust comment: Randomized multicenter diagnostic trial linking imaging modality to surgical outcome (normocalcemia); directly relevant to calcium homeostasis in PHPT with clear primary endpoint.

Study Details

PMID:38900416
Participants:57
Impact:FCH1 82% vs MIBI1 63% (sensitivity higher for FCH)
Trust score:4/5

clinical treatment effective rate

1 evidences

In elderly patients with heart failure and arrhythmia, adding dbcAMP-Ca to metoprolol improved clinical efficacy and multiple objective cardiac function measures compared with metoprolol alone.

Trust comment: Randomized controlled trial (n=102) with objective cardiac endpoints and statistically significant between-group differences, though treatment duration was relatively short.

Study Details

PMID:38948272
Participants:102
Impact:Experimental 94.12% (48/51) vs control 78.43% (40/51)
Trust score:4/5

left ventricular ejection fraction (LVEF) increase

1 evidences

In elderly patients with heart failure and arrhythmia, adding dbcAMP-Ca to metoprolol improved clinical efficacy and multiple objective cardiac function measures compared with metoprolol alone.

Trust comment: Randomized controlled trial (n=102) with objective cardiac endpoints and statistically significant between-group differences, though treatment duration was relatively short.

Study Details

PMID:38948272
Participants:102
Impact:Experimental +9.52 percentage points vs control +5.17 percentage points (after 4 weeks)
Trust score:4/5

NT-proBNP reduction

1 evidences

In elderly patients with heart failure and arrhythmia, adding dbcAMP-Ca to metoprolol improved clinical efficacy and multiple objective cardiac function measures compared with metoprolol alone.

Trust comment: Randomized controlled trial (n=102) with objective cardiac endpoints and statistically significant between-group differences, though treatment duration was relatively short.

Study Details

PMID:38948272
Participants:102
Impact:Experimental −2471.42 pg/mL vs control −1953.42 pg/mL (after 4 weeks)
Trust score:4/5

bone mineral content (BMC) change

1 evidences

Among adolescents with obesity in a 6-month program, overall BMC and BMD rose but many had low dietary calcium intake and some experienced declines in bone measures.

Trust comment: Objective DXA measurements and controlled trial data underpin findings, but this is a secondary analysis with limited sample and self-reported diet, which reduces certainty.

Study Details

PMID:38937331
Participants:71
Impact:Overall increase β=0.14 kg over 6 months
Trust score:4/5

bone mineral density (BMD) change

1 evidences

Among adolescents with obesity in a 6-month program, overall BMC and BMD rose but many had low dietary calcium intake and some experienced declines in bone measures.

Trust comment: Objective DXA measurements and controlled trial data underpin findings, but this is a secondary analysis with limited sample and self-reported diet, which reduces certainty.

Study Details

PMID:38937331
Participants:71
Impact:Overall increase β=0.04 g/m2 over 6 months
Trust score:4/5

dietary calcium intake (baseline)

1 evidences

Among adolescents with obesity in a 6-month program, overall BMC and BMD rose but many had low dietary calcium intake and some experienced declines in bone measures.

Trust comment: Objective DXA measurements and controlled trial data underpin findings, but this is a secondary analysis with limited sample and self-reported diet, which reduces certainty.

Study Details

PMID:38937331
Participants:71
Impact:Median ~383 mg/day (girls) and ~430 mg/day (boys); only 1 of 71 met 960 mg/day recommendation
Trust score:4/5

Merz Jawline Assessment Scale (MJAS) responder rate

1 evidences

Calcium hydroxyapatite (CaHA-CMC+) injections produced clinically meaningful, long-lasting jawline contour improvements up to 60 weeks and were generally well tolerated.

Trust comment: Randomized, multicenter, rater-blinded trial with 175 treated patients and long follow-up provides moderate-high confidence in efficacy and safety for this CaHA product.

Study Details

PMID:38934231
Participants:175
Impact:77.9% (12 weeks), 78.7% (24 weeks), 62.9% (48 weeks); at 60 weeks 74.6% with retreatment vs 43.5% without retreatment
Trust score:4/5

self-reported aesthetic improvement (SGAIS very much improved)

1 evidences

Calcium hydroxyapatite (CaHA-CMC+) injections produced clinically meaningful, long-lasting jawline contour improvements up to 60 weeks and were generally well tolerated.

Trust comment: Randomized, multicenter, rater-blinded trial with 175 treated patients and long follow-up provides moderate-high confidence in efficacy and safety for this CaHA product.

Study Details

PMID:38934231
Participants:175
Impact:93.4% (12 weeks), 85.6% (24 weeks), 68.5% (48 weeks)
Trust score:4/5

Beck Depression Inventory (BDI-II) change

1 evidences

As the comparator arm, adolescents receiving 500 mg calcium plus low‑dose vitamin D showed smaller improvements in depression scores than those receiving high‑dose vitamin D.

Trust comment: Large cluster RCT with adherence checks, but calcium was part of the comparator regimen (combined with low-dose vitamin D) and the trial focused on vitamin D effects, limiting direct inference about calcium alone.

Study Details

PMID:38931184
Participants:154
Impact:Calcium + low-dose vitamin D arm showed smaller/no significant reduction in depression scores compared with high-dose vitamin D (difference-in-difference favored high-dose vitamin D)
Trust score:3/5

vitamin D status after supplementation (calcium arm)

1 evidences

As the comparator arm, adolescents receiving 500 mg calcium plus low‑dose vitamin D showed smaller improvements in depression scores than those receiving high‑dose vitamin D.

Trust comment: Large cluster RCT with adherence checks, but calcium was part of the comparator regimen (combined with low-dose vitamin D) and the trial focused on vitamin D effects, limiting direct inference about calcium alone.

Study Details

PMID:38931184
Participants:154
Impact:Post-intervention: 36.3% sufficient, 41.6% insufficient, 22.1% deficient
Trust score:3/5

analgesic use (frequency)

1 evidences

In retreatment root canal patients, calcium hydroxide, chlorhexidine gel, or their mixture produced similar postoperative pain and flare-up rates over one week.

Trust comment: Randomized, stratified clinical trial with clearly reported methods and outcomes, moderate sample (n=108) and appropriate analyses.

Study Details

PMID:38849655
Participants:108
Impact:difference between groups (p<0.05)
Trust score:4/5

flare-up incidence

2 evidences

In root canal treatment of necrotic single-rooted teeth, calcium hydroxide paste produced similar post-operative pain and flare-up rates compared with propolis paste.

Trust comment: Well-conducted double-blind RCT with clear outcomes and 68 completers; moderate sample size and 15% dropout from planned 80.

Study Details

PMID:31936519
Participants:68
Impact:overall 14.8%; calcium hydroxide group 12% (vs propolis 17%)
Trust score:4/5

In retreatment root canal patients, calcium hydroxide, chlorhexidine gel, or their mixture produced similar postoperative pain and flare-up rates over one week.

Trust comment: Randomized, stratified clinical trial with clearly reported methods and outcomes, moderate sample (n=108) and appropriate analyses.

Study Details

PMID:38849655
Participants:108
Impact:no significant difference; single flare-up observed in CHX gel group
Trust score:4/5

offspring systolic blood pressure (female)

1 evidences

Children whose mothers took 1500 mg/day calcium in pregnancy had lower systolic blood pressure and altered growth patterns in female offspring but not in males.

Trust comment: Large, long-term randomized trial follow-up with high retention and robust longitudinal modeling (SITAR); appropriate adjustments reported.

Study Details

PMID:38839195
Participants:491
Impact:−2.13 ± 0.77 mmHg (Ca vs placebo; P = 0.005)
Trust score:5/5

peak height velocity (female)

1 evidences

Children whose mothers took 1500 mg/day calcium in pregnancy had lower systolic blood pressure and altered growth patterns in female offspring but not in males.

Trust comment: Large, long-term randomized trial follow-up with high retention and robust longitudinal modeling (SITAR); appropriate adjustments reported.

Study Details

PMID:38839195
Participants:491
Impact:−2.9% intensity (shallower height velocity curve; P = 0.009)
Trust score:5/5

sex-specific effect (male outcomes)

1 evidences

Children whose mothers took 1500 mg/day calcium in pregnancy had lower systolic blood pressure and altered growth patterns in female offspring but not in males.

Trust comment: Large, long-term randomized trial follow-up with high retention and robust longitudinal modeling (SITAR); appropriate adjustments reported.

Study Details

PMID:38839195
Participants:491
Impact:no consistent differences in blood pressure or growth in males
Trust score:5/5

socket bone density

1 evidences

Sockets filled with platelet-rich fibrin activated with calcium chloride (APRF) showed greater radiographic bone density over time than standard PRF.

Trust comment: Double-blind randomized design but small sample (n=60) and outcome based on radiographic scoring which may be less precise than volumetric measures.

Study Details

PMID:38834143
Participants:60
Impact:increased with APRF (activated with 10% CaCl2) vs PRF (statistically significant)
Trust score:3/5

bone formation by location

1 evidences

Sockets filled with platelet-rich fibrin activated with calcium chloride (APRF) showed greater radiographic bone density over time than standard PRF.

Trust comment: Double-blind randomized design but small sample (n=60) and outcome based on radiographic scoring which may be less precise than volumetric measures.

Study Details

PMID:38834143
Participants:60
Impact:maxillary sockets showed better bone formation than mandibular sockets
Trust score:3/5

30‑s chair stand test (lower limb strength)

1 evidences

In older men with low‑normal/low testosterone and mobility problems, the combination of testosterone, progressive resistance training and supplements (vitamin D, calcium, protein) improved lower‑limb strength, quality of life and HRV versus control.

Trust comment: Well‑conducted randomized factorial trial, but calcium was given together with testosterone, vitamin D and protein and with exercise, so calcium‑specific effects cannot be isolated.

Study Details

PMID:38890228
Participants:148
Impact:median +3 stands in combo group vs 0 in control (score change since baseline 3.0 vs 0; P = 0.0025)
Trust score:3/5

leg fat (DXA)

1 evidences

In older men with low‑normal/low testosterone and mobility problems, the combination of testosterone, progressive resistance training and supplements (vitamin D, calcium, protein) improved lower‑limb strength, quality of life and HRV versus control.

Trust comment: Well‑conducted randomized factorial trial, but calcium was given together with testosterone, vitamin D and protein and with exercise, so calcium‑specific effects cannot be isolated.

Study Details

PMID:38890228
Participants:148
Impact:reduced percentage/amount in combo (and TU) groups versus control (statistically significant reductions)
Trust score:3/5

heart rate variability (SD RR, SD2)

1 evidences

In older men with low‑normal/low testosterone and mobility problems, the combination of testosterone, progressive resistance training and supplements (vitamin D, calcium, protein) improved lower‑limb strength, quality of life and HRV versus control.

Trust comment: Well‑conducted randomized factorial trial, but calcium was given together with testosterone, vitamin D and protein and with exercise, so calcium‑specific effects cannot be isolated.

Study Details

PMID:38890228
Participants:148
Impact:increased in combo group versus control (significant improvement)
Trust score:3/5

posterolateral fusion performance (BCPµm vs autograft)

1 evidences

An intrapatient randomized trial found a biphasic calcium phosphate ceramic (BCPµm) was noninferior and statistically superior to autograft for CT‑assessed posterolateral fusion at 1 year.

Trust comment: Multicenter, randomized intrapatient controlled trial with objective CT fusion outcomes; radiographic differentiation of ceramic remnants vs bone is a noted limitation.

Study Details

PMID:38881258
Participants:91
Impact:BCPµm superior; absolute paired difference 39.6% in favor of BCPµm (95% CI 26.8–51.2; P < .001)
Trust score:4/5

segment‑level fusion rate (BCPµm vs autograft)

1 evidences

An intrapatient randomized trial found a biphasic calcium phosphate ceramic (BCPµm) was noninferior and statistically superior to autograft for CT‑assessed posterolateral fusion at 1 year.

Trust comment: Multicenter, randomized intrapatient controlled trial with objective CT fusion outcomes; radiographic differentiation of ceramic remnants vs bone is a noted limitation.

Study Details

PMID:38881258
Participants:91
Impact:BCPµm fused 79% of segments vs autograft 47% (absolute difference ~32 percentage points)
Trust score:4/5

procedure‑related serious adverse events

1 evidences

An intrapatient randomized trial found a biphasic calcium phosphate ceramic (BCPµm) was noninferior and statistically superior to autograft for CT‑assessed posterolateral fusion at 1 year.

Trust comment: Multicenter, randomized intrapatient controlled trial with objective CT fusion outcomes; radiographic differentiation of ceramic remnants vs bone is a noted limitation.

Study Details

PMID:38881258
Participants:91
Impact:no events directly attributable to BCPµm (24 serious events overall; 3 reoperations included graft removal)
Trust score:4/5

enamel calcium-to-phosphorus ratio

1 evidences

In vivo, weekly nanohydroxyapatite (nHAp) application after interproximal reduction led to enamel properties (Ca:P ratio, microhardness, surface roughness) closest to untouched enamel, outperforming monthly NaF varnish and controls.

Trust comment: Small randomized in vivo dental study (n=25) showing nHAp (a calcium‑containing agent) improved enamel remineralization compared with NaF and controls; limited group sizes (n=5) limit generalizability.

Study Details

PMID:38852104
Participants:25
Impact:closest to untouched enamel with nHAp (better than NaF and controls)
Trust score:3/5

enamel microhardness

1 evidences

In vivo, weekly nanohydroxyapatite (nHAp) application after interproximal reduction led to enamel properties (Ca:P ratio, microhardness, surface roughness) closest to untouched enamel, outperforming monthly NaF varnish and controls.

Trust comment: Small randomized in vivo dental study (n=25) showing nHAp (a calcium‑containing agent) improved enamel remineralization compared with NaF and controls; limited group sizes (n=5) limit generalizability.

Study Details

PMID:38852104
Participants:25
Impact:improved with nHAp versus immediate post‑IPR and better than NaF
Trust score:3/5

implant stability (ISQ)

1 evidences

Prospective randomized trial comparing biphasic calcium phosphate graft vs deproteinized bovine bone for sinus augmentation (56 patients, 60 sinuses); both materials showed similar biocompatibility and osteoconductivity at 6 months.

Trust comment: Randomized controlled clinical trial directly testing a calcium-containing graft material in humans; moderate sample size and no significant differences reported.

Study Details

PMID:30521656
Participants:56
Impact:ISQ values >60 for all implants and increased over 6 months; no implant failures
Trust score:3/5

post-operative pain

1 evidences

In root canal retreatment, calcium hydroxide had similar antibacterial effects to nano-forms, but nano-calcium hydroxide (and nano-silver) reduced postoperative pain at 48–72 hours.

Trust comment: Randomized clinical trial in humans with clear endpoints but small sample (n=69) limiting generalizability.

Study Details

PMID:34697657
Participants:69
Impact:reduced at 48 and 72 h with nano-Ag and nano-CH (p<0.05)
Trust score:3/5

insulin resistance (HOMA-IR)

1 evidences

Twelve weeks of vitamin D, K and calcium co-supplementation improved left carotid thickness and several metabolic markers in overweight diabetics with CHD.

Trust comment: Randomized double-blind placebo-controlled trial with clear reported differences but modest sample size and co-supplementation complicates attribution to calcium alone.

Study Details

PMID:27198036
Participants:66
Impact:HOMA-IR change: -0.4 (supplement) vs +0.7 (placebo), P=0.01
Trust score:4/5

BMI

1 evidences

12-week randomized trial in Chinese adults at risk of malnutrition: daily oral nutrition supplement increased weight, anthropometric measures, and multiple nutrient intakes.

Trust comment: Randomized controlled trial with adequate power and objective outcomes, but open-label, unblinded, and lacking body-composition measures.

Study Details

PMID:36141627
Participants:82
Impact:+0.578 kg/m2 (estimated mean group difference, p < 0.001)
Trust score:4/5

caries incidence

1 evidences

In children (6–9 y) with MIH, single applications of SDF resulted in fewer new caries and higher caries-arrest rates over 12 months than CPP-ACPFV; both prevented enamel breakdown and improved sensitivity.

Trust comment: Well-powered, randomized, double-blind split-mouth RCT with clear outcomes, though split-mouth design and 1-year follow-up limit generalizability.

Study Details

PMID:38778809
Participants:100
Impact:lower with SDF (e.g., 23 vs 49 affected teeth at 12 months)
Trust score:4/5

caries arrest rate

1 evidences

In children (6–9 y) with MIH, single applications of SDF resulted in fewer new caries and higher caries-arrest rates over 12 months than CPP-ACPFV; both prevented enamel breakdown and improved sensitivity.

Trust comment: Well-powered, randomized, double-blind split-mouth RCT with clear outcomes, though split-mouth design and 1-year follow-up limit generalizability.

Study Details

PMID:38778809
Participants:100
Impact:higher with SDF (87% vs 34.7% at 12 months)
Trust score:4/5

post-eruptive enamel breakdown (PEB) prevention

1 evidences

In children (6–9 y) with MIH, single applications of SDF resulted in fewer new caries and higher caries-arrest rates over 12 months than CPP-ACPFV; both prevented enamel breakdown and improved sensitivity.

Trust comment: Well-powered, randomized, double-blind split-mouth RCT with clear outcomes, though split-mouth design and 1-year follow-up limit generalizability.

Study Details

PMID:38778809
Participants:100
Impact:no significant difference between SDF and CPP-ACPFV
Trust score:4/5

hand grip strength

3 evidences

100 male type 2 diabetic patients assigned to aerobic or resistance training for 6 months; both exercise types increased serum calcium and handgrip strength and decreased PTH.

Trust comment: Intervention study with 6-month follow-up and clear biochemical/functional outcomes, but allocation method and blinding not fully described in abstract.

Study Details

PMID:26957979
Participants:100
Impact:significant increase in both groups after 6 months
Trust score:3/5

Sarcopenic older adults received combined exercise plus nutritional support (included BCAA and daily Caltrate: 600 mg calcium + 800 IU vitamin D3); after 12 weeks inflammatory cytokines decreased and muscle strength/mass improved.

Trust comment: Human RCT per‑protocol analysis (n=57) showing reductions in inflammatory markers and improved strength, but calcium was given as part of a multi‑component nutrition + exercise program so effects cannot be attributed to calcium alone.

Study Details

PMID:38032288
Participants:57
Impact:+2.89 kg (mean change), p<0.001
Trust score:3/5

Daily 1200 IU vitamin D prevented wintertime vitamin D deficiency but did not change hand grip strength or major hormone levels in young male conscripts.

Trust comment: Triple-blinded randomized placebo-controlled trial (analyzed n=53) with robust biochemical measures but limited power for secondary outcomes.

Study Details

PMID:35875694
Participants:53
Impact:No significant difference between vitamin D and placebo at any time point (no change)
Trust score:4/5

fractional calcium absorption (FCA)

1 evidences

In a randomized crossover study of healthy women, strenuous load-carriage exercise lowered ionized calcium, raised PTH, increased fractional calcium absorption, and produced a more positive calcium balance.

Trust comment: Randomized crossover human study with dual stable Ca isotopes and direct kinetic measures; rigorous methods but small sample size (n=21).

Study Details

PMID:38630876
Participants:21
Impact:increased by 2.7 percentage points (26.6% vs 23.9%; P<0.05)
Trust score:4/5

Serum calcium concentration

2 evidences

Two long-term dietary patterns affected several serum minerals over 24 months; serum calcium showed no significant change while other minerals (selenium, manganese, magnesium) increased and serum zinc decreased.

Trust comment: Large randomized dietary intervention with measured serum minerals (n=368 analyzed); intervention not targeted to calcium specifically but directly reports serum calcium outcomes.

Study Details

PMID:38701651
Participants:368
Impact:No significant change over 24 months
Trust score:4/5

Infants fed an amino-acid formula maintained normal blood phosphorus, calcium, and magnesium after 16 weeks, including those on acid-suppressive drugs.

Trust comment: Objective laboratory measures from a randomized trial subgroup support reliable mineral data, though subgroup/retrospective analysis and modest sample size limit certainty.

Study Details

PMID:31425366
Participants:66
Impact:2.67 → 2.62 mmol/L after 16 weeks (no clinically significant change; within reference range)
Trust score:4/5

serum zinc concentration

1 evidences

Two long-term dietary patterns affected several serum minerals over 24 months; serum calcium showed no significant change while other minerals (selenium, manganese, magnesium) increased and serum zinc decreased.

Trust comment: Large randomized dietary intervention with measured serum minerals (n=368 analyzed); intervention not targeted to calcium specifically but directly reports serum calcium outcomes.

Study Details

PMID:38701651
Participants:368
Impact:Decrease over 24 months
Trust score:4/5

serum selenium and magnesium concentrations

1 evidences

Two long-term dietary patterns affected several serum minerals over 24 months; serum calcium showed no significant change while other minerals (selenium, manganese, magnesium) increased and serum zinc decreased.

Trust comment: Large randomized dietary intervention with measured serum minerals (n=368 analyzed); intervention not targeted to calcium specifically but directly reports serum calcium outcomes.

Study Details

PMID:38701651
Participants:368
Impact:Increase over 24 months
Trust score:4/5

Treatment duration

1 evidences

Randomized single-blind trial comparing two calcium‑silicate dental pulp capping materials (TheraCal LC vs iRoot BP Plus) in pulpitis permanent teeth; both achieved similar 1‑year success but TheraCal LC had shorter procedure time and less early postoperative pain.

Trust comment: Well‑conducted randomized clinical trial with 1‑year follow‑up and objective outcomes, moderate sample size; single‑blind and some operator unblinding are limitations.

Study Details

PMID:38701294
Participants:104
Impact:TheraCal LC −9.9 min vs iRoot BP Plus (38.1→28.2 min)
Trust score:4/5

1‑year clinical success rate

1 evidences

Randomized single-blind trial comparing two calcium‑silicate dental pulp capping materials (TheraCal LC vs iRoot BP Plus) in pulpitis permanent teeth; both achieved similar 1‑year success but TheraCal LC had shorter procedure time and less early postoperative pain.

Trust comment: Well‑conducted randomized clinical trial with 1‑year follow‑up and objective outcomes, moderate sample size; single‑blind and some operator unblinding are limitations.

Study Details

PMID:38701294
Participants:104
Impact:No difference — both 90.4% (47/52)
Trust score:4/5

total fatigue (MFIS)

1 evidences

Pilot randomized controlled trial testing a multi‑mineral/vitamin supplement (SiderAL® Med, which includes algal calcium among other minerals) plus rehabilitation vs rehabilitation alone in post‑stroke patients; supplement group showed greater improvements in fatigue, motor and cognitive outcomes over 3 months.

Trust comment: Randomized pilot RCT with blinded assessors but small sample (n=24) and no patient blinding; promising but underpowered for definitive conclusions.

Study Details

PMID:38696891
Participants:24
Impact:Sid‑G median −24 points (54→30) vs CG −15 points (52→37); between‑group p=0.034 (T0–T3)
Trust score:3/5

motor performance (6‑minute walk test)

1 evidences

Pilot randomized controlled trial testing a multi‑mineral/vitamin supplement (SiderAL® Med, which includes algal calcium among other minerals) plus rehabilitation vs rehabilitation alone in post‑stroke patients; supplement group showed greater improvements in fatigue, motor and cognitive outcomes over 3 months.

Trust comment: Randomized pilot RCT with blinded assessors but small sample (n=24) and no patient blinding; promising but underpowered for definitive conclusions.

Study Details

PMID:38696891
Participants:24
Impact:Sid‑G +160 m median (85→245 m) vs CG +30 m (100→130 m); between‑group p<0.001
Trust score:3/5

cognitive processing speed (SDMT)

1 evidences

Pilot randomized controlled trial testing a multi‑mineral/vitamin supplement (SiderAL® Med, which includes algal calcium among other minerals) plus rehabilitation vs rehabilitation alone in post‑stroke patients; supplement group showed greater improvements in fatigue, motor and cognitive outcomes over 3 months.

Trust comment: Randomized pilot RCT with blinded assessors but small sample (n=24) and no patient blinding; promising but underpowered for definitive conclusions.

Study Details

PMID:38696891
Participants:24
Impact:Sid‑G +9 points (22→31) vs CG +8 (16→24); between‑group p=0.004
Trust score:3/5

total serum calcium

1 evidences

Randomized workplace nutrition intervention providing oral nutrition supplements (multi‑vitamin/mineral formula including minerals) plus education vs education alone in female workers; intervention improved biochemical micronutrient markers including serum zinc, iron, and total serum calcium and reduced micronutrient deficiency prevalence.

Trust comment: Large randomized study with objective biochemical endpoints; details on blinding not specified but findings on serum calcium and other minerals are plausible and statistically significant.

Study Details

PMID:38684383
Participants:500
Impact:Increase from 2.36 ± 0.15 mmol/L to 2.40 ± 0.09 mmol/L in intervention group (p<0.05)
Trust score:4/5

Serum zinc

1 evidences

Randomized workplace nutrition intervention providing oral nutrition supplements (multi‑vitamin/mineral formula including minerals) plus education vs education alone in female workers; intervention improved biochemical micronutrient markers including serum zinc, iron, and total serum calcium and reduced micronutrient deficiency prevalence.

Trust comment: Large randomized study with objective biochemical endpoints; details on blinding not specified but findings on serum calcium and other minerals are plausible and statistically significant.

Study Details

PMID:38684383
Participants:500
Impact:Increase from 49.0 ± 21.2 μg/dL to 53.6 ± 19.5 μg/dL in intervention group (p<0.05)
Trust score:4/5

malnutrition by BMI

1 evidences

Randomized workplace nutrition intervention providing oral nutrition supplements (multi‑vitamin/mineral formula including minerals) plus education vs education alone in female workers; intervention improved biochemical micronutrient markers including serum zinc, iron, and total serum calcium and reduced micronutrient deficiency prevalence.

Trust comment: Large randomized study with objective biochemical endpoints; details on blinding not specified but findings on serum calcium and other minerals are plausible and statistically significant.

Study Details

PMID:38684383
Participants:500
Impact:Control malnutrition rose 15.6%→21.3%; intervention remained unchanged (between‑group p<0.05)
Trust score:4/5

femoral neck bone mineral density

5 evidences

Feedback of high future fracture risk led to increased preventive behaviors including calcium use and reduced femoral neck bone loss over 10 years in premenopausal women.

Trust comment: 10-year follow-up of an RCT (n=470) with objective BMD measures and reported supplement use; good design though some attrition and observational long-term follow-up.

Study Details

PMID:29246678
Participants:470
Impact:attenuated loss by +0.023 g/cm² (β=0.023, 95% CI 0.005 to 0.041) from 2 to 12 years
Trust score:4/5

Eldecalcitol increased lumbar and hip bone mineral density more than alfacalcidol in osteoporotic patients not receiving vitamin D or calcium supplements.

Trust comment: Randomized, double-blind active-comparator trial with adequate sample size and clear BMD outcomes.

Study Details

PMID:31087185
Participants:265
Impact:+1.78% (eldecalcitol vs alfacalcidol at 12 months)
Trust score:4/5

Randomized double‑blind trial in postmenopausal women testing home meal replacements fortified with eggshell (natural calcium carbonate) and vitamin D vs control diet; fortified diet attenuated femoral‑neck BMD loss over 6 months compared with control.

Trust comment: Randomized double‑blind dietary intervention with DXA outcomes supports reliability, but small sample size (25 completers) limits statistical power and generalizability.

Study Details

PMID:38674843
Participants:25
Impact:Smaller decline in treatment vs control over 6 months (between‑group p=0.035)
Trust score:4/5

SNF472 given during hemodialysis modestly decreased hip and femoral-neck BMD over 1 year; the 600 mg dose showed a slightly greater BMD loss than placebo.

Trust comment: Randomized, placebo-controlled trial with a reasonable evaluable cohort (DXA-modified ITT n=202); results limited to hemodialysis population.

Study Details

PMID:33835939
Participants:202
Impact:Placebo −0.3% vs SNF472 600 mg −2.6% (600 mg: additional −2.3 percentage point loss over 52 weeks)
Trust score:4/5

12-month randomized trial in 30 kidney transplant recipients with hypercalcemia: subtotal parathyroidectomy normalized serum calcium in all patients and produced larger iPTH reductions and a significant increase in femoral neck BMD compared with cinacalcet.

Trust comment: Prospective randomized multicenter study with clinically relevant endpoints but small sample size and open-label design.

Study Details

PMID:26647424
Participants:30
Impact:significant increase after parathyroidectomy (magnitude not reported)
Trust score:4/5

dietary calcium intake (from HMR)

1 evidences

Randomized double‑blind trial in postmenopausal women testing home meal replacements fortified with eggshell (natural calcium carbonate) and vitamin D vs control diet; fortified diet attenuated femoral‑neck BMD loss over 6 months compared with control.

Trust comment: Randomized double‑blind dietary intervention with DXA outcomes supports reliability, but small sample size (25 completers) limits statistical power and generalizability.

Study Details

PMID:38674843
Participants:25
Impact:Treatment provided additional ≈261 mg/day dietary calcium and ≈10.3 μg/day vitamin D from study meals (intake increased to ~931 mg/d calcium total)
Trust score:4/5

serum lycopene (compliance marker)

1 evidences

Randomized double‑blind trial in postmenopausal women testing home meal replacements fortified with eggshell (natural calcium carbonate) and vitamin D vs control diet; fortified diet attenuated femoral‑neck BMD loss over 6 months compared with control.

Trust comment: Randomized double‑blind dietary intervention with DXA outcomes supports reliability, but small sample size (25 completers) limits statistical power and generalizability.

Study Details

PMID:38674843
Participants:25
Impact:Lycopene increased in treatment group only (reflects compliance; significant at 3 and 6 months)
Trust score:4/5

clinical success rate (6 months)

1 evidences

Seventy-five primary mandibular second molars in children (age 4–8) randomized to three obturation materials (Endoflas, Metapex, calcium hydroxide–ZnO mixture); all showed similar high clinical success at 6 months.

Trust comment: Randomized clinical trial with 75 treated teeth and 6-month follow-up; reasonable execution but limited follow-up duration.

Study Details

PMID:38616424
Participants:75
Impact:Endoflas 95.2%, Metapex 96.0%, CH–ZnO 95.8%; no significant differences between groups
Trust score:3/5

time to extubation

1 evidences

In 88 patients, 10 mg/kg IV calcium chloride given with neostigmine accelerated neuromuscular recovery and shortened time to extubation versus placebo.

Trust comment: Double-blind randomized controlled trial with 88 patients and clear, clinically relevant outcome differences.

Study Details

PMID:38615713
Participants:88
Impact:Median 6.5 min (calcium) vs 9.78 min (placebo), ~32% shorter (P < .001)
Trust score:4/5

time to neuromuscular recovery (TOFr 0.9)

1 evidences

In 88 patients, 10 mg/kg IV calcium chloride given with neostigmine accelerated neuromuscular recovery and shortened time to extubation versus placebo.

Trust comment: Double-blind randomized controlled trial with 88 patients and clear, clinically relevant outcome differences.

Study Details

PMID:38615713
Participants:88
Impact:Median 5.0 min (calcium) vs 7.1 min (placebo) (P < .001)
Trust score:4/5

residual neuromuscular blockade (RNMB) incidence

1 evidences

In 88 patients, 10 mg/kg IV calcium chloride given with neostigmine accelerated neuromuscular recovery and shortened time to extubation versus placebo.

Trust comment: Double-blind randomized controlled trial with 88 patients and clear, clinically relevant outcome differences.

Study Details

PMID:38615713
Participants:88
Impact:Lower incidence of RNMB at 5 and 10 min in calcium group vs placebo
Trust score:4/5

Schiff sensitivity score (evaporative air stimulus)

1 evidences

In an 8-week randomized, examiner-blind trial, all three dentifrices (test SnF2, positive control containing calcium sodium phosphosilicate, and negative control) produced significant within-group improvements in dentinal hypersensitivity and OHRQoL, but between-group differences were not statistically significant due to a strong placebo/center effect.

Trust comment: Large, randomized, examiner-blind RCT with robust endpoints and 196 mITT participants, but strong placebo/center effects limited between-group significance.

Study Details

PMID:38530474
Participants:196
Impact:–0.99 points (adjusted mean change, positive control, Week 8 vs baseline)
Trust score:4/5

Tactile threshold (Yeaple probe)

2 evidences

In an 8-week randomized, examiner-blind trial, all three dentifrices (test SnF2, positive control containing calcium sodium phosphosilicate, and negative control) produced significant within-group improvements in dentinal hypersensitivity and OHRQoL, but between-group differences were not statistically significant due to a strong placebo/center effect.

Trust comment: Large, randomized, examiner-blind RCT with robust endpoints and 196 mITT participants, but strong placebo/center effects limited between-group significance.

Study Details

PMID:38530474
Participants:196
Impact:+11.05 g (adjusted mean change, positive control, Week 8 vs baseline)
Trust score:4/5

Double-blind RCT in adults with dentine hypersensitivity showing the calcium-silicate/sodium-phosphate toothpaste reduced sensitivity versus control over 14–29 days.

Trust comment: Well-powered, double-blind RCT with consistent objective and subjective measures showing significant effects.

Study Details

PMID:32497553
Participants:247
Impact:Yeaple probe thresholds increased (improved) in CSSP group vs control (p≤0.001)
Trust score:4/5

DHEQ-15 total score (OHRQoL)

1 evidences

In an 8-week randomized, examiner-blind trial, all three dentifrices (test SnF2, positive control containing calcium sodium phosphosilicate, and negative control) produced significant within-group improvements in dentinal hypersensitivity and OHRQoL, but between-group differences were not statistically significant due to a strong placebo/center effect.

Trust comment: Large, randomized, examiner-blind RCT with robust endpoints and 196 mITT participants, but strong placebo/center effects limited between-group significance.

Study Details

PMID:38530474
Participants:196
Impact:–11.30 points (adjusted mean change, positive control, Week 8 vs baseline)
Trust score:4/5

clinical success rate (first follow-up)

1 evidences

In children with infected primary molars, both calcium-enriched mixture cement pulpotomy and pulpectomy gave high success rates with no clear difference.

Trust comment: Multicentre randomized trial in children with clear participant numbers and objective outcomes; appropriate design though sample size moderate.

Study Details

PMID:38488954
Participants:94
Impact:PCEM 98.6% vs PM 96.4% (no significant difference)
Trust score:4/5

clinical success rate (second follow-up)

1 evidences

In children with infected primary molars, both calcium-enriched mixture cement pulpotomy and pulpectomy gave high success rates with no clear difference.

Trust comment: Multicentre randomized trial in children with clear participant numbers and objective outcomes; appropriate design though sample size moderate.

Study Details

PMID:38488954
Participants:94
Impact:PCEM 97.1% vs PM 91.1% (no significant difference)
Trust score:4/5

cancer mortality

1 evidences

Long-term follow-up of postmenopausal women randomized to calcium plus vitamin D showed reduced cancer mortality but a small increase in cardiovascular mortality, with no effect on all-cause mortality.

Trust comment: Very large randomized trial with long follow-up and clinically important outcomes; post-hoc analyses limit causal detail but overall high-quality evidence.

Study Details

PMID:38467003
Participants:36282
Impact:-7% (HR 0.93, 95% CI 0.87–0.99)
Trust score:5/5

cardiovascular disease (CVD) mortality

1 evidences

Long-term follow-up of postmenopausal women randomized to calcium plus vitamin D showed reduced cancer mortality but a small increase in cardiovascular mortality, with no effect on all-cause mortality.

Trust comment: Very large randomized trial with long follow-up and clinically important outcomes; post-hoc analyses limit causal detail but overall high-quality evidence.

Study Details

PMID:38467003
Participants:36282
Impact:+6% (HR 1.06, 95% CI 1.01–1.12)
Trust score:5/5

blood calcium

2 evidences

Adding somatostatin enema to standard care shortened symptom recovery and decreased inflammation; blood calcium rose after treatment.

Trust comment: Randomized clinical sample with clear outcomes, but calcium was a measured biomarker secondary to a non-calcium intervention (indirect relevance).

Study Details

PMID:28829514
Participants:79
Impact:increased (p<0.05)
Trust score:3/5

Phase 1 randomized, double-blind bioequivalence study of a denosumab biosimilar vs reference denosumab in healthy subjects; PK was bioequivalent and common adverse reactions included reductions in blood calcium and phosphate.

Trust comment: Well-conducted randomized double-blind phase 1 bioequivalence study in humans reporting PK and safety including decreases in serum calcium and phosphate; moderate trust for calcium-related adverse-effect reporting.

Study Details

PMID:33306418
Participants:102
Impact:decrease (common adverse reaction)
Trust score:3/5

clinical pregnancy rate

1 evidences

Randomized trial in women with diminished ovarian reserve testing oocyte activation with a calcium ionophore; small numerical increases in fertilization and pregnancy rates were observed but were not statistically different between groups.

Trust comment: Prospective randomized controlled study with a large sample (n=296); results reported but differences were not statistically significant per authors.

Study Details

PMID:26342247
Participants:296
Impact:+8.2 percentage points (21.0% vs 12.8%)
Trust score:4/5

Citrate accumulation incidence

1 evidences

In CICU patients receiving RCA-CRRT, using commercially available calcium-containing dialysate produced similar rates of metabolic complications, citrate accumulation, premature termination, and filter thrombus compared with calcium-free solutions.

Trust comment: Randomized single-center trial directly comparing Ca-containing vs Ca-free dialysates with moderate sample size; appropriate outcomes but limited power and single-center design.

Study Details

PMID:38439685
Participants:99
Impact:18.2% vs 12.1% vs 21.2% across groups; no significant difference
Trust score:3/5

Metabolic alkalosis incidence

1 evidences

In CICU patients receiving RCA-CRRT, using commercially available calcium-containing dialysate produced similar rates of metabolic complications, citrate accumulation, premature termination, and filter thrombus compared with calcium-free solutions.

Trust comment: Randomized single-center trial directly comparing Ca-containing vs Ca-free dialysates with moderate sample size; appropriate outcomes but limited power and single-center design.

Study Details

PMID:38439685
Participants:99
Impact:12.1% vs 0% vs 9.1% across groups; no significant difference
Trust score:3/5

Premature termination of treatment

1 evidences

In CICU patients receiving RCA-CRRT, using commercially available calcium-containing dialysate produced similar rates of metabolic complications, citrate accumulation, premature termination, and filter thrombus compared with calcium-free solutions.

Trust comment: Randomized single-center trial directly comparing Ca-containing vs Ca-free dialysates with moderate sample size; appropriate outcomes but limited power and single-center design.

Study Details

PMID:38439685
Participants:99
Impact:18.2% vs 9.1% vs 9.1%; no significant difference
Trust score:3/5

serum calcium at 24 h

1 evidences

In thyroidectomy patients, carbon nanoparticle use improved parathyroid preservation and early parathyroid function compared with controls/ICGT.

Trust comment: Randomized clinical study with clear participant numbers and clinically relevant biochemical endpoints; results are plausible though longer-term outcomes unclear.

Study Details

PMID:38429055
Participants:294
Impact:increased in carbon nanoparticle (CN) group (higher 24h postoperative calcium vs other groups)
Trust score:4/5

parathyroid hormone (PTH) at 24 h

1 evidences

In thyroidectomy patients, carbon nanoparticle use improved parathyroid preservation and early parathyroid function compared with controls/ICGT.

Trust comment: Randomized clinical study with clear participant numbers and clinically relevant biochemical endpoints; results are plausible though longer-term outcomes unclear.

Study Details

PMID:38429055
Participants:294
Impact:increased in CN group (higher PTH24h) and quicker functional recovery
Trust score:4/5

in‑situ parathyroid preservation

1 evidences

In thyroidectomy patients, carbon nanoparticle use improved parathyroid preservation and early parathyroid function compared with controls/ICGT.

Trust comment: Randomized clinical study with clear participant numbers and clinically relevant biochemical endpoints; results are plausible though longer-term outcomes unclear.

Study Details

PMID:38429055
Participants:294
Impact:increased with CN use; mediation analysis: ~23.05% of CN effect on PTH24h attributed to PGRIS
Trust score:4/5

incident fracture risk

1 evidences

In healthy older adults, higher serum phosphate (but not calcium) was linked to greater fracture risk in men; no association between serum calcium and fractures.

Trust comment: Large, well‑conducted cohort with adjudicated fractures and appropriate adjustments; direct measurement of serum calcium and fracture outcomes supports reliability.

Study Details

PMID:38426788
Participants:9915
Impact:no statistically significant association with serum calcium levels (both sexes)
Trust score:4/5

surface microhardness recovery (%SMHR)

1 evidences

Adding a calcium-containing compound (CSPS) to a fluoride toothpaste did not change enamel remineralization compared with fluoride alone.

Trust comment: Well-conducted randomized, investigator-blind crossover in situ non-inferiority trial with 77 subjects.

Study Details

PMID:28657702
Participants:77
Impact:no significant change vs 1500 ppm F dentifrice
Trust score:4/5

sleep quality (PSQI total score)

1 evidences

24-week RCT testing vitamin D and/or calcium in people with prediabetes; vitamin D+calcium improved PSQI vs baseline and calcium alone improved sleep in prespecified subgroups.

Trust comment: Randomized controlled trial with moderate sample size; post-hoc analysis for sleep reduces primary outcome strength but methods and sample are adequate.

Study Details

PMID:38366270
Participants:212
Impact:improved (PSQI decreased) in vitamin D+calcium vs baseline; calcium alone improved sleep in women, low baseline 25(OH)D, and menopausal subgroups (P<0.05)
Trust score:4/5

sleep efficiency — metabolic correlation

1 evidences

24-week RCT testing vitamin D and/or calcium in people with prediabetes; vitamin D+calcium improved PSQI vs baseline and calcium alone improved sleep in prespecified subgroups.

Trust comment: Randomized controlled trial with moderate sample size; post-hoc analysis for sleep reduces primary outcome strength but methods and sample are adequate.

Study Details

PMID:38366270
Participants:212
Impact:change in sleep efficiency negatively correlated with change in insulin efficiency (r=-0.264) and with change in beta-cell function (r=-0.304)
Trust score:4/5

total implant migration at 6 months

1 evidences

Randomized study comparing calcium‑phosphate (CP) coated vs titanium plasma spray (TPS) short hip stems; CP coating was associated with greater and more prolonged early implant migration.

Trust comment: Randomized, blinded RSA study with rigorous measurement but small single-center sample; objective RSA endpoints strengthen internal validity.

Study Details

PMID:38360840
Participants:60
Impact:CP 1.00 mm vs TPS 0.48 mm (+0.52 mm, p=0.019)
Trust score:4/5

total implant migration at 3 months

1 evidences

Randomized study comparing calcium‑phosphate (CP) coated vs titanium plasma spray (TPS) short hip stems; CP coating was associated with greater and more prolonged early implant migration.

Trust comment: Randomized, blinded RSA study with rigorous measurement but small single-center sample; objective RSA endpoints strengthen internal validity.

Study Details

PMID:38360840
Participants:60
Impact:CP 1.46 mm vs TPS 0.41 mm (+1.05 mm, p=0.009)
Trust score:4/5

proportion ceasing migration by 1 week

1 evidences

Randomized study comparing calcium‑phosphate (CP) coated vs titanium plasma spray (TPS) short hip stems; CP coating was associated with greater and more prolonged early implant migration.

Trust comment: Randomized, blinded RSA study with rigorous measurement but small single-center sample; objective RSA endpoints strengthen internal validity.

Study Details

PMID:38360840
Participants:60
Impact:65% of implants reached final position by 1 week (migration ≤0.3 mm) — CP group showed more prolonged migration than TPS
Trust score:4/5

dental sensitivity (Schiff air index)

1 evidences

Randomized trial in children comparing a zinc hydroxyapatite toothpaste vs a calcium sodium phosphosilicate toothpaste; both reduced dental sensitivity and improved periodontal indices over 6 months.

Trust comment: Randomized clinical trial but small sample and limited outcome reporting; dental endpoints directly relevant to calcium-containing formulation.

Study Details

PMID:38357755
Participants:40
Impact:reduced (significant) over 6 months
Trust score:3/5

periodontal inflammation (BoP)

1 evidences

Randomized trial in children comparing a zinc hydroxyapatite toothpaste vs a calcium sodium phosphosilicate toothpaste; both reduced dental sensitivity and improved periodontal indices over 6 months.

Trust comment: Randomized clinical trial but small sample and limited outcome reporting; dental endpoints directly relevant to calcium-containing formulation.

Study Details

PMID:38357755
Participants:40
Impact:reduced (significant) over 6 months
Trust score:3/5

total body less head (TBLH) bone mineral content (BMC) in girls

1 evidences

One-year randomized trial of milk+vitamin D vs calcium carbonate+vitamin D vs standard care in children/youth with T1DM; calcium (milk or pharmacological) improved bone mass and geometry, especially in girls.

Trust comment: Large randomized controlled trial in target population with DXA and pQCT outcomes; adequate sample and objective bone measures support reliability.

Study Details

PMID:38325238
Participants:203
Impact:higher at 12 months in supplemented groups vs control (end values: Group A 1011.8 g, B 983.2 g, C 792.8 g; p<0.05)
Trust score:4/5

TBLH bone mineral density (BMD) in girls

1 evidences

One-year randomized trial of milk+vitamin D vs calcium carbonate+vitamin D vs standard care in children/youth with T1DM; calcium (milk or pharmacological) improved bone mass and geometry, especially in girls.

Trust comment: Large randomized controlled trial in target population with DXA and pQCT outcomes; adequate sample and objective bone measures support reliability.

Study Details

PMID:38325238
Participants:203
Impact:higher at 12 months in supplemented groups vs control (p<0.05)
Trust score:4/5

cortical thickness (girls)

1 evidences

One-year randomized trial of milk+vitamin D vs calcium carbonate+vitamin D vs standard care in children/youth with T1DM; calcium (milk or pharmacological) improved bone mass and geometry, especially in girls.

Trust comment: Large randomized controlled trial in target population with DXA and pQCT outcomes; adequate sample and objective bone measures support reliability.

Study Details

PMID:38325238
Participants:203
Impact:greater percent increase in supplemented groups (A +17.9%; B +15.3% vs control +7.6%; p<0.05)
Trust score:4/5

Residual ridge resorption (height)

1 evidences

In edentulous older patients, 12 months of daily oral calcium (1000 mg elemental) plus vitamin D (500 IU) did not significantly reduce mandibular residual ridge resorption or change bone mineral density compared with no supplementation.

Trust comment: Randomized clinical trial with objective imaging (DEXA/CBCT) and pre-specified outcomes; open-label design and ~23% attrition limit certainty.

Study Details

PMID:38263558
Participants:116
Impact:Mean 1-year RRR height: 1.30 mm (supplement) vs 1.33 mm (no supplement); no significant difference
Trust score:4/5

Residual ridge resorption (width)

1 evidences

In edentulous older patients, 12 months of daily oral calcium (1000 mg elemental) plus vitamin D (500 IU) did not significantly reduce mandibular residual ridge resorption or change bone mineral density compared with no supplementation.

Trust comment: Randomized clinical trial with objective imaging (DEXA/CBCT) and pre-specified outcomes; open-label design and ~23% attrition limit certainty.

Study Details

PMID:38263558
Participants:116
Impact:Mean 1-year RRR width: 0.36 mm (supplement) vs 0.46 mm (no supplement); no significant difference
Trust score:4/5

bone mineral density (BMD) T-score

2 evidences

In hemodialysis patients with adynamic bone disease, the calcium-based binder (calcium carbonate) was associated with higher blood calcium, greater progression of coronary artery calcification and lower bone mineral density compared with lanthanum carbonate over 12 months.

Trust comment: Randomized, objective imaging (CT, DXA) outcomes in 92 patients support reliability, but single-center and open-label design limit blinding.

Study Details

PMID:29137107
Participants:92
Impact:decreased with calcium carbonate vs lanthanum carbonate (significant, P<0.001)
Trust score:4/5

In edentulous older patients, 12 months of daily oral calcium (1000 mg elemental) plus vitamin D (500 IU) did not significantly reduce mandibular residual ridge resorption or change bone mineral density compared with no supplementation.

Trust comment: Randomized clinical trial with objective imaging (DEXA/CBCT) and pre-specified outcomes; open-label design and ~23% attrition limit certainty.

Study Details

PMID:38263558
Participants:116
Impact:No significant between-group change in BMD or T-score after 12 months
Trust score:4/5

Bone volume fraction (BV/TV)

1 evidences

In sinus augmentation, biphasic calcium phosphate (HA/β-TCP 70/30) produced similar new bone formation, residual graft amount, and gene expression changes compared with deproteinized bovine bone mineral after ~6+ months.

Trust comment: Small randomized controlled clinical trial (n=24) with objective imaging/histology; limited sample size reduces precision.

Study Details

PMID:38317374
Participants:24
Impact:BCP 41.51% vs DBBM 40.97% (no significant difference)
Trust score:3/5

New bone formation (histology)

1 evidences

In sinus augmentation, biphasic calcium phosphate (HA/β-TCP 70/30) produced similar new bone formation, residual graft amount, and gene expression changes compared with deproteinized bovine bone mineral after ~6+ months.

Trust comment: Small randomized controlled clinical trial (n=24) with objective imaging/histology; limited sample size reduces precision.

Study Details

PMID:38317374
Participants:24
Impact:BCP 31.43% vs DBBM 30.09% (no significant difference)
Trust score:3/5

Residual graft fraction (GV/TV)

1 evidences

In sinus augmentation, biphasic calcium phosphate (HA/β-TCP 70/30) produced similar new bone formation, residual graft amount, and gene expression changes compared with deproteinized bovine bone mineral after ~6+ months.

Trust comment: Small randomized controlled clinical trial (n=24) with objective imaging/histology; limited sample size reduces precision.

Study Details

PMID:38317374
Participants:24
Impact:BCP 9.97% vs DBBM 14.41% (no significant difference)
Trust score:3/5

Pulpotomy success rate

2 evidences

Clinical comparison of Biodentine and MTA for pulpotomy in primary molars showed high success rates and no significant difference between agents up to 12 months.

Trust comment: In vivo clinical study on 90 treated primary molars with 12-month follow-up; reasonable clinical relevance but limited reporting detail on randomization/unit of analysis.

Study Details

PMID:27595722
Participants:90
Impact:95.5% success at up to 12 months; no significant difference between Biodentine and MTA (p≥0.05)
Trust score:3/5

Pulpotomy using a premixed calcium-silicate cement (Endocem) had high one-year success similar to ProRoot MTA; overall pulpotomy success ~94% with no significant difference between materials.

Trust comment: Randomized two-center clinical trial with 1-year follow-up and 71 evaluable teeth; well-conducted but underpowered vs planned sample size and limited to 1 year.

Study Details

PMID:38316823
Participants:71
Impact:Overall 94.4% (ProRoot 93.9% vs Endocem 97.1%; no significant difference)
Trust score:4/5

Calcific bridge formation (partial pulpotomy)

1 evidences

Pulpotomy using a premixed calcium-silicate cement (Endocem) had high one-year success similar to ProRoot MTA; overall pulpotomy success ~94% with no significant difference between materials.

Trust comment: Randomized two-center clinical trial with 1-year follow-up and 71 evaluable teeth; well-conducted but underpowered vs planned sample size and limited to 1 year.

Study Details

PMID:38316823
Participants:71
Impact:ProRoot 24.0% vs Endocem 40.0% (difference not statistically significant)
Trust score:4/5

Preterm birth incidence

1 evidences

Two large randomized trials (India and Tanzania) compared 500 mg vs 1500 mg daily calcium in pregnancy; 500 mg was noninferior to 1500 mg for preeclampsia overall.

Trust comment: Two large, double-blind, randomized, well-powered trials with high adherence and low loss to follow-up support high trustworthiness.

Study Details

PMID:38197817
Participants:22000
Impact:India: 11.4% (500 mg) vs 12.8% (1500 mg) (−1.4 percentage points; noninferior in India); Tanzania: 10.4% vs 9.7% (+0.7 percentage points; not noninferior)
Trust score:5/5

blood pressure

3 evidences

Healthy adults drank high- vs low-sodium/bicarbonate mineral water for 28 days; blood pressure did not differ, aldosterone fell (more with high-bicarbonate/sodium water), and urinary calcium excretion decreased in the high-bicarbonate/sodium group.

Trust comment: Randomized controlled intervention with objective measures but small sample and short duration limit generalizability.

Study Details

PMID:38124675
Participants:94
Impact:No between-group difference in change after 28 days
Trust score:3/5

In pregnant patients with hypertensive disorders, adding low-dose aspirin to labetalol + vitamin E + calcium improved clinical efficacy, lowered blood pressure and 24-h urine protein, and increased microRNA-126 and PLGF versus without aspirin.

Trust comment: Randomized controlled trial but calcium was included in both arms, so calcium-specific effects cannot be isolated; moderate sample size.

Study Details

PMID:36933245
Participants:130
Impact:Systolic and diastolic BP significantly lower in intervention vs control (P<0.05)
Trust score:3/5

In hyperinsulinemic adults, a 6-week high-dairy diet (increasing dietary calcium) did not change blood pressure or arterial stiffness but was associated with increases in body fat, fasting insulin and HOMA-IR.

Trust comment: Randomized cross-over human trial directly relevant to dietary calcium via dairy but small sample size limits power.

Study Details

PMID:37939366
Participants:27
Impact:no significant change after high dairy (higher calcium) intake
Trust score:3/5

Serum aldosterone

1 evidences

Healthy adults drank high- vs low-sodium/bicarbonate mineral water for 28 days; blood pressure did not differ, aldosterone fell (more with high-bicarbonate/sodium water), and urinary calcium excretion decreased in the high-bicarbonate/sodium group.

Trust comment: Randomized controlled intervention with objective measures but small sample and short duration limit generalizability.

Study Details

PMID:38124675
Participants:94
Impact:Decreased in both groups, with a larger reduction in the high-bicarbonate/high-sodium (HBS) group
Trust score:3/5

urinary calcium excretion

5 evidences

Healthy adults drank high- vs low-sodium/bicarbonate mineral water for 28 days; blood pressure did not differ, aldosterone fell (more with high-bicarbonate/sodium water), and urinary calcium excretion decreased in the high-bicarbonate/sodium group.

Trust comment: Randomized controlled intervention with objective measures but small sample and short duration limit generalizability.

Study Details

PMID:38124675
Participants:94
Impact:Decreased significantly in the HBS group (p=0.002)
Trust score:3/5

Measured serum/urine calcium, vitamin D, PTH and bone markers in osteoporotic women and analysed correlations with metabolic/cardiovascular risk markers.

Trust comment: Observational clinical study with standard biochemical assays in a modest sample size—associations reported but causality limited.

Study Details

PMID:28849089
Participants:71
Impact:inversely correlated with serum total calcium
Trust score:3/5

A controlled crossover feeding study found K-gluconate supplementation lowered urinary calcium excretion and increased urinary pH versus control, but did not produce significant differences in net calcium retention or % absorption.

Trust comment: Well-controlled crossover feeding trial with direct calcium balance measures, but modest sample size and some analyte-specific missing data reduced power for balance endpoints.

Study Details

PMID:34959951
Participants:30
Impact:Lower with K-gluconate supplement: 96 ± 10 mg/day vs control 115 ± 10 mg/day (p = 0.027)
Trust score:4/5

A 3-month dietary intervention in postmenopausal women increasing vegetables/herbs/fruit reduced urinary calcium excretion and lowered bone turnover markers in the group consuming phytochemical-rich selections, especially in osteopenic women.

Trust comment: Randomized dietary intervention with objective biomarkers and reasonable sample but short duration (3 months), non-randomized control and some selection bias limit generalizability.

Study Details

PMID:25856221
Participants:142
Impact:Group A −1.2 mmol/24h (−26%); Group B −1.3 mmol/24h (−24%); Control −0.61 mmol/24h (−2%)
Trust score:3/5

12-week randomized dietary supplement trial in adults with abdominal obesity; whey protein increased urinary calcium but did not change bone turnover markers or BMD.

Trust comment: Randomized controlled trial with objective biochemical measures but a post-hoc analysis and limited sample size for bone endpoints, reducing power for those outcomes.

Study Details

PMID:35422766
Participants:64
Impact:+1.12 mmol/day in WP-LoFi group; overall increase in protein groups (protein effect p=0.03)
Trust score:4/5

Olfactory function

2 evidences

Intranasal EDTA plus olfactory training improved sense of smell more than training alone and reduced nasal calcium levels.

Trust comment: Randomized controlled trial but small sample (n=50); endpoints clinically relevant and reported significant differences.

Study Details

PMID:37786364
Participants:50
Impact:Improvement in 88% vs 60% (EDTA+training vs training alone); +28 percentage points
Trust score:3/5

Randomized controlled trial testing intranasal 1% sodium phytate vs saline in post-COVID olfactory dysfunction; sodium phytate reduced nasal mucus calcium and produced significant olfactory improvement compared with saline.

Trust comment: Randomized, double-controlled trial showing biomarker and clinical changes, but small sample size limits precision and generalizability.

Study Details

PMID:38105576
Participants:52
Impact:Significant improvement from anosmia to hyposmia with sodium phytate vs no improvement with saline after 1 month
Trust score:3/5

Gait speed

1 evidences

In sarcopenic older adults, early supervised resistance training with nutritional support (including calcium) led to an earlier increase in lower‑leg muscle mass but did not improve physical function.

Trust comment: Randomized controlled trial in humans with clear numeric outcomes but calcium was given as part of a multi‑nutrient supplement, limiting attribution solely to calcium.

Study Details

PMID:32723507
Participants:57
Impact:no significant change (no group-time interaction)
Trust score:4/5

dietary calcium intake

10 evidences

12-week randomized trial in Chinese adults at risk of malnutrition: daily oral nutrition supplement increased weight, anthropometric measures, and multiple nutrient intakes.

Trust comment: Randomized controlled trial with adequate power and objective outcomes, but open-label, unblinded, and lacking body-composition measures.

Study Details

PMID:36141627
Participants:82
Impact:+254 mg/day (estimated mean group difference in calcium intake, p < 0.001)
Trust score:4/5

Crossover RCT: eating two calcium-fortified cereal bars daily for 3 weeks significantly increased women's dietary calcium intake (~+360 mg/day) without increasing energy intake or body weight.

Trust comment: Checklist: 1) Confirm relevance to Calcium (dietary calcium intervention); 2) extract main outcomes (calcium intake, energy, weight); 3) record participants (completed n=35); 4) rate trust — randomized crossover RCT with good compliance and appropriate dietary assessment but small sample and short duration.

Study Details

PMID:25941810
Participants:35
Impact:increase ≈ +360 mg/day (baseline 732 ±275 mg/d → intervention 1092 ±377 mg/d); % not meeting RDA decreased 88.6% → 60.0%
Trust score:4/5

One-year RCT in habitual snackers comparing daily almonds vs biscuits: diet quality improved with almonds but body weight did not change.

Trust comment: Registered 1-year randomized controlled trial (n=136) with objective measures and multiple follow-ups; well conducted though modest sample size.

Study Details

PMID:37156442
Participants:136
Impact:increase (statistically significant)
Trust score:4/5

A behavioral nutrition program increased children's dietary calcium intake for up to 12 months but did not change bone mineral accrual; higher calcium intake was associated with smaller BMI increases at some timepoints.

Trust comment: Randomized controlled trial with intention-to-treat analysis and multi-year follow-up but moderate attrition; appropriate methods and adjustments reported.

Study Details

PMID:28225052
Participants:139
Impact:median increase in BM-NE group (baseline 876 mg/day to 951 mg/day at end; significant increase at 6 and 12 months, p=0.04 and p=0.01)
Trust score:4/5

Cluster-randomized evaluation of an integrated nutrition package (including free calcium tablets) vs standard care showing improved supplement use, diet diversity and breastfeeding.

Trust comment: Large, cluster-randomized evaluation with high coverage and objective program monitoring; effect estimates reported and statistically tested.

Study Details

PMID:29021370
Participants:2000
Impact:+356 mg (average per capita intake increase)
Trust score:5/5

Dietary analysis of IF 5:2 showing decreased energy on study and that intake of several micronutrients, including calcium, was lower than recommended guidelines.

Trust comment: Small dietary analysis using 4-day food records from prior studies; useful signal but limited by sample size and self-reported intake.

Study Details

PMID:32199696
Participants:38
Impact:lower than recommended guidelines (insufficient calcium intake reported)
Trust score:3/5

Four-week randomized diet trial in women showing the Paleolithic diet led to greater short-term weight and fat loss and reduced dietary calcium intake compared to guidelines-based diet.

Trust comment: Randomized human trial reporting meaningful decrease in dietary calcium intake over 4 weeks but small sample and short duration limit confidence.

Study Details

PMID:27223304
Participants:39
Impact:decreased (significant reduction in intake on Paleolithic diet)
Trust score:3/5

Post-hoc analysis of an RCT comparing fasting + plant-based diet vs guideline diet in RA patients; both groups had dietary calcium below recommendations, with the guideline (DGE) group having higher calcium intake than the PBD group.

Trust comment: Randomized parent trial but this is a post-hoc nutritional analysis with modest sample size and self-reported food records, limiting certainty of absolute intake estimates.

Study Details

PMID:36839208
Participants:50
Impact:below recommended 1000 mg/day in both groups; DGE > PBD (week 4: 702.9 vs 513.1 mg/day, p=0.04; week 9: 731.6 vs 479.9 mg/day, p=0.02)
Trust score:3/5

Switching from low- to high-dairy intake for 6 weeks lowered both systolic and diastolic blood pressure in overweight middle-aged adults; effect appeared dependent on increased calcium intake.

Trust comment: Well-controlled randomized crossover trial with objective BP and urinary measures; moderate sample size and short intervention duration limit generalizability.

Study Details

PMID:31237322
Participants:46
Impact:+1237.8 ±303.0 mg/d (HDD vs LDD; p<0.001)
Trust score:4/5

In this cohort, pregnant women frequently did not meet recommended micronutrient intakes, including calcium, across trimesters.

Trust comment: Multicenter longitudinal FFQ-based analysis with 176 women using validated methods, but relies on self-reported intake and has typical FFQ limitations.

Study Details

PMID:35565911
Participants:176
Impact:below LARN recommendations in all trimesters (insufficient)
Trust score:4/5

Nickel content of NiTi archwires

1 evidences

Randomized in vivo study: using CPP-ACP during orthodontic treatment altered archwire surface and reduced nickel content compared to routine hygiene.

Trust comment: Randomized in vivo trial with objective microscopy and spectroscopy outcomes but small sample and single-center limits generalizability.

Study Details

PMID:38233156
Participants:40
Impact:Significantly decreased in CPP-ACP group (lowest nickel content; P < 0.001)
Trust score:3/5

Surface topography of archwires

1 evidences

Randomized in vivo study: using CPP-ACP during orthodontic treatment altered archwire surface and reduced nickel content compared to routine hygiene.

Trust comment: Randomized in vivo trial with objective microscopy and spectroscopy outcomes but small sample and single-center limits generalizability.

Study Details

PMID:38233156
Participants:40
Impact:CPP-ACP exposure produced smoother areas with microdefects/deposits versus pitting corrosion with fluoride toothpaste
Trust score:3/5

Cmax and AUC (bioequivalence)

1 evidences

Two 0.5-g calcium dobesilate capsule formulations were bioequivalent in 48 healthy volunteers under fasting and fed conditions with no serious adverse events.

Trust comment: Well-conducted randomized-sequence, crossover bioequivalence study in healthy volunteers with complete follow-up and appropriate PK endpoints.

Study Details

PMID:38226890
Participants:48
Impact:Test/reference GMR 90% CIs within 80%–125% for Cmax and AUC (fasting and fed)
Trust score:4/5

safety/adverse events

3 evidences

Two 0.5-g calcium dobesilate capsule formulations were bioequivalent in 48 healthy volunteers under fasting and fed conditions with no serious adverse events.

Trust comment: Well-conducted randomized-sequence, crossover bioequivalence study in healthy volunteers with complete follow-up and appropriate PK endpoints.

Study Details

PMID:38226890
Participants:48
Impact:No serious adverse events reported; comparable safety profiles
Trust score:4/5

Bioequivalence crossover in healthy volunteers: sodium levofolinate is bioequivalent to calcium levofolinate and sodium folinate; all well tolerated.

Trust comment: Standard single‑center randomized 3‑period crossover in 24 healthy subjects with validated assays; appropriate for bioequivalence assessment.

Study Details

PMID:36808267
Participants:24
Impact:8 subjects experienced AEs (10 cases); no serious or unexpected serious adverse reactions observed
Trust score:4/5

Multicenter randomized intrapatient trial (n=100 treated, efficacy n=87) comparing a β-TCP–rich biphasic calcium phosphate putty to autograft for posterolateral spinal fusion; fusion rates were similar and noninferiority was demonstrated at 1 year.

Trust comment: Randomized, multicenter, patient- and observer-blinded intrapatient noninferiority trial with objective CT-based fusion assessment; moderate sample size and 1-year follow-up limit longer-term inference.

Study Details

PMID:32080013
Participants:100
Impact:No serious adverse events directly attributed to the calcium phosphate putty
Trust score:4/5

Pulp vitality success rate (18 months)

1 evidences

Randomized clinical trial in teeth with reversible pulpitis: calcium-enriched mixture (CEM) cement performed comparably to MTA and better than calcium hydroxide for maintaining pulp vitality up to 18 months.

Trust comment: Randomized clinical trial with 127 completers and objective clinical/radiographic endpoints, though single-center and losses to follow-up reduce external validity.

Study Details

PMID:38219032
Participants:127
Impact:CEM 86.7% vs MTA 77.3% vs Calcium hydroxide 57.9% (overall success 74.8%)
Trust score:4/5

Periapical index (PAI) scores

1 evidences

Randomized clinical trial in teeth with reversible pulpitis: calcium-enriched mixture (CEM) cement performed comparably to MTA and better than calcium hydroxide for maintaining pulp vitality up to 18 months.

Trust comment: Randomized clinical trial with 127 completers and objective clinical/radiographic endpoints, though single-center and losses to follow-up reduce external validity.

Study Details

PMID:38219032
Participants:127
Impact:Significant intergroup differences at early follow-ups; CEM showed better PAI outcomes vs Dycal at 1 month (p<0.05)
Trust score:4/5

Incidence of metabolic bone disease (ALP > 900 IU/L at 45 days)

1 evidences

In preterm infants on parenteral nutrition, continuous calcium infusion reduced biochemical markers of metabolic bone disease and lowered its incidence versus intermittent bolus infusion.

Trust comment: Randomized, blinded clinical trial with predefined biochemical endpoints and 78 completers; single-center and absence of imaging (DEXA) limit definitive conclusions.

Study Details

PMID:38216920
Participants:78
Impact:Continuous 25% vs Intermittent 52.6% (absolute difference -27.6%; P < 0.05 for ALP-only criterion)
Trust score:4/5

Alkaline phosphatase (ALP) at 45 days

1 evidences

In preterm infants on parenteral nutrition, continuous calcium infusion reduced biochemical markers of metabolic bone disease and lowered its incidence versus intermittent bolus infusion.

Trust comment: Randomized, blinded clinical trial with predefined biochemical endpoints and 78 completers; single-center and absence of imaging (DEXA) limit definitive conclusions.

Study Details

PMID:38216920
Participants:78
Impact:Continuous mean 753.3 IU/L vs Intermittent mean 988.2 IU/L (difference ≈ -234.9 IU/L; P = 0.002)
Trust score:4/5

Serum calcium (45 days)

1 evidences

In preterm infants on parenteral nutrition, continuous calcium infusion reduced biochemical markers of metabolic bone disease and lowered its incidence versus intermittent bolus infusion.

Trust comment: Randomized, blinded clinical trial with predefined biochemical endpoints and 78 completers; single-center and absence of imaging (DEXA) limit definitive conclusions.

Study Details

PMID:38216920
Participants:78
Impact:No significant between-group difference at 45 days
Trust score:4/5

Lumbar spine aBMD change (12 months, denosumab)

1 evidences

Randomized comparative study of denosumab vs zoledronic acid in pediatric OI: denosumab increased BMD but caused frequent rebound hypercalcemia (31%), including hypercalcemic crises.

Trust comment: Prospective randomized comparative study with meaningful clinical and biochemical endpoints, but safety concerns (high hypercalcemia rates) and some early discontinuations affect interpretation.

Study Details

PMID:38198649
Participants:71
Impact:Increase of +29.3% vs baseline
Trust score:4/5

Incidence of rebound hypercalcemia

1 evidences

Randomized comparative study of denosumab vs zoledronic acid in pediatric OI: denosumab increased BMD but caused frequent rebound hypercalcemia (31%), including hypercalcemic crises.

Trust comment: Prospective randomized comparative study with meaningful clinical and biochemical endpoints, but safety concerns (high hypercalcemia rates) and some early discontinuations affect interpretation.

Study Details

PMID:38198649
Participants:71
Impact:Denosumab group 31.0% (13/42) vs Zoledronic acid 0%; hypercalcemic crisis in 14.3% (6/42)
Trust score:4/5

Femoral neck and total hip aBMD changes (12 months, denosumab)

1 evidences

Randomized comparative study of denosumab vs zoledronic acid in pediatric OI: denosumab increased BMD but caused frequent rebound hypercalcemia (31%), including hypercalcemic crises.

Trust comment: Prospective randomized comparative study with meaningful clinical and biochemical endpoints, but safety concerns (high hypercalcemia rates) and some early discontinuations affect interpretation.

Study Details

PMID:38198649
Participants:71
Impact:FN +27.8%, Total hip +30.2% vs baseline
Trust score:4/5

IL-6

1 evidences

Sarcopenic older adults received combined exercise plus nutritional support (included BCAA and daily Caltrate: 600 mg calcium + 800 IU vitamin D3); after 12 weeks inflammatory cytokines decreased and muscle strength/mass improved.

Trust comment: Human RCT per‑protocol analysis (n=57) showing reductions in inflammatory markers and improved strength, but calcium was given as part of a multi‑component nutrition + exercise program so effects cannot be attributed to calcium alone.

Study Details

PMID:38032288
Participants:57
Impact:−3.58 pg/mL (mean change), p=0.001
Trust score:3/5

osseous healing (angle Δα >20°)

1 evidences

Randomized phase IIa comparing β‑TCP bone graft substitute (calcium phosphate) with or without autologous BMC in proximal humerus fractures; no difference in radiologic healing or function; treatment well tolerated.

Trust comment: Randomized multicenter phase IIa but terminated early with 56 analyzed patients, reducing power; interventions involved a calcium‑based scaffold (β‑TCP) so findings are relevant to calcium‑containing implant use but not oral calcium supplementation.

Study Details

PMID:37995325
Participants:56
Impact:no significant difference between β‑TCP alone and β‑TCP+BMC (no reduction in complication rate; Δα ~6° both groups, p=0.326)
Trust score:3/5

systemic inflammatory markers

1 evidences

Randomized phase IIa comparing β‑TCP bone graft substitute (calcium phosphate) with or without autologous BMC in proximal humerus fractures; no difference in radiologic healing or function; treatment well tolerated.

Trust comment: Randomized multicenter phase IIa but terminated early with 56 analyzed patients, reducing power; interventions involved a calcium‑based scaffold (β‑TCP) so findings are relevant to calcium‑containing implant use but not oral calcium supplementation.

Study Details

PMID:37995325
Participants:56
Impact:no significant differences (IL‑6, CRP, leukocytes, PCT) between groups
Trust score:3/5

pulp survival

1 evidences

Randomized trial in adults comparing MTA vs calcium hydroxide pulp capping: at 36 months MTA had higher pulp survival than calcium hydroxide.

Trust comment: Randomized multicentre trial with 36-month follow-up; modest sample size (n=70) but clear outcome and statistically significant primary result.

Study Details

PMID:27891629
Participants:70
Impact:Calcium hydroxide group cumulative survival 52% at 36 months vs MTA 85% (P = 0.006)
Trust score:4/5

new-onset cardiac valve calcification (CVC) incidence

1 evidences

Large retrospective cohort of peritoneal dialysis patients found 12.4% developed new cardiac valve calcification; higher calcium-phosphate product (Ca×P) was an independent risk factor among others.

Trust comment: Large single-center retrospective cohort with robust modelling but limited by retrospective design and single-center data.

Study Details

PMID:37870850
Participants:1035
Impact:12.4% diagnosed during median 25-month follow-up
Trust score:4/5

calcium-phosphate product (Ca×P) association with CVC

1 evidences

Large retrospective cohort of peritoneal dialysis patients found 12.4% developed new cardiac valve calcification; higher calcium-phosphate product (Ca×P) was an independent risk factor among others.

Trust comment: Large single-center retrospective cohort with robust modelling but limited by retrospective design and single-center data.

Study Details

PMID:37870850
Participants:1035
Impact:OR 1.03 per unit increase in Ca×P (95% CI 1.00–1.05, p=0.02)
Trust score:4/5

serum calcium (Ca)

3 evidences

Large retrospective cohort of peritoneal dialysis patients found 12.4% developed new cardiac valve calcification; higher calcium-phosphate product (Ca×P) was an independent risk factor among others.

Trust comment: Large single-center retrospective cohort with robust modelling but limited by retrospective design and single-center data.

Study Details

PMID:37870850
Participants:1035
Impact:no significant independent association with CVC (p=0.11 in univariate; not significant in multivariate)
Trust score:4/5

In dialysis patients with secondary hyperparathyroidism, IV etelcalcetide over 1 year reduced PTH and lowered blood calcium and phosphate; hypocalcemia occurred in some patients.

Trust comment: Large multicenter human trial with central lab measurements but single-arm open-label extension limits causal inference.

Study Details

PMID:30859218
Participants:682
Impact:−8.4% (mean percent change, EAP)
Trust score:4/5

Six days of sodium phosphate in trained cyclists slightly increased submaximal work (lactate threshold) and raised serum phosphate but did not change serum calcium or overall VO2max; some individuals (responders) showed larger aerobic improvements.

Trust comment: Randomized, placebo-controlled crossover in trained humans with detailed physiologic measures; moderate sample size (n=22) limits generalizability; calcium-related outcome was directly measured.

Study Details

PMID:35057416
Participants:22
Impact:No significant change (0%)
Trust score:4/5

postoperative sensitivity (NRS/VAS)

1 evidences

Split-mouth RCT found application of a calcium phosphate-containing desensitizer did not significantly reduce postoperative sensitivity after composite restorations.

Trust comment: Randomized split-mouth design is appropriate but sample size small; findings credible for topical calcium phosphate desensitizer effect.

Study Details

PMID:37865810
Participants:47
Impact:no significant reduction (P>0.05; effect size <0.30)
Trust score:3/5

EMG / masticatory performance

1 evidences

In edentulous women given dentures, a daily multi-nutrient supplement (containing 150 mg calcium per serving) led to modest within-group improvements and a significant between-group increase in bone mineral density, but most between-group nutritional outcomes were not different.

Trust comment: Randomized controlled design with objective BMD measures but some reporting inconsistencies and relatively short follow-up limit confidence.

Study Details

PMID:37861611
Participants:121
Impact:improved within supplement group (p<0.01) but no consistent between-group differences
Trust score:3/5

quantitative blood loss

1 evidences

Double-blind RCT testing 1 g IV calcium chloride after cord clamping in intrapartum cesarean deliveries: no significant reduction in blood loss in the primary analysis, but planned subgroup excluding nonatonic bleeding showed ≈350 mL less blood loss with calcium.

Trust comment: Single-center, double-blind randomized placebo-controlled trial with pre-specified subgroup showing benefit; moderate sample size (n=120) limits precision.

Study Details

PMID:37917943
Participants:120
Impact:primary: median 840 mL (calcium) vs 1,051 mL (placebo); mean reduction 211 mL (95% CI −33 to 410), not statistically significant
Trust score:4/5

quantitative blood loss (atonic-only subgroup)

1 evidences

Double-blind RCT testing 1 g IV calcium chloride after cord clamping in intrapartum cesarean deliveries: no significant reduction in blood loss in the primary analysis, but planned subgroup excluding nonatonic bleeding showed ≈350 mL less blood loss with calcium.

Trust comment: Single-center, double-blind randomized placebo-controlled trial with pre-specified subgroup showing benefit; moderate sample size (n=120) limits precision.

Study Details

PMID:37917943
Participants:120
Impact:reduction ≈356 mL (95% CI 159–515), statistically significant
Trust score:4/5

reported side effects

1 evidences

Double-blind RCT testing 1 g IV calcium chloride after cord clamping in intrapartum cesarean deliveries: no significant reduction in blood loss in the primary analysis, but planned subgroup excluding nonatonic bleeding showed ≈350 mL less blood loss with calcium.

Trust comment: Single-center, double-blind randomized placebo-controlled trial with pre-specified subgroup showing benefit; moderate sample size (n=120) limits precision.

Study Details

PMID:37917943
Participants:120
Impact:similar rates between groups (38% vs 42%)
Trust score:4/5

horizontal alveolar ridge width gain

1 evidences

Pilot randomized clinical trial of a buccal plate repositioning technique using silica calcium phosphate nanocomposite graft showing mean horizontal ridge gain (~4.30 mm) comparable to other graft materials and allowing successful implant placement.

Trust comment: Small pilot randomized trial (n=24) of a surgical technique using a calcium-containing graft; limited sample but randomized design supports preliminary usefulness.

Study Details

PMID:37910834
Participants:24
Impact:mean gain ≈4.30 ± 0.94 mm with silica calcium phosphate nanocomposite (comparable to other graft types)
Trust score:3/5

implant placement success / primary stability

1 evidences

Pilot randomized clinical trial of a buccal plate repositioning technique using silica calcium phosphate nanocomposite graft showing mean horizontal ridge gain (~4.30 mm) comparable to other graft materials and allowing successful implant placement.

Trust comment: Small pilot randomized trial (n=24) of a surgical technique using a calcium-containing graft; limited sample but randomized design supports preliminary usefulness.

Study Details

PMID:37910834
Participants:24
Impact:successful implant placement achieved in all augmented ridges
Trust score:3/5

serum albumin-corrected total calcium

1 evidences

Randomized controlled trial showing that advising and achieving adequate dietary calcium intake (1,000–1,200 mg/day) in hypoparathyroidism patients non-adherent to supplements corrected hypocalcemia in most patients (87.5% reached target Ca) without short-term safety issues.

Trust comment: Prospective randomized controlled clinical trial with clear biochemical endpoints and good adherence in the intervention arm; sample modest but results clinically meaningful.

Study Details

PMID:37909613
Participants:67
Impact:increased from 7.29 mg/dL to 8.56 mg/dL in the dietary-intervention group (p<0.001)
Trust score:4/5

proportion reaching target serum Ca (8–9.5 mg/dL)

1 evidences

Randomized controlled trial showing that advising and achieving adequate dietary calcium intake (1,000–1,200 mg/day) in hypoparathyroidism patients non-adherent to supplements corrected hypocalcemia in most patients (87.5% reached target Ca) without short-term safety issues.

Trust comment: Prospective randomized controlled clinical trial with clear biochemical endpoints and good adherence in the intervention arm; sample modest but results clinically meaningful.

Study Details

PMID:37909613
Participants:67
Impact:87.5% in study group vs 8.5% in control
Trust score:4/5

salivary Streptococcus mutans levels

1 evidences

Randomized clinical trial in preschool children comparing NaF varnish alone versus NaF+TCP and NaF+CPP-ACP; no consistent advantage of calcium/phosphate-containing varnishes over conventional NaF in reducing S. mutans or L. fermentum counts over 24 months.

Trust comment: Well-powered randomized clinical trial (n=135) with qRT-PCR bacterial quantification and 24-month follow-up, though varnish application frequency was affected by COVID-19, which limits protocol fidelity.

Study Details

PMID:37899469
Participants:135
Impact:no consistent reduction with calcium/phosphate-containing varnishes vs conventional NaF over 24 months
Trust score:4/5

salivary/biofilm Lactobacillus fermentum levels

1 evidences

Randomized clinical trial in preschool children comparing NaF varnish alone versus NaF+TCP and NaF+CPP-ACP; no consistent advantage of calcium/phosphate-containing varnishes over conventional NaF in reducing S. mutans or L. fermentum counts over 24 months.

Trust comment: Well-powered randomized clinical trial (n=135) with qRT-PCR bacterial quantification and 24-month follow-up, though varnish application frequency was affected by COVID-19, which limits protocol fidelity.

Study Details

PMID:37899469
Participants:135
Impact:no consistent difference among varnish types over 24 months
Trust score:4/5

filter failure rate

1 evidences

In patients with liver failure receiving continuous KRT, regional citrate anticoagulation (RCA) prolonged filter lifespan but increased the risk of hypocalcemia.

Trust comment: Randomized controlled trial in humans with clear primary endpoint and relevant biochemical monitoring; moderate sample size and specialized population limit generalizability.

Study Details

PMID:37990929
Participants:89
Impact:RCA 27% vs no anticoagulation 56% (−29 percentage points)
Trust score:4/5

hypocalcemia incidence

4 evidences

In patients with liver failure receiving continuous KRT, regional citrate anticoagulation (RCA) prolonged filter lifespan but increased the risk of hypocalcemia.

Trust comment: Randomized controlled trial in humans with clear primary endpoint and relevant biochemical monitoring; moderate sample size and specialized population limit generalizability.

Study Details

PMID:37990929
Participants:89
Impact:RCA 82% vs no anticoagulation 51% (+31 percentage points)
Trust score:4/5

A perioperative multimodal nutrition protocol improved postoperative labs and recovery: higher albumin and electrolyte levels, fewer electrolyte disorders, and shorter hospital stay.

Trust comment: Randomized controlled trial with 187 patients and clinically relevant postoperative biochemical and recovery endpoints; results report differences in electrolytes including calcium.

Study Details

PMID:30817733
Participants:187
Impact:Reduced incidence of hypocalcemia in MNM group
Trust score:4/5

Adults with traumatic hemorrhagic shock receiving prehospital plasma had higher rates of hypocalcemia on admission; hypocalcemia predicted lower survival and greater need for massive transfusion.

Trust comment: Observational analysis of RCT participants (n=160) showing robust associations between admission hypocalcemia and worse clinical outcomes after prehospital plasma.

Study Details

PMID:32317575
Participants:160
Impact:+17 percentage points (53% vs 36%) with prehospital plasma; adjusted RR 1.48 (95% CI 1.03–2.12), p=0.03
Trust score:4/5

A multimodal nutrition protocol around knee replacement reduced albumin transfusions, electrolyte disorders including low calcium on day 1, and shortened hospital stay.

Trust comment: Randomized controlled trial with 162 patients and significant p-values; calcium-related outcomes were secondary but directly measured.

Study Details

PMID:28697860
Participants:162
Impact:reduced (P=0.028)
Trust score:4/5

severe hypocalcemia incidence

2 evidences

In the EVOLVE trial, initiation of cinacalcet was frequently followed by hypocalcemia (often asymptomatic) which usually resolved without intervention within 14 days.

Trust comment: Large randomized controlled trial (EVOLVE) post-hoc analysis with well-defined biochemical outcomes; high sample size supports reliability though analysis is post-hoc.

Study Details

PMID:29525393
Participants:3861
Impact:18.4% (cinacalcet) vs 4.4% (placebo); absolute difference +14.0 percentage points
Trust score:4/5

In patients with liver failure receiving continuous KRT, regional citrate anticoagulation (RCA) prolonged filter lifespan but increased the risk of hypocalcemia.

Trust comment: Randomized controlled trial in humans with clear primary endpoint and relevant biochemical monitoring; moderate sample size and specialized population limit generalizability.

Study Details

PMID:37990929
Participants:89
Impact:RCA 77% vs no anticoagulation 13% (+64 percentage points)
Trust score:4/5

Arterial stiffness

1 evidences

In hyperinsulinemic adults, a 6-week high-dairy diet (increasing dietary calcium) did not change blood pressure or arterial stiffness but was associated with increases in body fat, fasting insulin and HOMA-IR.

Trust comment: Randomized cross-over human trial directly relevant to dietary calcium via dairy but small sample size limits power.

Study Details

PMID:37939366
Participants:27
Impact:no significant change after high dairy intake
Trust score:3/5

GV change (CBCT at 3 mm)

1 evidences

Socket preservation trial: rhBMP-2 incorporated calcium phosphate material produced more new bone and faster material degradation than β-TCP or natural healing at 6 weeks.

Trust comment: Randomized clinical trial with CBCT and histology providing direct tissue-level outcomes, but modest sample size and short follow-up (6 weeks).

Study Details

PMID:37843657
Participants:36
Impact:rhBMP-2/BioCaP/β-TCP mean 373.19 vs β-TCP 112.26 GV (Δ +260.93 GV)
Trust score:4/5

new bone area

1 evidences

Socket preservation trial: rhBMP-2 incorporated calcium phosphate material produced more new bone and faster material degradation than β-TCP or natural healing at 6 weeks.

Trust comment: Randomized clinical trial with CBCT and histology providing direct tissue-level outcomes, but modest sample size and short follow-up (6 weeks).

Study Details

PMID:37843657
Participants:36
Impact:21.18% vs 13.44% (rhBMP-2 vs β-TCP); Δ +7.74 percentage points
Trust score:4/5

residual material area (%)

1 evidences

Socket preservation trial: rhBMP-2 incorporated calcium phosphate material produced more new bone and faster material degradation than β-TCP or natural healing at 6 weeks.

Trust comment: Randomized clinical trial with CBCT and histology providing direct tissue-level outcomes, but modest sample size and short follow-up (6 weeks).

Study Details

PMID:37843657
Participants:36
Impact:10.04% vs 20.60% (rhBMP-2 vs β-TCP); Δ −10.56 percentage points
Trust score:4/5

LF value reduction (remineralization)

1 evidences

Children at high caries risk received NaF varnishes (with or without calcium-containing additives); all varnishes reduced lesion signal (remineralized), with CPP-ACP combination giving the largest mean reduction.

Trust comment: Randomized, double-blind trial in children with objective LF outcomes and good completion rate, though moderate sample size.

Study Details

PMID:37831601
Participants:40
Impact:Reductions at 6 months: NaF+CPP-ACP −8.33 LF units; NaF −7.40; NaF+TCP −7.36; NaF+CXP −6.87 (all vs baseline)
Trust score:4/5

comparative effect

1 evidences

Children at high caries risk received NaF varnishes (with or without calcium-containing additives); all varnishes reduced lesion signal (remineralized), with CPP-ACP combination giving the largest mean reduction.

Trust comment: Randomized, double-blind trial in children with objective LF outcomes and good completion rate, though moderate sample size.

Study Details

PMID:37831601
Participants:40
Impact:No significant difference between NaF alone and other formulations overall; NaF+CPP-ACP > NaF+CXP (p<0.05)
Trust score:4/5

graft volume retention (VOL%)

1 evidences

Sinus graft RCT comparing bovine, porcine, and biphasic calcium phosphate substitutes: bovine and porcine graft volumes remained stable while synthetic BCP showed marked resorption.

Trust comment: Randomized clinical trial with 3D volumetric CBCT assessments; small sample but direct, objective measurements of calcium-based graft behavior.

Study Details

PMID:37823543
Participants:28
Impact:DBBM 103%±4 and DPBM 112%±23 (stable) vs BCP 66%±25 (significant decline)
Trust score:4/5

Nasal secretion calcium level

1 evidences

Intranasal EDTA plus olfactory training improved sense of smell more than training alone and reduced nasal calcium levels.

Trust comment: Randomized controlled trial but small sample (n=50); endpoints clinically relevant and reported significant differences.

Study Details

PMID:37786364
Participants:50
Impact:Significant decrease after EDTA vs training only (exact value not reported)
Trust score:3/5

Air pain improvement rate

1 evidences

Hydroxyapatite deposition by PJD reduced dentin hypersensitivity similarly to a calcium‑phosphate desensitizer over 12 weeks; non‑inferiority was not statistically demonstrated.

Trust comment: Randomized, split‑mouth RCT with blinded evaluators but small sample (n=34) and single‑blind design limits power.

Study Details

PMID:37759198
Participants:34
Impact:69.0% (PJD) vs 69.7% (TMD); non‑inferiority not demonstrated (p=0.196)
Trust score:3/5

Scratch pain improvement rate

1 evidences

Hydroxyapatite deposition by PJD reduced dentin hypersensitivity similarly to a calcium‑phosphate desensitizer over 12 weeks; non‑inferiority was not statistically demonstrated.

Trust comment: Randomized, split‑mouth RCT with blinded evaluators but small sample (n=34) and single‑blind design limits power.

Study Details

PMID:37759198
Participants:34
Impact:80.8% (PJD) vs 81.7% (TMD); non‑inferiority not demonstrated (p=0.247)
Trust score:3/5

Conversion to sinus rhythm within 30 minutes

1 evidences

Self‑administered intranasal etripamil converted ~60% of adjudicated PSVT episodes to sinus rhythm within 30 minutes (median 15.5 min); repeated use was generally safe with mostly mild local AEs.

Trust comment: Multicenter phase‑3 open‑label extension with ECG adjudication and moderate sample for safety (N=105); open‑label design limits efficacy comparisons.

Study Details

PMID:37753718
Participants:105
Impact:60.2% of positively adjudicated episodes (109/181); median time to conversion 15.5 minutes
Trust score:4/5

Conversion to sinus rhythm within 60 minutes

1 evidences

Self‑administered intranasal etripamil converted ~60% of adjudicated PSVT episodes to sinus rhythm within 30 minutes (median 15.5 min); repeated use was generally safe with mostly mild local AEs.

Trust comment: Multicenter phase‑3 open‑label extension with ECG adjudication and moderate sample for safety (N=105); open‑label design limits efficacy comparisons.

Study Details

PMID:37753718
Participants:105
Impact:~75.1% of episodes converted by 60 minutes
Trust score:4/5

Treatment‑emergent adverse events (TEAEs)

1 evidences

Self‑administered intranasal etripamil converted ~60% of adjudicated PSVT episodes to sinus rhythm within 30 minutes (median 15.5 min); repeated use was generally safe with mostly mild local AEs.

Trust comment: Multicenter phase‑3 open‑label extension with ECG adjudication and moderate sample for safety (N=105); open‑label design limits efficacy comparisons.

Study Details

PMID:37753718
Participants:105
Impact:42.9% of patients reported ≥1 TEAE; most were mild/local (nasal discomfort, congestion, rhinorrhea)
Trust score:4/5

iron metabolism indicators

1 evidences

Ferric citrate was non-inferior to sevelamer at lowering serum phosphorus in hemodialysis patients; corrected serum calcium and intact-PTH changes were similar, while ferric citrate improved iron indices and had more mild GI adverse events.

Trust comment: Phase III multicenter randomized trial with high completion rate; open-label design may introduce some bias but endpoints are objective.

Study Details

PMID:37812931
Participants:217
Impact:greater increases in ferric citrate group vs sevelamer group (significant)
Trust score:4/5

serum 25-hydroxyvitamin D (25OHD)

2 evidences

Overweight elderly participants all received 1000 mg elemental calcium/day plus either low or high vitamin D for 1 year; serum 25OHD rose more with high-dose vitamin D but there was little additional benefit on BMD or bone markers overall.

Trust comment: Large double-blind RCT (257 randomized, 222 completed) with objective endpoints; well-conducted but limited generalizability to overweight elderly.

Study Details

PMID:28276596
Participants:222
Impact:baseline 20 ng/mL → low-dose 26 ng/mL (+6 ng/mL); high-dose 36 ng/mL (+16 ng/mL) at 1 year
Trust score:4/5

Randomized single-blind RCT in 40 older women testing daily yogurt fortified with vitamin D3 (200 IU per pot twice daily) and calcium (400 mg per pot twice daily) for 3 months versus control yogurt; measured gait variability, cognition, grip strength and serum 25OHD.

Trust comment: Randomized controlled trial in humans with objective measures but small sample (n=40) and single-blind design limits generalizability.

Study Details

PMID:31779179
Participants:40
Impact:Higher in intervention versus control at 3 months (between-group difference p≤0.001); intervention stabilized/increased while control decreased
Trust score:3/5

albumin-corrected serum calcium

2 evidences

After 12 weeks of androgen deprivation therapy, patients showed early bone loss: small rise in serum calcium, increased bone resorption markers, and large decreases in stable calcium isotope ratios indicating net negative bone mineral balance.

Trust comment: Randomized, placebo-controlled substudy with robust biochemical and isotope measurements demonstrating consistent early changes in calcium and bone markers.

Study Details

PMID:37804569
Participants:87
Impact:increased by +0.04 mmol/L (95% CI 0.02 to 0.06)
Trust score:5/5

Personalized vitamin D3 loading followed by 2000 IU/day raised 25(OH)D to sufficiency in CRC patients; no cases of hypervitaminosis D or hypercalcemia occurred, though transient hypercalciuria was observed in some patients after loading dose.

Trust comment: Randomized, double-blind, placebo-controlled interim analysis with clear biochemical endpoints and safety monitoring; sample size for safety endpoints limited by interim nature.

Study Details

PMID:36364809
Participants:74
Impact:no meaningful change (no cases of hypercalcemia)
Trust score:4/5

stable calcium isotope ratio (δ44/42Ca) — serum

1 evidences

After 12 weeks of androgen deprivation therapy, patients showed early bone loss: small rise in serum calcium, increased bone resorption markers, and large decreases in stable calcium isotope ratios indicating net negative bone mineral balance.

Trust comment: Randomized, placebo-controlled substudy with robust biochemical and isotope measurements demonstrating consistent early changes in calcium and bone markers.

Study Details

PMID:37804569
Participants:87
Impact:decreased by ~20% after treatment
Trust score:5/5

stable calcium isotope ratio (δ44/42Ca) — urine

1 evidences

After 12 weeks of androgen deprivation therapy, patients showed early bone loss: small rise in serum calcium, increased bone resorption markers, and large decreases in stable calcium isotope ratios indicating net negative bone mineral balance.

Trust comment: Randomized, placebo-controlled substudy with robust biochemical and isotope measurements demonstrating consistent early changes in calcium and bone markers.

Study Details

PMID:37804569
Participants:87
Impact:decreased by >50% after treatment
Trust score:5/5

bone resorption markers (CTx, TRAcP5b)

1 evidences

After 12 weeks of androgen deprivation therapy, patients showed early bone loss: small rise in serum calcium, increased bone resorption markers, and large decreases in stable calcium isotope ratios indicating net negative bone mineral balance.

Trust comment: Randomized, placebo-controlled substudy with robust biochemical and isotope measurements demonstrating consistent early changes in calcium and bone markers.

Study Details

PMID:37804569
Participants:87
Impact:increased after 12 weeks (significant)
Trust score:5/5

resting energy expenditure (REE)

1 evidences

After weight loss, adding protein supplements (one arm included whey plus calcium) did not improve weight maintenance compared with control, although protein supplements increased diet-induced thermogenesis and resting energy expenditure.

Trust comment: Randomized, double-blind controlled trial with good sample size and objective measures, but calcium was included only as part of one protein supplement arm (not isolated).

Study Details

PMID:28679554
Participants:151
Impact:+243 kJ/day vs control
Trust score:4/5

surgical site infection risk (nomogram)

1 evidences

In 1,277 patients after lumbar fusion, a nomogram including serum calcium predicted surgical site infection risk; lower serum calcium was independently associated with higher SSI risk.

Trust comment: Large retrospective cohort with internal validation and clear multivariable analysis; observational design limits causal inference but findings on serum calcium as predictor are plausible.

Study Details

PMID:37625933
Participants:1277
Impact:Predictive nomogram showed good discrimination (AUC reported as favorable; internal validation performed)
Trust score:4/5

other independent predictors (albumin, glucose, etc.)

1 evidences

In 1,277 patients after lumbar fusion, a nomogram including serum calcium predicted surgical site infection risk; lower serum calcium was independently associated with higher SSI risk.

Trust comment: Large retrospective cohort with internal validation and clear multivariable analysis; observational design limits causal inference but findings on serum calcium as predictor are plausible.

Study Details

PMID:37625933
Participants:1277
Impact:Albumin and serum glucose among other clinical variables were independent predictors included in the nomogram (multivariable model)
Trust score:4/5

30-day secondary sepsis risk (nomogram)

1 evidences

Retrospective MIMIC-IV analysis produced a nomogram to predict 30-day sepsis in ICU TBI patients; lower serum calcium was an independent predictor of higher sepsis risk.

Trust comment: Large retrospective database study with internal validation using MIMIC-IV; robust for hypothesis generation though causal claims are limited by observational design.

Study Details

PMID:37596695
Participants:1167
Impact:Model developed to predict sepsis within 30 days in TBI ICU patients with internal validation; model reported good predictive performance
Trust score:4/5

other predictors (AKI, anemia, GCS, lactate)

1 evidences

Retrospective MIMIC-IV analysis produced a nomogram to predict 30-day sepsis in ICU TBI patients; lower serum calcium was an independent predictor of higher sepsis risk.

Trust comment: Large retrospective database study with internal validation using MIMIC-IV; robust for hypothesis generation though causal claims are limited by observational design.

Study Details

PMID:37596695
Participants:1167
Impact:AKI, anemia, lower GCS score, invasive ventilation and higher lactate were independently associated with higher sepsis risk
Trust score:4/5

survival to hospital admission

1 evidences

In 781 adult ED cardiac arrest cases, giving calcium during ED care was associated with lower chance of surviving to hospital admission.

Trust comment: Large retrospective cohort with adjustment and propensity analyses but nonrandomized design leaves residual confounding possible.

Study Details

PMID:37562663
Participants:781
Impact:-26% (RR 0.74; 95% CI 0.66–0.82)
Trust score:3/5

survival to admission (shockable rhythm)

1 evidences

In 781 adult ED cardiac arrest cases, giving calcium during ED care was associated with lower chance of surviving to hospital admission.

Trust comment: Large retrospective cohort with adjustment and propensity analyses but nonrandomized design leaves residual confounding possible.

Study Details

PMID:37562663
Participants:781
Impact:-40% (RR 0.60; 95% CI 0.50–0.72)
Trust score:3/5

survival to admission (non-shockable rhythm)

1 evidences

In 781 adult ED cardiac arrest cases, giving calcium during ED care was associated with lower chance of surviving to hospital admission.

Trust comment: Large retrospective cohort with adjustment and propensity analyses but nonrandomized design leaves residual confounding possible.

Study Details

PMID:37562663
Participants:781
Impact:-13% (RR 0.87; 95% CI 0.76–0.99)
Trust score:3/5

treatment success rate

4 evidences

Randomized study in children comparing MTA versus IRM as pulpal floor base after pulpectomy found similar overall success rates but faster lesion healing with MTA.

Trust comment: Randomized clinical study with blinded examiners but small sample size; outcomes clinically relevant and well assessed.

Study Details

PMID:27957486
Participants:50
Impact:MTA 76% vs IRM 64% at 18 months (difference not statistically significant)
Trust score:4/5

In children needing pulpectomy, an iodoform paste showed non-inferior 24‑month success versus a calcium hydroxide/iodoform paste.

Trust comment: Randomized non-inferiority RCT in children with 24‑month follow-up, low attrition; solid internal validity for clinical outcome.

Study Details

PMID:34856038
Participants:61
Impact:-8.4% (CaOH/Iodof 78.4% vs GP 86.8%; GP non-inferior)
Trust score:4/5

Adding rh-FGF-2 to a β-tricalcium phosphate scaffold improved periodontal regeneration versus β-TCP alone in adults.

Trust comment: Randomized, double-blinded, externally monitored multicenter RCT (n=88) — good design and reporting support moderate-high trust.

Study Details

PMID:26908630
Participants:88
Impact:+26 percentage points (71% in 0.3–0.4% rh-FGF-2/β-TCP vs 45% in control/0.1% groups)
Trust score:4/5

Randomized double-blind trial comparing root canal obturation with MTA vs gutta-percha, each with/without bone graft, in true combined endo-perio lesions; MTA+bone graft showed the best radiographic and clinical healing at 6 and 12 months.

Trust comment: Large randomized double-blind trial (n=120 teeth) with 1-year follow-up; results are robust though applicability limited to this dental condition.

Study Details

PMID:34201328
Participants:120
Impact:Highest success in MTA + bone graft (100%) at 6 and 12 months
Trust score:4/5

MoCA score (cognitive function)

1 evidences

Both normobaric and hyperbaric oxygen improved cognitive scores and brain oxygenation after mild TBI; HBOT produced greater improvements at 30 days.

Trust comment: Randomized controlled trial with objective measures and 104 completers; well-conducted though single-center with short (30 day) follow-up.

Study Details

PMID:37713814
Participants:104
Impact:+9.4 points (15.5 → 24.9) in HBOT at 30 days; significant vs baseline and vs NBH
Trust score:4/5

MMSE score (cognitive function)

1 evidences

Both normobaric and hyperbaric oxygen improved cognitive scores and brain oxygenation after mild TBI; HBOT produced greater improvements at 30 days.

Trust comment: Randomized controlled trial with objective measures and 104 completers; well-conducted though single-center with short (30 day) follow-up.

Study Details

PMID:37713814
Participants:104
Impact:+8.6 points (16.7 → 25.3) in HBOT at 30 days; significant vs baseline and vs NBH
Trust score:4/5

Cerebral oxygen saturation (rSO2)

1 evidences

Both normobaric and hyperbaric oxygen improved cognitive scores and brain oxygenation after mild TBI; HBOT produced greater improvements at 30 days.

Trust comment: Randomized controlled trial with objective measures and 104 completers; well-conducted though single-center with short (30 day) follow-up.

Study Details

PMID:37713814
Participants:104
Impact:+26.8 points (58.8 → 85.6) in HBOT at 30 days; significant vs baseline and vs NBH
Trust score:4/5

Brain injury / oxidative stress biomarkers (S100β, NSE, GFAP, HIF-1α, MDA)

1 evidences

Both normobaric and hyperbaric oxygen improved cognitive scores and brain oxygenation after mild TBI; HBOT produced greater improvements at 30 days.

Trust comment: Randomized controlled trial with objective measures and 104 completers; well-conducted though single-center with short (30 day) follow-up.

Study Details

PMID:37713814
Participants:104
Impact:Decreased significantly after intervention (T2–T3) vs baseline and vs control; greater reduction in HBOT than NBH at T3
Trust score:4/5

Proportion achieving target serum iPTH (60–240 pg/ml)

1 evidences

Upacicalcet significantly lowered serum iPTH and related bone/metabolic markers versus placebo with uncommon symptomatic hypocalcemia or GI adverse events.

Trust comment: Phase 3, multicenter, double-blind randomized placebo-controlled trial with prespecified endpoints and adequate sample size.

Study Details

PMID:37696667
Participants:135
Impact:67% (upacicalcet) vs 8% (placebo); difference +59% (P<0.001)
Trust score:5/5

≥30% and ≥50% reductions in iPTH

1 evidences

Upacicalcet significantly lowered serum iPTH and related bone/metabolic markers versus placebo with uncommon symptomatic hypocalcemia or GI adverse events.

Trust comment: Phase 3, multicenter, double-blind randomized placebo-controlled trial with prespecified endpoints and adequate sample size.

Study Details

PMID:37696667
Participants:135
Impact:≥30%: 81% vs 8%; ≥50%: 52% vs 4% (upacicalcet vs placebo; both P<0.001)
Trust score:5/5

Serum iPTH concentration (median)

1 evidences

Upacicalcet significantly lowered serum iPTH and related bone/metabolic markers versus placebo with uncommon symptomatic hypocalcemia or GI adverse events.

Trust comment: Phase 3, multicenter, double-blind randomized placebo-controlled trial with prespecified endpoints and adequate sample size.

Study Details

PMID:37696667
Participants:135
Impact:Upacicalcet median 364 → 161 pg/ml (overall percent change −53±23% vs placebo +8±38%, P<0.001)
Trust score:5/5

Serum corrected calcium (cCa)

2 evidences

Upacicalcet significantly lowered serum iPTH and related bone/metabolic markers versus placebo with uncommon symptomatic hypocalcemia or GI adverse events.

Trust comment: Phase 3, multicenter, double-blind randomized placebo-controlled trial with prespecified endpoints and adequate sample size.

Study Details

PMID:37696667
Participants:135
Impact:Mean cCa 9.3±0.7 → 8.8±0.6 mg/dl in upacicalcet group (statistically significant decrease vs placebo)
Trust score:5/5

Intravenous calcimimetic etelcalcetide in haemodialysis patients with secondary hyperparathyroidism reduced PTH and lowered serum calcium, phosphorus and FGF23 versus placebo.

Trust comment: Phase 3 randomized, double-blind, placebo-controlled trial with clear endpoints and 155 participants, high internal validity.

Study Details

PMID:28057872
Participants:155
Impact:decreased from baseline (significant vs placebo from Day 8)
Trust score:5/5

FGF23 and bone metabolic markers (BAP, P1NP, TRACP-5b)

1 evidences

Upacicalcet significantly lowered serum iPTH and related bone/metabolic markers versus placebo with uncommon symptomatic hypocalcemia or GI adverse events.

Trust comment: Phase 3, multicenter, double-blind randomized placebo-controlled trial with prespecified endpoints and adequate sample size.

Study Details

PMID:37696667
Participants:135
Impact:Significant decreases with upacicalcet (FGF23 median change ≈ −60% vs −3% placebo)
Trust score:5/5

endometrial thickness

1 evidences

Both drugs improved uterine blood flow measures and endometrial thickness; Sildenafil produced larger increases in endometrial thickness and greater RI reduction than Nifedipine.

Trust comment: Randomized controlled single-center trial with small sample and some baseline differences (BMI, baseline thickness) that may confound results.

Study Details

PMID:37675159
Participants:60
Impact:Sildenafil: 6.89±0.40 → 10.09±0.74 mm (+≈3.20 mm); Nifedipine: 6.57±0.67 → 9.34±0.50 mm (+≈2.77 mm); Sildenafil superior (P<0.001)
Trust score:3/5

Resistive index (RI) of uterine artery

1 evidences

Both drugs improved uterine blood flow measures and endometrial thickness; Sildenafil produced larger increases in endometrial thickness and greater RI reduction than Nifedipine.

Trust comment: Randomized controlled single-center trial with small sample and some baseline differences (BMI, baseline thickness) that may confound results.

Study Details

PMID:37675159
Participants:60
Impact:Sildenafil decreased RI from 1.06±0.14 → 0.62±0.06 (−0.44), greater reduction than Nifedipine (P<0.001)
Trust score:3/5

Pulsatility index (PI)

1 evidences

Both drugs improved uterine blood flow measures and endometrial thickness; Sildenafil produced larger increases in endometrial thickness and greater RI reduction than Nifedipine.

Trust comment: Randomized controlled single-center trial with small sample and some baseline differences (BMI, baseline thickness) that may confound results.

Study Details

PMID:37675159
Participants:60
Impact:Both treatments reduced PI; reduction larger with Sildenafil but difference not statistically significant (P=0.152)
Trust score:3/5

Clinical success rate (pulpotomy)

2 evidences

Pulpotomy with either MTA or calcium-enriched mixture had very high clinical success (~≥98%) at 2 and 5 years; radiographic advantage for MTA at 2 years but similar at 5 years.

Trust comment: Large multicenter randomized trial with long follow-up; calcium-containing biomaterial studied indirectly for dental outcomes.

Study Details

PMID:29178761
Participants:304
Impact:≥98% success at 2 and 5 years (no difference between MTA and CEM)
Trust score:4/5

Premixed calcium silicate cements (Endocem MTA Premixed, Well-Root PT) were non-inferior to ProRoot MTA for pulpotomy in primary molars; high success rates across materials.

Trust comment: Randomized clinical trial in pediatric patients with 12-month follow-up and appropriate analyses; good applicability to dental practice.

Study Details

PMID:37660882
Participants:52
Impact:ProRoot MTA 92%; Endocem MTA Premixed 84.9%; Well-Root PT 82% — differences not statistically significant
Trust score:4/5

Cumulative survival rate

1 evidences

Premixed calcium silicate cements (Endocem MTA Premixed, Well-Root PT) were non-inferior to ProRoot MTA for pulpotomy in primary molars; high success rates across materials.

Trust comment: Randomized clinical trial in pediatric patients with 12-month follow-up and appropriate analyses; good applicability to dental practice.

Study Details

PMID:37660882
Participants:52
Impact:No significant differences among the three materials over follow-up; ΔF values influenced prognosis
Trust score:4/5

Physical performance (vertical jump height)

1 evidences

1000 IU/day vitamin D3 for one month increased 25(OH)D and lowered PTH but did not improve measured physical performance.

Trust comment: Randomized trial with objective biochemical and performance measures and good completion (n=117); short duration (1 month) and lack of placebo reduce strength of conclusions.

Study Details

PMID:37735799
Participants:117
Impact:No significant change (Δ 0.85 cm; NS)
Trust score:4/5

serum 25-hydroxyvitamin D (25(OH)D)

5 evidences

Chinese postmenopausal women given 25,000 IU or 50,000 IU cholecalciferol every 4 weeks largely maintained vitamin D sufficiency without causing hyperparathyroidism or toxicity.

Trust comment: Randomized dosing with direct-observed administration and safety monitoring; indirect to Calcium (measures PTH/calcium) but primary focus is vitamin D.

Study Details

PMID:28429905
Participants:90
Impact:Mean levels after 16 weeks ~108.1 ± 20.4 nmol/L (25,000 IU/4-weekly) and ~114.7 ± 18.4 nmol/L (50,000 IU/4-weekly); >90% remained sufficient on lower dose
Trust score:3/5

Oral calcidiol (25‑OH vitamin D) quickly raised serum 25(OH)D above 30 ng/ml without altering serum calcium or other mineral metabolism markers over 3 months.

Trust comment: Randomized pharmacokinetic trial in postmenopausal women with clear biochemical endpoints and safety monitoring; directly relevant to mineral metabolism but not calcium supplementation per se.

Study Details

PMID:28815282
Participants:87
Impact:rapid increase to >30 ng/ml within 14 days across regimens
Trust score:4/5

In recurrent calcium stone formers with vitamin D deficiency, two vitamin D repletion protocols raised serum 25(OH)D, lowered PTH, and increased 24‑h urinary calcium without changing stone supersaturation.

Trust comment: Randomized clinical trial with pre-specified outcomes, dietary control and multivariable adjustment; moderate sample size and no placebo arm limit generalizability.

Study Details

PMID:37481570
Participants:62
Impact:+12.53 ng/mL (time effect; β 12.53, p<0.001; greater increase with 50,000 IU weekly vs 2000 IU daily)
Trust score:4/5

Daily vitamin D3 (600, 1000, 2000 IU) in deficient children increased vitamin D levels and substantially reduced secondary hyperparathyroidism; 2000 IU was most effective and no hypercalcaemia occurred.

Trust comment: Large randomized trial with high compliance and laboratory outcomes, though single-blind design and specific population limit generalizability.

Study Details

PMID:30843501
Participants:1008
Impact:post-supplementation means ≈36.5, 46.8, 70.0 nmol/L for 600, 1000, 2000 IU groups
Trust score:4/5

Older adults given calcifediol or vitamin D3 had faster and larger increases in blood vitamin D without causing high blood calcium.

Trust comment: Randomized, double-blind RCT in older adults with appropriate metabolite measures; moderate sample size but well-conducted.

Study Details

PMID:28433267
Participants:59
Impact:Increased rapidly; 10 µg calcifediol stabilized 25(OH)D at ~84–89 nmol/L (steady state by week 12); 20 µg vitamin D3 reached ~70 nmol/L by 16 weeks
Trust score:4/5

24-h urinary calcium

2 evidences

Both potassium citrate and hydrochlorothiazide reduced 24-h urinary calcium; potassium citrate increased urinary citrate more and had similar short-term stone recurrence.

Trust comment: Prospective randomized study (80 patients) with objective urine measures and 12-month imaging; moderate sample size.

Study Details

PMID:33904027
Participants:80
Impact:decreased to 205 mg/day (K-CIT) and 220.6 mg/day (HCT); both significantly reduced vs pretreatment
Trust score:4/5

In recurrent calcium stone formers with vitamin D deficiency, two vitamin D repletion protocols raised serum 25(OH)D, lowered PTH, and increased 24‑h urinary calcium without changing stone supersaturation.

Trust comment: Randomized clinical trial with pre-specified outcomes, dietary control and multivariable adjustment; moderate sample size and no placebo arm limit generalizability.

Study Details

PMID:37481570
Participants:62
Impact:+69.7 mg/24h (time effect; unadjusted β=69.70, 95% CI 52.34–87.06, p<0.001)
Trust score:4/5

Root sensitivity (VAS) — response to cold/toothbrushing/air

1 evidences

After non-surgical periodontal therapy, CSPS (calcium sodium phosphosilicate) and arginine dentifrices reduced patient‑reported root sensitivity within 2–4 weeks and effects persisted to 8 weeks.

Trust comment: Double-blind RCT with patient‑reported outcomes and small sample (n=45); CSPS is a calcium‑containing bioactive glass so findings are directly relevant to calcium‑containing dental materials.

Study Details

PMID:37475476
Participants:45
Impact:Reduced VAS scores (clinical relief onset: arginine Week 1–2 for some stimuli; CSPS Week 4; maintained to Week 8)
Trust score:3/5

Clinical/radiographic success (partial pulpotomy)

1 evidences

Partial pulpotomy in mature molars had high success across capping agents; calcium hydroxide performed similarly to other materials, while Emdogain showed less post‑operative pain and lower anti‑inflammatory intake.

Trust comment: Prospective randomized clinical trial with 12‑month follow-up and 110 treated teeth; direct clinical comparison of calcium hydroxide among capping agents supports credible dental outcome data.

Study Details

PMID:37460903
Participants:110
Impact:High success rates; no significant difference among calcium hydroxide, MTA, Biodentine, and Emdogain at follow-up
Trust score:4/5

Post‑operative pain / anti‑inflammatory intake

1 evidences

Partial pulpotomy in mature molars had high success across capping agents; calcium hydroxide performed similarly to other materials, while Emdogain showed less post‑operative pain and lower anti‑inflammatory intake.

Trust comment: Prospective randomized clinical trial with 12‑month follow-up and 110 treated teeth; direct clinical comparison of calcium hydroxide among capping agents supports credible dental outcome data.

Study Details

PMID:37460903
Participants:110
Impact:Significant difference: Emdogain associated with less post‑op pain and lower anti‑inflammatory use vs other agents (calcium hydroxide not superior)
Trust score:4/5

glycated hemoglobin (HbA1c)

1 evidences

In pregnant women with pre‑existing diabetes, an adapted DASH diet vs standard diet produced no difference in preeclampsia incidence; both groups improved glycated hemoglobin and some oxidative markers improved with DASH; calcium supplements (500 mg/day) were prescribed to women with low intake but not analyzed separately.

Trust comment: Randomized controlled dietary trial in humans with clear reporting; calcium carbonate was given to deficient participants but calcium-specific effects were not isolated in analyses.

Study Details

PMID:37457679
Participants:68
Impact:Decreased in both groups (SDG −0.6% mean; DDG −1.1% mean; both p=0.00)
Trust score:3/5

Glutathione peroxidase

1 evidences

In pregnant women with pre‑existing diabetes, an adapted DASH diet vs standard diet produced no difference in preeclampsia incidence; both groups improved glycated hemoglobin and some oxidative markers improved with DASH; calcium supplements (500 mg/day) were prescribed to women with low intake but not analyzed separately.

Trust comment: Randomized controlled dietary trial in humans with clear reporting; calcium carbonate was given to deficient participants but calcium-specific effects were not isolated in analyses.

Study Details

PMID:37457679
Participants:68
Impact:DDG increase +1588 μmol/L (mean change; p=0.03)
Trust score:3/5

Treatment failure / success (partial pulpotomy)

1 evidences

Partial pulpotomy using two calcium‑silicate materials (MTA Angelus vs Total Fill BC) showed similar long‑term success; Total Fill BC was associated with higher postoperative pain intensity.

Trust comment: Double‑blind randomized trial with median 2‑year follow-up and multivariable analyses; directly evaluates calcium‑containing silicate dental materials.

Study Details

PMID:37452640
Participants:123
Impact:Failure rates: MTA Angelus 10.8% vs Total Fill BC 17.5%; no statistically significant difference (adjusted HR 1.83, p=0.23)
Trust score:4/5

calcium pharmacokinetics (Tmax & absorption rate)

1 evidences

In 34 healthy adults, a liposomal multivitamin altered how some minerals and vitamins appeared in blood; serum calcium rose at 2 h after the liposomal MVM and some calcium PK markers (Tmax, absorption rate) differed; no side effects reported.

Trust comment: Randomized, double-blind, crossover human trial with detailed PK analysis but small completed sample (n=34).

Study Details

PMID:37447400
Participants:34
Impact:Tmax differed (p=0.032); distribution/absorption slope and rate differed (p=0.024)
Trust score:4/5

treatment-emergent adverse events

1 evidences

rhPTH(1-84) at 25 or 50 μg/d allowed a subset of hypoparathyroidism patients to reduce calcium and calcitriol supplements and was generally tolerated.

Trust comment: Randomized, dose-blinded multicenter trial but small sample and short duration; directly relevant to calcium supplement requirements in patients.

Study Details

PMID:28942334
Participants:42
Impact:reported by 58% (11/19) in 25 μg group and 74% (17/23) in 50 μg group
Trust score:3/5

Number of fractures per resident (2‑year)

1 evidences

Cluster‑randomized trial providing additional high‑calcium/high‑protein dairy to aged‑care residents reduced hip and other non‑vertebral fractures and was cost‑saving.

Trust comment: Large cluster‑randomized trial with verified fracture outcomes and robust economic analysis though some cost inputs were modelled from external sources.

Study Details

PMID:37389558
Participants:7224
Impact:Intervention 0.039 vs Control 0.059; difference −0.020 (95% CI −0.037 to −0.004)
Trust score:4/5

Hip and non‑vertebral fracture risk

1 evidences

Cluster‑randomized trial providing additional high‑calcium/high‑protein dairy to aged‑care residents reduced hip and other non‑vertebral fractures and was cost‑saving.

Trust comment: Large cluster‑randomized trial with verified fracture outcomes and robust economic analysis though some cost inputs were modelled from external sources.

Study Details

PMID:37389558
Participants:7224
Impact:Reduced hip and non‑vertebral fractures within 3–6 months (as per source trial) — reflected in mean difference above
Trust score:4/5

Cost-effectiveness (ICER)

1 evidences

Cluster‑randomized trial providing additional high‑calcium/high‑protein dairy to aged‑care residents reduced hip and other non‑vertebral fractures and was cost‑saving.

Trust comment: Large cluster‑randomized trial with verified fracture outcomes and robust economic analysis though some cost inputs were modelled from external sources.

Study Details

PMID:37389558
Participants:7224
Impact:Cost‑saving; ICER ≈ −AU$8,719 per fracture averted (typical case)
Trust score:4/5

lumbar spine T-score

1 evidences

Two-year randomized trial of exercise (with calcium + vitamin D supplementation) in postmenopausal women; high-impact training improved femoral neck T-scores more than fast walking.

Trust comment: Randomized 2-year trial directly involving calcium + vitamin D but small sample (34 completed) and limited power (51%), so moderate confidence.

Study Details

PMID:29040219
Participants:34
Impact:ΔControl = +0.27; ΔExperimental = +0.47 (difference not significant)
Trust score:3/5

systolic blood pressure (SBP)

1 evidences

Switching from low- to high-dairy intake for 6 weeks lowered both systolic and diastolic blood pressure in overweight middle-aged adults; effect appeared dependent on increased calcium intake.

Trust comment: Well-controlled randomized crossover trial with objective BP and urinary measures; moderate sample size and short intervention duration limit generalizability.

Study Details

PMID:31237322
Participants:46
Impact:−4.6 mm Hg (mean Δ LDD–HDD = −4.6 ±11.2 mm Hg); adjusted reductions up to ~−7 mm Hg in mixed models (p≈0.01–0.03)
Trust score:4/5

diastolic blood pressure (DBP)

1 evidences

Switching from low- to high-dairy intake for 6 weeks lowered both systolic and diastolic blood pressure in overweight middle-aged adults; effect appeared dependent on increased calcium intake.

Trust comment: Well-controlled randomized crossover trial with objective BP and urinary measures; moderate sample size and short intervention duration limit generalizability.

Study Details

PMID:31237322
Participants:46
Impact:−3.0 mm Hg (mean Δ = −3.0 ±6.7 mm Hg); adjusted reductions up to ~−5.5 mm Hg (p≈0.01)
Trust score:4/5

appetite score

1 evidences

Oral nutritional supplements plus dietary counseling increased energy and micronutrient intakes (including calcium), and improved appetite versus counseling alone in picky-eating children over 90 days.

Trust comment: Randomized, multi-center, double-blind trial with robust dietary assessment and high compliance—relevant indirect evidence about increasing calcium intake via supplements.

Study Details

PMID:37299491
Participants:321
Impact:Appetite improved significantly in both supplemented groups (ONS1 p=0.006; ONS2 p=0.024) versus control
Trust score:4/5

P1NP (bone formation marker)

8 evidences

Daily consumption of a dairy product enriched with calcium, vitamin D and other bone‑supporting nutrients for 24 weeks improved bone mass and bone turnover markers and mitigated BMD loss in menopausal women at risk of osteoporosis.

Trust comment: Randomized, double‑blind clinical trial with relevant bone outcomes and physiological effects; moderate sample and 17% dropout but clear between‑group biochemical and DXA findings.

Study Details

PMID:32722015
Participants:65
Impact:increase in EG vs decrease in CG (13.19 ng/mL vs −4.21 ng/mL; p < 0.05)
Trust score:4/5

Enhanced exercise and combined calcium plus vitamin D helped maintain or improve muscle strength in postmenopausal women at high osteoporosis risk.

Trust comment: Large randomized trial (n=614) in target population with significant biochemical and functional outcomes, though some effect sizes not fully reported.

Study Details

PMID:28695804
Participants:614
Impact:increased in Ca+VitD3 group C (P=0.016)
Trust score:4/5

Small randomized study: adding Greek yogurt (source of protein and calcium) to exercise increased bone formation markers versus placebo.

Trust comment: Randomized controlled trial but small sample (n=30); biomarker changes are statistically significant though clinical translation limited by size.

Study Details

PMID:31652407
Participants:30
Impact:increase (greater rise vs placebo)
Trust score:4/5

Small randomized study in postmenopausal osteopenic women: adding bioactive collagen peptides to calcium+vitamin D lowered bone turnover markers over 3 months compared with calcium+vitamin D alone.

Trust comment: Randomized, measured objective biochemical endpoints and registered, but small sample size and short duration limit confidence and generalizability.

Study Details

PMID:32131366
Participants:43
Impact:decreased (Group with CPs: -13.1% within-group; between-groups % change -13.1% vs -2.1%, p=0.011)
Trust score:3/5

Postmenopausal osteoporotic women received zoledronate; experimental groups received calcitriol plus calcium carbonate while controls received calcium carbonate alone—bone turnover markers fell and BMD rose, with greater marker declines and lumbar spine BMD increase when calcitriol was added.

Trust comment: Randomized human study (n=120) with measured BTM and BMD showing significant differences when calcitriol was added to calcium/zoledronate.

Study Details

PMID:32346686
Participants:120
Impact:decrease; greater decrease in calcitriol+calcium group vs calcium-only control at 6 months (P<0.05)
Trust score:4/5

A 3-month dietary intervention in postmenopausal women increasing vegetables/herbs/fruit reduced urinary calcium excretion and lowered bone turnover markers in the group consuming phytochemical-rich selections, especially in osteopenic women.

Trust comment: Randomized dietary intervention with objective biomarkers and reasonable sample but short duration (3 months), non-randomized control and some selection bias limit generalizability.

Study Details

PMID:25856221
Participants:142
Impact:Group B decrease −3.2 μg/L (p<0.01)
Trust score:3/5

Genetic variants in VDR and DBP were associated with baseline vitamin D status and bone turnover markers, and genotype (combined GRS) modified the response of 25OHD to calcium plus vitamin D supplementation during training.

Trust comment: Large randomized, double-blind, placebo-controlled supplementation trial with genetic subgroup analyses; completer analysis used (n=391) for response data.

Study Details

PMID:27683185
Participants:391
Impact:lower levels associated with VDR rs2228570 minor allele
Trust score:4/5

24-month randomized interventional study: pre-load vitamin D plus ongoing vitamin D, calcium, protein supplementation and exercise after bariatric surgery attenuated increases in bone turnover markers and reduced loss of aBMD and lean mass versus no intervention.

Trust comment: Large (n=220), prospective randomized interventional study with 24-month follow-up; combined intervention limits attribution to calcium alone but overall design is strong.

Study Details

PMID:26350034
Participants:220
Impact:increase +12% (intervention) vs +41.2% (non-intervention)
Trust score:4/5

stone fragmentation (no fragmentation vs fragmentation)

1 evidences

Randomized double-blind multicenter trial found the HCA-containing supplement (FagolitosPlus®) given before and after ESWL improved stone fragmentation in patients with calcium-containing renal stones compared with placebo.

Trust comment: Well-designed randomized double-blind placebo-controlled multicenter trial with meaningful clinical outcomes; per-protocol N=65 limits but findings consistent across ITT and PP analyses.

Study Details

PMID:37249658
Participants:65
Impact:Per-protocol: 0% no-fragmentation with HCA vs 16.7% no-fragmentation with placebo (all HCA patients showed fragmentation; p≈0.026)
Trust score:4/5

fragmentation distribution (quality of fragmentation)

1 evidences

Randomized double-blind multicenter trial found the HCA-containing supplement (FagolitosPlus®) given before and after ESWL improved stone fragmentation in patients with calcium-containing renal stones compared with placebo.

Trust comment: Well-designed randomized double-blind placebo-controlled multicenter trial with meaningful clinical outcomes; per-protocol N=65 limits but findings consistent across ITT and PP analyses.

Study Details

PMID:37249658
Participants:65
Impact:Higher proportion of 'very good' fragmentation in HCA group (60.7% vs 33.3% placebo); overall distribution difference p=0.028
Trust score:4/5

need for retreatment (new ESWL)

1 evidences

Randomized double-blind multicenter trial found the HCA-containing supplement (FagolitosPlus®) given before and after ESWL improved stone fragmentation in patients with calcium-containing renal stones compared with placebo.

Trust comment: Well-designed randomized double-blind placebo-controlled multicenter trial with meaningful clinical outcomes; per-protocol N=65 limits but findings consistent across ITT and PP analyses.

Study Details

PMID:37249658
Participants:65
Impact:No significant difference (HCA 13 required vs placebo 17; difference not statistically significant)
Trust score:4/5

success rate

1 evidences

Prospective randomized trial in immature nonvital teeth found regenerative endodontic procedures using nonsetting calcium hydroxide or modified triple antibiotic paste had similar high success and survival rates at 36 months.

Trust comment: Randomized clinical study with 36-month follow-up directly evaluating a calcium-containing medicament (calcium hydroxide) in humans; moderate sample size but clinically relevant outcomes.

Study Details

PMID:37225036
Participants:45
Impact:81.6% success at 36 months (no significant difference between Ca(OH)2 and TAP)
Trust score:4/5

Survival rate

1 evidences

Prospective randomized trial in immature nonvital teeth found regenerative endodontic procedures using nonsetting calcium hydroxide or modified triple antibiotic paste had similar high success and survival rates at 36 months.

Trust comment: Randomized clinical study with 36-month follow-up directly evaluating a calcium-containing medicament (calcium hydroxide) in humans; moderate sample size but clinically relevant outcomes.

Study Details

PMID:37225036
Participants:45
Impact:100% survival of treated teeth at 36 months
Trust score:4/5

radiographic root development (root length, dentin thickness, apical diameter)

1 evidences

Prospective randomized trial in immature nonvital teeth found regenerative endodontic procedures using nonsetting calcium hydroxide or modified triple antibiotic paste had similar high success and survival rates at 36 months.

Trust comment: Randomized clinical study with 36-month follow-up directly evaluating a calcium-containing medicament (calcium hydroxide) in humans; moderate sample size but clinically relevant outcomes.

Study Details

PMID:37225036
Participants:45
Impact:Observed in 47.9% (root length), 77.1% (dentin thickness), 89.6% (apical diameter) with no group differences
Trust score:4/5

pulpotomy clinical success

1 evidences

Split-mouth RCT in children comparing TheraCal (releases calcium) vs MTA for primary tooth pulpotomy: both materials showed very high and similar 12-month success rates.

Trust comment: Randomized split-mouth trial with blinded assessors and 12-month follow-up but small pediatric sample (41 children).

Study Details

PMID:37124935
Participants:41
Impact:no significant difference; TheraCal ~98% vs MTA ~99% at 12 months
Trust score:4/5

cardiovascular mortality

2 evidences

Large prospective cohort showing calcium channel blocker (CCB) use was associated with higher long-term all-cause and CVD mortality; associations were attenuated in patients receiving B-vitamin treatment.

Trust comment: Large, well-characterized observational cohort (n=3991) with long follow-up and multivariable adjustment; residual confounding and confounding by indication remain possible.

Study Details

PMID:37121550
Participants:3991
Impact:increased with CCB use (adjusted HR ≈1.35; ~+35%); association attenuated with B-vitamin treatment
Trust score:4/5

Secondary analysis of a large RCT in hemodialysis patients showed cinacalcet markedly reduced FGF23; patients with ≥30% FGF23 reduction had lower rates of cardiovascular death and events.

Trust comment: Large randomized trial secondary analysis (thousands of patients); treatment effect on FGF23 is randomized but outcome associations are observational within trial.

Study Details

PMID:26059012
Participants:2985
Impact:Associated relative hazard 0.66 (95% CI 0.50–0.87) for ≥30% FGF23 reduction
Trust score:4/5

intact FGF23

1 evidences

7-day randomized crossover trial in hemodialysis patients: therapeutic diet rapidly improved mineral markers (lower phosphate/PTH/FGF23) and increased serum calcium.

Trust comment: Randomized crossover design but small short-term study (n=33) with biochemical endpoints; limited duration for clinical outcomes.

Study Details

PMID:37120127
Participants:33
Impact:decrease (P = 0.001)
Trust score:3/5

Postoperative cognitive dysfunction (POCD) incidence

1 evidences

Preoperative scopolamine butylbromide reduced postoperative cognitive dysfunction cases and lowered related blood markers.

Trust comment: Randomized allocation with clear biomarker and clinical outcome differences reported; moderate-high internal validity though single-center details and broader generalizability not provided.

Study Details

PMID:28387891
Participants:142
Impact:reduced (4 cases in intervention vs 21 in control)
Trust score:4/5

Total body mass (postpartum)

1 evidences

In adolescents with low calcium intake, daily supplementation with 600 mg calcium + 200 IU vitamin D during pregnancy led to greater reductions in postpartum total and central fat mass over one year.

Trust comment: Randomized trial with objective DXA outcomes and significant adjusted effects but modest sample size limits generalizability.

Study Details

PMID:37166151
Participants:56
Impact:mean difference −3.32 kg (95% CI −6.12 to −0.52 kg) vs placebo
Trust score:4/5

trunk fat mass

1 evidences

In adolescents with low calcium intake, daily supplementation with 600 mg calcium + 200 IU vitamin D during pregnancy led to greater reductions in postpartum total and central fat mass over one year.

Trust comment: Randomized trial with objective DXA outcomes and significant adjusted effects but modest sample size limits generalizability.

Study Details

PMID:37166151
Participants:56
Impact:mean difference −1.25 kg (95% CI −2.34 to −0.15 kg) vs placebo
Trust score:4/5

android fat mass

1 evidences

In adolescents with low calcium intake, daily supplementation with 600 mg calcium + 200 IU vitamin D during pregnancy led to greater reductions in postpartum total and central fat mass over one year.

Trust comment: Randomized trial with objective DXA outcomes and significant adjusted effects but modest sample size limits generalizability.

Study Details

PMID:37166151
Participants:56
Impact:mean difference −0.29 kg (95% CI −0.53 to −0.04 kg) vs placebo
Trust score:4/5

left forearm BMD

1 evidences

Giving 60 g/day formula milk (rich in calcium and vitamin D) to 4–6 y children for 12 months increased forearm bone mass and caused short-term biomarker changes.

Trust comment: Cluster randomized controlled trial with objective bone measurements, adequate sample and high adherence though not double-blinded (minor limitation).

Study Details

PMID:37111231
Participants:174
Impact:+6.66% (12 months); +3.77% (6 months)
Trust score:5/5

left forearm BMC

1 evidences

Giving 60 g/day formula milk (rich in calcium and vitamin D) to 4–6 y children for 12 months increased forearm bone mass and caused short-term biomarker changes.

Trust comment: Cluster randomized controlled trial with objective bone measurements, adequate sample and high adherence though not double-blinded (minor limitation).

Study Details

PMID:37111231
Participants:174
Impact:+5.76% (12 months); +4.55% (6 months)
Trust score:5/5

calcaneus BMD

1 evidences

Giving 60 g/day formula milk (rich in calcium and vitamin D) to 4–6 y children for 12 months increased forearm bone mass and caused short-term biomarker changes.

Trust comment: Cluster randomized controlled trial with objective bone measurements, adequate sample and high adherence though not double-blinded (minor limitation).

Study Details

PMID:37111231
Participants:174
Impact:+2.83% (6 months); no significant difference at 12 months
Trust score:5/5

height gain

1 evidences

Giving 60 g/day formula milk (rich in calcium and vitamin D) to 4–6 y children for 12 months increased forearm bone mass and caused short-term biomarker changes.

Trust comment: Cluster randomized controlled trial with objective bone measurements, adequate sample and high adherence though not double-blinded (minor limitation).

Study Details

PMID:37111231
Participants:174
Impact:+0.34–0.45% (3–9 months), not significant at 12 months
Trust score:5/5

ICDAS score (white spot lesions) — Curodont (CR)

1 evidences

Compared a self-assembling peptide and a xylitol-coated calcium phosphate varnish for white spot lesions in 3–5 y children; only the peptide showed statistically significant lesion reduction.

Trust comment: Small randomized clinical trial with clear clinical endpoints but limited sample size and short follow-up for generalization.

Study Details

PMID:37106544
Participants:30
Impact:significant reduction at 6 months (P=0.05)
Trust score:3/5

WSL area (morphometric) — Curodont (CR)

1 evidences

Compared a self-assembling peptide and a xylitol-coated calcium phosphate varnish for white spot lesions in 3–5 y children; only the peptide showed statistically significant lesion reduction.

Trust comment: Small randomized clinical trial with clear clinical endpoints but limited sample size and short follow-up for generalization.

Study Details

PMID:37106544
Participants:30
Impact:significant reduction at 6 months (P=0.008)
Trust score:3/5

WSL area / ICDAS — Embrace (xylitol-coated calcium phosphate)

1 evidences

Compared a self-assembling peptide and a xylitol-coated calcium phosphate varnish for white spot lesions in 3–5 y children; only the peptide showed statistically significant lesion reduction.

Trust comment: Small randomized clinical trial with clear clinical endpoints but limited sample size and short follow-up for generalization.

Study Details

PMID:37106544
Participants:30
Impact:no significant change at 6 months
Trust score:3/5

enamel permeability (SEM droplets) — both groups

1 evidences

Compared a self-assembling peptide and a xylitol-coated calcium phosphate varnish for white spot lesions in 3–5 y children; only the peptide showed statistically significant lesion reduction.

Trust comment: Small randomized clinical trial with clear clinical endpoints but limited sample size and short follow-up for generalization.

Study Details

PMID:37106544
Participants:30
Impact:no significant reduction (CR P=0.06; EV P=0.21)
Trust score:3/5

white spot lesion (laser fluorescence)

1 evidences

In 4–5‑year‑old children, a calcium‑containing mineral toothpaste reduced white‑spot lesion laser‑fluorescence and showed remineralization similar to fluoride toothpaste over 1 month.

Trust comment: Small randomized clinical trial in children with objective measures but limited sample size and short follow‑up.

Study Details

PMID:37013280
Participants:26
Impact:decrease (LF scores decreased in both groups, p=0.001)
Trust score:3/5

remineralisation potential vs fluoride

1 evidences

In 4–5‑year‑old children, a calcium‑containing mineral toothpaste reduced white‑spot lesion laser‑fluorescence and showed remineralization similar to fluoride toothpaste over 1 month.

Trust comment: Small randomized clinical trial in children with objective measures but limited sample size and short follow‑up.

Study Details

PMID:37013280
Participants:26
Impact:no significant difference (p=0.866)
Trust score:3/5

salivary buffering capacity and pH

1 evidences

In 4–5‑year‑old children, a calcium‑containing mineral toothpaste reduced white‑spot lesion laser‑fluorescence and showed remineralization similar to fluoride toothpaste over 1 month.

Trust comment: Small randomized clinical trial in children with objective measures but limited sample size and short follow‑up.

Study Details

PMID:37013280
Participants:26
Impact:increased in both groups (not significant, p>0.05)
Trust score:3/5

streptococcus mutans prevalence

1 evidences

In 4–5‑year‑old children, a calcium‑containing mineral toothpaste reduced white‑spot lesion laser‑fluorescence and showed remineralization similar to fluoride toothpaste over 1 month.

Trust comment: Small randomized clinical trial in children with objective measures but limited sample size and short follow‑up.

Study Details

PMID:37013280
Participants:26
Impact:decreased in both groups (not significant, p>0.05)
Trust score:3/5

newly formed bone (histomorphometry)

1 evidences

Randomized human trial comparing injectable biphasic calcium phosphate (BCP) to bovine bone graft showed similar amounts of new bone and similar immunohistochemical markers at 6 months.

Trust comment: Randomized clinical trial in humans with histologic endpoints but small sample size limiting power.

Study Details

PMID:36982613
Participants:38
Impact:no significant difference between BCP (39.91 ± 8.49%) and ABB (41.73 ± 13.99%), p=0.629
Trust score:4/5

residual biomaterial percentage

1 evidences

Randomized human trial comparing injectable biphasic calcium phosphate (BCP) to bovine bone graft showed similar amounts of new bone and similar immunohistochemical markers at 6 months.

Trust comment: Randomized clinical trial in humans with histologic endpoints but small sample size limiting power.

Study Details

PMID:36982613
Participants:38
Impact:no significant difference (BCP 28.61 ± 11.38% vs ABB 31.72 ± 15.52%, p=0.485)
Trust score:4/5

Osx and BMP‑2 expression (immunohistochemistry)

1 evidences

Randomized human trial comparing injectable biphasic calcium phosphate (BCP) to bovine bone graft showed similar amounts of new bone and similar immunohistochemical markers at 6 months.

Trust comment: Randomized clinical trial in humans with histologic endpoints but small sample size limiting power.

Study Details

PMID:36982613
Participants:38
Impact:strong expression (+++ ) in both groups (no meaningful between‑group difference)
Trust score:4/5

total hip (TH) bone mineral density in females

1 evidences

Motivational interviewing increased dairy (calcium) intake in adolescents; in females consuming ≥4 servings/day for 12 months, total hip bone density increased, but no effect seen in males.

Trust comment: Randomized controlled trial in adolescents with objective DXA outcomes but modest sample size and incomplete follow‑up (~81% at 12 mo).

Study Details

PMID:36967160
Participants:94
Impact:greater increases in high‑dairy group: ~4.3% at 12 mo and ~7.5% at 24 mo vs control (3.7%→4.9%); between‑group p=0.04
Trust score:4/5

lumbar spine and other DXA outcomes

1 evidences

Motivational interviewing increased dairy (calcium) intake in adolescents; in females consuming ≥4 servings/day for 12 months, total hip bone density increased, but no effect seen in males.

Trust comment: Randomized controlled trial in adolescents with objective DXA outcomes but modest sample size and incomplete follow‑up (~81% at 12 mo).

Study Details

PMID:36967160
Participants:94
Impact:no consistent intervention effect (no significant changes overall)
Trust score:4/5

bone biomarkers

2 evidences

Motivational interviewing increased dairy (calcium) intake in adolescents; in females consuming ≥4 servings/day for 12 months, total hip bone density increased, but no effect seen in males.

Trust comment: Randomized controlled trial in adolescents with objective DXA outcomes but modest sample size and incomplete follow‑up (~81% at 12 mo).

Study Details

PMID:36967160
Participants:94
Impact:no differences among dairy groups in females or males
Trust score:4/5

Motivational interviewing increased dairy intake; in female adolescents who consumed ≥4 dairy servings/day for 12 months, total hip BMD increased more than controls, whereas males showed no DXA bone benefits.

Trust comment: Randomized trial with measured dietary (dairy/calcium) intake and DXA outcomes; moderate sample and 80.9% 12-month completion give reasonable confidence for female-specific effect.

Study Details

PMID:35015862
Participants:76
Impact:No differences among dairy groups
Trust score:4/5

CTx-1 (bone resorption)

1 evidences

Single 1000 mg calcium dose from milk or calcium carbonate acutely reduced bone resorption (CTX-1) and lowered PTH in postmenopausal women regardless of visceral fat.

Trust comment: Randomized three-period crossover with objective biochemical endpoints and frequent sampling; moderate sample size and open-label design.

Study Details

PMID:36967157
Participants:77
Impact:-44% (milk and calcium carbonate); -18% (juice control)
Trust score:4/5

Clinical/radiographic success (calcium hydroxide)

1 evidences

In primary molars, calcium hydroxide had high short-term clinical and radiographic success (similar to MTA), with no statistically significant differences between groups.

Trust comment: Randomized clinical trial in 60 teeth with objective outcomes but small sample and limited follow-up duration.

Study Details

PMID:36947754
Participants:60
Impact:88.2% success rate
Trust score:3/5

Between-group difference

1 evidences

In primary molars, calcium hydroxide had high short-term clinical and radiographic success (similar to MTA), with no statistically significant differences between groups.

Trust comment: Randomized clinical trial in 60 teeth with objective outcomes but small sample and limited follow-up duration.

Study Details

PMID:36947754
Participants:60
Impact:No statistically significant difference between CH, MTA, and FC groups (P>0.05)
Trust score:3/5

Forearm BMD T-score (drug-only: calcium+vit D+F)

1 evidences

Both groups receiving calcium + vitamin D (with fluoride) improved forearm BMD and wrist pain; adding laser acupuncture produced larger improvements.

Trust comment: Randomized trial with clear outcomes but calcium was given to all participants so supplement effects are not isolated.

Study Details

PMID:36944142
Participants:68
Impact:Improved from -2.844 to -2.597 (change +0.247)
Trust score:3/5

Wrist pain (VAS) (drug-only: calcium+vit D+F)

1 evidences

Both groups receiving calcium + vitamin D (with fluoride) improved forearm BMD and wrist pain; adding laser acupuncture produced larger improvements.

Trust comment: Randomized trial with clear outcomes but calcium was given to all participants so supplement effects are not isolated.

Study Details

PMID:36944142
Participants:68
Impact:Decreased from 7.50 to 4.24 (change -3.26)
Trust score:3/5

Clinical efficacy rate

1 evidences

In pregnant patients with hypertensive disorders, adding low-dose aspirin to labetalol + vitamin E + calcium improved clinical efficacy, lowered blood pressure and 24-h urine protein, and increased microRNA-126 and PLGF versus without aspirin.

Trust comment: Randomized controlled trial but calcium was included in both arms, so calcium-specific effects cannot be isolated; moderate sample size.

Study Details

PMID:36933245
Participants:130
Impact:96.92% (intervention) vs 83.08% (control)
Trust score:3/5

24 h urinary protein

1 evidences

In pregnant patients with hypertensive disorders, adding low-dose aspirin to labetalol + vitamin E + calcium improved clinical efficacy, lowered blood pressure and 24-h urine protein, and increased microRNA-126 and PLGF versus without aspirin.

Trust comment: Randomized controlled trial but calcium was included in both arms, so calcium-specific effects cannot be isolated; moderate sample size.

Study Details

PMID:36933245
Participants:130
Impact:Significantly lower in intervention vs control (P<0.05)
Trust score:3/5

6-minute walk distance (6MWT)

1 evidences

Intradialytic exercise for 6 months improved 12-month survival and led to increases in serum calcium, physical function, and nutritional markers.

Trust comment: Randomized controlled trial with blinded end-points and balanced groups, but single-center and modest sample size limits precision.

Study Details

PMID:37069527
Participants:74
Impact:+72 m (309 → 381 m over 6 months)
Trust score:4/5

serum potassium decrease

1 evidences

Oral calcium polystyrene sulfonate lowered serum potassium over 7 days; higher dose (30 g/day) had greater effect and was well tolerated.

Trust comment: Prospective randomized trial with adequate sample size for short-term efficacy, single-center and open-label design reduce generalizability.

Study Details

PMID:37063062
Participants:96
Impact:−0.94 mmol/L (30 g/day) vs −0.64 mmol/L (15 g/day) after 7 days
Trust score:4/5

proportion achieving normokalemia

1 evidences

Oral calcium polystyrene sulfonate lowered serum potassium over 7 days; higher dose (30 g/day) had greater effect and was well tolerated.

Trust comment: Prospective randomized trial with adequate sample size for short-term efficacy, single-center and open-label design reduce generalizability.

Study Details

PMID:37063062
Participants:96
Impact:77.6% (30 g/day) vs 57.4% (15 g/day); difference +20.2 percentage points (7 days)
Trust score:4/5

time to hemostasis

1 evidences

Calcium alginate and oxidized regenerated cellulose produced similar times to hemostasis, but more hemostatic products were used with ORC, favoring calcium alginate for practical use.

Trust comment: Randomized trial but very small sample and wide confidence intervals reduce reliability.

Study Details

PMID:37058598
Participants:28
Impact:no significant difference (ORC 93.8 s vs CA 67 s; P = 0.894)
Trust score:3/5

hemostatic product use

1 evidences

Calcium alginate and oxidized regenerated cellulose produced similar times to hemostasis, but more hemostatic products were used with ORC, favoring calcium alginate for practical use.

Trust comment: Randomized trial but very small sample and wide confidence intervals reduce reliability.

Study Details

PMID:37058598
Participants:28
Impact:ORC used 34 products vs CA 18 products (more use with ORC)
Trust score:3/5

postoperative serum calcium (day 1)

1 evidences

Modified thoracic breast approach thyroidectomy showed similar overall efficacy with fewer adverse effects and had higher serum calcium and PTH levels on postoperative day 1 compared with open surgery; levels equalized by day 5.

Trust comment: Randomized study with a reasonable sample size but limited detail on blinding and numeric reporting of calcium/PTH changes reduces certainty.

Study Details

PMID:37023317
Participants:100
Impact:decreased from preoperative levels in both groups; higher in the modified approach group vs control on day 1
Trust score:3/5

postoperative serum calcium (day 5)

1 evidences

Modified thoracic breast approach thyroidectomy showed similar overall efficacy with fewer adverse effects and had higher serum calcium and PTH levels on postoperative day 1 compared with open surgery; levels equalized by day 5.

Trust comment: Randomized study with a reasonable sample size but limited detail on blinding and numeric reporting of calcium/PTH changes reduces certainty.

Study Details

PMID:37023317
Participants:100
Impact:no difference between groups (returned toward baseline)
Trust score:3/5

TDI (olfactory) score

1 evidences

Topical intranasal DTPA significantly reduced nasal mucus calcium and improved smell scores in patients with post-COVID-19 anosmia.

Trust comment: Randomized, blinded trial with objective olfactory testing and biochemical measures, moderate sample size supports reliability.

Study Details

PMID:37018923
Participants:66
Impact:+8.64 points (11.75 → 20.39; clinically significant >6)
Trust score:4/5

clinical recovery rate

1 evidences

Topical intranasal DTPA significantly reduced nasal mucus calcium and improved smell scores in patients with post-COVID-19 anosmia.

Trust comment: Randomized, blinded trial with objective olfactory testing and biochemical measures, moderate sample size supports reliability.

Study Details

PMID:37018923
Participants:66
Impact:84% improved from anosmia to hyposmia in DTPA group (27/32; reported 84.38%)
Trust score:4/5

25-hydroxyvitamin D

6 evidences

Randomized double-blind trial in 150 postmenopausal women testing placebo, calcium+vitamin D, and calcium+vitamin D+genistein for 12 weeks; vitamin D rose in all groups and adding genistein produced no additional changes in vitamin D, calcium metabolism, or bone remodeling markers.

Trust comment: Well-conducted double-blind RCT (n=150) measuring relevant biomarkers, although seasonal increases in vitamin D limit attribution to supplementation.

Study Details

PMID:36919425
Participants:150
Impact:+~6 ng/mL (increase across groups)
Trust score:4/5

Daily vitamin D3 plus calcium reduced the amount of bone loss over 48 weeks after starting antiretroviral therapy compared with placebo.

Trust comment: Randomized, double-blind, placebo-controlled multicenter trial with adequate sample size and clear clinically relevant outcomes.

Study Details

PMID:26075752
Participants:165
Impact:median +61.2 nmol/L (vit D3+Ca) vs +1.7 nmol/L (placebo) at 48 weeks (P < 0.001)
Trust score:5/5

Small randomized study in postmenopausal women showing 12 weeks of moderate aerobic exercise increased PTH and vitamin D and altered ECG P-R interval; calcium changes not reported as significant.

Trust comment: Small randomized study with objective measures but limited sample size and reporting; no calcium supplementation tested.

Study Details

PMID:32208176
Participants:31
Impact:increase (P = 0.001 after 12 weeks; remained higher after detraining P = 0.014)
Trust score:3/5

Extended-release calcifediol normalized 25-hydroxyvitamin D and progressively reduced PTH with minimal effect on serum calcium in CKD patients.

Trust comment: Large multicenter randomized double-blind placebo-controlled trials with high completion rates; high-quality evidence for CKD population.

Study Details

PMID:27676085
Participants:429
Impact:normalized to >30 ng/mL in >95% of per-protocol subjects
Trust score:5/5

Structured sunlight exposure increased 25(OH)D levels and led to increases in calcium and albumin in elderly nursing-home residents.

Trust comment: Randomized experimental design but small sample (n=40) and short intervention (4 weeks); objective lab measures reported.

Study Details

PMID:33888407
Participants:40
Impact:increase of 8.06 ng/ml (intervention) vs 0.96 ng/ml (control); P = 0.008
Trust score:3/5

Weekly ergocalciferol in hemodialysis patients increased 25-hydroxyvitamin D levels without changing serum calcium or parathyroid hormone.

Trust comment: Small randomized trial with 35 completers showing clear vitamin D rises but no changes in calcium or PTH; sample size modest and short duration.

Study Details

PMID:30595565
Participants:35
Impact:increased from 12.00±4.90 to 29.89±9.48 ng/mL in intervention (significant); 42.1% normalized vs 0% in placebo (P=0.004)
Trust score:3/5

bone resorption marker (CTX)

4 evidences

Randomized double-blind trial in 150 postmenopausal women testing placebo, calcium+vitamin D, and calcium+vitamin D+genistein for 12 weeks; vitamin D rose in all groups and adding genistein produced no additional changes in vitamin D, calcium metabolism, or bone remodeling markers.

Trust comment: Well-conducted double-blind RCT (n=150) measuring relevant biomarkers, although seasonal increases in vitamin D limit attribution to supplementation.

Study Details

PMID:36919425
Participants:150
Impact:No additional change with genistein added to calcium+vitamin D
Trust score:4/5

Longitudinal study of 467 pregnant Gambian women showing small increases in peripheral bone density and marked biochemical changes between early second and third trimesters despite low habitual calcium intake.

Trust comment: Large longitudinal human cohort with objective pQCT and biochemical endpoints; well-powered and directly relevant to calcium economy in pregnancy.

Study Details

PMID:33784438
Participants:467
Impact:+23.0% (95% CI 15.09, 29.29)
Trust score:4/5

12-week randomized dietary supplement trial in adults with abdominal obesity; whey protein increased urinary calcium but did not change bone turnover markers or BMD.

Trust comment: Randomized controlled trial with objective biochemical measures but a post-hoc analysis and limited sample size for bone endpoints, reducing power for those outcomes.

Study Details

PMID:35422766
Participants:64
Impact:No change (adjusted change ≈0 μg/L; protein p≈0.23)
Trust score:4/5

Prospective randomized study in postmenopausal women given calcium + vitamin D with or without genistein; vitamin D increases associated with reductions in bone turnover markers, and genistein added no consistent additional benefit.

Trust comment: Randomized supplementation study with pharmacogenomic subanalysis; moderate sample size and clear null effect of genistein adjunct.

Study Details

PMID:29151102
Participants:102
Impact:CTX decreased in association with vitamin D increase (magnitude not reported)
Trust score:4/5

handgrip strength

2 evidences

Two-by-two factorial RCT in vitamin D–deficient young males testing cholecalciferol and/or elemental calcium supplementation vs placebo on handgrip strength and serum testosterone over 6 months (228 randomized, 180 completed).

Trust comment: Randomized, placebo-controlled factorial trial with 180 completers and objective muscle/testosterone measures; well-conducted and directly tests calcium (with vitamin D) supplementation effects.

Study Details

PMID:29095521
Participants:180
Impact:No significant difference between groups (post-intervention means ≈29–31 kg; P=0.28)
Trust score:4/5

Randomized controlled trial (3 groups, n=15 each) in oncology surgery patients comparing conventional care, calcium caseinate supplementation, and whey protein isolate (WPI) perioperatively; WPI group maintained handgrip strength and showed favorable body-composition changes.

Trust comment: Small randomized clinical trial (n=45) with clear endpoints but limited sample size and reporting details; calcium caseinate arm effects not clearly reported in abstract.

Study Details

PMID:36880717
Participants:45
Impact:Maintained with whey protein isolate (vs decline in control)
Trust score:3/5

Extracellular water

1 evidences

Randomized controlled trial (3 groups, n=15 each) in oncology surgery patients comparing conventional care, calcium caseinate supplementation, and whey protein isolate (WPI) perioperatively; WPI group maintained handgrip strength and showed favorable body-composition changes.

Trust comment: Small randomized clinical trial (n=45) with clear endpoints but limited sample size and reporting details; calcium caseinate arm effects not clearly reported in abstract.

Study Details

PMID:36880717
Participants:45
Impact:Decreased with whey protein isolate (p<0.02)
Trust score:3/5

Visceral mass

1 evidences

Randomized controlled trial (3 groups, n=15 each) in oncology surgery patients comparing conventional care, calcium caseinate supplementation, and whey protein isolate (WPI) perioperatively; WPI group maintained handgrip strength and showed favorable body-composition changes.

Trust comment: Small randomized clinical trial (n=45) with clear endpoints but limited sample size and reporting details; calcium caseinate arm effects not clearly reported in abstract.

Study Details

PMID:36880717
Participants:45
Impact:Increased with whey protein isolate (p<0.02)
Trust score:3/5

Plasma calcium

2 evidences

Extended-release niacin slightly lowered serum phosphate over 3 years but did not change calcium or other mineral markers.

Trust comment: Large randomized double-blind placebo-controlled trial (n=352) with clear numeric phosphate result; calcium-related markers showed null effects.

Study Details

PMID:29208626
Participants:352
Impact:no significant change over 3 years
Trust score:4/5

One month of lipid‑based micronutrient supplementation improved anthropometry and energy intake but did not change plasma vitamin D or calcium levels.

Trust comment: Randomized controlled trial but small sample (n=38) and short duration (1 month) limit confidence in biochemical endpoints for calcium status.

Study Details

PMID:36414575
Participants:38
Impact:no significant change (p=0.46)
Trust score:3/5

serum 25OHD

2 evidences

Randomized double-blind trial in women >60: yogurt fortified with vitamin D3 (400 IU) and additional calcium increased 25OHD and decreased PTH and bone resorption markers over 12 weeks.

Trust comment: Randomized double-blind trial with good adherence and clear biochemical endpoints, moderate sample size.

Study Details

PMID:25923487
Participants:48
Impact:+22.0 nmol/L (D84-D0) in fortified group vs +6.2 nmol/L in control
Trust score:4/5

Randomized double-blind trial (vitamin D + 500 mg calcium vs placebo) in infertile men: vitamin D+calcium raised vitamin D levels greatly but did not change serum AMH or semen-related AMH outcomes.

Trust comment: Well-conducted randomized double-blind clinical trial with large sample and pre-specified hormonal endpoints; provides direct evidence that adding vitamin D + 500 mg calcium did not change serum AMH.

Study Details

PMID:36855109
Participants:269
Impact:+93% (mean 46 → 89 nmol/L) in vitamin D + calcium group after 150 days
Trust score:4/5

serum AMH

1 evidences

Randomized double-blind trial (vitamin D + 500 mg calcium vs placebo) in infertile men: vitamin D+calcium raised vitamin D levels greatly but did not change serum AMH or semen-related AMH outcomes.

Trust comment: Well-conducted randomized double-blind clinical trial with large sample and pre-specified hormonal endpoints; provides direct evidence that adding vitamin D + 500 mg calcium did not change serum AMH.

Study Details

PMID:36855109
Participants:269
Impact:no significant change and no difference vs placebo (mean ~40 → 43 pmol/L, non-significant)
Trust score:4/5

semen quality (sperm concentration/count)

1 evidences

Randomized double-blind trial (vitamin D + 500 mg calcium vs placebo) in infertile men: vitamin D+calcium raised vitamin D levels greatly but did not change serum AMH or semen-related AMH outcomes.

Trust comment: Well-conducted randomized double-blind clinical trial with large sample and pre-specified hormonal endpoints; provides direct evidence that adding vitamin D + 500 mg calcium did not change serum AMH.

Study Details

PMID:36855109
Participants:269
Impact:low baseline AMH associated with markedly lower sperm concentration and count (observational associations)
Trust score:4/5

Vitamin D dietary intake

1 evidences

Post-hoc analysis of an RCT comparing fasting + plant-based diet vs guideline diet in RA patients; both groups had dietary calcium below recommendations, with the guideline (DGE) group having higher calcium intake than the PBD group.

Trust comment: Randomized parent trial but this is a post-hoc nutritional analysis with modest sample size and self-reported food records, limiting certainty of absolute intake estimates.

Study Details

PMID:36839208
Participants:50
Impact:higher in DGE than PBD at weeks 4 and 9 (e.g., week4: 5.9 vs 1.7 µg/day, p=0.04)
Trust score:3/5

fracture risk associated with low vitamin D

1 evidences

Large pediatric study showing lower vitamin D in children with fractures and that supplementation with vitamin D (2000 IU/day) + calcium (600 mg/day) raised vitamin D levels and was associated with improved callus formation; low vitamin D associated with higher fracture risk.

Trust comment: Large population with statistical analyses and intervention; however study design complex (multiple cohorts) and some outcomes (callus formation) are observational/qualitative, so moderate confidence.

Study Details

PMID:36833994
Participants:1577
Impact:under-normal vitamin D (<30 ng/mL) associated with 2.127× higher chance of fracture (age- and sex-adjusted)
Trust score:3/5

serum 25-OH-vitamin D after supplementation

1 evidences

Large pediatric study showing lower vitamin D in children with fractures and that supplementation with vitamin D (2000 IU/day) + calcium (600 mg/day) raised vitamin D levels and was associated with improved callus formation; low vitamin D associated with higher fracture risk.

Trust comment: Large population with statistical analyses and intervention; however study design complex (multiple cohorts) and some outcomes (callus formation) are observational/qualitative, so moderate confidence.

Study Details

PMID:36833994
Participants:1577
Impact:+53.44% (mean 23.9 → 44.76 ng/mL, p~1.2×10⁻³¹) with 2000 IU/day vitamin D + 600 mg/day calcium over 6 months
Trust score:3/5

serum total calcium after supplementation

1 evidences

Large pediatric study showing lower vitamin D in children with fractures and that supplementation with vitamin D (2000 IU/day) + calcium (600 mg/day) raised vitamin D levels and was associated with improved callus formation; low vitamin D associated with higher fracture risk.

Trust comment: Large population with statistical analyses and intervention; however study design complex (multiple cohorts) and some outcomes (callus formation) are observational/qualitative, so moderate confidence.

Study Details

PMID:36833994
Participants:1577
Impact:no significant change (mean 9.98 → 10.05 mg/dL, p=0.13)
Trust score:3/5

bony callus formation / healing

1 evidences

Large pediatric study showing lower vitamin D in children with fractures and that supplementation with vitamin D (2000 IU/day) + calcium (600 mg/day) raised vitamin D levels and was associated with improved callus formation; low vitamin D associated with higher fracture risk.

Trust comment: Large population with statistical analyses and intervention; however study design complex (multiple cohorts) and some outcomes (callus formation) are observational/qualitative, so moderate confidence.

Study Details

PMID:36833994
Participants:1577
Impact:improved/earlier callus formation observed with supplementation (qualitative)
Trust score:3/5

adverse effects

3 evidences

Local intra-canal calcium hydroxide reduced post‑root‑canal preparation pain but was less effective than triple‑antibiotic paste.

Trust comment: Single‑center randomized single‑blind RCT with 80 patients and appropriate statistical tests; moderate quality though single‑blind and limited to single‑rooted teeth.

Study Details

PMID:36833788
Participants:80
Impact:none reported related to medicaments
Trust score:4/5

Mouthwash containing calcium hydroxide reduced symptoms and signs of oral lichen planus but was less effective than clobetasol; no side effects reported in the mouthwash group.

Trust comment: Randomized controlled trial with validated clinical scales and 38 completers but limited sample size and short follow-up.

Study Details

PMID:33374791
Participants:38
Impact:0% reported adverse effects in mouthwash group
Trust score:4/5

In 97 CKD patients with hyperkalemia, both calcium and sodium polystyrene resins lowered potassium; calcium resin had fewer side effects.

Trust comment: Randomized controlled trial but single-center with modest sample size; moderate overall quality.

Study Details

PMID:25672163
Participants:97
Impact:no major adverse effects; CPS showed fewer side effects than SPS
Trust score:3/5

Clinical attachment level (CAL) gain

1 evidences

Randomized trial comparing enamel matrix derivative (EMD) alone versus EMD plus biphasic calcium phosphate graft; both improved clinical and radiographic measures at 12 months with no significant difference between groups.

Trust comment: Randomized controlled trial with standardized measurements but small sample size limits power to detect between-group differences.

Study Details

PMID:27958765
Participants:52
Impact:EMD/BC: 2.38 ± 2.17 mm (24.9%); EMD: 2.65 ± 2.18 mm (36.2%)
Trust score:4/5

Fasting plasma glucose (FPG)

4 evidences

In NAFLD patients on a weight-loss program, adding calcium to calcitriol produced greater improvements in some metabolic and liver biochemical parameters versus calcitriol alone.

Trust comment: Randomized, double-blind controlled trial (n=120) with clear between-group significance but short duration (12 weeks).

Study Details

PMID:27720403
Participants:120
Impact:significant decrease with calcium+calcitriol vs calcitriol alone (P < 0.001)
Trust score:4/5

Pregnant women at risk for pre-eclampsia received vitamin D3 plus 1000 mg/day calcium for 12 weeks and showed improved glycaemic markers, HDL, and glutathione versus placebo.

Trust comment: Double-blind RCT with clear metabolic outcomes but modest sample size (N=60); reasonable internal validity.

Study Details

PMID:26467311
Participants:60
Impact:mean change -5.7 (5.5) mg/dL vs -0.6 (12.6) mg/dL (P=0.04) but effect lost after adjustment
Trust score:4/5

In 60 women with gestational diabetes, 6 weeks of magnesium-zinc-calcium-vitamin D reduced inflammation and oxidative stress markers and modestly lowered fasting glucose.

Trust comment: Randomized, double-blind, placebo-controlled trial with adequate sample (n=60) but short duration (6 weeks) and multi-nutrient intervention.

Study Details

PMID:30922259
Participants:60
Impact:-4.3 mg/dL change in intervention (vs -0.9 mg/dL placebo), p=0.008
Trust score:4/5

In women with GDM, higher-dose vitamin D plus calcium (1000 IU D + 1000 mg Ca daily) for 6 weeks improved glucose, insulin and lipid measures and increased antioxidant marker compared with lower-dose.

Trust comment: Randomized controlled trial with 70 participants and clear metabolic endpoints, though short duration (6 weeks).

Study Details

PMID:33372392
Participants:70
Impact:Significant reduction (p=0.007) in 1000 IU D + 1000 mg Ca group
Trust score:4/5

LDL‑cholesterol

1 evidences

Double‑blind placebo‑controlled trial in middle‑aged healthy adults: calcium fructoborate for 30 days reduced several lipids and inflammatory markers vs placebo.

Trust comment: Double‑blind, placebo‑controlled randomized trial but small sample (78 completers) limits generalizability despite randomized design.

Study Details

PMID:25433580
Participants:78
Impact:significant decrease with CFB (both 112 mg and 56 mg groups) versus placebo (group differences significant; p<0.01)
Trust score:4/5

pharmacokinetics / bioequivalence

1 evidences

Bioequivalence crossover in healthy volunteers: sodium levofolinate is bioequivalent to calcium levofolinate and sodium folinate; all well tolerated.

Trust comment: Standard single‑center randomized 3‑period crossover in 24 healthy subjects with validated assays; appropriate for bioequivalence assessment.

Study Details

PMID:36808267
Participants:24
Impact:sodium levofolinate bioequivalent to calcium levofolinate and sodium folinate (comparable PK parameters)
Trust score:4/5

total body bone mineral content (TBBMC)

1 evidences

Double‑blind RCT in 9–11‑year‑olds: calcium supplementation (± soluble corn fibre) produced short‑term increases in bone indices at 6 months but no sustained between‑group differences at 12 months.

Trust comment: Large double‑blind randomized parallel‑arm trial with 243 children and DXA endpoints; good quality though some effects were transient and not sustained at 12 months.

Study Details

PMID:36808216
Participants:243
Impact:SCF+Ca: +27.14 g at 6 months and +40.28 g at 12 months vs baseline (significant within‑group), but no significant between‑group differences at 12 months
Trust score:4/5

total body bone mineral density (TBBMD)

1 evidences

Double‑blind RCT in 9–11‑year‑olds: calcium supplementation (± soluble corn fibre) produced short‑term increases in bone indices at 6 months but no sustained between‑group differences at 12 months.

Trust comment: Large double‑blind randomized parallel‑arm trial with 243 children and DXA endpoints; good quality though some effects were transient and not sustained at 12 months.

Study Details

PMID:36808216
Participants:243
Impact:increased at 6 months in SCF+Ca (+0.019 g/cm2) and Ca (+0.014 g/cm2) vs placebo, but not different among groups at 12 months
Trust score:4/5

Mortality

2 evidences

Children with clinical rickets who received vitamin D and calcium showed increased linear growth but remained at higher risk of death and severe pneumonia readmission.

Trust comment: Large prospective cohort (secondary analysis of an RCT) with high follow-up; diagnosis of rickets was clinical (limited specificity) which may bias some findings.

Study Details

PMID:29178404
Participants:1778
Impact:+61% risk (adjusted HR 1.61)
Trust score:4/5

In 100 severe sepsis patients, adding Xuebijing to CVVH was associated with higher post-treatment serum Ca2+ and better clinical outcomes versus CVVH alone.

Trust comment: Prospective case-control (randomized allocation stated) single-center study with modest sample size; outcome reporting lacks detailed numerical calcium values and may have bias risks.

Study Details

PMID:35685671
Participants:100
Impact:Study group 2% vs control 14% (p<0.05)
Trust score:3/5

Colorectal adenoma recurrence (DBP2 carriers)

1 evidences

Secondary analysis of RCT data finds calcium (1200 mg/day) reduced colorectal adenoma recurrence risk among participants with the DBP2 isoform but not among others.

Trust comment: Large randomized clinical trial dataset with preplanned biomarker genotyping but this is a secondary subgroup analysis limited to non-Hispanic White participants.

Study Details

PMID:36701139
Participants:1604
Impact:↓17% (RR 0.83, 95% CI 0.70-0.99) with calcium vs no calcium
Trust score:4/5

colorectal adenoma recurrence (non-DBP2)

1 evidences

Secondary analysis of RCT data finds calcium (1200 mg/day) reduced colorectal adenoma recurrence risk among participants with the DBP2 isoform but not among others.

Trust comment: Large randomized clinical trial dataset with preplanned biomarker genotyping but this is a secondary subgroup analysis limited to non-Hispanic White participants.

Study Details

PMID:36701139
Participants:1604
Impact:no significant change (RR 0.98, 95% CI 0.84-1.14) with calcium
Trust score:4/5

total mortality

1 evidences

Extended-follow-up of WHI randomized trial in Black women found daily calcium (1000 mg as calcium carbonate) plus vitamin D (400 IU) did not reduce total mortality, total cancer incidence, or CVD events compared with placebo.

Trust comment: Large randomized clinical trial subgroup with long follow-up and intent-to-treat analysis; high-quality evidence for the tested regimen in this population.

Study Details

PMID:36650676
Participants:3325
Impact:no significant difference between CaD and placebo
Trust score:5/5

total cancer incidence

1 evidences

Extended-follow-up of WHI randomized trial in Black women found daily calcium (1000 mg as calcium carbonate) plus vitamin D (400 IU) did not reduce total mortality, total cancer incidence, or CVD events compared with placebo.

Trust comment: Large randomized clinical trial subgroup with long follow-up and intent-to-treat analysis; high-quality evidence for the tested regimen in this population.

Study Details

PMID:36650676
Participants:3325
Impact:no significant difference between CaD and placebo
Trust score:5/5

cardiovascular events

2 evidences

Post-hoc analysis of a large hemodialysis RCT: low-dose oral alfacalcidol did not significantly change cardiovascular events or mortality and ALP did not modify effects.

Trust comment: Large randomized trial with blinded event adjudication and long follow-up; this is a post-hoc subgroup analysis which reduces power for interaction testing.

Study Details

PMID:36104443
Participants:959
Impact:No significant effect (overall HR ~1.25 in J-DAVID; p = 0.13) and no significant modification by ALP (P for interaction = 0.54)
Trust score:4/5

Extended-follow-up of WHI randomized trial in Black women found daily calcium (1000 mg as calcium carbonate) plus vitamin D (400 IU) did not reduce total mortality, total cancer incidence, or CVD events compared with placebo.

Trust comment: Large randomized clinical trial subgroup with long follow-up and intent-to-treat analysis; high-quality evidence for the tested regimen in this population.

Study Details

PMID:36650676
Participants:3325
Impact:no significant difference between CaD and placebo
Trust score:5/5

symptomatic hypocalcemia (within 48 h)

1 evidences

Giving calcium + vitamin D before and after thyroid surgery reduced early low-calcium symptoms and low calcium levels compared with starting supplements only after surgery.

Trust comment: Double-blind, randomized, placebo-controlled trial with adequate sample and statistically significant early outcomes.

Study Details

PMID:36799782
Participants:134
Impact:-13.9 percentage points (22.7% → 8.8%)
Trust score:5/5

biochemical hypocalcemia (24 h)

1 evidences

Giving calcium + vitamin D before and after thyroid surgery reduced early low-calcium symptoms and low calcium levels compared with starting supplements only after surgery.

Trust comment: Double-blind, randomized, placebo-controlled trial with adequate sample and statistically significant early outcomes.

Study Details

PMID:36799782
Participants:134
Impact:-19.9 percentage points (25.8% → 5.9%)
Trust score:5/5

corrected serum calcium (24–48 h)

1 evidences

Giving calcium + vitamin D before and after thyroid surgery reduced early low-calcium symptoms and low calcium levels compared with starting supplements only after surgery.

Trust comment: Double-blind, randomized, placebo-controlled trial with adequate sample and statistically significant early outcomes.

Study Details

PMID:36799782
Participants:134
Impact:+0.24 mg/dl at 24 h (8.71 vs 8.47 mg/dl); +0.23 mg/dl at 48 h (8.79 vs 8.56 mg/dl)
Trust score:5/5

Overall KOOS improvement (2-year)

1 evidences

A calcium-carbonate (aragonite) osteochondral implant improved knee function and reduced failures compared with microfracture/debridement.

Trust comment: Multicenter randomized controlled trial (level 1) showing consistent superior clinical outcomes for a calcium-carbonate scaffold.

Study Details

PMID:36779614
Participants:251
Impact:≈2-fold greater mean KOOS improvement vs control at 2 years
Trust score:4/5

Responder rate (≥30-point KOOS gain)

1 evidences

A calcium-carbonate (aragonite) osteochondral implant improved knee function and reduced failures compared with microfracture/debridement.

Trust comment: Multicenter randomized controlled trial (level 1) showing consistent superior clinical outcomes for a calcium-carbonate scaffold.

Study Details

PMID:36779614
Participants:251
Impact:+44.2 percentage points (77.8% vs 33.6%)
Trust score:4/5

Failure rate (need for secondary treatment)

1 evidences

A calcium-carbonate (aragonite) osteochondral implant improved knee function and reduced failures compared with microfracture/debridement.

Trust comment: Multicenter randomized controlled trial (level 1) showing consistent superior clinical outcomes for a calcium-carbonate scaffold.

Study Details

PMID:36779614
Participants:251
Impact:-14.2 percentage points (21.4% → 7.2%)
Trust score:4/5

Back squat 1-RM

1 evidences

Nine weeks of ACC supplementation increased maximal lower-body strength (back squat) compared with placebo; no significant change in bench press.

Trust comment: Small randomized double-blind trial with objective strength outcomes but limited sample size.

Study Details

PMID:36771244
Participants:31
Impact:Significant increase in Δ1-RM vs placebo (exact group delta not provided)
Trust score:3/5

Bench press 1-RM

2 evidences

High-dose caffeine (8 mg/kg) increased maximal strength in bench press, deadlift, and squat and raised plasma Ca2+ compared with placebo or lower dose.

Trust comment: Randomized, double-blind crossover with pre-specified power analysis and appropriate stats; moderate sample (n=21) limits precision but internal validity good.

Study Details

PMID:36432607
Participants:21
Impact:+6.9 kg (101.1 vs 94.2 kg vs placebo; p=0.01)
Trust score:4/5

Nine weeks of ACC supplementation increased maximal lower-body strength (back squat) compared with placebo; no significant change in bench press.

Trust comment: Small randomized double-blind trial with objective strength outcomes but limited sample size.

Study Details

PMID:36771244
Participants:31
Impact:No significant change vs placebo
Trust score:3/5

endothelial function (FMD)

1 evidences

In this randomized double-blind crossover RCT, calcium-caseinate (calcium-containing protein) did not reduce ambulatory blood pressure but did modestly improve endothelial function and lowered total cholesterol compared with control.

Trust comment: Well-designed randomized, double-blind, 3-way crossover RCT with objective ambulatory BP and vascular measures but modest sample size (38 completers) for subgroup comparisons.

Study Details

PMID:27797709
Participants:38
Impact:+0.11 percentage points (Δ) increased vs control
Trust score:4/5

albumin

1 evidences

Oral cancer patients randomized to professional nutritional support (including individualized micronutrient supplements such as calcium tablets when indicated) lost less weight and had more stable lab values including calcium compared with standard care.

Trust comment: Randomized trial with clear clinical endpoints but small sample (n=46), some measures only in intervention group, and potential allocation bias by weekday.

Study Details

PMID:35987809
Participants:46
Impact:more stable albumin values at before-discharge (T2; significant)
Trust score:3/5

circuit lifespan

1 evidences

In CRRT with regional citrate anticoagulation, using a calcium-containing replacement solution gave similar filter lifespan and clinical outcomes but greatly reduced continuous calcium infusion needs.

Trust comment: Single-center randomized trial with objective clinical and lab endpoints and clear randomization, but moderate sample size and single-center limits generalizability.

Study Details

PMID:36583864
Participants:64
Impact:no difference (mean 58.1 h vs 55.3 h; P=0.89)
Trust score:4/5

calcium infusion requirement

1 evidences

In CRRT with regional citrate anticoagulation, using a calcium-containing replacement solution gave similar filter lifespan and clinical outcomes but greatly reduced continuous calcium infusion needs.

Trust comment: Single-center randomized trial with objective clinical and lab endpoints and clear randomization, but moderate sample size and single-center limits generalizability.

Study Details

PMID:36583864
Participants:64
Impact:marked reduction (mean 1.47 mL/h vs 20.16 mL/h; P<0.01)
Trust score:4/5

systemic ionized calcium (iCa)

1 evidences

In CRRT with regional citrate anticoagulation, using a calcium-containing replacement solution gave similar filter lifespan and clinical outcomes but greatly reduced continuous calcium infusion needs.

Trust comment: Single-center randomized trial with objective clinical and lab endpoints and clear randomization, but moderate sample size and single-center limits generalizability.

Study Details

PMID:36583864
Participants:64
Impact:modestly lower early and at 72 h (post-72h iCa 0.93 vs 1.00 mmol/L; P=0.002); total Ca similar at 72 h (2.06 vs 2.15 mmol/L; P=0.37)
Trust score:4/5

disposition index (β-cell function)

1 evidences

2x2 factorial RCT (n=243) testing vitamin D (1600 IU/day) ± calcium (500 mg/day) for 24 weeks in prediabetes; vitamin D + calcium improved insulin secretion and β-cell function in vitamin D–insufficient individuals.

Trust comment: Randomized, placebo-controlled factorial trial with substantial sample size; subgroup effect in vitamin D–insufficient individuals warrants replication.

Study Details

PMID:36541437
Participants:243
Impact:adjusted change +0.31 (95% CI 0.07 to 0.56) after vitamin D + calcium in vitamin D–insufficient subgroup
Trust score:4/5

insulin secretion

1 evidences

2x2 factorial RCT (n=243) testing vitamin D (1600 IU/day) ± calcium (500 mg/day) for 24 weeks in prediabetes; vitamin D + calcium improved insulin secretion and β-cell function in vitamin D–insufficient individuals.

Trust comment: Randomized, placebo-controlled factorial trial with substantial sample size; subgroup effect in vitamin D–insufficient individuals warrants replication.

Study Details

PMID:36541437
Participants:243
Impact:increased (statistically significant improvement with vitamin D + calcium vs control)
Trust score:4/5

children dairy intake

1 evidences

Eight-week family web-based program (Family Nutriathlon) increased short-term dairy intake in children and parents but did not change fruit/vegetable intake or BMI vs general nutrition guidance.

Trust comment: Randomized family-clustered trial with objective dietary records but small sample, short follow-up, and self-reported dietary measures limiting strength of inference.

Study Details

PMID:36539753
Participants:43
Impact:+0.73 servings/day at POST1 vs control (estimate 0.73; 95% CI 0.25–1.22; P=0.0004)
Trust score:3/5

children calcium intake

1 evidences

Eight-week family web-based program (Family Nutriathlon) increased short-term dairy intake in children and parents but did not change fruit/vegetable intake or BMI vs general nutrition guidance.

Trust comment: Randomized family-clustered trial with objective dietary records but small sample, short follow-up, and self-reported dietary measures limiting strength of inference.

Study Details

PMID:36539753
Participants:43
Impact:group×time change significant (P=0.02); POST1 difference vs control +272 mg/day (P=0.02)
Trust score:3/5

parents dairy intake

1 evidences

Eight-week family web-based program (Family Nutriathlon) increased short-term dairy intake in children and parents but did not change fruit/vegetable intake or BMI vs general nutrition guidance.

Trust comment: Randomized family-clustered trial with objective dietary records but small sample, short follow-up, and self-reported dietary measures limiting strength of inference.

Study Details

PMID:36539753
Participants:43
Impact:+0.60 servings/day at POST1 vs control (estimate 0.60; 95% CI 0.05–1.12; P=0.03)
Trust score:3/5

predictors of post-op hypocalcemia

1 evidences

Retrospective study (n=238) developing a nomogram predicting post-parathyroidectomy hypocalcemia using preoperative PTH, serum Ca, and ALP; internally validated with high AUC.

Trust comment: Relatively large retrospective single-center cohort with internal train/test validation and good discrimination, but retrospective design and limited external validation reduce certainty.

Study Details

PMID:36531501
Participants:238
Impact:high PTH, low pre-op Ca, and high ALP identified as independent predictors (multivariate ORs significant)
Trust score:4/5

predictive model performance (AUC)

1 evidences

Retrospective study (n=238) developing a nomogram predicting post-parathyroidectomy hypocalcemia using preoperative PTH, serum Ca, and ALP; internally validated with high AUC.

Trust comment: Relatively large retrospective single-center cohort with internal train/test validation and good discrimination, but retrospective design and limited external validation reduce certainty.

Study Details

PMID:36531501
Participants:238
Impact:AUC 0.903 (training) and 0.948 (test) for the combined model
Trust score:4/5

fibroglandular breast tissue volume (FGBT)

1 evidences

Two-year RCT in premenopausal women found soy isoflavones reduced fibroglandular breast tissue and percent density; serum calcium modified some treatment effects.

Trust comment: High-quality 2-year double-blind RCT with MRI outcomes; calcium appears as a secondary/modifier variable rather than primary intervention.

Study Details

PMID:36513449
Participants:194
Impact:decrease estimated: −5.3 cc (1.2y), −12.1 cc (2.2y), −19.3 cc (3.3y) vs placebo
Trust score:4/5

fibroglandular breast tissue percent (FGBT%)

1 evidences

Two-year RCT in premenopausal women found soy isoflavones reduced fibroglandular breast tissue and percent density; serum calcium modified some treatment effects.

Trust comment: High-quality 2-year double-blind RCT with MRI outcomes; calcium appears as a secondary/modifier variable rather than primary intervention.

Study Details

PMID:36513449
Participants:194
Impact:decrease estimated: −1.37% (1.2y), −2.43% (2.2y), −3.50% (3.3y) vs placebo
Trust score:4/5

interaction with serum calcium

1 evidences

Two-year RCT in premenopausal women found soy isoflavones reduced fibroglandular breast tissue and percent density; serum calcium modified some treatment effects.

Trust comment: High-quality 2-year double-blind RCT with MRI outcomes; calcium appears as a secondary/modifier variable rather than primary intervention.

Study Details

PMID:36513449
Participants:194
Impact:treatment × calcium β = −2.705 for FBT and β = 0.588 for FGBT% (significant before BMI adjustment)
Trust score:4/5

pulp vitality

1 evidences

RCT comparing MTA versus calcium hydroxide for pulp capping in deep caries (100 teeth in 73 patients) found no significant difference in pulp vitality through 24 months; both materials clinically acceptable.

Trust comment: Randomized clinical trial with high recall and 24-month follow-up; direct comparison of a calcium-containing material (Ca(OH)2) vs MTA supports clinical conclusions.

Study Details

PMID:28581920
Participants:73
Impact:no significant difference at 6, 12, 24 months
Trust score:4/5

relative supersaturation of calcium oxalate

1 evidences

Randomized trial in overweight women showed both weight-loss diets increased urine volume and reduced relative supersaturation of calcium oxalate over 12 weeks.

Trust comment: Randomized controlled trial with 24 h urine measurements; directly reports effects on calcium oxalate stone risk factors though not a calcium-supplement trial.

Study Details

PMID:36501084
Participants:78
Impact:decreased significantly in both intervention groups (12 weeks)
Trust score:4/5

urine volume

2 evidences

Randomized trial in overweight women showed both weight-loss diets increased urine volume and reduced relative supersaturation of calcium oxalate over 12 weeks.

Trust comment: Randomized controlled trial with 24 h urine measurements; directly reports effects on calcium oxalate stone risk factors though not a calcium-supplement trial.

Study Details

PMID:36501084
Participants:78
Impact:increased significantly in both groups (12 weeks)
Trust score:4/5

In calcium stone formers, one week of tolvaptan increased urine volume, lowered urine osmolality and reduced urinary supersaturation of calcium-containing stones.

Trust comment: Randomized, double‑blind, placebo‑controlled crossover design but small sample size; outcomes measured directly and clearly reported for one-week treatment.

Study Details

PMID:26598423
Participants:21
Impact:Increased urine volume on tolvaptan (no exact volume reported)
Trust score:4/5

lesion area reduction

1 evidences

Randomized trial on post-orthodontic white spot lesions found BiominF (bioactive glass) produced greater lesion area reduction than Novamin and CPP-ACP (a calcium phosphate product).

Trust comment: Double-blind randomized controlled trial (small sample) comparing remineralizing agents including a calcium phosphate control (CPP-ACP); shows stronger effect for BiominF.

Study Details

PMID:36494113
Participants:60
Impact:Bio-BAG −64.8% vs N-BAG −32.2% and CPP-ACP −31.6% (T4, 6 months); Bio-BAG > control, p<0.001
Trust score:4/5

DIAGNOdent fluorescence

1 evidences

Randomized trial on post-orthodontic white spot lesions found BiominF (bioactive glass) produced greater lesion area reduction than Novamin and CPP-ACP (a calcium phosphate product).

Trust comment: Double-blind randomized controlled trial (small sample) comparing remineralizing agents including a calcium phosphate control (CPP-ACP); shows stronger effect for BiominF.

Study Details

PMID:36494113
Participants:60
Impact:reduced from 16.57 to 3.62 (Bio-BAG) indicating remineralization
Trust score:4/5

new bone formation

1 evidences

Adding platelet-rich products to beta-tricalcium phosphate graft did not increase new bone formation after sinus-floor augmentation.

Trust comment: Randomized clinical trial with objective histomorphometric outcomes but small sample (n=26) limiting power.

Study Details

PMID:28745027
Participants:26
Impact:no significant difference (control 33.40±10.43% vs P-PRP 34.83±10.12% vs PRF 32.03±6.34%; P>0.05)
Trust score:3/5

implant stability

1 evidences

Randomized trial in 45 patients (180 implants) comparing sinus floor elevation with different graft materials or no graft, assessing implant stability, success, and endo-sinus bone volume over 2 years.

Trust comment: Well-conducted randomized clinical study on calcium-containing graft materials but not a dietary calcium intervention; moderate relevance and quality.

Study Details

PMID:26315564
Participants:45
Impact:No significant difference between groups (p = 0.658)
Trust score:3/5

pulp vitality (SRSD + CS vs SRSD − CS)

1 evidences

Randomized clinical trial comparing SRSD vs SRFD for deep caries; use of calcium silicate-based material (CS) did not alter overall SRSD treatment success, and SRSD preserved pulp vitality better than SRFD at 2 years.

Trust comment: Randomized clinical trial with 2-year follow-up and blinded outcome assessment; some loss to follow-up and single-operator execution but overall robust design.

Study Details

PMID:36460919
Participants:134
Impact:100% vs 93.5% success at 2 years (absolute +6.5 percentage points)
Trust score:4/5

pulp exposure rate (SRSD vs SRFD)

1 evidences

Randomized clinical trial comparing SRSD vs SRFD for deep caries; use of calcium silicate-based material (CS) did not alter overall SRSD treatment success, and SRSD preserved pulp vitality better than SRFD at 2 years.

Trust comment: Randomized clinical trial with 2-year follow-up and blinded outcome assessment; some loss to follow-up and single-operator execution but overall robust design.

Study Details

PMID:36460919
Participants:134
Impact:10.9% vs 28.1% (SRSD lower by 17.2 percentage points)
Trust score:4/5

tertiary dentin formation (SRSD + CS vs SRSD − CS)

1 evidences

Randomized clinical trial comparing SRSD vs SRFD for deep caries; use of calcium silicate-based material (CS) did not alter overall SRSD treatment success, and SRSD preserved pulp vitality better than SRFD at 2 years.

Trust comment: Randomized clinical trial with 2-year follow-up and blinded outcome assessment; some loss to follow-up and single-operator execution but overall robust design.

Study Details

PMID:36460919
Participants:134
Impact:77.1% vs 22.6% at 2 years (absolute +54.5 percentage points)
Trust score:4/5

serum calcium at 48 h

1 evidences

Randomized trial of preoperative calcitriol (0.25 µg/day for 1 week) in parathyroidectomy patients; calcitriol increased post-op calcium at 48 h and reduced symptomatic hypocalcemia and hospital stay.

Trust comment: Randomized controlled trial with clear biochemical and clinical endpoints but modest sample size limits generalizability.

Study Details

PMID:36459369
Participants:80
Impact:8.57 vs 8.33 (absolute +0.24 at 48 h; statistically significant)
Trust score:4/5

symptomatic hypocalcemia rate

2 evidences

Randomized trial of preoperative calcitriol (0.25 µg/day for 1 week) in parathyroidectomy patients; calcitriol increased post-op calcium at 48 h and reduced symptomatic hypocalcemia and hospital stay.

Trust comment: Randomized controlled trial with clear biochemical and clinical endpoints but modest sample size limits generalizability.

Study Details

PMID:36459369
Participants:80
Impact:reduced (statistically significant; exact rates not provided in text)
Trust score:4/5

A single preoperative dose of dexamethasone reduced rates of postoperative hypocalcemia and voice dysfunction after total thyroidectomy.

Trust comment: Randomized, double-blind clinical trial with 192 patients showing clinically relevant reductions in hypocalcemia and voice dysfunction, but intervention is steroidal (not calcium supplementation).

Study Details

PMID:34473215
Participants:192
Impact:reduction 19% (95% CI 11.1%–27.7%)
Trust score:4/5

Hospital length of stay

1 evidences

Randomized trial of preoperative calcitriol (0.25 µg/day for 1 week) in parathyroidectomy patients; calcitriol increased post-op calcium at 48 h and reduced symptomatic hypocalcemia and hospital stay.

Trust comment: Randomized controlled trial with clear biochemical and clinical endpoints but modest sample size limits generalizability.

Study Details

PMID:36459369
Participants:80
Impact:shorter in intervention group (statistically significant)
Trust score:4/5

coronal discoloration (ΔE > 3.7) at 12 months

1 evidences

Randomized trial comparing three calcium silicate-based cements for pulpotomy; all caused measurable tooth discoloration, with MTA producing the highest rate of discoloration at 6 and 12 months.

Trust comment: Randomized clinical trial with objective spectrophotometric measurement; moderate sample and some exclusions but clinically relevant outcomes.

Study Details

PMID:36445467
Participants:95
Impact:MTA 87.5%; Biodentine 48%; TotalFill 53%
Trust score:4/5

buccal wall thickness effect on discoloration

1 evidences

Randomized trial comparing three calcium silicate-based cements for pulpotomy; all caused measurable tooth discoloration, with MTA producing the highest rate of discoloration at 6 and 12 months.

Trust comment: Randomized clinical trial with objective spectrophotometric measurement; moderate sample and some exclusions but clinically relevant outcomes.

Study Details

PMID:36445467
Participants:95
Impact:significant influence (p = 0.004)
Trust score:4/5

HOMA-IR

1 evidences

8-week randomized trial in vitamin D–deficient overweight/obese women with PCOS tested calcium, vitamin D, both, or placebo; co-supplementation improved some insulin and triglyceride measures.

Trust comment: Randomized double-blind placebo-controlled RCT with clear reported outcomes and adequate sample size per arm (n=26 groups), supporting moderate–high trust.

Study Details

PMID:25300649
Participants:104
Impact:decreased (P=0.04)
Trust score:4/5

deadlift 1-RM

1 evidences

High-dose caffeine (8 mg/kg) increased maximal strength in bench press, deadlift, and squat and raised plasma Ca2+ compared with placebo or lower dose.

Trust comment: Randomized, double-blind crossover with pre-specified power analysis and appropriate stats; moderate sample (n=21) limits precision but internal validity good.

Study Details

PMID:36432607
Participants:21
Impact:+12.1 kg (132.8 vs 120.7 kg vs placebo; p=0.03)
Trust score:4/5

squat 1-RM

1 evidences

High-dose caffeine (8 mg/kg) increased maximal strength in bench press, deadlift, and squat and raised plasma Ca2+ compared with placebo or lower dose.

Trust comment: Randomized, double-blind crossover with pre-specified power analysis and appropriate stats; moderate sample (n=21) limits precision but internal validity good.

Study Details

PMID:36432607
Participants:21
Impact:+10.7 kg (130.1 vs 119.4 kg vs placebo; p=0.01)
Trust score:4/5

plasma calcium (Ca2+) concentration

1 evidences

High-dose caffeine (8 mg/kg) increased maximal strength in bench press, deadlift, and squat and raised plasma Ca2+ compared with placebo or lower dose.

Trust comment: Randomized, double-blind crossover with pre-specified power analysis and appropriate stats; moderate sample (n=21) limits precision but internal validity good.

Study Details

PMID:36432607
Participants:21
Impact:+1.9 mg/dL (8.5 → 10.4 mg/dL; ≈+22%; p=0.001)
Trust score:4/5

rating of perceived exertion (RPE)

1 evidences

High-dose caffeine (8 mg/kg) increased maximal strength in bench press, deadlift, and squat and raised plasma Ca2+ compared with placebo or lower dose.

Trust comment: Randomized, double-blind crossover with pre-specified power analysis and appropriate stats; moderate sample (n=21) limits precision but internal validity good.

Study Details

PMID:36432607
Participants:21
Impact:increased (CF8 > placebo; 7.37 vs 4.87; p=0.04)
Trust score:4/5

risk of tooth sensitivity

1 evidences

Topical experimental gel containing calcium gluconate (plus other agents) applied before bleaching did not reduce risk or intensity of tooth sensitivity and did not affect whitening.

Trust comment: Randomized split‑mouth, double‑blind (operator not blinded) trial with adequate sample size for planned effect; direct calcium-containing topical intervention assessed.

Study Details

PMID:36418502
Participants:50
Impact:no reduction (odds ratio 0.65; 95% CI 0.10–4.09; p=1.0)
Trust score:4/5

tooth sensitivity intensity (VAS)

1 evidences

Topical experimental gel containing calcium gluconate (plus other agents) applied before bleaching did not reduce risk or intensity of tooth sensitivity and did not affect whitening.

Trust comment: Randomized split‑mouth, double‑blind (operator not blinded) trial with adequate sample size for planned effect; direct calcium-containing topical intervention assessed.

Study Details

PMID:36418502
Participants:50
Impact:no significant change (mean difference −0.34 VAS; 95% CI −1.0 to 0.3; p=0.31)
Trust score:4/5

tooth color change

2 evidences

Adding calcium to bleaching gel reduced transient tooth sensitivity; bleaching remained effective.

Trust comment: Randomized controlled clinical trial in adolescents (n=53); calcium-containing product associated with reduced sensitivity though magnitude not quantified.

Study Details

PMID:29211128
Participants:53
Impact:significant improvement after bleaching (no negative effect of calcium on efficacy)
Trust score:4/5

Topical experimental gel containing calcium gluconate (plus other agents) applied before bleaching did not reduce risk or intensity of tooth sensitivity and did not affect whitening.

Trust comment: Randomized split‑mouth, double‑blind (operator not blinded) trial with adequate sample size for planned effect; direct calcium-containing topical intervention assessed.

Study Details

PMID:36418502
Participants:50
Impact:no difference between experimental and placebo (ΔSGU ≈5.3 vs 5.2; p>0.32)
Trust score:4/5

plasma vitamin D

1 evidences

One month of lipid‑based micronutrient supplementation improved anthropometry and energy intake but did not change plasma vitamin D or calcium levels.

Trust comment: Randomized controlled trial but small sample (n=38) and short duration (1 month) limit confidence in biochemical endpoints for calcium status.

Study Details

PMID:36414575
Participants:38
Impact:no significant change (p=0.44)
Trust score:3/5

weight / MUAC / height / BMI-Z / energy intake

1 evidences

One month of lipid‑based micronutrient supplementation improved anthropometry and energy intake but did not change plasma vitamin D or calcium levels.

Trust comment: Randomized controlled trial but small sample (n=38) and short duration (1 month) limit confidence in biochemical endpoints for calcium status.

Study Details

PMID:36414575
Participants:38
Impact:significant increases in LNS vs placebo (weight, MUAC, height, BMI‑Z and energy intake; p≤0.005 to <0.001)
Trust score:3/5

return of spontaneous circulation (ROSC)

1 evidences

Pre-planned sub-study of a randomized trial in OHCA patients with PEA: intravenous calcium chloride (5 mmol) given during resuscitation was associated with lower rates of ROSC and lower 30‑day survival compared with placebo, suggesting possible harm.

Trust comment: Direct randomized comparison of calcium vs placebo but small subgroup sample with wide CIs; findings suggest harm but are imprecise.

Study Details

PMID:36403820
Participants:104
Impact:20% (calcium) vs 39% (placebo); −19 percentage points; RR 0.51 (95% CI 0.26–1.00)
Trust score:3/5

30‑day survival

2 evidences

Pre-planned sub-study of a randomized trial in OHCA patients with PEA: intravenous calcium chloride (5 mmol) given during resuscitation was associated with lower rates of ROSC and lower 30‑day survival compared with placebo, suggesting possible harm.

Trust comment: Direct randomized comparison of calcium vs placebo but small subgroup sample with wide CIs; findings suggest harm but are imprecise.

Study Details

PMID:36403820
Participants:104
Impact:2.2% (calcium) vs 13.6% (placebo); −11.4 percentage points; RR 0.16 (95% CI 0.02–1.26)
Trust score:3/5

In adults with out‑of‑hospital cardiac arrest, IV/IO calcium did not improve sustained return of spontaneous circulation and outcomes were numerically worse versus saline.

Trust comment: Double‑blind, placebo‑controlled RCT stopped early for potential harm; robust design and complete follow‑up increase confidence in results.

Study Details

PMID:34847226
Participants:391
Impact:-3.9% (calcium 5.2% vs saline 9.1%)
Trust score:5/5

neutrophil-to-lymphocyte ratio (NLR)

1 evidences

In hospitalized diabetic foot patients, lower blood calcium and albumin and higher neutrophil-to-lymphocyte ratio were associated with worse 6-month outcomes (minor/major amputation or death).

Trust comment: Single-center retrospective analysis of hospitalized patients with clear biomarker measurements and ROC/correlation analyses but possible selection bias and limited generalizability.

Study Details

PMID:36366862
Participants:156
Impact:+20.426 absolute (3.227 → 23.653 from healing to death; ≈+633% vs healing)
Trust score:3/5

hypercalciuria incidence

1 evidences

Personalized vitamin D3 loading followed by 2000 IU/day raised 25(OH)D to sufficiency in CRC patients; no cases of hypervitaminosis D or hypercalcemia occurred, though transient hypercalciuria was observed in some patients after loading dose.

Trust comment: Randomized, double-blind, placebo-controlled interim analysis with clear biochemical endpoints and safety monitoring; sample size for safety endpoints limited by interim nature.

Study Details

PMID:36364809
Participants:74
Impact:6 cases observed after loading dose (more frequent in vitamin D group; difference not statistically significant)
Trust score:4/5

Hyperkalemia incidence

1 evidences

Retrospective single-center study of 401 hemodialysis patients developing a nomogram for hyperkalemia risk; lower serum calcium was independently associated with higher hyperkalemia risk.

Trust comment: Single-center retrospective cohort (n=401) with appropriate modelling; observational design limits causal inference.

Study Details

PMID:36319967
Participants:401
Impact:39.65% overall
Trust score:3/5

Serum calcium — association with hyperkalemia

1 evidences

Retrospective single-center study of 401 hemodialysis patients developing a nomogram for hyperkalemia risk; lower serum calcium was independently associated with higher hyperkalemia risk.

Trust comment: Single-center retrospective cohort (n=401) with appropriate modelling; observational design limits causal inference.

Study Details

PMID:36319967
Participants:401
Impact:Multivariable OR 0.374 (95% CI 0.164–0.852); higher serum calcium associated with lower odds of hyperkalemia
Trust score:3/5

parathyroid hormone (PTH) reduction

1 evidences

Prospective cohort comparing etelcalcetide-treated hemodialysis patients (n=71) to historical controls (n=132); etelcalcetide substantially lowered PTH and improved calcium/phosphate control and clinical outcomes (fewer fractures, parathyroidectomies, lower CV mortality proportion).

Trust comment: Prospective cohort with a historical comparison (n=203); large PTH effects but non-randomized design and potential confounding limit causal claims.

Study Details

PMID:36283011
Participants:203
Impact:30% PTH reduction at 3 months in 54.9% (main) vs 9.1% (historical) (p<0.0001); target PTH at end: 73.2% vs 10.6% (p<0.0001)
Trust score:3/5

serum calcium and phosphorus

1 evidences

Prospective cohort comparing etelcalcetide-treated hemodialysis patients (n=71) to historical controls (n=132); etelcalcetide substantially lowered PTH and improved calcium/phosphate control and clinical outcomes (fewer fractures, parathyroidectomies, lower CV mortality proportion).

Trust comment: Prospective cohort with a historical comparison (n=203); large PTH effects but non-randomized design and potential confounding limit causal claims.

Study Details

PMID:36283011
Participants:203
Impact:Decreased in etelcalcetide group (magnitude not specified)
Trust score:3/5

Clinical outcomes (fractures, parathyroidectomy, CV events)

1 evidences

Prospective cohort comparing etelcalcetide-treated hemodialysis patients (n=71) to historical controls (n=132); etelcalcetide substantially lowered PTH and improved calcium/phosphate control and clinical outcomes (fewer fractures, parathyroidectomies, lower CV mortality proportion).

Trust comment: Prospective cohort with a historical comparison (n=203); large PTH effects but non-randomized design and potential confounding limit causal claims.

Study Details

PMID:36283011
Participants:203
Impact:Fewer fractures, fewer parathyroidectomies, and lower proportion of CV deaths in treated group versus historical controls (fractures ~3× higher in historical group)
Trust score:3/5

Quality of life (EQ-5D Index)

1 evidences

Single-center, single-blind RCT of Montage calcium phosphate bone putty vs wire cerclage alone after sternotomy (n=33 vs n=27): enhanced closure improved early physical recovery, quality of life, reduced incisional pain, improved respiratory recovery and shortened hospital stay.

Trust comment: Small single-center randomized trial (n=60) of a calcium phosphate device showing functional and patient-reported benefits; limited sample and single-center setting.

Study Details

PMID:36272766
Participants:60
Impact:Improved with enhanced sternal closure at day 5/discharge, week 2, and week 4 vs control
Trust score:3/5

Incisional pain

1 evidences

Single-center, single-blind RCT of Montage calcium phosphate bone putty vs wire cerclage alone after sternotomy (n=33 vs n=27): enhanced closure improved early physical recovery, quality of life, reduced incisional pain, improved respiratory recovery and shortened hospital stay.

Trust comment: Small single-center randomized trial (n=60) of a calcium phosphate device showing functional and patient-reported benefits; limited sample and single-center setting.

Study Details

PMID:36272766
Participants:60
Impact:Reduced at rest, breathing, sleeping, and walking at day 5/discharge vs control
Trust score:3/5

Respiratory recovery / FVC

1 evidences

Single-center, single-blind RCT of Montage calcium phosphate bone putty vs wire cerclage alone after sternotomy (n=33 vs n=27): enhanced closure improved early physical recovery, quality of life, reduced incisional pain, improved respiratory recovery and shortened hospital stay.

Trust comment: Small single-center randomized trial (n=60) of a calcium phosphate device showing functional and patient-reported benefits; limited sample and single-center setting.

Study Details

PMID:36272766
Participants:60
Impact:Higher proportion recovered to 60% baseline FVC by day 5/discharge; shortened hospital stay
Trust score:3/5

Composite primary endpoint (normocalcemia without active vitamin D/therapeutic calcium)

1 evidences

Phase 3 randomized double-blind multicenter trial (84 randomized; 79 completed) of TransCon PTH vs placebo in chronic hypoparathyroidism: TransCon PTH maintained normocalcemia while enabling independence from active vitamin D and therapeutic calcium and improved patient-reported outcomes and urine calcium.

Trust comment: Multicenter, randomized, double-blind phase 3 trial with prespecified composite clinical endpoints and robust statistical significance.

Study Details

PMID:36271471
Participants:79
Impact:79% (48/61) TransCon PTH vs 5% (1/21) placebo met endpoint at week 26 (p<0.0001)
Trust score:5/5

Elemental calcium dose / pill burden

1 evidences

Phase 3 randomized double-blind multicenter trial (84 randomized; 79 completed) of TransCon PTH vs placebo in chronic hypoparathyroidism: TransCon PTH maintained normocalcemia while enabling independence from active vitamin D and therapeutic calcium and improved patient-reported outcomes and urine calcium.

Trust comment: Multicenter, randomized, double-blind phase 3 trial with prespecified composite clinical endpoints and robust statistical significance.

Study Details

PMID:36271471
Participants:79
Impact:Mean elemental calcium decreased from 1748 mg to 274 mg at week 26; pill burden decreased from 6.7 to 0.5 daily (LS mean difference p<0.0001)
Trust score:5/5

24‑hour urine calcium

1 evidences

Phase 3 randomized double-blind multicenter trial (84 randomized; 79 completed) of TransCon PTH vs placebo in chronic hypoparathyroidism: TransCon PTH maintained normocalcemia while enabling independence from active vitamin D and therapeutic calcium and improved patient-reported outcomes and urine calcium.

Trust comment: Multicenter, randomized, double-blind phase 3 trial with prespecified composite clinical endpoints and robust statistical significance.

Study Details

PMID:36271471
Participants:79
Impact:Mean decreased from 392 mg/24h to 220 mg/24h in TransCon PTH group (p<0.0001); 60.7% vs 28.6% achieved ≤250 mg/24h (p=0.0213)
Trust score:5/5

CVVH calcium excretion (mmol/24h)

1 evidences

Model development/validation and retrospective cohort analysis showing patients on citrate-CVVH often have net negative calcium balance despite normal ionized calcium.

Trust comment: Large single-center cohort with model development and independent validation; retrospective design and single-center limit generalizability but methods and validation are robust.

Study Details

PMID:36342643
Participants:788
Impact:105.8 ± 19.3 mmol/24h (mean) measured/calculated excretion
Trust score:4/5

CVVH calcium balance (administered − excreted)

1 evidences

Model development/validation and retrospective cohort analysis showing patients on citrate-CVVH often have net negative calcium balance despite normal ionized calcium.

Trust comment: Large single-center cohort with model development and independent validation; retrospective design and single-center limit generalizability but methods and validation are robust.

Study Details

PMID:36342643
Participants:788
Impact:−12.0 ± 20.0 mmol/24h (mean negative balance)
Trust score:4/5

cumulative CVVH calcium balance

1 evidences

Model development/validation and retrospective cohort analysis showing patients on citrate-CVVH often have net negative calcium balance despite normal ionized calcium.

Trust comment: Large single-center cohort with model development and independent validation; retrospective design and single-center limit generalizability but methods and validation are robust.

Study Details

PMID:36342643
Participants:788
Impact:−86.3 ± 251.4 mmol (mean cumulative per patient)
Trust score:4/5

effect of higher ionized-Ca target (2021) on balance

1 evidences

Model development/validation and retrospective cohort analysis showing patients on citrate-CVVH often have net negative calcium balance despite normal ionized calcium.

Trust comment: Large single-center cohort with model development and independent validation; retrospective design and single-center limit generalizability but methods and validation are robust.

Study Details

PMID:36342643
Participants:788
Impact:+8.1 ± 22.2 mmol/24h (mean in 2021 after protocol change)
Trust score:4/5

serum 25(OH)D3 concentration

1 evidences

Randomized open study: single 120,000 IU oral vitamin D3 bolus in elderly increased multiple vitamin D metabolites without causing hypercalcemia.

Trust comment: Small randomized open trial with validated LC-MS/MS measurements; short follow-up and open design limit strength but biochemical outcomes are clear.

Study Details

PMID:36336861
Participants:58
Impact:increased (56.6% reached >30 ng/mL; all but one >20 ng/mL after dosing)
Trust score:3/5

vitamin D metabolites (3-epi-25(OH)D3, 1,25(OH)2D3, 24,25(OH)2D3)

1 evidences

Randomized open study: single 120,000 IU oral vitamin D3 bolus in elderly increased multiple vitamin D metabolites without causing hypercalcemia.

Trust comment: Small randomized open trial with validated LC-MS/MS measurements; short follow-up and open design limit strength but biochemical outcomes are clear.

Study Details

PMID:36336861
Participants:58
Impact:increased (significant rises by day 3; 24,25(OH)2D3 highest at day 7)
Trust score:3/5

hypercalcemia incidence

2 evidences

Randomized open study: single 120,000 IU oral vitamin D3 bolus in elderly increased multiple vitamin D metabolites without causing hypercalcemia.

Trust comment: Small randomized open trial with validated LC-MS/MS measurements; short follow-up and open design limit strength but biochemical outcomes are clear.

Study Details

PMID:36336861
Participants:58
Impact:no cases reported
Trust score:3/5

In 373 older adults randomized to 400, 4,000, or 10,000 IU/day vitamin D, higher doses raised urine calcium excretion and caused rare mild transient hypercalcemia, while serum calcium and safety events were otherwise similar.

Trust comment: Large, double‑blind RCT with prespecified secondary analyses measuring calcium outcomes and clinically relevant endpoints.

Study Details

PMID:31746327
Participants:373
Impact:15 participants (4%) overall; by group 400:0%, 4000:3%, 10000:9% (P=0.002); cases mild and transient
Trust score:4/5

bone mineral density

5 evidences

Randomized double-blind trial in postmenopausal women: high-dose vitamin D raised 25(OH)D and slightly increased calcium absorption but produced no changes in BMD, muscle function, or falls.

Trust comment: Randomized, double-blind, placebo-controlled trial (n=230) with objective isotope and DXA measures; single-center but well-powered for primary outcome.

Study Details

PMID:26237520
Participants:230
Impact:no between-arm change
Trust score:4/5

Denosumab reduced bone erosion and increased BMD; patients received calcium ≥600 mg/day and vitamin D and some denosumab regimens showed mild decreases in albumin‑adjusted serum calcium within normal range.

Trust comment: Large randomized double‑blind phase II trial with robust radiographic and biochemical endpoints, though calcium effects were secondary and values stayed within normal limits.

Study Details

PMID:26585988
Participants:340
Impact:Increased BMD at lumbar spine and total hip (statistically significant vs placebo)
Trust score:4/5

Randomized study in lactose-intolerant adults found milk fortified with inulin and vitamin D3 (and milk minerals) increased BMD at 6 weeks in the supplemented group, while other measures (calcium absorption, GI symptoms) showed non-significant changes.

Trust comment: Small randomized trial with short (6-week) follow-up and no significant between-group differences for most measures; limited power.

Study Details

PMID:29903135
Participants:42
Impact:increased in the fortified-milk group (P = 0.013)
Trust score:3/5

Three-month randomized trial testing probiotic adjunct (Probio-M8) plus standard therapy (calcium + calcitriol) vs placebo plus standard therapy in postmenopausal osteoporosis; probiotic co-administration improved biochemical markers of bone metabolism but not BMD at 3 months.

Trust comment: Small randomized adjunct trial with short duration (3 months); biochemical signals consistent but no BMD change and limited sample size/time restrict clinical conclusions.

Study Details

PMID:36334119
Participants:40
Impact:no significant change at 3 months
Trust score:3/5

6-month pilot RCT in osteopenic breast cancer survivors found no added bone or performance benefit from adding home exercise to calcium + vitamin D supplements.

Trust comment: Pilot randomized controlled trial in 43 participants; randomized design but small sample limits power.

Study Details

PMID:25730596
Participants:43
Impact:no significant difference (EX+SUPP vs SUPP)
Trust score:3/5

serum vitamin D3

1 evidences

Three-month randomized trial testing probiotic adjunct (Probio-M8) plus standard therapy (calcium + calcitriol) vs placebo plus standard therapy in postmenopausal osteoporosis; probiotic co-administration improved biochemical markers of bone metabolism but not BMD at 3 months.

Trust comment: Small randomized adjunct trial with short duration (3 months); biochemical signals consistent but no BMD change and limited sample size/time restrict clinical conclusions.

Study Details

PMID:36334119
Participants:40
Impact:increased with Probio-M8 co-administration
Trust score:3/5

serum parathyroid hormone (PTH)

1 evidences

Three-month randomized trial testing probiotic adjunct (Probio-M8) plus standard therapy (calcium + calcitriol) vs placebo plus standard therapy in postmenopausal osteoporosis; probiotic co-administration improved biochemical markers of bone metabolism but not BMD at 3 months.

Trust comment: Small randomized adjunct trial with short duration (3 months); biochemical signals consistent but no BMD change and limited sample size/time restrict clinical conclusions.

Study Details

PMID:36334119
Participants:40
Impact:decreased with Probio-M8 co-administration
Trust score:3/5

serum procalcitonin

1 evidences

Three-month randomized trial testing probiotic adjunct (Probio-M8) plus standard therapy (calcium + calcitriol) vs placebo plus standard therapy in postmenopausal osteoporosis; probiotic co-administration improved biochemical markers of bone metabolism but not BMD at 3 months.

Trust comment: Small randomized adjunct trial with short duration (3 months); biochemical signals consistent but no BMD change and limited sample size/time restrict clinical conclusions.

Study Details

PMID:36334119
Participants:40
Impact:decreased with Probio-M8 co-administration
Trust score:3/5

ridge contour increase (first 6 months)

1 evidences

Randomized trial comparing particulate vs collagenated soft-block biphasic calcium phosphate for guided bone regeneration around implants; block group showed larger early contour gains but 1-year soft-tissue dimensional outcomes were similar between groups.

Trust comment: Small randomized clinical trial using calcium-phosphate bone substitutes; outcomes are procedure-specific and sample size is limited but methodology is clinical RCT.

Study Details

PMID:36330670
Participants:35
Impact:block group diagonal +1.12 ± 0.78 mm and horizontal +2.79 ± 1.90 mm greater than particle group (first 6 months)
Trust score:3/5

1-year ridge contour change

1 evidences

Randomized trial comparing particulate vs collagenated soft-block biphasic calcium phosphate for guided bone regeneration around implants; block group showed larger early contour gains but 1-year soft-tissue dimensional outcomes were similar between groups.

Trust comment: Small randomized clinical trial using calcium-phosphate bone substitutes; outcomes are procedure-specific and sample size is limited but methodology is clinical RCT.

Study Details

PMID:36330670
Participants:35
Impact:no significant difference between groups at 1 year
Trust score:3/5

peri-implant mucosal thickness (1 year)

1 evidences

Randomized trial comparing particulate vs collagenated soft-block biphasic calcium phosphate for guided bone regeneration around implants; block group showed larger early contour gains but 1-year soft-tissue dimensional outcomes were similar between groups.

Trust comment: Small randomized clinical trial using calcium-phosphate bone substitutes; outcomes are procedure-specific and sample size is limited but methodology is clinical RCT.

Study Details

PMID:36330670
Participants:35
Impact:similar between groups
Trust score:3/5

WSL treatment success rate — Clinpro (f-TCP)

1 evidences

Randomized single-blind three-arm trial comparing f‑TCP-containing toothpaste (Clinpro), CPP-ACP varnish (MI Varnish), and home care for white spot lesion remineralization; both active agents outperformed control over 8 weeks.

Trust comment: Randomized single-blind trial with adequate sample size and clear clinical endpoints assessing calcium-containing remineralization agent; moderate-to-high reliability for the stated outcomes.

Study Details

PMID:36322154
Participants:105
Impact:67.61% success rate
Trust score:4/5

WSL treatment success rate — MI Varnish (CPP-ACP)

1 evidences

Randomized single-blind three-arm trial comparing f‑TCP-containing toothpaste (Clinpro), CPP-ACP varnish (MI Varnish), and home care for white spot lesion remineralization; both active agents outperformed control over 8 weeks.

Trust comment: Randomized single-blind trial with adequate sample size and clear clinical endpoints assessing calcium-containing remineralization agent; moderate-to-high reliability for the stated outcomes.

Study Details

PMID:36322154
Participants:105
Impact:60.59% success rate
Trust score:4/5

WSL treatment success rate — control

1 evidences

Randomized single-blind three-arm trial comparing f‑TCP-containing toothpaste (Clinpro), CPP-ACP varnish (MI Varnish), and home care for white spot lesion remineralization; both active agents outperformed control over 8 weeks.

Trust comment: Randomized single-blind trial with adequate sample size and clear clinical endpoints assessing calcium-containing remineralization agent; moderate-to-high reliability for the stated outcomes.

Study Details

PMID:36322154
Participants:105
Impact:32.43% success rate
Trust score:4/5

Clinpro vs MI Varnish

1 evidences

Randomized single-blind three-arm trial comparing f‑TCP-containing toothpaste (Clinpro), CPP-ACP varnish (MI Varnish), and home care for white spot lesion remineralization; both active agents outperformed control over 8 weeks.

Trust comment: Randomized single-blind trial with adequate sample size and clear clinical endpoints assessing calcium-containing remineralization agent; moderate-to-high reliability for the stated outcomes.

Study Details

PMID:36322154
Participants:105
Impact:no significant difference between active treatments
Trust score:4/5

pre-dialysis ionic calcium

1 evidences

Switching dialysis acid from acetate to citrate lowered pre-dialysis ionic calcium and increased PTH, reduced hypotension, and increased lean mass index over 16 weeks.

Trust comment: Prospective multicenter randomized crossover trial in humans with objective biochemical and clinical endpoints, moderate sample size.

Study Details

PMID:36210622
Participants:56
Impact:decrease (significant)
Trust score:4/5

hypotensive dialysis episodes

1 evidences

Switching dialysis acid from acetate to citrate lowered pre-dialysis ionic calcium and increased PTH, reduced hypotension, and increased lean mass index over 16 weeks.

Trust comment: Prospective multicenter randomized crossover trial in humans with objective biochemical and clinical endpoints, moderate sample size.

Study Details

PMID:36210622
Participants:56
Impact:decrease (14.1% -> 10.8% of sessions)
Trust score:4/5

Lean mass index

1 evidences

Switching dialysis acid from acetate to citrate lowered pre-dialysis ionic calcium and increased PTH, reduced hypotension, and increased lean mass index over 16 weeks.

Trust comment: Prospective multicenter randomized crossover trial in humans with objective biochemical and clinical endpoints, moderate sample size.

Study Details

PMID:36210622
Participants:56
Impact:increase (+0.96 ± 2.33 kg/m2)
Trust score:4/5

AF/atrial flutter inducibility

1 evidences

In patients referred for AF ablation, there was no significant difference in AF inducibility between (R)- and (S)-propafenone; both active enantiomers increased atrial flutter versus placebo.

Trust comment: Randomized human mechanistic trial with good size but confounded by sodium-channel blockade and high atrial flutter rates affecting primary outcome.

Study Details

PMID:36166682
Participants:165
Impact:no significant difference between (R)- and (S)-propafenone (R 84.5%, S 80.0%, placebo 63.2%)
Trust score:3/5

atrial flutter occurrence

1 evidences

In patients referred for AF ablation, there was no significant difference in AF inducibility between (R)- and (S)-propafenone; both active enantiomers increased atrial flutter versus placebo.

Trust comment: Randomized human mechanistic trial with good size but confounded by sodium-channel blockade and high atrial flutter rates affecting primary outcome.

Study Details

PMID:36166682
Participants:165
Impact:increase in active groups (R 32.4%, S 34.7% vs placebo 5.3%, p=0.029)
Trust score:3/5

radiographic periapical healing rate

1 evidences

One-visit RCT with final 2% CHX rinse produced similar postoperative pain and radiographic healing to two-visit treatment with calcium hydroxide dressing.

Trust comment: Prospective comparative clinical study (90 teeth) with 24-month follow-up and clinically relevant outcomes; good applicability though outcomes are procedure-specific.

Study Details

PMID:29603299
Participants:90
Impact:similar healing (OV 97.6% PAI1/2 vs TV 95% PAI1/2)
Trust score:4/5

thyroid-stimulating hormone (TSH)

1 evidences

Atorvastatin 20 mg/day modestly reduced corrected serum calcium at 12 weeks in lithium users compared to placebo.

Trust comment: Double-blind randomized placebo-controlled human trial with objective lab measurements, moderate size though small absolute calcium change.

Study Details

PMID:36153583
Participants:56
Impact:no significant change
Trust score:4/5

calcium intake (infants)

1 evidences

A 4-month RCT sending weekly SMS to caregivers increased some infant nutrient intakes; infants in the SMS feeding-practices group had higher protein, calcium, zinc and grain intake at 4–6 months.

Trust comment: Randomized multi-site trial with validated infant FFQ and good retention (84 and 79 completers); short duration (4 months) limits long-term inference.

Study Details

PMID:36249246
Participants:163
Impact:median control 429 mg → intervention 472 mg at 4–6 mo (difference ≈ +43 mg; p = 0.012)
Trust score:4/5

protein intake (infants)

1 evidences

A 4-month RCT sending weekly SMS to caregivers increased some infant nutrient intakes; infants in the SMS feeding-practices group had higher protein, calcium, zinc and grain intake at 4–6 months.

Trust comment: Randomized multi-site trial with validated infant FFQ and good retention (84 and 79 completers); short duration (4 months) limits long-term inference.

Study Details

PMID:36249246
Participants:163
Impact:median control 11.05 g → intervention 13.5 g at 4–6 mo (p = 0.022)
Trust score:4/5

total grains (oz)

1 evidences

A 4-month RCT sending weekly SMS to caregivers increased some infant nutrient intakes; infants in the SMS feeding-practices group had higher protein, calcium, zinc and grain intake at 4–6 months.

Trust comment: Randomized multi-site trial with validated infant FFQ and good retention (84 and 79 completers); short duration (4 months) limits long-term inference.

Study Details

PMID:36249246
Participants:163
Impact:median control 0.16 oz → intervention 0.28 oz at 4–6 mo (p < 0.05)
Trust score:4/5

plasma C7:0 (heptanoic acid)

1 evidences

Double-blind RCT testing personalized Mg supplementation to optimize Ca:Mg intake ratio (~2.3) showing increased circulating medium-chain fatty acids (C7:0, C8:0) and microbiome changes.

Trust comment: Large double-blind RCT with metabolomics and metagenomics measures; findings robust though focused on Mg intervention changing Ca:Mg ratio rather than testing calcium supplementation alone.

Study Details

PMID:36223712
Participants:240
Impact:increase 18.45% with Mg treatment vs −14.15% in placebo (P = 0.0126; q = 0.0324)
Trust score:4/5

plasma C8:0 (caprylic acid)

1 evidences

Double-blind RCT testing personalized Mg supplementation to optimize Ca:Mg intake ratio (~2.3) showing increased circulating medium-chain fatty acids (C7:0, C8:0) and microbiome changes.

Trust comment: Large double-blind RCT with metabolomics and metagenomics measures; findings robust though focused on Mg intervention changing Ca:Mg ratio rather than testing calcium supplementation alone.

Study Details

PMID:36223712
Participants:240
Impact:increase 25.28% with Mg treatment vs −10.12% in placebo (P = 0.0162; q = 0.0324)
Trust score:4/5

plasma sucrose

1 evidences

Double-blind RCT testing personalized Mg supplementation to optimize Ca:Mg intake ratio (~2.3) showing increased circulating medium-chain fatty acids (C7:0, C8:0) and microbiome changes.

Trust comment: Large double-blind RCT with metabolomics and metagenomics measures; findings robust though focused on Mg intervention changing Ca:Mg ratio rather than testing calcium supplementation alone.

Study Details

PMID:36223712
Participants:240
Impact:significantly reduced with Mg treatment vs placebo (P = 0.0036)
Trust score:4/5

intact parathyroid hormone (PTH)

2 evidences

In dialysis patients ferric citrate achieved similar phosphorus control and produced similar changes in serum calcium and PTH compared with sevelamer and/or calcium acetate over 52 weeks.

Trust comment: Large randomized phase 3 trial in dialysis patients with relevant biochemical outcomes; open-label design and mixed active control (including calcium acetate) are limitations.

Study Details

PMID:25958079
Participants:441
Impact:decrease: ferric citrate −167.1 ± 399.8 pg/mL vs active control −152.7 ± 392.1 pg/mL (similar)
Trust score:4/5

In hemodialysis patients, dialysate calcium 2.5 vs 3.0 mEq/L did not significantly change cardiovascular events or mortality; alfacalcidol produced a short-term rise in serum calcium and a short-term fall in PTH.

Trust comment: Post-hoc analysis of a randomized trial with long follow-up and serial labs but limited statistical power; results are plausible though not definitive.

Study Details

PMID:36070301
Participants:976
Impact:Transient decrease with alfacalcidol
Trust score:4/5

Composite cardiovascular events / all-cause mortality

1 evidences

In hemodialysis patients, dialysate calcium 2.5 vs 3.0 mEq/L did not significantly change cardiovascular events or mortality; alfacalcidol produced a short-term rise in serum calcium and a short-term fall in PTH.

Trust comment: Post-hoc analysis of a randomized trial with long follow-up and serial labs but limited statistical power; results are plausible though not definitive.

Study Details

PMID:36070301
Participants:976
Impact:No significant change by D-Ca (2.5 vs 3.0 mEq/L) or by alfacalcidol
Trust score:4/5

Coronary artery calcification progression (Agatston score)

1 evidences

Among hemodialysis patients at risk of vascular calcification, treatment with calcium carbonate did not delay or accelerate coronary artery calcification progression compared with a non-calcium binder (lanthanum) over 2 years.

Trust comment: Randomized controlled subsidiary analysis with objective CT-based CAC scoring but modest sample (full analysis set 123).

Study Details

PMID:36064876
Participants:123
Impact:No significant difference between calcium carbonate and lanthanum carbonate at 2 years
Trust score:4/5

Calcium/vitamin D adherence rate (pharmacy refills)

1 evidences

Randomized trial testing a smartphone app to improve adherence to prescribed supplements (including calcium/vitamin D) after bariatric surgery: the app did not improve objective pharmacy-based adherence or biochemical deficiency rates at 1 year.

Trust comment: Randomized trial with objective pharmacy refill adherence measures and biochemical outcomes; not primarily testing calcium effects but provides reliable indirect data on calcium supplementation adherence.

Study Details

PMID:36050801
Participants:140
Impact:No significant improvement with app (change ~−12.3% vs −11.5%, intervention vs control)
Trust score:3/5

Calcium ion / biochemical deficiency prevalence

1 evidences

Randomized trial testing a smartphone app to improve adherence to prescribed supplements (including calcium/vitamin D) after bariatric surgery: the app did not improve objective pharmacy-based adherence or biochemical deficiency rates at 1 year.

Trust comment: Randomized trial with objective pharmacy refill adherence measures and biochemical outcomes; not primarily testing calcium effects but provides reliable indirect data on calcium supplementation adherence.

Study Details

PMID:36050801
Participants:140
Impact:No significant difference between groups at 1 year
Trust score:3/5

Tooth demineralization scores (DIAGNOdent)

1 evidences

Split-mouth RCT in orthodontic patients: a calcium fluoride nanoparticle-containing primer reduced tooth demineralization scores over 6 months and lowered S. mutans at 1 month but did not change white-spot lesion incidence after appliance removal.

Trust comment: Double-blind split-mouth randomized trial with objective demineralization and microbiological measures but small sample size (31 patients).

Study Details

PMID:36049047
Participants:31
Impact:Decreased over 6 months with nCaF2-primer
Trust score:4/5

Streptococcus mutans colonization

1 evidences

Split-mouth RCT in orthodontic patients: a calcium fluoride nanoparticle-containing primer reduced tooth demineralization scores over 6 months and lowered S. mutans at 1 month but did not change white-spot lesion incidence after appliance removal.

Trust comment: Double-blind split-mouth randomized trial with objective demineralization and microbiological measures but small sample size (31 patients).

Study Details

PMID:36049047
Participants:31
Impact:Reduced at 1 month with nCaF2-primer
Trust score:4/5

White spot lesion incidence (photographic)

1 evidences

Split-mouth RCT in orthodontic patients: a calcium fluoride nanoparticle-containing primer reduced tooth demineralization scores over 6 months and lowered S. mutans at 1 month but did not change white-spot lesion incidence after appliance removal.

Trust comment: Double-blind split-mouth randomized trial with objective demineralization and microbiological measures but small sample size (31 patients).

Study Details

PMID:36049047
Participants:31
Impact:No significant difference at appliance removal
Trust score:4/5

mid-arm circumference

1 evidences

12-week randomized trial in Chinese adults at risk of malnutrition: daily oral nutrition supplement increased weight, anthropometric measures, and multiple nutrient intakes.

Trust comment: Randomized controlled trial with adequate power and objective outcomes, but open-label, unblinded, and lacking body-composition measures.

Study Details

PMID:36141627
Participants:82
Impact:+0.795 cm (estimated mean group difference, p < 0.001)
Trust score:4/5

serum calcium/phosphate/PTH

1 evidences

Post-hoc analysis of a large hemodialysis RCT: low-dose oral alfacalcidol did not significantly change cardiovascular events or mortality and ALP did not modify effects.

Trust comment: Large randomized trial with blinded event adjudication and long follow-up; this is a post-hoc subgroup analysis which reduces power for interaction testing.

Study Details

PMID:36104443
Participants:959
Impact:No significant between-group time-series differences modified by ALP (P for effect modification 0.21–0.55)
Trust score:4/5

24-h urinary calcium (calciuria)

1 evidences

Randomized pilot study: 3-month phytate (calcium–magnesium InsP6) supplementation reduced urinary calcium excretion and serum bone resorption marker compared with no treatment.

Trust comment: Randomized pilot study showing biologically plausible changes but limited by small sample size and short duration.

Study Details

PMID:36087116
Participants:23
Impact:Decrease of 34.5% (±14.5) in the phytate group; urinary calcium fell from ~321±52 mg to 226±45 mg (p < 0.05 vs baseline and vs control)
Trust score:3/5

CrossLaps (bone resorption marker)

1 evidences

Randomized pilot study: 3-month phytate (calcium–magnesium InsP6) supplementation reduced urinary calcium excretion and serum bone resorption marker compared with no treatment.

Trust comment: Randomized pilot study showing biologically plausible changes but limited by small sample size and short duration.

Study Details

PMID:36087116
Participants:23
Impact:Decrease of 29.1% (±12.2) in the phytate group (p < 0.05 vs control)
Trust score:3/5

HOMA-B (beta-cell function)

2 evidences

24-week randomized multicenter trial: telmisartan+rosuvastatin preserved beta-cell function, lowered fasting glucose and reduced new-onset diabetes risk versus amlodipine+rosuvastatin, without significant HOMA-IR difference.

Trust comment: Randomized multicenter trial with clear metabolic endpoints, but open-label and relatively short follow-up (24 weeks) limits longer-term inference.

Study Details

PMID:36086748
Participants:99
Impact:Telmisartan preserved HOMA-B (−6.0% change) vs amlodipine (−19.8% change); between-group p = 0.040
Trust score:4/5

In 104 overweight, vitamin D–deficient women with PCOS, 8 weeks of calcium plus vitamin D improved several inflammation and oxidative-stress biomarkers compared with placebo.

Trust comment: Randomized double-blind placebo-controlled trial with adequate sample size and clear biomarker changes, though short duration (8 weeks).

Study Details

PMID:26119844
Participants:104
Impact:decrease −11.1 (calcium+vitD) vs −8.6, −3.4, 13.7 in other groups (P=0.03)
Trust score:4/5

fasting glucose

2 evidences

Crossover RCT (64 completers) where 1 L/day of mineral water (bicarbonated vs low-mineral) for 8 weeks reduced LDL and fasting glucose; bicarbonated water increased urine pH and decreased urinary calcium/creatinine ratio.

Trust comment: Randomized, crossover design with objective biochemical measures; modest sample size but well-conducted.

Study Details

PMID:27367723
Participants:64
Impact:decreased (statistically significant)
Trust score:4/5

24-week randomized multicenter trial: telmisartan+rosuvastatin preserved beta-cell function, lowered fasting glucose and reduced new-onset diabetes risk versus amlodipine+rosuvastatin, without significant HOMA-IR difference.

Trust comment: Randomized multicenter trial with clear metabolic endpoints, but open-label and relatively short follow-up (24 weeks) limits longer-term inference.

Study Details

PMID:36086748
Participants:99
Impact:Telmisartan group: −3.2% vs amlodipine group: +3.8% from baseline to week 24 (between-group p = 0.003)
Trust score:4/5

new-onset diabetes (NODM)

1 evidences

24-week randomized multicenter trial: telmisartan+rosuvastatin preserved beta-cell function, lowered fasting glucose and reduced new-onset diabetes risk versus amlodipine+rosuvastatin, without significant HOMA-IR difference.

Trust comment: Randomized multicenter trial with clear metabolic endpoints, but open-label and relatively short follow-up (24 weeks) limits longer-term inference.

Study Details

PMID:36086748
Participants:99
Impact:Telmisartan 12.5% vs amlodipine 31.4% at 24 weeks (absolute difference 18.9 percentage points; p = 0.044)
Trust score:4/5

dietary calcium — OA outcomes

1 evidences

Post-hoc cohort analysis: dietary magnesium and potassium intake were associated with fewer OA symptoms, better quality of life, and greater muscle strength; dietary calcium showed no significant associations with OA outcomes.

Trust comment: Well-characterized cohort (post-hoc analysis) with repeated measures, but observational design limits causal inference and residual confounding is possible.

Study Details

PMID:36079832
Participants:392
Impact:No significant association with knee joint structures, symptoms, quality of life, or comorbid conditions (p > 0.05)
Trust score:3/5

dietary magnesium — OA symptoms

1 evidences

Post-hoc cohort analysis: dietary magnesium and potassium intake were associated with fewer OA symptoms, better quality of life, and greater muscle strength; dietary calcium showed no significant associations with OA outcomes.

Trust comment: Well-characterized cohort (post-hoc analysis) with repeated measures, but observational design limits causal inference and residual confounding is possible.

Study Details

PMID:36079832
Participants:392
Impact:Associated with lower total WOMAC score (β = −753.93) and improved AQoL (β = −7.61)
Trust score:3/5

dietary potassium — OA symptoms

1 evidences

Post-hoc cohort analysis: dietary magnesium and potassium intake were associated with fewer OA symptoms, better quality of life, and greater muscle strength; dietary calcium showed no significant associations with OA outcomes.

Trust comment: Well-characterized cohort (post-hoc analysis) with repeated measures, but observational design limits causal inference and residual confounding is possible.

Study Details

PMID:36079832
Participants:392
Impact:Associated with lower total WOMAC score (β = −87.72) and some AQoL subdomains
Trust score:3/5

vasopressor requirement (mephentermine)

1 evidences

Intravenous calcium gluconate given after spinal anaesthesia in cesarean patients had small effects on maternal hemodynamics and improved some neonatal blood-gas measures but did not significantly prevent hypotension.

Trust comment: Randomized double-blind trial in 60 humans but small sample and primary differences were not statistically significant for main endpoint.

Study Details

PMID:35945859
Participants:60
Impact:63.33% (calcium) vs 76.6% (saline); absolute −13.3%, difference not statistically significant (p=0.791)
Trust score:3/5

maternal heart rate

1 evidences

Intravenous calcium gluconate given after spinal anaesthesia in cesarean patients had small effects on maternal hemodynamics and improved some neonatal blood-gas measures but did not significantly prevent hypotension.

Trust comment: Randomized double-blind trial in 60 humans but small sample and primary differences were not statistically significant for main endpoint.

Study Details

PMID:35945859
Participants:60
Impact:Heart rate maintained near baseline with calcium; decreased in saline group at 8–16 min (time-specific decrease reported)
Trust score:3/5

neonatal umbilical venous blood-gas (pH and pCO2)

1 evidences

Intravenous calcium gluconate given after spinal anaesthesia in cesarean patients had small effects on maternal hemodynamics and improved some neonatal blood-gas measures but did not significantly prevent hypotension.

Trust comment: Randomized double-blind trial in 60 humans but small sample and primary differences were not statistically significant for main endpoint.

Study Details

PMID:35945859
Participants:60
Impact:Umbilical venous pH and pCO2 significantly better in calcium group (p=0.038)
Trust score:3/5

FGF23

3 evidences

In haemodialysis patients with secondary hyperparathyroidism, etelcalcetide treatment reduced FGF23; when hypocalcaemia was corrected with oral calcium (vs active vitamin D), greater suppression of FGF23 and of calciprotein particles was observed at 12 weeks.

Trust comment: Randomized open-label trial post-hoc analysis with modest sample and short follow-up; findings suggest oral calcium correction produced greater suppression of FGF23/CPPs than active vitamin D.

Study Details

PMID:35749253
Participants:124
Impact:decreased with etelcalcetide vs non-users (significant at week 6 and 12); E+Ca lower than E+D at week 12 (p=0.017)
Trust score:3/5

In advanced pre-dialysis CKD patients, sevelamer reduced serum p-cresyl sulfate and LDL-cholesterol versus calcium carbonate over 24 weeks; indoxyl sulfate did not change.

Trust comment: Randomized controlled single‑center trial with valid assays but small sample and many advanced CKD patients limit generalizability.

Study Details

PMID:34678981
Participants:33
Impact:Sevelamer prevented the FGF23 increase seen with calcium carbonate (between-group p=0.01)
Trust score:3/5

In a controlled crossover trial, potassium supplementation lowered FGF23 and fractional calcium excretion and increased plasma phosphate/TmP-GFR; sodium supplementation also lowered FGF23 but increased urinary (and fractional) calcium excretion.

Trust comment: Well-controlled, double-blind randomized placebo-controlled crossover with dietary control (n=36); post-hoc analysis but robust biochemical measures.

Study Details

PMID:32506135
Participants:36
Impact:decreased with potassium ≈−4.5% and with sodium ≈−4.2% (potassium P=0.01; sodium P=0.02)
Trust score:4/5

olfactory function (Sniffin' Sticks)

1 evidences

Intranasal sodium gluconate (a calcium-chelating agent) reduced nasal calcium and was associated with improved sense of smell one month after treatment in post‑COVID patients.

Trust comment: Prospective randomized blinded controlled trial (n=50) directly testing an agent that lowers local calcium; small sample and short follow-up.

Study Details

PMID:35942688
Participants:50
Impact:Clinical improvement from anosmia to hyposmia in sodium gluconate group compared with no improvement in saline group
Trust score:3/5

weight loss

1 evidences

Oral cancer patients randomized to professional nutritional support (including individualized micronutrient supplements such as calcium tablets when indicated) lost less weight and had more stable lab values including calcium compared with standard care.

Trust comment: Randomized trial with clear clinical endpoints but small sample (n=46), some measures only in intervention group, and potential allocation bias by weekday.

Study Details

PMID:35987809
Participants:46
Impact:reduced weight loss at discharge (T2) and at 6 months (T4); malnutrition prevalence 27.27% vs 45.83% (intervention vs control), ~-18.56 percentage points
Trust score:3/5

1-year survival

2 evidences

A 3-month post-discharge individualized nutritional program (including vitamin D3/calcium supplement among other components) did not improve 1- or 4-year survival versus usual care despite earlier short-term functional benefits.

Trust comment: Randomized human study including calcium as part of a multi-component intervention, but calcium's isolated effect cannot be determined and no long-term survival benefit was observed.

Study Details

PMID:28972236
Participants:210
Impact:intervention 66% vs control 73%; HR=0.933 (95% CI 0.675–1.289); no significant difference
Trust score:3/5

Giving intravenous calcium during out-of-hospital cardiac arrest reduced 1-year survival and favorable neurological outcomes compared with placebo.

Trust comment: Randomized, double-blind, placebo-controlled trial (n=391) providing robust RCT evidence though some estimates are imprecise.

Study Details

PMID:35917866
Participants:391
Impact:4.7% (calcium) vs 9.1% (placebo); risk ratio 0.51
Trust score:5/5

1-year survival with favorable neurological outcome (mRS ≤3)

1 evidences

Giving intravenous calcium during out-of-hospital cardiac arrest reduced 1-year survival and favorable neurological outcomes compared with placebo.

Trust comment: Randomized, double-blind, placebo-controlled trial (n=391) providing robust RCT evidence though some estimates are imprecise.

Study Details

PMID:35917866
Participants:391
Impact:3.6% (calcium) vs 8.6% (placebo); risk ratio 0.42
Trust score:5/5

Health-related quality of life

1 evidences

Giving intravenous calcium during out-of-hospital cardiac arrest reduced 1-year survival and favorable neurological outcomes compared with placebo.

Trust comment: Randomized, double-blind, placebo-controlled trial (n=391) providing robust RCT evidence though some estimates are imprecise.

Study Details

PMID:35917866
Participants:391
Impact:Suggested harm with calcium vs placebo; imprecise estimates (wide CIs)
Trust score:5/5

Association of coronary artery calcium (CAC) with bone mineral density (BMD) loss

1 evidences

In menopausal women, presence or progression of coronary artery calcium was associated with greater bone mineral density loss; menopausal hormone therapy (o-CEE or t-E2) reduced progression of bone loss.

Trust comment: Secondary analysis within a randomized trial (KEEPS) with validated CT and BMD measures and moderate sample size.

Study Details

PMID:35908457
Participants:374
Impact:Women with CAC>0 had greater BMD loss (o-CEE: −9.6 ±13.3 vs −3.1 ±19.5; t-E2: −11.7 ±26.2 vs +5.7 ±26.2; p≤0.001–0.0001)
Trust score:4/5

Effect of menopausal hormone therapy on BMD loss

1 evidences

In menopausal women, presence or progression of coronary artery calcium was associated with greater bone mineral density loss; menopausal hormone therapy (o-CEE or t-E2) reduced progression of bone loss.

Trust comment: Secondary analysis within a randomized trial (KEEPS) with validated CT and BMD measures and moderate sample size.

Study Details

PMID:35908457
Participants:374
Impact:Progression of bone loss reduced among women treated with o-CEE or t-E2 (treatment-modified relationship)
Trust score:4/5

Incidence of postoperative hypoparathyroidism at skin closure

1 evidences

Using near-infrared autofluorescence during thyroidectomy modestly lowered early postoperative hypoparathyroidism rates but differences were not statistically significant in this small trial.

Trust comment: Small single-blinded randomized pilot (n=60) with limited power and non-significant p-values for primary comparisons.

Study Details

PMID:35904639
Participants:60
Impact:23% (NIR-AF) vs 47% (control); absolute reduction 23.6% (p=0.058)
Trust score:3/5

Incidence of postoperative hypoparathyroidism on POD1

1 evidences

Using near-infrared autofluorescence during thyroidectomy modestly lowered early postoperative hypoparathyroidism rates but differences were not statistically significant in this small trial.

Trust comment: Small single-blinded randomized pilot (n=60) with limited power and non-significant p-values for primary comparisons.

Study Details

PMID:35904639
Participants:60
Impact:20% (NIR-AF) vs 33% (control); absolute reduction 13.3% (p=0.24)
Trust score:3/5

Postoperative calcium levels

1 evidences

Using near-infrared autofluorescence during thyroidectomy modestly lowered early postoperative hypoparathyroidism rates but differences were not statistically significant in this small trial.

Trust comment: Small single-blinded randomized pilot (n=60) with limited power and non-significant p-values for primary comparisons.

Study Details

PMID:35904639
Participants:60
Impact:No significant difference in absolute calcium on POD1 or POD2 between groups
Trust score:3/5

Calcium / PTH / testosterone / cortisol

1 evidences

Daily 1200 IU vitamin D prevented wintertime vitamin D deficiency but did not change hand grip strength or major hormone levels in young male conscripts.

Trust comment: Triple-blinded randomized placebo-controlled trial (analyzed n=53) with robust biochemical measures but limited power for secondary outcomes.

Study Details

PMID:35875694
Participants:53
Impact:No significant differences between groups for PTH, testosterone, cortisol; calcium largely similar (no meaningful change)
Trust score:4/5

gut microbiota composition

1 evidences

Adding Clostridium butyricum to rosuvastatin in NAFLD patients improved gut microbiota composition and reduced lipids, liver enzymes, fibrosis markers and inflammatory cytokines compared with rosuvastatin alone.

Trust comment: Randomized allocation (n=96) with multiple significant outcomes reported but limited methodological detail and single-center reporting reduce confidence.

Study Details

PMID:35869734
Participants:96
Impact:Lower Eubacterium rectale and higher Bacteroides thetaiotaomicron and Bifidobacteria in the combined treatment group (p<0.05)
Trust score:3/5

Blood lipids and free fatty acids

1 evidences

Adding Clostridium butyricum to rosuvastatin in NAFLD patients improved gut microbiota composition and reduced lipids, liver enzymes, fibrosis markers and inflammatory cytokines compared with rosuvastatin alone.

Trust comment: Randomized allocation (n=96) with multiple significant outcomes reported but limited methodological detail and single-center reporting reduce confidence.

Study Details

PMID:35869734
Participants:96
Impact:Lower TC, TG and FFA in combined group vs control (p<0.05)
Trust score:3/5

Liver function, fibrosis and inflammation markers

1 evidences

Adding Clostridium butyricum to rosuvastatin in NAFLD patients improved gut microbiota composition and reduced lipids, liver enzymes, fibrosis markers and inflammatory cytokines compared with rosuvastatin alone.

Trust comment: Randomized allocation (n=96) with multiple significant outcomes reported but limited methodological detail and single-center reporting reduce confidence.

Study Details

PMID:35869734
Participants:96
Impact:Lower TBIL, DBIL, ALT, AST, PIIIP, C-IV, HA, LN and lower TNF-α and IL-6 in combined group (p<0.05)
Trust score:3/5

Periapical lesion presence at 12 months

1 evidences

Pulpotomy using calcium-enriched mixture or MTA resulted in better one-year periapical healing than root canal therapy in symptomatic immature permanent molars.

Trust comment: Large randomized clinical trial (n=615) with one-year follow-up showing consistent clinical benefit of calcium-containing vital-pulp materials over RCT.

Study Details

PMID:35869721
Participants:615
Impact:MTA: 12/207 (7%); CEM: 9/205 (5%); RCT: 33/203 (18%) — vital pulp therapy superior to RCT (P<0.05)
Trust score:4/5

TLR-2 and TLR-4 gene expression

1 evidences

Pulpotomy using calcium-enriched mixture or MTA resulted in better one-year periapical healing than root canal therapy in symptomatic immature permanent molars.

Trust comment: Large randomized clinical trial (n=615) with one-year follow-up showing consistent clinical benefit of calcium-containing vital-pulp materials over RCT.

Study Details

PMID:35869721
Participants:615
Impact:No significant difference between treatment groups before and one year after treatment
Trust score:4/5

maternal calcium at delivery

1 evidences

Randomized trial substudy measured maternal and infant calcium and phosphate during pregnancy and after birth; found calcium levels unchanged and small decreases in phosphate with TDF exposure.

Trust comment: Large randomized trial with pre-specified biomarker measures in a substudy; calcium measurements robust though clinical impact minimal.

Study Details

PMID:35858874
Participants:478
Impact:no meaningful change (mean difference ≈ −0.05 to −0.06 mg/dL vs comparators)
Trust score:4/5

maternal phosphate at delivery

1 evidences

Randomized trial substudy measured maternal and infant calcium and phosphate during pregnancy and after birth; found calcium levels unchanged and small decreases in phosphate with TDF exposure.

Trust comment: Large randomized trial with pre-specified biomarker measures in a substudy; calcium measurements robust though clinical impact minimal.

Study Details

PMID:35858874
Participants:478
Impact:small decrease (mean difference −0.14 to −0.17 mg/dL in TDF arm vs comparators)
Trust score:4/5

maternal hypophosphatemia incidence

1 evidences

Randomized trial substudy measured maternal and infant calcium and phosphate during pregnancy and after birth; found calcium levels unchanged and small decreases in phosphate with TDF exposure.

Trust comment: Large randomized trial with pre-specified biomarker measures in a substudy; calcium measurements robust though clinical impact minimal.

Study Details

PMID:35858874
Participants:478
Impact:higher incidence in TDF arm (+~2.8 percentage points; 4.23% vs ~1.4%) — not clearly significant
Trust score:4/5

antibacterial effect vs Enterococcus faecalis

1 evidences

Dental RCT comparing garlic, calcium hydroxide, and their combo as root canal medicaments; garlic outperformed calcium hydroxide against Enterococcus faecalis.

Trust comment: Randomized double-blind dental trial but small, single-sex sample and limited generalizability to broader populations.

Study Details

PMID:35852013
Participants:66
Impact:calcium hydroxide showed no significant reduction after medicament placement (garlic superior)
Trust score:3/5

antibacterial effect vs Streptococcus spp.

1 evidences

Dental RCT comparing garlic, calcium hydroxide, and their combo as root canal medicaments; garlic outperformed calcium hydroxide against Enterococcus faecalis.

Trust comment: Randomized double-blind dental trial but small, single-sex sample and limited generalizability to broader populations.

Study Details

PMID:35852013
Participants:66
Impact:calcium hydroxide reduced Streptococcus similarly at 7 days but less than garlic at 14 days
Trust score:3/5

combination (Ca(OH)2 + garlic) efficacy

1 evidences

Dental RCT comparing garlic, calcium hydroxide, and their combo as root canal medicaments; garlic outperformed calcium hydroxide against Enterococcus faecalis.

Trust comment: Randomized double-blind dental trial but small, single-sex sample and limited generalizability to broader populations.

Study Details

PMID:35852013
Participants:66
Impact:combination reduced antibacterial effectiveness relative to garlic alone
Trust score:3/5

remineralization of MIH lesions (Ca glycerophosphate)

1 evidences

Children with MIH received calcium glycerophosphate, CPP-ACFP, or fluoride toothpaste; lesions improved over time in all groups with no clear between-group differences.

Trust comment: Randomized clinical trial in children with objective laser-fluorescence outcomes but modest sample size and limited long-term data.

Study Details

PMID:35830636
Participants:53
Impact:significant improvement over time; no significant difference versus other agents (p>0.05)
Trust score:3/5

comparative effectiveness vs other agents

1 evidences

Children with MIH received calcium glycerophosphate, CPP-ACFP, or fluoride toothpaste; lesions improved over time in all groups with no clear between-group differences.

Trust comment: Randomized clinical trial in children with objective laser-fluorescence outcomes but modest sample size and limited long-term data.

Study Details

PMID:35830636
Participants:53
Impact:no overall group difference in remineralization between CaGP, CPP-ACFP and fluoride control
Trust score:3/5

remineralization of early enamel lesions (tricalcium silicate)

1 evidences

Two-year RCT comparing tricalcium silicate paste to CPP-ACP and SDF-KI for early enamel lesions; TCS and CPP-ACP produced significant remineralization at 24 months.

Trust comment: Two-year randomized trial but small sample size; results supportive though limited by modest N and single-center design.

Study Details

PMID:35815478
Participants:45
Impact:significant remineralization after 24 months (p<0.05)
Trust score:3/5

Clinical success (DPC)

1 evidences

Randomized trial in children evaluating calcium hydroxide versus MTA for direct pulp capping; MTA after hemorrhage control gave more predictable outcomes and ferric sulfate + calcium hydroxide increased internal resorption risk.

Trust comment: Randomized clinical trial with 2-year follow-up in children and clear outcome reporting, though some subgroup sizes are small.

Study Details

PMID:35799339
Participants:55
Impact:94.1% (111/118 teeth) at 2 years
Trust score:4/5

Radiographic success (DPC)

1 evidences

Randomized trial in children evaluating calcium hydroxide versus MTA for direct pulp capping; MTA after hemorrhage control gave more predictable outcomes and ferric sulfate + calcium hydroxide increased internal resorption risk.

Trust comment: Randomized clinical trial with 2-year follow-up in children and clear outcome reporting, though some subgroup sizes are small.

Study Details

PMID:35799339
Participants:55
Impact:88.9% (105/118 teeth) at 2 years
Trust score:4/5

Internal resorption (FS + CH)

1 evidences

Randomized trial in children evaluating calcium hydroxide versus MTA for direct pulp capping; MTA after hemorrhage control gave more predictable outcomes and ferric sulfate + calcium hydroxide increased internal resorption risk.

Trust comment: Randomized clinical trial with 2-year follow-up in children and clear outcome reporting, though some subgroup sizes are small.

Study Details

PMID:35799339
Participants:55
Impact:Increased (significant) with ferric sulfate + calcium hydroxide
Trust score:4/5

24-h urinary volume

1 evidences

Randomized trial in calcium oxalate stone formers showing bicarbonate-rich mineral water increased urine volume, magnesium, citrate and urine pH versus plain water over 12 weeks, but did not change urinary oxalate or Tiselius index.

Trust comment: Prospective randomized controlled study with repeated 24‑h urine measures and clear effect sizes, though open‑label design is a limitation.

Study Details

PMID:35781772
Participants:51
Impact:Increased by 644.0 ml/24 h (95% CI 206.7 to 1081.3) vs plain water
Trust score:4/5

urinary pH and citrate

1 evidences

Randomized trial in calcium oxalate stone formers showing bicarbonate-rich mineral water increased urine volume, magnesium, citrate and urine pH versus plain water over 12 weeks, but did not change urinary oxalate or Tiselius index.

Trust comment: Prospective randomized controlled study with repeated 24‑h urine measures and clear effect sizes, though open‑label design is a limitation.

Study Details

PMID:35781772
Participants:51
Impact:pH increased by 0.477 (95% CI 0.149 to 0.804); sustained net increase in urinary citrate until week 12
Trust score:4/5

serum intact parathyroid hormone (iPTH)

1 evidences

Phase I/II randomized placebo‑controlled study of IV upacicalcet (a calcimimetic) in dialysis patients showing dose‑dependent plasma exposure, rapid dose‑dependent decreases in serum intact PTH and subsequent decreases in corrected calcium, and substantial dialysis removal.

Trust comment: Well‑designed randomized, placebo‑controlled phase I/II trial with pharmacokinetic/pharmacodynamic endpoints, but sample sizes per dose cohort are small.

Study Details

PMID:35763247
Participants:85
Impact:Rapid decrease within 10 min after dosing and dose-dependent reduction
Trust score:4/5

Serum corrected calcium (cCa2+)

1 evidences

Phase I/II randomized placebo‑controlled study of IV upacicalcet (a calcimimetic) in dialysis patients showing dose‑dependent plasma exposure, rapid dose‑dependent decreases in serum intact PTH and subsequent decreases in corrected calcium, and substantial dialysis removal.

Trust comment: Well‑designed randomized, placebo‑controlled phase I/II trial with pharmacokinetic/pharmacodynamic endpoints, but sample sizes per dose cohort are small.

Study Details

PMID:35763247
Participants:85
Impact:Tended to decrease after 6–18 h; dose-dependent decreases during multiple dosing
Trust score:4/5

Dialysis removal of drug

1 evidences

Phase I/II randomized placebo‑controlled study of IV upacicalcet (a calcimimetic) in dialysis patients showing dose‑dependent plasma exposure, rapid dose‑dependent decreases in serum intact PTH and subsequent decreases in corrected calcium, and substantial dialysis removal.

Trust comment: Well‑designed randomized, placebo‑controlled phase I/II trial with pharmacokinetic/pharmacodynamic endpoints, but sample sizes per dose cohort are small.

Study Details

PMID:35763247
Participants:85
Impact:High removal rate (≈79–100% depending on dose); upacicalcet levels fell with dialysis
Trust score:4/5

bone formation (P1NP)

2 evidences

Five days of low energy availability increased bone resorption and decreased bone formation in women but not in men.

Trust comment: Randomized crossover with objective biomarkers but small short-term sample limits generalizability.

Study Details

PMID:28847532
Participants:22
Impact:P1NP AUC decreased in women (P=0.01); no significant change in men
Trust score:3/5

Pregnant women in an individualized high-dairy-protein diet plus walking program had higher dietary calcium and protein intakes which was associated with reduced bone resorption and preserved bone formation during pregnancy and postpartum.

Trust comment: Randomized controlled trial with objective bone biomarkers and good completion rate, but calcium was increased together with protein/exercise so the calcium-specific effect is not isolated.

Study Details

PMID:35759368
Participants:187
Impact:maintained (no decline vs control)
Trust score:4/5

global cognitive function

1 evidences

In men receiving ADT, a 12-month exercise program plus daily protein, vitamin D and calcium supplementation did not produce significant between-group improvements in objective cognitive function compared with usual care.

Trust comment: Randomized controlled design but a secondary analysis with small sample, suboptimal exercise adherence and limited power for cognitive endpoints.

Study Details

PMID:35750461
Participants:70
Impact:no significant between-group improvement at 6 or 12 months
Trust score:3/5

verbal learning / memory

1 evidences

In men receiving ADT, a 12-month exercise program plus daily protein, vitamin D and calcium supplementation did not produce significant between-group improvements in objective cognitive function compared with usual care.

Trust comment: Randomized controlled design but a secondary analysis with small sample, suboptimal exercise adherence and limited power for cognitive endpoints.

Study Details

PMID:35750461
Participants:70
Impact:no significant between-group improvement at 6 or 12 months
Trust score:3/5

Working memory / learning

1 evidences

In men receiving ADT, a 12-month exercise program plus daily protein, vitamin D and calcium supplementation did not produce significant between-group improvements in objective cognitive function compared with usual care.

Trust comment: Randomized controlled design but a secondary analysis with small sample, suboptimal exercise adherence and limited power for cognitive endpoints.

Study Details

PMID:35750461
Participants:70
Impact:no significant between-group improvement at 6 or 12 months
Trust score:3/5

calciprotein particles (CPPs)

1 evidences

In haemodialysis patients with secondary hyperparathyroidism, etelcalcetide treatment reduced FGF23; when hypocalcaemia was corrected with oral calcium (vs active vitamin D), greater suppression of FGF23 and of calciprotein particles was observed at 12 weeks.

Trust comment: Randomized open-label trial post-hoc analysis with modest sample and short follow-up; findings suggest oral calcium correction produced greater suppression of FGF23/CPPs than active vitamin D.

Study Details

PMID:35749253
Participants:124
Impact:no overall etelcalcetide vs non-user difference, but CPPs lower in E+Ca vs E+D at week 12 (p<0.001)
Trust score:3/5

Serum 25-hydroxyvitamin D

4 evidences

Higher vitamin D doses increased blood vitamin D and were safe with no calcium toxicity; 800 IU/day corrected deficiency by day 14.

Trust comment: Masked randomized clinical trial in 73 extremely preterm infants with per-protocol analysis; reasonable internal validity though sample size is modest.

Study Details

PMID:35728797
Participants:73
Impact:+9, +23, +62 ng/mL (placebo, 200 IU/day, 800 IU/day; Day28 vs Day1)
Trust score:4/5

In obese adults with vitamin D deficiency, adding high-dose weekly vitamin D to a weight-loss diet raised vitamin D levels and reduced PTH, inflammatory markers, and fat mass.

Trust comment: Double-blind randomized controlled trial but small sample (n=44); endpoints and statistical significance are clearly reported.

Study Details

PMID:30246883
Participants:44
Impact:significant increase (P<0.001)
Trust score:3/5

6-month randomized placebo-controlled trial of combined calcium+vitamin D in vitamin D–deficient adults at risk for type 2 diabetes found no overall improvement in insulin secretion/sensitivity, though a prediabetes subgroup showed improved insulin sensitivity.

Trust comment: Randomized double-blind placebo-controlled trial with objective measures and clear reporting; limited by smaller than planned sample size and some baseline imbalances.

Study Details

PMID:25299668
Participants:80
Impact:increased by +48 nmol/L to mean 95 nmol/L (treatment) vs no change (placebo)
Trust score:4/5

A 13-week vitamin D, calcium and leucine-enriched whey protein supplement increased 25(OH)D, suppressed PTH and produced small but positive increases in total-body BMD.

Trust comment: Multicenter, randomized, double-blind controlled trial with adequate sample size, but relatively short duration (13 weeks) for bone outcomes.

Study Details

PMID:31338563
Participants:380
Impact:increased (+27.8 nmol/L; from 51.1 to 78.9 nmol/L)
Trust score:4/5

serum calcium concentrations / calcium toxicity

1 evidences

Higher vitamin D doses increased blood vitamin D and were safe with no calcium toxicity; 800 IU/day corrected deficiency by day 14.

Trust comment: Masked randomized clinical trial in 73 extremely preterm infants with per-protocol analysis; reasonable internal validity though sample size is modest.

Study Details

PMID:35728797
Participants:73
Impact:no vitamin D– or calcium-related toxicity observed
Trust score:4/5

predictive risk of severe bronchopulmonary dysplasia

1 evidences

Higher vitamin D doses increased blood vitamin D and were safe with no calcium toxicity; 800 IU/day corrected deficiency by day 14.

Trust comment: Masked randomized clinical trial in 73 extremely preterm infants with per-protocol analysis; reasonable internal validity though sample size is modest.

Study Details

PMID:35728797
Participants:73
Impact:reduced in 200 IU and 800 IU groups but difference not statistically significant
Trust score:4/5

internal resorption occurrence

1 evidences

In primary molar pulpotomies, choice of base material (including calcium hydroxide) did not change clinical or radiographic success rates over 2 years.

Trust comment: Two-year randomized controlled dental trial with clear clinical and radiographic endpoints and adequate follow-up; moderate sample (by teeth).

Study Details

PMID:35726548
Participants:105
Impact:15/105 teeth observed
Trust score:4/5

mean number of bacterial species per root canal sample

1 evidences

In primary endodontic infections, intracanal medications with Ca(OH)2+2% CHX gel or NAC showed broader antimicrobial activity than Ca(OH)2+saline; NAC eliminated several species resistant to Ca(OH)2 regimens.

Trust comment: Randomized clinical trial with microbiological endpoints but small sample (36 teeth); useful comparative data but limited power.

Study Details

PMID:35723751
Participants:36
Impact:decreased from 17.92 ± 13.18 (s1) to 6.8 ± 2.36 after instrumentation (s2)
Trust score:3/5

antimicrobial breadth: Ca(OH)2 + 2% CHX gel vs Ca(OH)2 + saline

1 evidences

In primary endodontic infections, intracanal medications with Ca(OH)2+2% CHX gel or NAC showed broader antimicrobial activity than Ca(OH)2+saline; NAC eliminated several species resistant to Ca(OH)2 regimens.

Trust comment: Randomized clinical trial with microbiological endpoints but small sample (36 teeth); useful comparative data but limited power.

Study Details

PMID:35723751
Participants:36
Impact:Ca(OH)2+2% CHX gel showed greater bacterial elimination than Ca(OH)2+saline
Trust score:3/5

NAC activity against resistant species

1 evidences

In primary endodontic infections, intracanal medications with Ca(OH)2+2% CHX gel or NAC showed broader antimicrobial activity than Ca(OH)2+saline; NAC eliminated several species resistant to Ca(OH)2 regimens.

Trust comment: Randomized clinical trial with microbiological endpoints but small sample (36 teeth); useful comparative data but limited power.

Study Details

PMID:35723751
Participants:36
Impact:NAC eliminated 8 of 12 species that were resistant to both Ca(OH)2 regimens
Trust score:3/5

seizure recurrence

1 evidences

In children with hypocalcemic seizures, oral elemental calcium given for 48 h was as effective as intravenous calcium for preventing early seizure recurrence and restoring serum calcium.

Trust comment: Randomized controlled trial in 60 children with clear outcomes and direct comparison of oral vs IV calcium; sample size modest.

Study Details

PMID:35704218
Participants:60
Impact:IV 10% vs Oral 13.3% (no significant difference, p=0.278)
Trust score:4/5

serum total calcium at 24 h

1 evidences

In children with hypocalcemic seizures, oral elemental calcium given for 48 h was as effective as intravenous calcium for preventing early seizure recurrence and restoring serum calcium.

Trust comment: Randomized controlled trial in 60 children with clear outcomes and direct comparison of oral vs IV calcium; sample size modest.

Study Details

PMID:35704218
Participants:60
Impact:IV 7.96 mg/dL vs Oral 8.23 mg/dL (p=0.476)
Trust score:4/5

serum total calcium at 48 h

1 evidences

In children with hypocalcemic seizures, oral elemental calcium given for 48 h was as effective as intravenous calcium for preventing early seizure recurrence and restoring serum calcium.

Trust comment: Randomized controlled trial in 60 children with clear outcomes and direct comparison of oral vs IV calcium; sample size modest.

Study Details

PMID:35704218
Participants:60
Impact:IV 8.50 mg/dL vs Oral 8.63 mg/dL (p=0.681)
Trust score:4/5

calcium supplementation (intervention)

1 evidences

Feasibility RCT protocol: a musculoskeletal health package (MHP) including calcium 1000 mg/day + vitamin D is offered to medium/high fracture-risk women undergoing pelvic radiotherapy; primary aim is feasibility, not efficacy.

Trust comment: Well-described randomized feasibility protocol with planned human recruitment (n=80) but no efficacy results reported yet.

Study Details

PMID:35701060
Participants:80
Impact:1000 mg once daily provided to medium/high risk participants (no outcome data reported in protocol)
Trust score:3/5

serum ionized calcium (Ca2+)

2 evidences

Randomized trial in septic shock patients comparing 0.9% NaCl, Ringer, and an acetate-sodium-potassium-magnesium-calcium-glucose solution; 0.9% NaCl caused more hyperchloraemia and lower serum Ca2+ early after resuscitation.

Trust comment: Large randomized trial (n=280) with serial biochemical measures; clear differences in electrolytes but single-center study.

Study Details

PMID:30309406
Participants:280
Impact:Lower in 0.9% NaCl group at 3 h (1.10±0.08 vs 1.15±0.09 and 1.12±0.10 mmol/L) and 6 h (1.12±0.10 vs 1.16±0.08 and 1.15±0.09 mmol/L)
Trust score:4/5

In 100 severe sepsis patients, adding Xuebijing to CVVH was associated with higher post-treatment serum Ca2+ and better clinical outcomes versus CVVH alone.

Trust comment: Prospective case-control (randomized allocation stated) single-center study with modest sample size; outcome reporting lacks detailed numerical calcium values and may have bias risks.

Study Details

PMID:35685671
Participants:100
Impact:Significantly higher in CVVH+Xuebijing group vs CVVH alone (reported as significant; exact values not provided)
Trust score:3/5

treatment effective rate

2 evidences

In 100 severe sepsis patients, adding Xuebijing to CVVH was associated with higher post-treatment serum Ca2+ and better clinical outcomes versus CVVH alone.

Trust comment: Prospective case-control (randomized allocation stated) single-center study with modest sample size; outcome reporting lacks detailed numerical calcium values and may have bias risks.

Study Details

PMID:35685671
Participants:100
Impact:Study group 98% vs control 86% (p<0.05)
Trust score:3/5

In patients with lung cancer and bone metastases, adding zoledronic acid to treatment reduced serum calcium, pain, inflammation and improved quality-of-life and immune markers compared with control.

Trust comment: Randomized single-center study (n=104) reporting significant clinical and biochemical improvements including reduced serum calcium; methods are described but limited detail reduces confidence to moderate.

Study Details

PMID:34938354
Participants:104
Impact:96.0% (research) vs 81.5% (control); +14.5 percentage points
Trust score:3/5

parathyroid hormone (PTH) at 30 min

1 evidences

In 77 adults undergoing laparoscopic cholecystectomy, anesthetic technique influenced short-term PTH and ionized calcium: sevoflurane raised PTH at 30 min; TIVA showed higher ionized calcium at 30 min versus sevoflurane.

Trust comment: Prospective randomized controlled trial with clear time-point measurements (n=77); moderate sample size and appropriate methods.

Study Details

PMID:35685611
Participants:77
Impact:Higher with sevoflurane vs desflurane and TIVA (p=0.01; sevoflurane vs desflurane p=0.005; vs TIVA p=0.001)
Trust score:4/5

ionized calcium at 30 min

1 evidences

In 77 adults undergoing laparoscopic cholecystectomy, anesthetic technique influenced short-term PTH and ionized calcium: sevoflurane raised PTH at 30 min; TIVA showed higher ionized calcium at 30 min versus sevoflurane.

Trust comment: Prospective randomized controlled trial with clear time-point measurements (n=77); moderate sample size and appropriate methods.

Study Details

PMID:35685611
Participants:77
Impact:Higher with TIVA vs sevoflurane (p=0.024)
Trust score:4/5

serum calcium (association with sepsis)

1 evidences

Retrospective ICU cohort analysis (n=1295) developed a nomogram predicting sepsis in acute pancreatitis; lower serum calcium was an independent protective factor (higher calcium → lower sepsis risk).

Trust comment: Large retrospective single-center database analysis with validated model performance, but observational design limits causal inference.

Study Details

PMID:35685488
Participants:1295
Impact:Protective; OR=0.841 (95% CI 0.730–0.970) per unit increase (lower calcium associated with higher sepsis risk)
Trust score:3/5

serum urate

1 evidences

In low-calcium-consuming young adult women, adding ~770 mg/day calcium (from calcium citrate or skim milk) for 45 days reduced serum urate (~14% for calcium citrate, ~17% for skim milk) without affecting PTH or vitamin D.

Trust comment: Randomized, placebo-controlled trial directly testing calcium sources but small sample (n=35) and short duration; results plausible but limited by size.

Study Details

PMID:35623880
Participants:35
Impact:Reduced by ~14% (calcium citrate) and ~17% (skim milk)
Trust score:4/5

ionic calcium

1 evidences

In low-calcium-consuming young adult women, adding ~770 mg/day calcium (from calcium citrate or skim milk) for 45 days reduced serum urate (~14% for calcium citrate, ~17% for skim milk) without affecting PTH or vitamin D.

Trust comment: Randomized, placebo-controlled trial directly testing calcium sources but small sample (n=35) and short duration; results plausible but limited by size.

Study Details

PMID:35623880
Participants:35
Impact:Decreased (magnitude not specified)
Trust score:4/5

PTH and vitamin D

1 evidences

In low-calcium-consuming young adult women, adding ~770 mg/day calcium (from calcium citrate or skim milk) for 45 days reduced serum urate (~14% for calcium citrate, ~17% for skim milk) without affecting PTH or vitamin D.

Trust comment: Randomized, placebo-controlled trial directly testing calcium sources but small sample (n=35) and short duration; results plausible but limited by size.

Study Details

PMID:35623880
Participants:35
Impact:No significant change
Trust score:4/5

olfactory function (TDI score)

1 evidences

Intranasal NTA reduced nasal mucus calcium and markedly improved sense of smell in COVID-19 patients.

Trust comment: Randomized, double-blind controlled trial with objective measures (Sniffin’ Sticks, ion-selective electrode) but single-center and modest sample size.

Study Details

PMID:35567630
Participants:58
Impact:+20.33 points (from 11.58 to 31.91 in NTA group)
Trust score:4/5

odor threshold (T) score

1 evidences

Intranasal NTA reduced nasal mucus calcium and markedly improved sense of smell in COVID-19 patients.

Trust comment: Randomized, double-blind controlled trial with objective measures (Sniffin’ Sticks, ion-selective electrode) but single-center and modest sample size.

Study Details

PMID:35567630
Participants:58
Impact:+7.27 points (from 2.55 to 9.82 in NTA group)
Trust score:4/5

sugars intake (% energy)

1 evidences

In this cohort, pregnant women frequently did not meet recommended micronutrient intakes, including calcium, across trimesters.

Trust comment: Multicenter longitudinal FFQ-based analysis with 176 women using validated methods, but relies on self-reported intake and has typical FFQ limitations.

Study Details

PMID:35565911
Participants:176
Impact:above recommended percentage (≈20–24% vs <15% recommendation)
Trust score:4/5

repetitions performed (performance)

1 evidences

Three weeks of amorphous calcium carbonate produced mixed results: possible attenuation of performance decline and reduced upper-body soreness but no clear reduction in inflammation or muscle damage markers.

Trust comment: Double-blind randomized trial with objective performance and biomarker measures but small sample and underpowered, producing mixed/inferential results.

Study Details

PMID:35565859
Participants:28
Impact:ACC showed greater repetitions vs placebo (~+35% at T4, ~+55% at T5 difference reported)
Trust score:3/5

upper-body muscle soreness

1 evidences

Three weeks of amorphous calcium carbonate produced mixed results: possible attenuation of performance decline and reduced upper-body soreness but no clear reduction in inflammation or muscle damage markers.

Trust comment: Double-blind randomized trial with objective performance and biomarker measures but small sample and underpowered, producing mixed/inferential results.

Study Details

PMID:35565859
Participants:28
Impact:reduced with ACC (very likely/likely beneficial at T4 and T5)
Trust score:3/5

inflammatory markers / CK

1 evidences

Three weeks of amorphous calcium carbonate produced mixed results: possible attenuation of performance decline and reduced upper-body soreness but no clear reduction in inflammation or muscle damage markers.

Trust comment: Double-blind randomized trial with objective performance and biomarker measures but small sample and underpowered, producing mixed/inferential results.

Study Details

PMID:35565859
Participants:28
Impact:no clear beneficial change (mixed/unclear effects; some measures negative or unclear)
Trust score:3/5

mean systolic blood pressure

1 evidences

In hypertensive postmenopausal women, calcium plus vitamin D supplementation was associated with an increase in 24-h ambulatory systolic and diastolic blood pressure over 8 weeks.

Trust comment: Triple-blind randomized clinical trial with 24-h ambulatory BP monitoring and 98 participants but short duration and single population focus.

Study Details

PMID:35562420
Participants:98
Impact:increase (p=0.047) after supplementation
Trust score:4/5

mean diastolic blood pressure

1 evidences

In hypertensive postmenopausal women, calcium plus vitamin D supplementation was associated with an increase in 24-h ambulatory systolic and diastolic blood pressure over 8 weeks.

Trust comment: Triple-blind randomized clinical trial with 24-h ambulatory BP monitoring and 98 participants but short duration and single population focus.

Study Details

PMID:35562420
Participants:98
Impact:increase (p=0.015) after supplementation
Trust score:4/5

BP in patients on calcium channel blockers (subgroup)

1 evidences

In hypertensive postmenopausal women, calcium plus vitamin D supplementation was associated with an increase in 24-h ambulatory systolic and diastolic blood pressure over 8 weeks.

Trust comment: Triple-blind randomized clinical trial with 24-h ambulatory BP monitoring and 98 participants but short duration and single population focus.

Study Details

PMID:35562420
Participants:98
Impact:notable increase vs baseline (systolic p=0.019; diastolic p=0.001)
Trust score:4/5

cardiovascular death risk

1 evidences

In haemodialysis patients, higher markers of cholesterol absorption were linked to greater risk of cardiovascular death; cholesterol synthesis markers showed the opposite association.

Trust comment: Large randomized trial dataset with robust measurements, but this is a post-hoc analysis (good quality overall).

Study Details

PMID:35512252
Participants:2332
Impact:+36% (HR 1.36 for 3rd vs 1st tertile of cholestanol/cholesterol)
Trust score:4/5

cholesterol absorption (cholestanol/cholesterol ratio)

1 evidences

In haemodialysis patients, higher markers of cholesterol absorption were linked to greater risk of cardiovascular death; cholesterol synthesis markers showed the opposite association.

Trust comment: Large randomized trial dataset with robust measurements, but this is a post-hoc analysis (good quality overall).

Study Details

PMID:35512252
Participants:2332
Impact:higher absorption associated with increased cardiovascular death risk (HR 1.36)
Trust score:4/5

cholesterol synthesis (lathosterol/cholesterol ratio)

1 evidences

In haemodialysis patients, higher markers of cholesterol absorption were linked to greater risk of cardiovascular death; cholesterol synthesis markers showed the opposite association.

Trust comment: Large randomized trial dataset with robust measurements, but this is a post-hoc analysis (good quality overall).

Study Details

PMID:35512252
Participants:2332
Impact:higher synthesis associated with decreased cardiovascular death risk (HR 0.81)
Trust score:4/5

urine calcium/creatinine ratio (Ca/Cr)

1 evidences

In vitamin D–deficient community adults, vitamin D with or without calcium showed no clear clinical benefit over placebo at 6 months, though combined vitamin D+calcium reduced PTH and increased urine Ca/Cr in adherent subjects.

Trust comment: Randomized double-blind trial but substantial loss to follow-up and modest adherence limit confidence in null clinical findings.

Study Details

PMID:35505326
Participants:277
Impact:increased from 0.208 to 0.255 in vitamin D + calcium group (+0.047 at 6 months)
Trust score:3/5

treatment success (healed or healing)

1 evidences

In retreatment of single-rooted teeth with periapical lesions, single-visit and two-visit approaches (two-visit used calcium hydroxide interappointment dressing) had similar healing outcomes at 24 months.

Trust comment: Randomized clinical trial with 24-month follow-up and good methodology; dental-specific but small drop-out (89 recalled).

Study Details

PMID:35488883
Participants:89
Impact:single-visit 95.4% vs two-visit 91.1%; no significant difference (p>0.05)
Trust score:4/5

failure rate

1 evidences

In retreatment of single-rooted teeth with periapical lesions, single-visit and two-visit approaches (two-visit used calcium hydroxide interappointment dressing) had similar healing outcomes at 24 months.

Trust comment: Randomized clinical trial with 24-month follow-up and good methodology; dental-specific but small drop-out (89 recalled).

Study Details

PMID:35488883
Participants:89
Impact:single-visit 4.5% vs two-visit 8.9% (no significant difference)
Trust score:4/5

serum albumin-adjusted calcium

2 evidences

In chronic postsurgical hypoparathyroidism, calcium citrate was as effective as calcium carbonate at maintaining serum calcium, reduced urinary oxalate excretion, and caused less constipation.

Trust comment: Double-blind crossover RCT with rigorous metabolic measures but small sample size (n=24) typical for this rare condition.

Study Details

PMID:35466449
Participants:24
Impact:no difference between Ca-citrate and Ca-carbonate (both maintained target calcium)
Trust score:4/5

Phase 1 randomized double-blind placebo-controlled trial of TransCon PTH showing dose-dependent increases in serum calcium with maintained urinary calcium excretion and increased renal phosphate excretion.

Trust comment: Well-conducted randomized double-blind phase 1 trial with detailed PK/PD and objective biochemical endpoints in healthy volunteers.

Study Details

PMID:32212275
Participants:132
Impact:dose-dependent increase (example: +1.54 mg/dL at single 124 μg cohort; +1.03 mg/dL at 24 μg/day MAD)
Trust score:4/5

urinary oxalate/creatinine

1 evidences

In chronic postsurgical hypoparathyroidism, calcium citrate was as effective as calcium carbonate at maintaining serum calcium, reduced urinary oxalate excretion, and caused less constipation.

Trust comment: Double-blind crossover RCT with rigorous metabolic measures but small sample size (n=24) typical for this rare condition.

Study Details

PMID:35466449
Participants:24
Impact:Ca-citrate: −2.46 mmol/mol vs Ca-carbonate: +7.42 mmol/mol (between-group p=0.029)
Trust score:4/5

constipation frequency

1 evidences

In chronic postsurgical hypoparathyroidism, calcium citrate was as effective as calcium carbonate at maintaining serum calcium, reduced urinary oxalate excretion, and caused less constipation.

Trust comment: Double-blind crossover RCT with rigorous metabolic measures but small sample size (n=24) typical for this rare condition.

Study Details

PMID:35466449
Participants:24
Impact:Ca-citrate 4.3% vs Ca-carbonate 30.4% (p=0.047)
Trust score:4/5

horizontal bone dimensional change

1 evidences

Using calcium phosphosilicate (CPS) bone grafts (with or without PRF) after tooth extraction reduced horizontal bone loss and maintained bone density at 6 months.

Trust comment: Small randomized human clinical trial with objective CBCT measures but limited sample size (n=30) and short follow-up.

Study Details

PMID:35353097
Participants:30
Impact:reduced (statistically significant vs control)
Trust score:3/5

vertical bone dimensional change

1 evidences

Using calcium phosphosilicate (CPS) bone grafts (with or without PRF) after tooth extraction reduced horizontal bone loss and maintained bone density at 6 months.

Trust comment: Small randomized human clinical trial with objective CBCT measures but limited sample size (n=30) and short follow-up.

Study Details

PMID:35353097
Participants:30
Impact:no significant change
Trust score:3/5

bone density (Hounsfield units)

1 evidences

Using calcium phosphosilicate (CPS) bone grafts (with or without PRF) after tooth extraction reduced horizontal bone loss and maintained bone density at 6 months.

Trust comment: Small randomized human clinical trial with objective CBCT measures but limited sample size (n=30) and short follow-up.

Study Details

PMID:35353097
Participants:30
Impact:maintained within 350–850 HU (D3) at 6 months
Trust score:3/5

nutritional status (ALB/TP/PA)

1 evidences

Adding systematic diet education and multidisciplinary nursing improved nutrition, lowered serum phosphorus and Ca×P product, and reduced anxiety in DKD patients on alogliptin.

Trust comment: Randomized allocation with clear biochemical outcomes in 90 patients, but single-center design and short follow-up limit generalizability.

Study Details

PMID:35340239
Participants:90
Impact:increased (P<0.001)
Trust score:3/5

calcium-phosphorus product

2 evidences

Adding systematic diet education and multidisciplinary nursing improved nutrition, lowered serum phosphorus and Ca×P product, and reduced anxiety in DKD patients on alogliptin.

Trust comment: Randomized allocation with clear biochemical outcomes in 90 patients, but single-center design and short follow-up limit generalizability.

Study Details

PMID:35340239
Participants:90
Impact:decreased (P<0.001)
Trust score:3/5

Randomized study in hemodialysis patients (105 completers) showing that adding rhubarb to medicinal activated carbon reduced serum phosphorus, calcium-phosphorus product, and PTH over 8 weeks.

Trust comment: Randomized trial with a reasonable completer number but limited reporting clarity and potential methodological concerns.

Study Details

PMID:30634204
Participants:105
Impact:decreased (treatment)
Trust score:3/5

lesion area

1 evidences

Both CPP-ACP (a calcium‑containing remineralizing agent) and resin infiltration reduced white spot lesion area and improved lesion color over 12 months.

Trust comment: Randomized clinical trial in children (n=60) with objective image and colorimetric measures; moderate sample size and follow-up support moderate confidence.

Study Details

PMID:35311975
Participants:60
Impact:reduced (significant)
Trust score:3/5

lesion color (aesthetic)

1 evidences

Both CPP-ACP (a calcium‑containing remineralizing agent) and resin infiltration reduced white spot lesion area and improved lesion color over 12 months.

Trust comment: Randomized clinical trial in children (n=60) with objective image and colorimetric measures; moderate sample size and follow-up support moderate confidence.

Study Details

PMID:35311975
Participants:60
Impact:improved (significant)
Trust score:3/5

lumbar spine bone mineral density

1 evidences

Post hoc analysis of two large phase‑3 trials showing romosozumab increased bone mineral density and reduced vertebral fractures across kidney function categories; hypocalcemia events were rare.

Trust comment: Large post hoc analysis of two randomized phase 3 trials (total >11k patients) with central imaging and robust statistical methods; limited by being subgroup/post hoc.

Study Details

PMID:35466448
Participants:11224
Impact:+10.9–13.7% LS mean increase (month 12, across eGFR subgroups)
Trust score:5/5

new vertebral fractures

2 evidences

Post hoc analysis of two large phase‑3 trials showing romosozumab increased bone mineral density and reduced vertebral fractures across kidney function categories; hypocalcemia events were rare.

Trust comment: Large post hoc analysis of two randomized phase 3 trials (total >11k patients) with central imaging and robust statistical methods; limited by being subgroup/post hoc.

Study Details

PMID:35466448
Participants:11224
Impact:relative risk reduction 70–84% (FRAME across eGFR subgroups)
Trust score:5/5

In osteoporosis patients given denosumab plus vitamin D and calcium supplements, supplementation raised 25(OH)D to sufficiency and denosumab increased BMD and reduced vertebral fracture risk versus placebo irrespective of baseline vitamin D status.

Trust comment: Large randomized, double-blind, placebo-controlled trial (prespecified subanalysis); high-quality evidence though subanalysis limits full certainty.

Study Details

PMID:32671481
Participants:956
Impact:Lower risk at 24 months in denosumab-treated subjects (deficient/insufficient baseline) vs placebo
Trust score:4/5

decrease in serum calcium / hypocalcemia events

1 evidences

Post hoc analysis of two large phase‑3 trials showing romosozumab increased bone mineral density and reduced vertebral fractures across kidney function categories; hypocalcemia events were rare.

Trust comment: Large post hoc analysis of two randomized phase 3 trials (total >11k patients) with central imaging and robust statistical methods; limited by being subgroup/post hoc.

Study Details

PMID:35466448
Participants:11224
Impact:19 patients in FRAME had decreased albumin-adjusted serum calcium (14 romosozumab vs 5 placebo); 3 investigator-reported mild-to-moderate hypocalcemia events across both trials
Trust score:5/5

uterine atony incidence

1 evidences

Pilot double‑blind RCT (n=40) found 1 g IV calcium chloride at cord clamping raised ionized calcium and was well tolerated; uterine atony occurred less frequently in calcium group (20% vs 50%) though result was not statistically significant.

Trust comment: Small double‑blind randomized pilot RCT with correct design but limited sample size and underpowered for definitive efficacy (p=0.07 for primary efficacy outcome).

Study Details

PMID:35447502
Participants:40
Impact:20% (calcium) vs 50% (placebo); relative risk 0.38, P = 0.07 (NNT ≈ 3.3)
Trust score:3/5

ionized serum calcium

3 evidences

One week of cinacalcet (30 mg/day) lowered blood calcium and PTH but did not significantly change arterial stiffness or heart function in hemodialysis patients.

Trust comment: Randomized double-blind crossover RCT with rigorous measures but small sample and some missing echocardiography data, likely underpowered for arterial stiffness endpoints.

Study Details

PMID:28538380
Participants:21
Impact:-0.06 mmol/L (1.11 → 1.05 mmol/L), P=0.04
Trust score:4/5

In women with primary hyperparathyroidism, parathyroidectomy (which corrects hypercalcemia) reduced premature heart beats and normalized QTc on 24-h ECG.

Trust comment: Randomized human study with objective ECG endpoints but small sample size (n=52).

Study Details

PMID:29875287
Participants:52
Impact:Elevated in PHPT vs controls (negative correlation with QTc)
Trust score:4/5

Pilot double‑blind RCT (n=40) found 1 g IV calcium chloride at cord clamping raised ionized calcium and was well tolerated; uterine atony occurred less frequently in calcium group (20% vs 50%) though result was not statistically significant.

Trust comment: Small double‑blind randomized pilot RCT with correct design but limited sample size and underpowered for definitive efficacy (p=0.07 for primary efficacy outcome).

Study Details

PMID:35447502
Participants:40
Impact:increased from 1.18 mmol/L baseline to peak 1.50–1.60 mmol/L after 1 g IV calcium
Trust score:3/5

adverse events/tolerability

1 evidences

Pilot double‑blind RCT (n=40) found 1 g IV calcium chloride at cord clamping raised ionized calcium and was well tolerated; uterine atony occurred less frequently in calcium group (20% vs 50%) though result was not statistically significant.

Trust comment: Small double‑blind randomized pilot RCT with correct design but limited sample size and underpowered for definitive efficacy (p=0.07 for primary efficacy outcome).

Study Details

PMID:35447502
Participants:40
Impact:no adverse events; similar side‑effect incidence to placebo
Trust score:3/5

length of hospital stay

1 evidences

A multimodal nutrition protocol around knee replacement reduced albumin transfusions, electrolyte disorders including low calcium on day 1, and shortened hospital stay.

Trust comment: Randomized controlled trial with 162 patients and significant p-values; calcium-related outcomes were secondary but directly measured.

Study Details

PMID:28697860
Participants:162
Impact:shorter (P<0.001)
Trust score:4/5

Dental calculus accumulation

1 evidences

Double-blind RCT testing a cuttlebone-derived aragonite toothpaste versus a commercial tartar-control toothpaste; aragonite reduced supragingival calculus and improved gingival inflammation and patient satisfaction over 9 months.

Trust comment: Well-designed double-blind RCT with prolonged follow-up, but industry funding and an author having company shares pose potential conflicts of interest.

Study Details

PMID:35419985
Participants:81
Impact:-30% with aragonite vs +15% with Crest at 3 months; between-group difference ≈ -45% (p=0.0001)
Trust score:3/5

Gingival inflammation (MGI)

1 evidences

Double-blind RCT testing a cuttlebone-derived aragonite toothpaste versus a commercial tartar-control toothpaste; aragonite reduced supragingival calculus and improved gingival inflammation and patient satisfaction over 9 months.

Trust comment: Well-designed double-blind RCT with prolonged follow-up, but industry funding and an author having company shares pose potential conflicts of interest.

Study Details

PMID:35419985
Participants:81
Impact:MGI decreased ~30% with aragonite vs ~18% with Crest; aragonite 22% lower than Crest (p=0.0059)
Trust score:3/5

patient satisfaction

1 evidences

Double-blind RCT testing a cuttlebone-derived aragonite toothpaste versus a commercial tartar-control toothpaste; aragonite reduced supragingival calculus and improved gingival inflammation and patient satisfaction over 9 months.

Trust comment: Well-designed double-blind RCT with prolonged follow-up, but industry funding and an author having company shares pose potential conflicts of interest.

Study Details

PMID:35419985
Participants:81
Impact:Higher satisfaction with aragonite at 9 months for texture, consistency, stickiness and overall (p<0.05)
Trust score:3/5

Calcium absorption (42Ca tracer)

1 evidences

Randomized 3-week crossover in young women showed that daily synbiotic yogurt (inulin + L. rhamnosus GG) increased fractional calcium absorption versus control in a majority of participants using a 42Ca tracer.

Trust comment: Mechanistically focused crossover study using isotopic tracer measurements (robust method) but with a small sample of healthy young women limiting generalizability.

Study Details

PMID:35411924
Participants:30
Impact:Increased with synbiotic yogurt in 19/30 women (~63% responders); SYN/CON 0–36h tracer ratio >1 in responders
Trust score:4/5

Responder proportion

1 evidences

Randomized 3-week crossover in young women showed that daily synbiotic yogurt (inulin + L. rhamnosus GG) increased fractional calcium absorption versus control in a majority of participants using a 42Ca tracer.

Trust comment: Mechanistically focused crossover study using isotopic tracer measurements (robust method) but with a small sample of healthy young women limiting generalizability.

Study Details

PMID:35411924
Participants:30
Impact:19 of 30 participants showed a beneficial absorption response to the synbiotic (≈63%)
Trust score:4/5

Timing/site of absorption

1 evidences

Randomized 3-week crossover in young women showed that daily synbiotic yogurt (inulin + L. rhamnosus GG) increased fractional calcium absorption versus control in a majority of participants using a 42Ca tracer.

Trust comment: Mechanistically focused crossover study using isotopic tracer measurements (robust method) but with a small sample of healthy young women limiting generalizability.

Study Details

PMID:35411924
Participants:30
Impact:Pattern of tracer recovery suggests enhanced absorption likely occurring in the large intestine (timed urine pools)
Trust score:4/5

Inflammatory markers (hs-CRP, TNF-α)

1 evidences

Non-blinded randomized study in chronic renal failure patients comparing high-flux hemodialysis versus conventional hemodiafiltration: high-flux dialysis was associated with greater reductions in inflammatory markers, improved antioxidant indices, better immune cell markers and improved calcium/phosphorus balance.

Trust comment: Randomized clinical study with clear pre/post biochemical endpoints, but reporting lacks detail on blinding and long-term outcomes, and methods descriptions are somewhat limited.

Study Details

PMID:35388330
Participants:92
Impact:Decreased after treatment in both groups but significantly more reduction in the high-flux group (p<0.05)
Trust score:3/5

Antioxidant markers (MDA, SOD)

1 evidences

Non-blinded randomized study in chronic renal failure patients comparing high-flux hemodialysis versus conventional hemodiafiltration: high-flux dialysis was associated with greater reductions in inflammatory markers, improved antioxidant indices, better immune cell markers and improved calcium/phosphorus balance.

Trust comment: Randomized clinical study with clear pre/post biochemical endpoints, but reporting lacks detail on blinding and long-term outcomes, and methods descriptions are somewhat limited.

Study Details

PMID:35388330
Participants:92
Impact:MDA decreased and SOD increased in both groups, with greater improvement in the high-flux group (p<0.05)
Trust score:3/5

Serum total calcium and phosphorus balance

1 evidences

Non-blinded randomized study in chronic renal failure patients comparing high-flux hemodialysis versus conventional hemodiafiltration: high-flux dialysis was associated with greater reductions in inflammatory markers, improved antioxidant indices, better immune cell markers and improved calcium/phosphorus balance.

Trust comment: Randomized clinical study with clear pre/post biochemical endpoints, but reporting lacks detail on blinding and long-term outcomes, and methods descriptions are somewhat limited.

Study Details

PMID:35388330
Participants:92
Impact:Higher serum total calcium and lower serum phosphorus after high-flux hemodialysis versus control (p<0.05); fewer calcium/phosphorus metabolic abnormalities in high-flux group
Trust score:3/5

blood pressure (SBP/DBP)

1 evidences

In a 6‑month weight‑loss RCT, calcium + vitamin D supplements or increased low‑fat dairy produced greater improvements in some cardiometabolic markers (blood pressure, lipid fractions, 25(OH)D and PTH) than hypocaloric diet alone.

Trust comment: Randomized, controlled weight‑loss trial with blinded supplements and objective measures; secondary complete‑case analysis reduced sample size which limits power but design and measurements are robust.

Study Details

PMID:35268057
Participants:97
Impact:SBP and DBP decreased in all groups; greater decreases in calcium+vitamin D (S) and dairy (D) groups vs control
Trust score:4/5

serum lipids

1 evidences

In a 6‑month weight‑loss RCT, calcium + vitamin D supplements or increased low‑fat dairy produced greater improvements in some cardiometabolic markers (blood pressure, lipid fractions, 25(OH)D and PTH) than hypocaloric diet alone.

Trust comment: Randomized, controlled weight‑loss trial with blinded supplements and objective measures; secondary complete‑case analysis reduced sample size which limits power but design and measurements are robust.

Study Details

PMID:35268057
Participants:97
Impact:triglycerides ↓ most in S; total cholesterol and LDL‑C ↓ most in D; HDL‑C ↑ most in S
Trust score:4/5

25(OH)D and PTH

1 evidences

In a 6‑month weight‑loss RCT, calcium + vitamin D supplements or increased low‑fat dairy produced greater improvements in some cardiometabolic markers (blood pressure, lipid fractions, 25(OH)D and PTH) than hypocaloric diet alone.

Trust comment: Randomized, controlled weight‑loss trial with blinded supplements and objective measures; secondary complete‑case analysis reduced sample size which limits power but design and measurements are robust.

Study Details

PMID:35268057
Participants:97
Impact:25(OH)D increased significantly in S and D groups; PTH decreased (notably in S)
Trust score:4/5

enamel mineral density (LF)

1 evidences

In 22 children with MIH, topical CPP-ACFP and calcium glycerophosphate reduced enamel hypomineralization over 3 months as measured by laser fluorescence.

Trust comment: Randomized crossover RCT with objective LF measures but small sample and short (3-month) follow-up, limiting generalizability.

Study Details

PMID:35253727
Participants:22
Impact:increased / decreased hypomineralization (significant change in LF values; p<0.05)
Trust score:3/5

≥20% mineral density increase (treatment comparison)

1 evidences

In 22 children with MIH, topical CPP-ACFP and calcium glycerophosphate reduced enamel hypomineralization over 3 months as measured by laser fluorescence.

Trust comment: Randomized crossover RCT with objective LF measures but small sample and short (3-month) follow-up, limiting generalizability.

Study Details

PMID:35253727
Participants:22
Impact:no significant difference between CPP-ACFP and CaGP (white/creamy p=0.970; yellow/brown p=0.948)
Trust score:3/5

Ca/Mg ratio — biochemical pregnancy

1 evidences

Pre-IVF serum Ca and Mg (expressed as Ca/Mg ratio) were analyzed: a higher baseline Ca/Mg ratio was associated with higher biochemical and clinical pregnancy rates and higher (trend) live birth rates.

Trust comment: Prospective subanalysis with 110 well-characterized women, extensive multivariable adjustment and objective lab measures, supporting moderate-high trust though sample size is modest.

Study Details

PMID:35222266
Participants:110
Impact:Q4 vs Q1 OR 6.58 (95% CI 1.31–33.04), p-trend=0.000
Trust score:4/5

Ca/Mg ratio — clinical pregnancy

1 evidences

Pre-IVF serum Ca and Mg (expressed as Ca/Mg ratio) were analyzed: a higher baseline Ca/Mg ratio was associated with higher biochemical and clinical pregnancy rates and higher (trend) live birth rates.

Trust comment: Prospective subanalysis with 110 well-characterized women, extensive multivariable adjustment and objective lab measures, supporting moderate-high trust though sample size is modest.

Study Details

PMID:35222266
Participants:110
Impact:Q4 vs Q1 OR 4.85 (95% CI 1.02–23.08), p-trend=0.000
Trust score:4/5

Ca/Mg ratio — live birth

1 evidences

Pre-IVF serum Ca and Mg (expressed as Ca/Mg ratio) were analyzed: a higher baseline Ca/Mg ratio was associated with higher biochemical and clinical pregnancy rates and higher (trend) live birth rates.

Trust comment: Prospective subanalysis with 110 well-characterized women, extensive multivariable adjustment and objective lab measures, supporting moderate-high trust though sample size is modest.

Study Details

PMID:35222266
Participants:110
Impact:Q4 vs Q1 OR 4.07 (95% CI 0.83–19.9), p-trend=0.000
Trust score:4/5

CPP-I (primary calciprotein particles)

1 evidences

Exploratory analysis of a randomized placebo-controlled trial in CKD stage 3b–4: lanthanum carbonate did not significantly change serum primary (CPP-I) or secondary (CPP-II) calciprotein particle levels over 96 weeks.

Trust comment: Randomized, placebo-controlled multicenter trial with moderate sample (n=253) and centralized blinded assays; exploratory sub-study but well conducted—findings robust for null effect on CPP.

Study Details

PMID:35212735
Participants:253
Impact:+22.8% (95% CI −39.2, 36.4) vs placebo at 96 weeks — not significant (P=0.65)
Trust score:4/5

CPP-II (secondary calciprotein particles)

1 evidences

Exploratory analysis of a randomized placebo-controlled trial in CKD stage 3b–4: lanthanum carbonate did not significantly change serum primary (CPP-I) or secondary (CPP-II) calciprotein particle levels over 96 weeks.

Trust comment: Randomized, placebo-controlled multicenter trial with moderate sample (n=253) and centralized blinded assays; exploratory sub-study but well conducted—findings robust for null effect on CPP.

Study Details

PMID:35212735
Participants:253
Impact:−18.3% (95% CI −40.0, 11.2) vs placebo at 96 weeks — not significant (P=0.20)
Trust score:4/5

CPP correlation with vascular markers

1 evidences

Exploratory analysis of a randomized placebo-controlled trial in CKD stage 3b–4: lanthanum carbonate did not significantly change serum primary (CPP-I) or secondary (CPP-II) calciprotein particle levels over 96 weeks.

Trust comment: Randomized, placebo-controlled multicenter trial with moderate sample (n=253) and centralized blinded assays; exploratory sub-study but well conducted—findings robust for null effect on CPP.

Study Details

PMID:35212735
Participants:253
Impact:No correlation between baseline CPP (I or II) and PWV or aortic calcification or their change at 96 weeks
Trust score:4/5

horizontal dimension of augmented hard tissue (HD)

1 evidences

Randomized trial in 40 patients comparing soft-block biphasic calcium phosphate (BCP+collagen) versus particulate BCP for peri-implant defects; no significant difference in augmented hard‑tissue horizontal dimension at 6 months.

Trust comment: Small randomized clinical trial directly using calcium‑phosphate bone substitutes (relevant to calcium biomaterials); limited sample size reduces confidence in small effect detection.

Study Details

PMID:35191065
Participants:40
Impact:median HD: soft-block 1.15 mm vs particulate 0.93 mm at 6 months (p=0.6)
Trust score:3/5

intact PTH target achievement

1 evidences

In dialysis patients with secondary hyperparathyroidism, evocalcet reduced PTH and FGF23 and, when combined with IV VDRA, improved corrected-calcium target attainment and reduced hypocalcemia incidence.

Trust comment: Large multicenter randomized phase-3 dataset with predefined efficacy/safety endpoints; ad-hoc subgrouping but clinically relevant outcomes.

Study Details

PMID:35176038
Participants:317
Impact:+11.5% (adjusted difference, HDG vs NDG)
Trust score:4/5

Corrected calcium target achievement

1 evidences

In dialysis patients with secondary hyperparathyroidism, evocalcet reduced PTH and FGF23 and, when combined with IV VDRA, improved corrected-calcium target attainment and reduced hypocalcemia incidence.

Trust comment: Large multicenter randomized phase-3 dataset with predefined efficacy/safety endpoints; ad-hoc subgrouping but clinically relevant outcomes.

Study Details

PMID:35176038
Participants:317
Impact:+16.4% (adjusted difference, HDG vs NDG)
Trust score:4/5

intact FGF23 levels

1 evidences

In dialysis patients with secondary hyperparathyroidism, evocalcet reduced PTH and FGF23 and, when combined with IV VDRA, improved corrected-calcium target attainment and reduced hypocalcemia incidence.

Trust comment: Large multicenter randomized phase-3 dataset with predefined efficacy/safety endpoints; ad-hoc subgrouping but clinically relevant outcomes.

Study Details

PMID:35176038
Participants:317
Impact:decrease (greater reduction in low-VDRA group vs high-VDRA group; p<0.005)
Trust score:4/5

tooth bleaching sensitivity

1 evidences

In-office tooth bleaching patients given desensitizing gels/pastes (including a nanostructured calcium phosphate paste) did not experience meaningful reductions in bleaching sensitivity nor change in color outcome.

Trust comment: Randomized clinical trial with balanced groups (n=75); small sample but appropriate design and outcomes measured clinically.

Study Details

PMID:35175011
Participants:75
Impact:no significant decrease with nanostructured calcium phosphate paste (no effect)
Trust score:4/5

color change

1 evidences

In-office tooth bleaching patients given desensitizing gels/pastes (including a nanostructured calcium phosphate paste) did not experience meaningful reductions in bleaching sensitivity nor change in color outcome.

Trust comment: Randomized clinical trial with balanced groups (n=75); small sample but appropriate design and outcomes measured clinically.

Study Details

PMID:35175011
Participants:75
Impact:no interference (no change)
Trust score:4/5

treatment success rate (12 months)

2 evidences

Randomized clinical comparison of two calcium-based dental capping materials (iRoot vs MTA) in pulpotomy; both showed high success and similar effectiveness at 12 months.

Trust comment: Randomized clinical trial with blinded patients/evaluators but small sample and some loss to follow-up, limiting precision.

Study Details

PMID:35165477
Participants:36
Impact:100% success in both groups
Trust score:3/5

Split-mouth randomized trial in 46 children comparing TheraCal vs MTA for direct pulp capping; after 12 months both materials showed high and similar success rates.

Trust comment: Randomized split-mouth clinical trial in children with 12-month follow-up and objective clinical/radiographic outcomes; moderate quality.

Study Details

PMID:29767382
Participants:46
Impact:TheraCal 91.8%; MTA 94.5%; difference not statistically significant (P>0.05)
Trust score:4/5

cure rate (12 months)

1 evidences

Randomized clinical comparison of two calcium-based dental capping materials (iRoot vs MTA) in pulpotomy; both showed high success and similar effectiveness at 12 months.

Trust comment: Randomized clinical trial with blinded patients/evaluators but small sample and some loss to follow-up, limiting precision.

Study Details

PMID:35165477
Participants:36
Impact:iRoot 94.4% vs MTA 100% (no significant difference)
Trust score:3/5

crown discoloration

1 evidences

Randomized clinical comparison of two calcium-based dental capping materials (iRoot vs MTA) in pulpotomy; both showed high success and similar effectiveness at 12 months.

Trust comment: Randomized clinical trial with blinded patients/evaluators but small sample and some loss to follow-up, limiting precision.

Study Details

PMID:35165477
Participants:36
Impact:iRoot 0 cases vs MTA 3 cases (less discoloration with iRoot)
Trust score:3/5

pulpotomy success rate (1 year)

1 evidences

Full pulpotomy using three calcium silicate materials gave high 1-year success and rapid pain relief in symptomatic permanent molars.

Trust comment: Well-designed randomized, double-blind RCT with 1-year follow-up and trial registration.

Study Details

PMID:35152464
Participants:146
Impact:92.3% overall (144/156 teeth attended follow-up)
Trust score:5/5

postoperative pain relief (first week)

1 evidences

Full pulpotomy using three calcium silicate materials gave high 1-year success and rapid pain relief in symptomatic permanent molars.

Trust comment: Well-designed randomized, double-blind RCT with 1-year follow-up and trial registration.

Study Details

PMID:35152464
Participants:146
Impact:96.9% reported complete relief or mild pain
Trust score:5/5

material comparison

1 evidences

Full pulpotomy using three calcium silicate materials gave high 1-year success and rapid pain relief in symptomatic permanent molars.

Trust comment: Well-designed randomized, double-blind RCT with 1-year follow-up and trial registration.

Study Details

PMID:35152464
Participants:146
Impact:No significant difference between MTA (91.8%), Biodentine (93.3%), and TotalFill (91.9%)
Trust score:5/5

stone expulsion rate

1 evidences

Mirabegron and tamsulosin increased stone expulsion rates compared with analgesic-only, with differences in mean expulsion time among groups.

Trust comment: Randomized, double-blinded controlled trial with moderate sample size though some exclusions reduced analyzed numbers.

Study Details

PMID:35100594
Participants:75
Impact:Increased significantly in mirabegron (group A) and tamsulosin (group B) vs control (group C)
Trust score:4/5

mean stone expulsion time

1 evidences

Mirabegron and tamsulosin increased stone expulsion rates compared with analgesic-only, with differences in mean expulsion time among groups.

Trust comment: Randomized, double-blinded controlled trial with moderate sample size though some exclusions reduced analyzed numbers.

Study Details

PMID:35100594
Participants:75
Impact:Group A (mirabegron) ~15 days; Group B (tamsulosin) ~25 days; Group C (control) ~12 days
Trust score:4/5

Workload at lactate threshold (WR_LT)

1 evidences

Six days of sodium phosphate in trained cyclists slightly increased submaximal work (lactate threshold) and raised serum phosphate but did not change serum calcium or overall VO2max; some individuals (responders) showed larger aerobic improvements.

Trust comment: Randomized, placebo-controlled crossover in trained humans with detailed physiologic measures; moderate sample size (n=22) limits generalizability; calcium-related outcome was directly measured.

Study Details

PMID:35057416
Participants:22
Impact:+2.8% increase after SP supplementation
Trust score:4/5

serum inorganic phosphate (Pi)

1 evidences

Six days of sodium phosphate in trained cyclists slightly increased submaximal work (lactate threshold) and raised serum phosphate but did not change serum calcium or overall VO2max; some individuals (responders) showed larger aerobic improvements.

Trust comment: Randomized, placebo-controlled crossover in trained humans with detailed physiologic measures; moderate sample size (n=22) limits generalizability; calcium-related outcome was directly measured.

Study Details

PMID:35057416
Participants:22
Impact:+9.0% increase after SP supplementation
Trust score:4/5

Total hip bone mineral density (TH BMD) in females

1 evidences

Motivational interviewing increased dairy intake; in female adolescents who consumed ≥4 dairy servings/day for 12 months, total hip BMD increased more than controls, whereas males showed no DXA bone benefits.

Trust comment: Randomized trial with measured dietary (dairy/calcium) intake and DXA outcomes; moderate sample and 80.9% 12-month completion give reasonable confidence for female-specific effect.

Study Details

PMID:35015862
Participants:76
Impact:Greater increases in high-dairy group vs control (12 mo: 4.3% vs 3.7%; 24 mo: 7.5% vs 4.9%)
Trust score:4/5

Weight gain (primary)

1 evidences

In preterm infants, a higher-protein formula with modified fat blend improved weight gain and was safe; some bone-mineral biomarkers (plasma phosphorus, alkaline phosphatase, urinary calcium/phosphorus ratio) differed between formulas but remained within normal ranges.

Trust comment: Well-conducted RCT in preterm infants with relevant bone-mineral biomarker data; calcium-related biomarkers changed but calcium intake was not the primary manipulated variable.

Study Details

PMID:35000893
Participants:160
Impact:Mean weight gain +3.09 g/day in experimental formula vs control (superiority achieved)
Trust score:3/5

Bone mineral biomarkers (plasma phosphorus, ALP, urinary Ca/P)

1 evidences

In preterm infants, a higher-protein formula with modified fat blend improved weight gain and was safe; some bone-mineral biomarkers (plasma phosphorus, alkaline phosphatase, urinary calcium/phosphorus ratio) differed between formulas but remained within normal ranges.

Trust comment: Well-conducted RCT in preterm infants with relevant bone-mineral biomarker data; calcium-related biomarkers changed but calcium intake was not the primary manipulated variable.

Study Details

PMID:35000893
Participants:160
Impact:Statistically different between groups on day 21 but values stayed within normal clinical ranges
Trust score:3/5

stool consistency

1 evidences

In preterm infants, a higher-protein formula with modified fat blend improved weight gain and was safe; some bone-mineral biomarkers (plasma phosphorus, alkaline phosphatase, urinary calcium/phosphorus ratio) differed between formulas but remained within normal ranges.

Trust comment: Well-conducted RCT in preterm infants with relevant bone-mineral biomarker data; calcium-related biomarkers changed but calcium intake was not the primary manipulated variable.

Study Details

PMID:35000893
Participants:160
Impact:Tended toward softer stools in experimental formula (P=0.07)
Trust score:3/5

weight loss (%TWL / BMI)

1 evidences

Long BPL RYGB led to faster and greater weight loss and better diabetes/dyslipidaemia control; it produced lower serum calcium and hemoglobin and higher PTH compared with standard RYGB, but values remained within normal range.

Trust comment: Randomized prospective trial with 150 randomized and 121 completers; outcomes and nutritional labs reported, though some nutritional differences were small and within normal ranges.

Study Details

PMID:34981324
Participants:121
Impact:Greater/faster weight loss and higher %TWL in long BPL RYGB vs standard RYGB (L-RYGB > S-RYGB)
Trust score:4/5

diabetes control

1 evidences

Long BPL RYGB led to faster and greater weight loss and better diabetes/dyslipidaemia control; it produced lower serum calcium and hemoglobin and higher PTH compared with standard RYGB, but values remained within normal range.

Trust comment: Randomized prospective trial with 150 randomized and 121 completers; outcomes and nutritional labs reported, though some nutritional differences were small and within normal ranges.

Study Details

PMID:34981324
Participants:121
Impact:Improved remission/control of diabetes in L-RYGB vs S-RYGB
Trust score:4/5

trabecular BMC / vBMD (tibia)

1 evidences

Adding collagen peptides to calcium + vitamin D for 12 months increased trabecular bone mass and vBMD at the tibia, prevented spine aBMD decline, and reduced bone turnover versus calcium + vitamin D alone.

Trust comment: Randomized 12-month study in postmenopausal women with clear imaging and marker endpoints; modest sample size but appropriate measures and statistical reporting.

Study Details

PMID:34980546
Participants:51
Impact:+5.24% trabecular BMC; +2.54% trabecular vBMD at 12 mo (Group A vs B)
Trust score:4/5

spine areal BMD

1 evidences

Adding collagen peptides to calcium + vitamin D for 12 months increased trabecular bone mass and vBMD at the tibia, prevented spine aBMD decline, and reduced bone turnover versus calcium + vitamin D alone.

Trust comment: Randomized 12-month study in postmenopausal women with clear imaging and marker endpoints; modest sample size but appropriate measures and statistical reporting.

Study Details

PMID:34980546
Participants:51
Impact:Higher mean spine aBMD in Group A vs Group B (p = 0.01)
Trust score:4/5

Urinary pH

1 evidences

A controlled crossover feeding study found K-gluconate supplementation lowered urinary calcium excretion and increased urinary pH versus control, but did not produce significant differences in net calcium retention or % absorption.

Trust comment: Well-controlled crossover feeding trial with direct calcium balance measures, but modest sample size and some analyte-specific missing data reduced power for balance endpoints.

Study Details

PMID:34959951
Participants:30
Impact:Higher with K-gluconate supplement: 6.54 ± 0.2 vs control 6.08 ± 0.2 (p = 0.0036)
Trust score:4/5

calcium retention (% and mg/d)

1 evidences

A controlled crossover feeding study found K-gluconate supplementation lowered urinary calcium excretion and increased urinary pH versus control, but did not produce significant differences in net calcium retention or % absorption.

Trust comment: Well-controlled crossover feeding trial with direct calcium balance measures, but modest sample size and some analyte-specific missing data reduced power for balance endpoints.

Study Details

PMID:34959951
Participants:30
Impact:No significant differences in absolute Ca retention or % absorption across interventions (supplement retention 260 ± 46 mg/d vs control 162 ± 58 mg/d; p = 0.27)
Trust score:4/5

calcium balance (24 h)

1 evidences

Randomized ICU trial comparing high vs low citrate dose during CVVH and measured calcium/magnesium balance and PTH/vitamin D over 24 h.

Trust comment: Randomized controlled trial with direct measurement of Ca/Mg balances and PTH but single-center and small sample (short 24-h window).

Study Details

PMID:34895160
Participants:33
Impact:High citrate: −9.27 mmol/d; Low citrate: −1.18 mmol/d (high group significantly more negative)
Trust score:4/5

magnesium balance (24 h)

1 evidences

Randomized ICU trial comparing high vs low citrate dose during CVVH and measured calcium/magnesium balance and PTH/vitamin D over 24 h.

Trust comment: Randomized controlled trial with direct measurement of Ca/Mg balances and PTH but single-center and small sample (short 24-h window).

Study Details

PMID:34895160
Participants:33
Impact:High citrate: −25.99 mmol/d vs Low citrate: −17.63 mmol/d (both negative; high more negative)
Trust score:4/5

iPTH

3 evidences

Randomized ICU trial comparing high vs low citrate dose during CVVH and measured calcium/magnesium balance and PTH/vitamin D over 24 h.

Trust comment: Randomized controlled trial with direct measurement of Ca/Mg balances and PTH but single-center and small sample (short 24-h window).

Study Details

PMID:34895160
Participants:33
Impact:Median decreased from 222 to 162 pg/mL at 24 h (−60 pg/mL, p=0.002)
Trust score:4/5

Pregnant women randomized to 1000 vs 2000 IU/day vitamin D: 2000 IU improved maternal 25(OH)D more, but glycemic, lipid and oxidative stress markers were similar; small decreases in maternal serum calcium occurred in both groups.

Trust comment: Randomized clinical trial in pregnant women with measured biochemical outcomes and good completion rate (73), high internal validity for reported endpoints.

Study Details

PMID:33054794
Participants:73
Impact:Decrease in intact PTH in both groups (1000 IU −4.18±7.5 pg/mL; 2000 IU −8.36±14.17 pg/mL); time P<0.001; between-group NS
Trust score:4/5

After parathyroidectomy patients received standard postoperative calcium; auricular plaster plus calcium improved quality of life more than calcium carbonate alone.

Trust comment: Small randomized study (n=34) using calcium supplementation as standard care; limited sample size and incomplete quantitative reporting reduce confidence.

Study Details

PMID:29354913
Participants:34
Impact:decreased postoperatively (significant at 1–8 weeks)
Trust score:3/5

bone resorption markers (CTX, TRAP)

1 evidences

Randomized double-blind trial of daily Ca+D vs placebo during 8 weeks of military training measuring bone markers and tibial microarchitecture.

Trust comment: Well-conducted randomized double-blind trial with high compliance but short duration (8 weeks) limiting long-term bone outcome assessment.

Study Details

PMID:34861430
Participants:100
Impact:Ca+D prevented increases in CTX and TRAP that occurred in placebo (group-by-time p<0.05)
Trust score:4/5

tibial microarchitecture / vBMD

1 evidences

Randomized double-blind trial of daily Ca+D vs placebo during 8 weeks of military training measuring bone markers and tibial microarchitecture.

Trust comment: Well-conducted randomized double-blind trial with high compliance but short duration (8 weeks) limiting long-term bone outcome assessment.

Study Details

PMID:34861430
Participants:100
Impact:No supplement effect; tibial microarchitectural changes occurred similarly in both groups (+1.07–2.12% distal vBMD)
Trust score:4/5

Pain (VAS)

3 evidences

In patients with lung cancer and bone metastases, adding zoledronic acid to treatment reduced serum calcium, pain, inflammation and improved quality-of-life and immune markers compared with control.

Trust comment: Randomized single-center study (n=104) reporting significant clinical and biochemical improvements including reduced serum calcium; methods are described but limited detail reduces confidence to moderate.

Study Details

PMID:34938354
Participants:104
Impact:Decreased significantly in research group vs control
Trust score:3/5

Stentoplasty using resorbable calcium-salt bone fillers in older adults with a single vertebral compression fracture reduced pain and disability and promoted bone formation over 3 years, with slight early loss of restored vertebral height.

Trust comment: Prospective randomized 3-arm clinical study with 3-year follow-up but small sample (n=42), limiting precision though methods and outcomes are clinically relevant.

Study Details

PMID:34040361
Participants:42
Impact:≈−5.3 points immediately post-op (7.7→~2.4)
Trust score:4/5

In a multicenter randomized trial, a biphasic synthetic bone filler (60% calcium sulfate/40% hydroxyapatite) was noninferior to autologous iliac bone graft for patient-reported physical function and pain at 26 weeks, with lower early postoperative pain and less intraoperative blood loss.

Trust comment: Large, multicenter randomized controlled trial with prespecified noninferiority endpoints and appropriate analyses.

Study Details

PMID:31809394
Participants:135
Impact:no significant difference at 26 weeks; lower immediate postoperative pain (day 1: ~−1.1 points for CBVF)
Trust score:5/5

Statin recommendation rate

1 evidences

In a randomized feasibility trial, using coronary artery calcium (CAC) scoring to guide statin recommendations reclassified many patients and led to fewer statin recommendations but higher physician acceptance and greater patient adherence compared with PCE-based guidance.

Trust comment: Large randomized feasibility trial assessing coronary artery calcium (a measure of arterial calcification) with good completion rate; relevant to arterial calcium but not calcium supplementation—moderate relevance.

Study Details

PMID:34922872
Participants:540
Impact:35.9% (CAC) vs 47.9% (PCE); −11.9 percentage points
Trust score:3/5

Patient adherence to statin at 3 months

1 evidences

In a randomized feasibility trial, using coronary artery calcium (CAC) scoring to guide statin recommendations reclassified many patients and led to fewer statin recommendations but higher physician acceptance and greater patient adherence compared with PCE-based guidance.

Trust comment: Large randomized feasibility trial assessing coronary artery calcium (a measure of arterial calcification) with good completion rate; relevant to arterial calcium but not calcium supplementation—moderate relevance.

Study Details

PMID:34922872
Participants:540
Impact:62.2% (CAC) vs 42.2% (PCE); +20.0 percentage points
Trust score:3/5

Overall reclassification by CAC vs PCE

1 evidences

In a randomized feasibility trial, using coronary artery calcium (CAC) scoring to guide statin recommendations reclassified many patients and led to fewer statin recommendations but higher physician acceptance and greater patient adherence compared with PCE-based guidance.

Trust comment: Large randomized feasibility trial assessing coronary artery calcium (a measure of arterial calcification) with good completion rate; relevant to arterial calcium but not calcium supplementation—moderate relevance.

Study Details

PMID:34922872
Participants:540
Impact:20.6% of subjects reclassified (CAC vs PCE)
Trust score:3/5

overall success rate

2 evidences

Tricalcium silicate pulpotomy in primary molars showed high long-term success, slightly higher than formocresol but not statistically significant.

Trust comment: Randomized clinical trial directly involving a calcium-containing restorative material but small sample limits power to detect differences.

Study Details

PMID:31882030
Participants:58
Impact:94.4% (both groups combined)
Trust score:3/5

In adults with carious pulp exposures, full pulpotomy with calcium‑containing biomaterials (MTA/CEM) produced similar 2‑year clinical/radiographic success to root canal therapy.

Trust comment: Large, well-conducted multicenter randomized trial with 2‑year outcomes and balanced arms; high trustworthiness.

Study Details

PMID:34854987
Participants:147
Impact:PMTA 100%, PCEM 97.9% (comparable to RCT 98%)
Trust score:5/5

pain relief (postop)

1 evidences

In adults with carious pulp exposures, full pulpotomy with calcium‑containing biomaterials (MTA/CEM) produced similar 2‑year clinical/radiographic success to root canal therapy.

Trust comment: Large, well-conducted multicenter randomized trial with 2‑year outcomes and balanced arms; high trustworthiness.

Study Details

PMID:34854987
Participants:147
Impact:no significant difference between arms (previously published secondary outcome)
Trust score:5/5

visible eczema incidence

1 evidences

Pilot RCT suggests antenatal installation of ion-exchange water softeners (reduced household calcium hardness) may lower infant eczema incidence at 6 months but study was small and not powered for efficacy.

Trust comment: Assessor‑blinded pilot RCT with small sample and limited power focused on feasibility; descriptive results only.

Study Details

PMID:34854157
Participants:67
Impact:-15% (water softener 33% vs control 48%; difference −15%, 95% CI −38 to 8.3%)
Trust score:3/5

parent‑reported doctor‑diagnosed eczema

1 evidences

Pilot RCT suggests antenatal installation of ion-exchange water softeners (reduced household calcium hardness) may lower infant eczema incidence at 6 months but study was small and not powered for efficacy.

Trust comment: Assessor‑blinded pilot RCT with small sample and limited power focused on feasibility; descriptive results only.

Study Details

PMID:34854157
Participants:67
Impact:-12% (35% vs 47%; difference −12%, 95% CI −44 to 20%)
Trust score:3/5

offspring bone mineral density (BMD) at 5 years

1 evidences

In this cohort, maternal dietary calcium intake and pregnancy bone resorption were not associated with offspring whole‑body BMD at age 5 years.

Trust comment: Prospective cohort with modest sample size (n=103) and adjustment for key covariates, but observational design limits causal inference.

Study Details

PMID:34853883
Participants:103
Impact:no association with maternal calcium intake or maternal uNTX (no effect)
Trust score:3/5

sustained return of spontaneous circulation (ROSC)

1 evidences

In adults with out‑of‑hospital cardiac arrest, IV/IO calcium did not improve sustained return of spontaneous circulation and outcomes were numerically worse versus saline.

Trust comment: Double‑blind, placebo‑controlled RCT stopped early for potential harm; robust design and complete follow‑up increase confidence in results.

Study Details

PMID:34847226
Participants:391
Impact:-7.6% (calcium 19% vs saline 27%; risk difference −7.6%)
Trust score:5/5

favorable neurological outcome at 30 days

1 evidences

In adults with out‑of‑hospital cardiac arrest, IV/IO calcium did not improve sustained return of spontaneous circulation and outcomes were numerically worse versus saline.

Trust comment: Double‑blind, placebo‑controlled RCT stopped early for potential harm; robust design and complete follow‑up increase confidence in results.

Study Details

PMID:34847226
Participants:391
Impact:-4.0% (calcium 3.6% vs saline 7.6%)
Trust score:5/5

remineralization rate

1 evidences

In children with MIH defects, remineralization agents (including calcium‑ and phosphate‑containing pastes) increased remineralization rates over 24 months with no significant differences between agents overall.

Trust comment: Randomized clinical study with modest sample and attrition; clinically relevant long follow‑up but limited power for subgroup differences.

Study Details

PMID:34821978
Participants:49
Impact:increased with all agents over 24 months (no significant difference between agents); calcium/phosphate pastes showed earlier effects compared to fluoride varnish
Trust score:3/5

jawline contour improvement (≥1-point MJAS)

1 evidences

Injection of calcium hydroxylapatite filler safely improved jawline contour compared with no treatment.

Trust comment: Randomized controlled study with large sample and long follow-up; results are clinically meaningful and safety monitoring was adequate.

Study Details

PMID:34784131
Participants:180
Impact:+66.8 percentage points (75.6% vs 8.8% response rate at 12 weeks)
Trust score:4/5

persistent aesthetic improvement at 48 weeks

1 evidences

Injection of calcium hydroxylapatite filler safely improved jawline contour compared with no treatment.

Trust comment: Randomized controlled study with large sample and long follow-up; results are clinically meaningful and safety monitoring was adequate.

Study Details

PMID:34784131
Participants:180
Impact:67.3% of initial responders showed persistent improvement
Trust score:4/5

corrected serum calcium (cCa)

1 evidences

Etelcalcetide given thrice-weekly reduced parathyroid hormone and maintained corrected serum calcium in hemodialysis patients.

Trust comment: Phase I randomized, double-blind trial with clear PK and safety endpoints but small sample typical for phase I.

Study Details

PMID:34774334
Participants:33
Impact:maintained >1.75 mmol/L (no clinically problematic hypocalcemia)
Trust score:4/5

depression score (MADRS)

1 evidences

Intensive neurorehabilitation improved mood and function in poststroke patients; vitamin D supplementation showed additional biochemical and some clinical changes.

Trust comment: Randomized controlled design but small final sample and some reporting inconsistencies limit confidence in attributing effects solely to vitamin D vs rehabilitation.

Study Details

PMID:34766589
Participants:29
Impact:−12.4 points (22.13 → 9.73 in vitamin D group)
Trust score:3/5

functional independence (FIM)

1 evidences

Intensive neurorehabilitation improved mood and function in poststroke patients; vitamin D supplementation showed additional biochemical and some clinical changes.

Trust comment: Randomized controlled design but small final sample and some reporting inconsistencies limit confidence in attributing effects solely to vitamin D vs rehabilitation.

Study Details

PMID:34766589
Participants:29
Impact:+36.8 points (58.73 → 95.53 in vitamin D group)
Trust score:3/5

bone resorption (CTX-1)

1 evidences

Single doses of 1000 mg calcium from milk or calcium carbonate acutely suppressed bone resorption (CTX-1) and lowered PTH in postmenopausal women, regardless of visceral fat.

Trust comment: Well-powered randomized crossover with frequent sampling and clear biochemical endpoints; results robust for acute effects on bone turnover and PTH.

Study Details

PMID:34751787
Participants:77
Impact:−44% suppression with milk or calcium carbonate (vs −18% with juice)
Trust score:4/5

protracted hypoparathyroidism incidence

1 evidences

Giving calcium plus vitamin D routinely after total thyroid removal reduced symptomatic low calcium but did not change long-term parathyroid failure compared with giving supplements only when symptoms occurred.

Trust comment: Prospective randomized clinical trial (n=203), registered and clinically relevant endpoints; open-label design lowers risk rating slightly.

Study Details

PMID:34748169
Participants:203
Impact:no significant difference (11/99 = 11.1% vs 17/104 = 16.3%; P=0.280)
Trust score:4/5

parathyroid hormone (PTH) recovery

2 evidences

Giving calcium plus vitamin D routinely after total thyroid removal reduced symptomatic low calcium but did not change long-term parathyroid failure compared with giving supplements only when symptoms occurred.

Trust comment: Prospective randomized clinical trial (n=203), registered and clinically relevant endpoints; open-label design lowers risk rating slightly.

Study Details

PMID:34748169
Participants:203
Impact:better recovery tendency with routine supplementation (qualitative)
Trust score:4/5

Using carbon nanoparticles in endoscopic thyroid surgery reduced accidental removal of parathyroids and sped recovery of parathyroid hormone; serum calcium was slightly higher but not significantly different.

Trust comment: Randomized human surgical trial with clear outcomes but small sample size limits precision.

Study Details

PMID:25761552
Participants:55
Impact:faster recovery in CN group; PTH higher at 1 week and 1 month vs control
Trust score:4/5

postoperative symptomatic hypocalcemia (incidence)

1 evidences

Giving calcium plus vitamin D routinely after total thyroid removal reduced symptomatic low calcium but did not change long-term parathyroid failure compared with giving supplements only when symptoms occurred.

Trust comment: Prospective randomized clinical trial (n=203), registered and clinically relevant endpoints; open-label design lowers risk rating slightly.

Study Details

PMID:34748169
Participants:203
Impact:−15.5 percentage points (26.92% vs 42.42%; P=0.020)
Trust score:4/5

postoperative hypocalcemia occurrence

1 evidences

Giving calcitriol before total thyroid removal did not reduce how often low calcium occurred but shortened how long low calcium lasted.

Trust comment: Multicenter randomized trial in humans with objective outcomes; primary endpoint negative but statistically significant shortening of hypocalcemia duration; limited power for primary outcome.

Study Details

PMID:34702443
Participants:246
Impact:no significant change (29.2% vs 33.6%; p=0.546)
Trust score:4/5

duration of postoperative hypocalcemia

1 evidences

Giving calcitriol before total thyroid removal did not reduce how often low calcium occurred but shortened how long low calcium lasted.

Trust comment: Multicenter randomized trial in humans with objective outcomes; primary endpoint negative but statistically significant shortening of hypocalcemia duration; limited power for primary outcome.

Study Details

PMID:34702443
Participants:246
Impact:shorter in intervention (3.5 vs 7.0 days; p=0.016)
Trust score:4/5

antibacterial effect

1 evidences

In root canal retreatment, calcium hydroxide had similar antibacterial effects to nano-forms, but nano-calcium hydroxide (and nano-silver) reduced postoperative pain at 48–72 hours.

Trust comment: Randomized clinical trial in humans with clear endpoints but small sample (n=69) limiting generalizability.

Study Details

PMID:34697657
Participants:69
Impact:nano-CH and nano-Ag equivalent to CH (no superiority)
Trust score:3/5

coronary artery calcium (CAC) score

1 evidences

In patients with diabetic kidney disease, gemigliptin did not change coronary calcium scores but reduced bone alkaline phosphatase and some urine kidney-injury biomarkers.

Trust comment: Randomized controlled trial in humans with objective biomarker endpoints; open-label design and short (6 month) follow-up limit long-term conclusions.

Study Details

PMID:34697593
Participants:182
Impact:no significant change between groups
Trust score:4/5

bone alkaline phosphatase (bALP)

1 evidences

In patients with diabetic kidney disease, gemigliptin did not change coronary calcium scores but reduced bone alkaline phosphatase and some urine kidney-injury biomarkers.

Trust comment: Randomized controlled trial in humans with objective biomarker endpoints; open-label design and short (6 month) follow-up limit long-term conclusions.

Study Details

PMID:34697593
Participants:182
Impact:decreased (−5.84 ± 10.65 μg/L vs 0.08 ± 11.45 μg/L; p<0.001)
Trust score:4/5

urine L-FABP (renal injury biomarker)

1 evidences

In patients with diabetic kidney disease, gemigliptin did not change coronary calcium scores but reduced bone alkaline phosphatase and some urine kidney-injury biomarkers.

Trust comment: Randomized controlled trial in humans with objective biomarker endpoints; open-label design and short (6 month) follow-up limit long-term conclusions.

Study Details

PMID:34697593
Participants:182
Impact:decreased (91.32 → 37.16 μg/mg creatinine; p<0.001)
Trust score:4/5

proportion with inadequate calcium intake (Wahls diet)

1 evidences

Among people with RRMS, the Wahls diet increased the proportion not getting enough calcium from food; supplements did not fully correct this shortfall.

Trust comment: Randomized parallel-group trial using 3-day weighed food records with good adherence, but dietary self-report and modest sample size limit precision.

Study Details

PMID:34684508
Participants:77
Impact:increased at 12 weeks (↑86.5% in proportion with inadequate intake; p<0.01) and remained higher after inclusion of supplements
Trust score:4/5

proportion with inadequate calcium intake (Swank vs Wahls at 12 weeks)

1 evidences

Among people with RRMS, the Wahls diet increased the proportion not getting enough calcium from food; supplements did not fully correct this shortfall.

Trust comment: Randomized parallel-group trial using 3-day weighed food records with good adherence, but dietary self-report and modest sample size limit precision.

Study Details

PMID:34684508
Participants:77
Impact:Swank had a lower proportion with inadequate calcium intake compared with Wahls at 12 weeks (p<0.01)
Trust score:4/5

white spot lesion incidence

1 evidences

In adolescents with braces, MI Varnish (CPP‑ACP, a calcium‑phosphate product) and ProSeal sealant provided similar, minimal protection against new white spot lesions over 12 months.

Trust comment: Prospective randomized trial in 40 adolescents with objective photo analysis but small sample limits precision.

Study Details

PMID:34679162
Participants:40
Impact:43% of patients developed new WSLs; no significant difference between MI Varnish and sealant
Trust score:3/5

tooth-level WSLs

1 evidences

In adolescents with braces, MI Varnish (CPP‑ACP, a calcium‑phosphate product) and ProSeal sealant provided similar, minimal protection against new white spot lesions over 12 months.

Trust comment: Prospective randomized trial in 40 adolescents with objective photo analysis but small sample limits precision.

Study Details

PMID:34679162
Participants:40
Impact:15% of teeth developed new WSLs
Trust score:3/5

serum p-cresyl sulfate

1 evidences

In advanced pre-dialysis CKD patients, sevelamer reduced serum p-cresyl sulfate and LDL-cholesterol versus calcium carbonate over 24 weeks; indoxyl sulfate did not change.

Trust comment: Randomized controlled single‑center trial with valid assays but small sample and many advanced CKD patients limit generalizability.

Study Details

PMID:34678981
Participants:33
Impact:Sevelamer reduced levels vs calcium carbonate (mean between-group difference −5.61 mg/L; p=0.04)
Trust score:3/5

serum indoxyl sulfate

1 evidences

In advanced pre-dialysis CKD patients, sevelamer reduced serum p-cresyl sulfate and LDL-cholesterol versus calcium carbonate over 24 weeks; indoxyl sulfate did not change.

Trust comment: Randomized controlled single‑center trial with valid assays but small sample and many advanced CKD patients limit generalizability.

Study Details

PMID:34678981
Participants:33
Impact:No significant difference between sevelamer and calcium carbonate (p=0.36)
Trust score:3/5

dentin hypersensitivity (VAS) reduction at 4 weeks

1 evidences

In adults with dentin hypersensitivity, an ionomeric sealant reduced pain more than placebo and calcium‑phosphate/fluoride varnish at 4 weeks; the calcium‑phosphate/fluoride varnish did not differ from placebo.

Trust comment: Well‑powered randomized double‑blind placebo‑controlled trial with clear patient‑reported outcomes.

Study Details

PMID:34676918
Participants:121
Impact:Ionomeric sealant mean VAS change 3.7±2.2 (greater than placebo 2.3±1.7 and Ca/PO4/F varnish 2.6±2.0); Ca/PO4/F varnish ≈ placebo
Trust score:4/5

all fractures

1 evidences

Providing additional dairy (increasing calcium and protein intake) to aged‑care residents reduced falls and fractures: fewer overall fractures, hip fractures, and falls over two years.

Trust comment: Large, cluster randomized trial with objective outcomes (incident reports, radiograph verification) and high ecological validity.

Study Details

PMID:34670754
Participants:7195
Impact:33% relative risk reduction (hazard ratio 0.67; P=0.02)
Trust score:5/5

Hip fractures

1 evidences

Providing additional dairy (increasing calcium and protein intake) to aged‑care residents reduced falls and fractures: fewer overall fractures, hip fractures, and falls over two years.

Trust comment: Large, cluster randomized trial with objective outcomes (incident reports, radiograph verification) and high ecological validity.

Study Details

PMID:34670754
Participants:7195
Impact:46% relative risk reduction (hazard ratio 0.54; P=0.005)
Trust score:5/5

falls

1 evidences

Providing additional dairy (increasing calcium and protein intake) to aged‑care residents reduced falls and fractures: fewer overall fractures, hip fractures, and falls over two years.

Trust comment: Large, cluster randomized trial with objective outcomes (incident reports, radiograph verification) and high ecological validity.

Study Details

PMID:34670754
Participants:7195
Impact:11% relative risk reduction (hazard ratio 0.89; P=0.04)
Trust score:5/5

material comparison (calcium hydroxide vs Biodentine/MTA)

1 evidences

Partial pulpotomy in immature permanent molars using Biodentine, MTA, or calcium hydroxide had high overall success (87%); Biodentine and MTA showed higher (but not statistically significant) success than calcium hydroxide; root lengths increased at 6 months.

Trust comment: Randomized trial on 50 patients with clear clinical/radiographic endpoints but modest sample size limits precision.

Study Details

PMID:34657018
Participants:50
Impact:Biodentine and MTA had higher success than calcium hydroxide but difference not statistically significant (P=0.09)
Trust score:3/5

root length development

1 evidences

Partial pulpotomy in immature permanent molars using Biodentine, MTA, or calcium hydroxide had high overall success (87%); Biodentine and MTA showed higher (but not statistically significant) success than calcium hydroxide; root lengths increased at 6 months.

Trust comment: Randomized trial on 50 patients with clear clinical/radiographic endpoints but modest sample size limits precision.

Study Details

PMID:34657018
Participants:50
Impact:Mesial and distal root lengths increased significantly at 6 months (P=0.01 and P=0.03)
Trust score:3/5

salivary pH

1 evidences

Randomized, double-blind trial in high-caries-risk children comparing quarterly application of two fluoride + calcium phosphate varnishes vs placebo over 12 months; varnishes did not change most salivary biomarkers.

Trust comment: Direct randomized clinical trial of calcium phosphate varnishes but with small completed sample (33) and substantial loss to follow-up; moderate confidence in results.

Study Details

PMID:34639351
Participants:33
Impact:no significant change at 12 months
Trust score:3/5

salivary lactic acid concentration

1 evidences

Randomized, double-blind trial in high-caries-risk children comparing quarterly application of two fluoride + calcium phosphate varnishes vs placebo over 12 months; varnishes did not change most salivary biomarkers.

Trust comment: Direct randomized clinical trial of calcium phosphate varnishes but with small completed sample (33) and substantial loss to follow-up; moderate confidence in results.

Study Details

PMID:34639351
Participants:33
Impact:no significant change during follow-up
Trust score:3/5

salivary calcium (and other chemical elements)

1 evidences

Randomized, double-blind trial in high-caries-risk children comparing quarterly application of two fluoride + calcium phosphate varnishes vs placebo over 12 months; varnishes did not change most salivary biomarkers.

Trust comment: Direct randomized clinical trial of calcium phosphate varnishes but with small completed sample (33) and substantial loss to follow-up; moderate confidence in results.

Study Details

PMID:34639351
Participants:33
Impact:no significant increase in salivary Ca after varnish application
Trust score:3/5

fasting serum insulin

2 evidences

In women with GDM, higher-dose vitamin D plus calcium (1000 IU D + 1000 mg Ca daily) for 6 weeks improved glucose, insulin and lipid measures and increased antioxidant marker compared with lower-dose.

Trust comment: Randomized controlled trial with 70 participants and clear metabolic endpoints, though short duration (6 weeks).

Study Details

PMID:33372392
Participants:70
Impact:Significant reduction (p<0.001) in 1000 IU D + 1000 mg Ca group
Trust score:4/5

Daily vitamin D plus 500 mg calcium for 150 days lowered fasting insulin and insulin resistance and raised HDL cholesterol in infertile men.

Trust comment: Large double-blind randomized trial with 307 men, but intervention combined vitamin D and calcium so effects cannot be attributed to calcium alone.

Study Details

PMID:34508607
Participants:307
Impact:-13% (65 vs 74 pmol/L vs placebo)
Trust score:4/5

HDL cholesterol

7 evidences

Daily calcium-rich supplement (with or without scFOS) lowered LDL and total cholesterol versus placebo after 24 months in postmenopausal women.

Trust comment: 24-month double-blind RCT with 300 participants showing lipid changes, though analysis is secondary.

Study Details

PMID:26669430
Participants:300
Impact:no significant change
Trust score:4/5

Daily vitamin D plus 500 mg calcium for 150 days lowered fasting insulin and insulin resistance and raised HDL cholesterol in infertile men.

Trust comment: Large double-blind randomized trial with 307 men, but intervention combined vitamin D and calcium so effects cannot be attributed to calcium alone.

Study Details

PMID:34508607
Participants:307
Impact:+0.06 mmol/L (+4.5%) (1.38 vs 1.32 mmol/L vs placebo)
Trust score:4/5

In NAFLD patients on a weight-loss program, adding calcium to calcitriol produced greater improvements in some metabolic and liver biochemical parameters versus calcitriol alone.

Trust comment: Randomized, double-blind controlled trial (n=120) with clear between-group significance but short duration (12 weeks).

Study Details

PMID:27720403
Participants:120
Impact:significant increase with calcium+calcitriol vs calcitriol alone (P < 0.001)
Trust score:4/5

Pregnant women at risk for pre-eclampsia received vitamin D3 plus 1000 mg/day calcium for 12 weeks and showed improved glycaemic markers, HDL, and glutathione versus placebo.

Trust comment: Double-blind RCT with clear metabolic outcomes but modest sample size (N=60); reasonable internal validity.

Study Details

PMID:26467311
Participants:60
Impact:increase +4.6 (8.3) mg/dL vs -2.9 (7.7) mg/dL (P=0.001)
Trust score:4/5

Adding 3–4 servings/day of dairy to a Mediterranean diet for 8 weeks modestly improved blood pressure and some lipid markers in people at CVD risk.

Trust comment: Randomized, controlled crossover trial directly increasing dietary calcium via dairy; moderate quality but small sample size (n=41).

Study Details

PMID:30351388
Participants:41
Impact:+0.04 mmol/L (mean difference vs control)
Trust score:4/5

Twelve weeks of vitamin D, K and calcium co-supplementation improved left carotid thickness and several metabolic markers in overweight diabetics with CHD.

Trust comment: Randomized double-blind placebo-controlled trial with clear reported differences but modest sample size and co-supplementation complicates attribution to calcium alone.

Study Details

PMID:27198036
Participants:66
Impact:+2.7 mg/dl (supplement) vs -2.5 mg/dl (placebo), P=0.002
Trust score:4/5

High-calcium milk powder (450 mg elemental Ca twice daily plus vitamin D) reduced lumbar spine bone loss in postmenopausal women over 24 months and reduced height loss.

Trust comment: Randomized controlled trial with 24-month follow-up and CACE analysis improves causal inference; moderate sample size limits generalizability.

Study Details

PMID:25626413
Participants:141
Impact:HDL increased at 12 months in calcium group (effect size 0.120; 95% CI 0.009–0.232; P = 0.034)
Trust score:4/5

risk of DCIS (entire follow-up)

1 evidences

In the WHI randomized trial, daily calcium (1000 mg) plus vitamin D (400 IU) was associated with a reduced risk of ductal carcinoma in situ (DCIS) over extended follow-up, with the effect strongest in the postintervention period.

Trust comment: Large, double-blind, placebo-controlled randomized trial with long follow-up and robust outcome ascertainment, though this is a post hoc analysis for DCIS.

Study Details

PMID:34476342
Participants:36282
Impact:-18% (HR 0.82; 95% CI 0.70–0.96)
Trust score:5/5

risk of DCIS (postintervention period)

1 evidences

In the WHI randomized trial, daily calcium (1000 mg) plus vitamin D (400 IU) was associated with a reduced risk of ductal carcinoma in situ (DCIS) over extended follow-up, with the effect strongest in the postintervention period.

Trust comment: Large, double-blind, placebo-controlled randomized trial with long follow-up and robust outcome ascertainment, though this is a post hoc analysis for DCIS.

Study Details

PMID:34476342
Participants:36282
Impact:-24% (HR 0.76; 95% CI 0.61–0.94)
Trust score:5/5

postoperative hypocalcemia at 24 hours

1 evidences

A single preoperative dose of dexamethasone reduced rates of postoperative hypocalcemia and voice dysfunction after total thyroidectomy.

Trust comment: Randomized, double-blind clinical trial with 192 patients showing clinically relevant reductions in hypocalcemia and voice dysfunction, but intervention is steroidal (not calcium supplementation).

Study Details

PMID:34473215
Participants:192
Impact:absolute reduction 24% (95% CI 11.9%–35.2%)
Trust score:4/5

postoperative hypocalcemia at 3 days

1 evidences

A single preoperative dose of dexamethasone reduced rates of postoperative hypocalcemia and voice dysfunction after total thyroidectomy.

Trust comment: Randomized, double-blind clinical trial with 192 patients showing clinically relevant reductions in hypocalcemia and voice dysfunction, but intervention is steroidal (not calcium supplementation).

Study Details

PMID:34473215
Participants:192
Impact:absolute reduction 4.2% (95% CI -0.44%–10.0%)
Trust score:4/5

voice dysfunction rate

1 evidences

A single preoperative dose of dexamethasone reduced rates of postoperative hypocalcemia and voice dysfunction after total thyroidectomy.

Trust comment: Randomized, double-blind clinical trial with 192 patients showing clinically relevant reductions in hypocalcemia and voice dysfunction, but intervention is steroidal (not calcium supplementation).

Study Details

PMID:34473215
Participants:192
Impact:reduction 25% (95% CI 13.7%–35.7%)
Trust score:4/5

SCASS (dentin hypersensitivity) immediate reduction — BioMin F (FCPS)

1 evidences

A randomized, triple-blind trial found that the calcium-containing BioMin F toothpaste (FCPS) reduced tooth sensitivity, with large sustained benefit at six weeks.

Trust comment: Well-conducted triple-blind RCT with 140 enrolled (128 analyzed) and appropriate outcome measures; directly evaluates a calcium-containing formulation (FCPS).

Study Details

PMID:34615511
Participants:128
Impact:−18.1% (immediate vs baseline)
Trust score:4/5

SCASS (dentin hypersensitivity) sustained reduction — BioMin F (FCPS)

1 evidences

A randomized, triple-blind trial found that the calcium-containing BioMin F toothpaste (FCPS) reduced tooth sensitivity, with large sustained benefit at six weeks.

Trust comment: Well-conducted triple-blind RCT with 140 enrolled (128 analyzed) and appropriate outcome measures; directly evaluates a calcium-containing formulation (FCPS).

Study Details

PMID:34615511
Participants:128
Impact:−61.1% (week 6 vs baseline)
Trust score:4/5

Prevalence of inadequate calcium intake

1 evidences

In Indonesian schoolchildren, dietary calcium and vitamin D intakes were widely inadequate, VDR promoter SNPs were not associated with height-for-age, and protein intake (not calcium) was positively associated with height-for-age z-score.

Trust comment: Cross-sectional study with 142 children and dietary assessment; relevant to calcium intake but observational design and vitamin D status was not measured, limiting causal inference.

Study Details

PMID:34578782
Participants:142
Impact:97.2% of children had inadequate calcium intake; median calcium = 328.22 mg/day
Trust score:3/5

Association: protein intake → height-for-age (HAZ)

1 evidences

In Indonesian schoolchildren, dietary calcium and vitamin D intakes were widely inadequate, VDR promoter SNPs were not associated with height-for-age, and protein intake (not calcium) was positively associated with height-for-age z-score.

Trust comment: Cross-sectional study with 142 children and dietary assessment; relevant to calcium intake but observational design and vitamin D status was not measured, limiting causal inference.

Study Details

PMID:34578782
Participants:142
Impact:positive association; β=0.034 per 1 g/day protein (P<0.001)
Trust score:3/5

VDR promoter SNPs (rs11568820, rs4516035) and HAZ

1 evidences

In Indonesian schoolchildren, dietary calcium and vitamin D intakes were widely inadequate, VDR promoter SNPs were not associated with height-for-age, and protein intake (not calcium) was positively associated with height-for-age z-score.

Trust comment: Cross-sectional study with 142 children and dietary assessment; relevant to calcium intake but observational design and vitamin D status was not measured, limiting causal inference.

Study Details

PMID:34578782
Participants:142
Impact:no significant association (rs11568820 P=0.706; rs4516035 P=0.868)
Trust score:3/5

Plasma calcium (9 years)

1 evidences

Longitudinal cohort nested in a prenatal nutrition trial: prenatal supplements had limited overall effects on child growth biomarkers; plasma calcium at 9 years showed inverse associations with adiposity measures.

Trust comment: Large, well-characterized human cohort with adjusted analyses of calcium and growth biomarkers; not a calcium-supplement trial but provides reliable associations.

Study Details

PMID:34467639
Participants:536
Impact:Inverse association with BAZ at 9 y (β = -0.05; p = 0.025)
Trust score:4/5

Plasma calcium (boys, 9 years)

1 evidences

Longitudinal cohort nested in a prenatal nutrition trial: prenatal supplements had limited overall effects on child growth biomarkers; plasma calcium at 9 years showed inverse associations with adiposity measures.

Trust comment: Large, well-characterized human cohort with adjusted analyses of calcium and growth biomarkers; not a calcium-supplement trial but provides reliable associations.

Study Details

PMID:34467639
Participants:536
Impact:Inverse association with WAZ in boys (β = -0.08; p = 0.017)
Trust score:4/5

STAT5b expression

1 evidences

Longitudinal cohort nested in a prenatal nutrition trial: prenatal supplements had limited overall effects on child growth biomarkers; plasma calcium at 9 years showed inverse associations with adiposity measures.

Trust comment: Large, well-characterized human cohort with adjusted analyses of calcium and growth biomarkers; not a calcium-supplement trial but provides reliable associations.

Study Details

PMID:34467639
Participants:536
Impact:Lower STAT5b in early-food vs usual-food group at 9 y (β = -0.21; p = 0.005)
Trust score:4/5

adiponectin

2 evidences

In screen-detected type 2 diabetes, intensified multifactorial treatment lowered hs-CRP more than routine care over 6 years; adiponectin unchanged.

Trust comment: Large randomized clinical trial with long follow-up and appropriate analyses showing a significant inflammation marker change.

Study Details

PMID:26109470
Participants:424
Impact:no significant difference after 6 years (Δ0.44 µg/mL; p=0.27)
Trust score:4/5

In adults with type 2 diabetes, daily vitamin D–fortified yogurt increased adiponectin; adding extra calcium (Ca+D yogurt) produced significant increases in SIRT1 and SIRT6 compared with baseline and versus plain yogurt.

Trust comment: Randomized, double-blind, placebo-controlled trial with clear participant count (n=75) and measured biomarker changes; moderate sample size limits generalizability.

Study Details

PMID:34389701
Participants:75
Impact:+60.4 µg/L (DY) and +57.5 µg/L (CDY) within-group increases from baseline
Trust score:4/5

SIRT1

1 evidences

In adults with type 2 diabetes, daily vitamin D–fortified yogurt increased adiponectin; adding extra calcium (Ca+D yogurt) produced significant increases in SIRT1 and SIRT6 compared with baseline and versus plain yogurt.

Trust comment: Randomized, double-blind, placebo-controlled trial with clear participant count (n=75) and measured biomarker changes; moderate sample size limits generalizability.

Study Details

PMID:34389701
Participants:75
Impact:+0.72 ng/mL (CDY vs baseline; significant; not significant in DY)
Trust score:4/5

SIRT6

1 evidences

In adults with type 2 diabetes, daily vitamin D–fortified yogurt increased adiponectin; adding extra calcium (Ca+D yogurt) produced significant increases in SIRT1 and SIRT6 compared with baseline and versus plain yogurt.

Trust comment: Randomized, double-blind, placebo-controlled trial with clear participant count (n=75) and measured biomarker changes; moderate sample size limits generalizability.

Study Details

PMID:34389701
Participants:75
Impact:+0.49 ng/mL (CDY vs baseline; significant; not significant in DY)
Trust score:4/5

serum CTx (bone resorption)

1 evidences

24-month randomized interventional study: pre-load vitamin D plus ongoing vitamin D, calcium, protein supplementation and exercise after bariatric surgery attenuated increases in bone turnover markers and reduced loss of aBMD and lean mass versus no intervention.

Trust comment: Large (n=220), prospective randomized interventional study with 24-month follow-up; combined intervention limits attribution to calcium alone but overall design is strong.

Study Details

PMID:26350034
Participants:220
Impact:increase +82.6% (intervention) vs +158.3% (non-intervention)
Trust score:4/5

central systolic blood pressure

1 evidences

In a randomized, double‑blind, three‑way crossover acute trial, Ca-caseinate (a calcium‑rich casein form) reduced postprandial triacylglycerol compared with whey, and showed a trend to lower central SBP; whey lowered peripheral SBP and improved some vascular measures.

Trust comment: Randomized, double‑blind, crossover human trial directly tests Ca-caseinate (calcium‑containing) with reasonable methodology but small acute sample size limits generalizability.

Study Details

PMID:29568003
Participants:27
Impact:Ca-caseinate tended to lower central SBP at 8 h compared with maltodextrin (p=0.052, trend)
Trust score:4/5

serum calcium and serum phosphorus

1 evidences

35-day randomized, double-blind, placebo-controlled trial in 64 healthy college students comparing 400 mg/day calcium supplement vs placebo with identical controlled diet: no significant differences in serum/urine metabolites, calcium-related hormones, or biochemical indicators.

Trust comment: Randomized, double-blind, placebo-controlled dietary RCT with strict intake control; short duration and young healthy sample limit generalizability.

Study Details

PMID:34445834
Participants:64
Impact:no significant change (P>0.05)
Trust score:4/5

Independence from conventional therapy (active vitamin D and calcium supplements)

1 evidences

A once-daily PTH prodrug (TransCon PTH) allowed most patients to stop active vitamin D and markedly reduce or stop calcium supplements while keeping blood calcium normal and improving quality of life.

Trust comment: Well‑conducted randomized double‑blind placebo‑controlled phase 2 trial in humans with validated clinical and patient‑reported endpoints; modest sample size and short blinded period reduce certainty.

Study Details

PMID:34347093
Participants:58
Impact:+82% achieved independence or reduced calcium to ≤500 mg/day at week 4 (36/44); +91% by week 26 (53/58); 76% eliminated both active vitamin D and calcium at week 26
Trust score:4/5

24‑hour urine calcium excretion

1 evidences

A once-daily PTH prodrug (TransCon PTH) allowed most patients to stop active vitamin D and markedly reduce or stop calcium supplements while keeping blood calcium normal and improving quality of life.

Trust comment: Well‑conducted randomized double‑blind placebo‑controlled phase 2 trial in humans with validated clinical and patient‑reported endpoints; modest sample size and short blinded period reduce certainty.

Study Details

PMID:34347093
Participants:58
Impact:−57% mean change (415 → 178 mg/24 h from baseline to week 26; −237 mg/24 h)
Trust score:4/5

Health‑related quality of life (SF‑36 and HPES)

1 evidences

A once-daily PTH prodrug (TransCon PTH) allowed most patients to stop active vitamin D and markedly reduce or stop calcium supplements while keeping blood calcium normal and improving quality of life.

Trust comment: Well‑conducted randomized double‑blind placebo‑controlled phase 2 trial in humans with validated clinical and patient‑reported endpoints; modest sample size and short blinded period reduce certainty.

Study Details

PMID:34347093
Participants:58
Impact:Statistically significant improvement in SF‑36 physical and mental scores vs placebo at week 4 (P<0.05) and sustained to week 26; HPES total symptom LS mean change ≈ −17.7 to −20 (P<0.001)
Trust score:4/5

Secondary hyperparathyroidism prevalence

1 evidences

Daily vitamin D3 (600, 1000, 2000 IU) in deficient children increased vitamin D levels and substantially reduced secondary hyperparathyroidism; 2000 IU was most effective and no hypercalcaemia occurred.

Trust comment: Large randomized trial with high compliance and laboratory outcomes, though single-blind design and specific population limit generalizability.

Study Details

PMID:30843501
Participants:1008
Impact:decreased from 31.7% to 8.4% (overall)
Trust score:4/5

Coronary artery calcification (CAC) score

1 evidences

Using lower‑calcium dialysate (1.25 mmol/L) accelerated progression of coronary artery calcification over 12 months compared with standard (1.5 mmol/L) dialysate.

Trust comment: Randomized clinical trial directly manipulating dialysate calcium with objective CT outcomes; moderate sample size and clear effect but single‑center/open‑label design limits score.

Study Details

PMID:28502735
Participants:76
Impact:CAC increased significantly in LCD group (P=0.004); LCD associated with higher odds of CAC progression (OR 5.72, 95% CI 1.22–26.84; P=0.027)
Trust score:4/5

Aortic valve calcification (AVC) prevalence

1 evidences

Cross-sectional CT-based study of AVC and CAC in 14,073 men aged 60–74 investigating associations with cardiovascular risk factors and biomarkers including serum calcium and phosphate.

Trust comment: Very large, well-characterized population with CT-based calcification measures; cross-sectional design limits causality but associations are robust.

Study Details

PMID:34376488
Participants:14073
Impact:58.0% had AVC>0; median AVC 6 AU (IQR 0–82)
Trust score:4/5

Serum calcium — association with AVC

1 evidences

Cross-sectional CT-based study of AVC and CAC in 14,073 men aged 60–74 investigating associations with cardiovascular risk factors and biomarkers including serum calcium and phosphate.

Trust comment: Very large, well-characterized population with CT-based calcification measures; cross-sectional design limits causality but associations are robust.

Study Details

PMID:34376488
Participants:14073
Impact:No significant association with AVC after adjustment (not associated)
Trust score:4/5

Serum phosphate — association with AVC

1 evidences

Cross-sectional CT-based study of AVC and CAC in 14,073 men aged 60–74 investigating associations with cardiovascular risk factors and biomarkers including serum calcium and phosphate.

Trust comment: Very large, well-characterized population with CT-based calcification measures; cross-sectional design limits causality but associations are robust.

Study Details

PMID:34376488
Participants:14073
Impact:Significantly associated with higher AVC (REC 2.25; 95% CI 1.66–3.10)
Trust score:4/5

1,25-dihydroxyvitamin D (1,25OH2D)

1 evidences

Randomized pharmacodynamic study comparing three cholecalciferol dosing schedules in vitamin D–deficient healthy adults, assessing vitamin D metabolites, regulators of calcium/phosphate homeostasis and bone turnover markers over 12 weeks.

Trust comment: Randomized human study with high completion (73/75), detailed PD measures and standardized assays; limited duration (12 weeks) for long-term bone outcomes.

Study Details

PMID:34371803
Participants:73
Impact:Increased ~+31–34% overall (earlier/greater rise with daily dosing)
Trust score:4/5

Ionized calcium and PTH

1 evidences

Randomized pharmacodynamic study comparing three cholecalciferol dosing schedules in vitamin D–deficient healthy adults, assessing vitamin D metabolites, regulators of calcium/phosphate homeostasis and bone turnover markers over 12 weeks.

Trust comment: Randomized human study with high completion (73/75), detailed PD measures and standardized assays; limited duration (12 weeks) for long-term bone outcomes.

Study Details

PMID:34371803
Participants:73
Impact:Ionized calcium showed only slight changes (no hypercalcemia); PTH decreased significantly after ~3 months
Trust score:4/5

Bone turnover markers (CTX-I, PINP, BALP)

1 evidences

Randomized pharmacodynamic study comparing three cholecalciferol dosing schedules in vitamin D–deficient healthy adults, assessing vitamin D metabolites, regulators of calcium/phosphate homeostasis and bone turnover markers over 12 weeks.

Trust comment: Randomized human study with high completion (73/75), detailed PD measures and standardized assays; limited duration (12 weeks) for long-term bone outcomes.

Study Details

PMID:34371803
Participants:73
Impact:Transient CTX-I increase at Day 28 (~+12%); PINP +4.9% at Day 28 then −7.1% at Day 112; BALP mild decrease (<10%) over time
Trust score:4/5

FGF-23

3 evidences

Randomized pharmacodynamic study comparing three cholecalciferol dosing schedules in vitamin D–deficient healthy adults, assessing vitamin D metabolites, regulators of calcium/phosphate homeostasis and bone turnover markers over 12 weeks.

Trust comment: Randomized human study with high completion (73/75), detailed PD measures and standardized assays; limited duration (12 weeks) for long-term bone outcomes.

Study Details

PMID:34371803
Participants:73
Impact:FGF-23 increased at follow-up time points (homeostatic response)
Trust score:4/5

High-flux hemodialysis (HFHD) reduced FGF-23 and inflammatory markers and increased 1,25-(OH)2VitD3 compared with low-flux dialysis in ESRD patients.

Trust comment: Randomized hemodialysis study with 60 patients; relevant to calcium/phosphate metabolism but excerpt lacks full methodological detail.

Study Details

PMID:26710869
Participants:60
Impact:significantly decreased in HFHD group vs LFHD after 3 months
Trust score:3/5

In dialysis patients, non-calcium phosphate binders reduced serum phosphorus and markedly lowered FGF-23 over 1 year; iPTH fell initially then returned near baseline.

Trust comment: Large randomized Phase 3 completer analysis with central lab measures; post‑hoc pooled analysis and completer-only set limit some generalizability.

Study Details

PMID:29846719
Participants:549
Impact:-64% (progressive decline over 1 year)
Trust score:4/5

Root caries lesion hardness at 3 months

1 evidences

Randomized clinical trial in xerostomic patients comparing CPP-ACP + 5% fluoride varnish vs 5% fluoride varnish alone for root caries over 12 months.

Trust comment: Randomized clinical trial with clear clinical endpoints and 12-month follow-up; moderate sample size (80) appropriate for dental outcomes.

Study Details

PMID:34352792
Participants:80
Impact:CPP-ACP + fluoride: 63.9% lesions hardened vs fluoride alone 39.3% (absolute +24.6%; p<0.01)
Trust score:4/5

Root caries outcomes at 6 and 12 months

1 evidences

Randomized clinical trial in xerostomic patients comparing CPP-ACP + 5% fluoride varnish vs 5% fluoride varnish alone for root caries over 12 months.

Trust comment: Randomized clinical trial with clear clinical endpoints and 12-month follow-up; moderate sample size (80) appropriate for dental outcomes.

Study Details

PMID:34352792
Participants:80
Impact:No significant between-group differences at 6 months (83.3% vs 74.2%; p=0.36) or 12 months (89.6% vs 81.7%; p=0.29)
Trust score:4/5

Lesion size / DIAGNOdent / plaque / surface roughness

1 evidences

Randomized clinical trial in xerostomic patients comparing CPP-ACP + 5% fluoride varnish vs 5% fluoride varnish alone for root caries over 12 months.

Trust comment: Randomized clinical trial with clear clinical endpoints and 12-month follow-up; moderate sample size (80) appropriate for dental outcomes.

Study Details

PMID:34352792
Participants:80
Impact:Both groups showed significant decreases in plaque index, surface roughness, lesion dimension and DIAGNOdent readings (p<0.05)
Trust score:4/5

Fetuin-A

1 evidences

Oral calcium carbonate produced modest changes in serum calcification propensity correlated with rises in serum calcium; some regulators (pyrophosphate, fetuin-A) showed correlations with serum calcium, but between-group differences were limited.

Trust comment: Randomized placebo-controlled trial in postmenopausal women but small sample and some analytes measured in a small subset; correlations rather than consistent between-group effects.

Study Details

PMID:26493812
Participants:41
Impact:no significant between-group differences overall but change at 3 months correlated with serum calcium (r=0.57, p=0.01)
Trust score:4/5

maternal blood pressure

2 evidences

In a healthy pregnant cohort with generally adequate intake, calcium intake was not associated with maternal blood pressure during pregnancy or at 5-year follow-up.

Trust comment: Large observational cohort (n=415) with measured intake/status; adequate power but observational design limits causal inference.

Study Details

PMID:34271366
Participants:415
Impact:no correlation with calcium intake across trimesters or at 5-year follow-up
Trust score:3/5

Randomized double-blind trial: IV calcium chloride raised ionized calcium but did not prevent oxytocin-associated blood pressure drop and had no effect on uterine tone, vasopressor use, or blood loss at the doses tested.

Trust comment: Checklist: 1) Confirm relevance to Calcium (IV calcium chloride administration); 2) extract main outcomes (ionized calcium, BP, uterine tone/blood loss); 3) record participants (60); 4) rate trust — double‑blind randomized placebo‑controlled trial in humans with direct calcium administration and clear null/positive findings; moderate sample size.

Study Details

PMID:25935422
Participants:60
Impact:blood pressure decreased in all groups after oxytocin with no difference between calcium and placebo (no attenuation)
Trust score:4/5

mean arterial pressure (trimester 1)

1 evidences

In a healthy pregnant cohort with generally adequate intake, calcium intake was not associated with maternal blood pressure during pregnancy or at 5-year follow-up.

Trust comment: Large observational cohort (n=415) with measured intake/status; adequate power but observational design limits causal inference.

Study Details

PMID:34271366
Participants:415
Impact:negative correlation with 25OHD at 13 weeks (r=-0.152, p=0.044)
Trust score:3/5

25OHD at 28 weeks

1 evidences

In a healthy pregnant cohort with generally adequate intake, calcium intake was not associated with maternal blood pressure during pregnancy or at 5-year follow-up.

Trust comment: Large observational cohort (n=415) with measured intake/status; adequate power but observational design limits causal inference.

Study Details

PMID:34271366
Participants:415
Impact:no correlation with BP at 28 or 34 weeks or at 5-year follow-up
Trust score:3/5

moderate/severe OHSS incidence

1 evidences

Intravenous calcium infusion was as effective as oral cabergoline in preventing OHSS in high-risk IVF patients, with similar pregnancy outcomes.

Trust comment: Randomized controlled trial (n=170), registered and adequately reported; provides direct clinical evidence for calcium infusion use.

Study Details

PMID:34270379
Participants:170
Impact:no significant difference (8.24% cabergoline vs 10.59% calcium, p=0.599)
Trust score:4/5

implantation/clinical/ongoing pregnancy rates

1 evidences

Intravenous calcium infusion was as effective as oral cabergoline in preventing OHSS in high-risk IVF patients, with similar pregnancy outcomes.

Trust comment: Randomized controlled trial (n=170), registered and adequately reported; provides direct clinical evidence for calcium infusion use.

Study Details

PMID:34270379
Participants:170
Impact:similar between groups (implantation 16.91% vs 15.84%, p=0.771; ongoing 30.59% vs 28.24%, p=0.736)
Trust score:4/5

sinus floor height gain

1 evidences

Using an in situ hardening biphasic calcium phosphate graft produced equivalent sinus floor height gain and implant stability to xenograft at 180 days.

Trust comment: Randomized clinical trial but small sample (42 patients) and some loss to follow-up; outcomes reported clearly for surgical setting.

Study Details

PMID:34269239
Participants:42
Impact:no significant difference between BCP and xenograft at 180 days
Trust score:3/5

implant stability (ITV, ISQ)

1 evidences

Using an in situ hardening biphasic calcium phosphate graft produced equivalent sinus floor height gain and implant stability to xenograft at 180 days.

Trust comment: Randomized clinical trial but small sample (42 patients) and some loss to follow-up; outcomes reported clearly for surgical setting.

Study Details

PMID:34269239
Participants:42
Impact:good primary stability in both groups; no significant difference
Trust score:3/5

OLP signs

1 evidences

An anti-inflammatory mouthwash containing calcium hydroxide reduced oral lichen planus signs and symptoms, but tacrolimus ointment produced greater improvement at 3 months.

Trust comment: Randomized clinical trial but mouthwash contained multiple active ingredients (calcium hydroxide plus others), so effects cannot be attributed to calcium alone.

Study Details

PMID:34252252
Participants:38
Impact:decrease (significant; less improvement than tacrolimus at 3 months)
Trust score:3/5

OLP symptoms

1 evidences

An anti-inflammatory mouthwash containing calcium hydroxide reduced oral lichen planus signs and symptoms, but tacrolimus ointment produced greater improvement at 3 months.

Trust comment: Randomized clinical trial but mouthwash contained multiple active ingredients (calcium hydroxide plus others), so effects cannot be attributed to calcium alone.

Study Details

PMID:34252252
Participants:38
Impact:decrease (significant; less improvement than tacrolimus at 3 months)
Trust score:3/5

Disease severity score

1 evidences

An anti-inflammatory mouthwash containing calcium hydroxide reduced oral lichen planus signs and symptoms, but tacrolimus ointment produced greater improvement at 3 months.

Trust comment: Randomized clinical trial but mouthwash contained multiple active ingredients (calcium hydroxide plus others), so effects cannot be attributed to calcium alone.

Study Details

PMID:34252252
Participants:38
Impact:decrease (significant; less improvement than tacrolimus at 3 months)
Trust score:3/5

Transient postoperative hypocalcemia

1 evidences

Near-infrared ICG angiography during total thyroidectomy improved parathyroid detection and was associated with lower early postoperative hypocalcemia rates compared with standard surgery.

Trust comment: Randomized surgical trial with objective calcium outcomes but single-center and modest sample size.

Study Details

PMID:34248023
Participants:58
Impact:reduced from 17.86% (standard group) to 6.67% (ICG group) on postoperative days 5–10
Trust score:3/5

Recurrence of chronic osteomyelitis

1 evidences

One-stage implantation of vancomycin-loaded calcium phosphate cement after debridement promoted filling of lesions, bone defect healing/osteogenesis in some patients, and reduced recurrence of chronic osteomyelitis over one year.

Trust comment: Randomized trial in humans using a calcium-containing implant; reporting is limited and attribution to calcium phosphate cement vs other factors is not fully detailed.

Study Details

PMID:34237973
Participants:98
Impact:reduced (high cure rate reported; exact rates not fully detailed)
Trust score:3/5

Bone defect healing / osteogenesis

1 evidences

One-stage implantation of vancomycin-loaded calcium phosphate cement after debridement promoted filling of lesions, bone defect healing/osteogenesis in some patients, and reduced recurrence of chronic osteomyelitis over one year.

Trust comment: Randomized trial in humans using a calcium-containing implant; reporting is limited and attribution to calcium phosphate cement vs other factors is not fully detailed.

Study Details

PMID:34237973
Participants:98
Impact:observed in some patients after one year with CPC particle absorption and defect healing
Trust score:3/5

Total sperm motility

1 evidences

Twelve weeks of 4000 IU/day vitamin D3 increased serum 25(OH)D, raised serum and seminal calcium, and significantly improved total and progressive sperm motility in men with asthenozoospermia.

Trust comment: Randomized, triple-blind, placebo-controlled trial with clear numeric reporting of calcium and semen outcomes.

Study Details

PMID:34225767
Participants:86
Impact:+5.06 percentage points mean change in VD3 group vs −1.44 in placebo (p<0.001)
Trust score:4/5

progressive sperm motility

1 evidences

Twelve weeks of 4000 IU/day vitamin D3 increased serum 25(OH)D, raised serum and seminal calcium, and significantly improved total and progressive sperm motility in men with asthenozoospermia.

Trust comment: Randomized, triple-blind, placebo-controlled trial with clear numeric reporting of calcium and semen outcomes.

Study Details

PMID:34225767
Participants:86
Impact:+8.84 percentage points mean change in VD3 group vs −0.86 in placebo (p<0.001)
Trust score:4/5

periapical defect fill (CBCTPAI)

1 evidences

Randomized double-blind trial comparing root canal obturation with MTA vs gutta-percha, each with/without bone graft, in true combined endo-perio lesions; MTA+bone graft showed the best radiographic and clinical healing at 6 and 12 months.

Trust comment: Large randomized double-blind trial (n=120 teeth) with 1-year follow-up; results are robust though applicability limited to this dental condition.

Study Details

PMID:34201328
Participants:120
Impact:MTA + bone graft: 100% defect fill at 6 and 12 months; GP + bone graft: 97% defect fill
Trust score:4/5

probing depth (PD)

1 evidences

Randomized double-blind trial comparing root canal obturation with MTA vs gutta-percha, each with/without bone graft, in true combined endo-perio lesions; MTA+bone graft showed the best radiographic and clinical healing at 6 and 12 months.

Trust comment: Large randomized double-blind trial (n=120 teeth) with 1-year follow-up; results are robust though applicability limited to this dental condition.

Study Details

PMID:34201328
Participants:120
Impact:Lower PD in bone graft groups vs no graft (statistically significant); GP had higher PD than MTA at 6 and 12 months
Trust score:4/5

pharmacokinetic bioequivalence

1 evidences

Phase 1 randomized, double-blind bioequivalence study of a denosumab biosimilar vs reference denosumab in healthy subjects; PK was bioequivalent and common adverse reactions included reductions in blood calcium and phosphate.

Trust comment: Well-conducted randomized double-blind phase 1 bioequivalence study in humans reporting PK and safety including decreases in serum calcium and phosphate; moderate trust for calcium-related adverse-effect reporting.

Study Details

PMID:33306418
Participants:102
Impact:Cmax GMR 98.74%, AUC0-t GMR 102.54%, AUC0-∞ GMR 102.18% (90% CIs within 80–125%)
Trust score:3/5

usual gait speed (HMB vs placebo)

1 evidences

In older women with low muscle mass, exercise improved strength and physical performance; calcium-HMB provided a small improvement in usual gait speed only.

Trust comment: Randomized double-blind placebo-controlled trial with adequate sample and clear outcomes; HMB was combined with calcium but effects were small and well reported.

Study Details

PMID:34081113
Participants:149
Impact:+0.06 m/s
Trust score:4/5

maximal gait speed (exercise vs education)

1 evidences

In older women with low muscle mass, exercise improved strength and physical performance; calcium-HMB provided a small improvement in usual gait speed only.

Trust comment: Randomized double-blind placebo-controlled trial with adequate sample and clear outcomes; HMB was combined with calcium but effects were small and well reported.

Study Details

PMID:34081113
Participants:149
Impact:+0.15 m/s
Trust score:4/5

knee extensor strength (exercise vs education)

1 evidences

In older women with low muscle mass, exercise improved strength and physical performance; calcium-HMB provided a small improvement in usual gait speed only.

Trust comment: Randomized double-blind placebo-controlled trial with adequate sample and clear outcomes; HMB was combined with calcium but effects were small and well reported.

Study Details

PMID:34081113
Participants:149
Impact:+22.0 N
Trust score:4/5

resting metabolic rate

1 evidences

In adults with type 2 diabetes, vitamin D with or without added calcium increased resting metabolic rate; vitamin D plus calcium reduced iPTH, TSH and anti-TPO antibodies.

Trust comment: Randomized double-blind clinical trial but moderate sample; effects on RMR and thyroid/ iPTH markers were statistically significant.

Study Details

PMID:34077684
Participants:75
Impact:increased (vitamin D ± calcium; p=0.001)
Trust score:4/5

intact parathyroid hormone (iPTH) (Ca+D group)

1 evidences

In adults with type 2 diabetes, vitamin D with or without added calcium increased resting metabolic rate; vitamin D plus calcium reduced iPTH, TSH and anti-TPO antibodies.

Trust comment: Randomized double-blind clinical trial but moderate sample; effects on RMR and thyroid/ iPTH markers were statistically significant.

Study Details

PMID:34077684
Participants:75
Impact:decreased (significant)
Trust score:4/5

TSH and anti-TPO antibody (Ca+D group)

1 evidences

In adults with type 2 diabetes, vitamin D with or without added calcium increased resting metabolic rate; vitamin D plus calcium reduced iPTH, TSH and anti-TPO antibodies.

Trust comment: Randomized double-blind clinical trial but moderate sample; effects on RMR and thyroid/ iPTH markers were statistically significant.

Study Details

PMID:34077684
Participants:75
Impact:decreased (significant)
Trust score:4/5

incidence symptomatic hypocalcemia

1 evidences

Preoperative calcitriol given for 1 week before thyroidectomy did not change postoperative serum calcium or hypocalcemia incidence versus placebo; one case of Grade 3 hypercalcemia occurred.

Trust comment: Randomized double-blind placebo-controlled Phase II trial with small sample focused on calcium outcomes; results showed no benefit and one adverse hypercalcemia event.

Study Details

PMID:34076308
Participants:47
Impact:0 events in both groups
Trust score:4/5

grade 3 hypercalcemia

1 evidences

Preoperative calcitriol given for 1 week before thyroidectomy did not change postoperative serum calcium or hypocalcemia incidence versus placebo; one case of Grade 3 hypercalcemia occurred.

Trust comment: Randomized double-blind placebo-controlled Phase II trial with small sample focused on calcium outcomes; results showed no benefit and one adverse hypercalcemia event.

Study Details

PMID:34076308
Participants:47
Impact:1 patient (calcitriol group)
Trust score:4/5

dentine hypersensitivity (CSPS)

1 evidences

In patients after non-surgical periodontal therapy, a dentifrice containing calcium sodium phosphosilicate (CSPS) produced immediate and sustained relief of dentine hypersensitivity up to 8 weeks; arginine gave shorter benefit (~2 weeks).

Trust comment: Double-blind randomized trial with small sample showing immediate and sustained symptomatic benefit for a calcium-containing bioactive glass dentifrice.

Study Details

PMID:34061357
Participants:45
Impact:immediate reduction and sustained through 8 weeks (Schiff/VAS)
Trust score:4/5

dentine hypersensitivity (arginine)

1 evidences

In patients after non-surgical periodontal therapy, a dentifrice containing calcium sodium phosphosilicate (CSPS) produced immediate and sustained relief of dentine hypersensitivity up to 8 weeks; arginine gave shorter benefit (~2 weeks).

Trust comment: Double-blind randomized trial with small sample showing immediate and sustained symptomatic benefit for a calcium-containing bioactive glass dentifrice.

Study Details

PMID:34061357
Participants:45
Impact:reduction through 2 weeks
Trust score:4/5

Schiff score ≥2 prevalence (CSPS)

1 evidences

In patients after non-surgical periodontal therapy, a dentifrice containing calcium sodium phosphosilicate (CSPS) produced immediate and sustained relief of dentine hypersensitivity up to 8 weeks; arginine gave shorter benefit (~2 weeks).

Trust comment: Double-blind randomized trial with small sample showing immediate and sustained symptomatic benefit for a calcium-containing bioactive glass dentifrice.

Study Details

PMID:34061357
Participants:45
Impact:reduced to ≈50% immediately and to ~9% at 2 weeks
Trust score:4/5

Ca. oxalate encrustation proportion (citrate group)

1 evidences

In patients with ureteral stents, potassium citrate markedly reduced calcium oxalate and uric acid components of stent encrustation compared with pre-stent stone composition; no effect on calcium phosphate.

Trust comment: Randomized clinical trial with clear biochemical/infrared spectroscopy outcomes; moderate sample and appropriate analyses showing significant changes in calcium-containing encrustation composition.

Study Details

PMID:34050877
Participants:65
Impact:decreased from 54.84% to 14.84% (p<0.001)
Trust score:4/5

uric acid encrustation proportion (citrate group)

1 evidences

In patients with ureteral stents, potassium citrate markedly reduced calcium oxalate and uric acid components of stent encrustation compared with pre-stent stone composition; no effect on calcium phosphate.

Trust comment: Randomized clinical trial with clear biochemical/infrared spectroscopy outcomes; moderate sample and appropriate analyses showing significant changes in calcium-containing encrustation composition.

Study Details

PMID:34050877
Participants:65
Impact:decreased from 30.60% to 6.36% (p<0.001)
Trust score:4/5

Ca. phosphate encrustation proportion

1 evidences

In patients with ureteral stents, potassium citrate markedly reduced calcium oxalate and uric acid components of stent encrustation compared with pre-stent stone composition; no effect on calcium phosphate.

Trust comment: Randomized clinical trial with clear biochemical/infrared spectroscopy outcomes; moderate sample and appropriate analyses showing significant changes in calcium-containing encrustation composition.

Study Details

PMID:34050877
Participants:65
Impact:no significant change (p=0.331)
Trust score:4/5

Lumbar spine BMD (LSBMD)

2 evidences

Vitamin D plus calcium for 48 weeks increased lumbar spine BMD and improved bone biomarkers; higher vitamin D dose produced larger z-score gains.

Trust comment: Large randomized trial (n=200) with clear clinical endpoints (BMD, biomarkers); open-label but randomized and well-reported.

Study Details

PMID:34125899
Participants:200
Impact:High-dose: +0.07 g/cm2; Standard-dose: +0.09 g/cm2 (both P<.001)
Trust score:4/5

Randomized open-label trial in Thai youth on TDF/FTC PrEP: vitamin D (200 IU) plus calcium (600 mg) supplementation twice daily led to greater lumbar spine BMD gains at 6 months versus no supplementation.

Trust comment: Randomized clinical trial with objective DXA outcomes and clear effect on lumbar spine BMD at 6 months; moderate follow-up losses but appropriate analyses.

Study Details

PMID:33040465
Participants:79
Impact:Median change +0.04 g/cm2 (supplemented) vs +0.02 g/cm2 (no supplement); between-group p=0.02; ≥3% increase in LSBMD: 67.6% vs 42.9% (p=0.03)
Trust score:4/5

LSBMD z-score

1 evidences

Vitamin D plus calcium for 48 weeks increased lumbar spine BMD and improved bone biomarkers; higher vitamin D dose produced larger z-score gains.

Trust comment: Large randomized trial (n=200) with clear clinical endpoints (BMD, biomarkers); open-label but randomized and well-reported.

Study Details

PMID:34125899
Participants:200
Impact:High-dose: +0.4 vs Standard-dose: +0.1 (difference significant, P=0.02)
Trust score:4/5

Bone metabolism biomarkers (25(OH)D, iPTH, CTX, PINP)

1 evidences

Vitamin D plus calcium for 48 weeks increased lumbar spine BMD and improved bone biomarkers; higher vitamin D dose produced larger z-score gains.

Trust comment: Large randomized trial (n=200) with clear clinical endpoints (BMD, biomarkers); open-label but randomized and well-reported.

Study Details

PMID:34125899
Participants:200
Impact:25(OH)D increased; iPTH, CTX, PINP decreased significantly in both groups (no between-group differences)
Trust score:4/5

Height, weight, HAZ, BMIZ (overall)

1 evidences

Ten‑year follow-up found no overall persistent effects of childhood probiotics/calcium on adolescent height or weight, though L. casei with regular calcium was associated with reduced BMIZ in females.

Trust comment: Follow-up of an RCT with objective anthropometric outcomes but with ~50% re-enrollment and potential confounding over 10 years, limiting confidence.

Study Details

PMID:34088920
Participants:238
Impact:No significant differences in long-term changes between intervention groups and control
Trust score:3/5

BMIZ in female adolescents (L. casei + regular calcium)

1 evidences

Ten‑year follow-up found no overall persistent effects of childhood probiotics/calcium on adolescent height or weight, though L. casei with regular calcium was associated with reduced BMIZ in females.

Trust comment: Follow-up of an RCT with objective anthropometric outcomes but with ~50% re-enrollment and potential confounding over 10 years, limiting confidence.

Study Details

PMID:34088920
Participants:238
Impact:Significant reduction in BMIZ: −0.5 SD (95% CI −0.8 to −0.003; P=0.048)
Trust score:3/5

disability (ODI)

1 evidences

Stentoplasty using resorbable calcium-salt bone fillers in older adults with a single vertebral compression fracture reduced pain and disability and promoted bone formation over 3 years, with slight early loss of restored vertebral height.

Trust comment: Prospective randomized 3-arm clinical study with 3-year follow-up but small sample (n=42), limiting precision though methods and outcomes are clinically relevant.

Study Details

PMID:34040361
Participants:42
Impact:≈−45 points immediately post-op (≈82→≈37)
Trust score:4/5

Osteogenesis (CT density inside VBS)

1 evidences

Stentoplasty using resorbable calcium-salt bone fillers in older adults with a single vertebral compression fracture reduced pain and disability and promoted bone formation over 3 years, with slight early loss of restored vertebral height.

Trust comment: Prospective randomized 3-arm clinical study with 3-year follow-up but small sample (n=42), limiting precision though methods and outcomes are clinically relevant.

Study Details

PMID:34040361
Participants:42
Impact:CT density inside VBS higher than outside at 1 and 3 years (P<0.05) — evidence of bone formation
Trust score:4/5

Low bone mineral density (low BMD)

1 evidences

Cross-sectional study of adults undergoing DXA found taking calcium tablets associated with substantially lower odds of low bone mineral density and was included as an input in an ANN osteoporosis risk model.

Trust comment: Large cross-sectional convenience sample (n=1419) with robust measurement of BMD but observational design and sampling limit causal inference and generalizability.

Study Details

PMID:34039329
Participants:1419
Impact:−56.9% odds (OR 0.431; 95% CI 0.334–0.558) associated with taking calcium tablets
Trust score:3/5

Receipt of calcium supplements

1 evidences

A cluster-randomized program to intensify antenatal nutrition services increased receipt and consumption of calcium supplements and modestly improved related maternal nutrition behaviors compared with standard care.

Trust comment: Large pair-matched cluster-randomized evaluation with repeated cross-sections and a longitudinal subcohort; pragmatic delivery and secular program changes may attenuate effect attribution but design is strong.

Study Details

PMID:34038529
Participants:1838
Impact:+14 percentage points (DID) for receipt (I-ANC vs S-ANC)
Trust score:4/5

Consumption of calcium supplements

1 evidences

A cluster-randomized program to intensify antenatal nutrition services increased receipt and consumption of calcium supplements and modestly improved related maternal nutrition behaviors compared with standard care.

Trust comment: Large pair-matched cluster-randomized evaluation with repeated cross-sections and a longitudinal subcohort; pragmatic delivery and secular program changes may attenuate effect attribution but design is strong.

Study Details

PMID:34038529
Participants:1838
Impact:+11.5 percentage points (DID) for consumption (I-ANC vs S-ANC)
Trust score:4/5

Number of calcium tablets received

1 evidences

A cluster-randomized program to intensify antenatal nutrition services increased receipt and consumption of calcium supplements and modestly improved related maternal nutrition behaviors compared with standard care.

Trust comment: Large pair-matched cluster-randomized evaluation with repeated cross-sections and a longitudinal subcohort; pragmatic delivery and secular program changes may attenuate effect attribution but design is strong.

Study Details

PMID:34038529
Participants:1838
Impact:≈+11 tablets (I-ANC vs S-ANC)
Trust score:4/5

Primary aldosteronism prediction (nomogram)

1 evidences

Retrospective study developed a nomogram to predict primary aldosteronism in hypertensive patients; serum calcium‑phosphorus product was one included predictor in the model.

Trust comment: Moderate-sized diagnostic modelling study (n=806) with internal validation; retrospective design and lack of external validation limit generalizability.

Study Details

PMID:34028647
Participants:806
Impact:Calcium–phosphorus product included as a predictor; nomogram AUC 0.73 (training) and 0.68 (validation)
Trust score:3/5

Tooth sensitivity after bleaching

1 evidences

Before in-office bleaching, applying nano-hydroxyapatite (a calcium-containing material) or neutral sodium fluoride reduced tooth sensitivity compared with placebo or CPP-ACP without affecting whitening.

Trust comment: Randomized clinical trial but small sample (n=64); outcome assessment appropriate and randomized allocation supports internal validity though sample size limits precision.

Study Details

PMID:34018341
Participants:64
Impact:n-HAP and NSF reduced sensitivity versus control/CPP-ACP (p<0.05) — no change in whitening efficacy
Trust score:3/5

safety outcomes

1 evidences

Multicenter randomized trial comparing rhPDGF-BB combined with beta-tricalcium phosphate–collagen matrix (a calcium phosphate graft substitute) versus autograft for ankle/hindfoot fusion; demonstrated noninferiority.

Trust comment: Prospective randomized multicenter trial (Level I) showing noninferiority of a β-TCP (calcium phosphate) matrix versus autograft, though some analyses pooled with other trials using propensity methods.

Study Details

PMID:31170812
Participants:104
Impact:Similar safety profiles between treatments
Trust score:4/5

composite cardiovascular events

1 evidences

In hemodialysis patients with hyperphosphatemia, lanthanum versus calcium carbonate showed no difference in the composite cardiovascular outcome, but lanthanum was associated with higher cardiovascular death and more secondary hyperparathyroidism.

Trust comment: Large randomized trial with blinded endpoint adjudication and long follow-up; open-label drug assignment is a limitation but overall high-quality evidence for comparisons of calcium carbonate.

Study Details

PMID:34003226
Participants:1851
Impact:no significant difference (lanthanum vs calcium: HR 1.11; difference 0.50 per 100 person-years; P = .37)
Trust score:4/5

Cardiovascular death

1 evidences

In hemodialysis patients with hyperphosphatemia, lanthanum versus calcium carbonate showed no difference in the composite cardiovascular outcome, but lanthanum was associated with higher cardiovascular death and more secondary hyperparathyroidism.

Trust comment: Large randomized trial with blinded endpoint adjudication and long follow-up; open-label drug assignment is a limitation but overall high-quality evidence for comparisons of calcium carbonate.

Study Details

PMID:34003226
Participants:1851
Impact:lanthanum had higher rate (difference 0.61 per 100 person-years; HR 1.51; P = .045) — implying calcium carbonate associated with lower cardiovascular death vs lanthanum
Trust score:4/5

secondary hyperparathyroidism

1 evidences

In hemodialysis patients with hyperphosphatemia, lanthanum versus calcium carbonate showed no difference in the composite cardiovascular outcome, but lanthanum was associated with higher cardiovascular death and more secondary hyperparathyroidism.

Trust comment: Large randomized trial with blinded endpoint adjudication and long follow-up; open-label drug assignment is a limitation but overall high-quality evidence for comparisons of calcium carbonate.

Study Details

PMID:34003226
Participants:1851
Impact:lanthanum had higher risk (difference 1.34 per 100 person-years; HR 1.62; P = .002) — calcium carbonate associated with lower incidence
Trust score:4/5

bone-specific alkaline phosphatase (BAP)

1 evidences

In 60-day bed-rest, resistive exercise increased markers of bone formation but did not significantly prevent rises in sclerostin or DKK1 compared with control.

Trust comment: Small controlled human bed-rest study (n=24) with repeated measures; limited sample size and male-only cohort reduce generalizability.

Study Details

PMID:26056021
Participants:24
Impact:Increased more with RE and RVE than control during bed rest (p ≤ 0.029)
Trust score:3/5

Roxadustat AUC0–∞ (exposure) with concomitant calcium acetate

1 evidences

Phase I randomized crossover study in healthy volunteers showed concomitant calcium acetate markedly reduced roxadustat exposure (AUC and Cmax); separating dosing by ≥1 hour attenuated the effect.

Trust comment: Well-controlled randomized crossover Phase I PK study in healthy volunteers with clear, quantitative PK endpoints showing substantial interaction with calcium acetate.

Study Details

PMID:33962762
Participants:79
Impact:-46% (90% CI 41.7%-50.9%) reduction
Trust score:4/5

Roxadustat Cmax with concomitant calcium acetate

1 evidences

Phase I randomized crossover study in healthy volunteers showed concomitant calcium acetate markedly reduced roxadustat exposure (AUC and Cmax); separating dosing by ≥1 hour attenuated the effect.

Trust comment: Well-controlled randomized crossover Phase I PK study in healthy volunteers with clear, quantitative PK endpoints showing substantial interaction with calcium acetate.

Study Details

PMID:33962762
Participants:79
Impact:-52% (90% CI 46.2%-57.2%) reduction
Trust score:4/5

Timing effect (AUC/Cmax when separated)

1 evidences

Phase I randomized crossover study in healthy volunteers showed concomitant calcium acetate markedly reduced roxadustat exposure (AUC and Cmax); separating dosing by ≥1 hour attenuated the effect.

Trust comment: Well-controlled randomized crossover Phase I PK study in healthy volunteers with clear, quantitative PK endpoints showing substantial interaction with calcium acetate.

Study Details

PMID:33962762
Participants:79
Impact:Reduction attenuated when roxadustat given ≥1 hour before/after calcium acetate (AUC reductions down to ~14–31% depending on timing)
Trust score:4/5

renal calcium clearance

1 evidences

Double-blind study (12 caffeine, 12 placebo) found high acute caffeine intake increased renal calcium clearance markedly over 6 hours.

Trust comment: Small double-blind clinical trial directly manipulating a factor that altered calcium renal clearance; limited sample size but clear acute effect reported.

Study Details

PMID:33852164
Participants:24
Impact:+77% (caffeine vs placebo)
Trust score:3/5

association with sodium clearance and urine volume

1 evidences

Double-blind study (12 caffeine, 12 placebo) found high acute caffeine intake increased renal calcium clearance markedly over 6 hours.

Trust comment: Small double-blind clinical trial directly manipulating a factor that altered calcium renal clearance; limited sample size but clear acute effect reported.

Study Details

PMID:33852164
Participants:24
Impact:positive correlation with sodium clearance and urine volume (no numeric correlation reported)
Trust score:3/5

stone recurrence

1 evidences

Both potassium citrate and hydrochlorothiazide reduced 24-h urinary calcium; potassium citrate increased urinary citrate more and had similar short-term stone recurrence.

Trust comment: Prospective randomized study (80 patients) with objective urine measures and 12-month imaging; moderate sample size.

Study Details

PMID:33904027
Participants:80
Impact:1/40 (K-CIT) vs 2/40 (HCT) at 12 months
Trust score:4/5

osseous integration

1 evidences

Two types of suture anchors (one containing hydroxyapatite/calcium materials) showed similar bone integration and clinical outcomes at 2 years.

Trust comment: Prospective randomized trial with 2-year follow-up and blinded CT assessment; modest sample and some loss to follow-up (51 with CT data).

Study Details

PMID:33892117
Participants:51
Impact:no difference at 24 months (P = 0.117)
Trust score:4/5

rotator cuff retear rate

1 evidences

Two types of suture anchors (one containing hydroxyapatite/calcium materials) showed similar bone integration and clinical outcomes at 2 years.

Trust comment: Prospective randomized trial with 2-year follow-up and blinded CT assessment; modest sample and some loss to follow-up (51 with CT data).

Study Details

PMID:33892117
Participants:51
Impact:8 total retears (2 Twinfix vs 6 Healicoil); difference not significant (P = 0.18)
Trust score:4/5

leg muscle strength

1 evidences

Exercise plus a multinutrient supplement (including calcium) modestly improved leg strength and mobility; per-protocol preserved femoral neck BMD and increased lean mass.

Trust comment: 12-month randomized controlled trial with objective DXA/pQCT outcomes and reasonable adherence reporting, though overall intervention adherence was modest.

Study Details

PMID:33867499
Participants:60
Impact:improved net difference +14.5% (95% CI -0.2 to 29.2); P = 0.007
Trust score:4/5

dynamic mobility (four-square-step test)

1 evidences

Exercise plus a multinutrient supplement (including calcium) modestly improved leg strength and mobility; per-protocol preserved femoral neck BMD and increased lean mass.

Trust comment: 12-month randomized controlled trial with objective DXA/pQCT outcomes and reasonable adherence reporting, though overall intervention adherence was modest.

Study Details

PMID:33867499
Participants:60
Impact:improved time by -9.3% (95% CI -17.3 to -1.3); P = 0.014
Trust score:4/5

femoral neck areal BMD (per-protocol)

1 evidences

Exercise plus a multinutrient supplement (including calcium) modestly improved leg strength and mobility; per-protocol preserved femoral neck BMD and increased lean mass.

Trust comment: 12-month randomized controlled trial with objective DXA/pQCT outcomes and reasonable adherence reporting, though overall intervention adherence was modest.

Study Details

PMID:33867499
Participants:60
Impact:preserved/increased +1.9% (0.1 to 3.8); P = 0.026
Trust score:4/5

grip strength

1 evidences

In sarcopenic older adults, early supervised resistance training with nutritional support (including calcium) led to an earlier increase in lower‑leg muscle mass but did not improve physical function.

Trust comment: Randomized controlled trial in humans with clear numeric outcomes but calcium was given as part of a multi‑nutrient supplement, limiting attribution solely to calcium.

Study Details

PMID:32723507
Participants:57
Impact:no significant change (no group-time interaction)
Trust score:4/5

25(OH)D level

1 evidences

Randomized children/adolescents to three vitamin D regimens; regimens with loading doses raised 25(OH)D and had small, variable effects on serum calcium and PTH.

Trust comment: Large randomized trial with objective biochemical outcomes; direct intervention was vitamin D (calcium measured as safety/biomarker), good sample size and follow-up though single-region pediatric population.

Study Details

PMID:27927221
Participants:637
Impact:Group2 median +225% and Group3 median +200% (initial→4 months); at 12 months Group1 −42.3%, Group2 −53.1%, Group3 +6.0% (median changes)
Trust score:4/5

total hip bone mineral density

3 evidences

Eldecalcitol increased lumbar and hip bone mineral density more than alfacalcidol in osteoporotic patients not receiving vitamin D or calcium supplements.

Trust comment: Randomized, double-blind active-comparator trial with adequate sample size and clear BMD outcomes.

Study Details

PMID:31087185
Participants:265
Impact:+1.33% (eldecalcitol vs alfacalcidol at 12 months)
Trust score:4/5

SNF472 given during hemodialysis modestly decreased hip and femoral-neck BMD over 1 year; the 600 mg dose showed a slightly greater BMD loss than placebo.

Trust comment: Randomized, placebo-controlled trial with a reasonable evaluable cohort (DXA-modified ITT n=202); results limited to hemodialysis population.

Study Details

PMID:33835939
Participants:202
Impact:Placebo −1.5% vs SNF472 600 mg −2.5% (600 mg: additional −1.0 percentage point loss over 52 weeks)
Trust score:4/5

Among patients after parathyroidectomy (randomized to cholecalciferol + calcium or calcium alone), higher baseline 24-h urinary calcium (>10 mmol/d) was associated with greater bone mineral density gains, notably at the total hip.

Trust comment: Moderate-quality analysis within a clinical trial (n=150); associations are reported but do not prove causation of supplementation effects.

Study Details

PMID:28522130
Participants:150
Impact:greater increase associated with baseline 24-h urinary calcium >10 mmol/d (independent association)
Trust score:3/5

Correlation coronary calcium vs BMD

1 evidences

SNF472 given during hemodialysis modestly decreased hip and femoral-neck BMD over 1 year; the 600 mg dose showed a slightly greater BMD loss than placebo.

Trust comment: Randomized, placebo-controlled trial with a reasonable evaluable cohort (DXA-modified ITT n=202); results limited to hemodialysis population.

Study Details

PMID:33835939
Participants:202
Impact:No correlation between change in coronary artery calcium volume and change in BMD
Trust score:4/5

Dose-proportional exposure (Cmax/AUC)

1 evidences

Asfotase alfa exposure increased with dose, showed dose-proportional activity across 0.5–3.0 mg/kg, a terminal half-life ~3.7–5.5 days, and marked accumulation with thrice-weekly dosing.

Trust comment: Phase 2a open-label PK study in adults (n=27) with rigorous PK sampling; small sample but appropriate for PK assessment.

Study Details

PMID:33822385
Participants:27
Impact:Exposure (Cmax, AUC) increased with increasing dose across studied range
Trust score:4/5

Terminal elimination half-life (t1/2)

1 evidences

Asfotase alfa exposure increased with dose, showed dose-proportional activity across 0.5–3.0 mg/kg, a terminal half-life ~3.7–5.5 days, and marked accumulation with thrice-weekly dosing.

Trust comment: Phase 2a open-label PK study in adults (n=27) with rigorous PK sampling; small sample but appropriate for PK assessment.

Study Details

PMID:33822385
Participants:27
Impact:t1/2 approximately 3.7–5.5 days across cohorts
Trust score:4/5

Accumulation with multiple dosing

1 evidences

Asfotase alfa exposure increased with dose, showed dose-proportional activity across 0.5–3.0 mg/kg, a terminal half-life ~3.7–5.5 days, and marked accumulation with thrice-weekly dosing.

Trust comment: Phase 2a open-label PK study in adults (n=27) with rigorous PK sampling; small sample but appropriate for PK assessment.

Study Details

PMID:33822385
Participants:27
Impact:Marked accumulation with 3×/week dosing (C_troughR range 3.1–4.7)
Trust score:4/5

Countermovement jump (CMJ) height

1 evidences

Co-supplementation of Ca-HMB and AAKG during a 12-day training camp prevented the decline in countermovement jump performance seen in the placebo group, without changing muscle damage markers.

Trust comment: Randomized, double-blind placebo-controlled trial in youth athletes but short duration (12 days) and modest completed sample (n=34).

Study Details

PMID:33805883
Participants:34
Impact:Supplement group maintained baseline CMJ; placebo showed significant decrease (placebo vs baseline p=0.002)
Trust score:3/5

Creatine kinase (CK)

1 evidences

Co-supplementation of Ca-HMB and AAKG during a 12-day training camp prevented the decline in countermovement jump performance seen in the placebo group, without changing muscle damage markers.

Trust comment: Randomized, double-blind placebo-controlled trial in youth athletes but short duration (12 days) and modest completed sample (n=34).

Study Details

PMID:33805883
Participants:34
Impact:CK rose during training in both groups with no between-group difference
Trust score:3/5

Well-being (subjective)

1 evidences

Co-supplementation of Ca-HMB and AAKG during a 12-day training camp prevented the decline in countermovement jump performance seen in the placebo group, without changing muscle damage markers.

Trust comment: Randomized, double-blind placebo-controlled trial in youth athletes but short duration (12 days) and modest completed sample (n=34).

Study Details

PMID:33805883
Participants:34
Impact:Earlier improvement in well-being scores in supplement group vs placebo, but no overall group difference
Trust score:3/5

Ki67 expression (proliferation)

1 evidences

A 90-day Aquamin (multi-mineral, ~800 mg Ca/day) intervention reduced colonic proliferation marker Ki67 (~20%) and increased differentiation markers (p21 ~99%, CK20 ~7%), with larger proteomic changes than calcium alone.

Trust comment: FDA-approved, double-blinded 90-day randomized trial (n=30) with molecular endpoints; small sample limits clinical outcome inference.

Study Details

PMID:33799486
Participants:30
Impact:Aquamin: ~20% reduction in Ki67 post-treatment vs baseline
Trust score:4/5

p21 expression (differentiation)

1 evidences

A 90-day Aquamin (multi-mineral, ~800 mg Ca/day) intervention reduced colonic proliferation marker Ki67 (~20%) and increased differentiation markers (p21 ~99%, CK20 ~7%), with larger proteomic changes than calcium alone.

Trust comment: FDA-approved, double-blinded 90-day randomized trial (n=30) with molecular endpoints; small sample limits clinical outcome inference.

Study Details

PMID:33799486
Participants:30
Impact:p21 increased ~99% with Aquamin (calcium alone increased ~117%)
Trust score:4/5

CK20 expression (differentiation)

1 evidences

A 90-day Aquamin (multi-mineral, ~800 mg Ca/day) intervention reduced colonic proliferation marker Ki67 (~20%) and increased differentiation markers (p21 ~99%, CK20 ~7%), with larger proteomic changes than calcium alone.

Trust comment: FDA-approved, double-blinded 90-day randomized trial (n=30) with molecular endpoints; small sample limits clinical outcome inference.

Study Details

PMID:33799486
Participants:30
Impact:CK20 increased ~7% with Aquamin
Trust score:4/5

trabecular volumetric BMD (radius)

1 evidences

Longitudinal study of 467 pregnant Gambian women showing small increases in peripheral bone density and marked biochemical changes between early second and third trimesters despite low habitual calcium intake.

Trust comment: Large longitudinal human cohort with objective pQCT and biochemical endpoints; well-powered and directly relevant to calcium economy in pregnancy.

Study Details

PMID:33784438
Participants:467
Impact:+1.15% (95% CI 0.55, 1.75)
Trust score:4/5

neuromuscular recovery time (to TOFr ≥0.9)

1 evidences

Randomized double-blind trial in surgical patients showing that adding calcium gluconate to neostigmine shortened early neuromuscular recovery and reduced early PORC incidence.

Trust comment: Randomized, double-blind, objective TOF measurements with appropriate monitoring; moderate sample and per-protocol analysis limit generalizability but supports a real calcium effect.

Study Details

PMID:33781234
Participants:78
Impact:median control 5.3 min vs Ca5 3.9 min vs Ca10 4.1 min; Ca10 shorter vs control (borderline significance, P=0.017)
Trust score:4/5

incidence of postoperative residual curarization (PORC) at 5 min

1 evidences

Randomized double-blind trial in surgical patients showing that adding calcium gluconate to neostigmine shortened early neuromuscular recovery and reduced early PORC incidence.

Trust comment: Randomized, double-blind, objective TOF measurements with appropriate monitoring; moderate sample and per-protocol analysis limit generalizability but supports a real calcium effect.

Study Details

PMID:33781234
Participants:78
Impact:control 12 vs Ca5 4 vs Ca10 4 (P=0.014)
Trust score:4/5

TOFr at 5 min

1 evidences

Randomized double-blind trial in surgical patients showing that adding calcium gluconate to neostigmine shortened early neuromuscular recovery and reduced early PORC incidence.

Trust comment: Randomized, double-blind, objective TOF measurements with appropriate monitoring; moderate sample and per-protocol analysis limit generalizability but supports a real calcium effect.

Study Details

PMID:33781234
Participants:78
Impact:median 0.87 control vs 0.92 Ca5 vs 0.93 Ca10 (no statistically significant difference after correction, P=0.098)
Trust score:4/5

Child total calcium intake

1 evidences

Randomized trial targeting parents to increase children's dietary calcium; children increased total calcium and dairy calcium intake at 8, 34, and 52 weeks while parental intake did not change.

Trust comment: Well-conducted randomized controlled trial with moderate sample size and sustained follow-up; outcomes reported with statistical significance though magnitude details are not provided here.

Study Details

PMID:33722312
Participants:239
Impact:Significant increase at weeks 8, 34 and 52 (P ≤ 0.001)
Trust score:4/5

Child calcium intake from dairy

1 evidences

Randomized trial targeting parents to increase children's dietary calcium; children increased total calcium and dairy calcium intake at 8, 34, and 52 weeks while parental intake did not change.

Trust comment: Well-conducted randomized controlled trial with moderate sample size and sustained follow-up; outcomes reported with statistical significance though magnitude details are not provided here.

Study Details

PMID:33722312
Participants:239
Impact:Significant increase at weeks 8, 34 and 52 (P ≤ 0.001)
Trust score:4/5

Parental calcium intake

1 evidences

Randomized trial targeting parents to increase children's dietary calcium; children increased total calcium and dairy calcium intake at 8, 34, and 52 weeks while parental intake did not change.

Trust comment: Well-conducted randomized controlled trial with moderate sample size and sustained follow-up; outcomes reported with statistical significance though magnitude details are not provided here.

Study Details

PMID:33722312
Participants:239
Impact:No significant increase
Trust score:4/5

total calcification score (Agatston)

1 evidences

Open-label randomized trial in haemodialysis patients comparing cinacalcet plus standard care vs standard care alone; no significant reduction in vascular calcification progression and more hypocalcaemia with cinacalcet.

Trust comment: Randomized trial with detailed imaging and biochemical endpoints but small sample and open-label design limit confidence.

Study Details

PMID:33757437
Participants:36
Impact:median change 488 vs 563 (cinacalcet vs control); P=0.053 (no significant difference)
Trust score:3/5

hypocalcaemia incidence

1 evidences

Open-label randomized trial in haemodialysis patients comparing cinacalcet plus standard care vs standard care alone; no significant reduction in vascular calcification progression and more hypocalcaemia with cinacalcet.

Trust comment: Randomized trial with detailed imaging and biochemical endpoints but small sample and open-label design limit confidence.

Study Details

PMID:33757437
Participants:36
Impact:11 vs 4 patients (cinacalcet vs control); P=0.01 (more hypocalcaemia with cinacalcet)
Trust score:3/5

iPTH at 12 months

1 evidences

Open-label randomized trial in haemodialysis patients comparing cinacalcet plus standard care vs standard care alone; no significant reduction in vascular calcification progression and more hypocalcaemia with cinacalcet.

Trust comment: Randomized trial with detailed imaging and biochemical endpoints but small sample and open-label design limit confidence.

Study Details

PMID:33757437
Participants:36
Impact:median 225 pg/mL vs 294 pg/mL (cinacalcet vs control); P=0.7 (no significant difference)
Trust score:3/5

lean body mass

2 evidences

Vitamin D (with calcium carbonate) given daily for 12 months modestly increased lower-leg strength in postmenopausal women with HIV but did not change muscle mass.

Trust comment: Randomized double-blind 12-month trial in humans (n=69); moderate sample size and appropriate strength measures support reasonable trustworthiness.

Study Details

PMID:33705355
Participants:69
Impact:no change
Trust score:4/5

Double-blind RCT: a multi-ingredient supplement (included 300 mg calcium citrate) plus resistance training increased lean body mass and some upper-body muscle size measures more than an isonitrogenous placebo.

Trust comment: Double-blind randomized controlled design but small sample and multiple active ingredients (including calcium) make attribution to calcium alone uncertain.

Study Details

PMID:33756525
Participants:26
Impact:+4.1 ± 1.3 kg (SUPP) vs +2.8 ± 1.7 kg (PL); P<0.05
Trust score:4/5

biceps brachii cross-sectional area and thickness

1 evidences

Double-blind RCT: a multi-ingredient supplement (included 300 mg calcium citrate) plus resistance training increased lean body mass and some upper-body muscle size measures more than an isonitrogenous placebo.

Trust comment: Double-blind randomized controlled design but small sample and multiple active ingredients (including calcium) make attribution to calcium alone uncertain.

Study Details

PMID:33756525
Participants:26
Impact:increased with SUPP (P<0.05)
Trust score:4/5

vastus lateralis cross-sectional area

1 evidences

Double-blind RCT: a multi-ingredient supplement (included 300 mg calcium citrate) plus resistance training increased lean body mass and some upper-body muscle size measures more than an isonitrogenous placebo.

Trust comment: Double-blind randomized controlled design but small sample and multiple active ingredients (including calcium) make attribution to calcium alone uncertain.

Study Details

PMID:33756525
Participants:26
Impact:no significant difference between groups
Trust score:4/5

lower extremity muscle strength

1 evidences

Vitamin D (with calcium carbonate) given daily for 12 months modestly increased lower-leg strength in postmenopausal women with HIV but did not change muscle mass.

Trust comment: Randomized double-blind 12-month trial in humans (n=69); moderate sample size and appropriate strength measures support reasonable trustworthiness.

Study Details

PMID:33705355
Participants:69
Impact:increase (statistically significant at 12 months)
Trust score:4/5

radiographic progression (medial joint space narrowing)

1 evidences

Lower baseline PRO-C2 (a marker of type II collagen formation) identifies patients with faster radiographic knee OA progression and higher odds of progression.

Trust comment: Two independent cohorts with validated biomarker assays and adjusted analyses; post-hoc/exploratory design and moderate sample sizes warrant moderate-to-high confidence.

Study Details

PMID:33687578
Participants:253
Impact:NYU: low vs high PRO-C2 mean JSN +0.52 mm (p=0.0078); SMC placebo: +0.24 mm (p=0.078); pooled Q1 vs Q4 +0.65 mm (p=0.0018)
Trust score:4/5

odds of progression (any JSN >0)

1 evidences

Lower baseline PRO-C2 (a marker of type II collagen formation) identifies patients with faster radiographic knee OA progression and higher odds of progression.

Trust comment: Two independent cohorts with validated biomarker assays and adjusted analyses; post-hoc/exploratory design and moderate sample sizes warrant moderate-to-high confidence.

Study Details

PMID:33687578
Participants:253
Impact:OR 3.4 (95% CI 1.4–8.6) for very low (Q1) vs high (Q4) PRO-C2
Trust score:4/5

sit-to-stand performance

1 evidences

An 8-week protein-rich home meal service increased protein and calcium intake and improved sit-to-stand performance in older adults compared with control.

Trust comment: Randomized controlled trial but small sample (n=67 completers) limits precision; objective nutrient measures and functional test strengthen findings.

Study Details

PMID:33684023
Participants:67
Impact:improved by -4.8 seconds versus control
Trust score:3/5

number of active lesions

1 evidences

44 children with early caries received either MI Varnish (CPP-ACP-F) or Duraphat; MI Varnish produced greater remineralization over follow-up.

Trust comment: Randomized controlled trial with objective lesion measures but small sample (n=44), so moderate-to-good reliability.

Study Details

PMID:33662244
Participants:44
Impact:Significantly decreased in MI Varnish group vs Duraphat at 18 weeks
Trust score:4/5

DIAGNOdent score

1 evidences

44 children with early caries received either MI Varnish (CPP-ACP-F) or Duraphat; MI Varnish produced greater remineralization over follow-up.

Trust comment: Randomized controlled trial with objective lesion measures but small sample (n=44), so moderate-to-good reliability.

Study Details

PMID:33662244
Participants:44
Impact:Significantly reduced in MI Varnish group vs Duraphat at 30 weeks
Trust score:4/5

average daily calcium intake

1 evidences

Observational analysis of 1,996 adults ≥50 found that relationship continuity with the DXA-ordering PCP was associated with higher daily calcium intake and greater likelihood of vitamin D supplementation at 52 weeks.

Trust comment: Large observational dataset with adjusted multilevel models shows associations but cannot prove causation.

Study Details

PMID:33635767
Participants:1996
Impact:Higher when the DXA-ordering provider was the patient's PCP (association)
Trust score:3/5

likelihood of vitamin D supplementation

1 evidences

Observational analysis of 1,996 adults ≥50 found that relationship continuity with the DXA-ordering PCP was associated with higher daily calcium intake and greater likelihood of vitamin D supplementation at 52 weeks.

Trust comment: Large observational dataset with adjusted multilevel models shows associations but cannot prove causation.

Study Details

PMID:33635767
Participants:1996
Impact:Increased when the DXA-ordering provider was the patient's PCP (association)
Trust score:3/5

postoperative hypocalcemia (clinical or biochemical)

1 evidences

82 patients undergoing total thyroidectomy were randomized to pre+post vs post-only calcium and calcitriol; preoperative supplementation did not reduce postoperative hypocalcemia or other outcomes.

Trust comment: Randomized clinical trial with clear endpoints and moderate sample size; results are internally consistent and directly address calcium supplementation practice.

Study Details

PMID:33631337
Participants:82
Impact:No significant reduction: 13.2% (intervention) vs 15.9% (control), p = 0.76
Trust score:4/5

need for intervention

1 evidences

82 patients undergoing total thyroidectomy were randomized to pre+post vs post-only calcium and calcitriol; preoperative supplementation did not reduce postoperative hypocalcemia or other outcomes.

Trust comment: Randomized clinical trial with clear endpoints and moderate sample size; results are internally consistent and directly address calcium supplementation practice.

Study Details

PMID:33631337
Participants:82
Impact:No significant difference (26.3% vs 34.1%, p = 0.48)
Trust score:4/5

postoperative calcium levels / length of stay / readmissions

1 evidences

82 patients undergoing total thyroidectomy were randomized to pre+post vs post-only calcium and calcitriol; preoperative supplementation did not reduce postoperative hypocalcemia or other outcomes.

Trust comment: Randomized clinical trial with clear endpoints and moderate sample size; results are internally consistent and directly address calcium supplementation practice.

Study Details

PMID:33631337
Participants:82
Impact:No significant differences between groups
Trust score:4/5

serum total calcium

2 evidences

Measured serum/urine calcium, vitamin D, PTH and bone markers in osteoporotic women and analysed correlations with metabolic/cardiovascular risk markers.

Trust comment: Observational clinical study with standard biochemical assays in a modest sample size—associations reported but causality limited.

Study Details

PMID:28849089
Participants:71
Impact:correlated with time since menopause and with bone resorption marker (crosslaps)
Trust score:3/5

Randomized PK study (75 randomized, 73 completed) comparing daily, weekly and bi-weekly high-dose cholecalciferol regimens in vitamin D–deficient healthy adults; daily dosing gave higher 25(OH)D exposure without safety signals.

Trust comment: Randomized human PK study with completed n=73, objective lab endpoints and safety monitoring; open-label but appropriate for PK.

Study Details

PMID:32471106
Participants:73
Impact:small, clinically negligible increases in total calcium (pooled +1.4% at day 56)
Trust score:4/5

fasting serum glucose (FSG)

1 evidences

Overweight people with low dietary calcium were randomized to energy reduction and/or calcium (400 mg + 125 IU vitamin D3 daily) for 2 years; calcium increased serum calcium and 25(OH)D3 but alone produced limited glycemic benefits, while energy reduction plus calcium produced the greatest improvements in fasting glucose and peripheral insulin sensitivity.

Trust comment: Large, long (2-year) randomized trial with clear biochemical and clinical outcomes reported; some attrition and complex interventions but overall high-quality.

Study Details

PMID:33589569
Participants:1021
Impact:calcium alone: non-significant ΔFSG (−0.04 mmol/L vs 0.17 mmol/L, P=0.250); energy reduction + calcium: greater reduction (ΔFSG −0.42 mmol/L, P<0.001 vs others)
Trust score:4/5

withdrawal intensity (CIWA-Ar)

1 evidences

Single-blind randomized trial in inpatient alcohol withdrawal: oral calcium carbonate (800 mg + vitamin D 5 µg daily) for 14 days reduced withdrawal severity faster and lowered craving versus control.

Trust comment: Randomized controlled pilot study showing symptomatic benefits, but small sample size and short duration limit generalizability.

Study Details

PMID:33567423
Participants:55
Impact:faster attenuation of withdrawal symptoms with calcium carbonate (significant vs control)
Trust score:3/5

alcohol craving (OCDS)

1 evidences

Single-blind randomized trial in inpatient alcohol withdrawal: oral calcium carbonate (800 mg + vitamin D 5 µg daily) for 14 days reduced withdrawal severity faster and lowered craving versus control.

Trust comment: Randomized controlled pilot study showing symptomatic benefits, but small sample size and short duration limit generalizability.

Study Details

PMID:33567423
Participants:55
Impact:significantly reduced craving with calcium carbonate vs sodium bicarbonate control
Trust score:3/5

serum CTX-1 (bone resorption)

1 evidences

Premenopausal Indian women taking a multi-micronutrient, protein-rich supplement containing calcium had improved bone turnover markers and some micronutrient status after 6 months.

Trust comment: Well-conducted double-blind RCT with relevant biochemical endpoints and adequate completion rate, though modest sample size and multi-nutrient intervention limit attribution to calcium alone.

Study Details

PMID:33530298
Participants:102
Impact:-33% (test) vs -23% (control) at 6 months; between-group p=0.132 (ns)
Trust score:4/5

c-OC/uc-OC ratio (vitamin K status)

1 evidences

Premenopausal Indian women taking a multi-micronutrient, protein-rich supplement containing calcium had improved bone turnover markers and some micronutrient status after 6 months.

Trust comment: Well-conducted double-blind RCT with relevant biochemical endpoints and adequate completion rate, though modest sample size and multi-nutrient intervention limit attribution to calcium alone.

Study Details

PMID:33530298
Participants:102
Impact:+53% (test) at 6 months; control non-significant; between-group p=0.047 (not significant at 2.5% threshold)
Trust score:4/5

s-PINP (bone formation)

1 evidences

Premenopausal Indian women taking a multi-micronutrient, protein-rich supplement containing calcium had improved bone turnover markers and some micronutrient status after 6 months.

Trust comment: Well-conducted double-blind RCT with relevant biochemical endpoints and adequate completion rate, though modest sample size and multi-nutrient intervention limit attribution to calcium alone.

Study Details

PMID:33530298
Participants:102
Impact:-21% (test) vs -9% (control) at 6 months; between-group p=0.007
Trust score:4/5

postoperative atrial fibrillation incidence

1 evidences

Randomized trial injecting calcium chloride into atrial ganglionated plexi during CABG significantly reduced postoperative atrial fibrillation and related arrhythmic events.

Trust comment: Well-powered randomized controlled trial (n=200) with clear reduction in POAF incidence and related outcomes, supporting moderate-high trust in effect.

Study Details

PMID:33413942
Participants:200
Impact:-58% (36% → 15%)
Trust score:4/5

POAF burden (first 7 days)

1 evidences

Randomized trial injecting calcium chloride into atrial ganglionated plexi during CABG significantly reduced postoperative atrial fibrillation and related arrhythmic events.

Trust comment: Well-powered randomized controlled trial (n=200) with clear reduction in POAF incidence and related outcomes, supporting moderate-high trust in effect.

Study Details

PMID:33413942
Participants:200
Impact:reduced
Trust score:4/5

use of antiarrhythmic therapy (amiodarone/esmolol)

1 evidences

Randomized trial injecting calcium chloride into atrial ganglionated plexi during CABG significantly reduced postoperative atrial fibrillation and related arrhythmic events.

Trust comment: Well-powered randomized controlled trial (n=200) with clear reduction in POAF incidence and related outcomes, supporting moderate-high trust in effect.

Study Details

PMID:33413942
Participants:200
Impact:reduced
Trust score:4/5

dentin hypersensitivity

2 evidences

All tested toothpastes reduced tooth sensitivity versus baseline; no formula was superior.

Trust comment: Randomized, examiner-blind, parallel-group trial with high completion (133/134) but exploratory and not powered for between-treatment differences.

Study Details

PMID:28390207
Participants:133
Impact:improved vs baseline (statistically significant at Weeks 2, 4, 8; p < 0.007)
Trust score:4/5

A calcium-phosphate-containing desensitizer (Teethmate) and a self-etch adhesive (Clearfil SE Bond 2) both significantly reduced dentin hypersensitivity over 6 months and were similarly effective, both outperforming placebo.

Trust comment: Randomized split-mouth RCT with 50 subjects and 6-month follow-up; moderate sample size and appropriate analyses though split-mouth design may have limitations.

Study Details

PMID:33439563
Participants:50
Impact:Teethmate and Clearfil SE Bond 2 both significantly decreased sensitivity vs baseline and were more effective than placebo (P<0.05)
Trust score:3/5

sealing ability

1 evidences

76 primary molar perforations repaired with MTA or premixed bioceramic; premixed bioceramic showed a trend to better sealing and superior clinical/radiographic performance at 6 and 12 months.

Trust comment: Randomized clinical component with moderate sample size (76 teeth); results show trends and some statistically significant longer‑term differences.

Study Details

PMID:33483869
Participants:76
Impact:premixed bioceramic slightly better than MTA (mean difference 0.020; p=0.058, not statistically significant)
Trust score:3/5

Clinical/radiographic success rate (Dycal)

1 evidences

Randomized, double-blind trial in children comparing Dycal (calcium hydroxide), Biodentine (bioactive tricalcium silicate), and TheraCal LC (resin-based tricalcium silicate); all materials had high clinical/radiographic success at 24 months but the resin-containing TheraCal LC showed worse histological pulp outcomes.

Trust comment: Randomized double-blind RCT with 24-month follow-up; moderate sample size and a small histology subset (n=23) limit generalizability but design is strong.

Study Details

PMID:33404764
Participants:109
Impact:100% at 24 months
Trust score:4/5

Clinical/radiographic success rate (Biodentine)

1 evidences

Randomized, double-blind trial in children comparing Dycal (calcium hydroxide), Biodentine (bioactive tricalcium silicate), and TheraCal LC (resin-based tricalcium silicate); all materials had high clinical/radiographic success at 24 months but the resin-containing TheraCal LC showed worse histological pulp outcomes.

Trust comment: Randomized double-blind RCT with 24-month follow-up; moderate sample size and a small histology subset (n=23) limit generalizability but design is strong.

Study Details

PMID:33404764
Participants:109
Impact:100% at 24 months
Trust score:4/5

Clinical/radiographic success rate (TheraCal LC)

1 evidences

Randomized, double-blind trial in children comparing Dycal (calcium hydroxide), Biodentine (bioactive tricalcium silicate), and TheraCal LC (resin-based tricalcium silicate); all materials had high clinical/radiographic success at 24 months but the resin-containing TheraCal LC showed worse histological pulp outcomes.

Trust comment: Randomized double-blind RCT with 24-month follow-up; moderate sample size and a small histology subset (n=23) limit generalizability but design is strong.

Study Details

PMID:33404764
Participants:109
Impact:93.3% at 24 months
Trust score:4/5

Histological pulp status (TheraCal LC vs Dycal/Biodentine)

1 evidences

Randomized, double-blind trial in children comparing Dycal (calcium hydroxide), Biodentine (bioactive tricalcium silicate), and TheraCal LC (resin-based tricalcium silicate); all materials had high clinical/radiographic success at 24 months but the resin-containing TheraCal LC showed worse histological pulp outcomes.

Trust comment: Randomized double-blind RCT with 24-month follow-up; moderate sample size and a small histology subset (n=23) limit generalizability but design is strong.

Study Details

PMID:33404764
Participants:109
Impact:Worse with TheraCal LC (statistically significant, p<0.05)
Trust score:4/5

Clinical/radiographic/microbiologic treatment success

1 evidences

Small randomized trial in children comparing traditional indirect pulp treatment with calcium hydroxide versus minimal excavation plus lesion sterilization/tissue repair (TAP); both approaches were effective clinically, radiographically, and microbiologically over follow-up.

Trust comment: Randomized controlled design but small sample (n=42) limits power; outcomes clinically relevant and follow-up reported.

Study Details

PMID:33402624
Participants:42
Impact:No significant difference between Ca(OH)2 IPT and LSTR with TAP (both effective)
Trust score:3/5

Bacterial counts

1 evidences

Small randomized trial in children comparing traditional indirect pulp treatment with calcium hydroxide versus minimal excavation plus lesion sterilization/tissue repair (TAP); both approaches were effective clinically, radiographically, and microbiologically over follow-up.

Trust comment: Randomized controlled design but small sample (n=42) limits power; outcomes clinically relevant and follow-up reported.

Study Details

PMID:33402624
Participants:42
Impact:Significant reduction in both groups (no between-group advantage reported)
Trust score:3/5

Periapical PGE2 level

1 evidences

Randomized clinical study in previously treated teeth with periapical lesions comparing intracanal Ca(OH)2 alone or with ibuprofen or ciprofloxacin: all Ca(OH)2-based pastes significantly lowered periapical PGE2; Ca(OH)2 + ciprofloxacin produced the largest PGE2 reduction vs Ca(OH)2 alone; no differences in postoperative pain among groups.

Trust comment: Randomized clinical study with a modest sample (n=66); biochemical outcome (PGE2) showed clear differences though clinical pain outcomes did not differ.

Study Details

PMID:33383182
Participants:66
Impact:Significant decrease in all groups; Ca(OH)2 + ciprofloxacin produced significantly greater reduction versus pure Ca(OH)2
Trust score:3/5

OLP clinical signs (Thongprasom score)

1 evidences

Mouthwash containing calcium hydroxide reduced symptoms and signs of oral lichen planus but was less effective than clobetasol; no side effects reported in the mouthwash group.

Trust comment: Randomized controlled trial with validated clinical scales and 38 completers but limited sample size and short follow-up.

Study Details

PMID:33374791
Participants:38
Impact:60% showed reduced signs; 30% complete remission
Trust score:4/5

OLP symptoms (NRS pain)

1 evidences

Mouthwash containing calcium hydroxide reduced symptoms and signs of oral lichen planus but was less effective than clobetasol; no side effects reported in the mouthwash group.

Trust comment: Randomized controlled trial with validated clinical scales and 38 completers but limited sample size and short follow-up.

Study Details

PMID:33374791
Participants:38
Impact:85% showed symptom reduction/remission
Trust score:4/5

Lipid profile (LDL, total cholesterol, HDL)

1 evidences

In women with GDM, higher-dose vitamin D plus calcium (1000 IU D + 1000 mg Ca daily) for 6 weeks improved glucose, insulin and lipid measures and increased antioxidant marker compared with lower-dose.

Trust comment: Randomized controlled trial with 70 participants and clear metabolic endpoints, though short duration (6 weeks).

Study Details

PMID:33372392
Participants:70
Impact:↓ LDL and total cholesterol, ↑ HDL (all p<0.001) in 1000 IU D + 1000 mg Ca group
Trust score:4/5

blood phosphate

1 evidences

Phase 1 randomized, double-blind bioequivalence study of a denosumab biosimilar vs reference denosumab in healthy subjects; PK was bioequivalent and common adverse reactions included reductions in blood calcium and phosphate.

Trust comment: Well-conducted randomized double-blind phase 1 bioequivalence study in humans reporting PK and safety including decreases in serum calcium and phosphate; moderate trust for calcium-related adverse-effect reporting.

Study Details

PMID:33306418
Participants:102
Impact:decrease (common adverse reaction)
Trust score:3/5

mean arterial pressure

1 evidences

Sub-study of a randomized trial in women with prior pre-eclampsia and low dietary calcium intake: 500 mg/day calcium vs placebo for up to 12 weeks pre-pregnancy; calcium modestly lowered systolic and mean arterial pressure at 12 weeks.

Trust comment: Large, multicentre randomized double-blind trial sub-study with standardized BP measurement and intention-to-treat analysis; moderate–high trust in blood-pressure findings.

Study Details

PMID:33302116
Participants:791
Impact:−2.0 mmHg (mean difference vs placebo; 95% CI 0.1 to 3.8; p=0.038)
Trust score:4/5

femoral neck BMD change

1 evidences

Older adults received calcium plus two doses of vitamin D; vitamin D forms correlated with some BMD changes but free/bioavailable forms were not clearly superior to total 25(OH)D.

Trust comment: 1-year double-blind RCT with 221 completers; well-powered for bone outcomes though calcium given to all arms and vitamin D was the randomized factor.

Study Details

PMID:33280041
Participants:221
Impact:Positive association with total 25(OH)D at 12 months
Trust score:4/5

Total body BMD % change

1 evidences

Older adults received calcium plus two doses of vitamin D; vitamin D forms correlated with some BMD changes but free/bioavailable forms were not clearly superior to total 25(OH)D.

Trust comment: 1-year double-blind RCT with 221 completers; well-powered for bone outcomes though calcium given to all arms and vitamin D was the randomized factor.

Study Details

PMID:33280041
Participants:221
Impact:Positive association with free and bioavailable 25(OH)D at 12 months
Trust score:4/5

Gut permeability biomarkers (anti-flagellin and anti-LPS IgA/IgG; combined permeability score)

1 evidences

Daily supplemental calcium (1,200 mg/day), with or without vitamin D, did not change circulating gut‑permeability biomarkers over 1 to 3–5 years in patients with colorectal adenoma.

Trust comment: Randomized, double-blind, placebo-controlled trial with adequate biomarker assays; moderate sample size limits detection of small effects.

Study Details

PMID:33229339
Participants:175
Impact:No appreciable change
Trust score:4/5

Weight change at 8 weeks' gestation

1 evidences

In this randomized substudy of women at high risk of preeclampsia, preconception and early‑pregnancy low‑dose calcium (500 mg/day until 20 weeks) produced small, non‑significant differences in maternal weight change at 8, 20, and 32 weeks compared with placebo.

Trust comment: Multicenter randomized trial with objective anthropometry and intention-to-treat analysis, but the substudy sample size provided limited power to detect small weight differences.

Study Details

PMID:33200626
Participants:457
Impact:Mean difference −0.4 kg (95% CI −1.4 to 0.6); P = 0.408 (not significant)
Trust score:4/5

Weight change at 20 weeks' gestation

1 evidences

In this randomized substudy of women at high risk of preeclampsia, preconception and early‑pregnancy low‑dose calcium (500 mg/day until 20 weeks) produced small, non‑significant differences in maternal weight change at 8, 20, and 32 weeks compared with placebo.

Trust comment: Multicenter randomized trial with objective anthropometry and intention-to-treat analysis, but the substudy sample size provided limited power to detect small weight differences.

Study Details

PMID:33200626
Participants:457
Impact:Mean difference −0.1 kg (95% CI −1.3 to 1.1); P = 0.811 (not significant)
Trust score:4/5

Weight change at 32 weeks' gestation

1 evidences

In this randomized substudy of women at high risk of preeclampsia, preconception and early‑pregnancy low‑dose calcium (500 mg/day until 20 weeks) produced small, non‑significant differences in maternal weight change at 8, 20, and 32 weeks compared with placebo.

Trust comment: Multicenter randomized trial with objective anthropometry and intention-to-treat analysis, but the substudy sample size provided limited power to detect small weight differences.

Study Details

PMID:33200626
Participants:457
Impact:Mean difference −0.6 kg (95% CI −2.2 to 1.0); P = 0.457 (not significant)
Trust score:4/5

skin laxity

1 evidences

Randomized prospective trial in 61 women testing combinations/sequences of subcision, microfocused ultrasound, and calcium hydroxylapatite injections for buttock/thigh skin irregularities; triple-modality combos gave greater improvement.

Trust comment: Randomized interventional study with blinded independent assessors and objective severity scores, moderate sample size (n=61).

Study Details

PMID:33196744
Participants:61
Impact:+1.88 score (triple vs any two modalities; 95% CI 0.66–5.37)
Trust score:4/5

skin dimpling severity

1 evidences

Randomized prospective trial in 61 women testing combinations/sequences of subcision, microfocused ultrasound, and calcium hydroxylapatite injections for buttock/thigh skin irregularities; triple-modality combos gave greater improvement.

Trust comment: Randomized interventional study with blinded independent assessors and objective severity scores, moderate sample size (n=61).

Study Details

PMID:33196744
Participants:61
Impact:+1.31 score (triple vs any two modalities; 95% CI 0.61–2.81)
Trust score:4/5

first stroke risk associated with high serum calcium (males)

1 evidences

Post-hoc analysis of CSPPT: hypertensive Chinese males with higher baseline albumin-corrected serum calcium had higher first stroke risk, and folic acid supplementation halved that excess risk.

Trust comment: Large randomized trial cohort with robust subgroup analysis showing interaction between baseline serum calcium and folic acid effect on stroke in men; post-hoc analysis so moderate risk of residual confounding.

Study Details

PMID:33148481
Participants:19644
Impact:High calcium (≥2.43 mmol/L) vs lower: 6.5% vs 2.3% first stroke; adjusted HR 2.47 (95% CI 1.72–3.55)
Trust score:4/5

effect of folic acid in high-calcium males

1 evidences

Post-hoc analysis of CSPPT: hypertensive Chinese males with higher baseline albumin-corrected serum calcium had higher first stroke risk, and folic acid supplementation halved that excess risk.

Trust comment: Large randomized trial cohort with robust subgroup analysis showing interaction between baseline serum calcium and folic acid effect on stroke in men; post-hoc analysis so moderate risk of residual confounding.

Study Details

PMID:33148481
Participants:19644
Impact:Enalapril+folic acid reduced first-stroke risk from 6.5% to 3.0% in high-calcium males; adjusted HR 0.49 (95% CI 0.35–0.68) — ~51% relative risk reduction
Trust score:4/5

Milk consumption adherence (fortified)

1 evidences

Feasibility RCT found fortified milk with calcium+vitamin D was acceptable, well adhered to, and safe in pregnant women with periodontitis.

Trust comment: Randomized, double-blind feasibility trial with clear methods and good adherence data but small sample and multi-component intervention limits efficacy inference.

Study Details

PMID:33143369
Participants:55
Impact:82.4% adherence in fortified group
Trust score:4/5

Acceptability (liking the milk)

1 evidences

Feasibility RCT found fortified milk with calcium+vitamin D was acceptable, well adhered to, and safe in pregnant women with periodontitis.

Trust comment: Randomized, double-blind feasibility trial with clear methods and good adherence data but small sample and multi-component intervention limits efficacy inference.

Study Details

PMID:33143369
Participants:55
Impact:Third trimester: 84% liked fortified vs 56% placebo (≈+28 percentage points)
Trust score:4/5

Retention/completeness

1 evidences

Feasibility RCT found fortified milk with calcium+vitamin D was acceptable, well adhered to, and safe in pregnant women with periodontitis.

Trust comment: Randomized, double-blind feasibility trial with clear methods and good adherence data but small sample and multi-component intervention limits efficacy inference.

Study Details

PMID:33143369
Participants:55
Impact:79.7% retention at end of study (T2); completers n=55
Trust score:4/5

Calcium inadequacy (powdered milk, age 3–4 years)

1 evidences

Dietary modelling using national survey data showed adding one serving of common milk products would substantially reduce population nutrient inadequacy, including calcium.

Trust comment: Large, nationally representative dietary modelling study with transparent methods; results are theoretical (modelling), not measured intervention effects.

Study Details

PMID:33138121
Participants:3864
Impact:Reduced from 84% to 62% (−22 percentage points)
Trust score:4/5

Iron, zinc, vitamin C and others (YCM/PCM scenario)

1 evidences

Dietary modelling using national survey data showed adding one serving of common milk products would substantially reduce population nutrient inadequacy, including calcium.

Trust comment: Large, nationally representative dietary modelling study with transparent methods; results are theoretical (modelling), not measured intervention effects.

Study Details

PMID:33138121
Participants:3864
Impact:Examples: iron 81%→71%, zinc 60%→34%, vitamin C 68%→14% depending on age and milk type
Trust score:4/5

Energy/macronutrient intakes

1 evidences

Dietary modelling using national survey data showed adding one serving of common milk products would substantially reduce population nutrient inadequacy, including calcium.

Trust comment: Large, nationally representative dietary modelling study with transparent methods; results are theoretical (modelling), not measured intervention effects.

Study Details

PMID:33138121
Participants:3864
Impact:Energy and macronutrient intakes increased across ages after adding one serving of milk
Trust score:4/5

stroke risk

1 evidences

Large randomized trial of daily calcium (1,000 mg) + vitamin D (400 IU) vs placebo in postmenopausal women; calcium/vitamin D did not change risks of major outcomes.

Trust comment: Large double-blind randomized placebo-controlled trial with long follow-up and robust outcomes reporting.

Study Details

PMID:33110042
Participants:20050
Impact:no modification by CaD (CaD did not alter association)
Trust score:5/5

total cardiovascular disease risk

1 evidences

Large randomized trial of daily calcium (1,000 mg) + vitamin D (400 IU) vs placebo in postmenopausal women; calcium/vitamin D did not change risks of major outcomes.

Trust comment: Large double-blind randomized placebo-controlled trial with long follow-up and robust outcomes reporting.

Study Details

PMID:33110042
Participants:20050
Impact:no modification by CaD (CaD did not alter association)
Trust score:5/5

hip fracture and major clinical outcomes

1 evidences

Large randomized trial of daily calcium (1,000 mg) + vitamin D (400 IU) vs placebo in postmenopausal women; calcium/vitamin D did not change risks of major outcomes.

Trust comment: Large double-blind randomized placebo-controlled trial with long follow-up and robust outcomes reporting.

Study Details

PMID:33110042
Participants:20050
Impact:no modification by CaD (no effect observed)
Trust score:5/5

sustained hypercalcemia (calcium acetate)

1 evidences

Pediatric randomized trial comparing sucroferric oxyhydroxide to a calcium-based phosphate binder (calcium acetate); calcium acetate was associated with more sustained hypercalcemia.

Trust comment: Randomized multicenter pediatric trial but small sample size, open-label comparator and early termination limit power and inference.

Study Details

PMID:33106892
Participants:85
Impact:21.1% incidence with calcium acetate vs 9.1% with SFOH
Trust score:3/5

serum phosphorus reduction (calcium acetate)

1 evidences

Pediatric randomized trial comparing sucroferric oxyhydroxide to a calcium-based phosphate binder (calcium acetate); calcium acetate was associated with more sustained hypercalcemia.

Trust comment: Randomized multicenter pediatric trial but small sample size, open-label comparator and early termination limit power and inference.

Study Details

PMID:33106892
Participants:85
Impact:LS mean change −1.903 mg/dL (FAS, p=0.0872; not statistically significant)
Trust score:3/5

withdrawals due to hypercalcemia (calcium acetate)

1 evidences

Pediatric randomized trial comparing sucroferric oxyhydroxide to a calcium-based phosphate binder (calcium acetate); calcium acetate was associated with more sustained hypercalcemia.

Trust comment: Randomized multicenter pediatric trial but small sample size, open-label comparator and early termination limit power and inference.

Study Details

PMID:33106892
Participants:85
Impact:3 subjects withdrew for hypercalcemia in CaAc group
Trust score:3/5

hs-CRP (inflammation)

2 evidences

Twelve weeks of magnesium-zinc-calcium-vitamin D co-supplementation in women with PCOS reduced hirsutism and some inflammation/oxidative stress markers and increased antioxidant capacity.

Trust comment: Randomized double-blind placebo-controlled trial including calcium as part of a multi-nutrient supplement; effects are credible but cannot be ascribed to calcium alone.

Study Details

PMID:28668998
Participants:60
Impact:-0.7 mg/L (supplement) vs +0.2 (placebo) after 12 weeks
Trust score:4/5

In 60 women with gestational diabetes, 6 weeks of magnesium-zinc-calcium-vitamin D reduced inflammation and oxidative stress markers and modestly lowered fasting glucose.

Trust comment: Randomized, double-blind, placebo-controlled trial with adequate sample (n=60) but short duration (6 weeks) and multi-nutrient intervention.

Study Details

PMID:30922259
Participants:60
Impact:-1.2 mg/L change in intervention (vs +0.8 mg/L placebo), p=0.01
Trust score:4/5

postobturation pain

1 evidences

Randomized clinical trial comparing a tricalcium silicate (calcium-containing) sealer to a resin-based sealer for root canal obturation; no difference in patient-reported postobturation pain.

Trust comment: Randomized clinical trial with blinded patients and assessors; adequate sample for outcome though limited to dental pain endpoints.

Study Details

PMID:33098889
Participants:160
Impact:no difference between tricalcium silicate (TotalFill BC) and AH Plus at days 1, 3, and 7 (P > .05); day1 pain 20.6%, day3 10.0%, day7 5.6%
Trust score:4/5

sealer extrusion (AH Plus vs TotalFill BC)

1 evidences

Randomized clinical trial comparing a tricalcium silicate (calcium-containing) sealer to a resin-based sealer for root canal obturation; no difference in patient-reported postobturation pain.

Trust comment: Randomized clinical trial with blinded patients and assessors; adequate sample for outcome though limited to dental pain endpoints.

Study Details

PMID:33098889
Participants:160
Impact:AH Plus associated with greater extrusion beyond apex (OR = 3.02; 95% CI 1.39–6.57)
Trust score:4/5

Lumbar spine and femoral neck BMD

1 evidences

Surgical study comparing radioguided vs classical parathyroidectomy in SHPT patients found improved post-op bone mineral density and better L4 T-score in the radioguided group.

Trust comment: Human surgical cohort with objective BMD outcomes but manuscript text provided is truncated and lacks full numerical detail for calcium endpoints.

Study Details

PMID:33047971
Participants:67
Impact:Significant improvement after operation in both groups; L4 T-score improved more in the experimental (99mTc-MIBI-guided) group (exact values not provided in text)
Trust score:3/5

Areal BMD (total hip, femoral neck, lumbar spine)

1 evidences

3-year randomized double-blind trial of MK‑7 added to calcium (800 mg/day) and vitamin D3 in postmenopausal osteopenic women: MK‑7 increased osteocalcin carboxylation but did not alter bone turnover, BMD, or microarchitecture versus placebo.

Trust comment: Large double-blind randomized trial with 3-year follow-up and co-supplementation with calcium and vitamin D; high methodological quality for the reported endpoints.

Study Details

PMID:33030563
Participants:142
Impact:aBMD decreased at sites with no difference between groups: total hip MK‑7 −1.5% vs placebo −2.4%; femoral neck −1.5% vs −1.0%; lumbar spine −1.8% vs −1.1%
Trust score:4/5

undercarboxylated osteocalcin

1 evidences

3-year randomized double-blind trial of MK‑7 added to calcium (800 mg/day) and vitamin D3 in postmenopausal osteopenic women: MK‑7 increased osteocalcin carboxylation but did not alter bone turnover, BMD, or microarchitecture versus placebo.

Trust comment: Large double-blind randomized trial with 3-year follow-up and co-supplementation with calcium and vitamin D; high methodological quality for the reported endpoints.

Study Details

PMID:33030563
Participants:142
Impact:Decreased in MK‑7 group −65.2% vs −0.03% in placebo (mean±SD); p≈0.09 (not statistically significant at conventional threshold)
Trust score:4/5

VIM (vimentin)

1 evidences

In people starting continuous ambulatory peritoneal dialysis, higher calcium concentration in dialysis fluid increased markers associated with epithelial-to-mesenchymal transition over 12 months but did not change short-term clinical complication rates.

Trust comment: Randomized pilot study in humans with objective biomarker measurements but single-center, per‑protocol analysis and modest sample size limit generalizability.

Study Details

PMID:33029812
Participants:102
Impact:+0.97 ng/mL at 12 months (6.98 vs 6.01 ng/mL; higher with 1.75 mmol/L Ca PDS)
Trust score:4/5

FSP1 (fibroblast‑specific protein 1)

1 evidences

In people starting continuous ambulatory peritoneal dialysis, higher calcium concentration in dialysis fluid increased markers associated with epithelial-to-mesenchymal transition over 12 months but did not change short-term clinical complication rates.

Trust comment: Randomized pilot study in humans with objective biomarker measurements but single-center, per‑protocol analysis and modest sample size limit generalizability.

Study Details

PMID:33029812
Participants:102
Impact:+0.59 ng/mL at 12 months (3.75 vs 3.16 ng/mL; higher with 1.75 mmol/L Ca PDS)
Trust score:4/5

E‑CAD (E‑cadherin)

1 evidences

In people starting continuous ambulatory peritoneal dialysis, higher calcium concentration in dialysis fluid increased markers associated with epithelial-to-mesenchymal transition over 12 months but did not change short-term clinical complication rates.

Trust comment: Randomized pilot study in humans with objective biomarker measurements but single-center, per‑protocol analysis and modest sample size limit generalizability.

Study Details

PMID:33029812
Participants:102
Impact:−11.15 ng/mL at 12 months (35.71 vs 46.86 ng/mL; lower with 1.75 mmol/L Ca PDS)
Trust score:4/5

vitamin D intake

1 evidences

Nutrition counseling (medical nutrition therapy) led people living with HIV to increase intake of calcium, vitamin D and other nutrients and to increase exercise over the intervention period.

Trust comment: Randomized trial with moderate sample size showing significant behavioral/nutrient intake changes, but convenience sampling and limited reporting of effect sizes reduce robustness.

Study Details

PMID:33027800
Participants:130
Impact:Increased (statistically significant vs baseline and vs control)
Trust score:3/5

Length of exercise

1 evidences

Nutrition counseling (medical nutrition therapy) led people living with HIV to increase intake of calcium, vitamin D and other nutrients and to increase exercise over the intervention period.

Trust comment: Randomized trial with moderate sample size showing significant behavioral/nutrient intake changes, but convenience sampling and limited reporting of effect sizes reduce robustness.

Study Details

PMID:33027800
Participants:130
Impact:Increased (statistically significant vs baseline and vs control)
Trust score:3/5

Basal cell carcinoma (BCC) incidence

1 evidences

In a large randomized trial of daily calcium (1200 mg) and/or vitamin D, calcium alone did not change basal cell carcinoma risk and showed suggestive to significant reductions in squamous cell carcinoma risk (especially when combined with vitamin D).

Trust comment: Large, multicenter, double‑blind randomized trial with long follow-up; high-quality design though this is a secondary analysis.

Study Details

PMID:33022713
Participants:2259
Impact:No effect (Calcium vs no calcium HR 1.01; 95% CI 0.74–1.39)
Trust score:5/5

Cutaneous squamous cell carcinoma (SCC) incidence — calcium alone

1 evidences

In a large randomized trial of daily calcium (1200 mg) and/or vitamin D, calcium alone did not change basal cell carcinoma risk and showed suggestive to significant reductions in squamous cell carcinoma risk (especially when combined with vitamin D).

Trust comment: Large, multicenter, double‑blind randomized trial with long follow-up; high-quality design though this is a secondary analysis.

Study Details

PMID:33022713
Participants:2259
Impact:Suggestive reduction (Calcium vs no calcium HR 0.60; 95% CI 0.36–1.01)
Trust score:5/5

Cutaneous squamous cell carcinoma (SCC) incidence — calcium + vitamin D

1 evidences

In a large randomized trial of daily calcium (1200 mg) and/or vitamin D, calcium alone did not change basal cell carcinoma risk and showed suggestive to significant reductions in squamous cell carcinoma risk (especially when combined with vitamin D).

Trust comment: Large, multicenter, double‑blind randomized trial with long follow-up; high-quality design though this is a secondary analysis.

Study Details

PMID:33022713
Participants:2259
Impact:Reduced (Both agents vs neither HR 0.42; 95% CI 0.19–0.91)
Trust score:5/5

Adherence rate (overall)

1 evidences

In rural Ethiopia, antenatal calcium taken with iron–folic acid was acceptable and most women achieved high adherence (~80%); regimens with fewer daily doses reduced total calcium consumed but did not increase adherence.

Trust comment: Mixed-methods household trial with objective electronic adherence monitoring (MEMS) but small sample and short duration limit external validity.

Study Details

PMID:33008855
Participants:48
Impact:Mean ~80% (no significant difference by assigned regimen)
Trust score:3/5

Calcium consumption — 2‑event regimen

1 evidences

In rural Ethiopia, antenatal calcium taken with iron–folic acid was acceptable and most women achieved high adherence (~80%); regimens with fewer daily doses reduced total calcium consumed but did not increase adherence.

Trust comment: Mixed-methods household trial with objective electronic adherence monitoring (MEMS) but small sample and short duration limit external validity.

Study Details

PMID:33008855
Participants:48
Impact:Mean 811.3 mg/day (±227) — significantly lower than 3‑event or 4‑event groups
Trust score:3/5

Calcium consumption — 3‑event regimen

1 evidences

In rural Ethiopia, antenatal calcium taken with iron–folic acid was acceptable and most women achieved high adherence (~80%); regimens with fewer daily doses reduced total calcium consumed but did not increase adherence.

Trust comment: Mixed-methods household trial with objective electronic adherence monitoring (MEMS) but small sample and short duration limit external validity.

Study Details

PMID:33008855
Participants:48
Impact:Mean 1,251.1 mg/day (±211.9) — higher consumption than 2‑event (P<0.01)
Trust score:3/5

mineralized tissue formation

1 evidences

In patients undergoing tooth extraction and socket grafting, a PLGA‑coated β‑tricalcium phosphate graft produced less new mineralized tissue at 20 weeks than freeze‑dried bone allograft, though implant placement and short‑term implant outcomes were comparable.

Trust comment: Multicenter randomized controlled trial with objective radiographic and histomorphometric outcomes, but small completed sample and dropout reduce precision.

Study Details

PMID:32996128
Participants:32
Impact:Lower with PLGA‑β‑TCP vs FDBA: 27.0% ±22.1% vs 38.2% ±12.5% (≈ −11.2 percentage points, P<0.05)
Trust score:4/5

Implant survival / peri‑implant bone level change

1 evidences

In patients undergoing tooth extraction and socket grafting, a PLGA‑coated β‑tricalcium phosphate graft produced less new mineralized tissue at 20 weeks than freeze‑dried bone allograft, though implant placement and short‑term implant outcomes were comparable.

Trust comment: Multicenter randomized controlled trial with objective radiographic and histomorphometric outcomes, but small completed sample and dropout reduce precision.

Study Details

PMID:32996128
Participants:32
Impact:No difference (no implant failures; negligible marginal bone change up to 12 months)
Trust score:4/5

Serum folate

1 evidences

Double-blind RCT of a multivitamin/mineral vs placebo in older adults on certain medications; MVMS increased folate and vitamin C status but did not significantly change serum calcium.

Trust comment: Double-blind placebo-controlled RCT in humans with small sample size and baseline nutrient status within normal ranges; directly measured calcium status but found no effect.

Study Details

PMID:33078646
Participants:54
Impact:change +7.5 ng/mL (MVMS) vs -1.6 ng/mL (placebo)
Trust score:3/5

plasma vitamin C

1 evidences

Double-blind RCT of a multivitamin/mineral vs placebo in older adults on certain medications; MVMS increased folate and vitamin C status but did not significantly change serum calcium.

Trust comment: Double-blind placebo-controlled RCT in humans with small sample size and baseline nutrient status within normal ranges; directly measured calcium status but found no effect.

Study Details

PMID:33078646
Participants:54
Impact:change +0.2 mg/dL (MVMS) vs 0.0 mg/dL (placebo)
Trust score:3/5

decline in serum ionic calcium (48 h)

1 evidences

Randomized controlled trial in term neonates undergoing phototherapy; covering the head reduced the decline in serum ionic calcium at 48 hours compared with no head cover.

Trust comment: Randomized controlled human neonatal study with clear quantitative calcium outcomes and adequate sample size for the primary biomarker outcome.

Study Details

PMID:33074196
Participants:112
Impact:reduced decline with head cover: -0.34 mg/dL vs -0.57 mg/dL (difference 0.23 mg/dL, p < 0.001)
Trust score:4/5

incidence of hypocalcemia

1 evidences

Randomized controlled trial in term neonates undergoing phototherapy; covering the head reduced the decline in serum ionic calcium at 48 hours compared with no head cover.

Trust comment: Randomized controlled human neonatal study with clear quantitative calcium outcomes and adequate sample size for the primary biomarker outcome.

Study Details

PMID:33074196
Participants:112
Impact:26.8% (no cover) vs 14.3% (cover) — difference not statistically significant
Trust score:4/5

new bone percentage

1 evidences

Randomized trial comparing biphasic calcium phosphate (BCP) vs deproteinized bovine bone mineral (DBBM) for sinus lift: new bone formation similar at 6 months; BCP left less residual graft material.

Trust comment: Randomized controlled clinical trial with histomorphometric endpoints and moderate sample (n=51); methods and outcomes appropriate for biomaterial comparison.

Study Details

PMID:32991652
Participants:51
Impact:BCP 35.9% vs DBBM 35.4% (no significant difference, P>0.05)
Trust score:4/5

residual graft material percentage

1 evidences

Randomized trial comparing biphasic calcium phosphate (BCP) vs deproteinized bovine bone mineral (DBBM) for sinus lift: new bone formation similar at 6 months; BCP left less residual graft material.

Trust comment: Randomized controlled clinical trial with histomorphometric endpoints and moderate sample (n=51); methods and outcomes appropriate for biomaterial comparison.

Study Details

PMID:32991652
Participants:51
Impact:BCP 25.3% vs DBBM 45.9% (BCP significantly lower, P<0.05)
Trust score:4/5

implant survival

2 evidences

Randomized trial comparing biphasic calcium phosphate (BCP) vs deproteinized bovine bone mineral (DBBM) for sinus lift: new bone formation similar at 6 months; BCP left less residual graft material.

Trust comment: Randomized controlled clinical trial with histomorphometric endpoints and moderate sample (n=51); methods and outcomes appropriate for biomaterial comparison.

Study Details

PMID:32991652
Participants:51
Impact:No significant difference up to loading (no numeric difference reported)
Trust score:4/5

Randomized trial of 60 implants comparing synthetic PLA vs collagen membranes with biphasic calcium phosphate graft: similar facial bone thickness loss at 6 months and all implants osseointegrated.

Trust comment: Randomized clinical trial using calcium phosphate graft material with objective CBCT measures; moderate sample and short 6-month follow-up limit long-term inference.

Study Details

PMID:29028848
Participants:60
Impact:all implants osseointegrated; no implant loss
Trust score:3/5

Incidence of oral mucositis

1 evidences

In children receiving stem cell transplants, adding a supersaturated calcium‑phosphate oral rinse gave slightly fewer and less severe mouth ulcers but was less well tolerated than toothbrushing; differences were not statistically significant.

Trust comment: Randomized prospective interventional pediatric trial (N=45) with clear endpoints but small sample and no significant differences, moderate quality.

Study Details

PMID:32964512
Participants:45
Impact:80.0% → 66.7% in SCPR group (−13.3 percentage points), not statistically significant (P=0.711)
Trust score:3/5

severity of oral mucositis (composite score)

1 evidences

In children receiving stem cell transplants, adding a supersaturated calcium‑phosphate oral rinse gave slightly fewer and less severe mouth ulcers but was less well tolerated than toothbrushing; differences were not statistically significant.

Trust comment: Randomized prospective interventional pediatric trial (N=45) with clear endpoints but small sample and no significant differences, moderate quality.

Study Details

PMID:32964512
Participants:45
Impact:Control mean 5.2 → SCPR mean 4.7 (−0.5 score), not statistically significant (P=0.71)
Trust score:3/5

tolerance of supersaturated calcium phosphate rinse (SCPR)

1 evidences

In children receiving stem cell transplants, adding a supersaturated calcium‑phosphate oral rinse gave slightly fewer and less severe mouth ulcers but was less well tolerated than toothbrushing; differences were not statistically significant.

Trust comment: Randomized prospective interventional pediatric trial (N=45) with clear endpoints but small sample and no significant differences, moderate quality.

Study Details

PMID:32964512
Participants:45
Impact:SCPR tolerance decreased post‑HSCT and was significantly worse than ESTB post‑HSCT (P=0.011)
Trust score:3/5

COX-2/15-HPGD expression ratio (full-length crypts)

1 evidences

Placebo-controlled trial: supplemental calcium (1,200 mg/day) and vitamin D (1,000 IU/day) reduced a biomarker ratio (COX-2/15-HPGD) linked to colorectal inflammation and carcinogenesis.

Trust comment: Randomized, placebo-controlled trial directly testing supplemental calcium with biomarker endpoints; moderate sample size and robust biomarker methods support reasonable trustworthiness.

Study Details

PMID:32917645
Participants:62
Impact:Calcium group decreased ratio by 46% relative to placebo at 1 year (P=0.002)
Trust score:4/5

COX-2/15-HPGD expression ratio in DBP2 genotype subgroup

1 evidences

Placebo-controlled trial: supplemental calcium (1,200 mg/day) and vitamin D (1,000 IU/day) reduced a biomarker ratio (COX-2/15-HPGD) linked to colorectal inflammation and carcinogenesis.

Trust comment: Randomized, placebo-controlled trial directly testing supplemental calcium with biomarker endpoints; moderate sample size and robust biomarker methods support reasonable trustworthiness.

Study Details

PMID:32917645
Participants:62
Impact:Among DBP2 carriers, calcium group decreased ratio by 75% relative to placebo (P=0.0002)
Trust score:4/5

tooth discoloration

1 evidences

Tested a new tricalcium silicate dental cement vs standard MTA in children's primary molar pulpotomies; both showed high success but the new cement avoided tooth discoloration.

Trust comment: Small randomized clinical dental trial in children with clear outcomes but limited sample size (33 patients) and 12-month follow-up.

Study Details

PMID:32876119
Participants:33
Impact:Bio-C Pulpo 0% vs MTA Angelus 10.31% (reduced with Bio-C Pulpo)
Trust score:3/5

caries arrest rate (surface-level)

1 evidences

Large double‑blind RCT in preschool children comparing AgNO3 + NaF varnish with vs without functionalized tricalcium phosphate (fTCP); adding fTCP improved caries‑arrest outcomes at 24 months.

Trust comment: Large (N=408 recruited, 356 completed), double‑blind randomized trial with intention‑to‑treat analysis showing statistically significant benefit of adding fTCP to NaF varnish.

Study Details

PMID:32866050
Participants:356
Impact:56.7% with fTCP vs 42.1% without fTCP at 24 months (absolute +14.6 percentage points)
Trust score:4/5

mean arrested carious surfaces per child

1 evidences

Large double‑blind RCT in preschool children comparing AgNO3 + NaF varnish with vs without functionalized tricalcium phosphate (fTCP); adding fTCP improved caries‑arrest outcomes at 24 months.

Trust comment: Large (N=408 recruited, 356 completed), double‑blind randomized trial with intention‑to‑treat analysis showing statistically significant benefit of adding fTCP to NaF varnish.

Study Details

PMID:32866050
Participants:356
Impact:2.6 vs 1.8 at 24 months (difference +0.8 surfaces per child)
Trust score:4/5

BMI-SDS

1 evidences

An 8-week intensive lifestyle program in children with abdominal obesity increased diet quality and improved some micronutrient intakes including calcium and vitamin D, and reduced BMI-SDS.

Trust comment: Randomized controlled lifestyle intervention with objective dietary and clinical measures and a moderate sample (n=107).

Study Details

PMID:30322156
Participants:107
Impact:−0.5 units
Trust score:4/5

HDL inflammatory index (HII)

1 evidences

In this nested case–control study within JUPITER, HDL inflammatory index (HII) showed a nonlinear relationship with incident CVD and mortality; HII 0.5–1.0 had lowest risk and HII 0–0.5 was associated with higher risk; rosuvastatin produced a small decrease in HII over 12 months.

Trust comment: High-quality nested analysis within a large randomized trial with robust biomarker assays, but observational case–control design and limited events for some subgroups reduce certainty.

Study Details

PMID:32799709
Participants:1034
Impact:HII 0–0.5: +53% CVD/mortality risk vs HII 0.5–1.0 (adj. HR 1.53; 95% CI 1.06–2.21)
Trust score:4/5

Rosuvastatin effect on HII

1 evidences

In this nested case–control study within JUPITER, HDL inflammatory index (HII) showed a nonlinear relationship with incident CVD and mortality; HII 0.5–1.0 had lowest risk and HII 0–0.5 was associated with higher risk; rosuvastatin produced a small decrease in HII over 12 months.

Trust comment: High-quality nested analysis within a large randomized trial with robust biomarker assays, but observational case–control design and limited events for some subgroups reduce certainty.

Study Details

PMID:32799709
Participants:1034
Impact:HII −5.3% over 12 months in statin arm (mean % change −5.3%; 95% CI −8.9 to −1.7), not significant vs placebo
Trust score:4/5

HDL particle number (HDL‑P) interaction

1 evidences

In this nested case–control study within JUPITER, HDL inflammatory index (HII) showed a nonlinear relationship with incident CVD and mortality; HII 0.5–1.0 had lowest risk and HII 0–0.5 was associated with higher risk; rosuvastatin produced a small decrease in HII over 12 months.

Trust comment: High-quality nested analysis within a large randomized trial with robust biomarker assays, but observational case–control design and limited events for some subgroups reduce certainty.

Study Details

PMID:32799709
Participants:1034
Impact:Higher HDL‑P associated with decreased CVD risk only when HII between 0.5–1.0
Trust score:4/5

Labial plate % bone loss

1 evidences

In 30 patients (32 sockets) grafted with biphasic calcium phosphate, sites covered by a PEG synthetic membrane lost less labial and coronal bone percentage than sites covered by porcine collagen membrane at 22 weeks.

Trust comment: Randomized controlled design but small sample size (30 patients/32 sockets) limits precision and generalizability.

Study Details

PMID:32799365
Participants:30
Impact:Test (PEG): −2.86% (SD 13.48) vs Control (collagen): 7.42% (SD 11.95); difference ≈ −10.3 percentage points
Trust score:3/5

Coronal socket % bone loss

1 evidences

In 30 patients (32 sockets) grafted with biphasic calcium phosphate, sites covered by a PEG synthetic membrane lost less labial and coronal bone percentage than sites covered by porcine collagen membrane at 22 weeks.

Trust comment: Randomized controlled design but small sample size (30 patients/32 sockets) limits precision and generalizability.

Study Details

PMID:32799365
Participants:30
Impact:Test (PEG): 13.45% (SD 11.97) vs Control: 28.59% (SD 16.97); difference ≈ −15.1 percentage points
Trust score:3/5

Need for further augmentation at implant placement

1 evidences

In 30 patients (32 sockets) grafted with biphasic calcium phosphate, sites covered by a PEG synthetic membrane lost less labial and coronal bone percentage than sites covered by porcine collagen membrane at 22 weeks.

Trust comment: Randomized controlled design but small sample size (30 patients/32 sockets) limits precision and generalizability.

Study Details

PMID:32799365
Participants:30
Impact:No difference (PEG n=5 vs CM n=4)
Trust score:3/5

Operation duration

1 evidences

Using 3D-printed planning and models with percutaneous reduction, cannulated screws and calcium sulfate cement grafting reduced operative time, blood loss and fluoroscopy use and produced better radiological and functional outcomes versus conventional technique.

Trust comment: Randomized allocation and reasonable sample (n=81) but single-center design and limited reporting of numeric effect sizes reduce certainty.

Study Details

PMID:32798112
Participants:81
Impact:Significantly decreased in 3D printing group vs conventional group
Trust score:3/5

Blood loss and fluoroscopy use

1 evidences

Using 3D-printed planning and models with percutaneous reduction, cannulated screws and calcium sulfate cement grafting reduced operative time, blood loss and fluoroscopy use and produced better radiological and functional outcomes versus conventional technique.

Trust comment: Randomized allocation and reasonable sample (n=81) but single-center design and limited reporting of numeric effect sizes reduce certainty.

Study Details

PMID:32798112
Participants:81
Impact:Both significantly decreased in 3D printing group
Trust score:3/5

Functional/radiological outcomes (AOFAS)

1 evidences

Using 3D-printed planning and models with percutaneous reduction, cannulated screws and calcium sulfate cement grafting reduced operative time, blood loss and fluoroscopy use and produced better radiological and functional outcomes versus conventional technique.

Trust comment: Randomized allocation and reasonable sample (n=81) but single-center design and limited reporting of numeric effect sizes reduce certainty.

Study Details

PMID:32798112
Participants:81
Impact:Improved radiological results postoperatively and higher AOFAS scores in 3D printing group
Trust score:3/5

Verbal memory (raloxifene)

1 evidences

In this 6-week double-blind randomized pilot (60 patients), adjunctive raloxifene improved verbal memory; isradipine (an L-type calcium channel blocker) improved verbal memory and some attention measures versus placebo, with no effect on processing speed or executive function.

Trust comment: Double-blind randomized pilot with modest size and short duration; promising but requires larger replication.

Study Details

PMID:32796392
Participants:60
Impact:Significant improvement with adjunctive raloxifene vs placebo
Trust score:3/5

Verbal memory and attention (isradipine)

1 evidences

In this 6-week double-blind randomized pilot (60 patients), adjunctive raloxifene improved verbal memory; isradipine (an L-type calcium channel blocker) improved verbal memory and some attention measures versus placebo, with no effect on processing speed or executive function.

Trust comment: Double-blind randomized pilot with modest size and short duration; promising but requires larger replication.

Study Details

PMID:32796392
Participants:60
Impact:Isradipine significantly improved verbal memory and some Stroop attention variables vs placebo
Trust score:3/5

Processing speed and executive function

1 evidences

In this 6-week double-blind randomized pilot (60 patients), adjunctive raloxifene improved verbal memory; isradipine (an L-type calcium channel blocker) improved verbal memory and some attention measures versus placebo, with no effect on processing speed or executive function.

Trust comment: Double-blind randomized pilot with modest size and short duration; promising but requires larger replication.

Study Details

PMID:32796392
Participants:60
Impact:No significant change with either drug
Trust score:3/5

Time to recovery (severe COVID-19)

1 evidences

In this halted phase 2 open-label trial (30 patients), the CRAC channel inhibitor Auxora showed acceptable safety and suggested efficacy signals in severe COVID-19: shorter median time to recovery and fewer patients reaching the composite of death or invasive mechanical ventilation versus standard of care.

Trust comment: Phase 2, randomized but open-label and stopped early with small sample (n=30); safety signals acceptable but efficacy needs confirmation in larger blinded trials.

Study Details

PMID:32795330
Participants:30
Impact:Median 5 days with Auxora vs 12 days with standard of care (recovery rate ratio 1.87; 95% CI 0.72–4.89)
Trust score:3/5

Intubation rate

1 evidences

In this halted phase 2 open-label trial (30 patients), the CRAC channel inhibitor Auxora showed acceptable safety and suggested efficacy signals in severe COVID-19: shorter median time to recovery and fewer patients reaching the composite of death or invasive mechanical ventilation versus standard of care.

Trust comment: Phase 2, randomized but open-label and stopped early with small sample (n=30); safety signals acceptable but efficacy needs confirmation in larger blinded trials.

Study Details

PMID:32795330
Participants:30
Impact:Auxora 18% (3/17) vs SOC 50% (4/8) in severe group
Trust score:3/5

Composite death or invasive mechanical ventilation

1 evidences

In this halted phase 2 open-label trial (30 patients), the CRAC channel inhibitor Auxora showed acceptable safety and suggested efficacy signals in severe COVID-19: shorter median time to recovery and fewer patients reaching the composite of death or invasive mechanical ventilation versus standard of care.

Trust comment: Phase 2, randomized but open-label and stopped early with small sample (n=30); safety signals acceptable but efficacy needs confirmation in larger blinded trials.

Study Details

PMID:32795330
Participants:30
Impact:Occurred in 18% with Auxora vs 56% with SOC (HR 0.23; 95% CI 0.05–0.96; p<0.05)
Trust score:3/5

composite functional index

1 evidences

12-month randomized double-blind trial in older adults: calcium HMB + vitamin D3 improved functional performance, with modest and time-limited gains in lean mass and leg strength, mainly in non-exercising participants.

Trust comment: Randomized, double-blind, placebo-controlled 12-month trial with registration and DSMB; moderate per-protocol completion (117) and some outcomes not sustained, so rated high but not perfect.

Study Details

PMID:32857128
Participants:117
Impact:Significant increase vs control (HMB+D) at 3 months (d=0.58, p=0.03), 6 months (d=0.70, p=0.04) and 12 months (d=0.67, p≈0.04)
Trust score:4/5

lean body mass (non-exercisers)

1 evidences

12-month randomized double-blind trial in older adults: calcium HMB + vitamin D3 improved functional performance, with modest and time-limited gains in lean mass and leg strength, mainly in non-exercising participants.

Trust comment: Randomized, double-blind, placebo-controlled 12-month trial with registration and DSMB; moderate per-protocol completion (117) and some outcomes not sustained, so rated high but not perfect.

Study Details

PMID:32857128
Participants:117
Impact:+0.44 ± 0.27 kg at 6 months (HMB+D) vs −0.33 ± 0.28 kg in control (p < 0.05); not sustained at 12 months
Trust score:4/5

knee extension peak torque (60°/s, non-exercisers)

1 evidences

12-month randomized double-blind trial in older adults: calcium HMB + vitamin D3 improved functional performance, with modest and time-limited gains in lean mass and leg strength, mainly in non-exercising participants.

Trust comment: Randomized, double-blind, placebo-controlled 12-month trial with registration and DSMB; moderate per-protocol completion (117) and some outcomes not sustained, so rated high but not perfect.

Study Details

PMID:32857128
Participants:117
Impact:HMB+D: +10.9 ± 5.7 Nm at 3 months vs control −5.2 ± 5.9 Nm at 3 months (p=0.04); control lost strength by 12 months while HMB+D maintained baseline
Trust score:4/5

gastric volume / antral CSA

1 evidences

Randomized double-blind study in ambulatory surgery patients: 200 mL carbohydrate drink 2 h pre-op had similar gastric emptying to water, reduced hunger, and no aspiration events.

Trust comment: Randomized, double-blinded RCT with objective ultrasound measures and low adverse events; modest sample size (64 completers) limits generalizability.

Study Details

PMID:32856619
Participants:64
Impact:No patients had predicted GV >1.5 mL/kg at induction; antral CSA was higher at 1 hour (T2) in carbohydrate group vs water (significant), returned to baseline by 2 hours
Trust score:4/5

hunger (VAS)

1 evidences

Randomized double-blind study in ambulatory surgery patients: 200 mL carbohydrate drink 2 h pre-op had similar gastric emptying to water, reduced hunger, and no aspiration events.

Trust comment: Randomized, double-blinded RCT with objective ultrasound measures and low adverse events; modest sample size (64 completers) limits generalizability.

Study Details

PMID:32856619
Participants:64
Impact:Significantly less hunger at 1 hour (T2) after carbohydrate beverage vs water (p<0.05)
Trust score:4/5

aspiration incidence

1 evidences

Randomized double-blind study in ambulatory surgery patients: 200 mL carbohydrate drink 2 h pre-op had similar gastric emptying to water, reduced hunger, and no aspiration events.

Trust comment: Randomized, double-blinded RCT with objective ultrasound measures and low adverse events; modest sample size (64 completers) limits generalizability.

Study Details

PMID:32856619
Participants:64
Impact:No instances of gastric regurgitation or pulmonary aspiration recorded in either group
Trust score:4/5

no pain at 72 hours (VAS)

1 evidences

Randomized trial in dental patients: calcium hydroxide mixed with dexamethasone and triple antibiotic paste both reduced postoperative endodontic pain compared with placebo.

Trust comment: Randomized controlled trial with clear outcome measures, but limited methodological details (blinding unclear) and single-center design reduce confidence.

Study Details

PMID:32829540
Participants:120
Impact:Group A (calcium hydroxide + dexamethasone): 55% pain-free at 72 h; Group B (triple antibiotic): 47.5% pain-free; Group C (placebo): 17.5% pain-free
Trust score:3/5

lumbar spine BMD (LS-BMD)

1 evidences

Postmenopausal osteoporotic women received zoledronate; experimental groups received calcitriol plus calcium carbonate while controls received calcium carbonate alone—bone turnover markers fell and BMD rose, with greater marker declines and lumbar spine BMD increase when calcitriol was added.

Trust comment: Randomized human study (n=120) with measured BTM and BMD showing significant differences when calcitriol was added to calcium/zoledronate.

Study Details

PMID:32346686
Participants:120
Impact:increase; LS BMD increase rate highest in high vitamin D + calcitriol group vs other groups at 6 months (P<0.05)
Trust score:4/5

Annual recurrence rate (BPPV)

1 evidences

Large multicenter randomized trial found vitamin D plus calcium supplementation (when vitamin D low) reduced BPPV recurrence rates over one year.

Trust comment: Large multicenter randomized trial with blinded outcome assessment showing a statistically significant reduction in BPPV recurrences, though supplementation strategy depended on baseline vitamin D levels.

Study Details

PMID:32759193
Participants:1050
Impact:0.83 recurrences/person-year (intervention) vs 1.10 (observation); absolute -0.27 recurrences/year; incidence rate ratio 0.76 (95% CI 0.66–0.87)
Trust score:4/5

lower extremity lean mass

1 evidences

In sarcopenic older adults, early supervised resistance training with nutritional support (including calcium) led to an earlier increase in lower‑leg muscle mass but did not improve physical function.

Trust comment: Randomized controlled trial in humans with clear numeric outcomes but calcium was given as part of a multi‑nutrient supplement, limiting attribution solely to calcium.

Study Details

PMID:32723507
Participants:57
Impact:+770.8 g (early intervention between baseline and 1st follow-up) vs +294.2 g (delayed)
Trust score:4/5

calcium (serum)

2 evidences

In pediatric ESRD patients, substituting some hemodialysis sessions with online hemodiafiltration improved biochemical markers including calcium/phosphorus/PTH and reduced inflammation over follow-up.

Trust comment: Prospective clinical study with measured calcium/phosphate/PTH outcomes in children; moderate sample size and single‑center design limit generalizability.

Study Details

PMID:32723294
Participants:31
Impact:+13.0% (3–9 months) and +19.99% (3–18 months) in HDF group (increase not statistically significant between groups)
Trust score:3/5

Whey protein versus carbohydrate supplementation during 9 weeks of military training did not affect serum calcium, vitamin D response to training, or bone turnover markers; vitamin D rose across training (likely sun exposure).

Trust comment: Double‑blind, placebo‑controlled human trial with adequate sample enrollment; cluster (platoon) allocation and variable analyte sample sizes reduce internal precision for some biomarkers.

Study Details

PMID:32722609
Participants:77
Impact:no significant change with supplementation (no group or group×time effect, p = 0.21)
Trust score:4/5

phosphorus (serum)

1 evidences

In pediatric ESRD patients, substituting some hemodialysis sessions with online hemodiafiltration improved biochemical markers including calcium/phosphorus/PTH and reduced inflammation over follow-up.

Trust comment: Prospective clinical study with measured calcium/phosphate/PTH outcomes in children; moderate sample size and single‑center design limit generalizability.

Study Details

PMID:32723294
Participants:31
Impact:-3.05% (3–9 months) in HDF group (short‑term significant)
Trust score:3/5

vitamin D (serum)

1 evidences

Whey protein versus carbohydrate supplementation during 9 weeks of military training did not affect serum calcium, vitamin D response to training, or bone turnover markers; vitamin D rose across training (likely sun exposure).

Trust comment: Double‑blind, placebo‑controlled human trial with adequate sample enrollment; cluster (platoon) allocation and variable analyte sample sizes reduce internal precision for some biomarkers.

Study Details

PMID:32722609
Participants:77
Impact:increase across training (main effect of time, p < 0.01)
Trust score:4/5

bone turnover markers (P1NP, CTX, P1NP/CTX ratio)

1 evidences

Whey protein versus carbohydrate supplementation during 9 weeks of military training did not affect serum calcium, vitamin D response to training, or bone turnover markers; vitamin D rose across training (likely sun exposure).

Trust comment: Double‑blind, placebo‑controlled human trial with adequate sample enrollment; cluster (platoon) allocation and variable analyte sample sizes reduce internal precision for some biomarkers.

Study Details

PMID:32722609
Participants:77
Impact:no significant effect of whey vs carbohydrate supplementation (no group or group×time interactions; p>0.5)
Trust score:4/5

bone mass / BMD

1 evidences

Daily consumption of a dairy product enriched with calcium, vitamin D and other bone‑supporting nutrients for 24 weeks improved bone mass and bone turnover markers and mitigated BMD loss in menopausal women at risk of osteoporosis.

Trust comment: Randomized, double‑blind clinical trial with relevant bone outcomes and physiological effects; moderate sample and 17% dropout but clear between‑group biochemical and DXA findings.

Study Details

PMID:32722015
Participants:65
Impact:bone mass increased in experimental group vs decline in control (EG +0.01 kg vs CG −0.01 kg; p < 0.05); BMD preserved in EG, declined in CG
Trust score:4/5

CTX (bone resorption marker)

6 evidences

Enhanced exercise and combined calcium plus vitamin D helped maintain or improve muscle strength in postmenopausal women at high osteoporosis risk.

Trust comment: Large randomized trial (n=614) in target population with significant biochemical and functional outcomes, though some effect sizes not fully reported.

Study Details

PMID:28695804
Participants:614
Impact:decreased in Ca+25OHD group D (P=0.011)
Trust score:4/5

Small randomized study: adding Greek yogurt (source of protein and calcium) to exercise increased bone formation markers versus placebo.

Trust comment: Randomized controlled trial but small sample (n=30); biomarker changes are statistically significant though clinical translation limited by size.

Study Details

PMID:31652407
Participants:30
Impact:decrease (both groups; GY attenuated early rise seen in placebo)
Trust score:4/5

Daily consumption of a dairy product enriched with calcium, vitamin D and other bone‑supporting nutrients for 24 weeks improved bone mass and bone turnover markers and mitigated BMD loss in menopausal women at risk of osteoporosis.

Trust comment: Randomized, double‑blind clinical trial with relevant bone outcomes and physiological effects; moderate sample and 17% dropout but clear between‑group biochemical and DXA findings.

Study Details

PMID:32722015
Participants:65
Impact:decrease in EG vs increase in CG (−0.05 ng/mL vs +0.04 ng/mL; p < 0.05)
Trust score:4/5

Small randomized study in postmenopausal osteopenic women: adding bioactive collagen peptides to calcium+vitamin D lowered bone turnover markers over 3 months compared with calcium+vitamin D alone.

Trust comment: Randomized, measured objective biochemical endpoints and registered, but small sample size and short duration limit confidence and generalizability.

Study Details

PMID:32131366
Participants:43
Impact:decreased (Group with CPs: -11.4% within-group, p=0.058; between-groups trend -11.4% vs +3.5%, p=0.079)
Trust score:3/5

A 3-month dietary intervention in postmenopausal women increasing vegetables/herbs/fruit reduced urinary calcium excretion and lowered bone turnover markers in the group consuming phytochemical-rich selections, especially in osteopenic women.

Trust comment: Randomized dietary intervention with objective biomarkers and reasonable sample but short duration (3 months), non-randomized control and some selection bias limit generalizability.

Study Details

PMID:25856221
Participants:142
Impact:In Group B osteopenic subgroup CTX −0.065 μg/L (p<0.01); no significant overall between-group change
Trust score:3/5

Postmenopausal osteoporotic women received zoledronate; experimental groups received calcitriol plus calcium carbonate while controls received calcium carbonate alone—bone turnover markers fell and BMD rose, with greater marker declines and lumbar spine BMD increase when calcitriol was added.

Trust comment: Randomized human study (n=120) with measured BTM and BMD showing significant differences when calcitriol was added to calcium/zoledronate.

Study Details

PMID:32346686
Participants:120
Impact:decrease; greater decrease in calcitriol+calcium group vs calcium-only control at 6 months (P<0.05)
Trust score:4/5

postoperative pain incidence

1 evidences

Single-visit endodontic retreatment caused less postoperative pain than two-visit treatments using calcium hydroxide or chlorhexidine.

Trust comment: Randomized clinical trial (n=150) directly comparing intracanal calcium hydroxide use; clear clinical endpoints and adequate sample size.

Study Details

PMID:30054099
Participants:150
Impact:Higher in calcium hydroxide and CHX two-visit groups vs single-visit at 1 day–1 month assessments (significant differences, P ≤ .05 at several timepoints)
Trust score:4/5

total effective rate

1 evidences

Adding calcium dobesilate to alprostadil improved neuropathy scores and overall effectiveness over 2 weeks.

Trust comment: Randomized clinical trial with clear clinical endpoints but short duration (2 weeks) and limited detail in the excerpt.

Study Details

PMID:30183208
Participants:120
Impact:increased (treatment group had significantly better total effective rate vs control; p<0.05)
Trust score:3/5

analgesic use

1 evidences

In root canal treatment of necrotic single-rooted teeth, calcium hydroxide paste produced similar post-operative pain and flare-up rates compared with propolis paste.

Trust comment: Well-conducted double-blind RCT with clear outcomes and 68 completers; moderate sample size and 15% dropout from planned 80.

Study Details

PMID:31936519
Participants:68
Impact:oral analgesic consumption ~9.6% of observations in calcium hydroxide group
Trust score:4/5

blood lipids

1 evidences

Daily low-fat milk fortified with 1000 mg calcium + 800 IU vitamin D3, alone or with exercise, did not improve blood pressure or blood lipids over 18 months in middle-aged and older men.

Trust comment: 18-month randomized factorial trial with 180 participants; direct evaluation of dietary calcium fortification—well-conducted secondary analysis.

Study Details

PMID:32666313
Participants:180
Impact:No effect of fortified milk or exercise on fasting lipids at any timepoint
Trust score:4/5

serum vitamin B-12

1 evidences

A 24‑week RCT of fortified milk (providing ~1008 mg Ca/day) plus exercise improved vitamin B‑12 and 25(OH)D levels and reduced bone turnover markers versus control.

Trust comment: Well‑conducted 24‑week RCT with good sample size and compliance; combined nutrition+exercise limits attribution to Calcium alone.

Study Details

PMID:32588047
Participants:163
Impact:+139 pmol/L (mean: 345 → 484 pmol/L at 24 wk)
Trust score:4/5

bone turnover (PINP, CTX)

2 evidences

A 24‑week RCT of fortified milk (providing ~1008 mg Ca/day) plus exercise improved vitamin B‑12 and 25(OH)D levels and reduced bone turnover markers versus control.

Trust comment: Well‑conducted 24‑week RCT with good sample size and compliance; combined nutrition+exercise limits attribution to Calcium alone.

Study Details

PMID:32588047
Participants:163
Impact:decrease (median PINP 41 → 29 μg/L; median CTX 276 → 239 pg/mL)
Trust score:4/5

In postmenopausal women receiving bisphosphonates (with daily calcium and vitamin D), bone turnover markers fell and an early positive bone balance developed, changes that were associated with later increases in spine and hip BMD.

Trust comment: Randomized treatment groups with serial biomarker and DXA measurements; calcium/vitamin D given to all as background, moderate‑high quality.

Study Details

PMID:31740343
Participants:391
Impact:Significant reduction after bisphosphonate treatment
Trust score:4/5

Individuals indicated for preventive treatment (relative reduction)

1 evidences

Compared CAC scoring vs SCORE model for CVD screening; CAC classified fewer individuals as increased risk and indicated less preventive treatment.

Trust comment: Large population-based randomized screening trial with robust sample size and clear outcome measures; directly evaluates coronary artery calcium scoring.

Study Details

PMID:32584979
Participants:25135
Impact:Women: −37.2%; Men: −28.8% (CAC vs SCORE)
Trust score:4/5

Risk classification by CAC (low/intermediate/high)

1 evidences

Compared CAC scoring vs SCORE model for CVD screening; CAC classified fewer individuals as increased risk and indicated less preventive treatment.

Trust comment: Large population-based randomized screening trial with robust sample size and clear outcome measures; directly evaluates coronary artery calcium scoring.

Study Details

PMID:32584979
Participants:25135
Impact:Low risk 76.0%; High 15.1%; Very high 8.9% (Agatston thresholds)
Trust score:4/5

White spot lesion complete reversal

1 evidences

Topical 5% sodium fluoride varnish with functionalized tri-calcium phosphate (fTCP) applied at baseline and 8 weeks reversed more white spot lesions vs placebo at 16 weeks.

Trust comment: Randomized investigator-blinded controlled trial with near-complete follow-up (57/59) showing clinically meaningful benefit of a calcium-containing dental product.

Study Details

PMID:32577707
Participants:57
Impact:62% (Varnish) vs 39% (Control); +23 percentage points at 16 weeks
Trust score:4/5

Patient/clinician perceived esthetic improvement

1 evidences

Topical 5% sodium fluoride varnish with functionalized tri-calcium phosphate (fTCP) applied at baseline and 8 weeks reversed more white spot lesions vs placebo at 16 weeks.

Trust comment: Randomized investigator-blinded controlled trial with near-complete follow-up (57/59) showing clinically meaningful benefit of a calcium-containing dental product.

Study Details

PMID:32577707
Participants:57
Impact:Significant positive correlation between patient and clinician ratings (P < 0.05)
Trust score:4/5

lean body mass/height

1 evidences

Twelve weeks of a leucine-enriched protein supplement (also containing 300 mg calcium and 800 IU vitamin D twice daily) increased lean body mass measures versus isocaloric placebo in adults ≥50, especially ages 50–64.

Trust comment: Randomized, double-blind, placebo-controlled trial with per-protocol analysis (n=111) showing significant increases in lean mass; calcium was included as part of the tested supplement complex.

Study Details

PMID:32570811
Participants:111
Impact:Intervention: 15.06 → 15.29 (+0.23); Control: 15.04 → 15.09 (+0.05) (time×group P=0.019)
Trust score:5/5

lean body mass/weight

1 evidences

Twelve weeks of a leucine-enriched protein supplement (also containing 300 mg calcium and 800 IU vitamin D twice daily) increased lean body mass measures versus isocaloric placebo in adults ≥50, especially ages 50–64.

Trust comment: Randomized, double-blind, placebo-controlled trial with per-protocol analysis (n=111) showing significant increases in lean mass; calcium was included as part of the tested supplement complex.

Study Details

PMID:32570811
Participants:111
Impact:Intervention: 63.38 → 63.68 (+0.30); Control: 63.85 → 63.29 (−0.56) (time×group P<0.001)
Trust score:5/5

25(OH)D (vitamin D status)

2 evidences

In Chinese postmenopausal women, daily fortified milk (1200 mg calcium + vitamin D + FOS-inulin) for 52 weeks increased 25(OH)D, suppressed bone turnover markers and preserved femoral neck BMD compared with regular milk.

Trust comment: Randomized 1-year trial directly testing calcium+vitamin D fortified milk with clear biochemical and DXA outcomes; moderate sample size and clinically relevant endpoints.

Study Details

PMID:28975432
Participants:121
Impact:+11.7 nmol/L (intervention 74.8 vs control 63.1 nmol/L; p<0.001)
Trust score:4/5

Twelve weeks of a leucine-enriched protein supplement (also containing 300 mg calcium and 800 IU vitamin D twice daily) increased lean body mass measures versus isocaloric placebo in adults ≥50, especially ages 50–64.

Trust comment: Randomized, double-blind, placebo-controlled trial with per-protocol analysis (n=111) showing significant increases in lean mass; calcium was included as part of the tested supplement complex.

Study Details

PMID:32570811
Participants:111
Impact:Intervention: 34.40 → 39.83 ng/mL (+5.43); Control: 35.30 → 29.24 ng/mL (−6.06) (time×group P<0.001)
Trust score:5/5

Lumbar spine BMD (resveratrol with calcium)

1 evidences

Low‑dose resveratrol (75 mg twice daily) increased lumbar spine and femoral neck BMD versus placebo; the BMD benefit was larger in women who regularly took calcium (and/or vitamin D).

Trust comment: Randomized, double‑blind, placebo‑controlled 2‑year crossover RCT with prespecified subgroup analyses; calcium findings are from small exploratory subgroups so interpret cautiously.

Study Details

PMID:32564438
Participants:125
Impact:+0.068 g/cm2 (treatment difference vs neither)
Trust score:5/5

Total hip BMD (resveratrol with calcium only, parallel subgroup)

1 evidences

Low‑dose resveratrol (75 mg twice daily) increased lumbar spine and femoral neck BMD versus placebo; the BMD benefit was larger in women who regularly took calcium (and/or vitamin D).

Trust comment: Randomized, double‑blind, placebo‑controlled 2‑year crossover RCT with prespecified subgroup analyses; calcium findings are from small exploratory subgroups so interpret cautiously.

Study Details

PMID:32564438
Participants:125
Impact:+0.039 g/cm2
Trust score:5/5

Hip fracture risk (resveratrol with vitamin D + calcium)

1 evidences

Low‑dose resveratrol (75 mg twice daily) increased lumbar spine and femoral neck BMD versus placebo; the BMD benefit was larger in women who regularly took calcium (and/or vitamin D).

Trust comment: Randomized, double‑blind, placebo‑controlled 2‑year crossover RCT with prespecified subgroup analyses; calcium findings are from small exploratory subgroups so interpret cautiously.

Study Details

PMID:32564438
Participants:125
Impact:−1.3% (absolute reduction in 10‑year hip fracture probability)
Trust score:5/5

urinary oxalate excretion

1 evidences

Healthy men given 200 g/day fructose for two weeks had higher serum uric acid, a small drop in ionized calcium with higher PTH, lower urine pH, higher urinary oxalate and lower urine magnesium—changes that raise kidney-stone risk.

Trust comment: Within-subject pre–post study in 33 men with robust lab measures; single-arm reporting and high fructose dose limit generalizability.

Study Details

PMID:30409184
Participants:33
Impact:increased +11.1 ±25.0 mg/24 h (p=0.016)
Trust score:3/5

fractional calcium excretion

1 evidences

In a controlled crossover trial, potassium supplementation lowered FGF23 and fractional calcium excretion and increased plasma phosphate/TmP-GFR; sodium supplementation also lowered FGF23 but increased urinary (and fractional) calcium excretion.

Trust comment: Well-controlled, double-blind randomized placebo-controlled crossover with dietary control (n=36); post-hoc analysis but robust biochemical measures.

Study Details

PMID:32506135
Participants:36
Impact:decreased ≈−10.6% with potassium (P=0.03); increased ≈+21.6% with sodium (P=0.004)
Trust score:4/5

global stent encrustation (intervention vs placebo)

1 evidences

Oral composition containing L-methionine (acidifier) and phytin (crystallization inhibitor) lowered urinary pH and markedly reduced ureteral stent encrustation versus placebo.

Trust comment: Multicenter, double-blind randomized placebo-controlled trial (n=105) with objective central lab measurements; good quality for outcome assessed.

Study Details

PMID:32503502
Participants:105
Impact:1.0% vs 8.2% of stent ends; relative risk ~8.2; p=0.018 (reduction)
Trust score:4/5

encrustation degree (sum of stent ends)

1 evidences

Oral composition containing L-methionine (acidifier) and phytin (crystallization inhibitor) lowered urinary pH and markedly reduced ureteral stent encrustation versus placebo.

Trust comment: Multicenter, double-blind randomized placebo-controlled trial (n=105) with objective central lab measurements; good quality for outcome assessed.

Study Details

PMID:32503502
Participants:105
Impact:mean 18.91 (intervention) vs 85.12 (placebo); p=0.025 (lower)
Trust score:4/5

urine pH reduction

1 evidences

Oral composition containing L-methionine (acidifier) and phytin (crystallization inhibitor) lowered urinary pH and markedly reduced ureteral stent encrustation versus placebo.

Trust comment: Multicenter, double-blind randomized placebo-controlled trial (n=105) with objective central lab measurements; good quality for outcome assessed.

Study Details

PMID:32503502
Participants:105
Impact:greater reduction in intervention (difference −0.47 vs placebo; p=0.018)
Trust score:4/5

musculoskeletal symptoms frequency

1 evidences

Compared diets of 20 HPP patients and 20 matched controls and related calcium/phosphorus intake to symptom frequency.

Trust comment: Cross-sectional matched study with small sample (40) and clear statistical associations but limited causal inference.

Study Details

PMID:32502243
Participants:40
Impact:very high or very low calcium intake associated with increased musculoskeletal symptoms (P < 0.01)
Trust score:3/5

neuropsychiatric symptoms frequency

1 evidences

Compared diets of 20 HPP patients and 20 matched controls and related calcium/phosphorus intake to symptom frequency.

Trust comment: Cross-sectional matched study with small sample (40) and clear statistical associations but limited causal inference.

Study Details

PMID:32502243
Participants:40
Impact:very high or very low calcium intake associated with increased neuropsychiatric symptoms (P < 0.001)
Trust score:3/5

dentine hypersensitivity (Schiff score)

1 evidences

Double-blind RCT in adults with dentine hypersensitivity showing the calcium-silicate/sodium-phosphate toothpaste reduced sensitivity versus control over 14–29 days.

Trust comment: Well-powered, double-blind RCT with consistent objective and subjective measures showing significant effects.

Study Details

PMID:32497553
Participants:247
Impact:Schiff scores significantly lower in CSSP group at 14, 28, 29 days (p<0.001 for most comparisons)
Trust score:4/5

patient-reported pain (VAS)

1 evidences

Double-blind RCT in adults with dentine hypersensitivity showing the calcium-silicate/sodium-phosphate toothpaste reduced sensitivity versus control over 14–29 days.

Trust comment: Well-powered, double-blind RCT with consistent objective and subjective measures showing significant effects.

Study Details

PMID:32497553
Participants:247
Impact:VAS pain significantly reduced in CSSP group (VAS at 14 days p<0.04; other comparisons p≤0.001)
Trust score:4/5

Lumbar spine BMD (L1–4)

1 evidences

Randomized trial in people ≥80 years with osteopenia comparing calcium+alfacalcidol ± alendronate over 18 months; assessed BMD, fractures, falls and biomarkers.

Trust comment: Randomized controlled trial with reasonable sample size and objective endpoints (DXA, fracture) though some baseline imbalances and borderline fracture significance.

Study Details

PMID:32495521
Participants:123
Impact:experiment group +5.07% vs control +2.30% after 18 months
Trust score:4/5

fragility fracture incidence

1 evidences

Randomized trial in people ≥80 years with osteopenia comparing calcium+alfacalcidol ± alendronate over 18 months; assessed BMD, fractures, falls and biomarkers.

Trust comment: Randomized controlled trial with reasonable sample size and objective endpoints (DXA, fracture) though some baseline imbalances and borderline fracture significance.

Study Details

PMID:32495521
Participants:123
Impact:experiment 8.1% (5/62) vs control 20.0% (12/60) (P = 0.057; RR 0.403)
Trust score:4/5

total/ionized calcium ratio (T/iCa)

1 evidences

Retrospective single-center study of ICU patients on citrate CVVH identifying factors that influence total/ionized calcium ratio (a marker of citrate accumulation).

Trust comment: Observational retrospective analysis with mixed models and 103 patients; appropriate for hypothesis-generating associations but not causal proof.

Study Details

PMID:32485438
Participants:103
Impact:T/iCa positively associated with citrate dose/target and modified by pH, phosphate, albumin, APACHE II and lactate (interactions reported)
Trust score:3/5

effect modification by phosphate

1 evidences

Retrospective single-center study of ICU patients on citrate CVVH identifying factors that influence total/ionized calcium ratio (a marker of citrate accumulation).

Trust comment: Observational retrospective analysis with mixed models and 103 patients; appropriate for hypothesis-generating associations but not causal proof.

Study Details

PMID:32485438
Participants:103
Impact:rising citrate dose associated with larger increases in T/iCa when phosphate was high and less when phosphate was low
Trust score:3/5

effect modification by pH/lactate

1 evidences

Retrospective single-center study of ICU patients on citrate CVVH identifying factors that influence total/ionized calcium ratio (a marker of citrate accumulation).

Trust comment: Observational retrospective analysis with mixed models and 103 patients; appropriate for hypothesis-generating associations but not causal proof.

Study Details

PMID:32485438
Participants:103
Impact:in acidosis, rising lactate associated with greater increases in T/iCa; pH itself a main independent predictor
Trust score:3/5

25-hydroxyvitamin D exposure (AUC & Cmax)

1 evidences

Randomized PK study (75 randomized, 73 completed) comparing daily, weekly and bi-weekly high-dose cholecalciferol regimens in vitamin D–deficient healthy adults; daily dosing gave higher 25(OH)D exposure without safety signals.

Trust comment: Randomized human PK study with completed n=73, objective lab endpoints and safety monitoring; open-label but appropriate for PK.

Study Details

PMID:32471106
Participants:73
Impact:daily regimen (Group A) produced higher AUC and Cmax (peak mean 81.0 ng/mL) vs weekly 63.6 ng/mL and bi-weekly 59.4 ng/mL
Trust score:4/5

achievement of target 25(OH)D levels

1 evidences

Randomized PK study (75 randomized, 73 completed) comparing daily, weekly and bi-weekly high-dose cholecalciferol regimens in vitamin D–deficient healthy adults; daily dosing gave higher 25(OH)D exposure without safety signals.

Trust comment: Randomized human PK study with completed n=73, objective lab endpoints and safety monitoring; open-label but appropriate for PK.

Study Details

PMID:32471106
Participants:73
Impact:most subjects reached ≥20 ng/mL quickly; by day 56–84 virtually all subjects had ≥30 ng/mL
Trust score:4/5

stair-climb ascent power

1 evidences

In women doing a 4-month exercise program, adding a protein- and micronutrient-fortified milk (contains calcium) did not improve the primary stair-climb power but produced small gains in lean mass and reductions in fat.

Trust comment: High-quality double-blind, placebo-controlled RCT with adequate sample size and objective measures; findings on calcium-specific effects are secondary within a multinutrient product.

Study Details

PMID:32469393
Participants:216
Impact:+3.6–4.3% in both groups (no additional benefit of supplement vs placebo)
Trust score:5/5

total body lean mass

1 evidences

In women doing a 4-month exercise program, adding a protein- and micronutrient-fortified milk (contains calcium) did not improve the primary stair-climb power but produced small gains in lean mass and reductions in fat.

Trust comment: High-quality double-blind, placebo-controlled RCT with adequate sample size and objective measures; findings on calcium-specific effects are secondary within a multinutrient product.

Study Details

PMID:32469393
Participants:216
Impact:+0.3 kg net difference (P=0.020)
Trust score:5/5

postoperative spontaneous pain

1 evidences

In 60 patients with irreversible pulpitis, calcium hydroxide mixed with lidocaine reduced postoperative spontaneous pain compared with calcium hydroxide mixed with saline during the first 4 days.

Trust comment: Small randomized clinical trial showing a clinically plausible effect but limited by sample size and preliminary design.

Study Details

PMID:32462277
Participants:60
Impact:reduced on days 1–4 in Ca(OH)2 + lidocaine group vs Ca(OH)2 + saline (significant, p<0.05)
Trust score:3/5

tooth sensitivity (absolute risk)

1 evidences

Randomized trial (5 groups) testing violet LED with/without peroxide gels for tooth whitening; LED+HP gave largest color change, LED alone least; tooth sensitivity varied by protocol; enamel Ca/P ratio did not decrease after treatments.

Trust comment: Well-conducted randomized, controlled trial with blinding of evaluators and sample size calculation; moderate sample size per group.

Study Details

PMID:32428059
Participants:90
Impact:LED 16%; LED/CP 61%; CP 44%; LED/HP 88%; HP 94.4%
Trust score:4/5

enamel calcium-to-phosphorus ratio (Ca/P)

1 evidences

Randomized trial (5 groups) testing violet LED with/without peroxide gels for tooth whitening; LED+HP gave largest color change, LED alone least; tooth sensitivity varied by protocol; enamel Ca/P ratio did not decrease after treatments.

Trust comment: Well-conducted randomized, controlled trial with blinding of evaluators and sample size calculation; moderate sample size per group.

Study Details

PMID:32428059
Participants:90
Impact:No significant decrease from baseline to 14 days for treatments; some between-group differences at timepoints (e.g., CP > LED/HP) but overall Ca/P maintained
Trust score:4/5

Survival (association with severe hypocalcemia)

1 evidences

Adults with traumatic hemorrhagic shock receiving prehospital plasma had higher rates of hypocalcemia on admission; hypocalcemia predicted lower survival and greater need for massive transfusion.

Trust comment: Observational analysis of RCT participants (n=160) showing robust associations between admission hypocalcemia and worse clinical outcomes after prehospital plasma.

Study Details

PMID:32317575
Participants:160
Impact:decreased survival associated with severe hypocalcemia; adjusted hazard ratio 1.07 (95% CI 1.02–1.13), p=0.01
Trust score:4/5

Massive transfusion (association with severe hypocalcemia)

1 evidences

Adults with traumatic hemorrhagic shock receiving prehospital plasma had higher rates of hypocalcemia on admission; hypocalcemia predicted lower survival and greater need for massive transfusion.

Trust comment: Observational analysis of RCT participants (n=160) showing robust associations between admission hypocalcemia and worse clinical outcomes after prehospital plasma.

Study Details

PMID:32317575
Participants:160
Impact:increased risk of massive transfusion with severe hypocalcemia; adjusted RR 2.70 (95% CI 1.13–6.46), p=0.03
Trust score:4/5

saliva mutans streptococci levels

1 evidences

Randomized trial in 92 children comparing fluoride varnishes with/without calcium-containing agents; all groups reduced cariogenic bacteria at 1 month, and varnish with tricalcium phosphate (TCP) showed greater and longer reductions up to 3 months.

Trust comment: Randomized controlled trial with objective microbiological outcomes showing TCP (a calcium phosphate agent) added to fluoride varnish reduced cariogenic bacteria up to 3 months; moderate sample size and surrogate endpoints.

Study Details

PMID:32356211
Participants:92
Impact:Significant decrease at 1 month in all groups; TCP-containing varnish showed greater reduction at 1 and 3 months (p < 0.05)
Trust score:3/5

saliva lactobacilli levels

1 evidences

Randomized trial in 92 children comparing fluoride varnishes with/without calcium-containing agents; all groups reduced cariogenic bacteria at 1 month, and varnish with tricalcium phosphate (TCP) showed greater and longer reductions up to 3 months.

Trust comment: Randomized controlled trial with objective microbiological outcomes showing TCP (a calcium phosphate agent) added to fluoride varnish reduced cariogenic bacteria up to 3 months; moderate sample size and surrogate endpoints.

Study Details

PMID:32356211
Participants:92
Impact:Significant decrease at 1 month in all groups; TCP-containing varnish showed greater reduction at 1 and 3 months (p < 0.05)
Trust score:3/5

treatment survival rate

1 evidences

Prospective randomized trial of partial pulpotomy in immature permanent teeth comparing iRoot BP Plus vs calcium hydroxide; 99 teeth analyzed and both materials had similar survival and root development, but the calcific bridge was thinner with iRoot BP Plus.

Trust comment: Randomized prospective controlled dental trial comparing a bioceramic material with calcium hydroxide (a calcium-based standard); direct comparison provides relevant evidence though outcome unit is teeth.

Study Details

PMID:32348009
Participants:99
Impact:No intergroup difference in survival rate or survival time
Trust score:4/5

calcific bridge thickness

1 evidences

Prospective randomized trial of partial pulpotomy in immature permanent teeth comparing iRoot BP Plus vs calcium hydroxide; 99 teeth analyzed and both materials had similar survival and root development, but the calcific bridge was thinner with iRoot BP Plus.

Trust comment: Randomized prospective controlled dental trial comparing a bioceramic material with calcium hydroxide (a calcium-based standard); direct comparison provides relevant evidence though outcome unit is teeth.

Study Details

PMID:32348009
Participants:99
Impact:iRoot BP Plus: 0.97 ± 0.13 mm vs calcium hydroxide: 1.36 ± 0.12 mm (p = 0.029)
Trust score:4/5

Fibre density of purchases

1 evidences

Experimental marketplace study testing how sugar taxes and front‑of‑pack labels changed nutrient density of snack purchases.

Trust comment: Large randomized experimental marketplace (n=3584) with clear within‑subject design and measured purchase outcomes.

Study Details

PMID:32304676
Participants:3584
Impact:+0.1 g/100 kcal with taxes; +0.4 g/100 kcal with multiple traffic light label; +0.3 g/100 kcal with health star rating
Trust score:4/5

Calcium density of purchases

1 evidences

Experimental marketplace study testing how sugar taxes and front‑of‑pack labels changed nutrient density of snack purchases.

Trust comment: Large randomized experimental marketplace (n=3584) with clear within‑subject design and measured purchase outcomes.

Study Details

PMID:32304676
Participants:3584
Impact:no significant change across tax or label conditions
Trust score:4/5

Protein density of purchases

1 evidences

Experimental marketplace study testing how sugar taxes and front‑of‑pack labels changed nutrient density of snack purchases.

Trust comment: Large randomized experimental marketplace (n=3584) with clear within‑subject design and measured purchase outcomes.

Study Details

PMID:32304676
Participants:3584
Impact:no significant change across tax or label conditions
Trust score:4/5

Relative oral bioavailability (calcium glucoheptonate vs calcium carbonate)

1 evidences

Single‑dose, randomized two‑period crossover in healthy adults comparing pharmacokinetics of calcium glucoheptonate versus calcium carbonate.

Trust comment: Randomized crossover PK study in healthy adults with validated assays but small sample (n=24); standard methods used.

Study Details

PMID:32302064
Participants:24
Impact:≈92% at 6 h and ≈89% at 12 h
Trust score:4/5

Cmax (geometric mean ratio test/reference)

1 evidences

Single‑dose, randomized two‑period crossover in healthy adults comparing pharmacokinetics of calcium glucoheptonate versus calcium carbonate.

Trust comment: Randomized crossover PK study in healthy adults with validated assays but small sample (n=24); standard methods used.

Study Details

PMID:32302064
Participants:24
Impact:~99% at 6 h and ~96% at 12 h (similar Cmax)
Trust score:4/5

AUC0–t (geometric mean ratio test/reference)

1 evidences

Single‑dose, randomized two‑period crossover in healthy adults comparing pharmacokinetics of calcium glucoheptonate versus calcium carbonate.

Trust comment: Randomized crossover PK study in healthy adults with validated assays but small sample (n=24); standard methods used.

Study Details

PMID:32302064
Participants:24
Impact:~91.2% at 6 h and ~86.1% at 12 h
Trust score:4/5

Cognitive function (age >65, high baseline Ca:Mg ratio)

1 evidences

Randomized trial testing personalized magnesium supplementation to lower dietary Ca:Mg ratio; in adults >65 with high Ca:Mg ratio, lowering the ratio improved cognition and altered APOE methylation.

Trust comment: Double‑blind randomized trial nested in a larger RCT (n=250); subgroup effects reported for older participants with high Ca:Mg ratios.

Study Details

PMID:32280092
Participants:250
Impact:+9.1% improvement with personalized Mg supplementation to lower Ca:Mg ratio (p=0.03)
Trust score:4/5

5‑mC at APOE cg13496662 and cg06750524

1 evidences

Randomized trial testing personalized magnesium supplementation to lower dietary Ca:Mg ratio; in adults >65 with high Ca:Mg ratio, lowering the ratio improved cognition and altered APOE methylation.

Trust comment: Double‑blind randomized trial nested in a larger RCT (n=250); subgroup effects reported for older participants with high Ca:Mg ratios.

Study Details

PMID:32280092
Participants:250
Impact:significant reductions in 5‑mC at cg13496662 (p=0.02) and cg06750524 (p=0.03)
Trust score:4/5

Mediation by APOE methylation

1 evidences

Randomized trial testing personalized magnesium supplementation to lower dietary Ca:Mg ratio; in adults >65 with high Ca:Mg ratio, lowering the ratio improved cognition and altered APOE methylation.

Trust comment: Double‑blind randomized trial nested in a larger RCT (n=250); subgroup effects reported for older participants with high Ca:Mg ratios.

Study Details

PMID:32280092
Participants:250
Impact:cognitive benefit partially mediated by reductions in 5‑mC (p for indirect effect = 0.05)
Trust score:4/5

total hip BMD

1 evidences

In severely obese adults over 12 weeks, a traditional Brazilian diet increased spine and hip BMD and lowered PTH, while extra virgin olive oil supplementation increased serum calcium.

Trust comment: Well-conducted randomized trial with DXA-measured BMD and biochemical outcomes, though short duration (12 weeks) and mostly female sample limit generalizability.

Study Details

PMID:32032997
Participants:97
Impact:significant increase in DieTBra group (paired P=0.029)
Trust score:4/5

bowel movement frequency

1 evidences

In overweight/obese adults licogliflozin increased loose stools and bowel movements; reducing meal carbohydrate reduced stool effects, and calcium carbonate 1 g did not alter the stool changes.

Trust comment: Randomized, crossover study with small cohorts and clear outcomes; direct evidence that calcium carbonate 1 g did not affect licogliflozin-induced stool changes.

Study Details

PMID:32236953
Participants:24
Impact:Significantly higher change from baseline with 50% vs 25% and 0% carbohydrate meals (P < 0.01)
Trust score:4/5

loose stools (Bristol 6–7)

1 evidences

In overweight/obese adults licogliflozin increased loose stools and bowel movements; reducing meal carbohydrate reduced stool effects, and calcium carbonate 1 g did not alter the stool changes.

Trust comment: Randomized, crossover study with small cohorts and clear outcomes; direct evidence that calcium carbonate 1 g did not affect licogliflozin-induced stool changes.

Study Details

PMID:32236953
Participants:24
Impact:Fewer Bristol 6–7 stools following 0% carbohydrate meal (no numeric data in excerpt)
Trust score:4/5

effect of calcium carbonate (1 g)

1 evidences

In overweight/obese adults licogliflozin increased loose stools and bowel movements; reducing meal carbohydrate reduced stool effects, and calcium carbonate 1 g did not alter the stool changes.

Trust comment: Randomized, crossover study with small cohorts and clear outcomes; direct evidence that calcium carbonate 1 g did not affect licogliflozin-induced stool changes.

Study Details

PMID:32236953
Participants:24
Impact:no effect on licogliflozin-associated stool changes
Trust score:4/5

fractional excretion of calcium (FECa)

1 evidences

Phase 1 randomized double-blind placebo-controlled trial of TransCon PTH showing dose-dependent increases in serum calcium with maintained urinary calcium excretion and increased renal phosphate excretion.

Trust comment: Well-conducted randomized double-blind phase 1 trial with detailed PK/PD and objective biochemical endpoints in healthy volunteers.

Study Details

PMID:32212275
Participants:132
Impact:remained within normal range (~0.4–2%), no marked increase despite higher sCa
Trust score:4/5

TMP/GFR (phosphaturic effect) / serum phosphate

1 evidences

Phase 1 randomized double-blind placebo-controlled trial of TransCon PTH showing dose-dependent increases in serum calcium with maintained urinary calcium excretion and increased renal phosphate excretion.

Trust comment: Well-conducted randomized double-blind phase 1 trial with detailed PK/PD and objective biochemical endpoints in healthy volunteers.

Study Details

PMID:32212275
Participants:132
Impact:decrease (dose-dependent, significant; TMP/GFR p=0.0022)
Trust score:4/5

P-R interval (ECG)

1 evidences

Small randomized study in postmenopausal women showing 12 weeks of moderate aerobic exercise increased PTH and vitamin D and altered ECG P-R interval; calcium changes not reported as significant.

Trust comment: Small randomized study with objective measures but limited sample size and reporting; no calcium supplementation tested.

Study Details

PMID:32208176
Participants:31
Impact:increase (P = 0.020) after 12 weeks exercise
Trust score:3/5

treatment compliance

2 evidences

100 adults ≥50 y in a randomized cross-over trial: monthly vitamin D alone produced higher compliance than daily vitamin D+calcium, with similar changes in 25(OH)D.

Trust comment: Randomized cross-over human study with objective compliance and biochemical endpoints; appropriate design and sample size for compliance outcome.

Study Details

PMID:26100413
Participants:100
Impact:monthly vitamin D compliance 100% vs daily vitamin D+calcium 96.2% (period1) and 91.7% (period2); p<0.0001
Trust score:4/5

Small randomized study in postmenopausal osteopenic women: adding bioactive collagen peptides to calcium+vitamin D lowered bone turnover markers over 3 months compared with calcium+vitamin D alone.

Trust comment: Randomized, measured objective biochemical endpoints and registered, but small sample size and short duration limit confidence and generalizability.

Study Details

PMID:32131366
Participants:43
Impact:higher with CPs-containing supplement (100% vs 77%; p=0.027)
Trust score:3/5

Abdominal pain (VAS)

1 evidences

Adding IV calcium gluconate to morphine rapidly and substantially reduced abdominal pain from lead poisoning versus morphine alone.

Trust comment: Randomized single-center single-blind RCT (n=50) with objective VAS measurements but limited sample size.

Study Details

PMID:32188492
Participants:50
Impact:−15.7 mm vs −3.2 mm at 60 min (morphine+Ca vs morphine alone); P<0.001
Trust score:4/5

Abdominal pain (VAS) — early reduction

1 evidences

Adding IV calcium gluconate to morphine rapidly and substantially reduced abdominal pain from lead poisoning versus morphine alone.

Trust comment: Randomized single-center single-blind RCT (n=50) with objective VAS measurements but limited sample size.

Study Details

PMID:32188492
Participants:50
Impact:Greater pain reduction at 15 and 30 min with calcium added (mean VAS 58.0 and 53.6 vs 64.6 and 63.8)
Trust score:4/5

Serum 25‑hydroxyvitamin D (calcidiol) and PTH

1 evidences

Six months of a vitamin D + calcium + leucine‑enriched whey protein drink (up to 2 servings/day) did not impair kidney function or cause vitamin D/calcium toxicity in sarcopenic older adults.

Trust comment: Large multicenter randomized trial with objective lab endpoints and 6‑month follow-up supporting safety of the calcium‑containing product.

Study Details

PMID:32162241
Participants:379
Impact:Calcidiol increased to ~70–80 nmol/L with supplementation; PTH decreased
Trust score:4/5

C-reactive protein (CRP)

2 evidences

In colorectal adenoma patients, 1.0 or 2.0 g/day calcium for 4 months did not change circulating inflammation or oxidative stress biomarkers.

Trust comment: Randomized, double-blind, placebo-controlled trial (n=193) with objective biomarker endpoints; null results reported clearly.

Study Details

PMID:26304464
Participants:193
Impact:no appreciable change (P > 0.4)
Trust score:4/5

Randomized trial in severe acute pancreatitis where combination therapy improved clinical outcomes and raised serum calcium compared with conventional care.

Trust comment: Prospective randomized controlled trial (n=100) with clear pre/post biochemical and clinical endpoints; calcium measured and reported.

Study Details

PMID:31662003
Participants:100
Impact:-127.7 g/l (combination group: 208.4 → 80.7 g/l)
Trust score:4/5

bone stiffness index (calcaneal SI)

1 evidences

Large group-randomized after-school intervention (calcium-rich snacks, physical activity, education) in 6–9 year olds that produced modest improvements in bone-related behaviors and small improvements in bone stiffness for some groups.

Trust comment: Large, cluster-randomized, community-based RCT with objective outcomes but incomplete bone measurements and some measurement/fidelity limitations.

Study Details

PMID:32093625
Participants:1434
Impact:+0.6 units/year in B+P vs −2.1 units/year in control (B+P vs C p=0.05); pooled girls +2.1 units/year (p<0.01)
Trust score:4/5

physical activity (MET/WBF scores)

1 evidences

Large group-randomized after-school intervention (calcium-rich snacks, physical activity, education) in 6–9 year olds that produced modest improvements in bone-related behaviors and small improvements in bone stiffness for some groups.

Trust comment: Large, cluster-randomized, community-based RCT with objective outcomes but incomplete bone measurements and some measurement/fidelity limitations.

Study Details

PMID:32093625
Participants:1434
Impact:+~1.89 MET units/year (B+P vs C); increased WBF (B+P) — significant increases in reported physical activity for B+P and for boys in intervention
Trust score:4/5

total calcium intake

1 evidences

Large group-randomized after-school intervention (calcium-rich snacks, physical activity, education) in 6–9 year olds that produced modest improvements in bone-related behaviors and small improvements in bone stiffness for some groups.

Trust comment: Large, cluster-randomized, community-based RCT with objective outcomes but incomplete bone measurements and some measurement/fidelity limitations.

Study Details

PMID:32093625
Participants:1434
Impact:No significant change (no increase vs control)
Trust score:4/5

posterolateral fusion rate (AttraX Putty)

1 evidences

Multicenter randomized intrapatient trial (n=100 treated, efficacy n=87) comparing a β-TCP–rich biphasic calcium phosphate putty to autograft for posterolateral spinal fusion; fusion rates were similar and noninferiority was demonstrated at 1 year.

Trust comment: Randomized, multicenter, patient- and observer-blinded intrapatient noninferiority trial with objective CT-based fusion assessment; moderate sample size and 1-year follow-up limit longer-term inference.

Study Details

PMID:32080013
Participants:100
Impact:55% fused (AttraX) vs 52% fused (autograft) at 1 year
Trust score:4/5

noninferiority (fusion performance)

1 evidences

Multicenter randomized intrapatient trial (n=100 treated, efficacy n=87) comparing a β-TCP–rich biphasic calcium phosphate putty to autograft for posterolateral spinal fusion; fusion rates were similar and noninferiority was demonstrated at 1 year.

Trust comment: Randomized, multicenter, patient- and observer-blinded intrapatient noninferiority trial with objective CT-based fusion assessment; moderate sample size and 1-year follow-up limit longer-term inference.

Study Details

PMID:32080013
Participants:100
Impact:Absolute difference 2.3% (90% CI −9.1% to +13.7%); within 15% noninferiority margin
Trust score:4/5

milk intake (category)

1 evidences

A 6-week social media plus text-message program modestly improved calcium knowledge and produced small, non-significant increases in calcium intake, with greater engagement when texts were added.

Trust comment: Randomized trial with validated calcium-specific questionnaire and intention-to-treat analysis but substantial missing self-reported intake data and short follow-up.

Study Details

PMID:32044755
Participants:148
Impact:41.2% moved to a higher milk intake category in Facebook+text group (OR 1.77 vs control; completers-only OR 4.99)
Trust score:4/5

calcium intake (non-milk)

1 evidences

A 6-week social media plus text-message program modestly improved calcium knowledge and produced small, non-significant increases in calcium intake, with greater engagement when texts were added.

Trust comment: Randomized trial with validated calcium-specific questionnaire and intention-to-treat analysis but substantial missing self-reported intake data and short follow-up.

Study Details

PMID:32044755
Participants:148
Impact:mean change +65.5 mg/day (Facebook+text) vs +43.0 mg/day (control) (not significant, P=.57)
Trust score:4/5

calcium knowledge score

1 evidences

A 6-week social media plus text-message program modestly improved calcium knowledge and produced small, non-significant increases in calcium intake, with greater engagement when texts were added.

Trust comment: Randomized trial with validated calcium-specific questionnaire and intention-to-treat analysis but substantial missing self-reported intake data and short follow-up.

Study Details

PMID:32044755
Participants:148
Impact:mean increase +2.9 points (out of 18) in Facebook+text group (P<.001)
Trust score:4/5

total intracanal bacterial count

1 evidences

Intracanal calcium hydroxide combined with ciprofloxacin reduced intracanal bacterial load more than calcium hydroxide alone or with ibuprofen after 7 days.

Trust comment: Randomized clinical study with quantitative PCR bacteriological outcomes, moderate sample size (n=45) and clear in vivo antibacterial findings.

Study Details

PMID:32034789
Participants:45
Impact:greater reduction with Ca(OH)2 + Ciprofloxacin (S3 mean ~0.49×10^2) vs Ca(OH)2 alone (~1.25×10^2) and Ca(OH)2 + Ibuprofen (~0.76×10^2)
Trust score:4/5

positive root canals at S3

1 evidences

Intracanal calcium hydroxide combined with ciprofloxacin reduced intracanal bacterial load more than calcium hydroxide alone or with ibuprofen after 7 days.

Trust comment: Randomized clinical study with quantitative PCR bacteriological outcomes, moderate sample size (n=45) and clear in vivo antibacterial findings.

Study Details

PMID:32034789
Participants:45
Impact:fewer positive cases with Ca(OH)2 + Ciprofloxacin (8/15) vs Ca(OH)2 alone (13/15) and Ca(OH)2 + Ibuprofen (13/15) (P<0.05)
Trust score:4/5

total spine BMD

1 evidences

In severely obese adults over 12 weeks, a traditional Brazilian diet increased spine and hip BMD and lowered PTH, while extra virgin olive oil supplementation increased serum calcium.

Trust comment: Well-conducted randomized trial with DXA-measured BMD and biochemical outcomes, though short duration (12 weeks) and mostly female sample limit generalizability.

Study Details

PMID:32032997
Participants:97
Impact:significant increase in DieTBra group (between-groups P=0.040; paired P=0.016)
Trust score:4/5

base excess (24 h)

1 evidences

In burned critically ill patients, Plasmalyte produced similar base excess to Ringer lactate but led to higher gluconate accumulation and significantly lower ionized calcium levels.

Trust comment: Randomized trial in a small but well-defined critical care population with direct biochemical measurements; limited sample size reduces precision.

Study Details

PMID:32027547
Participants:28
Impact:no significant difference between Plasmalyte and Ringer lactate
Trust score:4/5

plasma gluconate concentration

1 evidences

In burned critically ill patients, Plasmalyte produced similar base excess to Ringer lactate but led to higher gluconate accumulation and significantly lower ionized calcium levels.

Trust comment: Randomized trial in a small but well-defined critical care population with direct biochemical measurements; limited sample size reduces precision.

Study Details

PMID:32027547
Participants:28
Impact:higher accumulation with Plasmalyte (significant)
Trust score:4/5

urinary KIM-1 fold-change (primary)

1 evidences

Multicentre RCT found no evidence that rosuvastatin prevented aminoglycoside nephrotoxicity by primary KIM-1 outcome, though some secondary NGAL measures suggested possible benefit; overall inconclusive.

Trust comment: Well-designed multi-centre randomized trial using validated kidney injury biomarkers, but lower than expected nephrotoxicity reduced power to detect effects.

Study Details

PMID:32020028
Participants:44
Impact:control 1.85 vs rosuvastatin 2.00; treatment difference 1.08 (95% CI 0.87–1.35), P=0.48 (no protective effect)
Trust score:4/5

urinary NGAL AUC

1 evidences

Multicentre RCT found no evidence that rosuvastatin prevented aminoglycoside nephrotoxicity by primary KIM-1 outcome, though some secondary NGAL measures suggested possible benefit; overall inconclusive.

Trust comment: Well-designed multi-centre randomized trial using validated kidney injury biomarkers, but lower than expected nephrotoxicity reduced power to detect effects.

Study Details

PMID:32020028
Participants:44
Impact:AUC lower in rosuvastatin group (treatment difference significant, p=0.03) but baseline imbalance complicates interpretation
Trust score:4/5

serum creatinine / AKI events

1 evidences

Multicentre RCT found no evidence that rosuvastatin prevented aminoglycoside nephrotoxicity by primary KIM-1 outcome, though some secondary NGAL measures suggested possible benefit; overall inconclusive.

Trust comment: Well-designed multi-centre randomized trial using validated kidney injury biomarkers, but lower than expected nephrotoxicity reduced power to detect effects.

Study Details

PMID:32020028
Participants:44
Impact:no significant treatment effect on serum creatinine; 4 participants met KDIGO AKI criteria (2 control stage 3, 2 intervention stage 1)
Trust score:4/5

new bone volume fraction

1 evidences

Prospective randomized trial comparing biphasic calcium phosphate graft vs deproteinized bovine bone for sinus augmentation (56 patients, 60 sinuses); both materials showed similar biocompatibility and osteoconductivity at 6 months.

Trust comment: Randomized controlled clinical trial directly testing a calcium-containing graft material in humans; moderate sample size and no significant differences reported.

Study Details

PMID:30521656
Participants:56
Impact:Observed higher in calcium phosphate group vs bovine bone, but difference was not statistically significant
Trust score:3/5

femoral neck bone loss in postmenopausal women

1 evidences

Low-dose vitamin K2 reduced femoral neck bone loss in postmenopausal women; adding calcium + vitamin D3 provided no extra benefit.

Trust comment: Large randomized controlled trial (n=311, 1-year) with subgroup effects limited to postmenopausal women.

Study Details

PMID:32060566
Participants:311
Impact:Significantly lower with 90 µg VK2 vs placebo (treatment×time p=0.006)
Trust score:4/5

serum cOC/ucOC ratio

1 evidences

Low-dose vitamin K2 reduced femoral neck bone loss in postmenopausal women; adding calcium + vitamin D3 provided no extra benefit.

Trust comment: Large randomized controlled trial (n=311, 1-year) with subgroup effects limited to postmenopausal women.

Study Details

PMID:32060566
Participants:311
Impact:Increased in intervention groups (treatment×time significant)
Trust score:4/5

co-supplementation with calcium + vitamin D3

1 evidences

Low-dose vitamin K2 reduced femoral neck bone loss in postmenopausal women; adding calcium + vitamin D3 provided no extra benefit.

Trust comment: Large randomized controlled trial (n=311, 1-year) with subgroup effects limited to postmenopausal women.

Study Details

PMID:32060566
Participants:311
Impact:No additional effect compared with VK2 alone
Trust score:4/5

annualised Vpeak progression

1 evidences

Higher circulating ApoCIII-Lp(a) (with OxPL) identifies patients with mild-moderate aortic stenosis who progress faster and have higher rates of valve replacement or cardiac death.

Trust comment: Moderate-sized observational cohort (n=218) with proteomic confirmation; associative evidence rather than causal.

Study Details

PMID:32054669
Participants:218
Impact:Significantly faster with elevated ApoCIII-Lp(a) (p<0.001)
Trust score:3/5

risk of AVR/cardiac death

1 evidences

Higher circulating ApoCIII-Lp(a) (with OxPL) identifies patients with mild-moderate aortic stenosis who progress faster and have higher rates of valve replacement or cardiac death.

Trust comment: Moderate-sized observational cohort (n=218) with proteomic confirmation; associative evidence rather than causal.

Study Details

PMID:32054669
Participants:218
Impact:Higher in patients with elevated ApoCIII-Lp(a) (p=0.03)
Trust score:3/5

hypocalcaemia incidence at day 5

1 evidences

Low early postoperative PTH reliably predicts later hypocalcemia after total thyroidectomy and identifies patients needing higher calcium supplementation.

Trust comment: Prospective cohort study with clear predictive analysis and adequate sample size (n=143).

Study Details

PMID:32046865
Participants:143
Impact:36.4% (52/143)
Trust score:4/5

PTH <2.9 pmol/L (1 h post-op) predicting hypocalcaemia

1 evidences

Low early postoperative PTH reliably predicts later hypocalcemia after total thyroidectomy and identifies patients needing higher calcium supplementation.

Trust comment: Prospective cohort study with clear predictive analysis and adequate sample size (n=143).

Study Details

PMID:32046865
Participants:143
Impact:AUC 0.748; sensitivity 76.9%, specificity 71.4%
Trust score:4/5

post-operative endodontic pain

1 evidences

In root canal treatment of necrotic single-rooted teeth, calcium hydroxide paste produced similar post-operative pain and flare-up rates compared with propolis paste.

Trust comment: Well-conducted double-blind RCT with clear outcomes and 68 completers; moderate sample size and 15% dropout from planned 80.

Study Details

PMID:31936519
Participants:68
Impact:no significant difference between calcium hydroxide and propolis at 4, 12, 24, 48, 72 h (between-group differences non-significant; e.g., 12 h mean difference −0.92)
Trust score:4/5

molidustat AUC

1 evidences

In healthy men, concomitant oral calcium reduced molidustat exposure (notably Cmax) but did not alter the erythropoietin (EPO) pharmacodynamic response.

Trust comment: Randomized, open-label crossover pharmacokinetic studies in 42 healthy volunteers with clear numerical PK/PD outcomes; high internal validity for interaction assessment.

Study Details

PMID:31919558
Participants:42
Impact:reduced by ~15% with concurrent calcium (depending on prandial state)
Trust score:4/5

molidustat Cmax

1 evidences

In healthy men, concomitant oral calcium reduced molidustat exposure (notably Cmax) but did not alter the erythropoietin (EPO) pharmacodynamic response.

Trust comment: Randomized, open-label crossover pharmacokinetic studies in 42 healthy volunteers with clear numerical PK/PD outcomes; high internal validity for interaction assessment.

Study Details

PMID:31919558
Participants:42
Impact:reduced by ~47% with concurrent calcium
Trust score:4/5

endogenous EPO response

1 evidences

In healthy men, concomitant oral calcium reduced molidustat exposure (notably Cmax) but did not alter the erythropoietin (EPO) pharmacodynamic response.

Trust comment: Randomized, open-label crossover pharmacokinetic studies in 42 healthy volunteers with clear numerical PK/PD outcomes; high internal validity for interaction assessment.

Study Details

PMID:31919558
Participants:42
Impact:no meaningful change with calcium coadministration
Trust score:4/5

HbA1c change

1 evidences

Large human study included a clinical cohort where calcium plus vitamin D was used as a comparator; denosumab treatment reduced DPP4 and improved GLP-1 and glycemic control compared with calcium plus vitamin D in observational cohort analysis.

Trust comment: High-quality randomized biopsy study (N≈48) plus a large non-randomized clinical cohort (115 per group) used for glycemic comparisons; observational cohort comparisons limit causal inference regarding calcium+vitamin D.

Study Details

PMID:31911667
Participants:115
Impact:denosumab produced a greater decrease in HbA1c over 12 months compared with calcium plus vitamin D (statistically significant; reported P values <0.01)
Trust score:3/5

serum DPP4

1 evidences

Large human study included a clinical cohort where calcium plus vitamin D was used as a comparator; denosumab treatment reduced DPP4 and improved GLP-1 and glycemic control compared with calcium plus vitamin D in observational cohort analysis.

Trust comment: High-quality randomized biopsy study (N≈48) plus a large non-randomized clinical cohort (115 per group) used for glycemic comparisons; observational cohort comparisons limit causal inference regarding calcium+vitamin D.

Study Details

PMID:31911667
Participants:115
Impact:denosumab reduced circulating DPP4 vs placebo (significant); comparator calcium+vitD group showed less HbA1c reduction in cohort analysis
Trust score:3/5

GLP-1 levels

1 evidences

Large human study included a clinical cohort where calcium plus vitamin D was used as a comparator; denosumab treatment reduced DPP4 and improved GLP-1 and glycemic control compared with calcium plus vitamin D in observational cohort analysis.

Trust comment: High-quality randomized biopsy study (N≈48) plus a large non-randomized clinical cohort (115 per group) used for glycemic comparisons; observational cohort comparisons limit causal inference regarding calcium+vitamin D.

Study Details

PMID:31911667
Participants:115
Impact:increase in total GLP-1 following denosumab vs placebo (significant)
Trust score:3/5

Alveolar flange width change

1 evidences

A synthetic, partially resorbable calcium-phosphate–containing bone substitute performed similarly to Bio-Oss® in preserving post-extraction alveolar ridge dimensions and promoted greater osteoid formation and resorption/replacement by new bone.

Trust comment: Randomized, double-blind clinical trial with blinded evaluators and histologic/radiographic endpoints, but small sample size and short follow-up (6 months).

Study Details

PMID:31972958
Participants:33
Impact:experimental −0.6 ± 1.4 mm vs control −0.9 ± 1.3 mm (no significant difference)
Trust score:4/5

Alveolar flange height change

1 evidences

A synthetic, partially resorbable calcium-phosphate–containing bone substitute performed similarly to Bio-Oss® in preserving post-extraction alveolar ridge dimensions and promoted greater osteoid formation and resorption/replacement by new bone.

Trust comment: Randomized, double-blind clinical trial with blinded evaluators and histologic/radiographic endpoints, but small sample size and short follow-up (6 months).

Study Details

PMID:31972958
Participants:33
Impact:experimental −0.3 ± 0.7 mm vs control −0.1 ± 0.9 mm (no significant difference)
Trust score:4/5

Osteoid matrix / osteogenesis (histology)

1 evidences

A synthetic, partially resorbable calcium-phosphate–containing bone substitute performed similarly to Bio-Oss® in preserving post-extraction alveolar ridge dimensions and promoted greater osteoid formation and resorption/replacement by new bone.

Trust comment: Randomized, double-blind clinical trial with blinded evaluators and histologic/radiographic endpoints, but small sample size and short follow-up (6 months).

Study Details

PMID:31972958
Participants:33
Impact:greater osteoid activity and intragranular bone formation with experimental material (qualitative)
Trust score:4/5

postpartum depression (PPD) score

1 evidences

Vitamin D with or without calcium modestly reduced postpartum depression scores; no change in estradiol or inflammatory markers between groups.

Trust comment: Randomized double-blind trial with clear outcomes, but modest sample size and combined interventions limit isolating a pure calcium effect.

Study Details

PMID:31900080
Participants:81
Impact:-1.7 ±3.44 (vitamin D + calcium), -4.16 ±5.90 (vitamin D alone), +0.25 ±2.81 (placebo); p=0.008
Trust score:4/5

Estradiol

1 evidences

Vitamin D with or without calcium modestly reduced postpartum depression scores; no change in estradiol or inflammatory markers between groups.

Trust comment: Randomized double-blind trial with clear outcomes, but modest sample size and combined interventions limit isolating a pure calcium effect.

Study Details

PMID:31900080
Participants:81
Impact:no significant change between groups
Trust score:4/5

inflammatory markers (IL-6, TNFα)

2 evidences

Vitamin D with or without calcium modestly reduced postpartum depression scores; no change in estradiol or inflammatory markers between groups.

Trust comment: Randomized double-blind trial with clear outcomes, but modest sample size and combined interventions limit isolating a pure calcium effect.

Study Details

PMID:31900080
Participants:81
Impact:no significant change between groups
Trust score:4/5

Adding somatostatin enema to standard care shortened symptom recovery and decreased inflammation; blood calcium rose after treatment.

Trust comment: Randomized clinical sample with clear outcomes, but calcium was a measured biomarker secondary to a non-calcium intervention (indirect relevance).

Study Details

PMID:28829514
Participants:79
Impact:decreased (p<0.05)
Trust score:3/5

pulpotomy success rate (tricalcium silicate)

1 evidences

Tricalcium silicate pulpotomy in primary molars showed high long-term success, slightly higher than formocresol but not statistically significant.

Trust comment: Randomized clinical trial directly involving a calcium-containing restorative material but small sample limits power to detect differences.

Study Details

PMID:31882030
Participants:58
Impact:97.3% (36/37)
Trust score:3/5

pulpotomy success rate (formocresol)

1 evidences

Tricalcium silicate pulpotomy in primary molars showed high long-term success, slightly higher than formocresol but not statistically significant.

Trust comment: Randomized clinical trial directly involving a calcium-containing restorative material but small sample limits power to detect differences.

Study Details

PMID:31882030
Participants:58
Impact:91.4% (32/35)
Trust score:3/5

knee laxity (KT-1000 side-to-side difference)

1 evidences

Using a silicate-substituted calcium phosphate bone substitute produced similar knee stability, function, and complication rates as autologous bone graft at ~3 years.

Trust comment: Prospective randomized controlled trial (Level I) with 2+ year follow-up but modest sample size.

Study Details

PMID:31864574
Participants:37
Impact:no significant difference (0.9 ±1.5 mm vs 0.7 ±2.0 mm; P=0.731)
Trust score:4/5

functional scores (Tegner, Lysholm, IKDC)

1 evidences

Using a silicate-substituted calcium phosphate bone substitute produced similar knee stability, function, and complication rates as autologous bone graft at ~3 years.

Trust comment: Prospective randomized controlled trial (Level I) with 2+ year follow-up but modest sample size.

Study Details

PMID:31864574
Participants:37
Impact:both groups improved from baseline with no between-group difference (P≥0.396)
Trust score:4/5

revision surgery rate

1 evidences

Using a silicate-substituted calcium phosphate bone substitute produced similar knee stability, function, and complication rates as autologous bone graft at ~3 years.

Trust comment: Prospective randomized controlled trial (Level I) with 2+ year follow-up but modest sample size.

Study Details

PMID:31864574
Participants:37
Impact:control 22% vs Si-CaP 11% (no significant difference; P=0.660)
Trust score:4/5

FGF23 (active form)

1 evidences

In CKD patients, paricalcitol lowered PTH substantially and increased circulating FGF23 over 12 weeks.

Trust comment: Randomized 12-week trial with complete measurements and clear biochemical endpoints in CKD patients.

Study Details

PMID:31863599
Participants:88
Impact:increase +107 pg/mL (95% CI 44–170); P=0.001
Trust score:4/5

25-hydroxyvitamin D (25-OHD) at week 4

1 evidences

A single 300,000 IU dose (stoss) raised vitamin D to similar week-4 levels as weekly dosing, with lower levels by week-12; no calcium or PTH abnormalities at week-4.

Trust comment: Randomized prospective pediatric trial with measured biochemical safety and efficacy outcomes though modest sample size.

Study Details

PMID:31860537
Participants:39
Impact:stoss 53.6 ±17.3 ng/mL vs weekly 54.6 ±17.5 ng/mL (equivalent)
Trust score:4/5

25-hydroxyvitamin D (25-OHD) at week 12

1 evidences

A single 300,000 IU dose (stoss) raised vitamin D to similar week-4 levels as weekly dosing, with lower levels by week-12; no calcium or PTH abnormalities at week-4.

Trust comment: Randomized prospective pediatric trial with measured biochemical safety and efficacy outcomes though modest sample size.

Study Details

PMID:31860537
Participants:39
Impact:stoss 29.8 ±7.1 ng/mL vs weekly 40.4 ±11.9 ng/mL (P=0.04)
Trust score:4/5

serum calcium and PTH (safety)

1 evidences

A single 300,000 IU dose (stoss) raised vitamin D to similar week-4 levels as weekly dosing, with lower levels by week-12; no calcium or PTH abnormalities at week-4.

Trust comment: Randomized prospective pediatric trial with measured biochemical safety and efficacy outcomes though modest sample size.

Study Details

PMID:31860537
Participants:39
Impact:normal at week 4 in stoss group (no hypercalcemia reported)
Trust score:4/5

predictive performance (AUC)

1 evidences

A machine-learning model that included coronary artery calcium improved long-term prediction of MI and cardiac death compared with standard risk scores and CAC alone.

Trust comment: Large prospective cohort with long follow-up and quantitative coronary calcium measures, but observational and not an intervention on calcium.

Study Details

PMID:31853543
Participants:1912
Impact:ML AUC 0.82 vs ASCVD 0.77 and CAC 0.77 (P<0.05)
Trust score:3/5

risk stratification (high ML score)

1 evidences

A machine-learning model that included coronary artery calcium improved long-term prediction of MI and cardiac death compared with standard risk scores and CAC alone.

Trust comment: Large prospective cohort with long follow-up and quantitative coronary calcium measures, but observational and not an intervention on calcium.

Study Details

PMID:31853543
Participants:1912
Impact:higher ML score associated with HR 10.38 for events (P<0.001); multivariable HR 2.94 (P=0.005)
Trust score:3/5

Stride time variability (CoV of stride time)

1 evidences

Randomized single-blind RCT in 40 older women testing daily yogurt fortified with vitamin D3 (200 IU per pot twice daily) and calcium (400 mg per pot twice daily) for 3 months versus control yogurt; measured gait variability, cognition, grip strength and serum 25OHD.

Trust comment: Randomized controlled trial in humans with objective measures but small sample (n=40) and single-blind design limits generalizability.

Study Details

PMID:31779179
Participants:40
Impact:1.9% (intervention) vs 2.7% (control) at 3 months (−0.8 percentage points; p=0.049)
Trust score:3/5

Swing time variability (CoV)

1 evidences

Randomized single-blind RCT in 40 older women testing daily yogurt fortified with vitamin D3 (200 IU per pot twice daily) and calcium (400 mg per pot twice daily) for 3 months versus control yogurt; measured gait variability, cognition, grip strength and serum 25OHD.

Trust comment: Randomized controlled trial in humans with objective measures but small sample (n=40) and single-blind design limits generalizability.

Study Details

PMID:31779179
Participants:40
Impact:2.9% (intervention) vs 4.5% (control) at 3 months (−1.6 percentage points; p=0.002)
Trust score:3/5

Global cognitive performance (MMSE)

1 evidences

Randomized single-blind RCT in 40 older women testing daily yogurt fortified with vitamin D3 (200 IU per pot twice daily) and calcium (400 mg per pot twice daily) for 3 months versus control yogurt; measured gait variability, cognition, grip strength and serum 25OHD.

Trust comment: Randomized controlled trial in humans with objective measures but small sample (n=40) and single-blind design limits generalizability.

Study Details

PMID:31779179
Participants:40
Impact:+1.4 points (28.5 vs 27.1 at 3 months; p=0.010)
Trust score:3/5

Broad gene expression (buffy coat)

1 evidences

Double-blind RCT in healthy young adults (33 enrolled, 30 completed) randomized to 600, 4000 or 10,000 IU/day vitamin D3 for 24 weeks assessing serum 25(OH)D, PTH, calcium and genome-wide gene expression in white blood cells.

Trust comment: Well-controlled double-blind trial with clear biochemical and genomic outcomes but limited by small sample size.

Study Details

PMID:31776371
Participants:30
Impact:Differentially expressed genes: 162 (600 IU), 320 (4000 IU), 1289 (10,000 IU) after supplementation
Trust score:4/5

Total colonic bacterial DNA

1 evidences

90-day randomized trial in 30 healthy adults comparing Aquamin (multi-mineral product delivering 800 mg calcium/day) vs calcium alone vs placebo; collected colon biopsies and stool pre/post to assess microbiota and metabolomics.

Trust comment: Human randomized trial with complete follow-up (n=30) showing microbiome/metabolome changes; small sample and preliminary findings limit certainty.

Study Details

PMID:31771942
Participants:30
Impact:Decreased after Aquamin (P=0.0001); decline larger than with calcium alone
Trust score:3/5

Total bile acids (colonic/stool)

1 evidences

90-day randomized trial in 30 healthy adults comparing Aquamin (multi-mineral product delivering 800 mg calcium/day) vs calcium alone vs placebo; collected colon biopsies and stool pre/post to assess microbiota and metabolomics.

Trust comment: Human randomized trial with complete follow-up (n=30) showing microbiome/metabolome changes; small sample and preliminary findings limit certainty.

Study Details

PMID:31771942
Participants:30
Impact:Decreased with Aquamin (P=0.0375)
Trust score:3/5

Stool acetate (short-chain fatty acid)

1 evidences

90-day randomized trial in 30 healthy adults comparing Aquamin (multi-mineral product delivering 800 mg calcium/day) vs calcium alone vs placebo; collected colon biopsies and stool pre/post to assess microbiota and metabolomics.

Trust comment: Human randomized trial with complete follow-up (n=30) showing microbiome/metabolome changes; small sample and preliminary findings limit certainty.

Study Details

PMID:31771942
Participants:30
Impact:Slight increase with Aquamin (P<0.0001)
Trust score:3/5

total cholesterol (TC)

1 evidences

Randomized dietary trial comparing isolipidic diets with different fat sources (including milk fat with added calcium) on LDL and other cardiovascular markers.

Trust comment: Large randomized double-blind dietary trial; appropriate design though some subgroup findings need confirmation.

Study Details

PMID:31712768
Participants:172
Impact:higher with spring milk fat vs vegetable fat
Trust score:4/5

apo C3 and CRP

1 evidences

Randomized dietary trial comparing isolipidic diets with different fat sources (including milk fat with added calcium) on LDL and other cardiovascular markers.

Trust comment: Large randomized double-blind dietary trial; appropriate design though some subgroup findings need confirmation.

Study Details

PMID:31712768
Participants:172
Impact:subgroup differences observed between diets (noted for TC, apo C3, CRP)
Trust score:4/5

added ibuprofen or ciprofloxacin to Ca(OH)2

1 evidences

Randomized clinical study testing calcium hydroxide (with or without ibuprofen or ciprofloxacin) on RANKL and OPG levels in periapical lesions.

Trust comment: Randomized controlled clinical study in humans with clear biochemical outcomes, but limited by sample size and single outcome measures.

Study Details

PMID:31706622
Participants:66
Impact:no additional benefit on lowering RANKL/OPG compared with Ca(OH)2 alone
Trust score:3/5

SF-12 Physical Component Score (PCS)

1 evidences

In a multicenter randomized trial, a biphasic synthetic bone filler (60% calcium sulfate/40% hydroxyapatite) was noninferior to autologous iliac bone graft for patient-reported physical function and pain at 26 weeks, with lower early postoperative pain and less intraoperative blood loss.

Trust comment: Large, multicenter randomized controlled trial with prespecified noninferiority endpoints and appropriate analyses.

Study Details

PMID:31809394
Participants:135
Impact:no significant difference (noninferior; adjusted difference ≈ −0.1 points)
Trust score:5/5

Intraoperative blood loss

3 evidences

Compared two thyroid surgery techniques; LSJ shortened operation time and reduced intraoperative blood loss; postoperative calcium and parathyroid hormone changes were similar between groups.

Trust comment: Prospective randomized single-center trial with 190 patients and clear outcome reporting; surgical focus but calcium-related measures reported and not different between groups.

Study Details

PMID:25582310
Participants:190
Impact:-9 ml (47 ± 18 ml CT vs 38 ± 14 ml LSJ; p = 0.002)
Trust score:4/5

In a multicenter randomized trial, a biphasic synthetic bone filler (60% calcium sulfate/40% hydroxyapatite) was noninferior to autologous iliac bone graft for patient-reported physical function and pain at 26 weeks, with lower early postoperative pain and less intraoperative blood loss.

Trust comment: Large, multicenter randomized controlled trial with prespecified noninferiority endpoints and appropriate analyses.

Study Details

PMID:31809394
Participants:135
Impact:reduced (~196 mL vs 109 mL; ~−87 mL with CBVF)
Trust score:5/5

In liver surgery patients, Plasmalyte-148 led to lower ionized calcium, lower clotting times, less blood loss and fewer postoperative hemoglobin drops compared with Hartmann's solution.

Trust comment: Multicentre double-blind RCT measuring calcium-related labs but not testing calcium supplementation; moderate sample size and direct biochemical measurements.

Study Details

PMID:25407026
Participants:60
Impact:median 300 mL vs 500 mL (PL vs HS)
Trust score:3/5

T50 (serum calcification propensity)

1 evidences

Oral calcium carbonate produced modest changes in serum calcification propensity correlated with rises in serum calcium; some regulators (pyrophosphate, fetuin-A) showed correlations with serum calcium, but between-group differences were limited.

Trust comment: Randomized placebo-controlled trial in postmenopausal women but small sample and some analytes measured in a small subset; correlations rather than consistent between-group effects.

Study Details

PMID:26493812
Participants:41
Impact:T50 declined in both groups; change correlated with serum total calcium at 4 h (r=−0.32, p=0.05) and 8 h (r=−0.39, p=0.01)
Trust score:4/5

dentin hypersensitivity (VAS, tactile)

1 evidences

In a double-blind randomized trial, the combination of CPP-ACPF paste (a calcium/phosphate/flouride complex) plus photobiomodulation produced the largest and durable reductions in dentin hypersensitivity and improved patient-reported oral quality of life at one month.

Trust comment: Double-blind randomized controlled trial with appropriate outcomes but small sample (21 completers) limits broader generalizability.

Study Details

PMID:31790452
Participants:21
Impact:substantially decreased (CPP-ACPF+PBM: ~70% reduction at one month vs baseline)
Trust score:4/5

dentin hypersensitivity (VAS, evaporative)

1 evidences

In a double-blind randomized trial, the combination of CPP-ACPF paste (a calcium/phosphate/flouride complex) plus photobiomodulation produced the largest and durable reductions in dentin hypersensitivity and improved patient-reported oral quality of life at one month.

Trust comment: Double-blind randomized controlled trial with appropriate outcomes but small sample (21 completers) limits broader generalizability.

Study Details

PMID:31790452
Participants:21
Impact:substantially decreased (CPP-ACPF+PBM: ~77% reduction at one month vs baseline)
Trust score:4/5

oral health-related quality of life (DHEQ)

1 evidences

In a double-blind randomized trial, the combination of CPP-ACPF paste (a calcium/phosphate/flouride complex) plus photobiomodulation produced the largest and durable reductions in dentin hypersensitivity and improved patient-reported oral quality of life at one month.

Trust comment: Double-blind randomized controlled trial with appropriate outcomes but small sample (21 completers) limits broader generalizability.

Study Details

PMID:31790452
Participants:21
Impact:improved (significant DHEQ reduction with CPP-ACPF+PBM at one month)
Trust score:4/5

Hypercalciuria (24‑h urine calcium)

1 evidences

In 373 older adults randomized to 400, 4,000, or 10,000 IU/day vitamin D, higher doses raised urine calcium excretion and caused rare mild transient hypercalcemia, while serum calcium and safety events were otherwise similar.

Trust comment: Large, double‑blind RCT with prespecified secondary analyses measuring calcium outcomes and clinically relevant endpoints.

Study Details

PMID:31746327
Participants:373
Impact:Overall 23% (400:17%, 4000:22%, 10000:31%); increased with higher doses (P=0.01)
Trust score:4/5

Bone balance

1 evidences

In postmenopausal women receiving bisphosphonates (with daily calcium and vitamin D), bone turnover markers fell and an early positive bone balance developed, changes that were associated with later increases in spine and hip BMD.

Trust comment: Randomized treatment groups with serial biomarker and DXA measurements; calcium/vitamin D given to all as background, moderate‑high quality.

Study Details

PMID:31740343
Participants:391
Impact:Initial positive bone balance observed (early, e.g., week 4)
Trust score:4/5

BMD (lumbar spine, total hip)

1 evidences

In postmenopausal women receiving bisphosphonates (with daily calcium and vitamin D), bone turnover markers fell and an early positive bone balance developed, changes that were associated with later increases in spine and hip BMD.

Trust comment: Randomized treatment groups with serial biomarker and DXA measurements; calcium/vitamin D given to all as background, moderate‑high quality.

Study Details

PMID:31740343
Participants:391
Impact:Increases in BMD correlated with reductions in turnover and early balance changes
Trust score:4/5

Salivary Streptococcus mutans prevalence (SMPC)

1 evidences

In 127 high‑caries‑risk preschool children, CPP‑ACP dentifrice reduced salivary Streptococcus mutans; CPP‑ACP produced the largest reduction over 6 months compared with fluoride alone or sequential use.

Trust comment: Double‑blinded randomized clinical trial in children assessing a calcium‑containing dental agent (CPP‑ACP) with objective microbial outcomes.

Study Details

PMID:31732883
Participants:127
Impact:Decreased in all groups; CPP‑ACP showed the largest reduction over 6 months
Trust score:4/5

Early reduction at 3 months (fluoride/combination)

1 evidences

In 127 high‑caries‑risk preschool children, CPP‑ACP dentifrice reduced salivary Streptococcus mutans; CPP‑ACP produced the largest reduction over 6 months compared with fluoride alone or sequential use.

Trust comment: Double‑blinded randomized clinical trial in children assessing a calcium‑containing dental agent (CPP‑ACP) with objective microbial outcomes.

Study Details

PMID:31732883
Participants:127
Impact:Significant within‑group decreases at 3 months in fluoride and combination groups
Trust score:4/5

temporary postoperative hypocalcemia rate

1 evidences

Using near-infrared autofluorescence to identify parathyroid glands during total thyroidectomy reduced early postoperative hypocalcemia and improved parathyroid preservation.

Trust comment: Multicenter randomized clinical trial with adequate sample size and clinically relevant endpoints, improving early hypocalcemia risk.

Study Details

PMID:31693081
Participants:241
Impact:reduced by 12.6 percentage points (21.7% → 9.1%)
Trust score:4/5

parathyroid autotransplantation rate

1 evidences

Using near-infrared autofluorescence to identify parathyroid glands during total thyroidectomy reduced early postoperative hypocalcemia and improved parathyroid preservation.

Trust comment: Multicenter randomized clinical trial with adequate sample size and clinically relevant endpoints, improving early hypocalcemia risk.

Study Details

PMID:31693081
Participants:241
Impact:reduced (13.3% → 3.3%)
Trust score:4/5

inadvertent parathyroid gland resection rate

1 evidences

Using near-infrared autofluorescence to identify parathyroid glands during total thyroidectomy reduced early postoperative hypocalcemia and improved parathyroid preservation.

Trust comment: Multicenter randomized clinical trial with adequate sample size and clinically relevant endpoints, improving early hypocalcemia risk.

Study Details

PMID:31693081
Participants:241
Impact:reduced (11.7% → 2.5%)
Trust score:4/5

24-h urinary calcium and other urinary metabolites

1 evidences

Three months of atorvastatin (20 mg/day) in recurrent calcium-stone formers did not change 24-h urinary metabolites or urinary markers of oxidative stress and tubular injury.

Trust comment: Randomized double-blind placebo-controlled trial but small completed sample and short duration limits power to detect metabolic effects.

Study Details

PMID:31692870
Participants:28
Impact:no significant change after atorvastatin
Trust score:3/5

urinary malondialdehyde (U-MDA/Cr)

1 evidences

Three months of atorvastatin (20 mg/day) in recurrent calcium-stone formers did not change 24-h urinary metabolites or urinary markers of oxidative stress and tubular injury.

Trust comment: Randomized double-blind placebo-controlled trial but small completed sample and short duration limits power to detect metabolic effects.

Study Details

PMID:31692870
Participants:28
Impact:no significant change
Trust score:3/5

urinary NGAL (U-NGAL/Cr)

1 evidences

Three months of atorvastatin (20 mg/day) in recurrent calcium-stone formers did not change 24-h urinary metabolites or urinary markers of oxidative stress and tubular injury.

Trust comment: Randomized double-blind placebo-controlled trial but small completed sample and short duration limits power to detect metabolic effects.

Study Details

PMID:31692870
Participants:28
Impact:no significant change
Trust score:3/5

25-hydroxyvitamin D (25(OH)D) response

1 evidences

Small randomized supplementation trial showing baseline DNA methylation patterns predict how much 25(OH)D rises after vitamin D3.

Trust comment: Randomized trial but small sample and primarily exploratory epigenetic associations; findings are hypothesis-generating.

Study Details

PMID:31667917
Participants:64
Impact:reduced response associated with higher baseline methylation of cg07873128 (OSBPL5)
Trust score:3/5

baseline DNA methylation (CYP family, VDR genes)

1 evidences

Small randomized supplementation trial showing baseline DNA methylation patterns predict how much 25(OH)D rises after vitamin D3.

Trust comment: Randomized trial but small sample and primarily exploratory epigenetic associations; findings are hypothesis-generating.

Study Details

PMID:31667917
Participants:64
Impact:modulates 25(OH)D response
Trust score:3/5

APACHE II score (disease severity)

1 evidences

Randomized trial in severe acute pancreatitis where combination therapy improved clinical outcomes and raised serum calcium compared with conventional care.

Trust comment: Prospective randomized controlled trial (n=100) with clear pre/post biochemical and clinical endpoints; calcium measured and reported.

Study Details

PMID:31662003
Participants:100
Impact:-7.1 points (combination group baseline 12.5 → day 7 5.4)
Trust score:4/5

P1NP/CTX ratio

1 evidences

Small randomized study: adding Greek yogurt (source of protein and calcium) to exercise increased bone formation markers versus placebo.

Trust comment: Randomized controlled trial but small sample (n=30); biomarker changes are statistically significant though clinical translation limited by size.

Study Details

PMID:31652407
Participants:30
Impact:increase (shift toward formation)
Trust score:4/5

Infused fluid volume

1 evidences

In 100 women having hysteroscopy, manual infusion reduced infused and collected fluid volumes versus pump infusion; small postoperative decreases in serum calcium occurred in both groups and second postoperative pain was higher with manual infusion.

Trust comment: Randomized controlled trial with clear participant numbers and reported statistics; moderate sample size limits precision for some electrolyte effects.

Study Details

PMID:31628359
Participants:100
Impact:-374 mL (981±639 mL MI vs 1355±789 mL PI; P=0.009; ≈28% reduction)
Trust score:4/5

Serum calcium level (postoperative change)

1 evidences

In 100 women having hysteroscopy, manual infusion reduced infused and collected fluid volumes versus pump infusion; small postoperative decreases in serum calcium occurred in both groups and second postoperative pain was higher with manual infusion.

Trust comment: Randomized controlled trial with clear participant numbers and reported statistics; moderate sample size limits precision for some electrolyte effects.

Study Details

PMID:31628359
Participants:100
Impact:Decrease ~−0.7 mg/dL (MI) and −0.8 mg/dL (PI); no between-group difference; change negatively correlated with fluid deficit (ρ=−0.26, P=0.046)
Trust score:4/5

Second postoperative pain score

1 evidences

In 100 women having hysteroscopy, manual infusion reduced infused and collected fluid volumes versus pump infusion; small postoperative decreases in serum calcium occurred in both groups and second postoperative pain was higher with manual infusion.

Trust comment: Randomized controlled trial with clear participant numbers and reported statistics; moderate sample size limits precision for some electrolyte effects.

Study Details

PMID:31628359
Participants:100
Impact:+0.37 points (0.71±0.73 MI vs 0.34±0.66 PI; P=0.008)
Trust score:4/5

Streptococcus mutans count

2 evidences

Randomized trial in 60 children comparing three fluoride varnishes (one containing CPP‑ACP, a calcium‑phosphate carrier); no significant differences between varnish types and no effect of prior oral prophylaxis on S. mutans counts.

Trust comment: Randomized design but small sample and limited outcome reporting; CPP‑ACP (a calcium‑containing agent) effects were not statistically superior.

Study Details

PMID:31584030
Participants:60
Impact:All groups showed reductions but no statistically significant difference between varnish types (CPP‑ACP showed greatest non-significant reduction)
Trust score:3/5

Daily CPP-ACP (Tooth Mousse) reduced Streptococcus mutans counts in plaque of high-caries preschool children over 15 days, but reduction was not significantly greater than placebo plus health education.

Trust comment: Triple-blind randomized trial in children with clear outcome measures; moderate sample size and short follow-up limit generalizability.

Study Details

PMID:27557918
Participants:40
Impact:-59% from baseline in CPP-ACP group vs -52% in placebo at 15 days; no significant difference vs control (P=0.27)
Trust score:4/5

Effect of prior oral prophylaxis

1 evidences

Randomized trial in 60 children comparing three fluoride varnishes (one containing CPP‑ACP, a calcium‑phosphate carrier); no significant differences between varnish types and no effect of prior oral prophylaxis on S. mutans counts.

Trust comment: Randomized design but small sample and limited outcome reporting; CPP‑ACP (a calcium‑containing agent) effects were not statistically superior.

Study Details

PMID:31584030
Participants:60
Impact:No effect (no significant difference between subgroups with or without prior prophylaxis)
Trust score:3/5

Serum calcium / calcium-phosphorus

1 evidences

Randomized double‑blind trial in 160 perimenopausal women comparing placebo, soy isoflavone, calcium, and soy+calcium; soy, calcium, and the combination attenuated BMD loss, with the combination producing greater improvements than either alone.

Trust comment: Well‑designed double‑blind RCT with adequate sample size and clear reported group differences over 6 months, though numeric effect sizes were not provided in the summary.

Study Details

PMID:31583921
Participants:160
Impact:Mean calcium/phosphorus and vitamin D levels increased in the isoflavone+calcium group (statistically significant vs control)
Trust score:4/5

Markers of bone turnover and hormones (osteocalcin, LH, FSH)

1 evidences

Randomized double‑blind trial in 160 perimenopausal women comparing placebo, soy isoflavone, calcium, and soy+calcium; soy, calcium, and the combination attenuated BMD loss, with the combination producing greater improvements than either alone.

Trust comment: Well‑designed double‑blind RCT with adequate sample size and clear reported group differences over 6 months, though numeric effect sizes were not provided in the summary.

Study Details

PMID:31583921
Participants:160
Impact:Osteocalcin, LH and FSH decreased in the isoflavone+calcium group (statistically significant)
Trust score:4/5

Urinary NTX/CRT (bone resorption)

1 evidences

Two-year RCT of dried beancurd (contains isoflavones, calcium, protein) vs rice cake showing improved lumbar spine BMD in postmenopausal women.

Trust comment: Large randomized 2-year trial with clear BMD and biomarker outcomes; moderate-high quality though dried beancurd is a multi-component food rather than isolated calcium.

Study Details

PMID:31489467
Participants:300
Impact:Decreased
Trust score:4/5

Right proximal femur BMD

1 evidences

Two-year RCT of dried beancurd (contains isoflavones, calcium, protein) vs rice cake showing improved lumbar spine BMD in postmenopausal women.

Trust comment: Large randomized 2-year trial with clear BMD and biomarker outcomes; moderate-high quality though dried beancurd is a multi-component food rather than isolated calcium.

Study Details

PMID:31489467
Participants:300
Impact:No significant change
Trust score:4/5

Total serum calcium (TSCa) accuracy for symptomatic hypocalcemia

1 evidences

Randomized multicenter study comparing preventive, reactive, and predictive strategies to manage transient hypocalcemia after thyroidectomy.

Trust comment: Prospective randomized multicenter study directly addressing calcium management with clear diagnostic and cost-effectiveness data; reasonably high quality.

Study Details

PMID:31472003
Participants:169
Impact:84.6% accuracy vs ionized calcium 50.0%
Trust score:4/5

Incidence identified by TSCa at 24 h

1 evidences

Randomized multicenter study comparing preventive, reactive, and predictive strategies to manage transient hypocalcemia after thyroidectomy.

Trust comment: Prospective randomized multicenter study directly addressing calcium management with clear diagnostic and cost-effectiveness data; reasonably high quality.

Study Details

PMID:31472003
Participants:169
Impact:24.8% hypocalcemia at 24 h; additional 10.6% at 48 h
Trust score:4/5

iPTH as predictor

1 evidences

Randomized multicenter study comparing preventive, reactive, and predictive strategies to manage transient hypocalcemia after thyroidectomy.

Trust comment: Prospective randomized multicenter study directly addressing calcium management with clear diagnostic and cost-effectiveness data; reasonably high quality.

Study Details

PMID:31472003
Participants:169
Impact:Low sensitivity
Trust score:4/5

BMD (lumbar spine)

1 evidences

Small randomized open-label trial comparing Ayurvedic formulation plus vitamin D3 and calcium vs vitamin D3 and calcium alone in osteopenia; found improved BMD and biomarkers with add-on therapy.

Trust comment: Randomized but open-label with small sample and incomplete reporting; both arms received calcium so effects are of add-on therapy rather than calcium alone.

Study Details

PMID:31460771
Participants:65
Impact:Improved at 6 and 12 months (maximum benefit at lumbar spine)
Trust score:3/5

Bone-specific biomarkers (vitamin D3, TRAP-5b, osteocalcin)

1 evidences

Small randomized open-label trial comparing Ayurvedic formulation plus vitamin D3 and calcium vs vitamin D3 and calcium alone in osteopenia; found improved BMD and biomarkers with add-on therapy.

Trust comment: Randomized but open-label with small sample and incomplete reporting; both arms received calcium so effects are of add-on therapy rather than calcium alone.

Study Details

PMID:31460771
Participants:65
Impact:Significant improvement in biomarkers reported
Trust score:3/5

FRAX / quality-of-life scores

1 evidences

Small randomized open-label trial comparing Ayurvedic formulation plus vitamin D3 and calcium vs vitamin D3 and calcium alone in osteopenia; found improved BMD and biomarkers with add-on therapy.

Trust comment: Randomized but open-label with small sample and incomplete reporting; both arms received calcium so effects are of add-on therapy rather than calcium alone.

Study Details

PMID:31460771
Participants:65
Impact:Improved (reported)
Trust score:3/5

incident colorectal adenoma

1 evidences

Higher total calcium intake (around 1200–1600 mg/day) was associated with lower risk of certain colorectal precancerous lesions and distal colorectal cancer; effects were strongest when Ca:Mg ratio was 1.7–2.5.

Trust comment: Large prospective PLCO dataset with dietary assessment and long follow-up; observational design with potential residual confounding but robust sample size and multiple sensitivity analyses.

Study Details

PMID:31543516
Participants:107194
Impact:-18% (OR 0.82, 95% CI 0.68–0.97) for 1200–1600 mg/day vs 600–1200 mg/day
Trust score:4/5

metachronous (recurrent) adenoma

1 evidences

Higher total calcium intake (around 1200–1600 mg/day) was associated with lower risk of certain colorectal precancerous lesions and distal colorectal cancer; effects were strongest when Ca:Mg ratio was 1.7–2.5.

Trust comment: Large prospective PLCO dataset with dietary assessment and long follow-up; observational design with potential residual confounding but robust sample size and multiple sensitivity analyses.

Study Details

PMID:31543516
Participants:107194
Impact:no significant association (ORs ~1.00; P-trend 0.15)
Trust score:4/5

colorectal cancer incidence (distal CRC)

1 evidences

Higher total calcium intake (around 1200–1600 mg/day) was associated with lower risk of certain colorectal precancerous lesions and distal colorectal cancer; effects were strongest when Ca:Mg ratio was 1.7–2.5.

Trust comment: Large prospective PLCO dataset with dietary assessment and long follow-up; observational design with potential residual confounding but robust sample size and multiple sensitivity analyses.

Study Details

PMID:31543516
Participants:107194
Impact:inverse trend overall (P=0.03); distal CRC −25% (HR 0.75, 95% CI 0.58–0.97) for 1200–1600 mg/day vs 600–1200
Trust score:4/5

systolic blood pressure (interaction)

1 evidences

In premenopausal women, urinary isoflavone excretion modified the relationship between serum calcium and blood pressure — isoflavone exposure tended to normalize systolic BP responses to varying calcium levels and reduced diastolic BP modestly.

Trust comment: Randomized double-blind placebo-controlled trial with ~197 participants; reported effects rely on per-protocol/excretion-based analyses rather than primary intention-to-treat results.

Study Details

PMID:31535213
Participants:197
Impact:isoflavones moderated calcium effects on SBP (per-protocol interaction; net SBP difference between max vs no isoflavone excretion up to −17.7 to +13.8 mmHg depending on serum calcium)
Trust score:4/5

serum phosphorus concentration

1 evidences

Infants fed an amino-acid formula maintained normal blood phosphorus, calcium, and magnesium after 16 weeks, including those on acid-suppressive drugs.

Trust comment: Objective laboratory measures from a randomized trial subgroup support reliable mineral data, though subgroup/retrospective analysis and modest sample size limit certainty.

Study Details

PMID:31425366
Participants:66
Impact:2.05 → 1.96 mmol/L after 16 weeks (within reference range; no deficiency)
Trust score:4/5

Serum magnesium concentration

1 evidences

Infants fed an amino-acid formula maintained normal blood phosphorus, calcium, and magnesium after 16 weeks, including those on acid-suppressive drugs.

Trust comment: Objective laboratory measures from a randomized trial subgroup support reliable mineral data, though subgroup/retrospective analysis and modest sample size limit certainty.

Study Details

PMID:31425366
Participants:66
Impact:0.95 → 0.95 mmol/L after 16 weeks (no change; within reference range)
Trust score:4/5

whole-body bone mineral density

1 evidences

In adherent premenopausal women, soy isoflavone exposure decreased whole-body bone mineral density only when serum calcium was low; hip and spine BMD were unaffected.

Trust comment: Randomized long-term trial with objective BMD measures, but key result derived from adherent-subgroup analyses and interaction models rather than intention-to-treat.

Study Details

PMID:31421395
Participants:129
Impact:Decreased with isoflavone exposure when serum calcium was low (interaction present; regression coefficient for genistein excretion −0.042; effect seen in adherent subjects)
Trust score:3/5

hip and spine bone mineral density

1 evidences

In adherent premenopausal women, soy isoflavone exposure decreased whole-body bone mineral density only when serum calcium was low; hip and spine BMD were unaffected.

Trust comment: Randomized long-term trial with objective BMD measures, but key result derived from adherent-subgroup analyses and interaction models rather than intention-to-treat.

Study Details

PMID:31421395
Participants:129
Impact:No effect detected
Trust score:3/5

serum calcium (effect modifier)

1 evidences

In adherent premenopausal women, soy isoflavone exposure decreased whole-body bone mineral density only when serum calcium was low; hip and spine BMD were unaffected.

Trust comment: Randomized long-term trial with objective BMD measures, but key result derived from adherent-subgroup analyses and interaction models rather than intention-to-treat.

Study Details

PMID:31421395
Participants:129
Impact:Low serum calcium levels modified isoflavone effect on whole-body BMD (decrease observed only when serum Ca was low)
Trust score:3/5

Bone mineral density (total body, lumbar spine, total hip)

1 evidences

In adolescents, milk powder fortified with calcium (300–900 mg/day) plus vitamin D for 1.5 years did not produce greater bone density gains versus control, but altered PTH and IGF-1.

Trust comment: Randomized, cluster-assigned controlled trial with long follow-up and objective measures (DXA, biomarkers); limitations include modest vitamin D dose and some loss to follow-up.

Study Details

PMID:31375874
Participants:181
Impact:Increased from baseline in all groups during growth; no significant treatment effect versus control (no between-group difference)
Trust score:4/5

enamel demineralization

1 evidences

An ACP-containing adhesive reduced enamel demineralization during 6 months of orthodontic treatment.

Trust comment: Triple-blinded randomized split-mouth RCT with objective DIAGNOdent measurements but small patient sample (23).

Study Details

PMID:31358717
Participants:23
Impact:reduced (significantly lower vs control)
Trust score:4/5

plaque accumulation

1 evidences

Restorations with calcium silicate cement (Biodentine) were associated with more plaque and greater gingival inflammation vs glass‑ionomer over 6 months.

Trust comment: Randomized clinical trial but small sample and limited to local clinical indices, reducing generalizability.

Study Details

PMID:31358713
Participants:28
Impact:increased (higher PI at 1, 3, 6 months; significant)
Trust score:3/5

gingival inflammation

1 evidences

Restorations with calcium silicate cement (Biodentine) were associated with more plaque and greater gingival inflammation vs glass‑ionomer over 6 months.

Trust comment: Randomized clinical trial but small sample and limited to local clinical indices, reducing generalizability.

Study Details

PMID:31358713
Participants:28
Impact:increased (higher GI at 1, 3, 6 months; significant)
Trust score:3/5

bleeding on probing

1 evidences

Restorations with calcium silicate cement (Biodentine) were associated with more plaque and greater gingival inflammation vs glass‑ionomer over 6 months.

Trust comment: Randomized clinical trial but small sample and limited to local clinical indices, reducing generalizability.

Study Details

PMID:31358713
Participants:28
Impact:increased (higher BOP vs GIC; significant)
Trust score:3/5

urinary calcium

3 evidences

Cross-sectional study showing long-term environmental cadmium exposure alters urinary mineral balance, including increased urinary calcium.

Trust comment: Reasonable sample and statistics showing association, but observational design with potential confounding.

Study Details

PMID:27029362
Participants:298
Impact:Median 173.80 vs 142.42 μg/g·cr (exposed vs control); P<0.001 (increase)
Trust score:3/5

PTH therapy let most patients reduce or stop oral calcium while keeping blood calcium normal.

Trust comment: Small (n=24) open-label extension with clinical endpoints—useful but limited by size and open-label design.

Study Details

PMID:26684150
Participants:24
Impact:decreased by Week 24
Trust score:3/5

A limeade-based supplement (containing potassium and citrate) for 6 months increased urinary pH, citrate and potassium excretion, reduced urinary calcium and oxalate, improved antioxidant status and lowered urinary supersaturation in recurrent stone patients.

Trust comment: Phase 2 double-blind randomized placebo-controlled study with 74 patients showing consistent biochemical improvements relevant to calcium stone risk.

Study Details

PMID:30225852
Participants:74
Impact:significant decrease with LPR
Trust score:4/5

Total osteocalcin (tOC)

1 evidences

One year of 1.2 g/day elemental calcium lowered total and undercarboxylated osteocalcin but did not change HbA1c or body composition.

Trust comment: Post-hoc analysis of a large double-blind, placebo-controlled randomized trial with robust sample size, though exploratory in nature.

Study Details

PMID:31342138
Participants:1368
Impact:-17% vs placebo
Trust score:4/5

undercarboxylated osteocalcin (ucOC)

1 evidences

One year of 1.2 g/day elemental calcium lowered total and undercarboxylated osteocalcin but did not change HbA1c or body composition.

Trust comment: Post-hoc analysis of a large double-blind, placebo-controlled randomized trial with robust sample size, though exploratory in nature.

Study Details

PMID:31342138
Participants:1368
Impact:-22% vs placebo
Trust score:4/5

glycated haemoglobin (HbA1c)

1 evidences

One year of 1.2 g/day elemental calcium lowered total and undercarboxylated osteocalcin but did not change HbA1c or body composition.

Trust comment: Post-hoc analysis of a large double-blind, placebo-controlled randomized trial with robust sample size, though exploratory in nature.

Study Details

PMID:31342138
Participants:1368
Impact:no significant change
Trust score:4/5

Total body bone mineral density

1 evidences

A 13-week vitamin D, calcium and leucine-enriched whey protein supplement increased 25(OH)D, suppressed PTH and produced small but positive increases in total-body BMD.

Trust comment: Multicenter, randomized, double-blind controlled trial with adequate sample size, but relatively short duration (13 weeks) for bone outcomes.

Study Details

PMID:31338563
Participants:380
Impact:small increase (~2%; significant vs control)
Trust score:4/5

intact PTH

1 evidences

Extended-hours haemodialysis lowered serum phosphate, produced a small increase in serum calcium, and did not change PTH over 12 months.

Trust comment: Large randomized multicentre trial with blinded endpoint assessment; outcomes and adjustments reported clearly.

Study Details

PMID:31299919
Participants:200
Impact:no significant change
Trust score:4/5

enamel calcium content

1 evidences

Hydrogen-peroxide bleaching reduced enamel calcium and phosphorus versus baseline and increased tooth sensitivity (in‑office technique produced the least sensitivity).

Trust comment: Randomized clinical trial with defined groups and repeated measures of enamel minerals and clinical parameters.

Study Details

PMID:31295393
Participants:75
Impact:decreased vs baseline (all techniques)
Trust score:4/5

enamel phosphorus content

1 evidences

Hydrogen-peroxide bleaching reduced enamel calcium and phosphorus versus baseline and increased tooth sensitivity (in‑office technique produced the least sensitivity).

Trust comment: Randomized clinical trial with defined groups and repeated measures of enamel minerals and clinical parameters.

Study Details

PMID:31295393
Participants:75
Impact:decreased vs baseline; in-office higher at day 8 vs others
Trust score:4/5

tooth sensitivity

3 evidences

Hydrogen-peroxide bleaching reduced enamel calcium and phosphorus versus baseline and increased tooth sensitivity (in‑office technique produced the least sensitivity).

Trust comment: Randomized clinical trial with defined groups and repeated measures of enamel minerals and clinical parameters.

Study Details

PMID:31295393
Participants:75
Impact:increased over time; in‑office lowest
Trust score:4/5

Randomized double‑blind trial in 24 patients: adding CPP‑ACP reduced tooth sensitivity at day 3 and did not impair bleaching efficacy.

Trust comment: Randomized double‑blind placebo‑controlled trial (small sample, 24 participants) gives direct evidence for a calcium‑containing agent (CPP‑ACP); limited power but good internal validity.

Study Details

PMID:30121734
Participants:24
Impact:Reduced at day 3 in CPP‑ACP group compared with placebo (statistically significant)
Trust score:4/5

Adding calcium to bleaching gel reduced transient tooth sensitivity; bleaching remained effective.

Trust comment: Randomized controlled clinical trial in adolescents (n=53); calcium-containing product associated with reduced sensitivity though magnitude not quantified.

Study Details

PMID:29211128
Participants:53
Impact:decreased (reduction reported; greater with 20% H2O2)
Trust score:4/5

rice calcium content

1 evidences

Cooking rice with slaked lime substantially increased rice calcium content in a dose-dependent way and fortified rice was acceptable to participants, especially when served with other foods.

Trust comment: Large acceptability experiment with objective calcium measurements, but bioavailability and longer-term nutritional outcomes were not assessed.

Study Details

PMID:31272212
Participants:400
Impact:increased dose-dependently to 76.03 → 811.23 mg/kg across lime concentrations (0→10 g/500 g rice)
Trust score:3/5

meal acceptability

1 evidences

Cooking rice with slaked lime substantially increased rice calcium content in a dose-dependent way and fortified rice was acceptable to participants, especially when served with other foods.

Trust comment: Large acceptability experiment with objective calcium measurements, but bioavailability and longer-term nutritional outcomes were not assessed.

Study Details

PMID:31272212
Participants:400
Impact:higher when served with additional foods; highest acceptability at 7.5 g lime concentration
Trust score:3/5

implant survival rate

1 evidences

In this randomized double-blind trial, calcium phosphate-coated and uncoated SLA dental implants had comparable 1-year survival and marginal bone stability with no complications.

Trust comment: Randomized double-blind trial assessing a calcium-phosphate implant coating (relevant to calcium-containing material), but small sample and short follow-up limit generalizability.

Study Details

PMID:31317669
Participants:34
Impact:no implant failures (100% survival)
Trust score:3/5

marginal bone level change

1 evidences

In this randomized double-blind trial, calcium phosphate-coated and uncoated SLA dental implants had comparable 1-year survival and marginal bone stability with no complications.

Trust comment: Randomized double-blind trial assessing a calcium-phosphate implant coating (relevant to calcium-containing material), but small sample and short follow-up limit generalizability.

Study Details

PMID:31317669
Participants:34
Impact:small bone loss (most <1 mm) and no clinically significant difference between CaP-coated and uncoated implants at 1 year
Trust score:3/5

complications/adverse events

1 evidences

In this randomized double-blind trial, calcium phosphate-coated and uncoated SLA dental implants had comparable 1-year survival and marginal bone stability with no complications.

Trust comment: Randomized double-blind trial assessing a calcium-phosphate implant coating (relevant to calcium-containing material), but small sample and short follow-up limit generalizability.

Study Details

PMID:31317669
Participants:34
Impact:no complications reported during first year
Trust score:3/5

lusutrombopag exposure (Cmax) - food effect

1 evidences

Three crossover PK studies in healthy subjects showed lusutrombopag exposure was not meaningfully affected by coadministration of calcium carbonate and only slightly decreased with food.

Trust comment: Well-controlled single-dose crossover PK studies in healthy volunteers showing no clinically relevant interaction with calcium carbonate.

Study Details

PMID:31303281
Participants:48
Impact:fed: Cmax ratios ≈0.90–0.97 (≈8–10% decrease)
Trust score:4/5

lusutrombopag exposure (AUC) - food effect

1 evidences

Three crossover PK studies in healthy subjects showed lusutrombopag exposure was not meaningfully affected by coadministration of calcium carbonate and only slightly decreased with food.

Trust comment: Well-controlled single-dose crossover PK studies in healthy volunteers showing no clinically relevant interaction with calcium carbonate.

Study Details

PMID:31303281
Participants:48
Impact:fed: AUC ratios ≈0.908–1.02 (no meaningful change)
Trust score:4/5

lusutrombopag exposure - calcium carbonate coadministration

1 evidences

Three crossover PK studies in healthy subjects showed lusutrombopag exposure was not meaningfully affected by coadministration of calcium carbonate and only slightly decreased with food.

Trust comment: Well-controlled single-dose crossover PK studies in healthy volunteers showing no clinically relevant interaction with calcium carbonate.

Study Details

PMID:31303281
Participants:48
Impact:Cmax ratio 1.08 (0.959–1.21) and AUC ratio 0.989 (0.913–1.07) — no clinically significant effect of calcium carbonate
Trust score:4/5

dentine hypersensitivity (VAS)

1 evidences

Toothpaste containing 5% fluorocalcium phosphosilicate reduced dentine hypersensitivity more than arginine-calcium carbonate toothpaste or placebo over one month.

Trust comment: Randomized clinical trial with 75 participants showing favorable clinical effect, but numeric effect sizes not reported in excerpt and single-month follow-up is short.

Study Details

PMID:31233629
Participants:75
Impact:greater reduction with 5% fluorocalcium phosphosilicate vs comparators (no numeric percent provided)
Trust score:3/5

clinical DH (tactile/evaporative stimuli)

1 evidences

Toothpaste containing 5% fluorocalcium phosphosilicate reduced dentine hypersensitivity more than arginine-calcium carbonate toothpaste or placebo over one month.

Trust comment: Randomized clinical trial with 75 participants showing favorable clinical effect, but numeric effect sizes not reported in excerpt and single-month follow-up is short.

Study Details

PMID:31233629
Participants:75
Impact:symptoms reduced in all groups but most in fluorocalcium phosphosilicate group
Trust score:3/5

pain VAS (airblast)

1 evidences

Application of a potassium oxalate strip plus brushing reduced tooth sensitivity more than brushing with arginine calcium carbonate toothpaste over 4 weeks.

Trust comment: Randomized, examiner-blind trial (n=80) with objective and subjective measures; short duration but adequate design for the question.

Study Details

PMID:31150729
Participants:80
Impact:decrease (significant vs baseline at 2 and 4 weeks); no significant between-group difference
Trust score:4/5

Schiff sensitivity score (airblast)

1 evidences

Application of a potassium oxalate strip plus brushing reduced tooth sensitivity more than brushing with arginine calcium carbonate toothpaste over 4 weeks.

Trust comment: Randomized, examiner-blind trial (n=80) with objective and subjective measures; short duration but adequate design for the question.

Study Details

PMID:31150729
Participants:80
Impact:decrease (significant vs baseline); oxalate group had significantly lower Schiff vs arginine calcium carbonate (p<0.0002)
Trust score:4/5

Yeaple tactile threshold

1 evidences

Application of a potassium oxalate strip plus brushing reduced tooth sensitivity more than brushing with arginine calcium carbonate toothpaste over 4 weeks.

Trust comment: Randomized, examiner-blind trial (n=80) with objective and subjective measures; short duration but adequate design for the question.

Study Details

PMID:31150729
Participants:80
Impact:increase (less sensitivity) (significant vs baseline); oxalate group higher vs arginine calcium carbonate (p<0.05)
Trust score:4/5

stroke risk with CEE therapy

1 evidences

In postmenopausal women, calcium plus vitamin D supplementation appeared to mitigate the increased stroke risk caused by conjugated equine estrogen.

Trust comment: Large randomized, double-blind, placebo-controlled trial (WHI) with long follow-up; high-quality evidence though this is a subgroup analysis.

Study Details

PMID:31145202
Participants:16089
Impact:CEE harmful in CaD-placebo: HR=2.19 (1.34–3.58); neutral in CaD group: HR=1.07 (0.66–1.73); P interaction=0.04 (CEE trial)
Trust score:5/5

coronary heart disease / total CVD

1 evidences

In postmenopausal women, calcium plus vitamin D supplementation appeared to mitigate the increased stroke risk caused by conjugated equine estrogen.

Trust comment: Large randomized, double-blind, placebo-controlled trial (WHI) with long follow-up; high-quality evidence though this is a subgroup analysis.

Study Details

PMID:31145202
Participants:16089
Impact:no significant CaD × HT interaction (no consistent modification)
Trust score:5/5

CEE + MPA trial interaction

1 evidences

In postmenopausal women, calcium plus vitamin D supplementation appeared to mitigate the increased stroke risk caused by conjugated equine estrogen.

Trust comment: Large randomized, double-blind, placebo-controlled trial (WHI) with long follow-up; high-quality evidence though this is a subgroup analysis.

Study Details

PMID:31145202
Participants:16089
Impact:no evidence CaD modified effects on CVD endpoints in CEE+MPA trial
Trust score:5/5

Offspring birth weight (MR IVW)

1 evidences

Large Mendelian randomisation study (primary UK Biobank analysis) testing causal effects of maternal circulating calcium (and 25[OH]D) on offspring birth weight, triangulated with instrumental-variable analyses from RCTs.

Trust comment: Large, well-conducted MR with multiple sensitivity analyses and triangulation with RCT instrumental-variable analyses, though calcium RCT evidence was limited and heterogeneous.

Study Details

PMID:31211782
Participants:190406
Impact:−20 g per 1 SD higher maternal calcium (95% CI −44 to 5 g), not statistically significant
Trust score:4/5

Offspring birth weight (MR-Egger / sensitivity)

1 evidences

Large Mendelian randomisation study (primary UK Biobank analysis) testing causal effects of maternal circulating calcium (and 25[OH]D) on offspring birth weight, triangulated with instrumental-variable analyses from RCTs.

Trust comment: Large, well-conducted MR with multiple sensitivity analyses and triangulation with RCT instrumental-variable analyses, though calcium RCT evidence was limited and heterogeneous.

Study Details

PMID:31211782
Participants:190406
Impact:MR-Egger estimate +41 g per 1 SD (95% CI −18 to 100 g), not significant; evidence of pleiotropy
Trust score:4/5

Offspring birth weight (RCT instrumental-variable)

1 evidences

Large Mendelian randomisation study (primary UK Biobank analysis) testing causal effects of maternal circulating calcium (and 25[OH]D) on offspring birth weight, triangulated with instrumental-variable analyses from RCTs.

Trust comment: Large, well-conducted MR with multiple sensitivity analyses and triangulation with RCT instrumental-variable analyses, though calcium RCT evidence was limited and heterogeneous.

Study Details

PMID:31211782
Participants:190406
Impact:+178 g per 1 SD higher maternal calcium (95% CI 121–236 g), significant but RCTs were small/at risk of bias
Trust score:4/5

Fusion rate (>50% osseous bridging at 24 weeks)

1 evidences

Multicenter randomized trial comparing rhPDGF-BB combined with beta-tricalcium phosphate–collagen matrix (a calcium phosphate graft substitute) versus autograft for ankle/hindfoot fusion; demonstrated noninferiority.

Trust comment: Prospective randomized multicenter trial (Level I) showing noninferiority of a β-TCP (calcium phosphate) matrix versus autograft, though some analyses pooled with other trials using propensity methods.

Study Details

PMID:31170812
Participants:104
Impact:rhPDGF-BB/β-TCP-collagen 68.1% vs autograft 68.4% (noninferior)
Trust score:4/5

Clinical healing at 52 weeks

1 evidences

Multicenter randomized trial comparing rhPDGF-BB combined with beta-tricalcium phosphate–collagen matrix (a calcium phosphate graft substitute) versus autograft for ankle/hindfoot fusion; demonstrated noninferiority.

Trust comment: Prospective randomized multicenter trial (Level I) showing noninferiority of a β-TCP (calcium phosphate) matrix versus autograft, though some analyses pooled with other trials using propensity methods.

Study Details

PMID:31170812
Participants:104
Impact:84.8% (treated) vs 90.7% (autograft)
Trust score:4/5

Radiographic adverse outcomes (resorption, furcation lesions)

1 evidences

Randomized trial in children comparing three cavity liners (calcium hydroxide, MTA, Portland cement) after selective caries removal; all liners performed similarly over 12 months.

Trust comment: Randomized clinical trial but small sample size (n=36 molars, 34 with 12-month follow-up), limiting precision and generalisability.

Study Details

PMID:31166415
Participants:34
Impact:0% internal/external resorption or furcation lesions across groups at 12 months
Trust score:3/5

Dentin barrier thickness

1 evidences

Randomized trial in children comparing three cavity liners (calcium hydroxide, MTA, Portland cement) after selective caries removal; all liners performed similarly over 12 months.

Trust comment: Randomized clinical trial but small sample size (n=36 molars, 34 with 12-month follow-up), limiting precision and generalisability.

Study Details

PMID:31166415
Participants:34
Impact:Significant intragroup increase over 12 months for all groups; MTA showed notable increase between 6–12 months
Trust score:3/5

urinary calcium:creatinine ratio

1 evidences

Crossover RCT (64 completers) where 1 L/day of mineral water (bicarbonated vs low-mineral) for 8 weeks reduced LDL and fasting glucose; bicarbonated water increased urine pH and decreased urinary calcium/creatinine ratio.

Trust comment: Randomized, crossover design with objective biochemical measures; modest sample size but well-conducted.

Study Details

PMID:27367723
Participants:64
Impact:decreased (bicarbonated water; p=0.011)
Trust score:4/5

mineral content of early caries lesions (∆F/fluorescence, lesion area)

1 evidences

Children with early caries using fluoride toothpaste, CPP-ACP crème (contains calcium), or both showed mineral gain in lesions over 6 months; no group was superior and combination provided no added benefit.

Trust comment: Randomized single-blinded clinical trial with objective QLF measurements; modest sample size but direct evaluation of a calcium-containing topical (CPP-ACP).

Study Details

PMID:31134470
Participants:114
Impact:Increase (significant mineral gain vs baseline at 3 and 6 months, p≤0.05 in all groups)
Trust score:4/5

additive benefit of fluoride + CPP-ACP

1 evidences

Children with early caries using fluoride toothpaste, CPP-ACP crème (contains calcium), or both showed mineral gain in lesions over 6 months; no group was superior and combination provided no added benefit.

Trust comment: Randomized single-blinded clinical trial with objective QLF measurements; modest sample size but direct evaluation of a calcium-containing topical (CPP-ACP).

Study Details

PMID:31134470
Participants:114
Impact:No additive benefit (combination not superior to either agent alone)
Trust score:4/5

treatment group differences

1 evidences

Children with early caries using fluoride toothpaste, CPP-ACP crème (contains calcium), or both showed mineral gain in lesions over 6 months; no group was superior and combination provided no added benefit.

Trust comment: Randomized single-blinded clinical trial with objective QLF measurements; modest sample size but direct evaluation of a calcium-containing topical (CPP-ACP).

Study Details

PMID:31134470
Participants:114
Impact:No significant differences between groups (p>0.05)
Trust score:4/5

Total body fat (%)

1 evidences

In early postmenopausal overweight/obese women on hypocaloric diets, calcium + vitamin D supplements better preserved BMD while increased low-fat dairy produced larger fat loss and better preservation of lean mass compared with diet alone.

Trust comment: Randomized, placebo-controlled trial with DXA outcomes and biochemical markers; good methods but 28.6% attrition and some missing data reduce certainty.

Study Details

PMID:31126121
Participants:135
Impact:Decrease (greater reduction in dairy and supplement groups vs control; dairy group showed the largest decrease)
Trust score:4/5

lean mass (preservation)

1 evidences

In early postmenopausal overweight/obese women on hypocaloric diets, calcium + vitamin D supplements better preserved BMD while increased low-fat dairy produced larger fat loss and better preservation of lean mass compared with diet alone.

Trust comment: Randomized, placebo-controlled trial with DXA outcomes and biochemical markers; good methods but 28.6% attrition and some missing data reduce certainty.

Study Details

PMID:31126121
Participants:135
Impact:Smaller loss (S and D groups had less lean mass loss vs control; D group best preserved lean mass)
Trust score:4/5

bone mineral density (BMD) at multiple sites

1 evidences

In early postmenopausal overweight/obese women on hypocaloric diets, calcium + vitamin D supplements better preserved BMD while increased low-fat dairy produced larger fat loss and better preservation of lean mass compared with diet alone.

Trust comment: Randomized, placebo-controlled trial with DXA outcomes and biochemical markers; good methods but 28.6% attrition and some missing data reduce certainty.

Study Details

PMID:31126121
Participants:135
Impact:Preservation/increase (S group: lower loss in total body and radius; gains at femoral neck and whole femur vs control)
Trust score:4/5

urinary CTX (bone resorption marker)

1 evidences

In early postmenopausal overweight/obese women on hypocaloric diets, calcium + vitamin D supplements better preserved BMD while increased low-fat dairy produced larger fat loss and better preservation of lean mass compared with diet alone.

Trust comment: Randomized, placebo-controlled trial with DXA outcomes and biochemical markers; good methods but 28.6% attrition and some missing data reduce certainty.

Study Details

PMID:31126121
Participants:135
Impact:Decrease in S group; increase in control group (opposite directions)
Trust score:4/5

pulp treatment success (vitality)

1 evidences

198 patients with deep caries received partial caries removal and were randomized to calcium hydroxide, RMGIC, or no liner; high success rates with no difference between groups.

Trust comment: Double-blind RCT with 12-month follow-up and 198 participants; direct test of a calcium-containing material (calcium hydroxide) with robust clinical outcome measures.

Study Details

PMID:31096259
Participants:198
Impact:CH 96.8% vs RMGIC 96.5% vs no liner 94.6% (no significant difference, p=0.811)
Trust score:4/5

Radiographic success rate at 12 months

1 evidences

In children needing pulpotomy, MTA gave best outcomes; calcium hydroxide mixed with PEG was better than calcium hydroxide with saline but both were inferior to MTA at 12 months.

Trust comment: Randomized controlled trial with blinded outcome assessment and predefined outcomes; small sample and some loss to follow-up limit certainty.

Study Details

PMID:31116277
Participants:39
Impact:MTA 100%; CH+PEG 73% (8/11); CH+saline 33% (5/15)
Trust score:4/5

Internal root resorption incidence at 12 months

1 evidences

In children needing pulpotomy, MTA gave best outcomes; calcium hydroxide mixed with PEG was better than calcium hydroxide with saline but both were inferior to MTA at 12 months.

Trust comment: Randomized controlled trial with blinded outcome assessment and predefined outcomes; small sample and some loss to follow-up limit certainty.

Study Details

PMID:31116277
Participants:39
Impact:MTA 0%; CH+PEG 18% (2/11); CH+saline 67% (9/15)
Trust score:4/5

Inter-radicular bone destruction at 12 months

1 evidences

In children needing pulpotomy, MTA gave best outcomes; calcium hydroxide mixed with PEG was better than calcium hydroxide with saline but both were inferior to MTA at 12 months.

Trust comment: Randomized controlled trial with blinded outcome assessment and predefined outcomes; small sample and some loss to follow-up limit certainty.

Study Details

PMID:31116277
Participants:39
Impact:MTA 0%; CH+PEG 9% (1/11); CH+saline 36% (5/15)
Trust score:4/5

Prosthesis and implant failure up to 5 years

1 evidences

Five-year RCT comparing short (5×5 mm) calcium‑incorporated implants versus longer implants in augmented bone: similar failure rates, fewer mandibular graft complications and slightly less peri-implant bone loss with short implants.

Trust comment: Well-conducted randomized trial with 5-year follow-up and objective measures; device-specific context and dropouts somewhat limit generalizability.

Study Details

PMID:31116187
Participants:80
Impact:No significant difference between short calcium‑incorporated implants and longer augmented implants (no significant difference)
Trust score:4/5

Complication rate (mandibles)

1 evidences

Five-year RCT comparing short (5×5 mm) calcium‑incorporated implants versus longer implants in augmented bone: similar failure rates, fewer mandibular graft complications and slightly less peri-implant bone loss with short implants.

Trust comment: Well-conducted randomized trial with 5-year follow-up and objective measures; device-specific context and dropouts somewhat limit generalizability.

Study Details

PMID:31116187
Participants:80
Impact:More complications with grafted mandibles: 17 vs 9 patients (difference 0.39; P=0.013)
Trust score:4/5

Peri-implant marginal bone loss at 5 years

1 evidences

Five-year RCT comparing short (5×5 mm) calcium‑incorporated implants versus longer implants in augmented bone: similar failure rates, fewer mandibular graft complications and slightly less peri-implant bone loss with short implants.

Trust comment: Well-conducted randomized trial with 5-year follow-up and objective measures; device-specific context and dropouts somewhat limit generalizability.

Study Details

PMID:31116187
Participants:80
Impact:Short implants: mandible 1.22 mm, maxilla 1.25 mm; longer implants: mandible 1.70 mm, maxilla 1.73 mm (longer implants ≈0.48 mm greater loss; P=0.004 mandible, P=0.024 maxilla)
Trust score:4/5

Success rate at 12 months

1 evidences

Randomized trial in permanent molars with pulp exposure: direct pulp capping with MTA had higher success and less postoperative pain than calcium hydroxide at 1 year.

Trust comment: Randomized clinical trial with 1-year follow-up and patient-centered outcomes; moderate sample size but clear result favoring MTA over calcium hydroxide.

Study Details

PMID:31104819
Participants:56
Impact:Calcium hydroxide 69%; MTA 93% (MTA significantly higher)
Trust score:4/5

Postoperative pain (VAS) at 18 hours

1 evidences

Randomized trial in permanent molars with pulp exposure: direct pulp capping with MTA had higher success and less postoperative pain than calcium hydroxide at 1 year.

Trust comment: Randomized clinical trial with 1-year follow-up and patient-centered outcomes; moderate sample size but clear result favoring MTA over calcium hydroxide.

Study Details

PMID:31104819
Participants:56
Impact:MTA 6.3 ± 9.5 vs CH 18.5 ± 20.8 (lower pain with MTA)
Trust score:4/5

lumbar bone mineral density

1 evidences

Eldecalcitol increased lumbar and hip bone mineral density more than alfacalcidol in osteoporotic patients not receiving vitamin D or calcium supplements.

Trust comment: Randomized, double-blind active-comparator trial with adequate sample size and clear BMD outcomes.

Study Details

PMID:31087185
Participants:265
Impact:+2.05% (eldecalcitol vs alfacalcidol at 12 months)
Trust score:4/5

serum intact PTH (iPTH)

1 evidences

Switching elderly hemodialysis patients to lower dialysate calcium (1.25 mmol/L) lowered serum calcium and Ca×P, raised iPTH, and improved vascular calcification indices over 12 months.

Trust comment: Randomized 12-month study (n=82) addressing relevant clinical endpoints, but limited methodological detail and likely single-center reduce certainty.

Study Details

PMID:26905433
Participants:82
Impact:increased significantly after 1 month
Trust score:3/5

Schiff sensitivity (evaporative)

1 evidences

A toothpaste containing small-particle calcium sodium phosphosilicate reduced dentin sensitivity over 8 weeks, similar to an arginine toothpaste.

Trust comment: Randomized, controlled 8-week human trial with good completion (147/151) and objective measures; moderate-high quality.

Study Details

PMID:30968066
Participants:147
Impact:decreased (significant vs baseline; greater improvement vs negative control from week 2; no difference vs arginine)
Trust score:4/5

Pain VAS (evaporative)

1 evidences

A toothpaste containing small-particle calcium sodium phosphosilicate reduced dentin sensitivity over 8 weeks, similar to an arginine toothpaste.

Trust comment: Randomized, controlled 8-week human trial with good completion (147/151) and objective measures; moderate-high quality.

Study Details

PMID:30968066
Participants:147
Impact:decreased (significant vs baseline)
Trust score:4/5

Tactile threshold

2 evidences

All toothpastes reduced dentin sensitivity; 5% CSPS improved tactile threshold at Week 4 versus an abrasivity-matched 0% formulation, but between-treatment differences were small and inconsistent.

Trust comment: Randomized, completed study with adequate sample size but exploratory findings and small/inconsistent between-group differences limit strength.

Study Details

PMID:27295867
Participants:134
Impact:5% CSPS improved tactile threshold at Week 4 vs 0% CSPS (P=0.0467); overall between-treatment differences were small/inconsistent
Trust score:3/5

A toothpaste containing small-particle calcium sodium phosphosilicate reduced dentin sensitivity over 8 weeks, similar to an arginine toothpaste.

Trust comment: Randomized, controlled 8-week human trial with good completion (147/151) and objective measures; moderate-high quality.

Study Details

PMID:30968066
Participants:147
Impact:increased (significant vs baseline; comparator > control at week 8, otherwise no between-group differences)
Trust score:4/5

Claudin-1 (CLDN1) expression

1 evidences

Daily supplemental calcium (1200 mg) modestly increased rectal mucosal expression of tight-junction proteins and MUC12 after one year, with stronger effects in participants with lower baseline vitamin D.

Trust comment: Subset (n=105) from a randomized chemoprevention trial testing 1200 mg/day calcium with standardized IHC and quantitative analysis; effects borderline/significant in vitamin D–low subgroup.

Study Details

PMID:30938860
Participants:105
Impact:+14% overall (P=0.17); +29% in baseline 25-OH-D <22.69 ng/mL subgroup (P=0.04)
Trust score:4/5

Occludin (OCLD) expression

1 evidences

Daily supplemental calcium (1200 mg) modestly increased rectal mucosal expression of tight-junction proteins and MUC12 after one year, with stronger effects in participants with lower baseline vitamin D.

Trust comment: Subset (n=105) from a randomized chemoprevention trial testing 1200 mg/day calcium with standardized IHC and quantitative analysis; effects borderline/significant in vitamin D–low subgroup.

Study Details

PMID:30938860
Participants:105
Impact:+23% overall (P=0.11); +36% in low 25-OH-D subgroup (P=0.06)
Trust score:4/5

Mucin-12 (MUC12) expression

1 evidences

Daily supplemental calcium (1200 mg) modestly increased rectal mucosal expression of tight-junction proteins and MUC12 after one year, with stronger effects in participants with lower baseline vitamin D.

Trust comment: Subset (n=105) from a randomized chemoprevention trial testing 1200 mg/day calcium with standardized IHC and quantitative analysis; effects borderline/significant in vitamin D–low subgroup.

Study Details

PMID:30938860
Participants:105
Impact:+22% overall (P=0.07); +35% in low 25-OH-D subgroup (P=0.05)
Trust score:4/5

PTH levels

1 evidences

Adding hemoperfusion (especially HA330-RHA) to hemodialysis reduced pruritus and inflammation and lowered PTH compared with hemodialysis alone.

Trust comment: Randomized allocation with 90 patients and repeated measures showing consistent changes, but single-center design and limited blinding reduce confidence.

Study Details

PMID:28328802
Participants:90
Impact:decreased in hemoperfusion groups compared with control
Trust score:3/5

health-related quality of life (SF-36)

1 evidences

In healthy older men, 12 months of calcium (1000 mg/day) plus vitamin D3 fortified milk did not improve quality of life or depressive symptoms versus control.

Trust comment: 12-month factorial randomized controlled trial (n=180) with validated outcomes and high adherence; well-conducted though secondary analysis.

Study Details

PMID:30993400
Participants:180
Impact:no significant change
Trust score:4/5

Depressive symptoms (CES-D)

1 evidences

In healthy older men, 12 months of calcium (1000 mg/day) plus vitamin D3 fortified milk did not improve quality of life or depressive symptoms versus control.

Trust comment: 12-month factorial randomized controlled trial (n=180) with validated outcomes and high adherence; well-conducted though secondary analysis.

Study Details

PMID:30993400
Participants:180
Impact:no significant change
Trust score:4/5

IL-17A in exhaled breath

1 evidences

In 23 children/teens with cystic fibrosis, calcitriol reduced airway IL-17A and improved serum calcium/PTH/phosphorus; low-dose cholecalciferol reduced airway IL-23.

Trust comment: Randomized, double-blind cross-over human trial but small sample (n=23) and pilot nature limit generalizability.

Study Details

PMID:30922377
Participants:23
Impact:-0.091 pg/mL (~-19%) after calcitriol (0.475 -> 0.384 pg/mL, p=0.008)
Trust score:3/5

IL-23 in exhaled breath

1 evidences

In 23 children/teens with cystic fibrosis, calcitriol reduced airway IL-17A and improved serum calcium/PTH/phosphorus; low-dose cholecalciferol reduced airway IL-23.

Trust comment: Randomized, double-blind cross-over human trial but small sample (n=23) and pilot nature limit generalizability.

Study Details

PMID:30922377
Participants:23
Impact:-1.57 pg/mL (~-17.6%) after cholecalciferol (8.90 -> 7.33 pg/mL, p=0.001)
Trust score:3/5

Serum calcium (blood)

1 evidences

In 23 children/teens with cystic fibrosis, calcitriol reduced airway IL-17A and improved serum calcium/PTH/phosphorus; low-dose cholecalciferol reduced airway IL-23.

Trust comment: Randomized, double-blind cross-over human trial but small sample (n=23) and pilot nature limit generalizability.

Study Details

PMID:30922377
Participants:23
Impact:+0.85 mg/dL (+24%) after calcitriol (3.50 -> 4.35 mg/dL, p=0.001)
Trust score:3/5

25(OH)D AUC (0-112 days)

1 evidences

Single-dose randomized PK study in healthy adults found the 100,000 IU soft capsule form produced higher 25(OH)D exposure (AUC, Cmax) than ampoule; PTH fell and serum calcium remained stable.

Trust comment: Randomized PK study in healthy adults (n=53) with appropriate endpoints; small sample but well conducted for pharmacokinetics.

Study Details

PMID:30917531
Participants:53
Impact:Group1 AUC 2499.4 vs Group2 2152.3 nmol·d/L; LogAUC diff 90%CI [-0.26; -0.06] (capsule superior)
Trust score:4/5

Cmax 25(OH)D

1 evidences

Single-dose randomized PK study in healthy adults found the 100,000 IU soft capsule form produced higher 25(OH)D exposure (AUC, Cmax) than ampoule; PTH fell and serum calcium remained stable.

Trust comment: Randomized PK study in healthy adults (n=53) with appropriate endpoints; small sample but well conducted for pharmacokinetics.

Study Details

PMID:30917531
Participants:53
Impact:28.5 ng/mL (capsule) vs 23.9 ng/mL (ampoule), p=0.002
Trust score:4/5

parathormone (PTH)

1 evidences

Single-dose randomized PK study in healthy adults found the 100,000 IU soft capsule form produced higher 25(OH)D exposure (AUC, Cmax) than ampoule; PTH fell and serum calcium remained stable.

Trust comment: Randomized PK study in healthy adults (n=53) with appropriate endpoints; small sample but well conducted for pharmacokinetics.

Study Details

PMID:30917531
Participants:53
Impact:PTH decreased: -20.0 ±22.8 pg/mL (capsule) and -12.0 ±23.3 pg/mL (ampoule) over 112 days
Trust score:4/5

25-hydroxyvitamin D (25OHD)

2 evidences

Genetic variants in VDR and DBP were associated with baseline vitamin D status and bone turnover markers, and genotype (combined GRS) modified the response of 25OHD to calcium plus vitamin D supplementation during training.

Trust comment: Large randomized, double-blind, placebo-controlled supplementation trial with genetic subgroup analyses; completer analysis used (n=391) for response data.

Study Details

PMID:27683185
Participants:391
Impact:response to Ca + vitamin D supplementation was modulated by genotype; higher genetic risk score required greater vitamin D intake to improve 25OHD
Trust score:4/5

Ca + D reduced some bone turnover markers, increased 25OHD, and showed a season-specific greater increase in bone strength index (summer only); little other effect on bone tissue.

Trust comment: Randomized controlled trial in 197 recruits with objective bone measures; co-administration of vitamin D complicates isolation of calcium effect.

Study Details

PMID:30902791
Participants:197
Impact:increased (p < .05)
Trust score:4/5

Bone formation/resorption markers (BAP, TRAP, OCN)

1 evidences

Ca + D reduced some bone turnover markers, increased 25OHD, and showed a season-specific greater increase in bone strength index (summer only); little other effect on bone tissue.

Trust comment: Randomized controlled trial in 197 recruits with objective bone measures; co-administration of vitamin D complicates isolation of calcium effect.

Study Details

PMID:30902791
Participants:197
Impact:decreased (p < .05)
Trust score:4/5

bone strength index (BSI)

1 evidences

Ca + D reduced some bone turnover markers, increased 25OHD, and showed a season-specific greater increase in bone strength index (summer only); little other effect on bone tissue.

Trust comment: Randomized controlled trial in 197 recruits with objective bone measures; co-administration of vitamin D complicates isolation of calcium effect.

Study Details

PMID:30902791
Participants:197
Impact:greater increase with Ca+D vs placebo in summer only (p < .05)
Trust score:4/5

PTH reduction (>30%)

1 evidences

Pooled clinical trials show etelcalcetide lowers PTH but commonly reduces blood calcium and can prolong QT; adverse effects are generally manageable with monitoring.

Trust comment: Large pooled phase‑3 randomized trials with open‑label extensions provide robust human safety/efficacy data.

Study Details

PMID:30875390
Participants:3005
Impact:74.7% achieved >30% PTH reduction with etelcalcetide vs 8.9% placebo (placebo-controlled pooled)
Trust score:5/5

Decreased serum calcium / hypocalcemia

1 evidences

Pooled clinical trials show etelcalcetide lowers PTH but commonly reduces blood calcium and can prolong QT; adverse effects are generally manageable with monitoring.

Trust comment: Large pooled phase‑3 randomized trials with open‑label extensions provide robust human safety/efficacy data.

Study Details

PMID:30875390
Participants:3005
Impact:Hypocalcemia/event of decreased blood calcium in etelcalcetide ~65.6% vs 10.3% placebo (placebo-controlled pooled)
Trust score:5/5

QTc prolongation

1 evidences

Pooled clinical trials show etelcalcetide lowers PTH but commonly reduces blood calcium and can prolong QT; adverse effects are generally manageable with monitoring.

Trust comment: Large pooled phase‑3 randomized trials with open‑label extensions provide robust human safety/efficacy data.

Study Details

PMID:30875390
Participants:3005
Impact:19.7% had QTcF increase 30–60 ms (etelcalcetide) vs 5.7% placebo; >60 ms in 1.2% vs 0%
Trust score:5/5

Postoperative hypocalcemia incidence

2 evidences

A surgical technique preserving superior parathyroid blood supply reduced early postoperative hypocalcemia and low parathyroid hormone compared with conventional surgery.

Trust comment: Randomized trial with clear outcome differences but potential confounding (imbalance in lymph node dissection) noted by authors.

Study Details

PMID:30872176
Participants:226
Impact:Observation 10.6% vs control 31.9% (−21.3 percentage points)
Trust score:3/5

Teriparatide given after thyroidectomy reduced low calcium events, shortened hospital stay, and decreased need for postdischarge calcium pills.

Trust comment: Small randomized phase II open-label human trial with clinically relevant endpoints but limited sample size.

Study Details

PMID:27525532
Participants:26
Impact:↓ from 84.6% (11/13) to 23.1% (3/13); RR 0.26 (95% CI 0.09–0.723), P = 0.006
Trust score:3/5

Postoperative low parathyroid hormone incidence

1 evidences

A surgical technique preserving superior parathyroid blood supply reduced early postoperative hypocalcemia and low parathyroid hormone compared with conventional surgery.

Trust comment: Randomized trial with clear outcome differences but potential confounding (imbalance in lymph node dissection) noted by authors.

Study Details

PMID:30872176
Participants:226
Impact:Observation 14.2% vs control 35.4% (−21.2 percentage points)
Trust score:3/5

Pulse wave velocity (arterial stiffness) in higher calcium subgroup

1 evidences

Parathyroidectomy lowered total cholesterol and, in patients with higher baseline ionized calcium, reduced arterial stiffness (PWV); ambulatory diastolic BP increased.

Trust comment: Randomized clinical trial with modest sample size and clear reported P values for main outcomes.

Study Details

PMID:30860588
Participants:69
Impact:PWV decreased significantly in patients with baseline ionized calcium ≥1.45 mmol/L (P = 0.03)
Trust score:4/5

ambulatory diastolic blood pressure

1 evidences

Parathyroidectomy lowered total cholesterol and, in patients with higher baseline ionized calcium, reduced arterial stiffness (PWV); ambulatory diastolic BP increased.

Trust comment: Randomized clinical trial with modest sample size and clear reported P values for main outcomes.

Study Details

PMID:30860588
Participants:69
Impact:Ambulatory diastolic BP increased after parathyroidectomy (reported as significant)
Trust score:4/5

serum phosphate (P)

1 evidences

In dialysis patients with secondary hyperparathyroidism, IV etelcalcetide over 1 year reduced PTH and lowered blood calcium and phosphate; hypocalcemia occurred in some patients.

Trust comment: Large multicenter human trial with central lab measurements but single-arm open-label extension limits causal inference.

Study Details

PMID:30859218
Participants:682
Impact:−3.6% (mean percent change, EAP)
Trust score:4/5

hypercalcemia / hypercalciuria

1 evidences

Daily vitamin D3 (600, 1000, 2000 IU) in deficient children increased vitamin D levels and substantially reduced secondary hyperparathyroidism; 2000 IU was most effective and no hypercalcaemia occurred.

Trust comment: Large randomized trial with high compliance and laboratory outcomes, though single-blind design and specific population limit generalizability.

Study Details

PMID:30843501
Participants:1008
Impact:no hypercalcemia; hypercalciuria in 2 participants
Trust score:4/5

osteocalcin (bone formation)

1 evidences

In children with celiac disease on a gluten-free diet, 3 months of oligofructose-enriched inulin increased some bone formation markers and limited some markers of bone resorption versus placebo.

Trust comment: Randomized placebo-controlled pilot with small sample size; signals on bone markers but limited power and short duration.

Study Details

PMID:30840918
Participants:34
Impact:increased (significant) in prebiotic group
Trust score:3/5

pyridinoline (bone resorption)

1 evidences

In children with celiac disease on a gluten-free diet, 3 months of oligofructose-enriched inulin increased some bone formation markers and limited some markers of bone resorption versus placebo.

Trust comment: Randomized placebo-controlled pilot with small sample size; signals on bone markers but limited power and short duration.

Study Details

PMID:30840918
Participants:34
Impact:stable in prebiotic group vs increased (≈2×) in placebo group
Trust score:3/5

N-terminal telopeptides (NTx)

1 evidences

In children with celiac disease on a gluten-free diet, 3 months of oligofructose-enriched inulin increased some bone formation markers and limited some markers of bone resorption versus placebo.

Trust comment: Randomized placebo-controlled pilot with small sample size; signals on bone markers but limited power and short duration.

Study Details

PMID:30840918
Participants:34
Impact:decreased in both groups
Trust score:3/5

clinical success rate (per-tooth)

1 evidences

In children receiving pulpotomy, using calcium hydroxide paste produced clinical and radiographic success rates similar to zinc oxide–eugenol over 12 months.

Trust comment: Randomized clinical trial but small sample (29 children) and outcomes reported per tooth limit precision of estimates.

Study Details

PMID:30837416
Participants:29
Impact:89.5–100% across groups; no significant difference (P=0.548)
Trust score:3/5

any colorectal adenoma (occurrence)

1 evidences

Posttreatment observational follow-up found no association between prior calcium supplementation and risk of recurrent colorectal adenomas at ~4.6 years.

Trust comment: Large randomized trial with long follow-up in observational phase; posttreatment analysis reduces causal certainty but sample size is robust.

Study Details

PMID:30833381
Participants:1121
Impact:RR 0.95 (95% CI 0.84–1.08) for calcium vs no calcium (no significant effect)
Trust score:4/5

advanced or multiple adenomas

1 evidences

Posttreatment observational follow-up found no association between prior calcium supplementation and risk of recurrent colorectal adenomas at ~4.6 years.

Trust comment: Large randomized trial with long follow-up in observational phase; posttreatment analysis reduces causal certainty but sample size is robust.

Study Details

PMID:30833381
Participants:1121
Impact:no difference by calcium treatment (no significant effect)
Trust score:4/5

FGF23 trajectory

1 evidences

Longitudinal study in hemodialysis patients identified distinct FGF23 patterns; low serum calcium was associated with a low-stable FGF23 trajectory which linked to lower mortality.

Trust comment: Large multicenter cohort with annual biomarker measurements and appropriate trajectory and survival modeling; observational associations (not randomized calcium intervention).

Study Details

PMID:30820005
Participants:919
Impact:Low serum calcium associated with the low‑stable FGF23 trajectory (predictor)
Trust score:4/5

all‑cause mortality

1 evidences

Longitudinal study in hemodialysis patients identified distinct FGF23 patterns; low serum calcium was associated with a low-stable FGF23 trajectory which linked to lower mortality.

Trust comment: Large multicenter cohort with annual biomarker measurements and appropriate trajectory and survival modeling; observational associations (not randomized calcium intervention).

Study Details

PMID:30820005
Participants:919
Impact:Low‑stable FGF23 trajectory associated with reduced mortality (HR 0.61)
Trust score:4/5

length of stay

1 evidences

A perioperative multimodal nutrition protocol improved postoperative labs and recovery: higher albumin and electrolyte levels, fewer electrolyte disorders, and shorter hospital stay.

Trust comment: Randomized controlled trial with 187 patients and clinically relevant postoperative biochemical and recovery endpoints; results report differences in electrolytes including calcium.

Study Details

PMID:30817733
Participants:187
Impact:Shorter hospital length of stay with MNM
Trust score:4/5

Sealant retention at 12 months

1 evidences

In a split‑mouth RCT in children, an amorphous calcium phosphate (ACP)–containing sealant showed slightly higher 12‑month retention and lower caries scores versus a fluoride‑releasing sealant, without a significant difference.

Trust comment: Double‑blind split‑mouth randomized design but small sample (32 children); directly tests a calcium‑containing dental material (ACP).

Study Details

PMID:30804314
Participants:32
Impact:Aegis (ACP) 72% vs Embrace 65.6% (no significant difference)
Trust score:4/5

Caries development

1 evidences

In a split‑mouth RCT in children, an amorphous calcium phosphate (ACP)–containing sealant showed slightly higher 12‑month retention and lower caries scores versus a fluoride‑releasing sealant, without a significant difference.

Trust comment: Double‑blind split‑mouth randomized design but small sample (32 children); directly tests a calcium‑containing dental material (ACP).

Study Details

PMID:30804314
Participants:32
Impact:Lower caries scores observed with ACP‑containing sealant vs comparator
Trust score:4/5

Clinical/radiographic success of IPT

1 evidences

In primary molars, calcium hydroxide as an indirect pulp‑capping material had high clinical and radiographic success (~94.4%) at 12 months, similar to other materials.

Trust comment: Randomized in vivo study with small sample size; directly assesses a calcium‑based dental material (calcium hydroxide) with 12‑month outcomes.

Study Details

PMID:30804309
Participants:54
Impact:Calcium hydroxide success 94.4% (17/18) at 12 months; comparable to alternatives (biodentine 100%)
Trust score:3/5

clinical and radiographic success

1 evidences

Randomized comparison in children of two root canal filling pastes (iodoform-based vs Calen®/ZO [calcium hydroxide/ZnO]); both had high clinical/radiographic success at 12 months.

Trust comment: Small randomized trial with blinded radiographic assessment but limited sample size (23 children, 27 teeth) reduces precision.

Study Details

PMID:30758402
Participants:23
Impact:no difference at 12 months
Trust score:3/5

level of root canal filling

1 evidences

Randomized comparison in children of two root canal filling pastes (iodoform-based vs Calen®/ZO [calcium hydroxide/ZnO]); both had high clinical/radiographic success at 12 months.

Trust comment: Small randomized trial with blinded radiographic assessment but limited sample size (23 children, 27 teeth) reduces precision.

Study Details

PMID:30758402
Participants:23
Impact:better in Calen®/ZO (calcium hydroxide/ZnO) group
Trust score:3/5

spinal BMD change (lower PA subgroup)

1 evidences

Subgroup analysis of an RCT (450 randomized, 418 with follow-up) found 500 mg/day calcium reduced spinal and femoral neck bone loss over 2 years in women with lower physical activity but not in those with higher activity.

Trust comment: Large randomized trial subgroup analysis with good follow-up (418), but subgroup nature limits causal certainty and generalizability.

Study Details

PMID:30734085
Participants:418
Impact:500 mg: -0.029 g/cm2 vs placebo -0.045 g/cm2 (less loss)
Trust score:4/5

femoral neck BMD change (lower PA subgroup)

1 evidences

Subgroup analysis of an RCT (450 randomized, 418 with follow-up) found 500 mg/day calcium reduced spinal and femoral neck bone loss over 2 years in women with lower physical activity but not in those with higher activity.

Trust comment: Large randomized trial subgroup analysis with good follow-up (418), but subgroup nature limits causal certainty and generalizability.

Study Details

PMID:30734085
Participants:418
Impact:500 mg: -0.027 g/cm2 vs placebo -0.038 g/cm2 (less loss)
Trust score:4/5

effect in higher PA subgroup

1 evidences

Subgroup analysis of an RCT (450 randomized, 418 with follow-up) found 500 mg/day calcium reduced spinal and femoral neck bone loss over 2 years in women with lower physical activity but not in those with higher activity.

Trust comment: Large randomized trial subgroup analysis with good follow-up (418), but subgroup nature limits causal certainty and generalizability.

Study Details

PMID:30734085
Participants:418
Impact:no significant difference between calcium and placebo
Trust score:4/5

25-hydroxyvitamin D (25OHD) change

1 evidences

Randomized study in postmenopausal women: one arm received 1000 mg calcium + 800 IU vitamin D (n=102) vs placebo (n=49) for 12 weeks; overall vitamin D levels at baseline and 12 weeks were similar between groups, and the Bat VDR haplotype was associated with lower baseline vitamin D and higher nonresponse.

Trust comment: Randomized supplementation trial with clear participant allocation but modest sample size and co-administration of vitamin D confounds isolating calcium-specific effects.

Study Details

PMID:30789807
Participants:151
Impact:+7 ng/ml (calcium+vitD group, 25→32 ng/ml) vs +6 ng/ml (placebo, 23→29 ng/ml); between-group difference not statistically significant (p>0.05)
Trust score:3/5

Nonresponder rate (Bat VDR haplotype)

1 evidences

Randomized study in postmenopausal women: one arm received 1000 mg calcium + 800 IU vitamin D (n=102) vs placebo (n=49) for 12 weeks; overall vitamin D levels at baseline and 12 weeks were similar between groups, and the Bat VDR haplotype was associated with lower baseline vitamin D and higher nonresponse.

Trust comment: Randomized supplementation trial with clear participant allocation but modest sample size and co-administration of vitamin D confounds isolating calcium-specific effects.

Study Details

PMID:30789807
Participants:151
Impact:15% nonresponders in Bat haplotype vs 9%, 2%, 3% in other haplotypes (p=0.001)
Trust score:3/5

dentin hypersensitivity (Schiff score)

1 evidences

Multicenter randomized trial in patients with dentin hypersensitivity showed that an 8% arginine + calcium carbonate prophylaxis/toothpaste produced greater and sustained reduction in sensitivity over 24 weeks versus control.

Trust comment: Multicenter randomized clinical trial with large completer sample and consistent, significant reductions favoring the calcium-containing arginine product.

Study Details

PMID:30710652
Participants:273
Impact:Test group −44.9% at 24 weeks vs −32.7% control; between-group pooled difference at visits up to 24 weeks (e.g., 24w) ≈17.2% favoring test
Trust score:4/5

immediate sensitivity reduction after single application

1 evidences

Multicenter randomized trial in patients with dentin hypersensitivity showed that an 8% arginine + calcium carbonate prophylaxis/toothpaste produced greater and sustained reduction in sensitivity over 24 weeks versus control.

Trust comment: Multicenter randomized clinical trial with large completer sample and consistent, significant reductions favoring the calcium-containing arginine product.

Study Details

PMID:30710652
Participants:273
Impact:Test group −23.6% immediate vs −8.8% control (BL1)
Trust score:4/5

treatment success rate (clinical and radiographic)

1 evidences

Partial pulpotomy with either ProRoot MTA or Biodentine successfully preserved teeth in children/adolescents; Biodentine caused much less grey discoloration.

Trust comment: Randomized controlled noninferiority trial with moderate sample size and ~32-month follow-up; results are directly reported and clear.

Study Details

PMID:30638262
Participants:67
Impact:Overall 90%; ProRoot MTA 92% vs Biodentine 87% (difference 5%; P=0.487, non-significant)
Trust score:4/5

perceptible grey discoloration

1 evidences

Partial pulpotomy with either ProRoot MTA or Biodentine successfully preserved teeth in children/adolescents; Biodentine caused much less grey discoloration.

Trust comment: Randomized controlled noninferiority trial with moderate sample size and ~32-month follow-up; results are directly reported and clear.

Study Details

PMID:30638262
Participants:67
Impact:ProRoot MTA 80% vs Biodentine 27% (large decrease; P<0.001)
Trust score:4/5

postprandial glucose association with coronary calcium progression

1 evidences

In patients with type 2 diabetes, higher postprandial glucose was associated with progression of coronary calcification, while higher fetuin-A was associated with less progression; serum calcium and related markers showed no association.

Trust comment: Prospective clinical study with repeated CT-based calcium scoring and multivariate analysis; moderate sample (n=45) limits power but methods are appropriate.

Study Details

PMID:30616461
Participants:45
Impact:Postprandial glucose correlated with absolute change (Spearman rho 0.295, p=0.049) and relative change (rho 0.376, p=0.01); independent predictor in multivariate model (standardized beta ≈ +0.308, p=0.038)
Trust score:4/5

fetuin-A association with coronary calcium progression

1 evidences

In patients with type 2 diabetes, higher postprandial glucose was associated with progression of coronary calcification, while higher fetuin-A was associated with less progression; serum calcium and related markers showed no association.

Trust comment: Prospective clinical study with repeated CT-based calcium scoring and multivariate analysis; moderate sample (n=45) limits power but methods are appropriate.

Study Details

PMID:30616461
Participants:45
Impact:Fetuin-A inversely correlated with relative change in calcium score (rho −0.345, p=0.02); independent predictor in multivariate model (standardized beta ≈ −0.298, p=0.044)
Trust score:4/5

serum calcium/phosphate/parathormone effect

1 evidences

In patients with type 2 diabetes, higher postprandial glucose was associated with progression of coronary calcification, while higher fetuin-A was associated with less progression; serum calcium and related markers showed no association.

Trust comment: Prospective clinical study with repeated CT-based calcium scoring and multivariate analysis; moderate sample (n=45) limits power but methods are appropriate.

Study Details

PMID:30616461
Participants:45
Impact:No association detected with baseline coronary calcification or its progression
Trust score:4/5

radial total BMD

1 evidences

Supplementing pregnant women with 1000 mg Ca/day improved postpartum bone recovery at 12 months compared with placebo.

Trust comment: Randomized placebo-controlled design but small sample size and high attrition (~53% lost to 12-month follow-up) reduce confidence in generalizability.

Study Details

PMID:30649176
Participants:30
Impact:greater increase vs placebo (P = 0.02) at 12 months postpartum
Trust score:3/5

tibial cortical BMD

1 evidences

Supplementing pregnant women with 1000 mg Ca/day improved postpartum bone recovery at 12 months compared with placebo.

Trust comment: Randomized placebo-controlled design but small sample size and high attrition (~53% lost to 12-month follow-up) reduce confidence in generalizability.

Study Details

PMID:30649176
Participants:30
Impact:greater increase vs placebo (P = 0.03) at 12 months postpartum
Trust score:3/5

tibial trabecular/total BMD

1 evidences

Supplementing pregnant women with 1000 mg Ca/day improved postpartum bone recovery at 12 months compared with placebo.

Trust comment: Randomized placebo-controlled design but small sample size and high attrition (~53% lost to 12-month follow-up) reduce confidence in generalizability.

Study Details

PMID:30649176
Participants:30
Impact:trend toward higher values vs placebo (P < 0.06) at 12 months postpartum
Trust score:3/5

incident atrial fibrillation

1 evidences

Daily calcium plus vitamin D supplementation did not affect incidence of atrial fibrillation in postmenopausal women over ~4.5 years.

Trust comment: - Checklist: 1) Confirm direct relevance (Ca+D supplementation studied); 2) Extract primary outcomes (incident AF); 3) Count participants and assess quality. Large randomized trial secondary analysis with robust sample size and claims-based outcome ascertainment; moderate-high trust.

Study Details

PMID:30685677
Participants:16801
Impact:no significant effect: HR 1.02 for CaD vs placebo (95% CI 0.92–1.13)
Trust score:4/5

baseline 25-hydroxyvitamin D and AF risk

1 evidences

Daily calcium plus vitamin D supplementation did not affect incidence of atrial fibrillation in postmenopausal women over ~4.5 years.

Trust comment: - Checklist: 1) Confirm direct relevance (Ca+D supplementation studied); 2) Extract primary outcomes (incident AF); 3) Count participants and assess quality. Large randomized trial secondary analysis with robust sample size and claims-based outcome ascertainment; moderate-high trust.

Study Details

PMID:30685677
Participants:16801
Impact:no significant association (lowest vs highest subgroup HR 0.92; 95% CI 0.66–1.28)
Trust score:4/5

pre-eclampsia (primary outcome)

1 evidences

Daily 500 mg calcium from before pregnancy until 20 weeks did not significantly reduce recurrent pre-eclampsia overall, though highly compliant women showed fewer cases.

Trust comment: Large multicentre double-blind randomized placebo-controlled trial with rigorous methods and pre-specified outcomes; primary result was not statistically significant.

Study Details

PMID:30696573
Participants:579
Impact:reduced from 29% (placebo) to 23% (calcium) among pregnancies ≥20 weeks (RR 0.80), p=0.121 (not significant); ~6 percentage-point absolute reduction (~20% relative)
Trust score:5/5

pre-eclampsia or pregnancy loss (composite)

1 evidences

Daily 500 mg calcium from before pregnancy until 20 weeks did not significantly reduce recurrent pre-eclampsia overall, though highly compliant women showed fewer cases.

Trust comment: Large multicentre double-blind randomized placebo-controlled trial with rigorous methods and pre-specified outcomes; primary result was not statistically significant.

Study Details

PMID:30696573
Participants:579
Impact:33% (calcium) vs 41% (placebo), RR 0.82, p=0.050 (borderline significance); ~18% relative reduction
Trust score:5/5

per-protocol (compliance >80%) pre-eclampsia

1 evidences

Daily 500 mg calcium from before pregnancy until 20 weeks did not significantly reduce recurrent pre-eclampsia overall, though highly compliant women showed fewer cases.

Trust comment: Large multicentre double-blind randomized placebo-controlled trial with rigorous methods and pre-specified outcomes; primary result was not statistically significant.

Study Details

PMID:30696573
Participants:579
Impact:21% (calcium) vs 32% (placebo), RR 0.66, p=0.037; ~11 percentage-point absolute reduction (~34% relative)
Trust score:5/5

hip BMD

1 evidences

In people with HIV, ART type and vitamin D status associate with bone mineral density; higher serum calcium was associated with lower lumbar spine BMD.

Trust comment: Observational analyses from a randomized ART simplification trial baseline (n=160); associative findings subject to confounding but biologically plausible.

Study Details

PMID:26659069
Participants:160
Impact:TDF-FTC use associated with lower hip BMD, more pronounced in those with 25(OH)D ≥50 nmol/L
Trust score:3/5

initial elemental calcium + calcitriol effect

1 evidences

In hemodialysis patients with osteoporosis, initial elemental calcium plus calcitriol mitigated early denosumab-induced drops in serum calcium, and both denosumab and alendronate increased lumbar spine BMD at 12 months.

Trust comment: Randomized controlled trial in humans; calcium+calcitriol was used as adjunct and shown to prevent early hypocalcemia, but the study was small and not primarily designed to test calcium alone.

Study Details

PMID:30690785
Participants:48
Impact:markedly ameliorated denosumab-induced decrease in serum corrected calcium during the first 2 weeks
Trust score:3/5

lumbar spine BMD (12 months)

1 evidences

In hemodialysis patients with osteoporosis, initial elemental calcium plus calcitriol mitigated early denosumab-induced drops in serum calcium, and both denosumab and alendronate increased lumbar spine BMD at 12 months.

Trust comment: Randomized controlled trial in humans; calcium+calcitriol was used as adjunct and shown to prevent early hypocalcemia, but the study was small and not primarily designed to test calcium alone.

Study Details

PMID:30690785
Participants:48
Impact:both denosumab and alendronate increased LSBMD compared with baseline (12-month gains)
Trust score:3/5

tibia bone mineral content (BMC)

1 evidences

Recruits with a dietary pattern high in calcium, potassium and protein had higher tibia bone mineral content and strength measures.

Trust comment: Cross-sectional analysis of 401 recruits with objective pQCT bone measures; associations are statistically significant but observational so causality is limited.

Study Details

PMID:30615068
Participants:401
Impact:positive association (metaphysis P=0.004; diaphysis P=0.0002; diaphyseal BMC remained after BMI adjustment P=0.005)
Trust score:3/5

tibia strength index

1 evidences

Recruits with a dietary pattern high in calcium, potassium and protein had higher tibia bone mineral content and strength measures.

Trust comment: Cross-sectional analysis of 401 recruits with objective pQCT bone measures; associations are statistically significant but observational so causality is limited.

Study Details

PMID:30615068
Participants:401
Impact:positive association (metaphysis P=0.01; diaphysis P=0.0006; diaphyseal strength remained after BMI adjustment P=0.01)
Trust score:3/5

tibia robustness

1 evidences

Recruits with a dietary pattern high in calcium, potassium and protein had higher tibia bone mineral content and strength measures.

Trust comment: Cross-sectional analysis of 401 recruits with objective pQCT bone measures; associations are statistically significant but observational so causality is limited.

Study Details

PMID:30615068
Participants:401
Impact:positive association (diaphysis P=0.02; attenuated after BMI adjustment)
Trust score:3/5

FGF23 (and FGFRs, Klotho)

1 evidences

In non-dialysis CKD-MBD patients, Ronghuang granule improved symptoms and markers of calcium/phosphorus metabolism compared with control.

Trust comment: Randomized trial with 65 completers showing biochemical improvements in calcium/phosphorus metabolism, but single-center and traditional-medicine context limit generalizability.

Study Details

PMID:30613009
Participants:65
Impact:reduced in treatment group (P<0.05); remained unchanged in control
Trust score:3/5

clinical success

1 evidences

In children needing pulpotomy, Biodentine (a calcium-silicate cement) and formocresol showed similarly high clinical and radiographic success over 12 months.

Trust comment: Well-designed split-mouth randomized trial with blinded outcome assessment and objective radiographic endpoints; limited by short (12-month) follow-up and modest patient count.

Study Details

PMID:30612569
Participants:37
Impact:100% for both Biodentine and formocresol at 3, 6, and 12 months (no significant difference)
Trust score:4/5

radiographic success

2 evidences

In children needing pulpotomy, Biodentine (a calcium-silicate cement) and formocresol showed similarly high clinical and radiographic success over 12 months.

Trust comment: Well-designed split-mouth randomized trial with blinded outcome assessment and objective radiographic endpoints; limited by short (12-month) follow-up and modest patient count.

Study Details

PMID:30612569
Participants:37
Impact:Biodentine 100% vs formocresol 98.1% at 12 months (no significant difference)
Trust score:4/5

Randomized trial (N=302) using calcium-enriched mixture cement across four vital pulp therapies showed favorable and comparable clinical and radiographic outcomes at 1 year.

Trust comment: Large randomized clinical trial with blinded participants and 1-year follow-up; relevant to calcium-containing dental material (local), not systemic calcium supplementation.

Study Details

PMID:29397215
Participants:302
Impact:favorable and comparable across arms at 1 year
Trust score:4/5

pulp canal obliteration (PCO)

1 evidences

In children needing pulpotomy, Biodentine (a calcium-silicate cement) and formocresol showed similarly high clinical and radiographic success over 12 months.

Trust comment: Well-designed split-mouth randomized trial with blinded outcome assessment and objective radiographic endpoints; limited by short (12-month) follow-up and modest patient count.

Study Details

PMID:30612569
Participants:37
Impact:Biodentine 17.8% vs formocresol 12.5% (no significant difference)
Trust score:4/5

femoral bone tunnel enlargement

1 evidences

Using a calcium phosphate-hybridized tendon graft reduced femoral bone tunnel enlargement at 1 year and had similar clinical outcomes to conventional grafts over 2 years.

Trust comment: Randomized controlled trial with 90 patients and 2-year follow-up demonstrating reduced femoral tunnel enlargement; generally well-conducted though with some missing data and limited longer-term follow-up.

Study Details

PMID:30594226
Participants:90
Impact:CSA increase at 1 year: 24.1±49.8% (CaP) vs 63.8±66.1% (conventional); P=0.006 (smaller enlargement with CaP)
Trust score:4/5

clinical outcomes (stability, scores, re-rupture)

1 evidences

Using a calcium phosphate-hybridized tendon graft reduced femoral bone tunnel enlargement at 1 year and had similar clinical outcomes to conventional grafts over 2 years.

Trust comment: Randomized controlled trial with 90 patients and 2-year follow-up demonstrating reduced femoral tunnel enlargement; generally well-conducted though with some missing data and limited longer-term follow-up.

Study Details

PMID:30594226
Participants:90
Impact:no significant difference between groups over 2 years
Trust score:4/5

ridge width loss (-3 mm)

1 evidences

Use of biphasic calcium sulfate/hydroxyapatite (BCS/HA) for socket preservation reduced bone and width loss and showed more vital bone vs bovine xenograft.

Trust comment: Randomized clinical trial with objective clinical and histologic endpoints but small sample size (n=33).

Study Details

PMID:30592368
Participants:33
Impact:BCS/HA: 0.5 mm; BDX: 1.56 mm; Control: 2.96 mm (post-op reductions)
Trust score:4/5

vertical bone loss

1 evidences

Use of biphasic calcium sulfate/hydroxyapatite (BCS/HA) for socket preservation reduced bone and width loss and showed more vital bone vs bovine xenograft.

Trust comment: Randomized clinical trial with objective clinical and histologic endpoints but small sample size (n=33).

Study Details

PMID:30592368
Participants:33
Impact:BCS/HA: 0.65 mm; BDX: 0.25 mm; Control: 1.71 mm (post-op)
Trust score:4/5

vital bone proportion (histology)

1 evidences

Use of biphasic calcium sulfate/hydroxyapatite (BCS/HA) for socket preservation reduced bone and width loss and showed more vital bone vs bovine xenograft.

Trust comment: Randomized clinical trial with objective clinical and histologic endpoints but small sample size (n=33).

Study Details

PMID:30592368
Participants:33
Impact:BCS/HA > BDX (BDX had greater residual scaffold and less vital bone)
Trust score:4/5

serum phosphorus level

1 evidences

Oral activated charcoal delayed hyperphosphatemia and reduced serum phosphate; calcium carbonate treatment was associated with larger increases in coronary artery calcification compared with lanthanum carbonate or charcoal.

Trust comment: Randomized two-phase clinical study with objective biochemical and CT outcomes; single-center and moderate sample size limits generalizability.

Study Details

PMID:30588573
Participants:97
Impact:OAC group lowered serum phosphorus from month 3 onward vs placebo (P=0.000)
Trust score:4/5

Hyperphosphatemia incidence

1 evidences

Oral activated charcoal delayed hyperphosphatemia and reduced serum phosphate; calcium carbonate treatment was associated with larger increases in coronary artery calcification compared with lanthanum carbonate or charcoal.

Trust comment: Randomized two-phase clinical study with objective biochemical and CT outcomes; single-center and moderate sample size limits generalizability.

Study Details

PMID:30588573
Participants:97
Impact:OAC 28.57% vs placebo 79.17% at 12 months (P=0.000)
Trust score:4/5

coronary artery calcification score (CACS)

1 evidences

Oral activated charcoal delayed hyperphosphatemia and reduced serum phosphate; calcium carbonate treatment was associated with larger increases in coronary artery calcification compared with lanthanum carbonate or charcoal.

Trust comment: Randomized two-phase clinical study with objective biochemical and CT outcomes; single-center and moderate sample size limits generalizability.

Study Details

PMID:30588573
Participants:97
Impact:At 12 months CC 526.1±71.0 > OAC 426.0±100.8 > LC 338.8±134.9 (P<0.05); calcium carbonate associated with larger CACS increases over follow-up
Trust score:4/5

osteocalcin

1 evidences

Genetic variants in VDR and DBP were associated with baseline vitamin D status and bone turnover markers, and genotype (combined GRS) modified the response of 25OHD to calcium plus vitamin D supplementation during training.

Trust comment: Large randomized, double-blind, placebo-controlled supplementation trial with genetic subgroup analyses; completer analysis used (n=391) for response data.

Study Details

PMID:27683185
Participants:391
Impact:lower levels associated with VDR rs2228570 minor allele
Trust score:4/5

newly formed bone area

1 evidences

Small randomized trial comparing calcium-phosphate-coated bovine bone vs standard bovine bone for sinus augmentation found no significant differences in new bone formation or radiographic outcomes.

Trust comment: Randomized multicenter design but small sample size (25 patients) limits precision.

Study Details

PMID:30570584
Participants:25
Impact:no significant difference (InduCera ~21.4% vs Bio-Oss ~23.0%)
Trust score:3/5

radiographic final alveolar bone height

1 evidences

Small randomized trial comparing calcium-phosphate-coated bovine bone vs standard bovine bone for sinus augmentation found no significant differences in new bone formation or radiographic outcomes.

Trust comment: Randomized multicenter design but small sample size (25 patients) limits precision.

Study Details

PMID:30570584
Participants:25
Impact:no significant difference between groups
Trust score:3/5

shrinkage rate of grafted volume

1 evidences

Small randomized trial comparing calcium-phosphate-coated bovine bone vs standard bovine bone for sinus augmentation found no significant differences in new bone formation or radiographic outcomes.

Trust comment: Randomized multicenter design but small sample size (25 patients) limits precision.

Study Details

PMID:30570584
Participants:25
Impact:no significant difference between groups
Trust score:3/5

25(OH) vitamin D

2 evidences

Forty adults with low vitamin D were randomized to daily or monthly cholecalciferol; vitamin D levels rose and serum calcium increased modestly, with decreased PTH and reduced bone turnover on longer monthly treatment.

Trust comment: Randomized study with complete follow-up but small sample limits generalizability; findings are indirect for calcium (via vitamin D effects).

Study Details

PMID:30563215
Participants:40
Impact:increased (~+13–14 ng/mL on average after 6 months)
Trust score:3/5

Measured serum/urine calcium, vitamin D, PTH and bone markers in osteoporotic women and analysed correlations with metabolic/cardiovascular risk markers.

Trust comment: Observational clinical study with standard biochemical assays in a modest sample size—associations reported but causality limited.

Study Details

PMID:28849089
Participants:71
Impact:commonly low (median <30 ng/ml) and lower in MetS group
Trust score:3/5

Bone turnover

1 evidences

Forty adults with low vitamin D were randomized to daily or monthly cholecalciferol; vitamin D levels rose and serum calcium increased modestly, with decreased PTH and reduced bone turnover on longer monthly treatment.

Trust comment: Randomized study with complete follow-up but small sample limits generalizability; findings are indirect for calcium (via vitamin D effects).

Study Details

PMID:30563215
Participants:40
Impact:decreased (observed at 18 months with monthly treatment; PTH decreased)
Trust score:3/5

plasma parathyroid hormone (PTH)

1 evidences

In PHPT patients unable to undergo surgery, cinacalcet markedly lowered serum calcium and PTH and normalized calcium in most treated subjects.

Trust comment: Phase 3 double‑blind randomized controlled trial with clear endpoints but modest sample size.

Study Details

PMID:25637076
Participants:67
Impact:Mean change −23.8% (cinacalcet) vs −1.01% (placebo); P<0.001
Trust score:4/5

Colorectal crypt differentiation (p21)

1 evidences

In 104 colorectal adenoma patients, calcium supplementation (1,200 mg/day) was associated with increased markers of differentiation but also with modestly increased proliferation and decreased apoptosis-related ratios in rectal crypts.

Trust comment: Randomized, double-blind adjunct biomarker RCT with objective immunohistochemical endpoints but moderate sample size and some group imbalances limit precision.

Study Details

PMID:30557404
Participants:104
Impact:+23% (estimated, calcium vs no calcium)
Trust score:4/5

Proliferation in upper 40% of crypts (mib-1)

1 evidences

In 104 colorectal adenoma patients, calcium supplementation (1,200 mg/day) was associated with increased markers of differentiation but also with modestly increased proliferation and decreased apoptosis-related ratios in rectal crypts.

Trust comment: Randomized, double-blind adjunct biomarker RCT with objective immunohistochemical endpoints but moderate sample size and some group imbalances limit precision.

Study Details

PMID:30557404
Participants:104
Impact:+29% (estimated, calcium vs no calcium)
Trust score:4/5

Apoptosis relative to proliferation (bax/mib-1, whole crypt)

1 evidences

In 104 colorectal adenoma patients, calcium supplementation (1,200 mg/day) was associated with increased markers of differentiation but also with modestly increased proliferation and decreased apoptosis-related ratios in rectal crypts.

Trust comment: Randomized, double-blind adjunct biomarker RCT with objective immunohistochemical endpoints but moderate sample size and some group imbalances limit precision.

Study Details

PMID:30557404
Participants:104
Impact:−25% (estimated, calcium vs no calcium)
Trust score:4/5

probing pocket depth reduction

1 evidences

Adding a biphasic calcium phosphate bone graft to enamel matrix derivative did not improve periodontal healing versus enamel matrix alone over 3 years.

Trust comment: Randomized, multicenter, 36-month follow-up but small sample (n=30) limits precision.

Study Details

PMID:26174080
Participants:30
Impact:significant reduction in both groups (p<0.001); no between-group difference
Trust score:4/5

Incidence of stone recurrence (composite symptomatic or radiologic)

1 evidences

Protocol for a large randomized, double-blind, placebo-controlled trial (n=416 planned) testing HCTZ dose-response to prevent recurrence of calcium-containing kidney stones; no outcome data reported yet.

Trust comment: High-quality, large multicenter randomized trial protocol directly relevant to calcium-containing stones and renal calcium handling, but this record is a protocol with no results yet.

Study Details

PMID:30526528
Participants:416
Impact:Primary outcome defined; protocol only — no results reported yet
Trust score:4/5

Urinary biochemistry (including calciuria)

1 evidences

Protocol for a large randomized, double-blind, placebo-controlled trial (n=416 planned) testing HCTZ dose-response to prevent recurrence of calcium-containing kidney stones; no outcome data reported yet.

Trust comment: High-quality, large multicenter randomized trial protocol directly relevant to calcium-containing stones and renal calcium handling, but this record is a protocol with no results yet.

Study Details

PMID:30526528
Participants:416
Impact:Planned secondary outcome to assess HCTZ effects on urinary calcium and other parameters — no results yet
Trust score:4/5

Safety endpoints (hypokalemia, hyponatremia, hypomagnesemia, etc.)

1 evidences

Protocol for a large randomized, double-blind, placebo-controlled trial (n=416 planned) testing HCTZ dose-response to prevent recurrence of calcium-containing kidney stones; no outcome data reported yet.

Trust comment: High-quality, large multicenter randomized trial protocol directly relevant to calcium-containing stones and renal calcium handling, but this record is a protocol with no results yet.

Study Details

PMID:30526528
Participants:416
Impact:Planned safety outcomes to be monitored — no results yet
Trust score:4/5

Residual bone graft volume

1 evidences

Prospective randomized trial comparing biphasic calcium phosphate graft vs deproteinized bovine bone for sinus augmentation (56 patients, 60 sinuses); both materials showed similar biocompatibility and osteoconductivity at 6 months.

Trust comment: Randomized controlled clinical trial directly testing a calcium-containing graft material in humans; moderate sample size and no significant differences reported.

Study Details

PMID:30521656
Participants:56
Impact:Higher residual graft volume in bovine bone group vs calcium phosphate, not statistically significant
Trust score:3/5

Dentin hypersensitivity pain (VAS, evaporative/tactile)

1 evidences

Double-blind randomized trial (n=70) testing NovaMin® (calcium sodium phosphosilicate) paste and Nd:YAG laser for cervical dentin hypersensitivity; all groups showed pain reduction from baseline and treatments were equally effective.

Trust comment: Randomized double-blind clinical trial directly testing a calcium-containing topical paste (NovaMin®) with moderate sample size; outcome shows reduction in pain but no superiority over control in this report.

Study Details

PMID:30506227
Participants:70
Impact:Pain reduced at 5 min, 1 week, and 4 weeks vs baseline for all groups; no between-group differences (all treatments equally effective)
Trust score:3/5

radiographic peri-implant bone loss

2 evidences

Randomized trial comparing bovine bone vs synthetic β-tricalcium phosphate grafts for horizontal bone augmentation found no significant differences in bone loss, complications, or patient-reported outcomes at 3 years.

Trust comment: Randomized, double-blind RCT with 3-year follow-up but modest sample size limiting precision.

Study Details

PMID:30515484
Participants:50
Impact:BB 1.61 mm vs CJ 1.02 mm (difference 0.54 mm; P=0.31)
Trust score:4/5

Double-blind RCT comparing bovine bone + membrane vs pure β-tricalcium phosphate (a calcium phosphate) + membrane for horizontal augmentation: no major differences, with a small (0.24 mm) less peri-implant radiographic bone loss favoring the β-TCP group.

Trust comment: Double-blind randomized trial with 50 patients and 12-month follow-up; high methodological quality though effect sizes were small.

Study Details

PMID:26355171
Participants:50
Impact:0.24 mm less bone loss favoring β-TCP group (P=0.0464)
Trust score:4/5

complications

2 evidences

Multicenter randomized pilot trial: titanium implants with a calcium-incorporated surface showed similar implant/prosthesis survival, complications, and marginal bone level changes compared with control RBM surfaces at 3 years.

Trust comment: Randomized multicenter pilot with 3-year follow-up (60 patients); well-conducted but pilot-sized, limiting power to detect small differences.

Study Details

PMID:26355169
Participants:60
Impact:no significant difference (P=0.91)
Trust score:4/5

Randomized trial comparing bovine bone vs synthetic β-tricalcium phosphate grafts for horizontal bone augmentation found no significant differences in bone loss, complications, or patient-reported outcomes at 3 years.

Trust comment: Randomized, double-blind RCT with 3-year follow-up but modest sample size limiting precision.

Study Details

PMID:30515484
Participants:50
Impact:6 complications in 5 patients (BB) vs 3 in 3 patients (CJ); RR 1.32, P=1.00
Trust score:4/5

implant failure

1 evidences

Randomized trial comparing bovine bone vs synthetic β-tricalcium phosphate grafts for horizontal bone augmentation found no significant differences in bone loss, complications, or patient-reported outcomes at 3 years.

Trust comment: Randomized, double-blind RCT with 3-year follow-up but modest sample size limiting precision.

Study Details

PMID:30515484
Participants:50
Impact:no implant failures in either group
Trust score:4/5

MSH2/mib-1 ratio

1 evidences

In a 1-year randomized trial, vitamin D with or without calcium (1200 mg) tended to increase MSH2 relative to proliferation and TGFβ1 and decrease TGFα/TGFβ1 in normal colorectal mucosa, but changes were not statistically significant.

Trust comment: Pilot randomized, double-blind trial with biomarker endpoints and modest sample size; most changes were not statistically significant.

Study Details

PMID:30499618
Participants:104
Impact:+47% (vitamin D alone) and +62% (vitamin D + calcium) in upper crypts (not statistically significant)
Trust score:3/5

TGF‑β1 expression

1 evidences

In a 1-year randomized trial, vitamin D with or without calcium (1200 mg) tended to increase MSH2 relative to proliferation and TGFβ1 and decrease TGFα/TGFβ1 in normal colorectal mucosa, but changes were not statistically significant.

Trust comment: Pilot randomized, double-blind trial with biomarker endpoints and modest sample size; most changes were not statistically significant.

Study Details

PMID:30499618
Participants:104
Impact:+41% (vitamin D) and +78% (vitamin D + calcium) in upper crypts (not statistically significant)
Trust score:3/5

TGFα/TGFβ1 ratio

1 evidences

In a 1-year randomized trial, vitamin D with or without calcium (1200 mg) tended to increase MSH2 relative to proliferation and TGFβ1 and decrease TGFα/TGFβ1 in normal colorectal mucosa, but changes were not statistically significant.

Trust comment: Pilot randomized, double-blind trial with biomarker endpoints and modest sample size; most changes were not statistically significant.

Study Details

PMID:30499618
Participants:104
Impact:−25% (vitamin D) and −44% (vitamin D + calcium) in upper crypts (not statistically significant)
Trust score:3/5

24 h urinary albumin/protein

1 evidences

In 100 DKD patients randomized to calcium dobesilate for 3 months, albuminuria and urinary protein decreased and inflammatory and endothelial-dysfunction markers improved, while GFR was unchanged.

Trust comment: Prospective randomized controlled study (n=100) showing short-term improvements in albuminuria and biomarkers; 3-month duration limits long-term inference.

Study Details

PMID:30476916
Participants:100
Impact:significant decrease after 3 months of calcium dobesilate treatment
Trust score:4/5

inflammatory markers (PTX3, MCP-1, hsCRP, ICAM)

1 evidences

In 100 DKD patients randomized to calcium dobesilate for 3 months, albuminuria and urinary protein decreased and inflammatory and endothelial-dysfunction markers improved, while GFR was unchanged.

Trust comment: Prospective randomized controlled study (n=100) showing short-term improvements in albuminuria and biomarkers; 3-month duration limits long-term inference.

Study Details

PMID:30476916
Participants:100
Impact:significant decreases post-treatment
Trust score:4/5

endothelial markers (VEGF, ET-1, NO)

1 evidences

In 100 DKD patients randomized to calcium dobesilate for 3 months, albuminuria and urinary protein decreased and inflammatory and endothelial-dysfunction markers improved, while GFR was unchanged.

Trust comment: Prospective randomized controlled study (n=100) showing short-term improvements in albuminuria and biomarkers; 3-month duration limits long-term inference.

Study Details

PMID:30476916
Participants:100
Impact:VEGF and ET-1 decreased; NO significantly increased post-treatment
Trust score:4/5

IGF1 (mid-childhood)

1 evidences

Maternal supplementation with 1500 mg Ca/day in pregnancy led to higher IGF1 in boys but lower IGF1 in girls at age ~7.5 years.

Trust comment: Randomized maternal calcium vs placebo with 290 children assessed at 7.5 years and reported precise biochemical outcomes, supporting moderate–high trust.

Study Details

PMID:30465917
Participants:290
Impact:boys +14.2% (M-Ca vs M-P); girls −17.8% (F-Ca vs F-P)
Trust score:4/5

IGFBP3 (mid-childhood)

1 evidences

Maternal supplementation with 1500 mg Ca/day in pregnancy led to higher IGF1 in boys but lower IGF1 in girls at age ~7.5 years.

Trust comment: Randomized maternal calcium vs placebo with 290 children assessed at 7.5 years and reported precise biochemical outcomes, supporting moderate–high trust.

Study Details

PMID:30465917
Participants:290
Impact:sex-specific interaction observed (direction similar to IGF1; group differences smaller; exact % not reported)
Trust score:4/5

apical radiolucency resolution (percentage reduction at 3 months)

1 evidences

In root canal treatment, calcium hydroxide with or without 2% chlorhexidine both led to large radiographic reduction of apical radiolucency at 3 months; combination showed numerically greater but not statistically significant healing.

Trust comment: Randomized clinical dental trial with 60 patients and objective radiographic outcome, but limited sample and single follow-up at 3 months.

Study Details

PMID:30465358
Participants:60
Impact:Ca(OH)2 alone 91.03% vs Ca(OH)2+2% CHX 97.26% (difference not statistically significant, p=0.13)
Trust score:3/5

ionized calcium (serum)

1 evidences

Healthy men given 200 g/day fructose for two weeks had higher serum uric acid, a small drop in ionized calcium with higher PTH, lower urine pH, higher urinary oxalate and lower urine magnesium—changes that raise kidney-stone risk.

Trust comment: Within-subject pre–post study in 33 men with robust lab measures; single-arm reporting and high fructose dose limit generalizability.

Study Details

PMID:30409184
Participants:33
Impact:decreased −0.017 ±0.030 mmol/L (p=0.003)
Trust score:3/5

processing speed

1 evidences

A Mediterranean diet supplemented with dairy (to meet calcium needs) improved processing speed and multiple mood measures versus a low-fat control in older adults at cardiovascular risk.

Trust comment: Randomized crossover RCT with n=41 and objective cognitive/mood measures, but modest sample size and short (8-week) interventions.

Study Details

PMID:30409085
Participants:41
Impact:improved (p=0.04)
Trust score:3/5

total mood disturbance

1 evidences

A Mediterranean diet supplemented with dairy (to meet calcium needs) improved processing speed and multiple mood measures versus a low-fat control in older adults at cardiovascular risk.

Trust comment: Randomized crossover RCT with n=41 and objective cognitive/mood measures, but modest sample size and short (8-week) interventions.

Study Details

PMID:30409085
Participants:41
Impact:reduced (improved) (p=0.01)
Trust score:3/5

depression

1 evidences

A Mediterranean diet supplemented with dairy (to meet calcium needs) improved processing speed and multiple mood measures versus a low-fat control in older adults at cardiovascular risk.

Trust comment: Randomized crossover RCT with n=41 and objective cognitive/mood measures, but modest sample size and short (8-week) interventions.

Study Details

PMID:30409085
Participants:41
Impact:reduced (improved) (p=0.03)
Trust score:3/5

plasma calcium concentration

2 evidences

Randomized double-blind trial in obese hypertensive adults: 3 months of Spirulina (2 g/day) decreased serum iron but did not markedly change serum calcium or magnesium.

Trust comment: Well-conducted randomized double-blind placebo-controlled trial (n=50) with ITT analysis; significant finding limited to iron only.

Study Details

PMID:26779620
Participants:50
Impact:+0.14 mmol/L (3.41 → 3.55 mmol/L), non-significant (p=0.202)
Trust score:4/5

In hemodialysis patients, L-carnitine supplementation increased plasma calcium and phosphate but did not change PTH or FGF23 over one year.

Trust comment: Multicentre double-blind randomized trial (n=92, 1 year) with appropriate design; some assay limits noted for Klotho measurements but overall moderate–high quality.

Study Details

PMID:30408788
Participants:92
Impact:increased (greater rise in L-carnitine group vs placebo)
Trust score:4/5

plasma phosphate concentration

1 evidences

In hemodialysis patients, L-carnitine supplementation increased plasma calcium and phosphate but did not change PTH or FGF23 over one year.

Trust comment: Multicentre double-blind randomized trial (n=92, 1 year) with appropriate design; some assay limits noted for Klotho measurements but overall moderate–high quality.

Study Details

PMID:30408788
Participants:92
Impact:increased (greater rise in L-carnitine group vs placebo)
Trust score:4/5

25(OH)D (vitamin D)

2 evidences

Three‑month randomized, placebo‑controlled pilot in children with celiac disease: prebiotic (Synergy 1) increased vitamin D and E levels but did not change serum mineral concentrations overall.

Trust comment: Randomized, double‑blind placebo‑controlled pilot with 30 completers but small sample size limits precision.

Study Details

PMID:30445682
Participants:30
Impact:Median plasma 25(OH)D increased by +42% (to 28.57 ng/mL) in Synergy 1 group (p=0.012) vs no change in placebo
Trust score:3/5

12‑week double‑blind RCT in CKD 3–4 patients: daily 8000 IU cholecalciferol raised 25(OH)D, increased 1,25(OH)D and mitigated further rises in PTH versus placebo, without hypercalcaemia.

Trust comment: Large, double‑blind randomized placebo‑controlled trial with predefined endpoints and safety monitoring; clinically relevant biochemical outcomes.

Study Details

PMID:29156056
Participants:95
Impact:+104.1 nmol/L (57.5 → 161.6 nmol/L) in treatment group
Trust score:5/5

Vitamin E (α‑tocopherol)

1 evidences

Three‑month randomized, placebo‑controlled pilot in children with celiac disease: prebiotic (Synergy 1) increased vitamin D and E levels but did not change serum mineral concentrations overall.

Trust comment: Randomized, double‑blind placebo‑controlled pilot with 30 completers but small sample size limits precision.

Study Details

PMID:30445682
Participants:30
Impact:Mean vitamin E increased by +19% (to 27.46 µmol/L) in Synergy 1 group (p=0.031) vs no change in placebo
Trust score:3/5

True fractional calcium absorption (TFCA)

1 evidences

26‑week randomized, double‑blind trial of two PPIs vs placebo in postmenopausal women found no clinically meaningful effects on calcium absorption, BMD, or mineral levels despite increases in bone‑turnover markers.

Trust comment: Well‑conducted randomized trial with adequate sample size for primary outcomes, but 26 weeks may be short for long‑term bone outcomes.

Study Details

PMID:30445008
Participants:115
Impact:No reduction in TFCA with PPI therapy (no significant between‑group change)
Trust score:3/5

bone turnover markers (P1NP, CTx)

1 evidences

26‑week randomized, double‑blind trial of two PPIs vs placebo in postmenopausal women found no clinically meaningful effects on calcium absorption, BMD, or mineral levels despite increases in bone‑turnover markers.

Trust comment: Well‑conducted randomized trial with adequate sample size for primary outcomes, but 26 weeks may be short for long‑term bone outcomes.

Study Details

PMID:30445008
Participants:115
Impact:Esomeprazole and dexlansoprazole groups showed increases vs placebo: P1NP +18.2% and +19.2%; CTX +22.0% and +27.4%, but values remained within normal ranges
Trust score:3/5

Serum/urine minerals, BMD, PTH

1 evidences

26‑week randomized, double‑blind trial of two PPIs vs placebo in postmenopausal women found no clinically meaningful effects on calcium absorption, BMD, or mineral levels despite increases in bone‑turnover markers.

Trust comment: Well‑conducted randomized trial with adequate sample size for primary outcomes, but 26 weeks may be short for long‑term bone outcomes.

Study Details

PMID:30445008
Participants:115
Impact:No significant changes between groups at 26 weeks
Trust score:3/5

homocysteine

2 evidences

Randomized placebo‑controlled trial: weekly high‑dose vitamin D3 for 2 months increased 25(OH)D and serum calcium/phosphorus, lowered PTH, homocysteine, body weight and BMI in overweight reproductive‑age women.

Trust comment: Randomized, double‑blind trial with 100 participants and clear reported effects, but short follow‑up (2 months) and limited detail on magnitudes for some outcomes.

Study Details

PMID:30442234
Participants:100
Impact:Significant decrease after 1 and 2 months of vitamin D3 (treatment vs placebo)
Trust score:3/5

Randomized single-blinded study where both arms received vitamin D plus 800 mg calcium; adding B vitamins produced larger reductions in plasma TMAO and lowered homocysteine compared with vitamin D (with calcium) alone.

Trust comment: Small randomized but non-placebo-controlled trial; calcium was co-administered in both arms so effects cannot be attributed to calcium specifically.

Study Details

PMID:27569255
Participants:52
Impact:decreased with vitamin D + B vitamins compared with vitamin D alone
Trust score:3/5

body weight / BMI

2 evidences

Crossover RCT: eating two calcium-fortified cereal bars daily for 3 weeks significantly increased women's dietary calcium intake (~+360 mg/day) without increasing energy intake or body weight.

Trust comment: Checklist: 1) Confirm relevance to Calcium (dietary calcium intervention); 2) extract main outcomes (calcium intake, energy, weight); 3) record participants (completed n=35); 4) rate trust — randomized crossover RCT with good compliance and appropriate dietary assessment but small sample and short duration.

Study Details

PMID:25941810
Participants:35
Impact:no significant change over the intervention period
Trust score:4/5

Randomized placebo‑controlled trial: weekly high‑dose vitamin D3 for 2 months increased 25(OH)D and serum calcium/phosphorus, lowered PTH, homocysteine, body weight and BMI in overweight reproductive‑age women.

Trust comment: Randomized, double‑blind trial with 100 participants and clear reported effects, but short follow‑up (2 months) and limited detail on magnitudes for some outcomes.

Study Details

PMID:30442234
Participants:100
Impact:Significant reductions in body weight and BMI in vitamin D3 group vs placebo (reported as statistically significant; exact values not provided)
Trust score:3/5

25(OH)D, calcium, phosphorus, PTH

1 evidences

Randomized placebo‑controlled trial: weekly high‑dose vitamin D3 for 2 months increased 25(OH)D and serum calcium/phosphorus, lowered PTH, homocysteine, body weight and BMI in overweight reproductive‑age women.

Trust comment: Randomized, double‑blind trial with 100 participants and clear reported effects, but short follow‑up (2 months) and limited detail on magnitudes for some outcomes.

Study Details

PMID:30442234
Participants:100
Impact:25(OH)D, calcium and phosphorus increased significantly; PTH decreased significantly in treatment group
Trust score:3/5

BMI and waist circumference

1 evidences

Randomized study in obese vitamin‑D‑deficient women: combined high‑dose cholecalciferol plus calcium with a weight‑loss diet produced larger decreases in weight, BMI, waist circumference, body fat, glycemia, PTH and lipids vs controls.

Trust comment: Randomized intervention with reported large effects but small sample (45) and limited methodological detail; risk of bias and confounding possible.

Study Details

PMID:30442233
Participants:45
Impact:BMI −4.61 ± 2 kg/m2; waist −11.41 ± 8.9 cm (Diet/Ca/D vs Diet/Ca and control)
Trust score:3/5

PTH, fasting blood glucose, lipids

1 evidences

Randomized study in obese vitamin‑D‑deficient women: combined high‑dose cholecalciferol plus calcium with a weight‑loss diet produced larger decreases in weight, BMI, waist circumference, body fat, glycemia, PTH and lipids vs controls.

Trust comment: Randomized intervention with reported large effects but small sample (45) and limited methodological detail; risk of bias and confounding possible.

Study Details

PMID:30442233
Participants:45
Impact:PTH −27.58 pg/mL; FBG −25.81 mg/dL; Total cholesterol −0.56 mmol/L; Triglycerides −0.53 mmol/L (Diet/Ca/D vs Diet/Ca and control)
Trust score:3/5

bone union progression

1 evidences

Randomized trial in 54 patients comparing tri-calcium phosphate (TCP) granules versus allogenous bone chip for bone grafting in opening wedge high tibial osteotomy; bone union and clinical scores were similar between groups.

Trust comment: Prospective randomized controlled trial (Level 1) with clear clinical and radiographic endpoints but modest sample size (n=54).

Study Details

PMID:30377715
Participants:54
Impact:no significant difference between TCP and allogenous bone chip
Trust score:4/5

WOMAC score

1 evidences

Randomized trial in 54 patients comparing tri-calcium phosphate (TCP) granules versus allogenous bone chip for bone grafting in opening wedge high tibial osteotomy; bone union and clinical scores were similar between groups.

Trust comment: Prospective randomized controlled trial (Level 1) with clear clinical and radiographic endpoints but modest sample size (n=54).

Study Details

PMID:30377715
Participants:54
Impact:no significant difference between groups
Trust score:4/5

Pain (VAS score)

1 evidences

Randomized trial in 54 patients comparing tri-calcium phosphate (TCP) granules versus allogenous bone chip for bone grafting in opening wedge high tibial osteotomy; bone union and clinical scores were similar between groups.

Trust comment: Prospective randomized controlled trial (Level 1) with clear clinical and radiographic endpoints but modest sample size (n=54).

Study Details

PMID:30377715
Participants:54
Impact:no significant difference between groups
Trust score:4/5

Intact PTH (iPTH)

4 evidences

Randomized placebo-controlled 16-week trial in vitamin D-deficient overweight/obese adults: cholecalciferol raised 25(OH)D and lowered iPTH but did not change serum calcium, phosphate, iFGF-23, or whole-body BMD.

Trust comment: Randomized placebo-controlled trial with objective biochemical and BMD endpoints; moderate sample size and 16-week duration limits long-term inference.

Study Details

PMID:30367939
Participants:54
Impact:decreased with cholecalciferol
Trust score:4/5

12‑week double‑blind RCT in CKD 3–4 patients: daily 8000 IU cholecalciferol raised 25(OH)D, increased 1,25(OH)D and mitigated further rises in PTH versus placebo, without hypercalcaemia.

Trust comment: Large, double‑blind randomized placebo‑controlled trial with predefined endpoints and safety monitoring; clinically relevant biochemical outcomes.

Study Details

PMID:29156056
Participants:95
Impact:Mean change −0.7 pmol/L (treatment) vs +1.6 pmol/L (placebo); between-group difference ~−2.3 pmol/L (P=0.0048)
Trust score:5/5

12-month randomized trial in 30 kidney transplant recipients with hypercalcemia: subtotal parathyroidectomy normalized serum calcium in all patients and produced larger iPTH reductions and a significant increase in femoral neck BMD compared with cinacalcet.

Trust comment: Prospective randomized multicenter study with clinically relevant endpoints but small sample size and open-label design.

Study Details

PMID:26647424
Participants:30
Impact:greater reduction with parathyroidectomy (exact magnitude not reported)
Trust score:4/5

Extended-release calcifediol normalized 25-hydroxyvitamin D and progressively reduced PTH with minimal effect on serum calcium in CKD patients.

Trust comment: Large multicenter randomized double-blind placebo-controlled trials with high completion rates; high-quality evidence for CKD population.

Study Details

PMID:27676085
Participants:429
Impact:≥10% reduction in 72% of subjects; ≥30% reductions in 22% (12w), 40% (26w), 50% (52w)
Trust score:5/5

serum calcium / phosphate / iFGF-23 / whole-body BMD

1 evidences

Randomized placebo-controlled 16-week trial in vitamin D-deficient overweight/obese adults: cholecalciferol raised 25(OH)D and lowered iPTH but did not change serum calcium, phosphate, iFGF-23, or whole-body BMD.

Trust comment: Randomized placebo-controlled trial with objective biochemical and BMD endpoints; moderate sample size and 16-week duration limits long-term inference.

Study Details

PMID:30367939
Participants:54
Impact:no significant change with cholecalciferol
Trust score:4/5

serum-corrected calcium (PD)

1 evidences

Randomized, double-blind two-period cross-over PK/PD study in 54 healthy pre-menopausal women comparing biosimilar RGB-10 and reference teriparatide; pharmacokinetics and serum-calcium responses were highly similar and bioequivalence criteria met.

Trust comment: Well-conducted randomized crossover PK/PD study in healthy volunteers with robust bioequivalence and PD (serum calcium) assessments.

Study Details

PMID:30357438
Participants:54
Impact:no clinically significant difference between RGB-10 and reference (GMR ≈99.9% for AUC and Cmax)
Trust score:4/5

teriparatide exposure (AUC, Cmax)

1 evidences

Randomized, double-blind two-period cross-over PK/PD study in 54 healthy pre-menopausal women comparing biosimilar RGB-10 and reference teriparatide; pharmacokinetics and serum-calcium responses were highly similar and bioequivalence criteria met.

Trust comment: Well-conducted randomized crossover PK/PD study in healthy volunteers with robust bioequivalence and PD (serum calcium) assessments.

Study Details

PMID:30357438
Participants:54
Impact:8–10% lower for RGB-10 vs reference but 94.12% CIs within 80–125% bioequivalence range
Trust score:4/5

post-operative hypocalcaemia

1 evidences

Preoperative high-dose vitamin D vs placebo in thyroidectomy patients: overall no significant reduction in postoperative hypocalcaemia, but benefit seen in a subgroup after stratification by day-1 PTH.

Trust comment: Randomized, double-blind, placebo-controlled trial with clear calcium-related clinical endpoints; good quality though many participants were vitamin D replete at baseline.

Study Details

PMID:30387163
Participants:150
Impact:29% (cholecalciferol) vs 38% (placebo), −9 ppt (P=0.23); subgroup HR 0.56 (P=0.04)
Trust score:4/5

secondary calcium-related endpoints

1 evidences

Preoperative high-dose vitamin D vs placebo in thyroidectomy patients: overall no significant reduction in postoperative hypocalcaemia, but benefit seen in a subgroup after stratification by day-1 PTH.

Trust comment: Randomized, double-blind, placebo-controlled trial with clear calcium-related clinical endpoints; good quality though many participants were vitamin D replete at baseline.

Study Details

PMID:30387163
Participants:150
Impact:no overall between-group differences
Trust score:4/5

serum calcium (albumin-corrected)

1 evidences

4-week study of patiromer in hyperkalemic patients showing no change in serum calcium but reductions in urine phosphate and decreases in intact PTH and 1,25-dihydroxyvitamin D.

Trust comment: Human randomized study with relevant mineral metabolism markers, but short duration and exploratory/post-hoc analyses limit strength for calcium-specific conclusions.

Study Details

PMID:30381412
Participants:112
Impact:0.0 ± 0.5 mg/dL (no change, P=0.78)
Trust score:3/5

24-hour urine phosphate

1 evidences

4-week study of patiromer in hyperkalemic patients showing no change in serum calcium but reductions in urine phosphate and decreases in intact PTH and 1,25-dihydroxyvitamin D.

Trust comment: Human randomized study with relevant mineral metabolism markers, but short duration and exploratory/post-hoc analyses limit strength for calcium-specific conclusions.

Study Details

PMID:30381412
Participants:112
Impact:median −43.0 mg/24h (P=0.004)
Trust score:3/5

iPTH percent change

1 evidences

Randomized dose-finding trial in hemodialysis patients with secondary hyperparathyroidism showing dose-dependent decreases in iPTH and associated decreases in calcium/phosphate parameters for active arms.

Trust comment: Well-designed randomized, double-blind dose-finding study with objective biochemical endpoints; short treatment period (3 weeks) is a limitation.

Study Details

PMID:30379826
Participants:151
Impact:evocalcet 1 mg −10.56%, 2 mg −20.16% vs placebo +5.44% (EOT)
Trust score:4/5

Corrected calcium

1 evidences

Randomized dose-finding trial in hemodialysis patients with secondary hyperparathyroidism showing dose-dependent decreases in iPTH and associated decreases in calcium/phosphate parameters for active arms.

Trust comment: Well-designed randomized, double-blind dose-finding study with objective biochemical endpoints; short treatment period (3 weeks) is a limitation.

Study Details

PMID:30379826
Participants:151
Impact:decrease observed in evocalcet and cinacalcet groups (time-course decrease from baseline)
Trust score:4/5

wound healing time

1 evidences

Small randomized study of calcium alginate dressing vs petrolatum gauze after great-toe nail surgery: dressing reduced bleeding, pain duration, and shortened wound healing time.

Trust comment: Randomized but small sample and limited reporting; direct study of a calcium-containing dressing with significant clinical outcomes reported.

Study Details

PMID:30378323
Participants:40
Impact:9.40 days vs 11.35 days (−1.95 days, P<0.05)
Trust score:3/5

pain duration (median)

1 evidences

Small randomized study of calcium alginate dressing vs petrolatum gauze after great-toe nail surgery: dressing reduced bleeding, pain duration, and shortened wound healing time.

Trust comment: Randomized but small sample and limited reporting; direct study of a calcium-containing dressing with significant clinical outcomes reported.

Study Details

PMID:30378323
Participants:40
Impact:24 h (treatment) vs 72 h (control)
Trust score:3/5

postoperative bleeding

1 evidences

Small randomized study of calcium alginate dressing vs petrolatum gauze after great-toe nail surgery: dressing reduced bleeding, pain duration, and shortened wound healing time.

Trust comment: Randomized but small sample and limited reporting; direct study of a calcium-containing dressing with significant clinical outcomes reported.

Study Details

PMID:30378323
Participants:40
Impact:fewer bleeding cases in treatment group (P<0.05)
Trust score:3/5

morning systolic blood pressure

1 evidences

Adding 3–4 servings/day of dairy to a Mediterranean diet for 8 weeks modestly improved blood pressure and some lipid markers in people at CVD risk.

Trust comment: Randomized, controlled crossover trial directly increasing dietary calcium via dairy; moderate quality but small sample size (n=41).

Study Details

PMID:30351388
Participants:41
Impact:-1.6 mm Hg (mean difference vs control)
Trust score:4/5

clinic systolic blood pressure

1 evidences

Adding 3–4 servings/day of dairy to a Mediterranean diet for 8 weeks modestly improved blood pressure and some lipid markers in people at CVD risk.

Trust comment: Randomized, controlled crossover trial directly increasing dietary calcium via dairy; moderate quality but small sample size (n=41).

Study Details

PMID:30351388
Participants:41
Impact:-3.5 mm Hg (mean difference vs control)
Trust score:4/5

coronal surface caries progression

1 evidences

In head-and-neck radiotherapy patients, adding CPP-ACP (a calcium phosphate–containing crème) to fluoride significantly reduced coronal surface caries progression.

Trust comment: Randomized controlled trial directly testing a calcium–phosphate containing biomimetic (CPP-ACP) with fluoride; small sample but clinically relevant outcome.

Study Details

PMID:30341773
Participants:24
Impact:-51% (significant reduction vs placebo, P < 0.05)
Trust score:4/5

resting salivary flow rate

1 evidences

In head-and-neck radiotherapy patients, adding CPP-ACP (a calcium phosphate–containing crème) to fluoride significantly reduced coronal surface caries progression.

Trust comment: Randomized controlled trial directly testing a calcium–phosphate containing biomimetic (CPP-ACP) with fluoride; small sample but clinically relevant outcome.

Study Details

PMID:30341773
Participants:24
Impact:significantly reduced post-radiotherapy in both groups (P < 0.001)
Trust score:4/5

calcium intake (dietary)

1 evidences

An 8-week intensive lifestyle program in children with abdominal obesity increased diet quality and improved some micronutrient intakes including calcium and vitamin D, and reduced BMI-SDS.

Trust comment: Randomized controlled lifestyle intervention with objective dietary and clinical measures and a moderate sample (n=107).

Study Details

PMID:30322156
Participants:107
Impact:increased (higher intake and improved compliance vs usual care)
Trust score:4/5

Vitamin D adequacy

1 evidences

An 8-week intensive lifestyle program in children with abdominal obesity increased diet quality and improved some micronutrient intakes including calcium and vitamin D, and reduced BMI-SDS.

Trust comment: Randomized controlled lifestyle intervention with objective dietary and clinical measures and a moderate sample (n=107).

Study Details

PMID:30322156
Participants:107
Impact:+10 percentage points compliance (51%→61%) in intensive care
Trust score:4/5

Pulpotomy success rate (clinical/radiographic)

1 evidences

Split-mouth trial in children comparing 5% sodium hypochlorite vs saline as haemostatic agents during calcium hydroxide pulpotomies found no significant difference in 12-month clinical/radiographic success.

Trust comment: Small randomized split-mouth clinical trial with objective outcomes but limited sample size (n=30).

Study Details

PMID:30317420
Participants:30
Impact:no significant difference at 12 months; 5% NaOCl showed lower success (not statistically significant)
Trust score:3/5

Serum chloride (Cl-)

1 evidences

Randomized trial in septic shock patients comparing 0.9% NaCl, Ringer, and an acetate-sodium-potassium-magnesium-calcium-glucose solution; 0.9% NaCl caused more hyperchloraemia and lower serum Ca2+ early after resuscitation.

Trust comment: Large randomized trial (n=280) with serial biochemical measures; clear differences in electrolytes but single-center study.

Study Details

PMID:30309406
Participants:280
Impact:Higher in 0.9% NaCl group at 24 h (107.5±5.6 vs 106.1±4.8 and 105.1±4.2 mmol/L)
Trust score:4/5

Lumbar spine BMD / T-score / Z-score

1 evidences

18-month randomized double-blind trial of three calcium/vitamin-fortified dairy products found improvement in lumbar spine bone measures and changes in bone resorption markers, with no differences between products.

Trust comment: Randomized double-blind trial with substantial sample (n=210) and DEXA/biomarker endpoints, though reporting across multiple sites was mixed.

Study Details

PMID:30307302
Participants:210
Impact:increased (reported improvement in lumbar spine after treatment)
Trust score:4/5

TRAP (bone resorption marker)

1 evidences

18-month randomized double-blind trial of three calcium/vitamin-fortified dairy products found improvement in lumbar spine bone measures and changes in bone resorption markers, with no differences between products.

Trust comment: Randomized double-blind trial with substantial sample (n=210) and DEXA/biomarker endpoints, though reporting across multiple sites was mixed.

Study Details

PMID:30307302
Participants:210
Impact:+20.7% to +29.5%
Trust score:4/5

MCP-1 (inflammation)

1 evidences

In obese adults with vitamin D deficiency, adding high-dose weekly vitamin D to a weight-loss diet raised vitamin D levels and reduced PTH, inflammatory markers, and fat mass.

Trust comment: Double-blind randomized controlled trial but small sample (n=44); endpoints and statistical significance are clearly reported.

Study Details

PMID:30246883
Participants:44
Impact:significant decrease (P<0.05)
Trust score:3/5

whole-body bone mineral density (BMD)

1 evidences

In patients with type 2 diabetes, 500 mg/day resveratrol for 6 months modestly improved whole-body bone density and content and altered phosphorus and vitamin D markers compared to placebo.

Trust comment: Large, double-blind randomized placebo-controlled trial with centralized DXA and biochemical measures; high internal validity for measured endpoints.

Study Details

PMID:30237505
Participants:179
Impact:adjusted mean difference vs placebo +0.03 g/cm² (95% CI 0.02–0.05), P<0.001
Trust score:4/5

Whole-body bone mineral content (BMC)

1 evidences

In patients with type 2 diabetes, 500 mg/day resveratrol for 6 months modestly improved whole-body bone density and content and altered phosphorus and vitamin D markers compared to placebo.

Trust comment: Large, double-blind randomized placebo-controlled trial with centralized DXA and biochemical measures; high internal validity for measured endpoints.

Study Details

PMID:30237505
Participants:179
Impact:adjusted mean difference vs placebo +63.8 g (95% CI 30.9–96.7), P<0.001
Trust score:4/5

operation time

2 evidences

In thyroidectomy patients, use of the LigaSure Small Jaw reduced operative time and intraoperative bleeding and was associated with less symptomatic hypocalcemia and smaller postoperative decreases in total and ionized calcium compared to conventional clamp-and-tie.

Trust comment: Large randomized controlled trial with objective calcium measurements and clinically relevant endpoints; single-surgeon and single-blind limitations noted.

Study Details

PMID:30236136
Participants:535
Impact:reduction with LSJ vs HS: ≈56 min less (total thyroidectomy) and ≈21 min less (subtotal), P<0.01
Trust score:4/5

Randomized trial in adults: percutaneous fixation with calcium sulfate cement (CSC) had shorter operation time and fewer wound-healing complications than minimally invasive sinus tarsi plate fixation; overall functional scores were similar.

Trust comment: Prospective randomized trial with clear clinical endpoints but modest sample size and some loss to follow-up.

Study Details

PMID:27422705
Participants:80
Impact:PR+CSC 39.7 min vs MISTA 64.2 min (operation time -24.5 min)
Trust score:4/5

symptomatic hypocalcemia (total thyroidectomy)

1 evidences

In thyroidectomy patients, use of the LigaSure Small Jaw reduced operative time and intraoperative bleeding and was associated with less symptomatic hypocalcemia and smaller postoperative decreases in total and ionized calcium compared to conventional clamp-and-tie.

Trust comment: Large randomized controlled trial with objective calcium measurements and clinically relevant endpoints; single-surgeon and single-blind limitations noted.

Study Details

PMID:30236136
Participants:535
Impact:HS 12.6% vs LSJ 8.1% (reduction ≈4.5 percentage points), P=0.03
Trust score:4/5

postoperative total and ionized calcium levels

1 evidences

In thyroidectomy patients, use of the LigaSure Small Jaw reduced operative time and intraoperative bleeding and was associated with less symptomatic hypocalcemia and smaller postoperative decreases in total and ionized calcium compared to conventional clamp-and-tie.

Trust comment: Large randomized controlled trial with objective calcium measurements and clinically relevant endpoints; single-surgeon and single-blind limitations noted.

Study Details

PMID:30236136
Participants:535
Impact:less severe postoperative decrease with LSJ vs HS (P<0.01)
Trust score:4/5

IPC clinical success (tooth vitality)

1 evidences

In teeth with reversible pulpitis, indirect pulp capping with either calcium silicate cement (Biodentine™) or glass ionomer (Fuji IX™) showed similar clinical success and restoration integrity at 2 years (overall IPC success 72%).

Trust comment: Randomized clinical trial but small sample and outcome is dental-material specific; relevant to calcium-containing restorative material rather than systemic Calcium.

Study Details

PMID:30232625
Participants:53
Impact:overall 72% success at 24 months; no difference between Biodentine and Fuji IX
Trust score:3/5

restoration integrity (USPHS/FDI criteria)

1 evidences

In teeth with reversible pulpitis, indirect pulp capping with either calcium silicate cement (Biodentine™) or glass ionomer (Fuji IX™) showed similar clinical success and restoration integrity at 2 years (overall IPC success 72%).

Trust comment: Randomized clinical trial but small sample and outcome is dental-material specific; relevant to calcium-containing restorative material rather than systemic Calcium.

Study Details

PMID:30232625
Participants:53
Impact:no difference between materials at 12 and 24 months
Trust score:3/5

urinary citrate and pH

1 evidences

A limeade-based supplement (containing potassium and citrate) for 6 months increased urinary pH, citrate and potassium excretion, reduced urinary calcium and oxalate, improved antioxidant status and lowered urinary supersaturation in recurrent stone patients.

Trust comment: Phase 2 double-blind randomized placebo-controlled study with 74 patients showing consistent biochemical improvements relevant to calcium stone risk.

Study Details

PMID:30225852
Participants:74
Impact:significant increase with LPR vs placebo
Trust score:4/5

urinary total antioxidant status / supersaturation

1 evidences

A limeade-based supplement (containing potassium and citrate) for 6 months increased urinary pH, citrate and potassium excretion, reduced urinary calcium and oxalate, improved antioxidant status and lowered urinary supersaturation in recurrent stone patients.

Trust comment: Phase 2 double-blind randomized placebo-controlled study with 74 patients showing consistent biochemical improvements relevant to calcium stone risk.

Study Details

PMID:30225852
Participants:74
Impact:increased antioxidant status and decreased urinary supersaturation; no stone recurrence during trial
Trust score:4/5

pre-treatment serum calcium

1 evidences

Among children with ADHD treated with a broad-spectrum micronutrient formula, pre-treatment serum calcium levels did not meaningfully predict clinical response; overall, serum nutrient levels had limited value as predictors.

Trust comment: Secondary/exploratory analysis from a randomized trial with modest sample size; predictors are exploratory and not definitive.

Study Details

PMID:30217770
Participants:71
Impact:no consistent predictive association with treatment response
Trust score:3/5

overall treatment response predictors

1 evidences

Among children with ADHD treated with a broad-spectrum micronutrient formula, pre-treatment serum calcium levels did not meaningfully predict clinical response; overall, serum nutrient levels had limited value as predictors.

Trust comment: Secondary/exploratory analysis from a randomized trial with modest sample size; predictors are exploratory and not definitive.

Study Details

PMID:30217770
Participants:71
Impact:no single pre-treatment nutrient or demographic variable consistently predicted response across outcomes
Trust score:3/5

Michigan Diabetic Neuropathy Score (MDNS)

1 evidences

Adding calcium dobesilate to alprostadil improved neuropathy scores and overall effectiveness over 2 weeks.

Trust comment: Randomized clinical trial with clear clinical endpoints but short duration (2 weeks) and limited detail in the excerpt.

Study Details

PMID:30183208
Participants:120
Impact:decreased (significantly lower in combined treatment vs alprostadil alone after 2 weeks; p<0.05 or p<0.01)
Trust score:3/5

Michigan Neuropathy Screening Instrument (MNSI)

1 evidences

Adding calcium dobesilate to alprostadil improved neuropathy scores and overall effectiveness over 2 weeks.

Trust comment: Randomized clinical trial with clear clinical endpoints but short duration (2 weeks) and limited detail in the excerpt.

Study Details

PMID:30183208
Participants:120
Impact:decreased (significantly lower in combined treatment vs control; p<0.05 or p<0.01)
Trust score:3/5

tactile sensitivity

1 evidences

In adults with dentine hypersensitivity, a 5% CSPS (calcium-containing) toothpaste reduced sensitivity within 1 week and provided continued benefit over 11 weeks, with similar efficacy to an 8% arginine/calcium carbonate paste.

Trust comment: Randomized, examiner-blind controlled trial with objective clinical measures; exploratory but adequately conducted.

Study Details

PMID:28219674
Participants:135
Impact:statistically significant reduction from baseline; significant benefit vs fluoride control by Week 11
Trust score:4/5

hydroxyapatite crystallization potential

1 evidences

First-in-human double-blind randomized study (20 healthy volunteers, 8 haemodialysis patients) found IV SNF472 was well tolerated and markedly reduced hydroxyapatite crystallization potential in HD patients.

Trust comment: Early-phase randomized, placebo-controlled human study with clear pharmacodynamic effect on hydroxyapatite formation but small sample size.

Study Details

PMID:30280390
Participants:28
Impact:Reduced by 80.0% ± 2.4% with SNF472 9 mg/kg vs 8.7% ± 21.0% with placebo in HD patients (P < 0.001)
Trust score:3/5

low calcium intake prevalence

1 evidences

Measured how commercial infant products and fortified staple foods contributed to nutrient intakes in infants; found many children had low calcium intakes despite fortification.

Trust comment: Well-powered cohort with 24‑h recalls and clear reporting, but observational design, variable sample sizes across ages and potential recall/attrition biases limit causal inference.

Study Details

PMID:30216697
Participants:715
Impact:≈75% of children had low calcium intakes at 12 and 18 months
Trust score:3/5

calcium density of complementary diet

1 evidences

Measured how commercial infant products and fortified staple foods contributed to nutrient intakes in infants; found many children had low calcium intakes despite fortification.

Trust comment: Well-powered cohort with 24‑h recalls and clear reporting, but observational design, variable sample sizes across ages and potential recall/attrition biases limit causal inference.

Study Details

PMID:30216697
Participants:715
Impact:lower in fortified-staple consumers at 12 months vs nonconsumers
Trust score:3/5

adequacy for fortificant nutrients (all eight) at 12 months

1 evidences

Measured how commercial infant products and fortified staple foods contributed to nutrient intakes in infants; found many children had low calcium intakes despite fortification.

Trust comment: Well-powered cohort with 24‑h recalls and clear reporting, but observational design, variable sample sizes across ages and potential recall/attrition biases limit causal inference.

Study Details

PMID:30216697
Participants:715
Impact:51.4% of fortified-staple consumers vs 25.0% of nonconsumers had adequate intakes (>EAR) (P=0.005)
Trust score:3/5

6-minute walk distance

1 evidences

78 patients were randomized and 58 completed 12 months; Algisyl (injectable calcium alginate hydrogel) plus standard therapy improved exercise capacity and symptoms at 12 months but was associated with higher mortality in the treated group.

Trust comment: Randomized multicenter trial with modest sample size and open-label design; objective exercise outcomes improved but mortality signal raises safety concerns.

Study Details

PMID:26555602
Participants:58
Impact:statistically significant increase (P<0.001)
Trust score:3/5

Tooth colour change (ΔE)

1 evidences

Randomized double‑blind trial in 24 patients: adding CPP‑ACP reduced tooth sensitivity at day 3 and did not impair bleaching efficacy.

Trust comment: Randomized double‑blind placebo‑controlled trial (small sample, 24 participants) gives direct evidence for a calcium‑containing agent (CPP‑ACP); limited power but good internal validity.

Study Details

PMID:30121734
Participants:24
Impact:No significant difference between CPP‑ACP and placebo groups in overall colour change (ΔE)
Trust score:4/5

ECG peaked T‑wave frequency

1 evidences

In 58 hemodialysis patients with hyperkalemia, 3 weeks of calcium‑polystyrene sulfonate reduced serum potassium and phosphorus without causing volume overload or electrolyte imbalance.

Trust comment: Prospective randomized crossover trial (n=58) directly tests a calcium‑containing potassium binder with clear primary outcome improvement and assessment of safety.

Study Details

PMID:30109784
Participants:58
Impact:Peaked T‑wave less frequent with Ca‑PS (13.8% vs 31.03%, P<0.01)
Trust score:4/5

Serum phosphorus and serum calcium

1 evidences

In 58 hemodialysis patients with hyperkalemia, 3 weeks of calcium‑polystyrene sulfonate reduced serum potassium and phosphorus without causing volume overload or electrolyte imbalance.

Trust comment: Prospective randomized crossover trial (n=58) directly tests a calcium‑containing potassium binder with clear primary outcome improvement and assessment of safety.

Study Details

PMID:30109784
Participants:58
Impact:Serum phosphorus decreased with Ca‑PS; no significant change in serum calcium
Trust score:4/5

bacterial load reduction (S2 to S3, qPCR)

1 evidences

Randomized clinical trial of intracanal medications in infected single-rooted teeth comparing triple antibiotic solution vs calcium hydroxide in 2% chlorhexidine over 1 week.

Trust comment: Randomized clinical trial with qPCR bacterial quantification and adequate reporting; moderate sample (47 canals) and clinically relevant endpoint.

Study Details

PMID:30144986
Participants:47
Impact:Triple antibiotic: 97% reduction; calcium hydroxide/CHX: 39% reduction (only antibiotic group reached statistical significance, P < .01)
Trust score:4/5

qPCR-negative S3 samples

1 evidences

Randomized clinical trial of intracanal medications in infected single-rooted teeth comparing triple antibiotic solution vs calcium hydroxide in 2% chlorhexidine over 1 week.

Trust comment: Randomized clinical trial with qPCR bacterial quantification and adequate reporting; moderate sample (47 canals) and clinically relevant endpoint.

Study Details

PMID:30144986
Participants:47
Impact:Significantly more negative S3 samples in antibiotic group vs calcium hydroxide group (P < .05)
Trust score:4/5

procollagen I N‑terminal propeptide (bone turnover)

1 evidences

In post-RYGB patients given 1200 mg elemental calcium daily, calcium citrate and calcium carbonate produced similar small changes in PTH, but citrate produced larger reductions in bone turnover markers.

Trust comment: Double-blind randomized trial directly comparing two calcium formulations in humans; small sample limits precision but design is strong.

Study Details

PMID:30107042
Participants:39
Impact:−16.6% (citrate) vs −3.2% (carbonate), P=0.021
Trust score:4/5

osteocalcin (bone turnover)

1 evidences

In post-RYGB patients given 1200 mg elemental calcium daily, calcium citrate and calcium carbonate produced similar small changes in PTH, but citrate produced larger reductions in bone turnover markers.

Trust comment: Double-blind randomized trial directly comparing two calcium formulations in humans; small sample limits precision but design is strong.

Study Details

PMID:30107042
Participants:39
Impact:−17.2% (citrate) vs −4.3% (carbonate), P=0.007
Trust score:4/5

muscle thickness

1 evidences

In young men undergoing resistance training, supplementation with α‑HICA, HMB‑FA, or HMB‑Ca produced no added benefit to muscle thickness or performance versus placebo.

Trust comment: Double‑blind randomized human trial with clear negative findings; HMB‑Ca (a calcium salt of HMB) was studied but no calcium‑specific effects were reported.

Study Details

PMID:30102677
Participants:40
Impact:time‑dependent increase with training (P<0.001); no additional effect of any supplement (including HMB‑Ca)
Trust score:4/5

one‑repetition maximum (bench press and squat)

1 evidences

In young men undergoing resistance training, supplementation with α‑HICA, HMB‑FA, or HMB‑Ca produced no added benefit to muscle thickness or performance versus placebo.

Trust comment: Double‑blind randomized human trial with clear negative findings; HMB‑Ca (a calcium salt of HMB) was studied but no calcium‑specific effects were reported.

Study Details

PMID:30102677
Participants:40
Impact:improved with training (P<0.001); no between‑group (supplement) differences
Trust score:4/5

Wingate peak power / performance measures

1 evidences

In young men undergoing resistance training, supplementation with α‑HICA, HMB‑FA, or HMB‑Ca produced no added benefit to muscle thickness or performance versus placebo.

Trust comment: Double‑blind randomized human trial with clear negative findings; HMB‑Ca (a calcium salt of HMB) was studied but no calcium‑specific effects were reported.

Study Details

PMID:30102677
Participants:40
Impact:time improvements observed but no supplement group effects (no ergogenic effect)
Trust score:4/5

total fat intake

1 evidences

Adding walnuts to the diet increased intake of calcium and several fats and raised calories when intake was not calorie-controlled.

Trust comment: Well-powered randomized crossover trial (n=112) with controlled dietary assessment, though not primarily a calcium intervention.

Study Details

PMID:30068215
Participants:112
Impact:+379.0 ± 90.3 g (walnut-included) vs -136.5 ± 92.7 g (walnut-excluded); P < .01
Trust score:4/5

dentinal hypersensitivity (visual analog scale)

1 evidences

In 80 patients with dentinal hypersensitivity, topical 8% arginine–calcium carbonate toothpaste reduced sensitivity; combining the toothpaste with iontophoresis produced greater and faster reduction over 4 weeks.

Trust comment: Small clinical trial of a topical calcium-containing formulation showed benefit for dentinal hypersensitivity; methods and blinding are not well reported so risk of bias is moderate.

Study Details

PMID:30074006
Participants:80
Impact:significant reduction from week 1 through week 4 with 8% arginine–calcium carbonate plus iontophoresis versus toothpaste alone
Trust score:3/5

Schiff dentinal hypersensitivity score

1 evidences

In 80 patients with dentinal hypersensitivity, topical 8% arginine–calcium carbonate toothpaste reduced sensitivity; combining the toothpaste with iontophoresis produced greater and faster reduction over 4 weeks.

Trust comment: Small clinical trial of a topical calcium-containing formulation showed benefit for dentinal hypersensitivity; methods and blinding are not well reported so risk of bias is moderate.

Study Details

PMID:30074006
Participants:80
Impact:significant improvement with combined iontophoresis and 8% arginine–calcium carbonate (P < 0.05)
Trust score:3/5

muscle sympathetic nerve activity (MSNA)

1 evidences

Exercise training after CRT increased exercise capacity, reduced sympathetic nerve activity, improved vascular conductance, and altered skeletal muscle Ca2+-handling gene expression.

Trust comment: Small interventional human study with mechanistic gene-expression endpoints; useful but limited by sample size.

Study Details

PMID:27591218
Participants:30
Impact:↓ (significant in ET group, P = 0.001)
Trust score:3/5

Fusion rate

2 evidences

PEEK cages filled with calcium sulphate/DBM performed similarly to autograft for cervical fusion, with less blood loss and fewer donor-site complications.

Trust comment: Prospective randomized clinical trial with 2-year follow-up and objective radiologic/clinical outcomes; moderate sample size.

Study Details

PMID:25432324
Participants:68
Impact:no difference between CS/DBM and autograft
Trust score:4/5

In patients needing ACDF, empty PEEK cages and PEEK cages filled with β-tricalcium phosphate showed similar fusion and clinical outcomes at 24 months.

Trust comment: Prospective randomized controlled trial with 2-year follow-up but small sample (n=45) limits precision.

Study Details

PMID:29322313
Participants:45
Impact:no difference (~98% fused at 24 months)
Trust score:4/5

VIP secretion

1 evidences

Intracanal calcium hydroxide increased VIP secretion in periapical lesions after treatment in re-treated root canals.

Trust comment: Randomized controlled clinical trial in humans with moderate sample size and objective ELISA measurements; direct study of a calcium-containing medicament.

Study Details

PMID:29948282
Participants:60
Impact:increased (post-treatment vs pre-treatment, statistically significant)
Trust score:4/5

non-heme iron bioavailability

1 evidences

In fasted women, 800 mg elemental calcium as calcium citrate significantly reduced non-heme iron absorption compared with calcium chloride; effect varied by calcium salt.

Trust comment: Randomized single-blind crossover with radioactive iron absorption measures is methodologically sound but limited by small sample size, reducing generalizability.

Study Details

PMID:29895376
Participants:27
Impact:decreased significantly with 800 mg elemental calcium as calcium citrate versus calcium chloride (P = 0.018)
Trust score:3/5

Supraventricular and ventricular premature beats

1 evidences

In women with primary hyperparathyroidism, parathyroidectomy (which corrects hypercalcemia) reduced premature heart beats and normalized QTc on 24-h ECG.

Trust comment: Randomized human study with objective ECG endpoints but small sample size (n=52).

Study Details

PMID:29875287
Participants:52
Impact:Significant reduction after parathyroidectomy (vs baseline)
Trust score:4/5

treatment efficacy (ORS III vs ORS I)

1 evidences

Compared two oral rehydration salts in children with neurally mediated syncope; electrolytes including serum calcium showed no meaningful change and clinical efficacy was similar between salts.

Trust comment: Randomized pediatric trial measuring electrolytes including calcium but small sample and some unclear reporting of electrolyte p-values; relevant but not focused on calcium supplementation specifically.

Study Details

PMID:29886470
Participants:76
Impact:no significant difference (79.59% vs 62.96%)
Trust score:3/5

HUTT negative conversion rate

1 evidences

Compared two oral rehydration salts in children with neurally mediated syncope; electrolytes including serum calcium showed no meaningful change and clinical efficacy was similar between salts.

Trust comment: Randomized pediatric trial measuring electrolytes including calcium but small sample and some unclear reporting of electrolyte p-values; relevant but not focused on calcium supplementation specifically.

Study Details

PMID:29886470
Participants:76
Impact:no significant difference (51.02% vs 48.16%)
Trust score:3/5

type I muscle fiber satellite cell content

1 evidences

Older men took a multi-ingredient supplement (which included 400 mg Ca per dose) or control for 7 weeks; exercise increased type I muscle fiber satellite cells but the supplement did not change that response.

Trust comment: Randomized double-blind human trial where calcium was a component of a multi-ingredient supplement; small sample size limits confidence in isolating calcium-specific effects.

Study Details

PMID:29878269
Participants:27
Impact:increased at 24 h and 48 h after exercise in both groups; no difference between supplement and control
Trust score:3/5

type II muscle fiber satellite cell content

1 evidences

Older men took a multi-ingredient supplement (which included 400 mg Ca per dose) or control for 7 weeks; exercise increased type I muscle fiber satellite cells but the supplement did not change that response.

Trust comment: Randomized double-blind human trial where calcium was a component of a multi-ingredient supplement; small sample size limits confidence in isolating calcium-specific effects.

Study Details

PMID:29878269
Participants:27
Impact:no significant change after exercise in either group
Trust score:3/5

hemostasis at 5 minutes

1 evidences

In hemodialysis patients after angioplasty, a calcium-alginate hemostatic sheet increased early hemostasis rates and was safe.

Trust comment: Randomized controlled trial with 200 participants and clear, clinically relevant endpoint and statistical analysis.

Study Details

PMID:29846686
Participants:200
Impact:+18 percentage points (57% with CA sheet vs 39% control)
Trust score:4/5

pocket probing depth (PD)

1 evidences

As adjuncts to scaling/root planing, locally delivered rosuvastatin or metformin gels improved pocket depth, attachment level, and bone fill versus placebo; rosuvastatin showed the greatest benefit.

Trust comment: Randomized clinical trial with modest sample size (n=90) and positive results, but numeric effect sizes not reported in the supplied text.

Study Details

PMID:29802627
Participants:90
Impact:greater reduction with rosuvastatin and metformin versus placebo (rosuvastatin > metformin)
Trust score:3/5

clinical attachment level (CAL)

1 evidences

As adjuncts to scaling/root planing, locally delivered rosuvastatin or metformin gels improved pocket depth, attachment level, and bone fill versus placebo; rosuvastatin showed the greatest benefit.

Trust comment: Randomized clinical trial with modest sample size (n=90) and positive results, but numeric effect sizes not reported in the supplied text.

Study Details

PMID:29802627
Participants:90
Impact:greater gain with rosuvastatin and metformin versus placebo (rosuvastatin > metformin)
Trust score:3/5

percentage bone fill

2 evidences

As adjuncts to scaling/root planing, locally delivered rosuvastatin or metformin gels improved pocket depth, attachment level, and bone fill versus placebo; rosuvastatin showed the greatest benefit.

Trust comment: Randomized clinical trial with modest sample size (n=90) and positive results, but numeric effect sizes not reported in the supplied text.

Study Details

PMID:29802627
Participants:90
Impact:improved with rosuvastatin and metformin versus placebo; rosuvastatin showed the largest increase
Trust score:3/5

Adding rh-FGF-2 to a β-tricalcium phosphate scaffold improved periodontal regeneration versus β-TCP alone in adults.

Trust comment: Randomized, double-blinded, externally monitored multicenter RCT (n=88) — good design and reporting support moderate-high trust.

Study Details

PMID:26908630
Participants:88
Impact:75% and 71% (higher-concentration groups) vs 63% and 61% (control/low-dose)
Trust score:4/5

overall success rate (24 months)

1 evidences

In 25 children with paired molars, partial pulpotomy with mineral trioxide aggregate and formocresol pulpotomy had similar clinical and radiographic success at 24 months (no significant differences).

Trust comment: Randomized split-mouth design with 24-month follow-up but small sample size (n=25) limits precision.

Study Details

PMID:29793564
Participants:25
Impact:no significant difference (PP 81.8% vs FP 95.2% at 24 months)
Trust score:3/5

body weight (24-week change)

1 evidences

Post-hoc analysis of a 24-week caloric-restriction trial found that baseline Prevotella/Bacteroides ratio predicted greater weight and fat loss (high P/B or 0-Prevotella lost ~4 kg more than low P/B); no weight-loss differences were seen between the two diets that differed in dairy (calcium) content.

Trust comment: Human randomized dietary trial with objective DXA outcomes and registered protocol, but current results are from a post-hoc subgroup analysis with modest sample size.

Study Details

PMID:29777234
Participants:52
Impact:Low P/B: −6.15 kg; High P/B: −9.96 kg; Difference (High vs Low): −3.80 kg (High lost more)
Trust score:4/5

body fat (24-week change)

1 evidences

Post-hoc analysis of a 24-week caloric-restriction trial found that baseline Prevotella/Bacteroides ratio predicted greater weight and fat loss (high P/B or 0-Prevotella lost ~4 kg more than low P/B); no weight-loss differences were seen between the two diets that differed in dairy (calcium) content.

Trust comment: Human randomized dietary trial with objective DXA outcomes and registered protocol, but current results are from a post-hoc subgroup analysis with modest sample size.

Study Details

PMID:29777234
Participants:52
Impact:Low P/B: −5.18 kg; High P/B: −8.98 kg; Difference ≈ −3.80 kg (High lost more)
Trust score:4/5

effect of dietary fiber on weight loss in high P/B

1 evidences

Post-hoc analysis of a 24-week caloric-restriction trial found that baseline Prevotella/Bacteroides ratio predicted greater weight and fat loss (high P/B or 0-Prevotella lost ~4 kg more than low P/B); no weight-loss differences were seen between the two diets that differed in dairy (calcium) content.

Trust comment: Human randomized dietary trial with objective DXA outcomes and registered protocol, but current results are from a post-hoc subgroup analysis with modest sample size.

Study Details

PMID:29777234
Participants:52
Impact:Higher fiber intake associated with additional ~−5.1 kg weight loss (mean difference 5.1 kg, 95% CI 1.7–8.6)
Trust score:4/5

body mass

1 evidences

On a hypocaloric diet, fortified yogurt (contains calcium among other ingredients) led to greater improvements in body composition and metabolic markers than plain yogurt over 10 weeks.

Trust comment: Well-conducted randomized trial but intervention was a multi-nutrient fortified yogurt (calcium plus protein, vitamin D, probiotics), so effects cannot be attributed to Calcium alone.

Study Details

PMID:29724529
Participants:87
Impact:PY Δ=-4.3±1.9 kg vs FY Δ=-5.1±3.0 kg over 10 weeks
Trust score:3/5

body fat mass

1 evidences

On a hypocaloric diet, fortified yogurt (contains calcium among other ingredients) led to greater improvements in body composition and metabolic markers than plain yogurt over 10 weeks.

Trust comment: Well-conducted randomized trial but intervention was a multi-nutrient fortified yogurt (calcium plus protein, vitamin D, probiotics), so effects cannot be attributed to Calcium alone.

Study Details

PMID:29724529
Participants:87
Impact:significantly reduced with FY vs PY (p=0.023)
Trust score:3/5

waist circumference

1 evidences

On a hypocaloric diet, fortified yogurt (contains calcium among other ingredients) led to greater improvements in body composition and metabolic markers than plain yogurt over 10 weeks.

Trust comment: Well-conducted randomized trial but intervention was a multi-nutrient fortified yogurt (calcium plus protein, vitamin D, probiotics), so effects cannot be attributed to Calcium alone.

Study Details

PMID:29724529
Participants:87
Impact:significant reduction with FY vs PY (p=0.002)
Trust score:3/5

parathyroid hormone

3 evidences

Adding nicotinamide to calcium-based phosphate binders lowered serum phosphorus and improved lipid parameters in pediatric hemodialysis patients.

Trust comment: Randomized 6-month trial in 60 children with clear biochemical endpoints and reported adverse events; moderate sample size but appropriate design.

Study Details

PMID:26420678
Participants:60
Impact:decrease versus control (p=0.02)
Trust score:4/5

Randomized study in hemodialysis patients (105 completers) showing that adding rhubarb to medicinal activated carbon reduced serum phosphorus, calcium-phosphorus product, and PTH over 8 weeks.

Trust comment: Randomized trial with a reasonable completer number but limited reporting clarity and potential methodological concerns.

Study Details

PMID:30634204
Participants:105
Impact:decreased (treatment)
Trust score:3/5

Extended-release niacin slightly lowered serum phosphate over 3 years but did not change calcium or other mineral markers.

Trust comment: Large randomized double-blind placebo-controlled trial (n=352) with clear numeric phosphate result; calcium-related markers showed null effects.

Study Details

PMID:29208626
Participants:352
Impact:no significant change over 3 years
Trust score:4/5

fusion rate at 12 months

1 evidences

Silicated calcium phosphate graft (a calcium-containing material) produced similar spinal fusion rates and clinical improvement to BMP-2 over 24 months.

Trust comment: Randomized multicenter Phase IV trial with objective radiographic fusion endpoints; moderate sample size but randomized design supports moderate–high trust.

Study Details

PMID:29652784
Participants:103
Impact:SiCaP 71.4% vs BMP-2 74.1%
Trust score:4/5

fusion rate at 24 months

1 evidences

Silicated calcium phosphate graft (a calcium-containing material) produced similar spinal fusion rates and clinical improvement to BMP-2 over 24 months.

Trust comment: Randomized multicenter Phase IV trial with objective radiographic fusion endpoints; moderate sample size but randomized design supports moderate–high trust.

Study Details

PMID:29652784
Participants:103
Impact:SiCaP 78.6% vs BMP-2 84.8%
Trust score:4/5

clinical outcomes (pain/disability)

1 evidences

Silicated calcium phosphate graft (a calcium-containing material) produced similar spinal fusion rates and clinical improvement to BMP-2 over 24 months.

Trust comment: Randomized multicenter Phase IV trial with objective radiographic fusion endpoints; moderate sample size but randomized design supports moderate–high trust.

Study Details

PMID:29652784
Participants:103
Impact:similar improvements in both groups over time (no significant differences)
Trust score:4/5

anthropometric indices

1 evidences

Vitamin D supplementation for 3 months reduced body size measures and produced significant changes in calcium-related labs.

Trust comment: Double-blind randomized controlled trial (n=66) with reported significant outcomes; direct intervention was vitamin D not calcium supplement but calcium-related labs were measured.

Study Details

PMID:29615318
Participants:66
Impact:decrease (significant vs control)
Trust score:4/5

calcium deposit resolution (radiographic)

1 evidences

Ten-year follow-up found most calcific deposits resolved and symptoms/function improved regardless of original ultrasound treatment.

Trust comment: Long-term follow-up of an RCT with small sample (37 patients, 45 shoulders); informative but limited power and potential attrition over 10 years.

Study Details

PMID:29613883
Participants:37
Impact:78% resolved in ultrasound group vs 83% in sham at 10 yrs; greater resolution in ultrasound at 9 months (P=0.045)
Trust score:3/5

shoulder symptoms (Binder score)

1 evidences

Ten-year follow-up found most calcific deposits resolved and symptoms/function improved regardless of original ultrasound treatment.

Trust comment: Long-term follow-up of an RCT with small sample (37 patients, 45 shoulders); informative but limited power and potential attrition over 10 years.

Study Details

PMID:29613883
Participants:37
Impact:improved vs baseline (no difference between groups)
Trust score:3/5

shoulder function (Constant score)

1 evidences

Ten-year follow-up found most calcific deposits resolved and symptoms/function improved regardless of original ultrasound treatment.

Trust comment: Long-term follow-up of an RCT with small sample (37 patients, 45 shoulders); informative but limited power and potential attrition over 10 years.

Study Details

PMID:29613883
Participants:37
Impact:improved vs baseline (no difference between groups)
Trust score:3/5

plaque fluid fluoride concentration

1 evidences

Giving calcium-containing gummies before fluoride varnish did not increase plaque fluoride retention or improve adherence in children.

Trust comment: Randomized, multicenter, analyst-blind pediatric trial (n=44) with appropriate analyses showing null effects; moderate sample size.

Study Details

PMID:29609017
Participants:44
Impact:no significant pre-post change and no difference between gummy vs no-gummy groups
Trust score:4/5

plaque solid fluoride concentration

1 evidences

Giving calcium-containing gummies before fluoride varnish did not increase plaque fluoride retention or improve adherence in children.

Trust comment: Randomized, multicenter, analyst-blind pediatric trial (n=44) with appropriate analyses showing null effects; moderate sample size.

Study Details

PMID:29609017
Participants:44
Impact:no significant pre-post change and no difference between groups
Trust score:4/5

post-treatment adherence (questionnaire)

1 evidences

Giving calcium-containing gummies before fluoride varnish did not increase plaque fluoride retention or improve adherence in children.

Trust comment: Randomized, multicenter, analyst-blind pediatric trial (n=44) with appropriate analyses showing null effects; moderate sample size.

Study Details

PMID:29609017
Participants:44
Impact:no difference between groups
Trust score:4/5

serum 25(OH)D (vitamin D status)

2 evidences

Interventions including tailor-made vitamin-D/K salmon and vitamin D+calcium tablets (and calcium supplements in fish groups) produced favorable changes in some bone turnover markers and vitamin D status in postmenopausal women over 12 weeks.

Trust comment: Randomized trial with objective biomarkers and good compliance; sample size moderate and intervention combined nutrients (vitamin D/K and calcium), complicating isolation of calcium-specific effects.

Study Details

PMID:27542236
Participants:122
Impact:+13.7 nmol/L (Tablets); +11.4 nmol/L (HD/HK); −1.2 nmol/L (LD/HK); +12.1 nmol/L (HD/LK); between-group p<0.001
Trust score:4/5

Two years of daily calcium and vitamin D–fortified milk raised vitamin D levels, increased femoral neck BMD, and improved glucose and lipid measures in healthy postmenopausal women.

Trust comment: Large (N=500), randomized, double-blind 2-year RCT in the target population; generally high quality though limited to postmenopausal women.

Study Details

PMID:29676968
Participants:500
Impact:increase in intervention groups A and B vs control after 24 months (significant)
Trust score:4/5

femoral neck bone mineral density (BMD)

1 evidences

Two years of daily calcium and vitamin D–fortified milk raised vitamin D levels, increased femoral neck BMD, and improved glucose and lipid measures in healthy postmenopausal women.

Trust comment: Large (N=500), randomized, double-blind 2-year RCT in the target population; generally high quality though limited to postmenopausal women.

Study Details

PMID:29676968
Participants:500
Impact:significant increase after 24 months
Trust score:4/5

glucose and lipid profile

1 evidences

Two years of daily calcium and vitamin D–fortified milk raised vitamin D levels, increased femoral neck BMD, and improved glucose and lipid measures in healthy postmenopausal women.

Trust comment: Large (N=500), randomized, double-blind 2-year RCT in the target population; generally high quality though limited to postmenopausal women.

Study Details

PMID:29676968
Participants:500
Impact:favorable changes (reductions reported in HbA1c, total cholesterol, LDL-C, apolipoprotein B100)
Trust score:4/5

pain intensity

1 evidences

In women with primary dysmenorrhea, 1000 mg calcium alone reduced menstrual pain vs placebo; calcium+vitamin D showed a non-significant pain reduction; no effect on menstrual blood loss.

Trust comment: Double-blind randomized trial with clear outcomes and reported effect sizes, but modest sample size limits precision.

Study Details

PMID:27296057
Participants:85
Impact:Calcium-alone: adjusted difference -1.6 on 10-cm VAS vs placebo (95% CI -2.6 to -0.6); Calcium+vitD: -0.7 (95% CI -1.6 to 0.3), not significant
Trust score:4/5

postprandial triacylglycerol (TAG) iAUC

1 evidences

In a randomized, double‑blind, three‑way crossover acute trial, Ca-caseinate (a calcium‑rich casein form) reduced postprandial triacylglycerol compared with whey, and showed a trend to lower central SBP; whey lowered peripheral SBP and improved some vascular measures.

Trust comment: Randomized, double‑blind, crossover human trial directly tests Ca-caseinate (calcium‑containing) with reasonable methodology but small acute sample size limits generalizability.

Study Details

PMID:29568003
Participants:27
Impact:Ca-caseinate lower than whey (iAUC0–8h: 6.43 vs 8.10; overall treatment p<0.001)
Trust score:4/5

flow-mediated dilation (FMD) / endothelial function

1 evidences

In a randomized, double‑blind, three‑way crossover acute trial, Ca-caseinate (a calcium‑rich casein form) reduced postprandial triacylglycerol compared with whey, and showed a trend to lower central SBP; whey lowered peripheral SBP and improved some vascular measures.

Trust comment: Randomized, double‑blind, crossover human trial directly tests Ca-caseinate (calcium‑containing) with reasonable methodology but small acute sample size limits generalizability.

Study Details

PMID:29568003
Participants:27
Impact:Ca-caseinate produced gradual improvement in FMD (similar to whey at 5 h)
Trust score:4/5

calcitriol (1,25‑OH2 D3)

1 evidences

In an 8-week controlled feeding trial, the DASH diet modestly lowered active vitamin D (calcitriol) but did not change PTH or blood ionized calcium.

Trust comment: Randomized, multicenter controlled feeding trial with centralized assays and good adherence; moderate sample size and prespecified mineral metabolism outcomes.

Study Details

PMID:29562597
Participants:334
Impact:−3.32 pg/mL (DASH vs control, mean difference)
Trust score:4/5

implant/prosthesis failure

2 evidences

At 3 years, short (5×5 mm) calcium‑incorporated implants performed similarly to longer implants in augmented bone but grafted mandibles had more complications and longer implants had slightly greater bone loss.

Trust comment: Randomized controlled trial with 3‑year follow‑up and objective outcome measures; moderate sample and some dropouts.

Study Details

PMID:29557400
Participants:73
Impact:no significant difference up to 3 years (no difference)
Trust score:4/5

Multicenter randomized pilot trial: titanium implants with a calcium-incorporated surface showed similar implant/prosthesis survival, complications, and marginal bone level changes compared with control RBM surfaces at 3 years.

Trust comment: Randomized multicenter pilot with 3-year follow-up (60 patients); well-conducted but pilot-sized, limiting power to detect small differences.

Study Details

PMID:26355169
Participants:60
Impact:no failures in either group
Trust score:4/5

complications (mandible grafted vs short implants)

1 evidences

At 3 years, short (5×5 mm) calcium‑incorporated implants performed similarly to longer implants in augmented bone but grafted mandibles had more complications and longer implants had slightly greater bone loss.

Trust comment: Randomized controlled trial with 3‑year follow‑up and objective outcome measures; moderate sample and some dropouts.

Study Details

PMID:29557400
Participants:73
Impact:+9 patients (17 vs 8) more complications in mandibular grafted group
Trust score:4/5

peri‑implant marginal bone loss (long vs short)

1 evidences

At 3 years, short (5×5 mm) calcium‑incorporated implants performed similarly to longer implants in augmented bone but grafted mandibles had more complications and longer implants had slightly greater bone loss.

Trust comment: Randomized controlled trial with 3‑year follow‑up and objective outcome measures; moderate sample and some dropouts.

Study Details

PMID:29557400
Participants:73
Impact:+0.29 mm (mandible, longer vs short) and +0.39 mm (maxilla, longer vs short) greater loss
Trust score:4/5

25‑hydroxyvitamin D (25(OH)D)

1 evidences

Over 12 months, vitamin D supplementation (given with calcium) substantially increased 25(OH)D compared with calcium alone or control; calcium alone produced smaller increases than vitamin D.

Trust comment: Randomized open‑label pilot with 124 completers; measured clinical biomarker but open‑label design and pilot size limit strength of inference specifically for calcium's independent effect.

Study Details

PMID:29542862
Participants:124
Impact:Arm A (VitD+calcium, UC): +17.47 ±13.01 ng/mL; Arm B (calcium only, UC): +5.30 ±6.28 ng/mL; Arm C (control, UC): +2.02 ±6.19 ng/mL
Trust score:3/5

Serum chloride

1 evidences

Higher soy isoflavone exposure was associated with a small increase in serum calcium and a decrease in serum chloride in premenopausal women.

Trust comment: Well-conducted 2-year double-blind RCT in humans but findings depend on adherent subgroup (associations not seen in full intention-to-treat), lowering certainty slightly.

Study Details

PMID:29183775
Participants:166
Impact:-1.45 mEq/L (mean change associated with higher isoflavone excretion)
Trust score:4/5

SSA/P incidence during treatment phase

1 evidences

Large randomized chemoprevention trial in patients with prior adenoma: calcium (1200 mg/day) and vitamin D (1000 IU/day) showed no effect on SSA/Ps during treatment but higher SSA/P risk emerged 6–10 years after supplementation began.

Trust comment: Large multicentre randomized trial with long follow-up and adjusted analyses; credible evidence though observational-latent timing of effect warrants cautious interpretation.

Study Details

PMID:29496722
Participants:2058
Impact:No effect of calcium or vitamin D on SSA/P incidence during treatment
Trust score:4/5

SSA/P incidence in observational phase (6–10 years)

1 evidences

Large randomized chemoprevention trial in patients with prior adenoma: calcium (1200 mg/day) and vitamin D (1000 IU/day) showed no effect on SSA/Ps during treatment but higher SSA/P risk emerged 6–10 years after supplementation began.

Trust comment: Large multicentre randomized trial with long follow-up and adjusted analyses; credible evidence though observational-latent timing of effect warrants cautious interpretation.

Study Details

PMID:29496722
Participants:2058
Impact:Elevated risk associated with calcium alone (aRR 2.65; 95% CI 1.43–4.91) and calcium+vitamin D (aRR 3.81; 95% CI 1.25–11.64)
Trust score:4/5

alkaline phosphatase (ALP)

1 evidences

In VLBW infants, mixed-model analysis linked calcium and phosphorus intake to changes in serum/urine Ca–P parameters (e.g., sP, urinary Ca, TrP, ALP) during first 14 days.

Trust comment: Randomized/controlled early supplementation study within a nutrition trial with repeated measures and mixed-model analysis; sample modest but analyses quantify intake–biomarker relationships.

Study Details

PMID:27916815
Participants:70
Impact:ALP decreased −44.94 U/L per mmol/kg calcium intake (ALP increased with protein and phosphorus intake)
Trust score:4/5

hypocalcemia incidence within 16 weeks

1 evidences

In the EVOLVE trial, initiation of cinacalcet was frequently followed by hypocalcemia (often asymptomatic) which usually resolved without intervention within 14 days.

Trust comment: Large randomized controlled trial (EVOLVE) post-hoc analysis with well-defined biochemical outcomes; high sample size supports reliability though analysis is post-hoc.

Study Details

PMID:29525393
Participants:3861
Impact:58.3% (cinacalcet) vs 14.9% (placebo); absolute difference +43.4 percentage points
Trust score:4/5

resolution of hypocalcemia

1 evidences

In the EVOLVE trial, initiation of cinacalcet was frequently followed by hypocalcemia (often asymptomatic) which usually resolved without intervention within 14 days.

Trust comment: Large randomized controlled trial (EVOLVE) post-hoc analysis with well-defined biochemical outcomes; high sample size supports reliability though analysis is post-hoc.

Study Details

PMID:29525393
Participants:3861
Impact:majority resolved spontaneously within 14 days
Trust score:4/5

bleaching sensitivity (VAS)

1 evidences

Pre-bleaching application of a calcium phosphate–based desensitizer markedly reduced bleaching-associated sensitivity during treatment and up to one week, without affecting whitening.

Trust comment: Randomized, double-blind, placebo-controlled crossover trial (n=50) with clear clinical outcomes and low risk of bias.

Study Details

PMID:29520944
Participants:50
Impact:significantly reduced with calcium phosphate paste vs placebo during treatment and up to 1 week (average scores ≈0 for paste between days 1–7)
Trust score:4/5

tooth whitening efficacy

1 evidences

Pre-bleaching application of a calcium phosphate–based desensitizer markedly reduced bleaching-associated sensitivity during treatment and up to one week, without affecting whitening.

Trust comment: Randomized, double-blind, placebo-controlled crossover trial (n=50) with clear clinical outcomes and low risk of bias.

Study Details

PMID:29520944
Participants:50
Impact:no adverse effect on whitening; similar shade improvement at 1 day and 1 week
Trust score:4/5

dentin hypersensitivity (VAS)

1 evidences

Both self-assembling peptide matrix and an arginine+calcium carbonate toothpaste reduced dentin hypersensitivity; the peptide gel gave faster patient-perceived benefit.

Trust comment: Pilot randomized study with modest sample size and objective/subjective measures; reasonable internal validity but limited power.

Study Details

PMID:29520816
Participants:45
Impact:both treatments produced significant reduction in VAS scores throughout study (no major difference overall)
Trust score:3/5

patient satisfaction/pain-free status

1 evidences

Both self-assembling peptide matrix and an arginine+calcium carbonate toothpaste reduced dentin hypersensitivity; the peptide gel gave faster patient-perceived benefit.

Trust comment: Pilot randomized study with modest sample size and objective/subjective measures; reasonable internal validity but limited power.

Study Details

PMID:29520816
Participants:45
Impact:higher early satisfaction and more pain-free patients with peptide gel at day 7 and day 90
Trust score:3/5

tubule occlusion (SEM)

1 evidences

Both self-assembling peptide matrix and an arginine+calcium carbonate toothpaste reduced dentin hypersensitivity; the peptide gel gave faster patient-perceived benefit.

Trust comment: Pilot randomized study with modest sample size and objective/subjective measures; reasonable internal validity but limited power.

Study Details

PMID:29520816
Participants:45
Impact:both products showed tubule occlusion on microscopy supporting clinical effects
Trust score:3/5

femoral 18F-NaF PET activity (TBR)

1 evidences

In adults with PXE, etidronate reduced CT-measured arterial calcification and lowered subretinal neovascular events versus placebo but did not change femoral PET activity (TBR).

Trust comment: Randomized trial (n=74) with objective imaging outcomes; moderate sample size limits precision but findings are clinically meaningful.

Study Details

PMID:29519353
Participants:74
Impact:no significant difference (increase 6% in etidronate vs 7% in placebo; p=0.465)
Trust score:3/5

CT arterial calcification

1 evidences

In adults with PXE, etidronate reduced CT-measured arterial calcification and lowered subretinal neovascular events versus placebo but did not change femoral PET activity (TBR).

Trust comment: Randomized trial (n=74) with objective imaging outcomes; moderate sample size limits precision but findings are clinically meaningful.

Study Details

PMID:29519353
Participants:74
Impact:decreased 4% (etidronate) vs increased 8% (placebo); between-group difference significant (p=0.001)
Trust score:3/5

subretinal neovascularization events

1 evidences

In adults with PXE, etidronate reduced CT-measured arterial calcification and lowered subretinal neovascular events versus placebo but did not change femoral PET activity (TBR).

Trust comment: Randomized trial (n=74) with objective imaging outcomes; moderate sample size limits precision but findings are clinically meaningful.

Study Details

PMID:29519353
Participants:74
Impact:fewer events with etidronate (1 vs 9; p=0.007)
Trust score:3/5

faecal total SCFA (acetate)

1 evidences

62 healthy adults completed 8 weeks of high-phosphorus supplementation with varying calcium doses (0, 500, 1000 mg Ca); calcium co-supplementation was associated with higher faecal acetate/total SCFA and, in men, shifts in gut microbiome; no major changes in faecal genotoxicity.

Trust comment: Randomized, double-blind, placebo-controlled human intervention with 62 completers showing calcium-associated changes in faecal SCFA and microbiome; limited by single stool sampling and small microbiome subgroup.

Study Details

PMID:29452584
Participants:62
Impact:P1000/Ca500: total SCFA 76 ±22 μmol/g vs P1000/Ca0 55 ±18 μmol/g after 8 weeks (increase; P1000/Ca500 vs P1000/Ca0, p ≤ 0.05)
Trust score:4/5

gut microbiome composition (men subgroup)

1 evidences

62 healthy adults completed 8 weeks of high-phosphorus supplementation with varying calcium doses (0, 500, 1000 mg Ca); calcium co-supplementation was associated with higher faecal acetate/total SCFA and, in men, shifts in gut microbiome; no major changes in faecal genotoxicity.

Trust comment: Randomized, double-blind, placebo-controlled human intervention with 62 completers showing calcium-associated changes in faecal SCFA and microbiome; limited by single stool sampling and small microbiome subgroup.

Study Details

PMID:29452584
Participants:62
Impact:men in P1000/Ca1000 had significantly different community vs P1000/Ca0 (PERMANOVA R = 0.778, p = 0.01) with changes in specific OTUs
Trust score:4/5

faecal pH

1 evidences

62 healthy adults completed 8 weeks of high-phosphorus supplementation with varying calcium doses (0, 500, 1000 mg Ca); calcium co-supplementation was associated with higher faecal acetate/total SCFA and, in men, shifts in gut microbiome; no major changes in faecal genotoxicity.

Trust comment: Randomized, double-blind, placebo-controlled human intervention with 62 completers showing calcium-associated changes in faecal SCFA and microbiome; limited by single stool sampling and small microbiome subgroup.

Study Details

PMID:29452584
Participants:62
Impact:decreased in P1000/Ca1000 group after 8 weeks (placebo 7.0 ±0.7 vs 6.5 ±0.6; p ≤ 0.05)
Trust score:4/5

hypocalcaemia incidence on POD10

1 evidences

In adults with ≥1 well-perfused parathyroid gland by ICG, omitting routine immediate postop calcium/PTH testing and supplementation was non-inferior to standard care—no hypocalcaemia observed.

Trust comment: Well-designed randomized trial with adequate sample size per power calculation and clear clinical endpoints.

Study Details

PMID:29405252
Participants:146
Impact:0% in both groups (non-inferior)
Trust score:5/5

calcium level on POD10

1 evidences

In adults with ≥1 well-perfused parathyroid gland by ICG, omitting routine immediate postop calcium/PTH testing and supplementation was non-inferior to standard care—no hypocalcaemia observed.

Trust comment: Well-designed randomized trial with adequate sample size per power calculation and clear clinical endpoints.

Study Details

PMID:29405252
Participants:146
Impact:control 2.31 mmol/l vs intervention 2.30 mmol/l; no significant difference (P=0.480)
Trust score:5/5

PTH level on POD10

1 evidences

In adults with ≥1 well-perfused parathyroid gland by ICG, omitting routine immediate postop calcium/PTH testing and supplementation was non-inferior to standard care—no hypocalcaemia observed.

Trust comment: Well-designed randomized trial with adequate sample size per power calculation and clear clinical endpoints.

Study Details

PMID:29405252
Participants:146
Impact:control 4.44 pmol/l vs intervention 4.88 pmol/l; no significant difference (P=0.217)
Trust score:5/5

clinical success of VPTs

1 evidences

Randomized trial (N=302) using calcium-enriched mixture cement across four vital pulp therapies showed favorable and comparable clinical and radiographic outcomes at 1 year.

Trust comment: Large randomized clinical trial with blinded participants and 1-year follow-up; relevant to calcium-containing dental material (local), not systemic calcium supplementation.

Study Details

PMID:29397215
Participants:302
Impact:favorable and comparable across all four arms at 1 year
Trust score:4/5

white-spot lesion remineralisation (DIAGNOdent)

1 evidences

Randomized trial in children: CPP-ACP remineralised white-spot lesions similarly to fluoride; best remineralisation when CPP-ACP combined with fluoride.

Trust comment: Randomized clinical trial directly testing a calcium-containing topical product with objective lesion measures, but small sample size limits confidence.

Study Details

PMID:29372191
Participants:36
Impact:CPP-ACP ≈ fluoride; CPP-ACP + fluoride = greatest improvement (best outcome)
Trust score:3/5

ASPA methylation

1 evidences

In older adults, adding B-vitamins to vitamin D plus calcium changed methylation at some aging-related CpG sites and was associated with higher odds of accelerated epigenetic aging after 1 year.

Trust comment: Randomized human trial but small sample and modest effect sizes with short (1 year) follow-up.

Study Details

PMID:29395637
Participants:63
Impact:Mean change 1.40 ±4.02 (D+Ca+B) vs −0.96 ±5.12 (D+Ca); p=0.046
Trust score:3/5

PDE4C methylation

1 evidences

In older adults, adding B-vitamins to vitamin D plus calcium changed methylation at some aging-related CpG sites and was associated with higher odds of accelerated epigenetic aging after 1 year.

Trust comment: Randomized human trial but small sample and modest effect sizes with short (1 year) follow-up.

Study Details

PMID:29395637
Participants:63
Impact:Mean change 1.95 ±3.57 (D+Ca+B) vs 0.22 ±3.57 (D+Ca); adjusted p=0.062
Trust score:3/5

Accelerated epigenetic aging (odds)

1 evidences

In older adults, adding B-vitamins to vitamin D plus calcium changed methylation at some aging-related CpG sites and was associated with higher odds of accelerated epigenetic aging after 1 year.

Trust comment: Randomized human trial but small sample and modest effect sizes with short (1 year) follow-up.

Study Details

PMID:29395637
Participants:63
Impact:Odds ratio 5.26 (95% CI 1.51–18.28) for D+Ca+B vs D+Ca
Trust score:3/5

Renal calcium excretion

1 evidences

In 62 healthy adults, high phosphorus (1000 mg/day) with differing calcium (0, 500, 1000 mg/day) altered mineral handling: fasting plasma phosphate unchanged, high P without Ca reduced renal calcium excretion and disturbed calcium balance, while calcium supplementation mitigated negative effects; transient FGF23 rise at 4 weeks and modest decreases in some bone turnover markers with Ca supplementation.

Trust comment: Randomized, double‑blind, placebo‑controlled intervention with relevant biochemical measures and reasonable sample size (n=62 completed); moderate external generalizability.

Study Details

PMID:26786148
Participants:62
Impact:P1000/Ca0: renal Ca excretion decreased significantly vs placebo (4 weeks p=0.001; 8 weeks p=0.029), indicating altered Ca handling without Ca supplementation
Trust score:4/5

Urine albumin excretion

1 evidences

In patients with diabetic nephropathy, monthly high-dose vitamin D injections for 6 months reduced urine albumin excretion, improved estimated GFR, and lowered plasma renin compared with placebo.

Trust comment: Randomized double-blind placebo-controlled trial with 82 completers showing clinically relevant renal and renin changes, but short duration and single-center limits generalizability.

Study Details

PMID:29386413
Participants:82
Impact:Mean reduction −51.8 mg/g (treatment) vs −22.4 mg/g (control); between-group p=0.001
Trust score:4/5

GFR (eGFR)

1 evidences

In patients with diabetic nephropathy, monthly high-dose vitamin D injections for 6 months reduced urine albumin excretion, improved estimated GFR, and lowered plasma renin compared with placebo.

Trust comment: Randomized double-blind placebo-controlled trial with 82 completers showing clinically relevant renal and renin changes, but short duration and single-center limits generalizability.

Study Details

PMID:29386413
Participants:82
Impact:Increase +7.1 mL/min (treatment) vs +0.7 mL/min (control); between-group p=0.03
Trust score:4/5

Plasma renin

1 evidences

In patients with diabetic nephropathy, monthly high-dose vitamin D injections for 6 months reduced urine albumin excretion, improved estimated GFR, and lowered plasma renin compared with placebo.

Trust comment: Randomized double-blind placebo-controlled trial with 82 completers showing clinically relevant renal and renin changes, but short duration and single-center limits generalizability.

Study Details

PMID:29386413
Participants:82
Impact:Mean reduction −5.7 pg/mL (treatment) vs −0.77 pg/mL (control); between-group p=0.006
Trust score:4/5

Quality of life (SF-36)

1 evidences

After parathyroidectomy patients received standard postoperative calcium; auricular plaster plus calcium improved quality of life more than calcium carbonate alone.

Trust comment: Small randomized study (n=34) using calcium supplementation as standard care; limited sample size and incomplete quantitative reporting reduce confidence.

Study Details

PMID:29354913
Participants:34
Impact:improved; auricular plaster+calcium superior to calcium alone
Trust score:3/5

Fractional calcium absorption (FCA) — ELD

1 evidences

Randomized trial in postmenopausal osteoporosis patients: oral eldecalcitol (ELD) and alfacalcidol (ALF) markedly increased intestinal fractional calcium absorption compared with plain vitamin D3 or control over 4 weeks.

Trust comment: Randomized human trial using gold-standard double isotope FCA measurement but small sample and short duration; methods and direct calcium outcomes are credible.

Study Details

PMID:29273827
Participants:38
Impact:22.6% → 33.7% (+59.5%)
Trust score:4/5

Fractional calcium absorption (FCA) — ALF

1 evidences

Randomized trial in postmenopausal osteoporosis patients: oral eldecalcitol (ELD) and alfacalcidol (ALF) markedly increased intestinal fractional calcium absorption compared with plain vitamin D3 or control over 4 weeks.

Trust comment: Randomized human trial using gold-standard double isotope FCA measurement but small sample and short duration; methods and direct calcium outcomes are credible.

Study Details

PMID:29273827
Participants:38
Impact:22.7% → 30.2% (+45.9%)
Trust score:4/5

Fractional calcium absorption (FCA) — plain vitamin D3

1 evidences

Randomized trial in postmenopausal osteoporosis patients: oral eldecalcitol (ELD) and alfacalcidol (ALF) markedly increased intestinal fractional calcium absorption compared with plain vitamin D3 or control over 4 weeks.

Trust comment: Randomized human trial using gold-standard double isotope FCA measurement but small sample and short duration; methods and direct calcium outcomes are credible.

Study Details

PMID:29273827
Participants:38
Impact:21.5% → 24.7% (+16.7%; not statistically robust)
Trust score:4/5

clinical scores (JOA, ODI, VAS)

1 evidences

In patients needing ACDF, empty PEEK cages and PEEK cages filled with β-tricalcium phosphate showed similar fusion and clinical outcomes at 24 months.

Trust comment: Prospective randomized controlled trial with 2-year follow-up but small sample (n=45) limits precision.

Study Details

PMID:29322313
Participants:45
Impact:no difference at 24 months
Trust score:4/5

low back pain (VAS)

1 evidences

Thermal mineral water baths (high in calcium-magnesium-bicarbonate) plus usual care improved pain, disability and quality of life in chronic low back pain patients, with effects persisting at follow-up.

Trust comment: Randomized controlled follow-up with moderate sample size but limited detail on blinding and effect sizes in the text provided.

Study Details

PMID:29322254
Participants:105
Impact:significant improvement (p<0.001) in treatment group vs baseline
Trust score:3/5

disability (Oswestry)

1 evidences

Thermal mineral water baths (high in calcium-magnesium-bicarbonate) plus usual care improved pain, disability and quality of life in chronic low back pain patients, with effects persisting at follow-up.

Trust comment: Randomized controlled follow-up with moderate sample size but limited detail on blinding and effect sizes in the text provided.

Study Details

PMID:29322254
Participants:105
Impact:significant improvement (p<0.001) in treatment group vs baseline
Trust score:3/5

quality of life (EuroQol-5D)

1 evidences

Thermal mineral water baths (high in calcium-magnesium-bicarbonate) plus usual care improved pain, disability and quality of life in chronic low back pain patients, with effects persisting at follow-up.

Trust comment: Randomized controlled follow-up with moderate sample size but limited detail on blinding and effect sizes in the text provided.

Study Details

PMID:29322254
Participants:105
Impact:significant improvement (p<0.001) in treatment group vs baseline
Trust score:3/5

fasting plasma glucose

1 evidences

Six weeks of magnesium-zinc-calcium-vitamin D co-supplementation in gestational diabetes improved fasting glucose, insulin-related markers and some lipid markers versus placebo.

Trust comment: Randomized, double-blind, placebo-controlled trial with clear quantitative outcomes but relatively small sample (n=60).

Study Details

PMID:29316405
Participants:60
Impact:-0.37 ±0.09 mmol/L vs +0.01 ±0.09 mmol/L (P=0.003)
Trust score:4/5

serum insulin

2 evidences

8-week randomized trial in vitamin D–deficient overweight/obese women with PCOS tested calcium, vitamin D, both, or placebo; co-supplementation improved some insulin and triglyceride measures.

Trust comment: Randomized double-blind placebo-controlled RCT with clear reported outcomes and adequate sample size per arm (n=26 groups), supporting moderate–high trust.

Study Details

PMID:25300649
Participants:104
Impact:decreased (P=0.03)
Trust score:4/5

Six weeks of magnesium-zinc-calcium-vitamin D co-supplementation in gestational diabetes improved fasting glucose, insulin-related markers and some lipid markers versus placebo.

Trust comment: Randomized, double-blind, placebo-controlled trial with clear quantitative outcomes but relatively small sample (n=60).

Study Details

PMID:29316405
Participants:60
Impact:-21.0 ±4.8 pmol/L vs +7.2 ±4.8 pmol/L (P<0.001)
Trust score:4/5

insulin resistance indices (HOMA-IR, QUICKI, etc.)

1 evidences

In CKD patients, paricalcitol (VDR activator) produced a small rise in serum calcium and phosphate but did not change insulin resistance indices over 12 weeks.

Trust comment: Post-hoc analysis of a randomized placebo-controlled trial in CKD (moderate size); intervention raised calcium slightly but no IR effect detected.

Study Details

PMID:29307660
Participants:88
Impact:no change (P range 0.25–0.62)
Trust score:3/5

Daily calcium intake

3 evidences

Nutrition education and dietary intervention increased dietary calcium intake and improved lumbar spine and femoral neck BMD versus control over 6 months.

Trust comment: Randomized dietary intervention with significant BMD changes but potential for performance and measurement bias from non-blinding; moderate trust.

Study Details

PMID:27301220
Participants:90
Impact:Increased in intervention group vs control (P<0.05)
Trust score:3/5

After DXA, participants increased calcium intake, vitamin D supplementation and exercise over 52 weeks, but a mailed individualized-results letter plus brochure did not improve behaviors versus usual care.

Trust comment: Large randomized pragmatic trial (n=7749) with self-reported behavior outcomes; strong sample but self-report may bias measures.

Study Details

PMID:29307094
Participants:7749
Impact:increased over 52 weeks in both groups; no additional benefit of the intervention vs usual care
Trust score:4/5

An education and counseling program increased osteoporosis knowledge, self-efficacy, weekly exercise and daily calcium intake in at-risk women.

Trust comment: Randomized controlled behavioral trial but small sample (n=73); reports significant increases in reported calcium intake and related behaviors.

Study Details

PMID:28688497
Participants:73
Impact:increased (P<0.001)
Trust score:3/5

vitamin D supplementation

1 evidences

After DXA, participants increased calcium intake, vitamin D supplementation and exercise over 52 weeks, but a mailed individualized-results letter plus brochure did not improve behaviors versus usual care.

Trust comment: Large randomized pragmatic trial (n=7749) with self-reported behavior outcomes; strong sample but self-report may bias measures.

Study Details

PMID:29307094
Participants:7749
Impact:increased over 52 weeks in both groups; no additional benefit of the intervention vs usual care
Trust score:4/5

Weekly exercise sessions

1 evidences

After DXA, participants increased calcium intake, vitamin D supplementation and exercise over 52 weeks, but a mailed individualized-results letter plus brochure did not improve behaviors versus usual care.

Trust comment: Large randomized pragmatic trial (n=7749) with self-reported behavior outcomes; strong sample but self-report may bias measures.

Study Details

PMID:29307094
Participants:7749
Impact:increased over 52 weeks in both groups; no additional benefit of the intervention vs usual care
Trust score:4/5

enamel decalcification (EDI/ICDAS)

1 evidences

In orthodontic patients, daily MI Paste Plus plus quarterly MI Varnish did not significantly reduce white spot lesions over 12 months but increased salivary fluoride levels.

Trust comment: Randomized single-blind trial but small analyzed sample (n=37) limits statistical power.

Study Details

PMID:29299732
Participants:37
Impact:no significant difference between experimental and control at 12 months
Trust score:3/5

salivary fluoride

1 evidences

In orthodontic patients, daily MI Paste Plus plus quarterly MI Varnish did not significantly reduce white spot lesions over 12 months but increased salivary fluoride levels.

Trust comment: Randomized single-blind trial but small analyzed sample (n=37) limits statistical power.

Study Details

PMID:29299732
Participants:37
Impact:higher in experimental (0.20 ±0.26 ppm) vs control (0.04 ±0.04 ppm), P<0.01
Trust score:3/5

proportion achieving ≥75 nmol/L

1 evidences

Daily supplementation with 1000 IU vitamin D plus 500 mg calcium for six months increased serum 25(OH)D in schoolchildren; children with lower baseline levels benefited most.

Trust comment: Single-arm pre-post supplementation study (n=106) with objective vitamin D measurement but no randomized control group; moderate quality.

Study Details

PMID:29247782
Participants:106
Impact:44% overall achieved ≥75 nmol/L (64% of those deficient at baseline)
Trust score:3/5

use of calcium supplements

1 evidences

Feedback of high future fracture risk led to increased preventive behaviors including calcium use and reduced femoral neck bone loss over 10 years in premenopausal women.

Trust comment: 10-year follow-up of an RCT (n=470) with objective BMD measures and reported supplement use; good design though some attrition and observational long-term follow-up.

Study Details

PMID:29246678
Participants:470
Impact:+66% relative increase (RR=1.66, 95% CI 1.22 to 2.24)
Trust score:4/5

radiographic outcome

1 evidences

Pulpotomy with either MTA or calcium-enriched mixture had very high clinical success (~≥98%) at 2 and 5 years; radiographic advantage for MTA at 2 years but similar at 5 years.

Trust comment: Large multicenter randomized trial with long follow-up; calcium-containing biomaterial studied indirectly for dental outcomes.

Study Details

PMID:29178761
Participants:304
Impact:MTA superior at 2 years (P=0.005); similar outcomes at 5 years (P=0.413)
Trust score:4/5

height growth (HAZ monthly change)

1 evidences

Children with clinical rickets who received vitamin D and calcium showed increased linear growth but remained at higher risk of death and severe pneumonia readmission.

Trust comment: Large prospective cohort (secondary analysis of an RCT) with high follow-up; diagnosis of rickets was clinical (limited specificity) which may bias some findings.

Study Details

PMID:29178404
Participants:1778
Impact:+0.19 (adjusted regression coefficient per month)
Trust score:4/5

readmission with severe pneumonia

1 evidences

Children with clinical rickets who received vitamin D and calcium showed increased linear growth but remained at higher risk of death and severe pneumonia readmission.

Trust comment: Large prospective cohort (secondary analysis of an RCT) with high follow-up; diagnosis of rickets was clinical (limited specificity) which may bias some findings.

Study Details

PMID:29178404
Participants:1778
Impact:+37% risk (adjusted HR 1.37)
Trust score:4/5

fracture union rate

1 evidences

Percutaneous autologous platelet concentrate (activated with calcium gluconate) increased union rate numerically (78% vs 59%) but differences were not statistically significant and time to union was similar.

Trust comment: Small randomized study with limited power; calcium gluconate used as activator (indirect calcium relevance) and results were not statistically significant.

Study Details

PMID:29167980
Participants:40
Impact:PC: 78% vs control: 59% (+19 percentage points; P=0.296, not significant)
Trust score:3/5

time to union

1 evidences

Percutaneous autologous platelet concentrate (activated with calcium gluconate) increased union rate numerically (78% vs 59%) but differences were not statistically significant and time to union was similar.

Trust comment: Small randomized study with limited power; calcium gluconate used as activator (indirect calcium relevance) and results were not statistically significant.

Study Details

PMID:29167980
Participants:40
Impact:No significant difference (PC 15.33±9.91 weeks vs control 13.10±7.21 weeks; P=0.540)
Trust score:3/5

Total success rate (24 months)

1 evidences

In children needing pulpotomy, calcium silicate-based cements (MTA products and Biodentine) achieved high 24-month success rates similar to ferric sulfate.

Trust comment: Randomized split-mouth RCT with blinded outcome assessment and 24-month follow-up; moderate sample size and some dropouts.

Study Details

PMID:29226134
Participants:29
Impact:BD 82.75%; MTA-P 86.2%; ProRoot MTA 93.1%; FS 75.86% (no significant differences between groups)
Trust score:4/5

Pulp canal obliteration (PCO) incidence (24 months)

1 evidences

In children needing pulpotomy, calcium silicate-based cements (MTA products and Biodentine) achieved high 24-month success rates similar to ferric sulfate.

Trust comment: Randomized split-mouth RCT with blinded outcome assessment and 24-month follow-up; moderate sample size and some dropouts.

Study Details

PMID:29226134
Participants:29
Impact:BD 13.79%; MTA-P 10.34%; ProRoot MTA 3.45%; FS 0%
Trust score:4/5

Internal root resorption incidence

1 evidences

In children needing pulpotomy, calcium silicate-based cements (MTA products and Biodentine) achieved high 24-month success rates similar to ferric sulfate.

Trust comment: Randomized split-mouth RCT with blinded outcome assessment and 24-month follow-up; moderate sample size and some dropouts.

Study Details

PMID:29226134
Participants:29
Impact:FS 6.89%; MTA-P 3.44%; BD 3.44% (considered radiographic failure)
Trust score:4/5

Urine citrate

1 evidences

Potassium bicarbonate increased urine citrate dose‑dependently; urine citrate change related inversely to a bone formation marker but was not a reliable substitute for net acid excretion when assessing bone turnover and calcium excretion.

Trust comment: Randomized placebo‑controlled trial with 233 older adults and biochemical endpoints; results are internally consistent though some associations attenuated in multivariable models.

Study Details

PMID:29211866
Participants:233
Impact:Increased dose‑dependently after KHCO3 supplementation (P trend < 0.001)
Trust score:4/5

Association with bone formation (P1NP)

1 evidences

Potassium bicarbonate increased urine citrate dose‑dependently; urine citrate change related inversely to a bone formation marker but was not a reliable substitute for net acid excretion when assessing bone turnover and calcium excretion.

Trust comment: Randomized placebo‑controlled trial with 233 older adults and biochemical endpoints; results are internally consistent though some associations attenuated in multivariable models.

Study Details

PMID:29211866
Participants:233
Impact:Urine citrate change inversely associated with P1NP change (P = 0.021)
Trust score:4/5

NAE change associations

1 evidences

Potassium bicarbonate increased urine citrate dose‑dependently; urine citrate change related inversely to a bone formation marker but was not a reliable substitute for net acid excretion when assessing bone turnover and calcium excretion.

Trust comment: Randomized placebo‑controlled trial with 233 older adults and biochemical endpoints; results are internally consistent though some associations attenuated in multivariable models.

Study Details

PMID:29211866
Participants:233
Impact:NAE change positively associated with NTX and calcium excretion (P ≤ 0.003); urine citrate lost associations when both included in model
Trust score:4/5

BMD testing within 6 months

1 evidences

Education-based interventions increased bone mineral density testing and guideline-appropriate calcium and vitamin D use in men on ADT compared with usual care.

Trust comment: Single-center randomized phase 2 trial with clear feasibility and implementation outcomes; moderate sample and appropriate randomization.

Study Details

PMID:29211305
Participants:119
Impact:BHP+BHCC 78% vs usual care 36% (P < 0.001); BHP+FP 58% vs 36% (P = 0.047)
Trust score:4/5

guideline-appropriate calcium and vitamin D use

1 evidences

Education-based interventions increased bone mineral density testing and guideline-appropriate calcium and vitamin D use in men on ADT compared with usual care.

Trust comment: Single-center randomized phase 2 trial with clear feasibility and implementation outcomes; moderate sample and appropriate randomization.

Study Details

PMID:29211305
Participants:119
Impact:Both interventions increased use; BHP+FP significant (P = 0.039)
Trust score:4/5

Bisphosphonate prescriptions for high fracture risk

1 evidences

Education-based interventions increased bone mineral density testing and guideline-appropriate calcium and vitamin D use in men on ADT compared with usual care.

Trust comment: Single-center randomized phase 2 trial with clear feasibility and implementation outcomes; moderate sample and appropriate randomization.

Study Details

PMID:29211305
Participants:119
Impact:No men detected at high fracture risk; no bisphosphonate prescriptions reported
Trust score:4/5

length

1 evidences

Early higher enteral mineral intake did not improve growth or bone density at term age; higher calcium intake was associated with lower bone mineral content in regression analysis.

Trust comment: Randomized multi-center trial (109 randomized; 93 surviving included in growth analyses) but stopped early and underpowered with small DXA subset.

Study Details

PMID:29207479
Participants:93
Impact:phosphorus intake associated with +0.19 cm per mmol/kg (p=0.047)
Trust score:4/5

ridge width gain

1 evidences

Using calcium-containing alloplast (β-tricalcium phosphate/hydroxyapatite) with large particles produced greater ridge width gain than allograft or small particles.

Trust comment: Randomized controlled trial (n=23) with clear reported mm outcomes but small, single-center sample limits generalizability.

Study Details

PMID:29202263
Participants:23
Impact:alloplast large: 4.40 mm vs allograft large: 3.82 mm; large particle grafts yielded greater gain than small particle grafts
Trust score:3/5

lumbar BMD (L2)

1 evidences

Denosumab treatment improved lumbar spine bone mineral density in patients on home parenteral nutrition over 12 months.

Trust comment: Randomized controlled trial (n=49) but only 15 patients received 2 doses and were fully reassessed at 12 months, limiting certainty of results.

Study Details

PMID:29187046
Participants:49
Impact:increased from 0.801 to 0.946 g/cm2 (Δ+0.145) at 12 months
Trust score:3/5

lumbar BMD (L3)

1 evidences

Denosumab treatment improved lumbar spine bone mineral density in patients on home parenteral nutrition over 12 months.

Trust comment: Randomized controlled trial (n=49) but only 15 patients received 2 doses and were fully reassessed at 12 months, limiting certainty of results.

Study Details

PMID:29187046
Participants:49
Impact:increased from 0.857 to 0.979 g/cm2 (Δ+0.122) at 12 months
Trust score:3/5

Fluorescence loss (lesion depth, ∆F)

1 evidences

Randomized double-blind trial in adolescents testing MI Paste Plus (CPP‑ACPF with fluoride, calcium and phosphate) vs control paste for 12 months; no additional long‑term benefit of MI Paste Plus was demonstrated.

Trust comment: Well-designed double‑blind RCT with objective imaging and microbiological outcomes but moderate dropouts and compliance issues.

Study Details

PMID:29161371
Participants:51
Impact:+1.82 percentage points (MPP baseline T1 −8.07% → T5 −6.25%); +1.84 percentage points (control −8.94% → −7.10%); no significant between-group difference
Trust score:4/5

Relative abundance of aciduric bacteria

1 evidences

Randomized double-blind trial in adolescents testing MI Paste Plus (CPP‑ACPF with fluoride, calcium and phosphate) vs control paste for 12 months; no additional long‑term benefit of MI Paste Plus was demonstrated.

Trust comment: Well-designed double‑blind RCT with objective imaging and microbiological outcomes but moderate dropouts and compliance issues.

Study Details

PMID:29161371
Participants:51
Impact:−23.9 percentage points in MPP (53.2% → 29.3%; significant over time in MPP) with no between-group difference
Trust score:4/5

Lesion area / integrated fluorescence loss (IFL)

1 evidences

Randomized double-blind trial in adolescents testing MI Paste Plus (CPP‑ACPF with fluoride, calcium and phosphate) vs control paste for 12 months; no additional long‑term benefit of MI Paste Plus was demonstrated.

Trust comment: Well-designed double‑blind RCT with objective imaging and microbiological outcomes but moderate dropouts and compliance issues.

Study Details

PMID:29161371
Participants:51
Impact:No significant between-group change over 12 months
Trust score:4/5

1,25(OH)D

1 evidences

12‑week double‑blind RCT in CKD 3–4 patients: daily 8000 IU cholecalciferol raised 25(OH)D, increased 1,25(OH)D and mitigated further rises in PTH versus placebo, without hypercalcaemia.

Trust comment: Large, double‑blind randomized placebo‑controlled trial with predefined endpoints and safety monitoring; clinically relevant biochemical outcomes.

Study Details

PMID:29156056
Participants:95
Impact:+~38 pmol/L (64 → 102 pmol/L) in treatment group
Trust score:5/5

25(OH)D increase → PTH

1 evidences

Prospective randomized study in postmenopausal women given calcium + vitamin D with or without genistein; vitamin D increases associated with reductions in bone turnover markers, and genistein added no consistent additional benefit.

Trust comment: Randomized supplementation study with pharmacogenomic subanalysis; moderate sample size and clear null effect of genistein adjunct.

Study Details

PMID:29151102
Participants:102
Impact:Vitamin D rises were associated with reductions in PTH (magnitude not reported)
Trust score:4/5

25(OH)D status (population)

1 evidences

National cross‑sectional study in Portugal showing very low population 25(OH)D (median 13.8 ng/mL) and associations: low vitamin D linked with higher BMI, glucose and triglycerides; PTH associated with BMI and waist circumference.

Trust comment: Large, nationally sampled cross‑sectional study with robust measurements but limited by observational design and residual confounding.

Study Details

PMID:29149839
Participants:500
Impact:Median 25(OH)D 13.8 ng/mL; 37.7% deficient, 47.9% inadequate (85.6% below sufficiency)
Trust score:3/5

PTH level and body fat

1 evidences

National cross‑sectional study in Portugal showing very low population 25(OH)D (median 13.8 ng/mL) and associations: low vitamin D linked with higher BMI, glucose and triglycerides; PTH associated with BMI and waist circumference.

Trust comment: Large, nationally sampled cross‑sectional study with robust measurements but limited by observational design and residual confounding.

Study Details

PMID:29149839
Participants:500
Impact:Median PTH 38.1 pg/mL; PTH positively associated with BMI (β=0.475) and waist circumference (β=0.184)
Trust score:3/5

25(OH)D associations with metabolic parameters

1 evidences

National cross‑sectional study in Portugal showing very low population 25(OH)D (median 13.8 ng/mL) and associations: low vitamin D linked with higher BMI, glucose and triglycerides; PTH associated with BMI and waist circumference.

Trust comment: Large, nationally sampled cross‑sectional study with robust measurements but limited by observational design and residual confounding.

Study Details

PMID:29149839
Participants:500
Impact:25(OH)D inversely associated with triglycerides (β=−1.322) and glucose (β=−2.051)
Trust score:3/5

Postoperative parathyroid dysfunction (subclinical hypoparathyroidism)

1 evidences

Randomized trial comparing classic vs harmonic scalpel total thyroidectomy; both groups showed altered calcium and PTH postoperatively and greater subclinical parathyroid impairment after harmonic‑scalpel surgery.

Trust comment: Randomized surgical trial with objective biochemical testing, but excerpt lacks full numeric outcome details and clinical hypocalcaemia rates.

Study Details

PMID:29144799
Participants:269
Impact:Partial subclinical hypoparathyroidism was more common in the harmonic scalpel group (P<0.001)
Trust score:3/5

PTH response to bicarbonate stimulation

1 evidences

Randomized trial comparing classic vs harmonic scalpel total thyroidectomy; both groups showed altered calcium and PTH postoperatively and greater subclinical parathyroid impairment after harmonic‑scalpel surgery.

Trust comment: Randomized surgical trial with objective biochemical testing, but excerpt lacks full numeric outcome details and clinical hypocalcaemia rates.

Study Details

PMID:29144799
Participants:269
Impact:Difference in peak PTH levels after sodium bicarbonate test between techniques (statistically significant)
Trust score:3/5

total body less head bone mineral content (BMC)

1 evidences

In risperidone-treated boys, 9 months of calcium (1250 mg/day) plus vitamin D (400 IU/day) did not increase measured bone mass.

Trust comment: Randomized, double-blind, placebo-controlled pilot with small sample (38 completers) limiting power to detect modest effects.

Study Details

PMID:29112461
Participants:38
Impact:no significant change
Trust score:3/5

radius trabecular bone mineral density (BMD)

1 evidences

In risperidone-treated boys, 9 months of calcium (1250 mg/day) plus vitamin D (400 IU/day) did not increase measured bone mass.

Trust comment: Randomized, double-blind, placebo-controlled pilot with small sample (38 completers) limiting power to detect modest effects.

Study Details

PMID:29112461
Participants:38
Impact:no significant change
Trust score:3/5

plasma vitamin D concentration

1 evidences

In risperidone-treated boys, 9 months of calcium (1250 mg/day) plus vitamin D (400 IU/day) did not increase measured bone mass.

Trust comment: Randomized, double-blind, placebo-controlled pilot with small sample (38 completers) limiting power to detect modest effects.

Study Details

PMID:29112461
Participants:38
Impact:no significant change
Trust score:3/5

coronary artery calcification (CACS)

1 evidences

In hemodialysis patients with adynamic bone disease, the calcium-based binder (calcium carbonate) was associated with higher blood calcium, greater progression of coronary artery calcification and lower bone mineral density compared with lanthanum carbonate over 12 months.

Trust comment: Randomized, objective imaging (CT, DXA) outcomes in 92 patients support reliability, but single-center and open-label design limit blinding.

Study Details

PMID:29137107
Participants:92
Impact:increased with calcium carbonate vs lanthanum carbonate (significant, P<0.001)
Trust score:4/5

Hypercalciuria

2 evidences

In children with steroid-sensitive nephrotic syndrome, vitamin D3 plus calcium raised 25(OH)D levels but did not change bone mineral content/density or relapse rate; hypercalciuria was common in treated patients.

Trust comment: Randomized controlled trial in children with objective biochemical and DXA outcomes but small sample and short follow-up (6 months).

Study Details

PMID:28725977
Participants:43
Impact:occurred in 52% of treated patients (safety concern)
Trust score:4/5

Case-control study of infants <1 year with urinary tract stones versus controls assessing risk factors, VDR polymorphisms and metabolic causes.

Trust comment: Human case-control study with modest sample size and significant associations reported for hypercalciuria and feeding; observational design limits causal inference.

Study Details

PMID:29085969
Participants:120
Impact:present in 38% of stone cases
Trust score:3/5

Feeding with formula and multivitamins (A,C,D)

1 evidences

Case-control study of infants <1 year with urinary tract stones versus controls assessing risk factors, VDR polymorphisms and metabolic causes.

Trust comment: Human case-control study with modest sample size and significant associations reported for hypercalciuria and feeding; observational design limits causal inference.

Study Details

PMID:29085969
Participants:120
Impact:associated with increased risk of urinary tract stones (p<0.05)
Trust score:3/5

VDR ApaI CA genotype / C allele

1 evidences

Case-control study of infants <1 year with urinary tract stones versus controls assessing risk factors, VDR polymorphisms and metabolic causes.

Trust comment: Human case-control study with modest sample size and significant associations reported for hypercalciuria and feeding; observational design limits causal inference.

Study Details

PMID:29085969
Participants:120
Impact:associated with family history and with hypercalciuria (p<0.05)
Trust score:3/5

B-type natriuretic peptide (BNP)

1 evidences

Small double-blind RCT in heart failure patients testing high-dose vitamin D3 vs placebo; vitamin D levels rose markedly and some hormonal (PTH), BNP and QOL measures improved.

Trust comment: Randomized, double-blind human trial with appropriate measures and clear biochemical effects (large 25(OH)D change); small sample limits precision and generalizability.

Study Details

PMID:29084522
Participants:36
Impact:improved relative to placebo (treatment Δ +30 ±950 vs placebo Δ +400 ±1900; p=0.002)
Trust score:4/5

Number randomized

1 evidences

Sub-study describing recruitment and retention methods and metrics from the multi-country CAP trial of preconception calcium supplementation; reports screening, recruitment yields, and pregnancy/retention rates.

Trust comment: Large multi-center trial sub-study with detailed recruitment/retention data; high sample size and transparent reporting, though this sub-paper focuses on methods rather than clinical outcomes of calcium supplementation.

Study Details

PMID:29073916
Participants:1354
Impact:1354 non-pregnant women randomized (2563 screened)
Trust score:4/5

Pregnancy rate during follow-up

1 evidences

Sub-study describing recruitment and retention methods and metrics from the multi-country CAP trial of preconception calcium supplementation; reports screening, recruitment yields, and pregnancy/retention rates.

Trust comment: Large multi-center trial sub-study with detailed recruitment/retention data; high sample size and transparent reporting, though this sub-paper focuses on methods rather than clinical outcomes of calcium supplementation.

Study Details

PMID:29073916
Participants:1354
Impact:45.3% (614/1354) became pregnant by Sept 2016; 33.5% (454/1354) became pregnant within 1 year
Trust score:4/5

Pre-pregnancy visit attendance

1 evidences

Sub-study describing recruitment and retention methods and metrics from the multi-country CAP trial of preconception calcium supplementation; reports screening, recruitment yields, and pregnancy/retention rates.

Trust comment: Large multi-center trial sub-study with detailed recruitment/retention data; high sample size and transparent reporting, though this sub-paper focuses on methods rather than clinical outcomes of calcium supplementation.

Study Details

PMID:29073916
Participants:1354
Impact:~78% attended first pre-pregnancy visit; subsequent PPV attendance ≥86% but timely attendance lower (57–83%)
Trust score:4/5

new bone formation (μm²)

1 evidences

Randomized comparison of β-tricalcium phosphate (ChronOS), Bio‑Oss, autogenous bone graft, and combinations for maxillary sinus augmentation in humans; assessed new bone formation and immunohistochemical markers.

Trust comment: Small randomized human trial (30 sinuses) with histomorphometric and IHC outcomes; limited sample size but randomized design.

Study Details

PMID:29100829
Participants:30
Impact:ChronOS 83,787 (≈−31% vs autogenous 121,917); ChronOS+autograft 99,295 (≈−19% vs autogenous); Bio‑Oss 65,717 (≈−46% vs autogenous); Bio‑Oss+autograft 56,230 (≈−54% vs autogenous) (median areas)
Trust score:3/5

bone maturation markers (Runx2/VEGF/osteocalcin)

1 evidences

Randomized comparison of β-tricalcium phosphate (ChronOS), Bio‑Oss, autogenous bone graft, and combinations for maxillary sinus augmentation in humans; assessed new bone formation and immunohistochemical markers.

Trust comment: Small randomized human trial (30 sinuses) with histomorphometric and IHC outcomes; limited sample size but randomized design.

Study Details

PMID:29100829
Participants:30
Impact:Bio‑Oss groups showed immunolabeling consistent with greater graft maturation vs autogenous grafts (qualitative increase)
Trust score:3/5

Vitality (VT)

1 evidences

Post hoc analysis of the REPLACE randomized, double-blind, placebo-controlled trial assessing whether rhPTH(1-84) added to optimized conventional therapy (including oral calcium and active vitamin D) improves SF-36 health-related quality-of-life domains.

Trust comment: Phase-3 randomized, double-blind, placebo-controlled trial with 122 patients; HRQoL endpoint exploratory and between-group differences were not significant overall.

Study Details

PMID:29099947
Participants:122
Impact:+3.7 points (MMRM LS mean change from baseline, P<0.001) in rhPTH(1-84) group
Trust score:4/5

physical component summary (PCS)

1 evidences

Post hoc analysis of the REPLACE randomized, double-blind, placebo-controlled trial assessing whether rhPTH(1-84) added to optimized conventional therapy (including oral calcium and active vitamin D) improves SF-36 health-related quality-of-life domains.

Trust comment: Phase-3 randomized, double-blind, placebo-controlled trial with 122 patients; HRQoL endpoint exploratory and between-group differences were not significant overall.

Study Details

PMID:29099947
Participants:122
Impact:+2.0 points (LS mean change, P<0.05) in rhPTH(1-84) group
Trust score:4/5

Bodily pain (BP) and General health (GH)

1 evidences

Post hoc analysis of the REPLACE randomized, double-blind, placebo-controlled trial assessing whether rhPTH(1-84) added to optimized conventional therapy (including oral calcium and active vitamin D) improves SF-36 health-related quality-of-life domains.

Trust comment: Phase-3 randomized, double-blind, placebo-controlled trial with 122 patients; HRQoL endpoint exploratory and between-group differences were not significant overall.

Study Details

PMID:29099947
Participants:122
Impact:BP +2.0 points and GH +2.0 points (within rhPTH group, P<0.05); between-group differences not significant overall
Trust score:4/5

serum total testosterone

1 evidences

Two-by-two factorial RCT in vitamin D–deficient young males testing cholecalciferol and/or elemental calcium supplementation vs placebo on handgrip strength and serum testosterone over 6 months (228 randomized, 180 completed).

Trust comment: Randomized, placebo-controlled factorial trial with 180 completers and objective muscle/testosterone measures; well-conducted and directly tests calcium (with vitamin D) supplementation effects.

Study Details

PMID:29095521
Participants:180
Impact:Mean testosterone decreased over 6 months but change was similar across all groups (no treatment effect)
Trust score:4/5

calcium intake from formula

1 evidences

Randomized open-label study comparing a yogurt-textured, calcium-supplemented amino-acid formula versus standard liquid amino-acid formula in infants/children with severe cow's milk allergy; assessed symptoms, nutrient intake, anthropometrics over 28 days.

Trust comment: Small (N=34), short-duration (28-day), open-label randomized study; shows increased calcium intake from the fortified formula and short-term anthropometric changes, but limited by sample size and duration.

Study Details

PMID:29095347
Participants:34
Impact:Higher calcium intake in test (yogurt-type) formula vs reference (P=0.012 overall; P=0.006 for <12 months)
Trust score:3/5

anthropometric z-scores

1 evidences

Randomized open-label study comparing a yogurt-textured, calcium-supplemented amino-acid formula versus standard liquid amino-acid formula in infants/children with severe cow's milk allergy; assessed symptoms, nutrient intake, anthropometrics over 28 days.

Trust comment: Small (N=34), short-duration (28-day), open-label randomized study; shows increased calcium intake from the fortified formula and short-term anthropometric changes, but limited by sample size and duration.

Study Details

PMID:29095347
Participants:34
Impact:Increases in weight-for-height, weight-for-age, and BMI-for-age z-scores at day 28 were greater in test group (P≈0.021–0.023)
Trust score:3/5

Clinical success rate (18 months)

1 evidences

Mixture containing calcium hydroxide used as root‑filling in children had high success and resorbed at a rate similar to roots.

Trust comment: Double-blind randomized controlled trial with calculated sample size, low loss to follow-up, and objective radiographic outcomes (high/moderate quality).

Study Details

PMID:29073902
Participants:155
Impact:MPRCF 96.2% vs Vitapex 71.4% (+24.8 percentage points)
Trust score:4/5

Radiographic success rate (18 months)

1 evidences

Mixture containing calcium hydroxide used as root‑filling in children had high success and resorbed at a rate similar to roots.

Trust comment: Double-blind randomized controlled trial with calculated sample size, low loss to follow-up, and objective radiographic outcomes (high/moderate quality).

Study Details

PMID:29073902
Participants:155
Impact:MPRCF 92.5% vs Vitapex 53.6% (+38.9 percentage points)
Trust score:4/5

Filling resorption rate relative to root (18 months)

1 evidences

Mixture containing calcium hydroxide used as root‑filling in children had high success and resorbed at a rate similar to roots.

Trust comment: Double-blind randomized controlled trial with calculated sample size, low loss to follow-up, and objective radiographic outcomes (high/moderate quality).

Study Details

PMID:29073902
Participants:155
Impact:MPRCF same-rate resorption in 87.1% vs Vitapex resorbed faster in 84% (Vitapex faster-resorption associated with ~55% failure)
Trust score:4/5

Combined clinical and radiographic success (12 months)

1 evidences

In children, a Ca3SiO5-based substitute and a Ca(OH)2-based liner produced similarly high clinical and radiographic success after 12 months.

Trust comment: Randomized split‑mouth design with 12‑month follow-up but moderate losses to follow-up (80→60 completed); outcomes are objective and clinically relevant.

Study Details

PMID:29070160
Participants:60
Impact:Ca3SiO5 98.3% (59/60) vs Ca(OH)2 95% (57/60); no significant difference (P>0.05)
Trust score:4/5

Tooth shade improvement (immediate)

1 evidences

Single supervised application of a PAP-based non‑peroxide gel containing calcium lactate gluconate produced immediate tooth whitening sustained at 24 h with few transient soft‑tissue effects.

Trust comment: Double‑blind placebo‑controlled RCT but small sample (n=40) and short follow-up (24 h); moderate internal validity for short-term effects.

Study Details

PMID:29069156
Participants:40
Impact:Mean shade change ≈2.26 units (baseline 9.84 → immediate 7.58) in active vs no change in placebo (P<0.001)
Trust score:3/5

Tooth shade maintenance (24 h)

1 evidences

Single supervised application of a PAP-based non‑peroxide gel containing calcium lactate gluconate produced immediate tooth whitening sustained at 24 h with few transient soft‑tissue effects.

Trust comment: Double‑blind placebo‑controlled RCT but small sample (n=40) and short follow-up (24 h); moderate internal validity for short-term effects.

Study Details

PMID:29069156
Participants:40
Impact:Effect largely maintained at 24 h (mean 7.79; Δ ≈2.05 vs baseline)
Trust score:3/5

Gingival irritation/tooth sensitivity

1 evidences

Single supervised application of a PAP-based non‑peroxide gel containing calcium lactate gluconate produced immediate tooth whitening sustained at 24 h with few transient soft‑tissue effects.

Trust comment: Double‑blind placebo‑controlled RCT but small sample (n=40) and short follow-up (24 h); moderate internal validity for short-term effects.

Study Details

PMID:29069156
Participants:40
Impact:Examiner-observed gingival irritation in 10–15% (test) immediately, transient; no examiner-observed hypersensitivity in test group
Trust score:3/5

femoral neck T-score

1 evidences

Two-year randomized trial of exercise (with calcium + vitamin D supplementation) in postmenopausal women; high-impact training improved femoral neck T-scores more than fast walking.

Trust comment: Randomized 2-year trial directly involving calcium + vitamin D but small sample (34 completed) and limited power (51%), so moderate confidence.

Study Details

PMID:29040219
Participants:34
Impact:ΔControl = -0.04; ΔExperimental = +0.28 (experimental > control, significant)
Trust score:3/5

T-score trajectory (overall)

1 evidences

Two-year randomized trial of exercise (with calcium + vitamin D supplementation) in postmenopausal women; high-impact training improved femoral neck T-scores more than fast walking.

Trust comment: Randomized 2-year trial directly involving calcium + vitamin D but small sample (34 completed) and limited power (51%), so moderate confidence.

Study Details

PMID:29040219
Participants:34
Impact:no decrease in T-scores after 2 years in both groups
Trust score:3/5

cardiovascular event rate with CAC

1 evidences

Cohort of 252 hypertensive patients followed ~13 years: coronary artery calcification (CAC) and left ventricular hypertrophy (LVH) each predict higher cardiovascular event risk, especially when both present.

Trust comment: Well-characterized cohort with long follow-up and clear associations; observational design limits causal inference.

Study Details

PMID:29036433
Participants:252
Impact:43.4% vs 21.5% without CAC (+21.9 percentage points)
Trust score:4/5

cardiovascular event rate with LVH

1 evidences

Cohort of 252 hypertensive patients followed ~13 years: coronary artery calcification (CAC) and left ventricular hypertrophy (LVH) each predict higher cardiovascular event risk, especially when both present.

Trust comment: Well-characterized cohort with long follow-up and clear associations; observational design limits causal inference.

Study Details

PMID:29036433
Participants:252
Impact:44% vs 31.6% without LVH (+12.4 percentage points)
Trust score:4/5

LVH effect in presence of CAC

1 evidences

Cohort of 252 hypertensive patients followed ~13 years: coronary artery calcification (CAC) and left ventricular hypertrophy (LVH) each predict higher cardiovascular event risk, especially when both present.

Trust comment: Well-characterized cohort with long follow-up and clear associations; observational design limits causal inference.

Study Details

PMID:29036433
Participants:252
Impact:61.4% vs 36.5% without LVH (+24.9 percentage points); HR with LVH if CAC present = 4.4
Trust score:4/5

facial bone thickness reduction at implant platform

1 evidences

Randomized trial of 60 implants comparing synthetic PLA vs collagen membranes with biphasic calcium phosphate graft: similar facial bone thickness loss at 6 months and all implants osseointegrated.

Trust comment: Randomized clinical trial using calcium phosphate graft material with objective CBCT measures; moderate sample and short 6-month follow-up limit long-term inference.

Study Details

PMID:29028848
Participants:60
Impact:test 34.30% vs control 34.80% (no significant difference)
Trust score:3/5

facial bone thickness reduction range (2–6 mm levels)

1 evidences

Randomized trial of 60 implants comparing synthetic PLA vs collagen membranes with biphasic calcium phosphate graft: similar facial bone thickness loss at 6 months and all implants osseointegrated.

Trust comment: Randomized clinical trial using calcium phosphate graft material with objective CBCT measures; moderate sample and short 6-month follow-up limit long-term inference.

Study Details

PMID:29028848
Participants:60
Impact:test 19.81–34.30% vs control 19.52–34.80% (no significant differences)
Trust score:3/5

Calcium supplement consumption (pregnancy)

1 evidences

Cluster-randomized evaluation of an integrated nutrition package (including free calcium tablets) vs standard care showing improved supplement use, diet diversity and breastfeeding.

Trust comment: Large, cluster-randomized evaluation with high coverage and objective program monitoring; effect estimates reported and statistically tested.

Study Details

PMID:29021370
Participants:2000
Impact:+12.8 percentage points (increase in women who consumed calcium supplements)
Trust score:5/5

Number of calcium tablets consumed

1 evidences

Cluster-randomized evaluation of an integrated nutrition package (including free calcium tablets) vs standard care showing improved supplement use, diet diversity and breastfeeding.

Trust comment: Large, cluster-randomized evaluation with high coverage and objective program monitoring; effect estimates reported and statistically tested.

Study Details

PMID:29021370
Participants:2000
Impact:+50 tablets (difference-in-difference effect)
Trust score:5/5

Bone turnover markers (CTx-1 and PINP)

1 evidences

In Chinese postmenopausal women, daily fortified milk (1200 mg calcium + vitamin D + FOS-inulin) for 52 weeks increased 25(OH)D, suppressed bone turnover markers and preserved femoral neck BMD compared with regular milk.

Trust comment: Randomized 1-year trial directly testing calcium+vitamin D fortified milk with clear biochemical and DXA outcomes; moderate sample size and clinically relevant endpoints.

Study Details

PMID:28975432
Participants:121
Impact:significant suppression (CTx-1 p=0.018; PINP p=0.004)
Trust score:4/5

4-year survival

1 evidences

A 3-month post-discharge individualized nutritional program (including vitamin D3/calcium supplement among other components) did not improve 1- or 4-year survival versus usual care despite earlier short-term functional benefits.

Trust comment: Randomized human study including calcium as part of a multi-component intervention, but calcium's isolated effect cannot be determined and no long-term survival benefit was observed.

Study Details

PMID:28972236
Participants:210
Impact:intervention 29% vs control 30%; HR=0.928 (95% CI 0.671–1.283); no significant difference
Trust score:3/5

Short-term functional outcomes (previously reported)

1 evidences

A 3-month post-discharge individualized nutritional program (including vitamin D3/calcium supplement among other components) did not improve 1- or 4-year survival versus usual care despite earlier short-term functional benefits.

Trust comment: Randomized human study including calcium as part of a multi-component intervention, but calcium's isolated effect cannot be determined and no long-term survival benefit was observed.

Study Details

PMID:28972236
Participants:210
Impact:positive effects on weight, lean mass, functional limitations and falls (not linked to long-term survival in this analysis)
Trust score:3/5

physical performance

1 evidences

6-month pilot RCT in osteopenic breast cancer survivors found no added bone or performance benefit from adding home exercise to calcium + vitamin D supplements.

Trust comment: Pilot randomized controlled trial in 43 participants; randomized design but small sample limits power.

Study Details

PMID:25730596
Participants:43
Impact:no significant difference
Trust score:3/5

supplemental calcium intake

1 evidences

Cluster-randomized trial in pregnant women comparing standard (3×500 mg/day) vs low-dose (2×500 mg/day) antenatal calcium regimens: the simpler lower-dose regimen led to substantially lower calcium intake.

Trust comment: Large cluster-randomized trial with 990 participants and objective pill-count primary outcome; well-powered and directly tests calcium supplementation regimens.

Study Details

PMID:28878035
Participants:990
Impact:low-dose mean 810 mg/day vs standard mean 1198 mg/day (difference −388 mg/day; 95% CI 341–434 mg/day) — inferior to standard
Trust score:4/5

adherence rate

1 evidences

Cluster-randomized trial in pregnant women comparing standard (3×500 mg/day) vs low-dose (2×500 mg/day) antenatal calcium regimens: the simpler lower-dose regimen led to substantially lower calcium intake.

Trust comment: Large cluster-randomized trial with 990 participants and objective pill-count primary outcome; well-powered and directly tests calcium supplementation regimens.

Study Details

PMID:28878035
Participants:990
Impact:no difference between regimens; overall adherence 80%
Trust score:4/5

primary supplement reduction to ≤500 mg/d calcium and ≤0.25 μg/d calcitriol

1 evidences

rhPTH(1-84) at 25 or 50 μg/d allowed a subset of hypoparathyroidism patients to reduce calcium and calcitriol supplements and was generally tolerated.

Trust comment: Randomized, dose-blinded multicenter trial but small sample and short duration; directly relevant to calcium supplement requirements in patients.

Study Details

PMID:28942334
Participants:42
Impact:achieved in 21% (4/19) of 25 μg group and 26% (6/23) of 50 μg group at week 8
Trust score:3/5

≥50% reduction in calcium and calcitriol doses (secondary)

1 evidences

rhPTH(1-84) at 25 or 50 μg/d allowed a subset of hypoparathyroidism patients to reduce calcium and calcitriol supplements and was generally tolerated.

Trust comment: Randomized, dose-blinded multicenter trial but small sample and short duration; directly relevant to calcium supplement requirements in patients.

Study Details

PMID:28942334
Participants:42
Impact:achieved in 11% (2/19) of 25 μg group and 26% (6/23) of 50 μg group at week 8
Trust score:3/5

major adverse cardiovascular events

1 evidences

In symptomatic outpatients, coronary artery calcium (CAC) score predicted cardiovascular events reasonably well and most events occurred in patients with measurable CAC.

Trust comment: Large multicenter randomized trial subgroup analysis with robust clinical endpoints; high sample size supports reliability.

Study Details

PMID:28847895
Participants:4209
Impact:CAC discriminatory C-statistic 0.67 vs functional testing 0.64; most events had measurable CAC at baseline
Trust score:4/5

test abnormality distribution

1 evidences

In symptomatic outpatients, coronary artery calcium (CAC) score predicted cardiovascular events reasonably well and most events occurred in patients with measurable CAC.

Trust comment: Large multicenter randomized trial subgroup analysis with robust clinical endpoints; high sample size supports reliability.

Study Details

PMID:28847895
Participants:4209
Impact:More patients classified as abnormal by CAC (65.4% mildly–severely) than by functional testing (22.0% mildly–severely)
Trust score:4/5

markers of calcium metabolism (PTH, ACa)

1 evidences

Five days of low energy availability increased bone resorption and decreased bone formation in women but not in men.

Trust comment: Randomized crossover with objective biomarkers but small short-term sample limits generalizability.

Study Details

PMID:28847532
Participants:22
Impact:no significant differences between sexes following low EA
Trust score:3/5

urine albumin-creatinine ratio (ACR)

1 evidences

Adding cilnidipine to RAS blockade reduced urine albumin-creatinine ratio from baseline; cilnidipine showed greater anti-albuminuric effect than amlodipine in patients with diabetes duration ≥10 years.

Trust comment: Randomized multicentre trial with clear clinical endpoints and per-protocol analysis, but modest sample size and open-label design are limitations.

Study Details

PMID:28840637
Participants:57
Impact:Cilnidipine decreased ACR: −53.0±123.2 mg/g (12 wk) and −57.3±106.9 mg/g (24 wk); greater between-group reduction in diabetes ≥10 years (−84.7±106.8 vs −9.5±79.2 at 12 wk)
Trust score:4/5

PAI-1

1 evidences

Adding cilnidipine to RAS blockade reduced urine albumin-creatinine ratio from baseline; cilnidipine showed greater anti-albuminuric effect than amlodipine in patients with diabetes duration ≥10 years.

Trust comment: Randomized multicentre trial with clear clinical endpoints and per-protocol analysis, but modest sample size and open-label design are limitations.

Study Details

PMID:28840637
Participants:57
Impact:greater decrease with cilnidipine at 12 weeks (−2.8±10.1 ng/mL vs +2.2±16.1, P=0.011)
Trust score:4/5

white spot lesion appearance

1 evidences

Applying CPP-ACP paste twice daily after braces did not improve white spot lesions compared with normal fluoride toothpaste over 36 months.

Trust comment: Randomized small clinical trial with long follow-up but limited sample size.

Study Details

PMID:28835597
Participants:41
Impact:no improvement vs control after 36 months
Trust score:3/5

oral Streptococcus mutans and Lactobacillus counts

1 evidences

Applying CPP-ACP paste twice daily after braces did not improve white spot lesions compared with normal fluoride toothpaste over 36 months.

Trust comment: Randomized small clinical trial with long follow-up but limited sample size.

Study Details

PMID:28835597
Participants:41
Impact:no significant change vs control
Trust score:3/5

bioavailable 25-(OH)D

1 evidences

In HIV-positive adults receiving vitamin D plus calcium, bioavailable 25(OH)D rose more in black than nonblack participants but bone markers and BMD changes were similar between races at 48 weeks.

Trust comment: Secondary analysis of a randomized, double-blind trial with complete-data subgroup (129); relevant to calcium as co-supplement but inference limited to study population.

Study Details

PMID:28832406
Participants:129
Impact:greater increase in black vs nonblack participants at 48 weeks
Trust score:4/5

bone mineral density / bone turnover markers

1 evidences

In HIV-positive adults receiving vitamin D plus calcium, bioavailable 25(OH)D rose more in black than nonblack participants but bone markers and BMD changes were similar between races at 48 weeks.

Trust comment: Secondary analysis of a randomized, double-blind trial with complete-data subgroup (129); relevant to calcium as co-supplement but inference limited to study population.

Study Details

PMID:28832406
Participants:129
Impact:no between-race difference in change at 48 weeks
Trust score:4/5

fat-mass loss

1 evidences

Among overweight adults on a 24-week calorie-restricted diet, high-dairy (higher calcium) intake did not increase fecal fat excretion or accelerate weight/fat loss versus low-dairy.

Trust comment: Randomized controlled trial with clear endpoints and reported group differences; moderate sample size.

Study Details

PMID:28829923
Participants:80
Impact:HD: -7.8% ± 1.3% vs LD: -8.5% ± 1.1% (P = 0.76)
Trust score:4/5

fecal fat excretion

1 evidences

Among overweight adults on a 24-week calorie-restricted diet, high-dairy (higher calcium) intake did not increase fecal fat excretion or accelerate weight/fat loss versus low-dairy.

Trust comment: Randomized controlled trial with clear endpoints and reported group differences; moderate sample size.

Study Details

PMID:28829923
Participants:80
Impact:HD: -0.57 ± 0.76 g vs LD: 0.46 ± 0.70 g (P = 0.12)
Trust score:4/5

symptom recovery time (abdominal pain/distention, bowel sounds, first defecation)

1 evidences

Adding somatostatin enema to standard care shortened symptom recovery and decreased inflammation; blood calcium rose after treatment.

Trust comment: Randomized clinical sample with clear outcomes, but calcium was a measured biomarker secondary to a non-calcium intervention (indirect relevance).

Study Details

PMID:28829514
Participants:79
Impact:shorter recovery times (p<0.05)
Trust score:3/5

dentinal bridge formation

1 evidences

Partial pulpotomy using calcium-containing materials showed different healing: Biodentine and MTA gave better dentinal bridge formation and clinical outcomes than TheraCal.

Trust comment: Small randomized clinical trial with histologic endpoints and objective measures, but limited sample size (27 teeth).

Study Details

PMID:28822566
Participants:27
Impact:Biodentine 100% vs TheraCal 11% vs ProRoot MTA 56% (P = .001)
Trust score:4/5

pulp inflammation

1 evidences

Partial pulpotomy using calcium-containing materials showed different healing: Biodentine and MTA gave better dentinal bridge formation and clinical outcomes than TheraCal.

Trust comment: Small randomized clinical trial with histologic endpoints and objective measures, but limited sample size (27 teeth).

Study Details

PMID:28822566
Participants:27
Impact:absent in all groups at 8 weeks
Trust score:4/5

postoperative pain at 1 week

1 evidences

Partial pulpotomy using calcium-containing materials showed different healing: Biodentine and MTA gave better dentinal bridge formation and clinical outcomes than TheraCal.

Trust comment: Small randomized clinical trial with histologic endpoints and objective measures, but limited sample size (27 teeth).

Study Details

PMID:28822566
Participants:27
Impact:TheraCal: 2 patients (20%) reported significant pain
Trust score:4/5

neuromuscular recovery time (TOFr to 0.9)

1 evidences

Giving calcium chloride with neostigmine sped early neuromuscular recovery after surgery.

Trust comment: Randomized double-blind trial with objective neuromuscular monitoring; sample size modest but methods strong.

Study Details

PMID:28763316
Participants:53
Impact:-1.7 min (median 5.0 vs 6.7 min; P=0.007)
Trust score:4/5

TOF ratio at 5 min

1 evidences

Giving calcium chloride with neostigmine sped early neuromuscular recovery after surgery.

Trust comment: Randomized double-blind trial with objective neuromuscular monitoring; sample size modest but methods strong.

Study Details

PMID:28763316
Participants:53
Impact:+19 percentage points (median 87% vs 68%; P=0.002)
Trust score:4/5

incidence of postoperative residual curarisation (PORC) at 5 min

1 evidences

Giving calcium chloride with neostigmine sped early neuromuscular recovery after surgery.

Trust comment: Randomized double-blind trial with objective neuromuscular monitoring; sample size modest but methods strong.

Study Details

PMID:28763316
Participants:53
Impact:-31.5 percentage points (50.0% vs 81.5%; P=0.016)
Trust score:4/5

femoral tunnel cross-sectional area increase

1 evidences

Calcium phosphate‑hybridized tendon grafts reduced femoral bone tunnel enlargement one year after ACL reconstruction.

Trust comment: Randomized trial with objective CT measures and 1‑year follow-up; outcomes clinically relevant though some numeric details not provided in excerpt.

Study Details

PMID:28748492
Participants:73
Impact:significant reduction in increase at 1 year (CaP vs control; exact values not reported in excerpt)
Trust score:4/5

femoral tunnel anterior-posterior and proximal-distal diameter increases

1 evidences

Calcium phosphate‑hybridized tendon grafts reduced femoral bone tunnel enlargement one year after ACL reconstruction.

Trust comment: Randomized trial with objective CT measures and 1‑year follow-up; outcomes clinically relevant though some numeric details not provided in excerpt.

Study Details

PMID:28748492
Participants:73
Impact:significant reduction in diameter increases on the femoral side (no numeric values provided)
Trust score:4/5

tunnel wall translation (posterior and distal)

1 evidences

Calcium phosphate‑hybridized tendon grafts reduced femoral bone tunnel enlargement one year after ACL reconstruction.

Trust comment: Randomized trial with objective CT measures and 1‑year follow-up; outcomes clinically relevant though some numeric details not provided in excerpt.

Study Details

PMID:28748492
Participants:73
Impact:posterior wall showed greater anterior shift and distal wall showed reduced distal shift with CaP (directional changes reported; no numeric values provided)
Trust score:4/5

residual graft particle area

1 evidences

Adding platelet-rich products to beta-tricalcium phosphate graft did not increase new bone formation after sinus-floor augmentation.

Trust comment: Randomized clinical trial with objective histomorphometric outcomes but small sample (n=26) limiting power.

Study Details

PMID:28745027
Participants:26
Impact:no significant difference (control 30.39±10.29% vs P-PRP 28.98±7.94% vs PRF 32.66±7.46%; P>0.05)
Trust score:3/5

osteoprogenitor/inflammatory cells

1 evidences

Adding platelet-rich products to beta-tricalcium phosphate graft did not increase new bone formation after sinus-floor augmentation.

Trust comment: Randomized clinical trial with objective histomorphometric outcomes but small sample (n=26) limiting power.

Study Details

PMID:28745027
Participants:26
Impact:osteoprogenitor cells lower and inflammatory cells higher in PRF group (P<0.01)
Trust score:3/5

weight gain

1 evidences

A new human milk fortifier (higher protein:energy, includes similar mineral/calcium content) increased weight gain in preterm infants; small changes in blood and urine calcium but no change in bone mineral density.

Trust comment: Multicenter, double-blind randomized trial with objective growth and biochemical measures; moderate sample size and early stopping for efficacy.

Study Details

PMID:28727654
Participants:153
Impact:+2.3 g/day (adjusted D1–D21; 95% CI 0.4 to 4.2), superior to control
Trust score:4/5

bone mineral content/density (BMC/BMD)

2 evidences

In children with steroid-sensitive nephrotic syndrome, vitamin D3 plus calcium raised 25(OH)D levels but did not change bone mineral content/density or relapse rate; hypercalciuria was common in treated patients.

Trust comment: Randomized controlled trial in children with objective biochemical and DXA outcomes but small sample and short follow-up (6 months).

Study Details

PMID:28725977
Participants:43
Impact:no significant change (BMC p=0.44; BMD p=0.64)
Trust score:4/5

A new human milk fortifier (higher protein:energy, includes similar mineral/calcium content) increased weight gain in preterm infants; small changes in blood and urine calcium but no change in bone mineral density.

Trust comment: Multicenter, double-blind randomized trial with objective growth and biochemical measures; moderate sample size and early stopping for efficacy.

Study Details

PMID:28727654
Participants:153
Impact:no significant difference (no change; not significant)
Trust score:4/5

25(OH)D (vitamin D) levels

1 evidences

In children with steroid-sensitive nephrotic syndrome, vitamin D3 plus calcium raised 25(OH)D levels but did not change bone mineral content/density or relapse rate; hypercalciuria was common in treated patients.

Trust comment: Randomized controlled trial in children with objective biochemical and DXA outcomes but small sample and short follow-up (6 months).

Study Details

PMID:28725977
Participants:43
Impact:significant increase at 6 weeks (T1) and 6 months (T2) versus control (P<0.001)
Trust score:4/5

wheal size (skin prick test)

1 evidences

Short RCT in adults found oral calcium carbonate did not reduce skin-prick-test wheal size or itching compared to placebo.

Trust comment: Randomized, double-blind, placebo-controlled trial but small sample (n=40); outcome measures direct and appropriate for allergy question.

Study Details

PMID:28724883
Participants:40
Impact:no difference vs placebo at 4 and 72 hours (P>0.05)
Trust score:4/5

pruritus intensity

1 evidences

Short RCT in adults found oral calcium carbonate did not reduce skin-prick-test wheal size or itching compared to placebo.

Trust comment: Randomized, double-blind, placebo-controlled trial but small sample (n=40); outcome measures direct and appropriate for allergy question.

Study Details

PMID:28724883
Participants:40
Impact:no difference vs placebo (P>0.05)
Trust score:4/5

whole body lean mass

1 evidences

A 20-week randomized double-blind trial in older men: twice-daily multi-ingredient supplement (whey protein, creatine, 400 mg calcium, vitamin D, n-3 PUFA) increased lean mass and strength and improved some metabolic markers compared with control.

Trust comment: - Checklist: (1) Confirm supplement contains calcium (400 mg per drink) as part of multi-ingredient formula; (2) Identify main outcomes (lean mass, strength, metabolic markers); (3) Use completers (38) for participant count and extract numerical changes. Randomized, double-blind, placebo-controlled trial with modest sample (n=49 randomized, 38 completers); multi-ingredient design prevents attribution to calcium alone but results robust for the combined product—rated 4 for quality.

Study Details

PMID:28719669
Participants:38
Impact:+0.7 kg (increase in SUPP group after 6 weeks)
Trust score:4/5

muscle strength (sum of all 1RMs)

1 evidences

A 20-week randomized double-blind trial in older men: twice-daily multi-ingredient supplement (whey protein, creatine, 400 mg calcium, vitamin D, n-3 PUFA) increased lean mass and strength and improved some metabolic markers compared with control.

Trust comment: - Checklist: (1) Confirm supplement contains calcium (400 mg per drink) as part of multi-ingredient formula; (2) Identify main outcomes (lean mass, strength, metabolic markers); (3) Use completers (38) for participant count and extract numerical changes. Randomized, double-blind, placebo-controlled trial with modest sample (n=49 randomized, 38 completers); multi-ingredient design prevents attribution to calcium alone but results robust for the combined product—rated 4 for quality.

Study Details

PMID:28719669
Participants:38
Impact:+3% during Phase 1 (6 wk), further +20% during Phase 2 (with exercise)
Trust score:4/5

newly formed bone (histomorphometry at 6 months)

1 evidences

Randomized double-blind clinical trial in 48 volunteers comparing two biphasic calcium phosphate biomaterials in dental sockets; biomaterial B1 (HA 60.3% / β-TCP 39.7%) produced the greatest new bone formation at 6 months.

Trust comment: - Checklist: (1) Confirm direct calcium-material intervention (biphasic calcium phosphate biomaterials) in humans; (2) Identify main outcomes (new bone formation, connective tissue, residual biomaterial); (3) Use randomized double-blind design and reported histomorphometric values. Randomized, double-blind trial with clear histological endpoints and n=48 supports moderate–high trust (4).

Study Details

PMID:28703478
Participants:48
Impact:B1: 69.3% ± 6.03% new bone (highest among groups)
Trust score:4/5

serum markers of mineral metabolism (calcium, phosphorus, 25(OH)D, 1,25(OH)2D, iPTH, FGF23)

1 evidences

12-week randomized placebo-controlled trial of IL-1 blockade (rilonacept) in CKD patients: inflammation (hsCRP) decreased but there were no significant changes in serum markers of mineral metabolism (calcium, phosphate, vitamin D metabolites, iPTH, FGF23); a small pilot substudy showed a near-significant trend toward improved 400 m walk time.

Trust comment: - Checklist: (1) Confirm intervention and relevance to mineral metabolism (IL-1 inhibition effects on CKD‑MBD markers measured); (2) Identify main outcomes (mineral markers and physical function); (3) Use completers (n=39) and extract numerical changes. Randomized, placebo-controlled trial with small sample and secondary/pilot endpoints—measurements reliable but underpowered for small effects, rated 4.

Study Details

PMID:28699886
Participants:39
Impact:No significant change after 12 weeks (no meaningful % change)
Trust score:4/5

endurance (400-m walk time)

1 evidences

12-week randomized placebo-controlled trial of IL-1 blockade (rilonacept) in CKD patients: inflammation (hsCRP) decreased but there were no significant changes in serum markers of mineral metabolism (calcium, phosphate, vitamin D metabolites, iPTH, FGF23); a small pilot substudy showed a near-significant trend toward improved 400 m walk time.

Trust comment: - Checklist: (1) Confirm intervention and relevance to mineral metabolism (IL-1 inhibition effects on CKD‑MBD markers measured); (2) Identify main outcomes (mineral markers and physical function); (3) Use completers (n=39) and extract numerical changes. Randomized, placebo-controlled trial with small sample and secondary/pilot endpoints—measurements reliable but underpowered for small effects, rated 4.

Study Details

PMID:28699886
Participants:39
Impact:Near-significant improvement in rilonacept group: 312→281 s (−31 s) vs placebo 275→273 s (p≈0.07)
Trust score:4/5

albumin transfusion amount

1 evidences

A multimodal nutrition protocol around knee replacement reduced albumin transfusions, electrolyte disorders including low calcium on day 1, and shortened hospital stay.

Trust comment: Randomized controlled trial with 162 patients and significant p-values; calcium-related outcomes were secondary but directly measured.

Study Details

PMID:28697860
Participants:162
Impact:reduced (P=0.021)
Trust score:4/5

muscle strength

1 evidences

Enhanced exercise and combined calcium plus vitamin D helped maintain or improve muscle strength in postmenopausal women at high osteoporosis risk.

Trust comment: Large randomized trial (n=614) in target population with significant biochemical and functional outcomes, though some effect sizes not fully reported.

Study Details

PMID:28695804
Participants:614
Impact:sustained with enhanced exercise and combined Ca+vitamin D (over 2 years, P<0.05)
Trust score:4/5

short-term muscular strength improvement (Ca+vitD)

1 evidences

Enhanced exercise and combined calcium plus vitamin D helped maintain or improve muscle strength in postmenopausal women at high osteoporosis risk.

Trust comment: Large randomized trial (n=614) in target population with significant biochemical and functional outcomes, though some effect sizes not fully reported.

Study Details

PMID:28695804
Participants:614
Impact:improved within short period (P<0.05)
Trust score:4/5

weekly exercise duration

1 evidences

An education and counseling program increased osteoporosis knowledge, self-efficacy, weekly exercise and daily calcium intake in at-risk women.

Trust comment: Randomized controlled behavioral trial but small sample (n=73); reports significant increases in reported calcium intake and related behaviors.

Study Details

PMID:28688497
Participants:73
Impact:increased (P<0.001)
Trust score:3/5

lesion depth

1 evidences

In an in situ human model, adding 5% CSPS to an SMFP dentifrice did not improve enamel lesion remineralization versus the same fluoride dentifrice without CSPS.

Trust comment: Randomized, investigator-blind, crossover in situ human study with objective endpoint measurements; sample size moderate for in situ design.

Study Details

PMID:28219056
Participants:77
Impact:no significant difference (p=0.6622)
Trust score:4/5

weight regain

1 evidences

After weight loss, adding protein supplements (one arm included whey plus calcium) did not improve weight maintenance compared with control, although protein supplements increased diet-induced thermogenesis and resting energy expenditure.

Trust comment: Randomized, double-blind controlled trial with good sample size and objective measures, but calcium was included only as part of one protein supplement arm (not isolated).

Study Details

PMID:28679554
Participants:151
Impact:Whey+ (whey with calcium) 2.19 ± 4.6 kg (no difference vs control 2.23 ± 3.8 kg)
Trust score:4/5

diet-induced thermogenesis (DIT)

1 evidences

After weight loss, adding protein supplements (one arm included whey plus calcium) did not improve weight maintenance compared with control, although protein supplements increased diet-induced thermogenesis and resting energy expenditure.

Trust comment: Randomized, double-blind controlled trial with good sample size and objective measures, but calcium was included only as part of one protein supplement arm (not isolated).

Study Details

PMID:28679554
Participants:151
Impact:≈ +30 kJ per 2.5 h vs control
Trust score:4/5

post-operative sensitivity

1 evidences

After tooth bleaching, CPP-ACPF reduced immediate post-operative sensitivity (notably after the first session) vs control; NovaMin showed only short-term reduction and neither agent affected bleaching color change.

Trust comment: Randomized, double-blind clinical trial in humans with objective color measures; moderate sample size (51 completers) supports findings though groups were small.

Study Details

PMID:28678953
Participants:51
Impact:CPP-ACPF significantly reduced sensitivity after the first bleaching session (vs control); NovaMin reduced sensitivity only in the first session (transient)
Trust score:4/5

enamel fluoride uptake (EFU)

1 evidences

Adding a calcium-containing compound (CSPS) to a fluoride toothpaste did not change enamel remineralization compared with fluoride alone.

Trust comment: Well-conducted randomized, investigator-blind crossover in situ non-inferiority trial with 77 subjects.

Study Details

PMID:28657702
Participants:77
Impact:no significant change vs 1500 ppm F dentifrice
Trust score:4/5

DIAGNOdent value (smooth surfaces)

1 evidences

Daily local application of CPP-ACFP for 4 weeks significantly remineralized initial enamel caries (white spot lesions).

Trust comment: Small in vivo randomized study (30 volunteers) with lesion-level analysis; positive results but limited sample and short duration.

Study Details

PMID:28656922
Participants:30
Impact:significant decrease after 4 weeks (remineralization)
Trust score:3/5

DIAGNOdent value (occlusal surfaces)

1 evidences

Daily local application of CPP-ACFP for 4 weeks significantly remineralized initial enamel caries (white spot lesions).

Trust comment: Small in vivo randomized study (30 volunteers) with lesion-level analysis; positive results but limited sample and short duration.

Study Details

PMID:28656922
Participants:30
Impact:significant decrease after 4 weeks (remineralization)
Trust score:3/5

incidence of hematologic malignancy

1 evidences

Calcium plus vitamin D supplementation was associated with a lower risk of developing hematologic malignancies, especially lymphoid types, but did not significantly reduce death from these cancers overall.

Trust comment: Large randomized controlled trial (WHI) secondary analysis with 34,763 participants; high-quality data though post hoc analyses.

Study Details

PMID:28654155
Participants:34763
Impact:-20% incidence (HR 0.80, 95% CI 0.65-0.99)
Trust score:5/5

hematologic malignancy-specific mortality

1 evidences

Calcium plus vitamin D supplementation was associated with a lower risk of developing hematologic malignancies, especially lymphoid types, but did not significantly reduce death from these cancers overall.

Trust comment: Large randomized controlled trial (WHI) secondary analysis with 34,763 participants; high-quality data though post hoc analyses.

Study Details

PMID:28654155
Participants:34763
Impact:no significant change (HR 0.77, 95% CI 0.53-1.11)
Trust score:5/5

lymphoid malignancy mortality

1 evidences

Calcium plus vitamin D supplementation was associated with a lower risk of developing hematologic malignancies, especially lymphoid types, but did not significantly reduce death from these cancers overall.

Trust comment: Large randomized controlled trial (WHI) secondary analysis with 34,763 participants; high-quality data though post hoc analyses.

Study Details

PMID:28654155
Participants:34763
Impact:-54% mortality (HR 0.46, 95% CI 0.24-0.89)
Trust score:5/5

lutein AUC (TAG-rich lipoprotein fraction)

1 evidences

Supplemental calcium (500 or 1000 mg) did not alter absorption of carotenoids from a spinach meal in healthy men.

Trust comment: Randomized, double-blind crossover trial well-controlled but small (25 subjects).

Study Details

PMID:28651681
Participants:25
Impact:no significant change with 500 or 1000 mg supplemental Ca
Trust score:4/5

β-carotene AUC (TAG-rich lipoprotein fraction)

1 evidences

Supplemental calcium (500 or 1000 mg) did not alter absorption of carotenoids from a spinach meal in healthy men.

Trust comment: Randomized, double-blind crossover trial well-controlled but small (25 subjects).

Study Details

PMID:28651681
Participants:25
Impact:no significant change with 500 or 1000 mg supplemental Ca
Trust score:4/5

β-cryptoxanthin AUC (TAG-rich lipoprotein fraction)

1 evidences

Supplemental calcium (500 or 1000 mg) did not alter absorption of carotenoids from a spinach meal in healthy men.

Trust comment: Randomized, double-blind crossover trial well-controlled but small (25 subjects).

Study Details

PMID:28651681
Participants:25
Impact:no significant change with 500 or 1000 mg supplemental Ca
Trust score:4/5

severe hypercalcemia incidence

1 evidences

Daily vitamin D3 at 10 or 30 µg did not cause severe high blood calcium in infants; mild hypercalcemia was more common at 6 months than at 12 months.

Trust comment: Large cohort (987 infants) with measured biochemical outcomes at 6 and 12 months; reliable for safety assessment regarding calcium levels.

Study Details

PMID:28647736
Participants:987
Impact:none observed (0 cases)
Trust score:4/5

Mild hypercalcemia incidence

1 evidences

Daily vitamin D3 at 10 or 30 µg did not cause severe high blood calcium in infants; mild hypercalcemia was more common at 6 months than at 12 months.

Trust comment: Large cohort (987 infants) with measured biochemical outcomes at 6 and 12 months; reliable for safety assessment regarding calcium levels.

Study Details

PMID:28647736
Participants:987
Impact:28% at 6 months; 2% at 12 months
Trust score:4/5

25-hydroxyvitamin D correlation with ionized calcium

1 evidences

Daily vitamin D3 at 10 or 30 µg did not cause severe high blood calcium in infants; mild hypercalcemia was more common at 6 months than at 12 months.

Trust comment: Large cohort (987 infants) with measured biochemical outcomes at 6 and 12 months; reliable for safety assessment regarding calcium levels.

Study Details

PMID:28647736
Participants:987
Impact:small positive correlation (r = 0.149); slightly higher 25-OHD in infants with mild hypercalcemia
Trust score:4/5

partial pulpotomy success rate (MTA)

1 evidences

In mature permanent molars with pulp exposure, MTA had higher success than calcium hydroxide over 2 years.

Trust comment: Randomized clinical trial with 2-year follow-up and clear outcome measures; sample size modest but results clinically relevant for calcium hydroxide as a dental agent.

Study Details

PMID:28673494
Participants:50
Impact:85% at 2 years
Trust score:4/5

partial pulpotomy success rate (calcium hydroxide)

1 evidences

In mature permanent molars with pulp exposure, MTA had higher success than calcium hydroxide over 2 years.

Trust comment: Randomized clinical trial with 2-year follow-up and clear outcome measures; sample size modest but results clinically relevant for calcium hydroxide as a dental agent.

Study Details

PMID:28673494
Participants:50
Impact:43% at 2 years
Trust score:4/5

Hirsutism score

1 evidences

Twelve weeks of magnesium-zinc-calcium-vitamin D co-supplementation in women with PCOS reduced hirsutism and some inflammation/oxidative stress markers and increased antioxidant capacity.

Trust comment: Randomized double-blind placebo-controlled trial including calcium as part of a multi-nutrient supplement; effects are credible but cannot be ascribed to calcium alone.

Study Details

PMID:28668998
Participants:60
Impact:-2.4 points (supplement) vs -0.1 (placebo) after 12 weeks
Trust score:4/5

total antioxidant capacity (TAC)

3 evidences

Twelve weeks of magnesium-zinc-calcium-vitamin D co-supplementation in women with PCOS reduced hirsutism and some inflammation/oxidative stress markers and increased antioxidant capacity.

Trust comment: Randomized double-blind placebo-controlled trial including calcium as part of a multi-nutrient supplement; effects are credible but cannot be ascribed to calcium alone.

Study Details

PMID:28668998
Participants:60
Impact:+46.6 mmol/L (supplement) vs -7.7 (placebo) after 12 weeks
Trust score:4/5

In 60 vitamin D-deficient women with PCOS, 8 weeks of vitamin D–K–calcium co-supplementation lowered free testosterone and DHEAS and improved antioxidant capacity versus placebo.

Trust comment: Randomized, double-blind, placebo-controlled trial (n=60) with clear biomarker outcomes but short duration and modest sample size.

Study Details

PMID:27050252
Participants:60
Impact:increase +75.7±126.1 vs −80.4±242.8 mmol/l (p=0.005)
Trust score:4/5

In 104 overweight, vitamin D–deficient women with PCOS, 8 weeks of calcium plus vitamin D improved several inflammation and oxidative-stress biomarkers compared with placebo.

Trust comment: Randomized double-blind placebo-controlled trial with adequate sample size and clear biomarker changes, though short duration (8 weeks).

Study Details

PMID:26119844
Participants:104
Impact:increase +35.2 mmol/L (P=0.006)
Trust score:4/5

postfilter ionized calcium (iCa)

1 evidences

In plasma exchange with citrate anticoagulation, filtered plasma iCa is modestly lower than postfilter iCa and shows modest agreement; neither iCa correlated with bedside clotting time.

Trust comment: Large number of treatments and paired measurements; directly relevant to clinical calcium monitoring though limited to procedural context.

Study Details

PMID:28664840
Participants:140
Impact:mean 0.39 ± 0.14 mmol/L
Trust score:4/5

filtered plasma ionized calcium (iCa)

1 evidences

In plasma exchange with citrate anticoagulation, filtered plasma iCa is modestly lower than postfilter iCa and shows modest agreement; neither iCa correlated with bedside clotting time.

Trust comment: Large number of treatments and paired measurements; directly relevant to clinical calcium monitoring though limited to procedural context.

Study Details

PMID:28664840
Participants:140
Impact:mean 0.33 ± 0.11 mmol/L; mean difference -0.07 mmol/L vs postfilter
Trust score:4/5

correlation with bedside clotting time

1 evidences

In plasma exchange with citrate anticoagulation, filtered plasma iCa is modestly lower than postfilter iCa and shows modest agreement; neither iCa correlated with bedside clotting time.

Trust comment: Large number of treatments and paired measurements; directly relevant to clinical calcium monitoring though limited to procedural context.

Study Details

PMID:28664840
Participants:140
Impact:no significant correlation (postfilter r=0.03; filtered plasma r=0.09)
Trust score:4/5

Endotoxin levels

1 evidences

In infected root canals, a 14-day calcium hydroxide dressing markedly lowered endotoxin levels; photodynamic therapy helped reduce bacteria in one-visit treatments but did not affect endotoxins.

Trust comment: Small randomized clinical trial with objective microbiologic measures but limited sample size, so moderate confidence in findings.

Study Details

PMID:28619613
Participants:24
Impact:two-visit with 14-day Ca(OH)2 reduced median endotoxin from 1.041 to 0.094 EU/mL
Trust score:3/5

Bacterial colony-forming units (CFU)

1 evidences

In infected root canals, a 14-day calcium hydroxide dressing markedly lowered endotoxin levels; photodynamic therapy helped reduce bacteria in one-visit treatments but did not affect endotoxins.

Trust comment: Small randomized clinical trial with objective microbiologic measures but limited sample size, so moderate confidence in findings.

Study Details

PMID:28619613
Participants:24
Impact:chemo-mechanical preparation reduced CFUs; supplemental PDT further reduced bacteria in one-visit but not in two-visit with Ca(OH)2
Trust score:3/5

Effect of PDT on endotoxins

1 evidences

In infected root canals, a 14-day calcium hydroxide dressing markedly lowered endotoxin levels; photodynamic therapy helped reduce bacteria in one-visit treatments but did not affect endotoxins.

Trust comment: Small randomized clinical trial with objective microbiologic measures but limited sample size, so moderate confidence in findings.

Study Details

PMID:28619613
Participants:24
Impact:no significant effect
Trust score:3/5

Bone mineral density (BMD) at baseline

1 evidences

In middle-aged men, dietary calcium intake was not associated with baseline bone mineral density or bone loss over 2 years, though higher calcium intake correlated with slightly lower PTH.

Trust comment: Cohort analysis with reasonable sample size and measured biomarkers, but limited to men and observational associations; moderate quality.

Study Details

PMID:28606219
Participants:323
Impact:no association with dietary calcium intake
Trust score:3/5

Rate of bone loss over 2 years

1 evidences

In middle-aged men, dietary calcium intake was not associated with baseline bone mineral density or bone loss over 2 years, though higher calcium intake correlated with slightly lower PTH.

Trust comment: Cohort analysis with reasonable sample size and measured biomarkers, but limited to men and observational associations; moderate quality.

Study Details

PMID:28606219
Participants:323
Impact:no association with dietary calcium intake
Trust score:3/5

Blood mineral concentrations (including calcium and phosphorus)

1 evidences

Infants with cow's milk allergy fed an amino acid–based formula for 16 weeks generally had mineral blood values within age-specific reference ranges and median calcium/phosphorus intakes above recommendations.

Trust comment: Randomized, double-blind controlled trial with central laboratory analyses but substantial dropout for blood measurements (40%), reducing certainty somewhat.

Study Details

PMID:28604516
Participants:66
Impact:within age-specific reference ranges after 16 weeks
Trust score:4/5

Median calcium and phosphorus intake from formula

1 evidences

Infants with cow's milk allergy fed an amino acid–based formula for 16 weeks generally had mineral blood values within age-specific reference ranges and median calcium/phosphorus intakes above recommendations.

Trust comment: Randomized, double-blind controlled trial with central laboratory analyses but substantial dropout for blood measurements (40%), reducing certainty somewhat.

Study Details

PMID:28604516
Participants:66
Impact:above Adequate Intake (AI) indicating low prevalence of inadequate intake
Trust score:4/5

baseline parathyroid hormone (PTH)

1 evidences

CASR genetic variants showed modest associations with baseline mineral metabolism measures and with biochemical response to cinacalcet; some SNPs linked to fracture risk which was attenuated by cinacalcet.

Trust comment: Large, randomized clinical-trial cohort with genotyping and biochemical endpoints; secondary genetic analyses show modest, population-specific associations.

Study Details

PMID:28630081
Participants:1852
Impact:modest increase associated with CASR SNPs in European ancestry group (P ≤ 0.03)
Trust score:4/5

baseline serum calcium

1 evidences

CASR genetic variants showed modest associations with baseline mineral metabolism measures and with biochemical response to cinacalcet; some SNPs linked to fracture risk which was attenuated by cinacalcet.

Trust comment: Large, randomized clinical-trial cohort with genotyping and biochemical endpoints; secondary genetic analyses show modest, population-specific associations.

Study Details

PMID:28630081
Participants:1852
Impact:modest decrease associated with CASR SNPs in African ancestry group (P = 0.04)
Trust score:4/5

percent reduction in PTH at 20 weeks

1 evidences

CASR genetic variants showed modest associations with baseline mineral metabolism measures and with biochemical response to cinacalcet; some SNPs linked to fracture risk which was attenuated by cinacalcet.

Trust comment: Large, randomized clinical-trial cohort with genotyping and biochemical endpoints; secondary genetic analyses show modest, population-specific associations.

Study Details

PMID:28630081
Participants:1852
Impact:reduced percent reduction (less decline) associated with minor allele in EA (P ≤ 0.03)
Trust score:4/5

serum calcium AUC (0–10 h)

1 evidences

In a randomized crossover trial, calcium bioavailability from three mineral waters was equivalent to milk and a calcium supplement in healthy adults.

Trust comment: Randomized crossover human study but small sample (n=21); methods appropriate for bioavailability outcomes.

Study Details

PMID:28628402
Participants:21
Impact:no significant difference between mineral waters, milk, and supplement
Trust score:3/5

24-hour urinary calcium excretion

1 evidences

In a randomized crossover trial, calcium bioavailability from three mineral waters was equivalent to milk and a calcium supplement in healthy adults.

Trust comment: Randomized crossover human study but small sample (n=21); methods appropriate for bioavailability outcomes.

Study Details

PMID:28628402
Participants:21
Impact:no significant difference between test products
Trust score:3/5

serum parathormone / phosphate

1 evidences

In a randomized crossover trial, calcium bioavailability from three mineral waters was equivalent to milk and a calcium supplement in healthy adults.

Trust comment: Randomized crossover human study but small sample (n=21); methods appropriate for bioavailability outcomes.

Study Details

PMID:28628402
Participants:21
Impact:no differences between groups
Trust score:3/5

female offspring height

1 evidences

In a randomized trial (maternal 1500 mg Ca/day), offspring at 8–12 y showed sex-specific effects: females of supplemented mothers were shorter with smaller bones and lower BMC, while males tended to have greater size and higher fat mass.

Trust comment: Randomized maternal supplementation trial with large sample, DXA/pQCT outcomes and long follow-up; sex-specific/post-hoc analyses and some attenuation after size-adjustment reduce certainty.

Study Details

PMID:28583879
Participants:447
Impact:-1.0%
Trust score:4/5

female offspring whole-body BMC

1 evidences

In a randomized trial (maternal 1500 mg Ca/day), offspring at 8–12 y showed sex-specific effects: females of supplemented mothers were shorter with smaller bones and lower BMC, while males tended to have greater size and higher fat mass.

Trust comment: Randomized maternal supplementation trial with large sample, DXA/pQCT outcomes and long follow-up; sex-specific/post-hoc analyses and some attenuation after size-adjustment reduce certainty.

Study Details

PMID:28583879
Participants:447
Impact:-4.6%
Trust score:4/5

male offspring fat mass

1 evidences

In a randomized trial (maternal 1500 mg Ca/day), offspring at 8–12 y showed sex-specific effects: females of supplemented mothers were shorter with smaller bones and lower BMC, while males tended to have greater size and higher fat mass.

Trust comment: Randomized maternal supplementation trial with large sample, DXA/pQCT outcomes and long follow-up; sex-specific/post-hoc analyses and some attenuation after size-adjustment reduce certainty.

Study Details

PMID:28583879
Participants:447
Impact:+11.6%
Trust score:4/5

endodontic emergency treatment rate

1 evidences

RCT comparing MTA versus calcium hydroxide for pulp capping in deep caries (100 teeth in 73 patients) found no significant difference in pulp vitality through 24 months; both materials clinically acceptable.

Trust comment: Randomized clinical trial with high recall and 24-month follow-up; direct comparison of a calcium-containing material (Ca(OH)2) vs MTA supports clinical conclusions.

Study Details

PMID:28581920
Participants:73
Impact:Ca(OH)2: 4 teeth; MTA: 2 teeth (out of 49/51 teeth)
Trust score:4/5

MHGS improvement

1 evidences

Injecting calcium hydroxylapatite into the dorsal hands significantly improved hand volume appearance for up to 12 months with mostly minor injection-related side effects.

Trust comment: Multicenter randomized single-blind trial with validated outcomes and adequate sample, supporting moderate-high trust.

Study Details

PMID:28562435
Participants:114
Impact:+75% achieved ≥1-point improvement at 3 months; effect generally maintained through 12 months
Trust score:4/5

Subject-reported improvement

1 evidences

Injecting calcium hydroxylapatite into the dorsal hands significantly improved hand volume appearance for up to 12 months with mostly minor injection-related side effects.

Trust comment: Multicenter randomized single-blind trial with validated outcomes and adequate sample, supporting moderate-high trust.

Study Details

PMID:28562435
Participants:114
Impact:98% reported improvement at 3 months; 86% at 12 months
Trust score:4/5

Bone mass (Speed of Sound, SOS)

1 evidences

Eggshell-derived calcium (300 mg/day) increased bone mass over 12 months and was more effective than calcium carbonate in this small postmenopausal cohort.

Trust comment: Small randomized single-blind trial with objective bone mass measure but limited sample size, yielding moderate trust.

Study Details

PMID:28552876
Participants:54
Impact:Significant increase at 12 months in eggshell calcium group; greater increase than calcium carbonate
Trust score:3/5

Daily elemental calcium dose

1 evidences

Titrating calcium carbonate in hemodialysis patients achieved and maintained lower serum phosphate over 26 weeks without increased adverse events.

Trust comment: Pilot randomized trial in dialysis patients with modest sample size; findings are feasible but limited by size and duration.

Study Details

PMID:28550080
Participants:104
Impact:Median 1800 mg/day (intensive) vs 0 mg/day (liberalized) at 26 weeks
Trust score:3/5

proportion of progressors

1 evidences

Using lower‑calcium dialysate (1.25 mmol/L) accelerated progression of coronary artery calcification over 12 months compared with standard (1.5 mmol/L) dialysate.

Trust comment: Randomized clinical trial directly manipulating dialysate calcium with objective CT outcomes; moderate sample size and clear effect but single‑center/open‑label design limits score.

Study Details

PMID:28502735
Participants:76
Impact:Higher proportion of progressors in LCD vs SCD (P=0.0229)
Trust score:4/5

Aortic stiffness (cf-PWV)

1 evidences

One week of cinacalcet (30 mg/day) lowered blood calcium and PTH but did not significantly change arterial stiffness or heart function in hemodialysis patients.

Trust comment: Randomized double-blind crossover RCT with rigorous measures but small sample and some missing echocardiography data, likely underpowered for arterial stiffness endpoints.

Study Details

PMID:28538380
Participants:21
Impact:numerical decrease −0.35 m/s (not significant, P=0.139)
Trust score:4/5

circulating IGF-1

1 evidences

In a randomized, double-blind, placebo-controlled trial, supplemental elemental calcium (1.0 or 2.0 g/day) did not appreciably change circulating IGF-1, IGFBP-3, or their molar ratio versus placebo.

Trust comment: Randomized, double-blind, placebo-controlled trial with adequate sample size for biomarker outcomes; direct test of supplemental calcium.

Study Details

PMID:28467661
Participants:193
Impact:no appreciable change with calcium supplementation vs placebo
Trust score:4/5

circulating IGFBP-3

1 evidences

In a randomized, double-blind, placebo-controlled trial, supplemental elemental calcium (1.0 or 2.0 g/day) did not appreciably change circulating IGF-1, IGFBP-3, or their molar ratio versus placebo.

Trust comment: Randomized, double-blind, placebo-controlled trial with adequate sample size for biomarker outcomes; direct test of supplemental calcium.

Study Details

PMID:28467661
Participants:193
Impact:no appreciable change with calcium supplementation vs placebo
Trust score:4/5

IGF-1 : IGFBP-3 molar ratio

1 evidences

In a randomized, double-blind, placebo-controlled trial, supplemental elemental calcium (1.0 or 2.0 g/day) did not appreciably change circulating IGF-1, IGFBP-3, or their molar ratio versus placebo.

Trust comment: Randomized, double-blind, placebo-controlled trial with adequate sample size for biomarker outcomes; direct test of supplemental calcium.

Study Details

PMID:28467661
Participants:193
Impact:no appreciable change with calcium supplementation vs placebo
Trust score:4/5

saliva fetuin-A

1 evidences

Patients with sialolithiasis had lower serum calcium and higher saliva fetuin-A, saliva phosphorus, and saliva total protein compared with controls, suggesting local biochemical differences in stone formers.

Trust comment: Small case-control study with 20 patients and 20 controls; direct measurements of serum/saliva electrolytes including calcium but limited sample size.

Study Details

PMID:28457217
Participants:40
Impact:higher in patients vs controls (P = 0.001)
Trust score:3/5

saliva phosphorus

1 evidences

Patients with sialolithiasis had lower serum calcium and higher saliva fetuin-A, saliva phosphorus, and saliva total protein compared with controls, suggesting local biochemical differences in stone formers.

Trust comment: Small case-control study with 20 patients and 20 controls; direct measurements of serum/saliva electrolytes including calcium but limited sample size.

Study Details

PMID:28457217
Participants:40
Impact:higher in patients vs controls (P = 0.05)
Trust score:3/5

hyperparathyroidism / safety

1 evidences

Chinese postmenopausal women given 25,000 IU or 50,000 IU cholecalciferol every 4 weeks largely maintained vitamin D sufficiency without causing hyperparathyroidism or toxicity.

Trust comment: Randomized dosing with direct-observed administration and safety monitoring; indirect to Calcium (measures PTH/calcium) but primary focus is vitamin D.

Study Details

PMID:28429905
Participants:90
Impact:Neither dose was associated with hyperparathyroidism or toxicity
Trust score:3/5

Calcium absorption

2 evidences

Randomized, placebo-controlled vitamin D3 dosing study (placebo, 800, 2000, 4000 IU) in 71 subjects measuring free and total 25(OH)D, calcium absorption via dual isotopes, PTH, and bone turnover markers.

Trust comment: Controlled randomized dosing with direct calcium absorption measurement via dual isotopes; good internal validity.

Study Details

PMID:26312580
Participants:71
Impact:No added predictive value of free 25(OH)D vs total 25(OH)D for calcium absorption (no advantage)
Trust score:4/5

Randomized study in lactose-intolerant adults found milk fortified with inulin and vitamin D3 (and milk minerals) increased BMD at 6 weeks in the supplemented group, while other measures (calcium absorption, GI symptoms) showed non-significant changes.

Trust comment: Small randomized trial with short (6-week) follow-up and no significant between-group differences for most measures; limited power.

Study Details

PMID:29903135
Participants:42
Impact:increased in the fortified-milk group but change not statistically significant
Trust score:3/5

Pro-inflammatory cytokines (IL-1β, IL-2, IL-6, CX3CL1, TNF-α)

1 evidences

Soldiers taking HMB calcium (with or without a probiotic) during intense military training showed reduced inflammatory cytokines and the probiotic+CaHMB group had better muscle integrity than CaHMB alone.

Trust comment: Randomized human study with objective biochemical and imaging endpoints but small sample (n=26) limits precision.

Study Details

PMID:28408697
Participants:26
Impact:significant decrease vs control
Trust score:4/5

IL-10

1 evidences

Soldiers taking HMB calcium (with or without a probiotic) during intense military training showed reduced inflammatory cytokines and the probiotic+CaHMB group had better muscle integrity than CaHMB alone.

Trust comment: Randomized human study with objective biochemical and imaging endpoints but small sample (n=26) limits precision.

Study Details

PMID:28408697
Participants:26
Impact:significant decrease (CaHMB + BC30 vs control only)
Trust score:4/5

Apparent diffusion coefficient (muscle integrity marker)

1 evidences

Soldiers taking HMB calcium (with or without a probiotic) during intense military training showed reduced inflammatory cytokines and the probiotic+CaHMB group had better muscle integrity than CaHMB alone.

Trust comment: Randomized human study with objective biochemical and imaging endpoints but small sample (n=26) limits precision.

Study Details

PMID:28408697
Participants:26
Impact:decrease (CaHMB + BC30 vs CaHMB alone), indicating improved muscle integrity
Trust score:4/5

serum insulin concentration

1 evidences

Vitamin D-deficient women with PCOS given combined calcium+D+K for 8 weeks had improved insulin sensitivity markers and lower triglycerides/VLDL versus placebo.

Trust comment: Double-blind, placebo-controlled RCT with reported numeric effects but modest sample size (n=55) and limited to vitamin D-deficient PCOS women.

Study Details

PMID:28407660
Participants:55
Impact:-1.9 ±3.5 µIU/mL (supplement) vs +1.8 ±6.6 µIU/mL (placebo); significant decrease vs placebo
Trust score:4/5

Preterm dialysis interruption due to clotting

1 evidences

In maintenance dialysis patients the citrate-containing dialysate plus heparin-grafted membrane regimen was noninferior to regional citrate anticoagulation for preventing clotting; clinically relevant hypocalcaemia occurred only with RCA.

Trust comment: Randomized crossover trial with clear session-level outcomes; small patient number (n=25) but clinically measured calcium changes reported.

Study Details

PMID:28407129
Participants:25
Impact:5.7% of sessions (CiTED) vs 6.2% (RCA); CiTED met noninferiority criteria
Trust score:4/5

Systemic ionized calcium concentration

1 evidences

In maintenance dialysis patients the citrate-containing dialysate plus heparin-grafted membrane regimen was noninferior to regional citrate anticoagulation for preventing clotting; clinically relevant hypocalcaemia occurred only with RCA.

Trust comment: Randomized crossover trial with clear session-level outcomes; small patient number (n=25) but clinically measured calcium changes reported.

Study Details

PMID:28407129
Participants:25
Impact:significantly lower in RCA; clinically relevant hypocalcaemia observed only in RCA arm
Trust score:4/5

Dentin hypersensitivity (VAS, Schiff score, tactile threshold)

1 evidences

Both CSPS-containing dentifrices (a calcium-containing bioactive) produced significant reductions in dentin hypersensitivity over 8 weeks; non-inferiority margin was not formally met but no significant differences between groups were found.

Trust comment: Large randomized, examiner-blind trial with objective measures (n=304); however non-inferiority margin was not met, complicating interpretation.

Study Details

PMID:28391662
Participants:304
Impact:statistically significant reduction from baseline for both dentifrices; no significant difference between groups
Trust score:4/5

tooth vitality

1 evidences

Using a calcium hydroxide liner during stepwise caries removal provided no added short-term benefit for tooth vitality.

Trust comment: Randomized clinical trial with 98 patients and clear outcomes; limited to 90-day follow-up so medium–high confidence.

Study Details

PMID:28343596
Participants:98
Impact:no difference at 90 days (no additional benefit)
Trust score:4/5

dentin bacterial contamination

1 evidences

Using a calcium hydroxide liner during stepwise caries removal provided no added short-term benefit for tooth vitality.

Trust comment: Randomized clinical trial with 98 patients and clear outcomes; limited to 90-day follow-up so medium–high confidence.

Study Details

PMID:28343596
Participants:98
Impact:decreased after provisional restoration (darker, harder, drier, less contaminated) irrespective of liner use
Trust score:4/5

olfactory threshold (PEA)

1 evidences

A single application of sodium citrate nasal spray transiently improved smell sensitivity in some patients, likely via lowering nasal mucus calcium.

Trust comment: Small randomized double-blind trial (n=55) with short-term outcomes and plausible mechanism (calcium chelation), moderate confidence but limited duration and single application.

Study Details

PMID:28339165
Participants:55
Impact:improved (statistically significant) — 32% of intervention arm responders; effect peaks 30–60 min
Trust score:3/5

olfactory threshold (other odors)

1 evidences

A single application of sodium citrate nasal spray transiently improved smell sensitivity in some patients, likely via lowering nasal mucus calcium.

Trust comment: Small randomized double-blind trial (n=55) with short-term outcomes and plausible mechanism (calcium chelation), moderate confidence but limited duration and single application.

Study Details

PMID:28339165
Participants:55
Impact:improved for 1-butanol and eucalyptol vs placebo (P<0.05)
Trust score:3/5

clinically meaningful hypercalcemia (stage 5)

1 evidences

Oral paricalcitol reduced intact PTH in children with CKD (stages 3–5) with an acceptable safety profile, though some hypercalcemia occurred in stage 5 patients.

Trust comment: Phase 3 multicenter randomized placebo-controlled trial (children 10–16 y) with clear biochemical endpoints and prespecified analyses, high reliability.

Study Details

PMID:28332096
Participants:61
Impact:occurred in 23% of stage 5 children during treatment
Trust score:5/5

tibial bone mineral content (BMC)

1 evidences

Adding three extra daily dairy servings to raise calcium intake had no effect on most measures of bone mass or body composition in 8–16-year-olds, except for greater tibial BMC gain.

Trust comment: Large randomized controlled trial (n=240) with objective DXA outcomes; well-powered for common effects but limited to early puberty age range.

Study Details

PMID:28330908
Participants:240
Impact:greater gain in dairy (higher calcium) group (P=0.02)
Trust score:4/5

total-body/axial BMD and BMC

1 evidences

Adding three extra daily dairy servings to raise calcium intake had no effect on most measures of bone mass or body composition in 8–16-year-olds, except for greater tibial BMC gain.

Trust comment: Large randomized controlled trial (n=240) with objective DXA outcomes; well-powered for common effects but limited to early puberty age range.

Study Details

PMID:28330908
Participants:240
Impact:no significant difference between dairy (≈1500 mg Ca/d) and control (≈1000 mg Ca/d) groups
Trust score:4/5

pruritus severity (VAS)

1 evidences

Adding hemoperfusion (especially HA330-RHA) to hemodialysis reduced pruritus and inflammation and lowered PTH compared with hemodialysis alone.

Trust comment: Randomized allocation with 90 patients and repeated measures showing consistent changes, but single-center design and limited blinding reduce confidence.

Study Details

PMID:28328802
Participants:90
Impact:decreased significantly in hemoperfusion groups vs control; greatest improvement with HA330
Trust score:3/5

CRP (inflammation)

1 evidences

Adding hemoperfusion (especially HA330-RHA) to hemodialysis reduced pruritus and inflammation and lowered PTH compared with hemodialysis alone.

Trust comment: Randomized allocation with 90 patients and repeated measures showing consistent changes, but single-center design and limited blinding reduce confidence.

Study Details

PMID:28328802
Participants:90
Impact:decreased in hemoperfusion groups; greater reduction with HA330 vs HA130
Trust score:3/5

radiographic healing/tooth loss

1 evidences

Placing 1-week intracanal calcium hydroxide (two-visit treatment) did not improve 1-year healing but was associated with more short-term post-treatment pain and analgesic use than single-visit treatment.

Trust comment: Multicentre randomized controlled trial (n=199) with 1-year follow-up and patient-centered outcomes; robust design though some loss to follow-up.

Study Details

PMID:28327693
Participants:199
Impact:no significant difference at 1 year between single-visit and two-visit (with Ca(OH)2) groups
Trust score:4/5

post-treatment pain

1 evidences

Placing 1-week intracanal calcium hydroxide (two-visit treatment) did not improve 1-year healing but was associated with more short-term post-treatment pain and analgesic use than single-visit treatment.

Trust comment: Multicentre randomized controlled trial (n=199) with 1-year follow-up and patient-centered outcomes; robust design though some loss to follow-up.

Study Details

PMID:28327693
Participants:199
Impact:greater pain in two-visit with calcium hydroxide at 1 and 2 weeks; higher analgesic use (week1 mean 1.44 vs 0.53 tablets)
Trust score:4/5

knowledge of exercise and calcium benefits

1 evidences

Education and the mobile app increased bone-health knowledge and were associated with changes in some blood markers including calcium.

Trust comment: Randomized controlled trial in 82 women with measured biochemical outcomes, but small sample and reported changes lack detailed effect sizes in the provided text.

Study Details

PMID:28388981
Participants:82
Impact:increased vs control
Trust score:3/5

S100b (serum)

1 evidences

Preoperative scopolamine butylbromide reduced postoperative cognitive dysfunction cases and lowered related blood markers.

Trust comment: Randomized allocation with clear biomarker and clinical outcome differences reported; moderate-high internal validity though single-center details and broader generalizability not provided.

Study Details

PMID:28387891
Participants:142
Impact:lower in intervention group vs control (p < 0.05)
Trust score:4/5

neuron-specific enolase (NSE, plasma)

1 evidences

Preoperative scopolamine butylbromide reduced postoperative cognitive dysfunction cases and lowered related blood markers.

Trust comment: Randomized allocation with clear biomarker and clinical outcome differences reported; moderate-high internal validity though single-center details and broader generalizability not provided.

Study Details

PMID:28387891
Participants:142
Impact:lower in intervention group vs control (p < 0.05)
Trust score:4/5

lumbar spine BMD (Z-score)

1 evidences

Prospective cohort analysis showing that longer periods of adequate dietary calcium intake in early childhood are associated with higher bone mineral density at age 7.

Trust comment: Prospective longitudinal cohort with dietary records and DXA measures in 179 children; observational design limits causal inference but data are direct and measured.

Study Details

PMID:28351509
Participants:179
Impact:Each 100 mg/day increase in calcium intake was associated with a +0.089 (95% CI 0.021–0.157) change in LS BMD z-score (p=0.011).
Trust score:4/5

long-term adequate calcium and BMD

1 evidences

Prospective cohort analysis showing that longer periods of adequate dietary calcium intake in early childhood are associated with higher bone mineral density at age 7.

Trust comment: Prospective longitudinal cohort with dietary records and DXA measures in 179 children; observational design limits causal inference but data are direct and measured.

Study Details

PMID:28351509
Participants:179
Impact:Maintaining calcium probability of adequacy >95% over 3 years was associated with an increase in LS BMD z-score of +0.773 (95% CI 0.282–1.264).
Trust score:4/5

All-type cancer incidence

1 evidences

Large randomized placebo-controlled trial of vitamin D3 plus calcium (1500 mg/day) vs placebo in older women found a non-significant reduction in all-cancer incidence over 4 years and some increased adverse events.

Trust comment: Large, double-blind randomized controlled trial with high completion rate; primary cancer outcome showed a non-significant trend and adverse events were monitored.

Study Details

PMID:28350929
Participants:2064
Impact:Treatment 3.89% vs placebo 5.58% (difference 1.69%, 95% CI -0.06% to 3.46%; P=0.06); Cox HR 0.70 (95% CI 0.47–1.02) — not statistically significant.
Trust score:5/5

renal calculi

1 evidences

Large randomized placebo-controlled trial of vitamin D3 plus calcium (1500 mg/day) vs placebo in older women found a non-significant reduction in all-cancer incidence over 4 years and some increased adverse events.

Trust comment: Large, double-blind randomized controlled trial with high completion rate; primary cancer outcome showed a non-significant trend and adverse events were monitored.

Study Details

PMID:28350929
Participants:2064
Impact:Renal stones occurred more in treatment: 16 vs 10 cases (treatment vs placebo).
Trust score:5/5

elevated serum calcium

1 evidences

Large randomized placebo-controlled trial of vitamin D3 plus calcium (1500 mg/day) vs placebo in older women found a non-significant reduction in all-cancer incidence over 4 years and some increased adverse events.

Trust comment: Large, double-blind randomized controlled trial with high completion rate; primary cancer outcome showed a non-significant trend and adverse events were monitored.

Study Details

PMID:28350929
Participants:2064
Impact:Elevated serum calcium: 6 cases in treatment vs 2 in placebo.
Trust score:5/5

body fat percentage gain

1 evidences

In overweight adolescent girls randomized to increase dairy calcium to ≥1200 mg/day versus maintain ≤600 mg/day, there was no reduction in body fat gain over 12 months.

Trust comment: Large (n=274), randomized controlled trial, registered and well-reported, showing a null effect of increased dairy calcium on fat gain.

Study Details

PMID:28298396
Participants:274
Impact:+0.40% ±0.53% (dairy vs control; not statistically significant)
Trust score:4/5

Weight change

1 evidences

In overweight adolescent girls randomized to increase dairy calcium to ≥1200 mg/day versus maintain ≤600 mg/day, there was no reduction in body fat gain over 12 months.

Trust comment: Large (n=274), randomized controlled trial, registered and well-reported, showing a null effect of increased dairy calcium on fat gain.

Study Details

PMID:28298396
Participants:274
Impact:no significant difference between groups over 12 months
Trust score:4/5

microbial count reduction

1 evidences

In children with infected primary teeth, calcium hydroxide dressings reduced bacterial counts; adding chlorhexidine did not improve results and pure calcium hydroxide had greater complete elimination.

Trust comment: Randomized in vivo clinical trial in 40 children with microbiological endpoints and appropriate statistical analysis.

Study Details

PMID:28292338
Participants:40
Impact:significant reduction in anaerobic, aerobic, black-pigmented bacilli, streptococci and S. mutans after 30 days
Trust score:4/5

complete microbial elimination

1 evidences

In children with infected primary teeth, calcium hydroxide dressings reduced bacterial counts; adding chlorhexidine did not improve results and pure calcium hydroxide had greater complete elimination.

Trust comment: Randomized in vivo clinical trial in 40 children with microbiological endpoints and appropriate statistical analysis.

Study Details

PMID:28292338
Participants:40
Impact:greater with calcium hydroxide alone vs calcium hydroxide + chlorhexidine (P<0.05)
Trust score:4/5

dentin hardening / remineralization

1 evidences

After partial caries removal and sealing, dentin darkened and hardened in all groups; resin-modified glass ionomer reduced dentinal tubule lumen size more than calcium hydroxide or control.

Trust comment: Small in vivo study with histologic/ultrastructural assessment; relevant to calcium-containing liner but limited sample size.

Study Details

PMID:28292334
Participants:27
Impact:observed in all groups after 3 months (macroscopic hardening)
Trust score:3/5

dentinal tubule lumen size

1 evidences

After partial caries removal and sealing, dentin darkened and hardened in all groups; resin-modified glass ionomer reduced dentinal tubule lumen size more than calcium hydroxide or control.

Trust comment: Small in vivo study with histologic/ultrastructural assessment; relevant to calcium-containing liner but limited sample size.

Study Details

PMID:28292334
Participants:27
Impact:significant reduction with resin-modified glass ionomer cement versus calcium hydroxide and control
Trust score:3/5

serum calcium level at 3 months

1 evidences

Randomized trial of early versus later bisphosphonate start after hip fracture; all patients received calcium (1000 mg/day) and vitamin D and no symptomatic hypocalcemia occurred.

Trust comment: Randomized controlled trial with 100 enrolled and 90 completing primary follow-up; calcium was measured as a safety/biochemical outcome though not the primary intervention.

Study Details

PMID:28283937
Participants:90
Impact:week 2 group 9.1 mg/dL vs week 12 group 9.4 mg/dL (difference 0.3 mg/dL; P=0.008)
Trust score:4/5

symptomatic hypocalcemia

2 evidences

Randomized trial of early versus later bisphosphonate start after hip fracture; all patients received calcium (1000 mg/day) and vitamin D and no symptomatic hypocalcemia occurred.

Trust comment: Randomized controlled trial with 100 enrolled and 90 completing primary follow-up; calcium was measured as a safety/biochemical outcome though not the primary intervention.

Study Details

PMID:28283937
Participants:90
Impact:no patients developed symptomatic hypocalcemia
Trust score:4/5

In 106 patients after total thyroidectomy, routine oral calcium greatly reduced early symptomatic low calcium compared with no supplementation.

Trust comment: Prospective randomized study (n=106) with clear clinical and laboratory endpoints showing a large effect on symptomatic hypocalcemia.

Study Details

PMID:28039060
Participants:106
Impact:1.9% (calcium) vs 33.9% (no calcium); difference -32.0 percentage points (p<0.05)
Trust score:4/5

Serum ionized calcium (iCa) decrease

1 evidences

Taking 1000 mg chewable calcium 30 minutes before a 35-km cycling trial partially reduced the exercise-induced drop in serum ionized calcium and attenuated the rise in PTH but did not prevent increased bone resorption marker levels.

Trust comment: Randomized controlled trial in 51 competitive male cyclists with objective biochemical endpoints; moderate sample size and clear outcome measures.

Study Details

PMID:28248693
Participants:51
Impact:Attenuated with Ca: CA −0.13 mg/dL (≈−2.7%) vs PL −0.26 mg/dL (≈−5.3%); between-group P=0.03
Trust score:4/5

Parathyroid hormone (PTH) increase

1 evidences

Taking 1000 mg chewable calcium 30 minutes before a 35-km cycling trial partially reduced the exercise-induced drop in serum ionized calcium and attenuated the rise in PTH but did not prevent increased bone resorption marker levels.

Trust comment: Randomized controlled trial in 51 competitive male cyclists with objective biochemical endpoints; moderate sample size and clear outcome measures.

Study Details

PMID:28248693
Participants:51
Impact:Attenuated with Ca: CA +48.8 pg/mL (30.9→79.7) vs PL +74.4 pg/mL (37.1→111.5); between-group P=0.07 (ns)
Trust score:4/5

Bone resorption marker (C-terminal telopeptide, CTX)

1 evidences

Taking 1000 mg chewable calcium 30 minutes before a 35-km cycling trial partially reduced the exercise-induced drop in serum ionized calcium and attenuated the rise in PTH but did not prevent increased bone resorption marker levels.

Trust comment: Randomized controlled trial in 51 competitive male cyclists with objective biochemical endpoints; moderate sample size and clear outcome measures.

Study Details

PMID:28248693
Participants:51
Impact:Increased in both groups; no effect of Ca on change (CA 0.35→0.50 ng/mL; PL 0.36→0.54 ng/mL)
Trust score:4/5

Clinical success rate (indirect pulp capping)

2 evidences

Randomized trial in patients needing indirect pulp capping showed similar 12-month clinical success for calcium-silicate cement and glass ionomer, though CBCT revealed more healed lesions with the calcium-silicate material.

Trust comment: Randomized clinical trial with 53 patients and 12-month follow-up; moderate sample and objective imaging outcomes support moderate confidence.

Study Details

PMID:25710953
Participants:53
Impact:83.3% for both Biodentine (calcium silicate) and Fuji IX GIC; no significant difference
Trust score:3/5

In children undergoing indirect pulp capping, three materials (including calcium hydroxide) produced high clinical success and led to formation of reparative dentin with increased thickness and radiodensity at 6 months.

Trust comment: Randomized clinical trial in 94 children evaluating calcium hydroxide among other materials; direct relevance to a calcium-containing dental material and reasonably high trustworthiness.

Study Details

PMID:28169260
Participants:94
Impact:96.85% success
Trust score:4/5

Reparative dentin thickness

1 evidences

In children undergoing indirect pulp capping, three materials (including calcium hydroxide) produced high clinical success and led to formation of reparative dentin with increased thickness and radiodensity at 6 months.

Trust comment: Randomized clinical trial in 94 children evaluating calcium hydroxide among other materials; direct relevance to a calcium-containing dental material and reasonably high trustworthiness.

Study Details

PMID:28169260
Participants:94
Impact:increased at 6 months (statistically significant vs immediate postoperative)
Trust score:4/5

Dentin radiodensity (HU)

1 evidences

In children undergoing indirect pulp capping, three materials (including calcium hydroxide) produced high clinical success and led to formation of reparative dentin with increased thickness and radiodensity at 6 months.

Trust comment: Randomized clinical trial in 94 children evaluating calcium hydroxide among other materials; direct relevance to a calcium-containing dental material and reasonably high trustworthiness.

Study Details

PMID:28169260
Participants:94
Impact:increased radiodensity at 6 months (statistically significant)
Trust score:4/5

bone mineral content / aBMD

1 evidences

A behavioral nutrition program increased children's dietary calcium intake for up to 12 months but did not change bone mineral accrual; higher calcium intake was associated with smaller BMI increases at some timepoints.

Trust comment: Randomized controlled trial with intention-to-treat analysis and multi-year follow-up but moderate attrition; appropriate methods and adjustments reported.

Study Details

PMID:28225052
Participants:139
Impact:no significant difference between intervention and usual care over 36 months
Trust score:4/5

BMI / adiposity

1 evidences

A behavioral nutrition program increased children's dietary calcium intake for up to 12 months but did not change bone mineral accrual; higher calcium intake was associated with smaller BMI increases at some timepoints.

Trust comment: Randomized controlled trial with intention-to-treat analysis and multi-year follow-up but moderate attrition; appropriate methods and adjustments reported.

Study Details

PMID:28225052
Participants:139
Impact:higher calcium intake associated with less increase in BMI at 18 and 24 months (negative association)
Trust score:4/5

evaporative (air) sensitivity

1 evidences

In adults with dentine hypersensitivity, a 5% CSPS (calcium-containing) toothpaste reduced sensitivity within 1 week and provided continued benefit over 11 weeks, with similar efficacy to an 8% arginine/calcium carbonate paste.

Trust comment: Randomized, examiner-blind controlled trial with objective clinical measures; exploratory but adequately conducted.

Study Details

PMID:28219674
Participants:135
Impact:statistically significant reduction from baseline; clinically relevant relief vs fluoride control within 1 week
Trust score:4/5

surface microhardness (SMH) recovery

1 evidences

In an in situ human model, adding 5% CSPS to an SMFP dentifrice did not improve enamel lesion remineralization versus the same fluoride dentifrice without CSPS.

Trust comment: Randomized, investigator-blind, crossover in situ human study with objective endpoint measurements; sample size moderate for in situ design.

Study Details

PMID:28219056
Participants:77
Impact:no significant difference between 927 ppm F with 5% CSPS and 927 ppm F without CSPS (p=0.6788)
Trust score:4/5

integrated mineral loss (subsurface lesions)

1 evidences

In an in situ human model, adding 5% CSPS to an SMFP dentifrice did not improve enamel lesion remineralization versus the same fluoride dentifrice without CSPS.

Trust comment: Randomized, investigator-blind, crossover in situ human study with objective endpoint measurements; sample size moderate for in situ design.

Study Details

PMID:28219056
Participants:77
Impact:no significant difference (p=0.5908)
Trust score:4/5

treatment success (clinical & radiographic)

1 evidences

In 7–9-year-old children with pulp exposures, Biodentine and MTA showed 100% clinical and radiographic success at 6 and 12 months and similar dentin bridge formation.

Trust comment: Split-mouth clinical study with objective outcomes but small sample size and short follow-up, limiting generalizability.

Study Details

PMID:28216271
Participants:29
Impact:100% success for both Biodentine and MTA at baseline, 6 and 12 months (no difference)
Trust score:3/5

fracture risk (lowest BMD-GRS quartile)

1 evidences

Large RCT of calcium (1000 mg) plus vitamin D (400 IU) vs placebo: protective effect on fracture risk was seen only in women with lowest genetic predisposition to low BMD.

Trust comment: Large randomized trial with long follow-up; subgroup genetic interaction analysis plausible but may require replication.

Study Details

PMID:28148500
Participants:5823
Impact:-40% (HR 0.60, 95% CI 0.44–0.81)
Trust score:4/5

fracture risk (higher BMD-GRS quartiles)

1 evidences

Large RCT of calcium (1000 mg) plus vitamin D (400 IU) vs placebo: protective effect on fracture risk was seen only in women with lowest genetic predisposition to low BMD.

Trust comment: Large randomized trial with long follow-up; subgroup genetic interaction analysis plausible but may require replication.

Study Details

PMID:28148500
Participants:5823
Impact:no significant effect
Trust score:4/5

>30% PTH reduction

1 evidences

IV etelcalcetide reduced PTH more often than oral cinacalcet in hemodialysis patients but caused more decreases in blood calcium.

Trust comment: Large, randomized, double-blind multicenter trial directly measuring PTH and calcium with clear results and robust design.

Study Details

PMID:28097356
Participants:683
Impact:68.2% with etelcalcetide vs 57.7% with cinacalcet (absolute +10.5% favoring etelcalcetide)
Trust score:5/5

>50% PTH reduction

1 evidences

IV etelcalcetide reduced PTH more often than oral cinacalcet in hemodialysis patients but caused more decreases in blood calcium.

Trust comment: Large, randomized, double-blind multicenter trial directly measuring PTH and calcium with clear results and robust design.

Study Details

PMID:28097356
Participants:683
Impact:52.4% with etelcalcetide vs 40.2% with cinacalcet (absolute +12.2% favoring etelcalcetide)
Trust score:5/5

decreased blood calcium (hypocalcemia)

1 evidences

IV etelcalcetide reduced PTH more often than oral cinacalcet in hemodialysis patients but caused more decreases in blood calcium.

Trust comment: Large, randomized, double-blind multicenter trial directly measuring PTH and calcium with clear results and robust design.

Study Details

PMID:28097356
Participants:683
Impact:occurrence 68.9% with etelcalcetide vs 59.8% with cinacalcet (more frequent with etelcalcetide)
Trust score:5/5

serum intact PTH (iPTH) target achievement

1 evidences

Intravenous calcimimetic etelcalcetide in haemodialysis patients with secondary hyperparathyroidism reduced PTH and lowered serum calcium, phosphorus and FGF23 versus placebo.

Trust comment: Phase 3 randomized, double-blind, placebo-controlled trial with clear endpoints and 155 participants, high internal validity.

Study Details

PMID:28057872
Participants:155
Impact:59.0% vs 1.3% achieving 60–240 pg/mL on Day 85 (difference +60.0%)
Trust score:5/5

≥30% reduction in serum iPTH

1 evidences

Intravenous calcimimetic etelcalcetide in haemodialysis patients with secondary hyperparathyroidism reduced PTH and lowered serum calcium, phosphorus and FGF23 versus placebo.

Trust comment: Phase 3 randomized, double-blind, placebo-controlled trial with clear endpoints and 155 participants, high internal validity.

Study Details

PMID:28057872
Participants:155
Impact:76.9% vs 5.2% achieving ≥30% reduction on Day 85 (difference +71.7%)
Trust score:5/5

serum iFGF23

1 evidences

Intravenous calcimimetic etelcalcetide in haemodialysis patients with secondary hyperparathyroidism reduced PTH and lowered serum calcium, phosphorus and FGF23 versus placebo.

Trust comment: Phase 3 randomized, double-blind, placebo-controlled trial with clear endpoints and 155 participants, high internal validity.

Study Details

PMID:28057872
Participants:155
Impact:median −72.0% (etelcalcetide) vs −3.7% (placebo) at Day 85
Trust score:5/5

plaque pH drop (acidification)

1 evidences

Small randomized crossover in situ study showing that applying CPP-ACP (a calcium‑containing mousse) preserves fluoride's buffering effect on plaque pH even when teeth are rinsed immediately.

Trust comment: Randomized crossover in situ study on 25 human participants; results are directly relevant but sample size is small.

Study Details

PMID:28052211
Participants:25
Impact:minimal pH drop in APF-30 and fluoride+CPP-ACP conditions (CPP-ACP preserved effect despite immediate rinsing)
Trust score:3/5

pH recovery speed

1 evidences

Small randomized crossover in situ study showing that applying CPP-ACP (a calcium‑containing mousse) preserves fluoride's buffering effect on plaque pH even when teeth are rinsed immediately.

Trust comment: Randomized crossover in situ study on 25 human participants; results are directly relevant but sample size is small.

Study Details

PMID:28052211
Participants:25
Impact:fastest recovery in APF-30 and fluoride+CPP-ACP groups
Trust score:3/5

fluoride inhibitory effect on plaque acidity

1 evidences

Small randomized crossover in situ study showing that applying CPP-ACP (a calcium‑containing mousse) preserves fluoride's buffering effect on plaque pH even when teeth are rinsed immediately.

Trust comment: Randomized crossover in situ study on 25 human participants; results are directly relevant but sample size is small.

Study Details

PMID:28052211
Participants:25
Impact:maintained when CPP-ACP applied to fluoridated teeth despite immediate water rinsing
Trust score:3/5

white spot lesion (WSL) incidence

1 evidences

Randomized clinical trial showing monthly in-office CPP-ACP paste application reduced the incidence of white spot lesions in orthodontic patients versus control.

Trust comment: Prospective randomized controlled clinical trial with 57 patients; moderate sample size and clinically relevant outcome.

Study Details

PMID:28045314
Participants:57
Impact:significantly lower incidence of WSL in CPP-ACP group compared to control
Trust score:4/5

lamellar bone area (histology)

1 evidences

Randomized controlled trial comparing silicate-substituted calcium phosphate (Si-CaP) graft substitute to autologous bone for tunnel augmentation in revision ACL, showing good integration and comparable outcomes.

Trust comment: Level I prospective randomized controlled trial (n=40) with histologic and radiographic endpoints; sample size is modest.

Study Details

PMID:28043751
Participants:40
Impact:Si-CaP: 41% lamellar bone vs autologous bone: 58% lamellar bone
Trust score:4/5

immature bone area (histology)

1 evidences

Randomized controlled trial comparing silicate-substituted calcium phosphate (Si-CaP) graft substitute to autologous bone for tunnel augmentation in revision ACL, showing good integration and comparable outcomes.

Trust comment: Level I prospective randomized controlled trial (n=40) with histologic and radiographic endpoints; sample size is modest.

Study Details

PMID:28043751
Participants:40
Impact:Si-CaP: 15% immature bone area
Trust score:4/5

tunnel filling rate (CT)

1 evidences

Randomized controlled trial comparing silicate-substituted calcium phosphate (Si-CaP) graft substitute to autologous bone for tunnel augmentation in revision ACL, showing good integration and comparable outcomes.

Trust comment: Level I prospective randomized controlled trial (n=40) with histologic and radiographic endpoints; sample size is modest.

Study Details

PMID:28043751
Participants:40
Impact:tibial tunnel filling: 86% (Si-CaP) vs 78% (autologous), P = 0.131 (trend)
Trust score:4/5

Postoperative PTH predictive value

1 evidences

In 106 patients after total thyroidectomy, routine oral calcium greatly reduced early symptomatic low calcium compared with no supplementation.

Trust comment: Prospective randomized study (n=106) with clear clinical and laboratory endpoints showing a large effect on symptomatic hypocalcemia.

Study Details

PMID:28039060
Participants:106
Impact:PTH at 12 and 24 h predicted early hypocalcemia (statistically significant)
Trust score:4/5

Calcium mass balance per procedure

1 evidences

In 30 chronic hemodialysis patients using regional citrate anticoagulation, targeting normal ionized calcium produced a larger positive calcium balance than aiming for mild hypocalcemia.

Trust comment: Randomized controlled single-center trial with direct measurements of calcium mass balance using validated methods but modest sample size.

Study Details

PMID:28030601
Participants:30
Impact:Normal iCa: +14.6 ± 8.3 mmol vs Low iCa: +7.2 ± 8.5 mmol (p = 0.024)
Trust score:4/5

Infused calcium

1 evidences

In 30 chronic hemodialysis patients using regional citrate anticoagulation, targeting normal ionized calcium produced a larger positive calcium balance than aiming for mild hypocalcemia.

Trust comment: Randomized controlled single-center trial with direct measurements of calcium mass balance using validated methods but modest sample size.

Study Details

PMID:28030601
Participants:30
Impact:Delivered calcium 58.3 ± 4.8 mmol (normal) vs 51.5 ± 8.2 mmol (low) (p = 0.010)
Trust score:4/5

iPTH response

1 evidences

In 30 chronic hemodialysis patients using regional citrate anticoagulation, targeting normal ionized calcium produced a larger positive calcium balance than aiming for mild hypocalcemia.

Trust comment: Randomized controlled single-center trial with direct measurements of calcium mass balance using validated methods but modest sample size.

Study Details

PMID:28030601
Participants:30
Impact:Greater increase in iPTH in low iCa target group (interaction p = 0.008)
Trust score:4/5

serum 25-hydroxyvitamin D (25(OH)D) change with Ca+vitamin D

1 evidences

Large randomized trials of calcium ± vitamin D showed calcium+vitamin D increased serum 25(OH)D, and a specific SNP (rs11185644) was associated with vitamin D response.

Trust comment: Large, well‑controlled randomized parent trials with genetic analysis; calcium was part of intervention but primary focus is vitamin D dose‑response genetics.

Study Details

PMID:28079136
Participants:2207
Impact:Mean change +24.31 nmol/L (CaMEWS) and +31.92 nmol/L (D&Cancer) in Ca+Vitamin D groups vs ~-1.02 and +0.36 nmol/L in Calcium-only groups
Trust score:4/5

serum calcium change

1 evidences

Large randomized trials of calcium ± vitamin D showed calcium+vitamin D increased serum 25(OH)D, and a specific SNP (rs11185644) was associated with vitamin D response.

Trust comment: Large, well‑controlled randomized parent trials with genetic analysis; calcium was part of intervention but primary focus is vitamin D dose‑response genetics.

Study Details

PMID:28079136
Participants:2207
Impact:No difference in serum calcium change between treatment and control groups
Trust score:4/5

genetic association: rs11185644 (RXRA)

1 evidences

Large randomized trials of calcium ± vitamin D showed calcium+vitamin D increased serum 25(OH)D, and a specific SNP (rs11185644) was associated with vitamin D response.

Trust comment: Large, well‑controlled randomized parent trials with genetic analysis; calcium was part of intervention but primary focus is vitamin D dose‑response genetics.

Study Details

PMID:28079136
Participants:2207
Impact:rs11185644 significantly associated with serum 25(OH)D dose-response after adjustment (Bonferroni‑adjusted P = 0.029)
Trust score:4/5

Recurrent colorectal adenomas

1 evidences

Large randomized trial of vitamin D3 and calcium supplements found no overall benefit of calcium on colorectal adenoma recurrence; vitamin D3 effects varied by VDR genotype.

Trust comment: Large, randomized, double-blind trial with long follow-up and rigorous analysis; calcium showed no significant effect or genotype interaction.

Study Details

PMID:27978548
Participants:2259
Impact:no significant reduction with calcium supplementation
Trust score:5/5

advanced colorectal adenomas (genotype interaction with vitamin D3)

1 evidences

Large randomized trial of vitamin D3 and calcium supplements found no overall benefit of calcium on colorectal adenoma recurrence; vitamin D3 effects varied by VDR genotype.

Trust comment: Large, randomized, double-blind trial with long follow-up and rigorous analysis; calcium showed no significant effect or genotype interaction.

Study Details

PMID:27978548
Participants:2259
Impact:vitamin D3 effect varied by VDR genotype; no significant interactions with calcium
Trust score:5/5

dentinal hypersensitivity (tactile/thermal/evaporative)

1 evidences

Randomized single-blind study comparing four toothpastes found the calcium sodium phosphosilicate (CSPS/NovaMin) toothpaste produced the best reduction in dentinal hypersensitivity at 2 months.

Trust comment: Randomized clinical design with adequate sample but single-blind and commercial products; outcome measured subjectively by VAS.

Study Details

PMID:27966503
Participants:160
Impact:greater reduction at 2 months with 5% CSPS (best among four groups)
Trust score:3/5

probing depth (PD) reduction

1 evidences

Randomized trial comparing enamel matrix derivative (EMD) alone versus EMD plus biphasic calcium phosphate graft; both improved clinical and radiographic measures at 12 months with no significant difference between groups.

Trust comment: Randomized controlled trial with standardized measurements but small sample size limits power to detect between-group differences.

Study Details

PMID:27958765
Participants:52
Impact:EMD/BC: 3.14 ± 1.95 mm (39.6%); EMD: 3.30 ± 1.89 mm (48.7%)
Trust score:4/5

infrabony component reduction

1 evidences

Randomized trial comparing enamel matrix derivative (EMD) alone versus EMD plus biphasic calcium phosphate graft; both improved clinical and radiographic measures at 12 months with no significant difference between groups.

Trust comment: Randomized controlled trial with standardized measurements but small sample size limits power to detect between-group differences.

Study Details

PMID:27958765
Participants:52
Impact:EMD/BC: 2.71 ± 1.79 mm (57.9%); EMD: 2.60 ± 2.03 mm (28.5%)
Trust score:4/5

healing time of lesions

1 evidences

Randomized study in children comparing MTA versus IRM as pulpal floor base after pulpectomy found similar overall success rates but faster lesion healing with MTA.

Trust comment: Randomized clinical study with blinded examiners but small sample size; outcomes clinically relevant and well assessed.

Study Details

PMID:27957486
Participants:50
Impact:faster healing with MTA (statistically significant)
Trust score:4/5

Plasma 25(OH)D

1 evidences

Older adults randomized to 4000 IU, 2000 IU or placebo daily: high-dose vitamin D greatly raised blood 25(OH)D, modestly lowered PTH and produced only trivial increases in blood calcium without clinical harms over 1 year.

Trust comment: Large, randomized, double-blind, placebo-controlled trial with pre-specified biochemical outcomes and good compliance; high internal validity for biochemical effects.

Study Details

PMID:27986983
Participants:305
Impact:Mean at 12 months: 137 nmol/L (4000 IU), 102 nmol/L (2000 IU), 53 nmol/L (placebo)
Trust score:5/5

plasma intact PTH

1 evidences

Older adults randomized to 4000 IU, 2000 IU or placebo daily: high-dose vitamin D greatly raised blood 25(OH)D, modestly lowered PTH and produced only trivial increases in blood calcium without clinical harms over 1 year.

Trust comment: Large, randomized, double-blind, placebo-controlled trial with pre-specified biochemical outcomes and good compliance; high internal validity for biochemical effects.

Study Details

PMID:27986983
Participants:305
Impact:12-month reduction from baseline: −22% (4000 IU) and −14% (2000 IU)
Trust score:5/5

albumin-corrected plasma calcium

1 evidences

Older adults randomized to 4000 IU, 2000 IU or placebo daily: high-dose vitamin D greatly raised blood 25(OH)D, modestly lowered PTH and produced only trivial increases in blood calcium without clinical harms over 1 year.

Trust comment: Large, randomized, double-blind, placebo-controlled trial with pre-specified biochemical outcomes and good compliance; high internal validity for biochemical effects.

Study Details

PMID:27986983
Participants:305
Impact:Mean at 12 months: 2.36 mmol/L (4000 IU), 2.34 mmol/L (2000 IU), 2.32 mmol/L (placebo); small, clinically trivial increases
Trust score:5/5

bone mineral density (lumbar spine & radius)

1 evidences

Six-month treadmill exercise in obese asthmatics on long-term corticosteroids increased bone mineral density and serum calcium and reduced PTH and inflammatory cytokines compared with controls.

Trust comment: Controlled intervention with modest sample size; demonstrates changes in calcium-related biomarkers but exercise (not calcium supplementation) was the intervention and randomization/details unclear.

Study Details

PMID:27917214
Participants:80
Impact:significant increase in BMD in exercise group versus control (no exact % reported)
Trust score:3/5

serum phosphorus (sP)

1 evidences

In VLBW infants, mixed-model analysis linked calcium and phosphorus intake to changes in serum/urine Ca–P parameters (e.g., sP, urinary Ca, TrP, ALP) during first 14 days.

Trust comment: Randomized/controlled early supplementation study within a nutrition trial with repeated measures and mixed-model analysis; sample modest but analyses quantify intake–biomarker relationships.

Study Details

PMID:27916815
Participants:70
Impact:sP increased 0.13 mmol/L per mmol/kg phosphorus intake and decreased −0.13 mmol/L per g/kg/day protein intake
Trust score:4/5

urinary calcium (uCa)

1 evidences

In VLBW infants, mixed-model analysis linked calcium and phosphorus intake to changes in serum/urine Ca–P parameters (e.g., sP, urinary Ca, TrP, ALP) during first 14 days.

Trust comment: Randomized/controlled early supplementation study within a nutrition trial with repeated measures and mixed-model analysis; sample modest but analyses quantify intake–biomarker relationships.

Study Details

PMID:27916815
Participants:70
Impact:uCa increased 0.35 mmol/L per mmol/kg calcium intake (and increased with protein intake)
Trust score:4/5

Hepcidin level

1 evidences

24-week RCT in chronic hemodialysis patients: lanthanum reduced FGF23 and showed a trend to lower hepcidin, whereas calcium carbonate did not produce those reductions.

Trust comment: Randomized multicenter RCT but small (46 recruited, 25 completers) limiting precision; findings on calcium carbonate reported but underpowered.

Study Details

PMID:27928636
Participants:25
Impact:No significant decline observed with calcium carbonate (decline trend seen only with lanthanum)
Trust score:3/5

Alkaline reserve (predialysis AR 20–22 mEq/L)

1 evidences

12-month randomized prospective study: intermittent oral sodium bicarbonate maintained recommended alkaline reserve and was associated with better vascular parameters compared with controls.

Trust comment: Prospective randomized design with 63 completers and objective measures (moderate quality), but subgroup analyses and potential confounding limit certainty.

Study Details

PMID:27928454
Participants:63
Impact:Increased proportion within recommended range: 93.1% (bicarbonate group) vs 35.3% (control) (+57.8 percentage points)
Trust score:3/5

Vascular calcification prevalence (end of study)

1 evidences

12-month randomized prospective study: intermittent oral sodium bicarbonate maintained recommended alkaline reserve and was associated with better vascular parameters compared with controls.

Trust comment: Prospective randomized design with 63 completers and objective measures (moderate quality), but subgroup analyses and potential confounding limit certainty.

Study Details

PMID:27928454
Participants:63
Impact:Lower in bicarbonate group: 51.9% (study) versus up to 92.9% in control subgroups (end-of-study subgroup range 51.9%–92.9%)
Trust score:3/5

Serum calcium (end values)

1 evidences

12-month randomized prospective study: intermittent oral sodium bicarbonate maintained recommended alkaline reserve and was associated with better vascular parameters compared with controls.

Trust comment: Prospective randomized design with 63 completers and objective measures (moderate quality), but subgroup analyses and potential confounding limit certainty.

Study Details

PMID:27928454
Participants:63
Impact:Mean 8.915 mg/dL in bicarbonate group versus up to 9.707 mg/dL in control subgroup 3 (difference ≈ −0.79 mg/dL vs highest control subgroup)
Trust score:3/5

duration of severe oral mucositis (WHO ≥3)

1 evidences

In children/adolescents undergoing myeloablative HCT, topical Caphosol (calcium phosphate) rinses did not reduce severe oral mucositis or related pain, opioid use, or infections compared with saline placebo.

Trust comment: Large multicentre randomized double-blind placebo-controlled phase III trial with objective endpoints supports high trustworthiness.

Study Details

PMID:27875526
Participants:220
Impact:no change (Caphosol 4.5±5.0 vs placebo 4.5±4.8 days; mean difference 0, P=0.99)
Trust score:5/5

mouth pain (Mouth Pain Categorical Rating / OMDQ)

1 evidences

In children/adolescents undergoing myeloablative HCT, topical Caphosol (calcium phosphate) rinses did not reduce severe oral mucositis or related pain, opioid use, or infections compared with saline placebo.

Trust comment: Large multicentre randomized double-blind placebo-controlled phase III trial with objective endpoints supports high trustworthiness.

Study Details

PMID:27875526
Participants:220
Impact:no significant difference between arms
Trust score:5/5

opioid analgesic use (incidence, dose, duration)

1 evidences

In children/adolescents undergoing myeloablative HCT, topical Caphosol (calcium phosphate) rinses did not reduce severe oral mucositis or related pain, opioid use, or infections compared with saline placebo.

Trust comment: Large multicentre randomized double-blind placebo-controlled phase III trial with objective endpoints supports high trustworthiness.

Study Details

PMID:27875526
Participants:220
Impact:no significant difference between arms
Trust score:5/5

composite olfactory threshold + identification score

1 evidences

Monorhinal intranasal sodium citrate produced a small statistically significant improvement in combined olfactory threshold and identification scores versus saline in post-infectious smell loss, but the effect did not reach clinical significance.

Trust comment: Prospective placebo-controlled trial with internal control; single-blind design and small, subclinical effect reduce confidence in clinical relevance.

Study Details

PMID:27860366
Participants:49
Impact:mean improvement +0.87±2.68 points (P=0.04) vs placebo; hyposmia subgroup +1.15±2.37 (P=0.02); effect size not clinically significant
Trust score:3/5

WSL visual regression (CPP-ACP)

1 evidences

In 21 children over 12 weeks, twice-daily CPP-ACP paste improved the appearance and remineralisation of white spot tooth lesions; added fluoride varnish provided no extra benefit.

Trust comment: Randomized clinical trial with objective measures (visual + laser fluorescence), high interexaminer reproducibility, but small final sample (n=21).

Study Details

PMID:27843950
Participants:21
Impact:+57% lesions regressed (CPP-ACP group; majority regressed vs control)
Trust score:4/5

WSL visual regression (CPP-ACP + fluoride varnish)

1 evidences

In 21 children over 12 weeks, twice-daily CPP-ACP paste improved the appearance and remineralisation of white spot tooth lesions; added fluoride varnish provided no extra benefit.

Trust comment: Randomized clinical trial with objective measures (visual + laser fluorescence), high interexaminer reproducibility, but small final sample (n=21).

Study Details

PMID:27843950
Participants:21
Impact:+75% lesions regressed (CPP-ACP + FV group)
Trust score:4/5

Remineralisation (laser fluorescence)

1 evidences

In 21 children over 12 weeks, twice-daily CPP-ACP paste improved the appearance and remineralisation of white spot tooth lesions; added fluoride varnish provided no extra benefit.

Trust comment: Randomized clinical trial with objective measures (visual + laser fluorescence), high interexaminer reproducibility, but small final sample (n=21).

Study Details

PMID:27843950
Participants:21
Impact:Significant mean LF decrease in CPP-ACP groups (p<0.001); order control ~ FV < CPP-ACP ~ CPP-ACP+FV
Trust score:4/5

Preterm birth (<37 weeks)

1 evidences

In a prospective cohort of 7,634 Tanzanian pregnant women, higher dietary calcium intake was associated with lower risks of preterm birth, extreme preterm birth, and neonatal mortality.

Trust comment: Large prospective cohort with adjusted analyses showing consistent trends, though dietary recall is observational and subject to measurement error.

Study Details

PMID:27819215
Participants:7634
Impact:Adjusted RR reduced across upper Ca quartiles (~0.77, 0.74, 0.76 for 2nd–4th quartiles; test for trend P<0.001)
Trust score:4/5

Extreme preterm birth (<34 weeks)

1 evidences

In a prospective cohort of 7,634 Tanzanian pregnant women, higher dietary calcium intake was associated with lower risks of preterm birth, extreme preterm birth, and neonatal mortality.

Trust comment: Large prospective cohort with adjusted analyses showing consistent trends, though dietary recall is observational and subject to measurement error.

Study Details

PMID:27819215
Participants:7634
Impact:Adjusted RR ~0.62–0.63 in upper Ca quartiles (test for trend P=0.002)
Trust score:4/5

Neonatal mortality

1 evidences

In a prospective cohort of 7,634 Tanzanian pregnant women, higher dietary calcium intake was associated with lower risks of preterm birth, extreme preterm birth, and neonatal mortality.

Trust comment: Large prospective cohort with adjusted analyses showing consistent trends, though dietary recall is observational and subject to measurement error.

Study Details

PMID:27819215
Participants:7634
Impact:Upper Ca quartile adjusted RR = 0.59 (95% CI 0.37–0.92); P≈0.029
Trust score:4/5

lumbar spine BMD change

2 evidences

12-month double-blind RCT in postpartum lactating women randomized to low, mid or high calcium milk powder; no significant differences between groups in BMD changes at 12 months.

Trust comment: Randomized, double-blind, placebo-controlled 12‑month trial with adequate sample size and objective DXA outcomes; no between-group differences observed.

Study Details

PMID:26522081
Participants:102
Impact:Low-Ca +2.11 (SD 4.90); Mid-Ca +2.21 (SD 3.77); High-Ca +2.32 (SD 4.66) (intention-to-treat)
Trust score:4/5

In postmenopausal women, 2-year milk powder supplementation with 900 mg Ca/day (plus vitamin D 800 IU) better prevented bone loss at the greater trochanter than 600 or 300 mg/day.

Trust comment: Large (n=210), double-blind randomized trial over 2 years with clinically relevant BMD endpoints; moderate–high quality.

Study Details

PMID:26438518
Participants:210
Impact:group A (300 mg) showed significant decrease over time (P=0.001); higher doses mitigated loss at some sites
Trust score:4/5

bone turnover markers (BTMs)

1 evidences

Randomized multicenter trial comparing ALN+eldecalcitol versus ALN+vitamin D+calcium found both increased BMD; ALN+eldecalcitol produced significantly greater femoral neck BMD gain and larger reductions in bone turnover markers.

Trust comment: Large randomized multicenter trial with central DXA reading and clinically relevant endpoints; unblinded design is a limitation but results are robust for BMD and BTMs.

Study Details

PMID:25592133
Participants:219
Impact:greater reductions with ALN+ELD versus ALN+VitD+Ca from 12 weeks onward
Trust score:4/5

hospitalization duration

1 evidences

Teriparatide given after thyroidectomy reduced low calcium events, shortened hospital stay, and decreased need for postdischarge calcium pills.

Trust comment: Small randomized phase II open-label human trial with clinically relevant endpoints but limited sample size.

Study Details

PMID:27525532
Participants:26
Impact:median ↓ 1 day (control 3 days → treatment 2 days), P = 0.012
Trust score:3/5

discontinuation of calcium supplementation at 1 month

1 evidences

Teriparatide given after thyroidectomy reduced low calcium events, shortened hospital stay, and decreased need for postdischarge calcium pills.

Trust comment: Small randomized phase II open-label human trial with clinically relevant endpoints but limited sample size.

Study Details

PMID:27525532
Participants:26
Impact:treatment 10/13 (76.9%) vs control 5/13 (38.5%) (greater discontinuation in treatment), P = 0.04 (interaction)
Trust score:3/5

peak aerobic capacity (VO2peak)

1 evidences

Exercise training after CRT increased exercise capacity, reduced sympathetic nerve activity, improved vascular conductance, and altered skeletal muscle Ca2+-handling gene expression.

Trust comment: Small interventional human study with mechanistic gene-expression endpoints; useful but limited by sample size.

Study Details

PMID:27591218
Participants:30
Impact:↑ (significant in ET group, P = 0.01)
Trust score:3/5

Na+/Ca2+ exchanger gene expression

1 evidences

Exercise training after CRT increased exercise capacity, reduced sympathetic nerve activity, improved vascular conductance, and altered skeletal muscle Ca2+-handling gene expression.

Trust comment: Small interventional human study with mechanistic gene-expression endpoints; useful but limited by sample size.

Study Details

PMID:27591218
Participants:30
Impact:↑ expression in skeletal muscle in ET vs NoET, P = 0.01
Trust score:3/5

any fracture risk (menopause <40 vs ≥50)

1 evidences

Earlier menopause (<40 y) was linked to higher fracture risk and this association was not altered by calcium + vitamin D or hormone therapy.

Trust comment: Large randomized controlled trial data (WHI) with robust sample size and long follow-up; high-quality evidence.

Study Details

PMID:27801706
Participants:21711
Impact:HR 1.36 (95% CI 1.11–1.67) — higher fracture risk with menopause <40
Trust score:4/5

any fracture risk (menopause <40 vs 40–49)

1 evidences

Earlier menopause (<40 y) was linked to higher fracture risk and this association was not altered by calcium + vitamin D or hormone therapy.

Trust comment: Large randomized controlled trial data (WHI) with robust sample size and long follow-up; high-quality evidence.

Study Details

PMID:27801706
Participants:21711
Impact:HR 1.30 (95% CI 1.06–1.60)
Trust score:4/5

effect modification by Ca+D or HT treatment

1 evidences

Earlier menopause (<40 y) was linked to higher fracture risk and this association was not altered by calcium + vitamin D or hormone therapy.

Trust comment: Large randomized controlled trial data (WHI) with robust sample size and long follow-up; high-quality evidence.

Study Details

PMID:27801706
Participants:21711
Impact:no alteration of menopause-age effect on fracture risk by Ca/D, HT, or combination (no interaction)
Trust score:4/5

24-h systolic blood pressure

1 evidences

In this randomized double-blind crossover RCT, calcium-caseinate (calcium-containing protein) did not reduce ambulatory blood pressure but did modestly improve endothelial function and lowered total cholesterol compared with control.

Trust comment: Well-designed randomized, double-blind, 3-way crossover RCT with objective ambulatory BP and vascular measures but modest sample size (38 completers) for subgroup comparisons.

Study Details

PMID:27797709
Participants:38
Impact:+0.6 mm Hg (Δ, calcium-caseinate vs baseline; no significant BP reduction)
Trust score:4/5

calcium intake from dairy

1 evidences

Targeted emailed messages increased dairy-based calcium intake at 1 week in all message conditions; the loss-framed plus self-regulatory-efficacy messages maintained the increase at 4 weeks.

Trust comment: Large randomized trial with behavioral outcomes and multiple follow-ups; objective intake amounts not reported in the abstract.

Study Details

PMID:27797014
Participants:732
Impact:increased at week 1; increase maintained at week 4 in LF+SRE condition
Trust score:4/5

self-regulatory efficacy

1 evidences

Targeted emailed messages increased dairy-based calcium intake at 1 week in all message conditions; the loss-framed plus self-regulatory-efficacy messages maintained the increase at 4 weeks.

Trust comment: Large randomized trial with behavioral outcomes and multiple follow-ups; objective intake amounts not reported in the abstract.

Study Details

PMID:27797014
Participants:732
Impact:increased after intervention
Trust score:4/5

outcome expectations

1 evidences

Targeted emailed messages increased dairy-based calcium intake at 1 week in all message conditions; the loss-framed plus self-regulatory-efficacy messages maintained the increase at 4 weeks.

Trust comment: Large randomized trial with behavioral outcomes and multiple follow-ups; objective intake amounts not reported in the abstract.

Study Details

PMID:27797014
Participants:732
Impact:increased after intervention
Trust score:4/5

endogenous PTH-1-84

1 evidences

Subcutaneous PTH fragments were rapidly absorbed and caused dose-dependent increases in serum calcium and suppression of endogenous PTH in healthy postmenopausal women.

Trust comment: Randomized, double-blind dose-escalation study in humans but small sample and short duration.

Study Details

PMID:27487342
Participants:33
Impact:suppressed/decreased during treatment
Trust score:3/5

recurrent SHPT

1 evidences

In dialysis patients with refractory SHPT, total parathyroidectomy alone suppressed PTH more effectively and showed no recurrences over 3 years compared with total parathyroidectomy plus autotransplantation; serum calcium was similar between groups.

Trust comment: Prospective randomized pilot trial with limited sample size and nonconfirmatory design; provides useful but preliminary human data.

Study Details

PMID:27741007
Participants:100
Impact:occurred in 4 TPTX+AT patients and 0 TPTX patients over 3 years
Trust score:3/5

fertilization rate

2 evidences

Randomized trial in women with diminished ovarian reserve testing oocyte activation with a calcium ionophore; small numerical increases in fertilization and pregnancy rates were observed but were not statistically different between groups.

Trust comment: Prospective randomized controlled study with a large sample (n=296); results reported but differences were not statistically significant per authors.

Study Details

PMID:26342247
Participants:296
Impact:+5.3 percentage points (60.7% vs 55.4%)
Trust score:4/5

Applying calcium ionophore after IMSI did not improve fertilization or cleavage and was associated with fewer top-quality embryos among fertilized oocytes.

Trust comment: Prospective randomized sibling-oocyte design but small sample (21 patients); findings specific to ART context.

Study Details

PMID:27734719
Participants:21
Impact:no significant change (similar between groups)
Trust score:3/5

top-quality embryo rate

1 evidences

Applying calcium ionophore after IMSI did not improve fertilization or cleavage and was associated with fewer top-quality embryos among fertilized oocytes.

Trust comment: Prospective randomized sibling-oocyte design but small sample (21 patients); findings specific to ART context.

Study Details

PMID:27734719
Participants:21
Impact:decreased with AOA (35.0% vs 53.5% per fertilized oocyte; per cycle 61.9% vs 95.24%)
Trust score:3/5

Calcium–phosphate product

1 evidences

In hypoparathyroid patients, rhPTH(1-84) reduced serum phosphate and calcium–phosphate product and allowed large reductions in active vitamin D dosing while maintaining serum calcium.

Trust comment: Randomized, double-blind, placebo-controlled phase III trial with prespecified endpoints and robust analyses.

Study Details

PMID:27734257
Participants:124
Impact:-0.4 mmol^2/L^2 (LS mean change baseline to Week 24 in rhPTH group vs -0.1 in placebo; P < 0.001)
Trust score:5/5

active vitamin D dose

1 evidences

In hypoparathyroid patients, rhPTH(1-84) reduced serum phosphate and calcium–phosphate product and allowed large reductions in active vitamin D dosing while maintaining serum calcium.

Trust comment: Randomized, double-blind, placebo-controlled phase III trial with prespecified endpoints and robust analyses.

Study Details

PMID:27734257
Participants:124
Impact:-77% from baseline at Week 24 (mean percent reduction in rhPTH group; vs -35% in placebo; P < 0.001)
Trust score:5/5

ALT (alanine aminotransferase)

1 evidences

In NAFLD patients on a weight-loss program, adding calcium to calcitriol produced greater improvements in some metabolic and liver biochemical parameters versus calcitriol alone.

Trust comment: Randomized, double-blind controlled trial (n=120) with clear between-group significance but short duration (12 weeks).

Study Details

PMID:27720403
Participants:120
Impact:significant decrease with calcium+calcitriol vs calcitriol alone (P < 0.001)
Trust score:4/5

bone mass

1 evidences

Measured calciotropic hormones, IGF-1, body composition and bone mass across puberty in adolescents; bone mass rose with Tanner stage while serum calcium did not change.

Trust comment: Moderate–high quality: reasonably large, well-characterized cohort and appropriate analyses (post hoc from RCT dataset).

Study Details

PMID:27676398
Participants:335
Impact:increased substantially across Tanner stages
Trust score:4/5

IGF-1 correlation with bone mass

1 evidences

Measured calciotropic hormones, IGF-1, body composition and bone mass across puberty in adolescents; bone mass rose with Tanner stage while serum calcium did not change.

Trust comment: Moderate–high quality: reasonably large, well-characterized cohort and appropriate analyses (post hoc from RCT dataset).

Study Details

PMID:27676398
Participants:335
Impact:robust correlate in early Tanner stages (R = 0.3–0.6)
Trust score:4/5

white spot lesion visual improvement (ICDAS)

1 evidences

Chewing gum containing bioavailable calcium (with or without fluoride) improved remineralization of white spot enamel lesions over 3 months compared with control.

Trust comment: Randomized double-blind RCT with objective OCT measures but small sample size (n=37).

Study Details

PMID:27639827
Participants:37
Impact:POs-Ca: 48% lesions regressed (score 2→1); POs-Ca+F: 45%; control: 30%
Trust score:4/5

optical boundary depth (OCT)

1 evidences

Chewing gum containing bioavailable calcium (with or without fluoride) improved remineralization of white spot enamel lesions over 3 months compared with control.

Trust comment: Randomized double-blind RCT with objective OCT measures but small sample size (n=37).

Study Details

PMID:27639827
Participants:37
Impact:Significant change in mean BD over 3 months with POs-Ca and POs-Ca+F (p<0.05); POs-Ca+F vs control significant after 1 month (p<0.05)
Trust score:4/5

hypocalcemia prevalence

1 evidences

In septic AKI patients on CRRT, many electrolyte disturbances improved after 24 h; hyperphosphatemia predicted higher 28- and 90-day mortality while calcium levels were not associated with mortality.

Trust comment: Post-hoc analysis of a prospective randomized CRRT trial with 210 patients and appropriate statistical modeling, but limited by post-hoc design and single-center data.

Study Details

PMID:27603344
Participants:210
Impact:37% → 8.5% (−28.5 percentage points after 24 h CRRT)
Trust score:4/5

hyperphosphatemia prevalence

1 evidences

In septic AKI patients on CRRT, many electrolyte disturbances improved after 24 h; hyperphosphatemia predicted higher 28- and 90-day mortality while calcium levels were not associated with mortality.

Trust comment: Post-hoc analysis of a prospective randomized CRRT trial with 210 patients and appropriate statistical modeling, but limited by post-hoc design and single-center data.

Study Details

PMID:27603344
Participants:210
Impact:59.5% → 31.0% (reduced after 24 h CRRT)
Trust score:4/5

hyperphosphatemia associated mortality

1 evidences

In septic AKI patients on CRRT, many electrolyte disturbances improved after 24 h; hyperphosphatemia predicted higher 28- and 90-day mortality while calcium levels were not associated with mortality.

Trust comment: Post-hoc analysis of a prospective randomized CRRT trial with 210 patients and appropriate statistical modeling, but limited by post-hoc design and single-center data.

Study Details

PMID:27603344
Participants:210
Impact:28-day mortality HR 2.25; 90-day mortality HR 2.65 (increased risk)
Trust score:4/5

linear growth

1 evidences

Observational cohort of Zambian infants found that micronutrient adequacy (including calcium) and dietary diversity were positively associated with linear growth to 18 months.

Trust comment: Large longitudinal observational study showing associations but not causal effects; calcium role inferred within micronutrient adequacy.

Study Details

PMID:27581574
Participants:811
Impact:positively associated with calcium micronutrient adequacy to 18 months (P ≤ 0.028)
Trust score:3/5

micronutrient adequacy (calcium)

1 evidences

Observational cohort of Zambian infants found that micronutrient adequacy (including calcium) and dietary diversity were positively associated with linear growth to 18 months.

Trust comment: Large longitudinal observational study showing associations but not causal effects; calcium role inferred within micronutrient adequacy.

Study Details

PMID:27581574
Participants:811
Impact:correlated with dietary diversity (ρ ≈ 0.36) and associated with subsequent linear growth
Trust score:3/5

dietary diversity

1 evidences

Observational cohort of Zambian infants found that micronutrient adequacy (including calcium) and dietary diversity were positively associated with linear growth to 18 months.

Trust comment: Large longitudinal observational study showing associations but not causal effects; calcium role inferred within micronutrient adequacy.

Study Details

PMID:27581574
Participants:811
Impact:positively associated with later linear growth independent of micronutrient adequacy
Trust score:3/5

Gastrointestinal symptoms

1 evidences

Randomized study in lactose-intolerant adults found milk fortified with inulin and vitamin D3 (and milk minerals) increased BMD at 6 weeks in the supplemented group, while other measures (calcium absorption, GI symptoms) showed non-significant changes.

Trust comment: Small randomized trial with short (6-week) follow-up and no significant between-group differences for most measures; limited power.

Study Details

PMID:29903135
Participants:42
Impact:ameliorated in both groups with no significant difference between them
Trust score:3/5

plasma TMAO

1 evidences

Randomized single-blinded study where both arms received vitamin D plus 800 mg calcium; adding B vitamins produced larger reductions in plasma TMAO and lowered homocysteine compared with vitamin D (with calcium) alone.

Trust comment: Small randomized but non-placebo-controlled trial; calcium was co-administered in both arms so effects cannot be attributed to calcium specifically.

Study Details

PMID:27569255
Participants:52
Impact:decrease larger with vitamin D + B vitamins (−2.8 μmol/L) than vitamin D alone (−0.5 μmol/L); P = 0.005
Trust score:3/5

betaine

1 evidences

Randomized single-blinded study where both arms received vitamin D plus 800 mg calcium; adding B vitamins produced larger reductions in plasma TMAO and lowered homocysteine compared with vitamin D (with calcium) alone.

Trust comment: Small randomized but non-placebo-controlled trial; calcium was co-administered in both arms so effects cannot be attributed to calcium specifically.

Study Details

PMID:27569255
Participants:52
Impact:increased with vitamin D + B vitamins compared with vitamin D alone
Trust score:3/5

serum vitamin D

1 evidences

8-week randomized trial in vitamin D–deficient overweight/obese women with PCOS tested calcium, vitamin D, both, or placebo; co-supplementation improved some insulin and triglyceride measures.

Trust comment: Randomized double-blind placebo-controlled RCT with clear reported outcomes and adequate sample size per arm (n=26 groups), supporting moderate–high trust.

Study Details

PMID:25300649
Participants:104
Impact:increased (P<0.001)
Trust score:4/5

functional outcome (mRS 0-2)

1 evidences

Small open-label randomized trial in ischemic stroke survivors with low vitamin D found no significant improvement in functional outcome but observed higher survival at 6 months with vitamin D plus calcium versus usual care.

Trust comment: Randomized trial but open-label with small sample size; mortality difference reached significance but requires larger confirmatory trials.

Study Details

PMID:27561415
Participants:53
Impact:higher proportion in intervention arm (adjusted OR 1.9) but not statistically significant (P = 0.31)
Trust score:3/5

survival (6-month)

1 evidences

Small open-label randomized trial in ischemic stroke survivors with low vitamin D found no significant improvement in functional outcome but observed higher survival at 6 months with vitamin D plus calcium versus usual care.

Trust comment: Randomized trial but open-label with small sample size; mortality difference reached significance but requires larger confirmatory trials.

Study Details

PMID:27561415
Participants:53
Impact:higher survival in supplementation arm (83.8% vs 59.5%); P = 0.049 (adjusted HR 0.26, P = 0.03)
Trust score:3/5

Calcium intake (daily)

1 evidences

A workplace behavioural intervention increased women's calcium intake substantially and increased load-bearing physical activity versus standard care at 4 weeks and 6 months.

Trust comment: Large cluster randomized trial with validated measures and appropriate cluster analysis, but outcomes are self-reported which may bias estimates.

Study Details

PMID:27552840
Participants:585
Impact:+343.2 mg/day at 4 weeks (adjusted, after exclusions); +290.5 mg/day at 6 months (adjusted)
Trust score:4/5

Meeting calcium RDA (≥800 mg/day)

1 evidences

A workplace behavioural intervention increased women's calcium intake substantially and increased load-bearing physical activity versus standard care at 4 weeks and 6 months.

Trust comment: Large cluster randomized trial with validated measures and appropriate cluster analysis, but outcomes are self-reported which may bias estimates.

Study Details

PMID:27552840
Participants:585
Impact:+47.0% (1st follow-up); +37.8% (2nd follow-up) in intervention vs control
Trust score:4/5

Serum ionised and total calcium

1 evidences

In postmenopausal women, a single 1 g oral calcium dose raised serum calcium and attenuated the normal post‑breakfast fall in systolic blood pressure compared with placebo over 6 hours.

Trust comment: Randomized crossover design in 40 well-characterized participants gives credible acute physiologic results, though sample is small and short-term.

Study Details

PMID:27543500
Participants:40
Impact:Increased after calcium dosing (p<0.0001 vs placebo)
Trust score:4/5

Systolic blood pressure (post-dose)

1 evidences

In postmenopausal women, a single 1 g oral calcium dose raised serum calcium and attenuated the normal post‑breakfast fall in systolic blood pressure compared with placebo over 6 hours.

Trust comment: Randomized crossover design in 40 well-characterized participants gives credible acute physiologic results, though sample is small and short-term.

Study Details

PMID:27543500
Participants:40
Impact:Attenuated reduction: ~6 mmHg less fall at 4 h and ~9 mmHg less fall at 6 h after calcium vs placebo (p=0.036 and p=0.002)
Trust score:4/5

urinary NTX (bone resorption)

1 evidences

Interventions including tailor-made vitamin-D/K salmon and vitamin D+calcium tablets (and calcium supplements in fish groups) produced favorable changes in some bone turnover markers and vitamin D status in postmenopausal women over 12 weeks.

Trust comment: Randomized trial with objective biomarkers and good compliance; sample size moderate and intervention combined nutrients (vitamin D/K and calcium), complicating isolation of calcium-specific effects.

Study Details

PMID:27542236
Participants:122
Impact:Decreases within groups: Tablets −13.2; HD/HK −15.8; LD/HK −6.2; HD/LK −11.7 (units as reported); between-group difference NS (p=0.413)
Trust score:4/5

GLU/GLA ratio (vitamin K–related osteocalcin carboxylation)

1 evidences

Interventions including tailor-made vitamin-D/K salmon and vitamin D+calcium tablets (and calcium supplements in fish groups) produced favorable changes in some bone turnover markers and vitamin D status in postmenopausal women over 12 weeks.

Trust comment: Randomized trial with objective biomarkers and good compliance; sample size moderate and intervention combined nutrients (vitamin D/K and calcium), complicating isolation of calcium-specific effects.

Study Details

PMID:27542236
Participants:122
Impact:Decreased in HD/HK (delta −0.14) with between-group p=0.010 indicating improved carboxylation status
Trust score:4/5

LL-37 (hCAP-18) gene expression

1 evidences

Single high-dose vitamin D3 raised cathelicidin gene expression and reduced inflammatory markers (hs-CRP, ESR); serum calcium increased within normal range and PTH fell.

Trust comment: Double-blind randomized controlled trial with moderate sample (86 completed) and clear significant biochemical and gene-expression results; primary intervention was vitamin D (indirectly affected calcium/PTH).

Study Details

PMID:27488327
Participants:86
Impact:↑ mean 3.13-fold (Vitamin D vs placebo), P < 0.001
Trust score:4/5

hs-CRP (inflammation marker)

1 evidences

Single high-dose vitamin D3 raised cathelicidin gene expression and reduced inflammatory markers (hs-CRP, ESR); serum calcium increased within normal range and PTH fell.

Trust comment: Double-blind randomized controlled trial with moderate sample (86 completed) and clear significant biochemical and gene-expression results; primary intervention was vitamin D (indirectly affected calcium/PTH).

Study Details

PMID:27488327
Participants:86
Impact:mean change −1.12 mg/L vs +0.17 mg/L (Vitamin D vs placebo), P = 0.036
Trust score:4/5

ESR (inflammation marker)

1 evidences

Single high-dose vitamin D3 raised cathelicidin gene expression and reduced inflammatory markers (hs-CRP, ESR); serum calcium increased within normal range and PTH fell.

Trust comment: Double-blind randomized controlled trial with moderate sample (86 completed) and clear significant biochemical and gene-expression results; primary intervention was vitamin D (indirectly affected calcium/PTH).

Study Details

PMID:27488327
Participants:86
Impact:mean change −5.76 mm/h vs −0.13 mm/h (Vitamin D vs placebo), P < 0.001
Trust score:4/5

height loss (mm per year)

1 evidences

Large randomized trial found daily 1000 mg calcium + 400 IU vitamin D did not prevent height loss in postmenopausal women.

Trust comment: Large, double-blind randomized clinical trial (WHI) with long follow-up and strong methodology directly testing calcium plus vitamin D supplementation.

Study Details

PMID:27483038
Participants:36282
Impact:Ca+D 1.28 mm/y vs placebo 1.26 mm/y (P = 0.35) — no significant effect
Trust score:5/5

risk of clinical height loss (≥1.5 in / 3.8 cm)

1 evidences

Large randomized trial found daily 1000 mg calcium + 400 IU vitamin D did not prevent height loss in postmenopausal women.

Trust comment: Large, double-blind randomized clinical trial (WHI) with long follow-up and strong methodology directly testing calcium plus vitamin D supplementation.

Study Details

PMID:27483038
Participants:36282
Impact:HR 1.00 (95% CI 0.81–1.23) — no effect
Trust score:5/5

visual white spot lesion score (WSL severity)

1 evidences

In post-orthodontic patients, twice-daily fluoride toothpaste improved white spot lesions; adding fluoride varnish or CPP-ACP cream produced additional within-group improvements but no clear superiority over toothpaste alone.

Trust comment: Small randomized clinical trial (n=45 randomized, 41 completed) relevant to topical calcium-containing agent (CPP-ACP) with adequate methods but limited sample size.

Study Details

PMID:27480987
Participants:41
Impact:decreased in all groups over 6 months; between-group differences not significant (P > 0.05)
Trust score:3/5

DIAGNOdent (objective demineralization measure)

1 evidences

In post-orthodontic patients, twice-daily fluoride toothpaste improved white spot lesions; adding fluoride varnish or CPP-ACP cream produced additional within-group improvements but no clear superiority over toothpaste alone.

Trust comment: Small randomized clinical trial (n=45 randomized, 41 completed) relevant to topical calcium-containing agent (CPP-ACP) with adequate methods but limited sample size.

Study Details

PMID:27480987
Participants:41
Impact:decreased in all groups at 3–6 months; between-group differences not significant
Trust score:3/5

bone calcium retention

1 evidences

Randomized crossover in 24 postmenopausal women showed soy isoflavone supplements increased bone calcium retention by ~3.4–7.6%; mixed natural-ratio isoflavones gave the largest benefit (~+7.6%); no difference by equol‑producer status.

Trust comment: Well-controlled crossover trial with precise 41Ca measurement but small sample (n=24) limits generalizability.

Study Details

PMID:26245807
Participants:24
Impact:+3.4% to +7.6% (most-effective soy formulation +7.6%); risedronate for comparison +15.3%
Trust score:3/5

lumbar spine bone mineral density (BMD)

1 evidences

Randomized open-label study comparing calcitriol, calcitriol+calcium carbonate, and calcium carbonate alone in GC-treated nephrotic syndrome patients; calcitriol groups showed less adverse change in bone markers and higher lumbar spine BMD at 24 weeks.

Trust comment: Small (n=66) randomized open-label trial with 24-week follow-up showing calcitriol superior to calcium carbonate for lumbar spine BMD; limited size and open-label design reduce confidence.

Study Details

PMID:26396095
Participants:66
Impact:+higher BMD with calcitriol vs calcium carbonate alone (calcitriol 0.805±0.203 g/cm2 vs calcium carbonate 0.615±0.225 g/cm2; p<0.05)
Trust score:3/5

total bacterial counts

1 evidences

Both NaOCl and CHX irrigation reduced bacterial counts; intracanal calcium hydroxide further reduced number of infected canals but increased bacterial load in the remaining positive cases.

Trust comment: Randomized clinical trial in humans assessing irrigants and intracanal calcium hydroxide with molecular quantification; moderate sample size (49 teeth).

Study Details

PMID:27452293
Participants:49
Impact:Decreased from S1 to S2 (P < .01); higher in S3 than S2 (P < .01)
Trust score:3/5

canals positive after intracanal calcium hydroxide

1 evidences

Both NaOCl and CHX irrigation reduced bacterial counts; intracanal calcium hydroxide further reduced number of infected canals but increased bacterial load in the remaining positive cases.

Trust comment: Randomized clinical trial in humans assessing irrigants and intracanal calcium hydroxide with molecular quantification; moderate sample size (49 teeth).

Study Details

PMID:27452293
Participants:49
Impact:NaOCl group: positive S2 35% -> S3 20%; CHX group: S2 41% -> S3 31% (calcium hydroxide reduced number of persistent infections)
Trust score:3/5

Enterococcus faecalis detection

1 evidences

Both NaOCl and CHX irrigation reduced bacterial counts; intracanal calcium hydroxide further reduced number of infected canals but increased bacterial load in the remaining positive cases.

Trust comment: Randomized clinical trial in humans assessing irrigants and intracanal calcium hydroxide with molecular quantification; moderate sample size (49 teeth).

Study Details

PMID:27452293
Participants:49
Impact:Detected in 1 S2 sample and none in S3
Trust score:3/5

survival benefit with sevelamer (vs calcium salts)

1 evidences

Post-hoc analysis in dialysis patients: sevelamer (calcium-free binder) linked to better survival; cinacalcet improved survival only when combined with sevelamer; vitamin D had no effect.

Trust comment: Post-hoc analysis of an open-label RCT with moderate sample size; results hypothesis-generating due to post-hoc nature.

Study Details

PMID:27443567
Participants:466
Impact:improved survival (overall cohort; mean follow-up 28 months)
Trust score:3/5

cinacalcet + sevelamer interaction on mortality

1 evidences

Post-hoc analysis in dialysis patients: sevelamer (calcium-free binder) linked to better survival; cinacalcet improved survival only when combined with sevelamer; vitamin D had no effect.

Trust comment: Post-hoc analysis of an open-label RCT with moderate sample size; results hypothesis-generating due to post-hoc nature.

Study Details

PMID:27443567
Participants:466
Impact:mortality -66% (HR 0.34) when cinacalcet used with sevelamer
Trust score:3/5

vitamin D effect on mortality

1 evidences

Post-hoc analysis in dialysis patients: sevelamer (calcium-free binder) linked to better survival; cinacalcet improved survival only when combined with sevelamer; vitamin D had no effect.

Trust comment: Post-hoc analysis of an open-label RCT with moderate sample size; results hypothesis-generating due to post-hoc nature.

Study Details

PMID:27443567
Participants:466
Impact:no change
Trust score:3/5

wound-related complications

1 evidences

Randomized trial in adults: percutaneous fixation with calcium sulfate cement (CSC) had shorter operation time and fewer wound-healing complications than minimally invasive sinus tarsi plate fixation; overall functional scores were similar.

Trust comment: Prospective randomized trial with clear clinical endpoints but modest sample size and some loss to follow-up.

Study Details

PMID:27422705
Participants:80
Impact:PR+CSC 7.1% vs MISTA 28.9% (complications -21.8 percentage points)
Trust score:4/5

functional outcome (AOFAS total score)

1 evidences

Randomized trial in adults: percutaneous fixation with calcium sulfate cement (CSC) had shorter operation time and fewer wound-healing complications than minimally invasive sinus tarsi plate fixation; overall functional scores were similar.

Trust comment: Prospective randomized trial with clear clinical endpoints but modest sample size and some loss to follow-up.

Study Details

PMID:27422705
Participants:80
Impact:PR+CSC 84.6 vs MISTA 82.5 (+2.1 points; not statistically different)
Trust score:4/5

pre-dialysis ionised calcium

1 evidences

RCT (n=50) comparing low vs high dialysate calcium over 12 months: low dialysate calcium lowered pre-dialysis ionised calcium and raised PTH but did not change vascular calcification, PWV, LVMI, or BMD.

Trust comment: Randomized controlled trial directly manipulating dialysate calcium with objective outcomes; moderate sample size.

Study Details

PMID:27364375
Participants:50
Impact:-0.12 mmol/L (LC group from baseline; p=0.0001)
Trust score:4/5

vascular calcification progression

1 evidences

RCT (n=50) comparing low vs high dialysate calcium over 12 months: low dialysate calcium lowered pre-dialysis ionised calcium and raised PTH but did not change vascular calcification, PWV, LVMI, or BMD.

Trust comment: Randomized controlled trial directly manipulating dialysate calcium with objective outcomes; moderate sample size.

Study Details

PMID:27364375
Participants:50
Impact:no progression (AA or SFA) in either group over 12 months
Trust score:4/5

Radiographic healing rate

1 evidences

In 65 children treated for rickets, 1000 mg and 2000 mg calcium produced faster radiographic healing than 500 mg; 2000 mg gave no added healing vs 1000 mg.

Trust comment: Randomized controlled trial in children with objective radiographic and BMD outcomes; moderate-to-high quality but modest sample size.

Study Details

PMID:27311415
Participants:62
Impact:1000 mg: -0.29 points/month vs 500 mg; 2000 mg: -0.36 points/month vs 500 mg (1000 and 2000 mg faster than 500 mg)
Trust score:4/5

Forearm diaphyseal areal BMD

1 evidences

In 65 children treated for rickets, 1000 mg and 2000 mg calcium produced faster radiographic healing than 500 mg; 2000 mg gave no added healing vs 1000 mg.

Trust comment: Randomized controlled trial in children with objective radiographic and BMD outcomes; moderate-to-high quality but modest sample size.

Study Details

PMID:27311415
Participants:62
Impact:2000 mg improved more rapidly than 500 mg and 1000 mg (p<0.001)
Trust score:4/5

Serum alkaline phosphatase and calcium

1 evidences

In 65 children treated for rickets, 1000 mg and 2000 mg calcium produced faster radiographic healing than 500 mg; 2000 mg gave no added healing vs 1000 mg.

Trust comment: Randomized controlled trial in children with objective radiographic and BMD outcomes; moderate-to-high quality but modest sample size.

Study Details

PMID:27311415
Participants:62
Impact:Alkaline phosphatase decreased and serum calcium increased similarly across dose groups
Trust score:4/5

menstrual blood loss

1 evidences

In women with primary dysmenorrhea, 1000 mg calcium alone reduced menstrual pain vs placebo; calcium+vitamin D showed a non-significant pain reduction; no effect on menstrual blood loss.

Trust comment: Double-blind randomized trial with clear outcomes and reported effect sizes, but modest sample size limits precision.

Study Details

PMID:27296057
Participants:85
Impact:No significant difference for either calcium-alone or calcium+vitD vs placebo
Trust score:4/5

Dentin hypersensitivity (clinical measures)

2 evidences

Toothpaste with 5% calcium sodium phosphosilicate reduced dentin hypersensitivity at 4 and 8 weeks versus baseline and showed greater improvements than many controls, though an abrasivity-matched 0% formulation had similar effects.

Trust comment: Randomized, examiner-blind trial with reasonable sample size; exploratory design and control formulation effects reduce certainty.

Study Details

PMID:27295868
Participants:137
Impact:Significant reductions from baseline at Week 4 and Week 8 (all P<0.01)
Trust score:3/5

All toothpastes reduced dentin sensitivity; 5% CSPS improved tactile threshold at Week 4 versus an abrasivity-matched 0% formulation, but between-treatment differences were small and inconsistent.

Trust comment: Randomized, completed study with adequate sample size but exploratory findings and small/inconsistent between-group differences limit strength.

Study Details

PMID:27295867
Participants:134
Impact:All treatments produced significant reductions from baseline at Weeks 4 and 8 (P≤0.001)
Trust score:3/5

Comparative efficacy vs controls

1 evidences

Toothpaste with 5% calcium sodium phosphosilicate reduced dentin hypersensitivity at 4 and 8 weeks versus baseline and showed greater improvements than many controls, though an abrasivity-matched 0% formulation had similar effects.

Trust comment: Randomized, examiner-blind trial with reasonable sample size; exploratory design and control formulation effects reduce certainty.

Study Details

PMID:27295868
Participants:137
Impact:5% CSPS showed greater improvements than most controls (Week 4) and all controls (Week 8), but abrasivity-matched 0% CSPS produced similar outcomes
Trust score:3/5

25-hydroxy vitamin D (25-OHD)

1 evidences

In preterm infants, higher vitamin D dose (1000 IU/day) increased serum calcium and vitamin D and improved bone mineralization and growth.

Trust comment: Randomized double-blind human RCT with clear biochemical and clinical outcomes, but the intervention was vitamin D (not calcium supplementation) so relevance to calcium-supplement effects is indirect.

Study Details

PMID:27325795
Participants:50
Impact:increase (significant, p<0.001)
Trust score:3/5

skeletal hypomineralization (incidence)

1 evidences

In preterm infants, higher vitamin D dose (1000 IU/day) increased serum calcium and vitamin D and improved bone mineralization and growth.

Trust comment: Randomized double-blind human RCT with clear biochemical and clinical outcomes, but the intervention was vitamin D (not calcium supplementation) so relevance to calcium-supplement effects is indirect.

Study Details

PMID:27325795
Participants:50
Impact:decrease (less frequent in 1000 IU group)
Trust score:3/5

serum AFB1-lysine adduct (AFB-Lys)

1 evidences

Daily low-dose ACCS100 (calcium montmorillonite clay) reduced a serum biomarker of aflatoxin exposure at 3 months without safety signal.

Trust comment: Randomized double-blind placebo-controlled trial with adequate sample size (n=234) showing a significant biomarker reduction and no safety signals.

Study Details

PMID:27321368
Participants:234
Impact:decrease at month 3 (low-dose 1.5 g significant, p=0.0005)
Trust score:4/5

serum biochemistry / adverse events

1 evidences

Daily low-dose ACCS100 (calcium montmorillonite clay) reduced a serum biomarker of aflatoxin exposure at 3 months without safety signal.

Trust comment: Randomized double-blind placebo-controlled trial with adequate sample size (n=234) showing a significant biomarker reduction and no safety signals.

Study Details

PMID:27321368
Participants:234
Impact:no significant changes; adverse event rates similar across groups
Trust score:4/5

odor identification (post-viral hyposmia)

1 evidences

One-off intranasal sodium citrate improved odor identification in patients with post-viral smell loss but not in other causes of hyposmia.

Trust comment: Prospective placebo-controlled, single-blind study (n=57) with a plausible calcium-mediated mechanism (citrate sequesters calcium) but limited sample and single application.

Study Details

PMID:27316224
Participants:57
Impact:improved (significant compared with saline placebo)
Trust score:3/5

odor threshold (all causes)

1 evidences

One-off intranasal sodium citrate improved odor identification in patients with post-viral smell loss but not in other causes of hyposmia.

Trust comment: Prospective placebo-controlled, single-blind study (n=57) with a plausible calcium-mediated mechanism (citrate sequesters calcium) but limited sample and single application.

Study Details

PMID:27316224
Participants:57
Impact:no significant change
Trust score:3/5

APC/β-catenin score (upper 40% of crypts)

1 evidences

Randomized, double-blind trial examined calcium (1200 mg/day) ± vitamin D; calcium alone produced minimal, non-significant changes in APC/β-catenin and E-cadherin in normal-appearing rectal mucosa.

Trust comment: Randomized, double-blind, placebo-controlled trial subset (n=104) with objective biomarker quantification; moderate sample size.

Study Details

PMID:27254743
Participants:104
Impact:Calcium vs no calcium: +1% (P=0.88; no significant change)
Trust score:4/5

Total E-cadherin expression

1 evidences

Randomized, double-blind trial examined calcium (1200 mg/day) ± vitamin D; calcium alone produced minimal, non-significant changes in APC/β-catenin and E-cadherin in normal-appearing rectal mucosa.

Trust comment: Randomized, double-blind, placebo-controlled trial subset (n=104) with objective biomarker quantification; moderate sample size.

Study Details

PMID:27254743
Participants:104
Impact:Calcium vs no calcium: +8% (P=0.31; not significant)
Trust score:4/5

APC/β-catenin score (vitamin D + calcium vs calcium)

1 evidences

Randomized, double-blind trial examined calcium (1200 mg/day) ± vitamin D; calcium alone produced minimal, non-significant changes in APC/β-catenin and E-cadherin in normal-appearing rectal mucosa.

Trust comment: Randomized, double-blind, placebo-controlled trial subset (n=104) with objective biomarker quantification; moderate sample size.

Study Details

PMID:27254743
Participants:104
Impact:Increase +35% (P=0.01) — indicates combo effect but not calcium-alone
Trust score:4/5

third-trimester mean arterial pressure

1 evidences

In 653 pregnant women, higher urinary cadmium was associated with small decreases in mean arterial pressure, with this association seen among women with high intake of micronutrients including calcium.

Trust comment: Moderately sized observational cohort (n=653) with multivariable adjustment; provides modest-quality evidence of associations and effect modification by micronutrient (including calcium) intake.

Study Details

PMID:27129315
Participants:653
Impact:-1.8 mmHg
Trust score:3/5

second-trimester mean arterial pressure

1 evidences

In 653 pregnant women, higher urinary cadmium was associated with small decreases in mean arterial pressure, with this association seen among women with high intake of micronutrients including calcium.

Trust comment: Moderately sized observational cohort (n=653) with multivariable adjustment; provides modest-quality evidence of associations and effect modification by micronutrient (including calcium) intake.

Study Details

PMID:27129315
Participants:653
Impact:-1.1 mmHg
Trust score:3/5

Osteocalcin (bone formation marker)

1 evidences

In 90 adults with type 2 diabetes, 12 weeks of daily yogurt fortified with 1000 IU vitamin D3 ± 500 mg calcium modestly improved vitamin D status and produced a modest decrease in intact PTH in the vitamin D+calcium group, especially in participants with baseline vitamin D deficiency/insufficiency; osteocalcin did not change.

Trust comment: Randomized, double‑blind trial in 90 diabetic adults with direct calcium-containing intervention but modest effects and limited duration.

Study Details

PMID:26780278
Participants:90
Impact:no significant change over 12 weeks
Trust score:3/5

caries increment (dmfs) with 500ppm F + TMP

1 evidences

600 children used low-fluoride toothpastes; TMP-supplemented low-fluoride paste gave fewer new caries than standard 1100 ppm F, while CaGP-supplemented paste performed similarly to 1100 ppm F.

Trust comment: Large, double-blind randomized controlled trial with 18-month follow-up; directly tests a calcium-containing additive (CaGP) in toothpaste.

Study Details

PMID:27163717
Participants:600
Impact:mean increment 0.26 vs 0.74 for 1100ppm F (significantly lower)
Trust score:4/5

caries increment (dmfs) with 500ppm F + CaGP

1 evidences

600 children used low-fluoride toothpastes; TMP-supplemented low-fluoride paste gave fewer new caries than standard 1100 ppm F, while CaGP-supplemented paste performed similarly to 1100 ppm F.

Trust comment: Large, double-blind randomized controlled trial with 18-month follow-up; directly tests a calcium-containing additive (CaGP) in toothpaste.

Study Details

PMID:27163717
Participants:600
Impact:mean increment 0.54 vs 0.74 for 1100ppm F (no significant difference)
Trust score:4/5

overall safety/efficacy in under-6s

1 evidences

600 children used low-fluoride toothpastes; TMP-supplemented low-fluoride paste gave fewer new caries than standard 1100 ppm F, while CaGP-supplemented paste performed similarly to 1100 ppm F.

Trust comment: Large, double-blind randomized controlled trial with 18-month follow-up; directly tests a calcium-containing additive (CaGP) in toothpaste.

Study Details

PMID:27163717
Participants:600
Impact:LFDs with phosphate salts reduced or matched caries outcomes versus 1100ppm F over 18 months
Trust score:4/5

total body bone mineral density (BMD)

1 evidences

65 completers on low-carb or low-fat energy-restricted diets lost similar weight; both groups had small decreases in total body BMD and increases in a bone resorption marker over 12 months.

Trust comment: Randomized dietary trial with moderate completion rate; directly measures bone outcomes but not Calcium supplementation specifically.

Study Details

PMID:27157472
Participants:65
Impact:decreased in both groups (LC: 1.26 to 1.22 g/cm2; LF: 1.26 to 1.23 g/cm2; P < 0.001 time)
Trust score:3/5

bone serum crosslaps (resorption marker)

1 evidences

65 completers on low-carb or low-fat energy-restricted diets lost similar weight; both groups had small decreases in total body BMD and increases in a bone resorption marker over 12 months.

Trust comment: Randomized dietary trial with moderate completion rate; directly measures bone outcomes but not Calcium supplementation specifically.

Study Details

PMID:27157472
Participants:65
Impact:increased in both groups (LC: 319.3 to 396.5 ng/L; LF: 276.3 to 365.9 ng/L; P < 0.001 time)
Trust score:3/5

total-body bone mineral content (BMC)

1 evidences

65 completers on low-carb or low-fat energy-restricted diets lost similar weight; both groups had small decreases in total body BMD and increases in a bone resorption marker over 12 months.

Trust comment: Randomized dietary trial with moderate completion rate; directly measures bone outcomes but not Calcium supplementation specifically.

Study Details

PMID:27157472
Participants:65
Impact:no significant change in either group over 12 months
Trust score:3/5

Serum 25(OH)D change

1 evidences

Pregnant adolescents given calcium + vitamin D had less postpartum bone loss for certain VDR genotypes compared with placebo.

Trust comment: Randomized controlled trial in humans with genotype interaction analysis but small sample size limits precision.

Study Details

PMID:27211082
Participants:56
Impact:Change from pregnancy to postpartum differed by supplementation for 1521 GG/1012 AA genotypes (P=0.004)
Trust score:4/5

postpartum bone loss (total BMD and femoral neck BMC/BMD)

1 evidences

Pregnant adolescents given calcium + vitamin D had less postpartum bone loss for certain VDR genotypes compared with placebo.

Trust comment: Randomized controlled trial in humans with genotype interaction analysis but small sample size limits precision.

Study Details

PMID:27211082
Participants:56
Impact:Supplementation minimized postpartum bone loss in adolescents with 1521 GG/1012 AA versus placebo (placebo subgroup showed greater reductions, P<0.05)
Trust score:4/5

total hip bone area (BA)

1 evidences

Pregnant adolescents given calcium + vitamin D had less postpartum bone loss for certain VDR genotypes compared with placebo.

Trust comment: Randomized controlled trial in humans with genotype interaction analysis but small sample size limits precision.

Study Details

PMID:27211082
Participants:56
Impact:In placebo, BA decreased from 5 to 20 wk in 1521 GG/1012 AA but increased in 1521 GC/1012 AG; this pattern was not seen in supplemented group (P<0.05)
Trust score:4/5

maximum left carotid intima-media thickness (CIMT)

1 evidences

Twelve weeks of vitamin D, K and calcium co-supplementation improved left carotid thickness and several metabolic markers in overweight diabetics with CHD.

Trust comment: Randomized double-blind placebo-controlled trial with clear reported differences but modest sample size and co-supplementation complicates attribution to calcium alone.

Study Details

PMID:27198036
Participants:66
Impact:Supplemented: -0.04 mm vs placebo: +0.04 mm (between-group difference, P=0.02)
Trust score:4/5

total 25(OH)D increase

1 evidences

High-dose vitamin D3 raised total and free 25(OH)D more than D2 and free 25(OH)D changes correlated with iPTH change.

Trust comment: Small, controlled human study measuring markers of calcium balance; indirect relevance to calcium physiology but limited size.

Study Details

PMID:27192696
Participants:38
Impact:D3: +27.6 ng/mL vs D2: +12.2 ng/mL (P=0.001)
Trust score:3/5

free 25(OH)D increase

1 evidences

High-dose vitamin D3 raised total and free 25(OH)D more than D2 and free 25(OH)D changes correlated with iPTH change.

Trust comment: Small, controlled human study measuring markers of calcium balance; indirect relevance to calcium physiology but limited size.

Study Details

PMID:27192696
Participants:38
Impact:D3: +6.2 pg/mL vs D2: +3.6 pg/mL (P=0.02)
Trust score:3/5

iPTH association

1 evidences

High-dose vitamin D3 raised total and free 25(OH)D more than D2 and free 25(OH)D changes correlated with iPTH change.

Trust comment: Small, controlled human study measuring markers of calcium balance; indirect relevance to calcium physiology but limited size.

Study Details

PMID:27192696
Participants:38
Impact:Percentage change in iPTH was significantly associated with change in free (but not total) 25(OH)D
Trust score:3/5

Endothelial function (flow-mediated dilatation)

1 evidences

In CKD patients, paricalcitol improved endothelial function but raised phosphate and slightly increased calcium.

Trust comment: Randomized controlled trial secondary analysis in 88 CKD patients with objective vascular and biochemical measures; moderate-high quality.

Study Details

PMID:27113290
Participants:88
Impact:+61% (PCT vs placebo)
Trust score:4/5

epicardial adipose tissue progression

1 evidences

In dialysis patients, epicardial fat increased more with calcium-based phosphate binders than with sevelamer, and sevelamer reduced LDL cholesterol.

Trust comment: Post-hoc substudy of an RCT with modest sample size; findings relevant to calcium-based binder use but limited by sample and non-significant between-group EAT difference.

Study Details

PMID:27102490
Participants:109
Impact:CPiB median +9.1% (p=0.005) vs SVL +3.9% (p=0.25); between-group p=0.34
Trust score:3/5

serum fetuin-A

1 evidences

In 48-week randomized treatment completers, both calcium carbonate and sevelamer groups showed decreased serum fetuin-A; calcium carbonate produced a larger serum calcium increase and fetuin-A decreases correlated with calcium increase and changes in iPTH and albumin.

Trust comment: Randomized, controlled trial with a 48-week per-protocol post-hoc analysis but small number of completers (n=50) and open-label design limit generalizability.

Study Details

PMID:27007989
Participants:50
Impact:Decreased by −33.05 μg/mL in calcium carbonate group (203.95 → 170.90 μg/mL, p=0.002)
Trust score:3/5

Δ fetuin-A correlations

1 evidences

In 48-week randomized treatment completers, both calcium carbonate and sevelamer groups showed decreased serum fetuin-A; calcium carbonate produced a larger serum calcium increase and fetuin-A decreases correlated with calcium increase and changes in iPTH and albumin.

Trust comment: Randomized, controlled trial with a 48-week per-protocol post-hoc analysis but small number of completers (n=50) and open-label design limit generalizability.

Study Details

PMID:27007989
Participants:50
Impact:Δfetuin-A associated with ΔCa (ρ=−0.230, p=0.040), ΔiPTH (ρ=0.306, p=0.031), Δalbumin (ρ=0.408, p=0.003)
Trust score:3/5

Urinary phosphorus and potassium

1 evidences

Cross-sectional study showing long-term environmental cadmium exposure alters urinary mineral balance, including increased urinary calcium.

Trust comment: Reasonable sample and statistics showing association, but observational design with potential confounding.

Study Details

PMID:27029362
Participants:298
Impact:Phosphorus and potassium decreased in exposed group (P<0.001)
Trust score:3/5

Correlation (cadmium with minerals)

1 evidences

Cross-sectional study showing long-term environmental cadmium exposure alters urinary mineral balance, including increased urinary calcium.

Trust comment: Reasonable sample and statistics showing association, but observational design with potential confounding.

Study Details

PMID:27029362
Participants:298
Impact:Urinary cadmium positively correlated with urinary Ca (r=0.31), Cu (r=0.61), Zn (r=0.38), I (r=0.25)
Trust score:3/5

free testosterone

1 evidences

In 60 vitamin D-deficient women with PCOS, 8 weeks of vitamin D–K–calcium co-supplementation lowered free testosterone and DHEAS and improved antioxidant capacity versus placebo.

Trust comment: Randomized, double-blind, placebo-controlled trial (n=60) with clear biomarker outcomes but short duration and modest sample size.

Study Details

PMID:27050252
Participants:60
Impact:decrease −2.1±1.6 vs +0.1±1.0 pg/ml (p<0.001)
Trust score:4/5

DHEAS

1 evidences

In 60 vitamin D-deficient women with PCOS, 8 weeks of vitamin D–K–calcium co-supplementation lowered free testosterone and DHEAS and improved antioxidant capacity versus placebo.

Trust comment: Randomized, double-blind, placebo-controlled trial (n=60) with clear biomarker outcomes but short duration and modest sample size.

Study Details

PMID:27050252
Participants:60
Impact:decrease −0.8±1.0 vs −0.1±0.5 μg/ml (p=0.006)
Trust score:4/5

bone regeneration (radiographic grade)

1 evidences

Randomized trial in patients with bone defects: porous hydroxyapatite/collagen implant produced superior radiographic bone regeneration versus porous β-TCP by 18–24 weeks, with more (non-serious) adverse events.

Trust comment: Randomized controlled trial in humans with clear radiographic endpoints and adequate sample analyzed (59 vs 60); follow-up 24 weeks; adverse events increased but non-serious.

Study Details

PMID:26961287
Participants:119
Impact:Higher frequency of highest-grade regeneration with HAp/Col vs β-TCP at 18 & 24 weeks (p=0.0004 and p=0.0254)
Trust score:4/5

proportion reaching maternal 25(OH)D ≥50 nmol/L at delivery

1 evidences

Protocol for a multicentre randomized trial comparing high- vs low-dose vitamin D in pregnant Middle Eastern women; primary outcomes are maternal 25(OH)D ≥50 nmol/L at delivery and infant bone mineral content at 1 month.

Trust comment: Well-described, powered randomized controlled trial protocol addressing calcium-related maternal/neonatal outcomes, but no results reported yet.

Study Details

PMID:26956166
Participants:280
Impact:no results reported (protocol)
Trust score:4/5

infant bone mineral content (BMC) at 1 month

1 evidences

Protocol for a multicentre randomized trial comparing high- vs low-dose vitamin D in pregnant Middle Eastern women; primary outcomes are maternal 25(OH)D ≥50 nmol/L at delivery and infant bone mineral content at 1 month.

Trust comment: Well-described, powered randomized controlled trial protocol addressing calcium-related maternal/neonatal outcomes, but no results reported yet.

Study Details

PMID:26956166
Participants:280
Impact:no results reported (protocol)
Trust score:4/5

clinical healing (primary molars)

1 evidences

Randomized clinical trial in children: 3Mixtatin treatment of primary molars with resorption resulted in markedly better clinical and radiographic healing at 24 months vs MTA.

Trust comment: Randomized clinical trial with 24-month follow-up and clear clinical/radiographic endpoints; moderate sample size (teeth n=80 from 65 children).

Study Details

PMID:26950808
Participants:65
Impact:3Mixtatin: 96.8% teeth clinically asymptomatic at 24 months vs ~51.4% clinical success implied for MTA (based on 48.6% with signs)
Trust score:4/5

radiographic arrested resorption

1 evidences

Randomized clinical trial in children: 3Mixtatin treatment of primary molars with resorption resulted in markedly better clinical and radiographic healing at 24 months vs MTA.

Trust comment: Randomized clinical trial with 24-month follow-up and clear clinical/radiographic endpoints; moderate sample size (teeth n=80 from 65 children).

Study Details

PMID:26950808
Participants:65
Impact:3Mixtatin: 96.8% arrested resorption on radiographs vs 18.9% in MTA group
Trust score:4/5

achievement of PTH ≤250 pg/mL

1 evidences

Double-blind placebo-controlled phase III trial: cinacalcet increased proportion achieving PTH ≤250 pg/mL and lowered serum calcium and phosphorus; mild hypocalcemia reported.

Trust comment: Placebo-controlled phase III RCT with objective biochemical endpoints; directly affects calcium/phosphate homeostasis but tests a drug (cinacalcet), not calcium supplementation.

Study Details

PMID:26940692
Participants:238
Impact:25.4% cinacalcet vs 3.5% placebo achieved target PTH
Trust score:3/5

serum calcium and phosphorus levels

1 evidences

Double-blind placebo-controlled phase III trial: cinacalcet increased proportion achieving PTH ≤250 pg/mL and lowered serum calcium and phosphorus; mild hypocalcemia reported.

Trust comment: Placebo-controlled phase III RCT with objective biochemical endpoints; directly affects calcium/phosphate homeostasis but tests a drug (cinacalcet), not calcium supplementation.

Study Details

PMID:26940692
Participants:238
Impact:both lower in cinacalcet group; mild-to-moderate hypocalcemia reported (drug-related)
Trust score:3/5

wound healing period

1 evidences

In malnourished older women after hip fracture, daily supplementation with CaHMB + vitamin D + protein sped wound healing, increased early mobility, and improved muscle strength versus standard nutrition.

Trust comment: Randomized controlled study in humans with clear clinical endpoints; intervention combined CaHMB with vitamin D and protein, so effects cannot be attributed to elemental calcium alone.

Study Details

PMID:26965178
Participants:75
Impact:shorter (P < 0.05)
Trust score:4/5

mobility at days 15 and 30

1 evidences

In malnourished older women after hip fracture, daily supplementation with CaHMB + vitamin D + protein sped wound healing, increased early mobility, and improved muscle strength versus standard nutrition.

Trust comment: Randomized controlled study in humans with clear clinical endpoints; intervention combined CaHMB with vitamin D and protein, so effects cannot be attributed to elemental calcium alone.

Study Details

PMID:26965178
Participants:75
Impact:+54.6 percentage points (81.3% vs 26.7%)
Trust score:4/5

muscle strength (day 30)

1 evidences

In malnourished older women after hip fracture, daily supplementation with CaHMB + vitamin D + protein sped wound healing, increased early mobility, and improved muscle strength versus standard nutrition.

Trust comment: Randomized controlled study in humans with clear clinical endpoints; intervention combined CaHMB with vitamin D and protein, so effects cannot be attributed to elemental calcium alone.

Study Details

PMID:26965178
Participants:75
Impact:increased (P < 0.05)
Trust score:4/5

horizontal ridge width change

1 evidences

Using a composite calcium-based graft in extraction sockets preserved horizontal ridge width better than natural healing, with similar bone area and less connective tissue at 4 months.

Trust comment: Randomized human clinical trial with objective clinical and histological outcomes but small sample size (n=36), supporting moderate-high confidence.

Study Details

PMID:26922214
Participants:36
Impact:Experimental (grafted) ~0.03 mm vs Control ~2.28 mm change (≈2.25 mm less horizontal loss with grafting; p=0.007 at -3mm, p=0.02 at -6mm)
Trust score:4/5

bone area fraction

1 evidences

Using a composite calcium-based graft in extraction sockets preserved horizontal ridge width better than natural healing, with similar bone area and less connective tissue at 4 months.

Trust comment: Randomized human clinical trial with objective clinical and histological outcomes but small sample size (n=36), supporting moderate-high confidence.

Study Details

PMID:26922214
Participants:36
Impact:Test 47.7% vs Control 52.6% (no significant difference; p=0.39)
Trust score:4/5

connective tissue percentage

1 evidences

Using a composite calcium-based graft in extraction sockets preserved horizontal ridge width better than natural healing, with similar bone area and less connective tissue at 4 months.

Trust comment: Randomized human clinical trial with objective clinical and histological outcomes but small sample size (n=36), supporting moderate-high confidence.

Study Details

PMID:26922214
Participants:36
Impact:Test 36.3% vs Control 46.7% (≈10.4% lower in grafted sites; p=0.013)
Trust score:4/5

clinical attachment gain / linear bone growth

1 evidences

Adding rh-FGF-2 to a β-tricalcium phosphate scaffold improved periodontal regeneration versus β-TCP alone in adults.

Trust comment: Randomized, double-blinded, externally monitored multicenter RCT (n=88) — good design and reporting support moderate-high trust.

Study Details

PMID:26908630
Participants:88
Impact:Dose-response improvement with plateau at 0.3–0.4% rh-FGF-2 achieving composite endpoint (≥1.5 mm attachment and ≥2.5 mm bone growth)
Trust score:4/5

urinary urea / creatinine (protein catabolism/lean-mass markers)

1 evidences

Over 24 weeks, higher dairy intake (~1200 mg calcium/day) versus low dairy changed urinary metabolites linked to energy, protein and gut microbial metabolism in overweight women on calorie restriction.

Trust comment: Randomized 24-week intervention with targeted metabolomics but small sample (n=38) and exploratory outcomes limit generalizability.

Study Details

PMID:26907339
Participants:38
Impact:increased (HD vs LD)
Trust score:3/5

urinary TMAO (gut microbial metabolite)

1 evidences

Over 24 weeks, higher dairy intake (~1200 mg calcium/day) versus low dairy changed urinary metabolites linked to energy, protein and gut microbial metabolism in overweight women on calorie restriction.

Trust comment: Randomized 24-week intervention with targeted metabolomics but small sample (n=38) and exploratory outcomes limit generalizability.

Study Details

PMID:26907339
Participants:38
Impact:decreased (HD vs LD)
Trust score:3/5

vascular calcification markers (IMT and AACS)

1 evidences

Switching elderly hemodialysis patients to lower dialysate calcium (1.25 mmol/L) lowered serum calcium and Ca×P, raised iPTH, and improved vascular calcification indices over 12 months.

Trust comment: Randomized 12-month study (n=82) addressing relevant clinical endpoints, but limited methodological detail and likely single-center reduce certainty.

Study Details

PMID:26905433
Participants:82
Impact:decreased at 6 and 12 months (improvement vs baseline and control)
Trust score:3/5

puncture-site hemostasis

1 evidences

In ~997 PICC insertions, calcium alginate dressings with hemostatic gauze gave better puncture-site hemostasis and lower one-week maintenance cost than gauze or alginate alone.

Trust comment: Large sample (n=997) and randomized groups but limited reporting and unclear methodological detail reduce confidence in effect size precision.

Study Details

PMID:26904891
Participants:997
Impact:improved in calcium alginate dressing + hemostatic gauze group (group C) vs gauze or alginate alone (statistically significant)
Trust score:3/5

catheter maintenance cost (1 week)

1 evidences

In ~997 PICC insertions, calcium alginate dressings with hemostatic gauze gave better puncture-site hemostasis and lower one-week maintenance cost than gauze or alginate alone.

Trust comment: Large sample (n=997) and randomized groups but limited reporting and unclear methodological detail reduce confidence in effect size precision.

Study Details

PMID:26904891
Participants:997
Impact:lowest in calcium alginate + gauze group (group C)
Trust score:3/5

verbal learning (ISL)

1 evidences

Apoaequorin supplement (regulates intracellular calcium) improved verbal learning and delayed recall versus placebo over 90 days.

Trust comment: Randomized double-blind placebo-controlled trial with adequate sample size; results reported as statistically significant though effect sizes not provided here.

Study Details

PMID:26878676
Participants:218
Impact:+significant improvement (no magnitude reported)
Trust score:4/5

delayed verbal recall (ISL-DR)

1 evidences

Apoaequorin supplement (regulates intracellular calcium) improved verbal learning and delayed recall versus placebo over 90 days.

Trust comment: Randomized double-blind placebo-controlled trial with adequate sample size; results reported as statistically significant though effect sizes not provided here.

Study Details

PMID:26878676
Participants:218
Impact:+significant improvement (no magnitude reported)
Trust score:4/5

fasting serum glucose

1 evidences

Chicory inulin (oligofructose-enriched) for 2 months raised serum calcium and improved glucose and some liver enzyme measures in female T2DM patients.

Trust comment: Randomized controlled trial but small, short duration, and limited to female patients, limiting generalizability.

Study Details

PMID:26872721
Participants:46
Impact:-significant reduction
Trust score:3/5

AST / ALP (liver enzymes)

1 evidences

Chicory inulin (oligofructose-enriched) for 2 months raised serum calcium and improved glucose and some liver enzyme measures in female T2DM patients.

Trust comment: Randomized controlled trial but small, short duration, and limited to female patients, limiting generalizability.

Study Details

PMID:26872721
Participants:46
Impact:-significant reduction
Trust score:3/5

FGF-23 vs serum calcium

1 evidences

In hemodialysis patients, higher FGF-23 levels correlated with higher serum calcium and with greater coronary artery calcification but not with carotid atherosclerosis.

Trust comment: Well-sized cross-sectional study showing associations (not causation) in HD patients; limited by observational design.

Study Details

PMID:26865177
Participants:229
Impact:positive correlation r=0.337, P<0.001
Trust score:3/5

FGF-23 vs coronary artery calcification (CACs)

1 evidences

In hemodialysis patients, higher FGF-23 levels correlated with higher serum calcium and with greater coronary artery calcification but not with carotid atherosclerosis.

Trust comment: Well-sized cross-sectional study showing associations (not causation) in HD patients; limited by observational design.

Study Details

PMID:26865177
Participants:229
Impact:positive correlation r=0.218, P=0.001
Trust score:3/5

FGF-23 vs carotid intima-media thickness (CA-IMT)

1 evidences

In hemodialysis patients, higher FGF-23 levels correlated with higher serum calcium and with greater coronary artery calcification but not with carotid atherosclerosis.

Trust comment: Well-sized cross-sectional study showing associations (not causation) in HD patients; limited by observational design.

Study Details

PMID:26865177
Participants:229
Impact:no significant association
Trust score:3/5

length increment

1 evidences

Fortified human milk produced similar overall growth to preterm formula, improved some bone‑metabolism markers and reduced sepsis and feeding intolerance in ELBW/VLBW infants.

Trust comment: Prospective, randomized controlled study with 122 infants and reported effect sizes; however sample limited to hospitalized ELBW/VLBW infants.

Study Details

PMID:26885925
Participants:122
Impact:+0.10 cm/week (0.89 ± 0.23 vs 0.79 ± 0.34 cm/week; P=0.04)
Trust score:4/5

calcium / bone metabolism markers

1 evidences

Fortified human milk produced similar overall growth to preterm formula, improved some bone‑metabolism markers and reduced sepsis and feeding intolerance in ELBW/VLBW infants.

Trust comment: Prospective, randomized controlled study with 122 infants and reported effect sizes; however sample limited to hospitalized ELBW/VLBW infants.

Study Details

PMID:26885925
Participants:122
Impact:calcium at birth lower in HMF group -0.13 mmol/L (2.19 vs 2.32 mmol/L, P=0.005); AKP at discharge higher +64.25 units (363.98 vs 299.73, P=0.004)
Trust score:4/5

sepsis and feeding intolerance incidence

1 evidences

Fortified human milk produced similar overall growth to preterm formula, improved some bone‑metabolism markers and reduced sepsis and feeding intolerance in ELBW/VLBW infants.

Trust comment: Prospective, randomized controlled study with 122 infants and reported effect sizes; however sample limited to hospitalized ELBW/VLBW infants.

Study Details

PMID:26885925
Participants:122
Impact:feeding intolerance -11.8 percentage points (6.5% vs 18.3%, P=0.04); sepsis -11.9 percentage points (4.8% vs 16.7%, P=0.03)
Trust score:4/5

plaque volume

1 evidences

Randomized AMI trial: intensive statin therapy increased dense calcium content in coronary plaques over 12 months.

Trust comment: Randomized blinded-endpoint trial with serial CTA and clear significant finding for dense calcium increase; moderate-high quality.

Study Details

PMID:26115069
Participants:96
Impact:no significant change between groups (p=0.57)
Trust score:4/5

bony stability (RSA translations/rotations)

1 evidences

Randomized patients receiving different graft materials after osteotomy; bone stability similar across groups, Calcibon group had lower QoL subscore at 2 years.

Trust comment: Randomized trial with 2-year RSA follow-up; moderate-high quality and directly evaluates a calcium-containing graft material's clinical outcome.

Study Details

PMID:26855045
Participants:45
Impact:no significant differences between grafting materials; translations/rotations close to zero
Trust score:4/5

KOOS quality of life subscore

1 evidences

Randomized patients receiving different graft materials after osteotomy; bone stability similar across groups, Calcibon group had lower QoL subscore at 2 years.

Trust comment: Randomized trial with 2-year RSA follow-up; moderate-high quality and directly evaluates a calcium-containing graft material's clinical outcome.

Study Details

PMID:26855045
Participants:45
Impact:lower in Calcibon (calcium phosphate cement) group at 2 years (clinically worse vs other grafts)
Trust score:4/5

plasma intact parathyroid hormone (PTH)

1 evidences

Cinacalcet in healthy volunteers produced expected pharmacokinetic behavior and lowered plasma PTH and serum calcium after single and multiple doses.

Trust comment: Well-described randomized PK/PD study in healthy volunteers with clear measurements; small sample size but methods appropriate.

Study Details

PMID:26804640
Participants:41
Impact:decreased after cinacalcet administration
Trust score:4/5

calcium intake below DRI

1 evidences

Pre-operative assessment of bariatric surgery candidates found many did not meet dietary reference intakes; 48% had calcium intake below DRI.

Trust comment: Cross-sectional preoperative nutritional assessment with a moderate sample size; observational design limits causal inference.

Study Details

PMID:26797718
Participants:100
Impact:48% of patients had calcium intake below Dietary Reference Intake
Trust score:3/5

plasma iron concentration

1 evidences

Randomized double-blind trial in obese hypertensive adults: 3 months of Spirulina (2 g/day) decreased serum iron but did not markedly change serum calcium or magnesium.

Trust comment: Well-conducted randomized double-blind placebo-controlled trial (n=50) with ITT analysis; significant finding limited to iron only.

Study Details

PMID:26779620
Participants:50
Impact:−3.65 μmol/L (16.63 → 12.98 μmol/L), ≈−21.9%, statistically significant (p=0.008)
Trust score:4/5

plasma magnesium concentration

1 evidences

Randomized double-blind trial in obese hypertensive adults: 3 months of Spirulina (2 g/day) decreased serum iron but did not markedly change serum calcium or magnesium.

Trust comment: Well-conducted randomized double-blind placebo-controlled trial (n=50) with ITT analysis; significant finding limited to iron only.

Study Details

PMID:26779620
Participants:50
Impact:no change (0.75 → 0.75 mmol/L, non-significant)
Trust score:4/5

stool frequency

2 evidences

Crossover pilot RCT in healthy women found that 500 mg/day elemental calcium (carbonate or phosphate) did not change stool frequency or stool form over study periods.

Trust comment: Small, short-duration randomized crossover pilot (n=27); outcomes directly measured and reported, but limited sample and period length.

Study Details

PMID:26771423
Participants:27
Impact:no change (mean 1.3 ± 0.1 stools/day in each period)
Trust score:3/5

Calcium phosphate co-administered with a probiotic increased faecal Lactobacillus spp.; calcium carbonate alone had no effect and stool frequency did not change.

Trust comment: Randomized, double-blind crossover design but small sample sizes (n=15 and n=17); outcomes measured objectively (qPCR/culture).

Study Details

PMID:26503737
Participants:32
Impact:no change
Trust score:4/5

stool form (constipation markers)

1 evidences

Crossover pilot RCT in healthy women found that 500 mg/day elemental calcium (carbonate or phosphate) did not change stool frequency or stool form over study periods.

Trust comment: Small, short-duration randomized crossover pilot (n=27); outcomes directly measured and reported, but limited sample and period length.

Study Details

PMID:26771423
Participants:27
Impact:no change (% stools with BSFS 1–2 ≈34% baseline, 34% Ca carbonate, 37% Ca phosphate)
Trust score:3/5

folate intake

1 evidences

In this small pilot secondary analysis, patients who reduced sodium intake ≥25% had larger decreases in dietary calcium intake but no adverse changes in overall nutritional status.

Trust comment: Small (n=38), secondary analysis of a pilot trial with measured dietary intakes—provides limited but direct data on calcium intake changes.

Study Details

PMID:28531423
Participants:38
Impact:median change +50 mcg/day (−101,167) vs −31 mcg/day (−221,51); p=0.04 between groups
Trust score:3/5

weight / nutritional status

1 evidences

In this small pilot secondary analysis, patients who reduced sodium intake ≥25% had larger decreases in dietary calcium intake but no adverse changes in overall nutritional status.

Trust comment: Small (n=38), secondary analysis of a pilot trial with measured dietary intakes—provides limited but direct data on calcium intake changes.

Study Details

PMID:28531423
Participants:38
Impact:no significant weight loss or adverse changes in hand‑grip strength or overall caloric intake between groups
Trust score:3/5

plaque re-growth (plaque area, Turesky plaque index)

1 evidences

In 23 healthy adults, CSPS-containing dentifrices showed no chemical anti-plaque benefit versus negative control; an active mouthrinse and SLS-containing dentifrices reduced plaque regrowth more than the experimental CSPS formulation.

Trust comment: Small, well-controlled crossover trial but small sample size (n=23) limits generalizability.

Study Details

PMID:26796897
Participants:23
Impact:active mouthrinse: significantly lower plaque re-growth at 96 h vs other treatments (p<0.05); experimental 5% CSPS dentifrice: significantly higher plaque re-growth vs active comparator
Trust score:3/5

anti-plaque effect of CSPS dentifrices

1 evidences

In 23 healthy adults, CSPS-containing dentifrices showed no chemical anti-plaque benefit versus negative control; an active mouthrinse and SLS-containing dentifrices reduced plaque regrowth more than the experimental CSPS formulation.

Trust comment: Small, well-controlled crossover trial but small sample size (n=23) limits generalizability.

Study Details

PMID:26796897
Participants:23
Impact:no significant chemical-therapeutic anti-plaque benefit of tested CSPS dentifrices vs negative control
Trust score:3/5

diastolic blood pressure (DBP) response

1 evidences

Pharmacogenetic analysis in 1,131 treatment‑naïve African Americans found suggestive (but not Bonferroni‑significant) gene-by-treatment interactions affecting systolic and diastolic BP response to common antihypertensive drugs.

Trust comment: Large, well-conducted randomized trial-based pharmacogenetic analysis but primary gene-by-treatment results did not reach multiple-testing significance.

Study Details

PMID:26791477
Participants:1131
Impact:REN rs6681776: among A/A minor-allele homozygotes, chlorthalidone DBP change −9.49 mmHg vs doxazosin −1.70 mmHg (P=0.007) — genotype-specific greater reduction with chlorthalidone
Trust score:3/5

systolic blood pressure (SBP) response

1 evidences

Pharmacogenetic analysis in 1,131 treatment‑naïve African Americans found suggestive (but not Bonferroni‑significant) gene-by-treatment interactions affecting systolic and diastolic BP response to common antihypertensive drugs.

Trust comment: Large, well-conducted randomized trial-based pharmacogenetic analysis but primary gene-by-treatment results did not reach multiple-testing significance.

Study Details

PMID:26791477
Participants:1131
Impact:F7 rs762637 and AGT rs5051 showed suggestive genotype-dependent differences (example: F7 rs762637 G/G: chlorthalidone −20.91 vs lisinopril −14.67 mmHg; A/A: lisinopril −22.53 vs chlorthalidone −15.67 mmHg; P≈0.02)
Trust score:3/5

fasting plasma phosphate

1 evidences

In 62 healthy adults, high phosphorus (1000 mg/day) with differing calcium (0, 500, 1000 mg/day) altered mineral handling: fasting plasma phosphate unchanged, high P without Ca reduced renal calcium excretion and disturbed calcium balance, while calcium supplementation mitigated negative effects; transient FGF23 rise at 4 weeks and modest decreases in some bone turnover markers with Ca supplementation.

Trust comment: Randomized, double‑blind, placebo‑controlled intervention with relevant biochemical measures and reasonable sample size (n=62 completed); moderate external generalizability.

Study Details

PMID:26786148
Participants:62
Impact:no significant change after 8 weeks across interventions
Trust score:4/5

bone turnover markers (osteocalcin, BAP, CTX)

1 evidences

In 62 healthy adults, high phosphorus (1000 mg/day) with differing calcium (0, 500, 1000 mg/day) altered mineral handling: fasting plasma phosphate unchanged, high P without Ca reduced renal calcium excretion and disturbed calcium balance, while calcium supplementation mitigated negative effects; transient FGF23 rise at 4 weeks and modest decreases in some bone turnover markers with Ca supplementation.

Trust comment: Randomized, double‑blind, placebo‑controlled intervention with relevant biochemical measures and reasonable sample size (n=62 completed); moderate external generalizability.

Study Details

PMID:26786148
Participants:62
Impact:Ca-supplemented groups (P1000/Ca500, P1000/Ca1000): modest decreases in osteocalcin, BAP and CTX after 4–8 weeks (≈ ~20% change; statistically significant for several markers)
Trust score:4/5

pulp capping clinical success rate

1 evidences

Laser irradiation combined with calcium-containing pulp capping agents produced higher 6-month clinical success rates than the agents alone in vital tooth pulp capping.

Trust comment: Randomized clinical trial directly assessing calcium-based pulp capping agents with clear outcome measures, but small sample size (n=60) limits precision.

Study Details

PMID:26723484
Participants:60
Impact:100% in both laser groups vs 73.3% (calcium hydroxide alone) and 66.6% (TheraCal alone)
Trust score:4/5

loss of tooth vitality / symptoms

1 evidences

Laser irradiation combined with calcium-containing pulp capping agents produced higher 6-month clinical success rates than the agents alone in vital tooth pulp capping.

Trust comment: Randomized clinical trial directly assessing calcium-based pulp capping agents with clear outcome measures, but small sample size (n=60) limits precision.

Study Details

PMID:26723484
Participants:60
Impact:no failures in laser groups during 6-month follow-up; failures occurred in non-laser groups
Trust score:4/5

treatment safety (radiographic changes)

1 evidences

Laser irradiation combined with calcium-containing pulp capping agents produced higher 6-month clinical success rates than the agents alone in vital tooth pulp capping.

Trust comment: Randomized clinical trial directly assessing calcium-based pulp capping agents with clear outcome measures, but small sample size (n=60) limits precision.

Study Details

PMID:26723484
Participants:60
Impact:no significant adverse radiographic changes reported among groups
Trust score:4/5

inflammatory markers (CRP, IL-6)

1 evidences

High-flux hemodialysis (HFHD) reduced FGF-23 and inflammatory markers and increased 1,25-(OH)2VitD3 compared with low-flux dialysis in ESRD patients.

Trust comment: Randomized hemodialysis study with 60 patients; relevant to calcium/phosphate metabolism but excerpt lacks full methodological detail.

Study Details

PMID:26710869
Participants:60
Impact:decreased in HFHD group vs LFHD after 3 months
Trust score:3/5

1,25-(OH)2VitD3

1 evidences

High-flux hemodialysis (HFHD) reduced FGF-23 and inflammatory markers and increased 1,25-(OH)2VitD3 compared with low-flux dialysis in ESRD patients.

Trust comment: Randomized hemodialysis study with 60 patients; relevant to calcium/phosphate metabolism but excerpt lacks full methodological detail.

Study Details

PMID:26710869
Participants:60
Impact:increased in HFHD group vs LFHD after 3 months
Trust score:3/5

oral calcium requirement

1 evidences

PTH therapy let most patients reduce or stop oral calcium while keeping blood calcium normal.

Trust comment: Small (n=24) open-label extension with clinical endpoints—useful but limited by size and open-label design.

Study Details

PMID:26684150
Participants:24
Impact:75% achieved ≥50% reduction; 58% eliminated oral calcium and active vitamin D
Trust score:3/5

serum calcium (normocalcemia)

1 evidences

PTH therapy let most patients reduce or stop oral calcium while keeping blood calcium normal.

Trust comment: Small (n=24) open-label extension with clinical endpoints—useful but limited by size and open-label design.

Study Details

PMID:26684150
Participants:24
Impact:maintained normal levels at Week 24 despite reductions in oral calcium
Trust score:3/5

self-efficacy for calcium intake

1 evidences

An 8-week online program improved older adults' calcium intake, knowledge, and confidence about bone-health behaviors.

Trust comment: Large randomized trial with behavioral outcomes, though reliance on self-report may limit objective measurement.

Study Details

PMID:26675352
Participants:866
Impact:improved vs control
Trust score:4/5

exercise behavior

1 evidences

An 8-week online program improved older adults' calcium intake, knowledge, and confidence about bone-health behaviors.

Trust comment: Large randomized trial with behavioral outcomes, though reliance on self-report may limit objective measurement.

Study Details

PMID:26675352
Participants:866
Impact:increased vs control
Trust score:4/5

immediate postoperative calcemia

1 evidences

Randomized trial found no major overall differences, but terminal-branch ligation was associated with higher immediate postoperative calcium and more patients discharged without supplements.

Trust comment: Prospective randomized trial (n=184) with clinical biochemical outcomes; randomized design and clinical endpoints increase trust.

Study Details

PMID:26708858
Participants:184
Impact:higher in terminal-branch ligation group (group B) — statistically significant
Trust score:4/5

Discharge without calcium/vitamin D supplementation

1 evidences

Randomized trial found no major overall differences, but terminal-branch ligation was associated with higher immediate postoperative calcium and more patients discharged without supplements.

Trust comment: Prospective randomized trial (n=184) with clinical biochemical outcomes; randomized design and clinical endpoints increase trust.

Study Details

PMID:26708858
Participants:184
Impact:greater number discharged without supplementation in group B — statistically significant
Trust score:4/5

CAC progression rate

1 evidences

Lowering dialysate calcium (to 1.25 mmol/L) slowed coronary calcification progression and improved low bone turnover in hemodialysis patients.

Trust comment: Large randomized controlled trial (n=425) with objective imaging and biopsy endpoints showing statistically significant effects.

Study Details

PMID:26701977
Participants:425
Impact:significantly lower in 1.25 mmol/L dialysate Ca group vs 1.75 mmol/L (P=0.03)
Trust score:5/5

Prevalence of low bone turnover

1 evidences

Lowering dialysate calcium (to 1.25 mmol/L) slowed coronary calcification progression and improved low bone turnover in hemodialysis patients.

Trust comment: Large randomized controlled trial (n=425) with objective imaging and biopsy endpoints showing statistically significant effects.

Study Details

PMID:26701977
Participants:425
Impact:decreased from 85.0% to 41.8% in 1.25 Ca group (P=0.001)
Trust score:5/5

Bone formation / trabecular thickness / bone volume

1 evidences

Lowering dialysate calcium (to 1.25 mmol/L) slowed coronary calcification progression and improved low bone turnover in hemodialysis patients.

Trust comment: Large randomized controlled trial (n=425) with objective imaging and biopsy endpoints showing statistically significant effects.

Study Details

PMID:26701977
Participants:425
Impact:higher at 24 months in 1.25 Ca group vs 1.75 Ca group
Trust score:5/5

colorectal adenoma recurrence

1 evidences

In high-risk patients who had colorectal adenomas removed, the aspirin-calcitriol-calcium regimen did not reduce adenoma recurrence over 3 years; older age increased recurrence risk.

Trust comment: Randomized clinical trial dataset with 427 patients and 3-year follow-up; robust design though this report focuses on risk factors rather than primary treatment effect details.

Study Details

PMID:26667088
Participants:427
Impact:No significant effect of aspirin-calcitriol-calcium treatment on recurrence (overall recurrence 25.8%; age ≤50: 19%; age >70: 35%)
Trust score:4/5

adenoma location (proximal vs distal)

1 evidences

In high-risk patients who had colorectal adenomas removed, the aspirin-calcitriol-calcium regimen did not reduce adenoma recurrence over 3 years; older age increased recurrence risk.

Trust comment: Randomized clinical trial dataset with 427 patients and 3-year follow-up; robust design though this report focuses on risk factors rather than primary treatment effect details.

Study Details

PMID:26667088
Participants:427
Impact:Older subjects had more proximal recurrent adenomas (16/25 proximal in >70 group vs 18/20 distal in ≤50 group)
Trust score:4/5

dentin/root sensitivity (VAS)

1 evidences

An in-office paste and at-home toothpaste containing 8% arginine and calcium carbonate prevented and reduced dentin/root sensitivity over 17 weeks compared to control.

Trust comment: Randomized trial (n=74) with repeated measures over 17 weeks showing consistent, significant benefit; topical calcium carbonate included as active ingredient.

Study Details

PMID:26660591
Participants:74
Impact:Significant decreases in VAS at weeks 8, 11, and 17 from baseline in the test group (p ≤ 0.003)
Trust score:4/5

dentin/root sensitivity (Schiff scale)

1 evidences

An in-office paste and at-home toothpaste containing 8% arginine and calcium carbonate prevented and reduced dentin/root sensitivity over 17 weeks compared to control.

Trust comment: Randomized trial (n=74) with repeated measures over 17 weeks showing consistent, significant benefit; topical calcium carbonate included as active ingredient.

Study Details

PMID:26660591
Participants:74
Impact:Significant decreases in Schiff scores at weeks 8 and 11 in the test group (p ≤ 0.014); marked inter-group differences at all time points (p < 0.001)
Trust score:4/5

1,25(OH)2D levels

1 evidences

In people with HIV, ART type and vitamin D status associate with bone mineral density; higher serum calcium was associated with lower lumbar spine BMD.

Trust comment: Observational analyses from a randomized ART simplification trial baseline (n=160); associative findings subject to confounding but biologically plausible.

Study Details

PMID:26659069
Participants:160
Impact:TDF-FTC use associated with higher 1,25(OH)2D in those with 25(OH)D ≥50 nmol/L
Trust score:3/5

IGF-I level

1 evidences

In women with anorexia nervosa, a 4-week protein‑fortified dairy product slightly raised IGF‑I and produced a small increase in serum calcium; no change in bone turnover markers.

Trust comment: Multicenter randomized double‑blind placebo‑controlled trial (good design) but calcium change was small and secondary to a protein/dairy intervention.

Study Details

PMID:26602423
Participants:62
Impact:+20.2% in intervention group; between-group increase +4.9 nmol/L (post-hoc, P=0.003)
Trust score:4/5

Urine osmolality

1 evidences

In calcium stone formers, one week of tolvaptan increased urine volume, lowered urine osmolality and reduced urinary supersaturation of calcium-containing stones.

Trust comment: Randomized, double‑blind, placebo‑controlled crossover design but small sample size; outcomes measured directly and clearly reported for one-week treatment.

Study Details

PMID:26598423
Participants:21
Impact:Decreased: mean 204 ± 96 vs 529 ± 213 mOsm/kg (tolvaptan vs placebo)
Trust score:4/5

Urinary supersaturation (Ca oxalate, Ca phosphate, uric acid)

1 evidences

In calcium stone formers, one week of tolvaptan increased urine volume, lowered urine osmolality and reduced urinary supersaturation of calcium-containing stones.

Trust comment: Randomized, double‑blind, placebo‑controlled crossover design but small sample size; outcomes measured directly and clearly reported for one-week treatment.

Study Details

PMID:26598423
Participants:21
Impact:Decreased supersaturation of calcium oxalate, calcium phosphate and uric acid
Trust score:4/5

Overall blood pressure

1 evidences

Daily 500 mg elemental calcium showed a small overall trend toward lower blood pressure and a modest, statistically significant diastolic BP reduction in women with prior severe pre‑eclampsia.

Trust comment: Randomized placebo‑controlled substudy with moderate sample but exploratory analyses and subgroup finding needs cautious interpretation.

Study Details

PMID:26597740
Participants:367
Impact:Trend to reduced BP of ~1–2.5 mmHg (not statistically significant overall)
Trust score:3/5

Diastolic BP (severe pre-eclampsia subgroup)

1 evidences

Daily 500 mg elemental calcium showed a small overall trend toward lower blood pressure and a modest, statistically significant diastolic BP reduction in women with prior severe pre‑eclampsia.

Trust comment: Randomized placebo‑controlled substudy with moderate sample but exploratory analyses and subgroup finding needs cautious interpretation.

Study Details

PMID:26597740
Participants:367
Impact:Calcium group −2.6 mmHg vs placebo +0.8 mmHg; mean difference −3.4 mmHg (95% CI −0.4 to −6.4; p=0.025)
Trust score:3/5

normocalcemia at 12 months

1 evidences

12-month randomized trial in 30 kidney transplant recipients with hypercalcemia: subtotal parathyroidectomy normalized serum calcium in all patients and produced larger iPTH reductions and a significant increase in femoral neck BMD compared with cinacalcet.

Trust comment: Prospective randomized multicenter study with clinically relevant endpoints but small sample size and open-label design.

Study Details

PMID:26647424
Participants:30
Impact:15/15 (100%) parathyroidectomy vs 10/15 (66.7%) cinacalcet
Trust score:4/5

circulating ionized calcium

1 evidences

Giving 2000 mg/day calcium plus vitamin D for 9 weeks increased blood ionized calcium but did not change iron status in military recruits.

Trust comment: Randomized double-blind placebo-controlled trial in healthy recruits with clear outcomes; moderate sample and short duration limit long-term inference.

Study Details

PMID:26625709
Participants:152
Impact:increase
Trust score:4/5

iron status

1 evidences

Giving 2000 mg/day calcium plus vitamin D for 9 weeks increased blood ionized calcium but did not change iron status in military recruits.

Trust comment: Randomized double-blind placebo-controlled trial in healthy recruits with clear outcomes; moderate sample and short duration limit long-term inference.

Study Details

PMID:26625709
Participants:152
Impact:no change
Trust score:4/5

Merz Hand Grading Scale (MHGS) score

1 evidences

Calcium hydroxylapatite filler improved hand appearance with all treated subjects showing ≥1-point MHGS improvement at 4 weeks.

Trust comment: Small randomized controlled cosmetic study using validated scales; short follow-up and small N reduce generalizability.

Study Details

PMID:26618470
Participants:30
Impact:≥1-point improvement in 100% treated subjects vs 0% control at 4 weeks
Trust score:3/5

Global Aesthetic Improvement Scale (GAIS) ratings

1 evidences

Calcium hydroxylapatite filler improved hand appearance with all treated subjects showing ≥1-point MHGS improvement at 4 weeks.

Trust comment: Small randomized controlled cosmetic study using validated scales; short follow-up and small N reduce generalizability.

Study Details

PMID:26618470
Participants:30
Impact:subjects rated 92.5% hands improved; physicians rated 100% hands improved
Trust score:3/5

dietary calcium consumption

1 evidences

Framed messages changed osteoporosis-prevention behaviors: gain-framed messages increased dietary calcium intake, while loss-framed messages increased calcium supplement use.

Trust comment: Behavioral experiments in humans with moderate sample sizes; relevant to calcium intake behavior but not clinical physiological outcomes.

Study Details

PMID:26603627
Participants:288
Impact:gain-framed messages produced greater increase
Trust score:3/5

calcium supplement use

1 evidences

Framed messages changed osteoporosis-prevention behaviors: gain-framed messages increased dietary calcium intake, while loss-framed messages increased calcium supplement use.

Trust comment: Behavioral experiments in humans with moderate sample sizes; relevant to calcium intake behavior but not clinical physiological outcomes.

Study Details

PMID:26603627
Participants:288
Impact:loss-framed messages produced greater increase
Trust score:3/5

peak VO2

1 evidences

78 patients were randomized and 58 completed 12 months; Algisyl (injectable calcium alginate hydrogel) plus standard therapy improved exercise capacity and symptoms at 12 months but was associated with higher mortality in the treated group.

Trust comment: Randomized multicenter trial with modest sample size and open-label design; objective exercise outcomes improved but mortality signal raises safety concerns.

Study Details

PMID:26555602
Participants:58
Impact:+2.10 mL/kg/min vs control (95% CI 0.96–3.24, P<0.001)
Trust score:3/5

hypocalcemia occurrence

1 evidences

Randomized comparison of three surgical approaches for secondary hyperparathyroidism in 63 patients with ESRD, with 6-month follow-up of calcium and PTH levels and complications.

Trust comment: Randomized human surgical trial (n=63) with clinical and biochemical endpoints; reasonable short-term evidence though details on magnitude of biochemical changes are limited.

Study Details

PMID:26531277
Participants:63
Impact:hypocalcemia occurrence was lowest in subtotal parathyroidectomy (SPTX) group (p<0.05 vs others)
Trust score:3/5

postoperative relapse rate

1 evidences

Randomized comparison of three surgical approaches for secondary hyperparathyroidism in 63 patients with ESRD, with 6-month follow-up of calcium and PTH levels and complications.

Trust comment: Randomized human surgical trial (n=63) with clinical and biochemical endpoints; reasonable short-term evidence though details on magnitude of biochemical changes are limited.

Study Details

PMID:26531277
Participants:63
Impact:relapse rate was highest in SPTX group (p<0.05 vs others)
Trust score:3/5

blood calcium and PTH changes

1 evidences

Randomized comparison of three surgical approaches for secondary hyperparathyroidism in 63 patients with ESRD, with 6-month follow-up of calcium and PTH levels and complications.

Trust comment: Randomized human surgical trial (n=63) with clinical and biochemical endpoints; reasonable short-term evidence though details on magnitude of biochemical changes are limited.

Study Details

PMID:26531277
Participants:63
Impact:no significant correlations between preoperative and postoperative blood calcium and PTH levels
Trust score:3/5

faecal Lactobacillus spp. counts

1 evidences

Calcium phosphate co-administered with a probiotic increased faecal Lactobacillus spp.; calcium carbonate alone had no effect and stool frequency did not change.

Trust comment: Randomized, double-blind crossover design but small sample sizes (n=15 and n=17); outcomes measured objectively (qPCR/culture).

Study Details

PMID:26503737
Participants:32
Impact:increase when probiotic given with calcium phosphate (4.83 → 5.79; P=0.02; ≈+0.96 log units)
Trust score:4/5

detection of administered probiotic strains

1 evidences

Calcium phosphate co-administered with a probiotic increased faecal Lactobacillus spp.; calcium carbonate alone had no effect and stool frequency did not change.

Trust comment: Randomized, double-blind crossover design but small sample sizes (n=15 and n=17); outcomes measured objectively (qPCR/culture).

Study Details

PMID:26503737
Participants:32
Impact:increased with all treatments (no difference among treatments)
Trust score:4/5

periodontal pocket depth (PPD)

1 evidences

A biphasic calcium phosphate/PLGA bone substitute improved periodontal pocket depth and CEJ position at 6 months compared with beta-TCP and was similar to deproteinised bovine bone.

Trust comment: Split-mouth clinical comparison with small sample (n=24); direct clinical outcomes reported but limited sample size and short follow-up (6 months).

Study Details

PMID:26495694
Participants:24
Impact:significant reduction with BCP/PLGA vs beta-TCP at 6 months
Trust score:3/5

cement–enamel junction (CEJ) position

1 evidences

A biphasic calcium phosphate/PLGA bone substitute improved periodontal pocket depth and CEJ position at 6 months compared with beta-TCP and was similar to deproteinised bovine bone.

Trust comment: Split-mouth clinical comparison with small sample (n=24); direct clinical outcomes reported but limited sample size and short follow-up (6 months).

Study Details

PMID:26495694
Participants:24
Impact:significant improvement with BCP/PLGA vs beta-TCP
Trust score:3/5

PPD and CEJ vs DPBB

1 evidences

A biphasic calcium phosphate/PLGA bone substitute improved periodontal pocket depth and CEJ position at 6 months compared with beta-TCP and was similar to deproteinised bovine bone.

Trust comment: Split-mouth clinical comparison with small sample (n=24); direct clinical outcomes reported but limited sample size and short follow-up (6 months).

Study Details

PMID:26495694
Participants:24
Impact:similar improvements with BCP/PLGA and deproteinised bovine bone (no significant difference)
Trust score:3/5

pyrophosphate

1 evidences

Oral calcium carbonate produced modest changes in serum calcification propensity correlated with rises in serum calcium; some regulators (pyrophosphate, fetuin-A) showed correlations with serum calcium, but between-group differences were limited.

Trust comment: Randomized placebo-controlled trial in postmenopausal women but small sample and some analytes measured in a small subset; correlations rather than consistent between-group effects.

Study Details

PMID:26493812
Participants:41
Impact:declined from baseline in placebo at 4 h and differed from calcium group at 4 h (p=0.04)
Trust score:4/5

Whole-body BMD change (%)

1 evidences

12-month double-blind RCT in postpartum lactating women randomized to low, mid or high calcium milk powder; no significant differences between groups in BMD changes at 12 months.

Trust comment: Randomized, double-blind, placebo-controlled 12‑month trial with adequate sample size and objective DXA outcomes; no between-group differences observed.

Study Details

PMID:26522081
Participants:102
Impact:Low-Ca −0.93 (SD 1.97); Mid-Ca −0.56 (SD 1.89); High-Ca −0.44 (SD 1.67) (intention-to-treat)
Trust score:4/5

Total left hip BMD change (%)

1 evidences

12-month double-blind RCT in postpartum lactating women randomized to low, mid or high calcium milk powder; no significant differences between groups in BMD changes at 12 months.

Trust comment: Randomized, double-blind, placebo-controlled 12‑month trial with adequate sample size and objective DXA outcomes; no between-group differences observed.

Study Details

PMID:26522081
Participants:102
Impact:Low-Ca −1.60 (SD 2.65); Mid-Ca −1.43 (SD 2.30); High-Ca −0.95 (SD 4.08) (intention-to-treat)
Trust score:4/5

serum insulin / HOMA-IR

1 evidences

Pregnant women at risk for pre-eclampsia received vitamin D3 plus 1000 mg/day calcium for 12 weeks and showed improved glycaemic markers, HDL, and glutathione versus placebo.

Trust comment: Double-blind RCT with clear metabolic outcomes but modest sample size (N=60); reasonable internal validity.

Study Details

PMID:26467311
Participants:60
Impact:insulin -2.8 (6.0) μIU/mL vs +7.7 (9.8) μIU/mL; HOMA-IR -0.8 (1.3) vs +1.6 (2.2) (both P<0.001)
Trust score:4/5

plasma total glutathione (GSH)

1 evidences

Pregnant women at risk for pre-eclampsia received vitamin D3 plus 1000 mg/day calcium for 12 weeks and showed improved glycaemic markers, HDL, and glutathione versus placebo.

Trust comment: Double-blind RCT with clear metabolic outcomes but modest sample size (N=60); reasonable internal validity.

Study Details

PMID:26467311
Participants:60
Impact:increase +23.4 (124.0) μM vs -94.8 (130.2) μM (P=0.001)
Trust score:4/5

recurrent colorectal adenomas (any)

1 evidences

Large randomized placebo-controlled trial: daily calcium (1200 mg) ± vitamin D3 did not significantly reduce recurrence of colorectal adenomas over 3–5 years.

Trust comment: Large, multicenter randomized double-blind trial (N=2259) with long follow-up and low risk of bias — high confidence.

Study Details

PMID:26465985
Participants:2259
Impact:adjusted risk ratio with calcium vs no calcium 0.95 (95% CI 0.85–1.06) — no significant reduction
Trust score:5/5

Advanced adenomas

1 evidences

Large randomized placebo-controlled trial: daily calcium (1200 mg) ± vitamin D3 did not significantly reduce recurrence of colorectal adenomas over 3–5 years.

Trust comment: Large, multicenter randomized double-blind trial (N=2259) with long follow-up and low risk of bias — high confidence.

Study Details

PMID:26465985
Participants:2259
Impact:no significant difference between calcium (± vitamin D) and control groups
Trust score:5/5

renal phosphate reabsorption (TmP/GFR)

1 evidences

Analysis of TPTD-treated patients (with all participants receiving daily calcium 610 mg + vitamin D 400 IU) showing that phosphate handling is linked to lumbar BMD response to teriparatide.

Trust comment: Randomized trial data with central lab measurements and clear results linking phosphate handling to BMD, though calcium supplementation was given to all and the study focuses on teriparatide; some limitations (no endogenous PTH or 25-OH vitamin D measurements).

Study Details

PMID:26478225
Participants:290
Impact:decreased with TPTD; higher (less-decreased) TmP/GFR associated with greater L-BMD increase (TmP/GFR ≥3.16 group had significantly greater L-BMD, p=0.032)
Trust score:4/5

lumbar bone mineral density (L-BMD)

1 evidences

Analysis of TPTD-treated patients (with all participants receiving daily calcium 610 mg + vitamin D 400 IU) showing that phosphate handling is linked to lumbar BMD response to teriparatide.

Trust comment: Randomized trial data with central lab measurements and clear results linking phosphate handling to BMD, though calcium supplementation was given to all and the study focuses on teriparatide; some limitations (no endogenous PTH or 25-OH vitamin D measurements).

Study Details

PMID:26478225
Participants:290
Impact:TPTD group increased L-BMD: +5.8% at 48 weeks and +6.7% at 72 weeks vs placebo +0.6% and +0.3% respectively (p<0.001)
Trust score:4/5

change in HbA1c in reference group

1 evidences

Population-based 10-year longitudinal study in non-diabetic adults assessing supplement intakes (including calcium) and changes in HbA1c; no significant association found for calcium supplementation and HbA1c change.

Trust comment: Large, population-based longitudinal study with long follow-up and thorough supplement assessment, but observational design limits causal inference and residual confounding is possible.

Study Details

PMID:26473975
Participants:2774
Impact:reference (no intake) increased by ~+0.1% over 10 years (βt ≈ +0.10% to +0.11%)
Trust score:3/5

greater trochanter BMD change

1 evidences

In postmenopausal women, 2-year milk powder supplementation with 900 mg Ca/day (plus vitamin D 800 IU) better prevented bone loss at the greater trochanter than 600 or 300 mg/day.

Trust comment: Large (n=210), double-blind randomized trial over 2 years with clinically relevant BMD endpoints; moderate–high quality.

Study Details

PMID:26438518
Participants:210
Impact:significantly better preservation/increase with 900 mg/day versus 600 and 300 mg/day (P significant; exact BMD values not quoted)
Trust score:4/5

Ward's triangle BMD change

1 evidences

In postmenopausal women, 2-year milk powder supplementation with 900 mg Ca/day (plus vitamin D 800 IU) better prevented bone loss at the greater trochanter than 600 or 300 mg/day.

Trust comment: Large (n=210), double-blind randomized trial over 2 years with clinically relevant BMD endpoints; moderate–high quality.

Study Details

PMID:26438518
Participants:210
Impact:increases in groups B (600 mg) and C (900 mg) (P=0.03 and P=0.004 respectively) compared with baseline
Trust score:4/5

postoperative favorable outcome

1 evidences

Calcium hydroxide mixed with either saline or 0.2% chlorhexidine gave similarly high favorable outcomes in root canal treatment.

Trust comment: Randomized clinical evaluation with modest participant number and outcomes assessed clinically/radiographically; small sample and tooth-level analysis limit generalizability.

Study Details

PMID:26423502
Participants:55
Impact:control 97.1% vs experimental 94.3% (no significant difference, p>0.05)
Trust score:3/5

calcium-phosphorus product (Ca×P)

1 evidences

Adding nicotinamide to calcium-based phosphate binders lowered serum phosphorus and improved lipid parameters in pediatric hemodialysis patients.

Trust comment: Randomized 6-month trial in 60 children with clear biochemical endpoints and reported adverse events; moderate sample size but appropriate design.

Study Details

PMID:26420678
Participants:60
Impact:significant decline versus control (p=0.0001)
Trust score:4/5

blood coagulability (TEG coagulation index)

1 evidences

Acute calcium supplementation modestly attenuated the diurnal fall in blood pressure and increased some measures of blood coagulability.

Trust comment: Randomized controlled trial with 100 participants and objective hemodynamic and coagulation measures; subgroup TEG limited to 40 participants.

Study Details

PMID:26420590
Participants:100
Impact:greater increase at 4 h in calcium citrate group versus control (P=0.03)
Trust score:4/5

adenoma recurrence rate

1 evidences

A 3-year randomized trial of a combination including calcium carbonate showed no reduction in colorectal adenoma recurrence versus placebo.

Trust comment: Large, randomized, double-blind, placebo-controlled multicenter trial stopped for futility; strong design but tested a combination therapy rather than calcium alone.

Study Details

PMID:26404953
Participants:1107
Impact:no significant difference (OR 0.95; 95% CI 0.61–1.48)
Trust score:4/5

bone turnover markers (osteocalcin, total N-terminal propeptide, β-collagen)

1 evidences

Randomized open-label study comparing calcitriol, calcitriol+calcium carbonate, and calcium carbonate alone in GC-treated nephrotic syndrome patients; calcitriol groups showed less adverse change in bone markers and higher lumbar spine BMD at 24 weeks.

Trust comment: Small (n=66) randomized open-label trial with 24-week follow-up showing calcitriol superior to calcium carbonate for lumbar spine BMD; limited size and open-label design reduce confidence.

Study Details

PMID:26396095
Participants:66
Impact:attenuated/less dramatic changes with calcitriol (p<0.05)
Trust score:3/5

serum calcium / phosphorus / ALP / PTH

1 evidences

Randomized open-label study comparing calcitriol, calcitriol+calcium carbonate, and calcium carbonate alone in GC-treated nephrotic syndrome patients; calcitriol groups showed less adverse change in bone markers and higher lumbar spine BMD at 24 weeks.

Trust comment: Small (n=66) randomized open-label trial with 24-week follow-up showing calcitriol superior to calcium carbonate for lumbar spine BMD; limited size and open-label design reduce confidence.

Study Details

PMID:26396095
Participants:66
Impact:no significant change
Trust score:3/5

dentin hypersensitivity (air blast stimulus)

1 evidences

Single-blind randomized crossover trial: a calcium phosphate-containing paste significantly reduced dentin hypersensitivity versus placebo up to 6 months.

Trust comment: Randomized, single-blind crossover with 35 patients and consistent significant differences versus placebo; moderate quality.

Study Details

PMID:26361810
Participants:35
Impact:-35% immediately (POST); -55% at 6 months (vs placebo -20% POST, -36% at 6 months)
Trust score:4/5

dentin hypersensitivity (probe scratching)

1 evidences

Single-blind randomized crossover trial: a calcium phosphate-containing paste significantly reduced dentin hypersensitivity versus placebo up to 6 months.

Trust comment: Randomized, single-blind crossover with 35 patients and consistent significant differences versus placebo; moderate quality.

Study Details

PMID:26361810
Participants:35
Impact:-21% immediately (POST); -54% at 6 months (vs placebo -11% POST, -30% at 6 months)
Trust score:4/5

vertical defect bone gain (difference BB vs CJ)

1 evidences

Double-blind RCT comparing bovine bone + membrane vs pure β-tricalcium phosphate (a calcium phosphate) + membrane for horizontal augmentation: no major differences, with a small (0.24 mm) less peri-implant radiographic bone loss favoring the β-TCP group.

Trust comment: Double-blind randomized trial with 50 patients and 12-month follow-up; high methodological quality though effect sizes were small.

Study Details

PMID:26355171
Participants:50
Impact:-0.15 mm (not significant)
Trust score:4/5

horizontal defect bone gain (difference BB vs CJ)

1 evidences

Double-blind RCT comparing bovine bone + membrane vs pure β-tricalcium phosphate (a calcium phosphate) + membrane for horizontal augmentation: no major differences, with a small (0.24 mm) less peri-implant radiographic bone loss favoring the β-TCP group.

Trust comment: Double-blind randomized trial with 50 patients and 12-month follow-up; high methodological quality though effect sizes were small.

Study Details

PMID:26355171
Participants:50
Impact:-0.27 mm (not significant)
Trust score:4/5

mean peri-implant marginal bone level change

1 evidences

Multicenter randomized pilot trial: titanium implants with a calcium-incorporated surface showed similar implant/prosthesis survival, complications, and marginal bone level changes compared with control RBM surfaces at 3 years.

Trust comment: Randomized multicenter pilot with 3-year follow-up (60 patients); well-conducted but pilot-sized, limiting power to detect small differences.

Study Details

PMID:26355169
Participants:60
Impact:no significant difference (mean difference = -0.02 mm)
Trust score:4/5

aBMD (lumbar spine, total hip, total body)

1 evidences

24-month randomized interventional study: pre-load vitamin D plus ongoing vitamin D, calcium, protein supplementation and exercise after bariatric surgery attenuated increases in bone turnover markers and reduced loss of aBMD and lean mass versus no intervention.

Trust comment: Large (n=220), prospective randomized interventional study with 24-month follow-up; combined intervention limits attribution to calcium alone but overall design is strong.

Study Details

PMID:26350034
Participants:220
Impact:less decline in aBMD in intervention group (p<0.005)
Trust score:4/5

language development 'total efficiency'

1 evidences

Children with cerebral palsy received rehabilitation with or without adjunctive vitamin D; the vitamin D group showed greater language and developmental improvements and increased vitamin D and calcium levels.

Trust comment: Moderate-quality controlled clinical comparison with clear improvements and statistical reporting, but non-detailed randomization and limited methodological detail reduce confidence.

Study Details

PMID:26365823
Participants:82
Impact:+21 percentage points (95.3% vs 74.4% in combination vs rehabilitation-only, P=0.032)
Trust score:3/5

Gesell Child Development Scale score

1 evidences

Children with cerebral palsy received rehabilitation with or without adjunctive vitamin D; the vitamin D group showed greater language and developmental improvements and increased vitamin D and calcium levels.

Trust comment: Moderate-quality controlled clinical comparison with clear improvements and statistical reporting, but non-detailed randomization and limited methodological detail reduce confidence.

Study Details

PMID:26365823
Participants:82
Impact:+17.1 points (70.4±11.3 vs 53.3±10.5, P=0.026) favoring vitamin D combination
Trust score:3/5

serum calcium levels

1 evidences

Children with cerebral palsy received rehabilitation with or without adjunctive vitamin D; the vitamin D group showed greater language and developmental improvements and increased vitamin D and calcium levels.

Trust comment: Moderate-quality controlled clinical comparison with clear improvements and statistical reporting, but non-detailed randomization and limited methodological detail reduce confidence.

Study Details

PMID:26365823
Participants:82
Impact:statistically increased in vitamin D combination group (P<0.05)
Trust score:3/5

total volume of infused citrate

1 evidences

Randomized study of citrate concentration in plasma exchange (4% vs 15%); 15% protocol greatly reduced infused citrate volume while maintaining anticoagulation and stable ionized calcium.

Trust comment: Randomized study with clear endpoints and adequate reporting; directly measured ionized and total-to-ionized calcium, supporting reliable conclusions on calcium-related safety.

Study Details

PMID:26365587
Participants:37
Impact:reduced from 502±77 mL (4% citrate) to 164±52 mL (15% citrate), P<0.001
Trust score:4/5

immunoglobulin G elimination rate (ER)

1 evidences

Randomized study of citrate concentration in plasma exchange (4% vs 15%); 15% protocol greatly reduced infused citrate volume while maintaining anticoagulation and stable ionized calcium.

Trust comment: Randomized study with clear endpoints and adequate reporting; directly measured ionized and total-to-ionized calcium, supporting reliable conclusions on calcium-related safety.

Study Details

PMID:26365587
Participants:37
Impact:comparable between groups (0.57±0.06 vs 0.55±0.10, P=0.18)
Trust score:4/5

ionized calcium during procedure

1 evidences

Randomized study of citrate concentration in plasma exchange (4% vs 15%); 15% protocol greatly reduced infused citrate volume while maintaining anticoagulation and stable ionized calcium.

Trust comment: Randomized study with clear endpoints and adequate reporting; directly measured ionized and total-to-ionized calcium, supporting reliable conclusions on calcium-related safety.

Study Details

PMID:26365587
Participants:37
Impact:stable and within target range with no significant metabolic disturbances or side effects
Trust score:4/5

ongoing pregnancy rate

1 evidences

Randomized trial in women with diminished ovarian reserve testing oocyte activation with a calcium ionophore; small numerical increases in fertilization and pregnancy rates were observed but were not statistically different between groups.

Trust comment: Prospective randomized controlled study with a large sample (n=296); results reported but differences were not statistically significant per authors.

Study Details

PMID:26342247
Participants:296
Impact:+4.8 percentage points (10.9% vs 6.1%)
Trust score:4/5

stool dry weight (24 h)

1 evidences

Randomized double-blind infant trial: formula with SN2-palmitate (closer to human milk fat structure) reduced stool dry weight, fat excretion, and calcium-soap excretion compared with control formula.

Trust comment: Multicenter, randomized, double-blind study in infants with clear endpoints and adequate sample size; directly relevant to calcium binding/excretion.

Study Details

PMID:26334255
Participants:159
Impact:-3.03 g (4.25 g vs 7.28 g; SN2-palmitate vs control)
Trust score:4/5

stool lipid (24 h)

1 evidences

Randomized double-blind infant trial: formula with SN2-palmitate (closer to human milk fat structure) reduced stool dry weight, fat excretion, and calcium-soap excretion compared with control formula.

Trust comment: Multicenter, randomized, double-blind study in infants with clear endpoints and adequate sample size; directly relevant to calcium binding/excretion.

Study Details

PMID:26334255
Participants:159
Impact:-0.40 g (0.79 g vs 1.19 g)
Trust score:4/5

calcium-soap (saponified fat) excretion

1 evidences

Randomized double-blind infant trial: formula with SN2-palmitate (closer to human milk fat structure) reduced stool dry weight, fat excretion, and calcium-soap excretion compared with control formula.

Trust comment: Multicenter, randomized, double-blind study in infants with clear endpoints and adequate sample size; directly relevant to calcium binding/excretion.

Study Details

PMID:26334255
Participants:159
Impact:-0.47 g (0.56 g vs 1.03 g)
Trust score:4/5

Implant success rate

1 evidences

Randomized trial in 45 patients (180 implants) comparing sinus floor elevation with different graft materials or no graft, assessing implant stability, success, and endo-sinus bone volume over 2 years.

Trust comment: Well-conducted randomized clinical study on calcium-containing graft materials but not a dietary calcium intervention; moderate relevance and quality.

Study Details

PMID:26315564
Participants:45
Impact:100% success after 2 years (all groups)
Trust score:3/5

Endo-sinus bone volume shrinkage

1 evidences

Randomized trial in 45 patients (180 implants) comparing sinus floor elevation with different graft materials or no graft, assessing implant stability, success, and endo-sinus bone volume over 2 years.

Trust comment: Well-conducted randomized clinical study on calcium-containing graft materials but not a dietary calcium intervention; moderate relevance and quality.

Study Details

PMID:26315564
Participants:45
Impact:DBB 66.34%; β-TCP 61.44%; coagulum/new bone 53.02%; β-TCP+DBB 33.47%
Trust score:3/5

absolute risk of tooth sensitivity

1 evidences

Randomized clinical trial in 40 patients testing nano-calcium phosphate paste (with fluoride and potassium nitrate) vs placebo for reducing tooth sensitivity during/after in-office bleaching.

Trust comment: Randomized clinical trial with clear outcomes and appropriate controls directly testing a calcium-containing paste; moderate-high trust.

Study Details

PMID:26313348
Participants:40
Impact:No difference between groups (p = 1.0)
Trust score:4/5

intensity of tooth sensitivity

1 evidences

Randomized clinical trial in 40 patients testing nano-calcium phosphate paste (with fluoride and potassium nitrate) vs placebo for reducing tooth sensitivity during/after in-office bleaching.

Trust comment: Randomized clinical trial with clear outcomes and appropriate controls directly testing a calcium-containing paste; moderate-high trust.

Study Details

PMID:26313348
Participants:40
Impact:No difference between groups (p = 0.53)
Trust score:4/5

Bleaching efficacy

1 evidences

Randomized clinical trial in 40 patients testing nano-calcium phosphate paste (with fluoride and potassium nitrate) vs placebo for reducing tooth sensitivity during/after in-office bleaching.

Trust comment: Randomized clinical trial with clear outcomes and appropriate controls directly testing a calcium-containing paste; moderate-high trust.

Study Details

PMID:26313348
Participants:40
Impact:No difference between groups (p = 0.67)
Trust score:4/5

PTH correlation

1 evidences

Randomized, placebo-controlled vitamin D3 dosing study (placebo, 800, 2000, 4000 IU) in 71 subjects measuring free and total 25(OH)D, calcium absorption via dual isotopes, PTH, and bone turnover markers.

Trust comment: Controlled randomized dosing with direct calcium absorption measurement via dual isotopes; good internal validity.

Study Details

PMID:26312580
Participants:71
Impact:PTH similarly correlated with free and total 25(OH)D at baseline and follow-up
Trust score:4/5

Free 25(OH)D response

1 evidences

Randomized, placebo-controlled vitamin D3 dosing study (placebo, 800, 2000, 4000 IU) in 71 subjects measuring free and total 25(OH)D, calcium absorption via dual isotopes, PTH, and bone turnover markers.

Trust comment: Controlled randomized dosing with direct calcium absorption measurement via dual isotopes; good internal validity.

Study Details

PMID:26312580
Participants:71
Impact:Free 25(OH)D rose to 10.4 pg/mL in 4000 IU group and closely tracked total 25(OH)D changes
Trust score:4/5

Post-dialysis serum calcium (>1.3 mM)

1 evidences

Study of electrolyte and acid-base changes during hemodialysis in 26 patients randomly assigned to 1.25 mM or 1.5 mM calcium dialysate, focusing on calcium load, phosphorus, and alkalinization.

Trust comment: Directly examines calcium loading during dialysis with small sample size; relevant but limited by sample size and acute-session focus.

Study Details

PMID:26306970
Participants:26
Impact:100% of patients with 1.5 mM bath vs 15% with 1.25 mM bath
Trust score:3/5

Phosphorus control

1 evidences

Study of electrolyte and acid-base changes during hemodialysis in 26 patients randomly assigned to 1.25 mM or 1.5 mM calcium dialysate, focusing on calcium load, phosphorus, and alkalinization.

Trust comment: Directly examines calcium loading during dialysis with small sample size; relevant but limited by sample size and acute-session focus.

Study Details

PMID:26306970
Participants:26
Impact:Phosphorus remained uncontrolled during sessions (no effective reduction reported)
Trust score:3/5

Alkalinization

1 evidences

Study of electrolyte and acid-base changes during hemodialysis in 26 patients randomly assigned to 1.25 mM or 1.5 mM calcium dialysate, focusing on calcium load, phosphorus, and alkalinization.

Trust comment: Directly examines calcium loading during dialysis with small sample size; relevant but limited by sample size and acute-session focus.

Study Details

PMID:26306970
Participants:26
Impact:50% had serum bicarbonate >30 mM and 23% had pH >7.5 at session end
Trust score:3/5

Mean urinary Ca/Cr ratio

1 evidences

Cross-sectional study of urinary Mg/Cr, Ca/Cr, and P/Cr ratios in 1403 healthy Lebanese schoolchildren to establish reference values and 95th percentiles.

Trust comment: Large, well-sampled cross-sectional population study providing normative calcium excretion data; high relevance for calcium metabolism references.

Study Details

PMID:26306589
Participants:1403
Impact:0.084 ± 0.101 mg/mg (0.237 ± 0.286 mM/mM)
Trust score:4/5

95th percentile Ca/Cr ratio (age-varying)

1 evidences

Cross-sectional study of urinary Mg/Cr, Ca/Cr, and P/Cr ratios in 1403 healthy Lebanese schoolchildren to establish reference values and 95th percentiles.

Trust comment: Large, well-sampled cross-sectional population study providing normative calcium excretion data; high relevance for calcium metabolism references.

Study Details

PMID:26306589
Participants:1403
Impact:95th percentile Ca/Cr = 0.27 mg/mg (0.76 mM/mM)
Trust score:4/5

Mean urinary Mg/Cr and P/Cr ratios

1 evidences

Cross-sectional study of urinary Mg/Cr, Ca/Cr, and P/Cr ratios in 1403 healthy Lebanese schoolchildren to establish reference values and 95th percentiles.

Trust comment: Large, well-sampled cross-sectional population study providing normative calcium excretion data; high relevance for calcium metabolism references.

Study Details

PMID:26306589
Participants:1403
Impact:Mg/Cr 0.122 ± 0.075 mg/mg; P/Cr 0.692 ± 0.417 mg/mg
Trust score:4/5

hs-CRP

2 evidences

In 104 overweight, vitamin D–deficient women with PCOS, 8 weeks of calcium plus vitamin D improved several inflammation and oxidative-stress biomarkers compared with placebo.

Trust comment: Randomized double-blind placebo-controlled trial with adequate sample size and clear biomarker changes, though short duration (8 weeks).

Study Details

PMID:26119844
Participants:104
Impact:decrease −948.3 ng/ml (calcium+vitD) vs increases/lesser changes in other groups (P=0.04)
Trust score:4/5

In screen-detected type 2 diabetes, intensified multifactorial treatment lowered hs-CRP more than routine care over 6 years; adiponectin unchanged.

Trust comment: Large randomized clinical trial with long follow-up and appropriate analyses showing a significant inflammation marker change.

Study Details

PMID:26109470
Participants:424
Impact:lower with intensive treatment (routine care 24% higher than intensive; p=0.0027)
Trust score:4/5

Cytokines (combined cytokine z-score / individual cytokines)

1 evidences

In colorectal adenoma patients, 1.0 or 2.0 g/day calcium for 4 months did not change circulating inflammation or oxidative stress biomarkers.

Trust comment: Randomized, double-blind, placebo-controlled trial (n=193) with objective biomarker endpoints; null results reported clearly.

Study Details

PMID:26304464
Participants:193
Impact:no appreciable change (P > 0.4)
Trust score:4/5

Oxidative stress (plasma F2-isoprostanes)

1 evidences

In colorectal adenoma patients, 1.0 or 2.0 g/day calcium for 4 months did not change circulating inflammation or oxidative stress biomarkers.

Trust comment: Randomized, double-blind, placebo-controlled trial (n=193) with objective biomarker endpoints; null results reported clearly.

Study Details

PMID:26304464
Participants:193
Impact:no appreciable change (P > 0.4)
Trust score:4/5

decalcification index (white spot lesions)

1 evidences

Tested a NovaMin (calcium sodium phosphosilicate) toothpaste vs regular fluoride toothpaste in orthodontic patients for 6 months; no benefit of NovaMin at 6 months.

Trust comment: Double-blind randomized clinical trial with clear endpoints and reasonable sample (44 completers); limitations include short follow-up, compliance issues, and subjective DI scoring.

Study Details

PMID:26268772
Participants:44
Impact:No significant difference between groups at 6 months; ReNew™ group mean DI increased ~+0.14 (0.33→0.47) and Crest® group increased ~+0.11 (0.33→0.44) from baseline to 6 months; Crest® showed a transient greater improvement at 3 months (0.33→0.24, P=0.0403)
Trust score:4/5

gingival index (gingival health)

1 evidences

Tested a NovaMin (calcium sodium phosphosilicate) toothpaste vs regular fluoride toothpaste in orthodontic patients for 6 months; no benefit of NovaMin at 6 months.

Trust comment: Double-blind randomized clinical trial with clear endpoints and reasonable sample (44 completers); limitations include short follow-up, compliance issues, and subjective DI scoring.

Study Details

PMID:26268772
Participants:44
Impact:No significant difference between groups at 3 or 6 months (trend toward improvement in ReNew™ at 3 months, not significant)
Trust score:4/5

plaque index (plaque levels)

1 evidences

Tested a NovaMin (calcium sodium phosphosilicate) toothpaste vs regular fluoride toothpaste in orthodontic patients for 6 months; no benefit of NovaMin at 6 months.

Trust comment: Double-blind randomized clinical trial with clear endpoints and reasonable sample (44 completers); limitations include short follow-up, compliance issues, and subjective DI scoring.

Study Details

PMID:26268772
Participants:44
Impact:No significant difference between groups at 3 or 6 months; within-group PI worsened in ReNew™ from baseline to 6 months (P=0.0405)
Trust score:4/5

histopathological response

1 evidences

Randomized comparison of acemannan vs calcium hydroxide for direct pulp capping in primary molars (6-month outcomes): similar clinical/radiographic success but acemannan showed better histology.

Trust comment: Randomized clinical study in children with modest sample size and short-term follow-up; relevant because calcium hydroxide (a calcium compound) was the comparator but not a nutrient intervention.

Study Details

PMID:26264630
Participants:37
Impact:Acemannan group had significantly better histopathological outcomes vs calcium hydroxide (P<0.05)
Trust score:3/5

bone resorption marker (CTx-1)

1 evidences

Twelve-week randomized study: calcium- and vitamin D–fortified milk (higher calcium + vitamin D + FOS-inulin) reduced bone resorption markers and PTH more than regular milk, especially in postmenopausal women.

Trust comment: Large randomized study with clear biochemical outcomes showing biologically plausible benefits of calcium/vitamin D–fortified milk; 12-week duration and marker-based endpoints are appropriate but not long-term bone outcomes.

Study Details

PMID:26264387
Participants:257
Impact:CTx-1 reduced in both groups; postmenopausal fortified-milk group showed significantly greater CTx-1 decrease vs postmenopausal control at 12 weeks (P<0.035)
Trust score:4/5

25-hydroxyvitamin D (vitamin D status)

1 evidences

Twelve-week randomized study: calcium- and vitamin D–fortified milk (higher calcium + vitamin D + FOS-inulin) reduced bone resorption markers and PTH more than regular milk, especially in postmenopausal women.

Trust comment: Large randomized study with clear biochemical outcomes showing biologically plausible benefits of calcium/vitamin D–fortified milk; 12-week duration and marker-based endpoints are appropriate but not long-term bone outcomes.

Study Details

PMID:26264387
Participants:257
Impact:Fortified milk improved 25(OH)D levels in intervention groups over 12 weeks
Trust score:4/5

total fractional calcium absorption

1 evidences

Randomized double-blind trial in postmenopausal women: high-dose vitamin D raised 25(OH)D and slightly increased calcium absorption but produced no changes in BMD, muscle function, or falls.

Trust comment: Randomized, double-blind, placebo-controlled trial (n=230) with objective isotope and DXA measures; single-center but well-powered for primary outcome.

Study Details

PMID:26237520
Participants:230
Impact:+1% (≈+10 mg/day) with high-dose cholecalciferol (vs -1.3% placebo and -2% low-dose)
Trust score:4/5

muscle function / falls

1 evidences

Randomized double-blind trial in postmenopausal women: high-dose vitamin D raised 25(OH)D and slightly increased calcium absorption but produced no changes in BMD, muscle function, or falls.

Trust comment: Randomized, double-blind, placebo-controlled trial (n=230) with objective isotope and DXA measures; single-center but well-powered for primary outcome.

Study Details

PMID:26237520
Participants:230
Impact:no between-arm change
Trust score:4/5

graft volume resorption (CBV loss)

1 evidences

Prospective randomized comparison of autogenous bone, autogenous+β-TCP, and β-TCP alone for sinus lift grafts assessing graft volume resorption at 6 months.

Trust comment: Small randomized prospective human study with objective CBCT volumetric endpoints; limited sample size reduces confidence.

Study Details

PMID:26232120
Participants:32
Impact:autogenous bone: -45.7% ±18.6%; autogenous+β-TCP: -43.8% ±18.4%; β-TCP alone: -38.3% ±16.6%
Trust score:3/5

enamel carious lesion remineralization (ΔF, lesion area, lesion volume)

1 evidences

Children used daily CPP-ACP paste plus fluoride toothpaste for one year; tooth lesions improved over time but CPP-ACP provided no additional benefit over fluoride toothpaste alone.

Trust comment: Randomized one‑year clinical trial with objective QLF measurements but moderate sample size; conclusions robust for this population.

Study Details

PMID:26228178
Participants:103
Impact:no significant improvement vs fluoride toothbrushing alone at 1 year
Trust score:4/5

lesion regression odds (ΔQ)

1 evidences

Children used daily CPP-ACP paste plus fluoride toothpaste for one year; tooth lesions improved over time but CPP-ACP provided no additional benefit over fluoride toothpaste alone.

Trust comment: Randomized one‑year clinical trial with objective QLF measurements but moderate sample size; conclusions robust for this population.

Study Details

PMID:26228178
Participants:103
Impact:no difference between groups (OR=1.03, 95% CI 0.31–3.39)
Trust score:4/5

fractional calcium absorption estimated from 3‑h serum tracer

1 evidences

In 29 postmenopausal women, serum calcium tracer levels at 1, 3 and 5 hours were compared to gold-standard 24‑h urine dual‑isotope measurement; serum measures correlated but did not reliably replace the gold standard across cohorts.

Trust comment: Gold‑standard dual‑isotope 24‑h urine reference and rigorous stats, but small sample and inconsistent validation across cohorts.

Study Details

PMID:26227019
Participants:29
Impact:Cohort1: ρ=0.72, R²=0.58 (no bias); not validated in Cohort2 (no correlation)
Trust score:4/5

fractional calcium absorption estimated from 5‑h serum tracer

1 evidences

In 29 postmenopausal women, serum calcium tracer levels at 1, 3 and 5 hours were compared to gold-standard 24‑h urine dual‑isotope measurement; serum measures correlated but did not reliably replace the gold standard across cohorts.

Trust comment: Gold‑standard dual‑isotope 24‑h urine reference and rigorous stats, but small sample and inconsistent validation across cohorts.

Study Details

PMID:26227019
Participants:29
Impact:Cohort2: correlated with 24‑h urine FCA (ρ=0.75) but explained only ~35% of variance overall; serum methods cannot replace 24‑h urine dual‑tracer
Trust score:4/5

total hip bone mineral density (BMD)

1 evidences

Daily vitamin D3 plus calcium reduced the amount of bone loss over 48 weeks after starting antiretroviral therapy compared with placebo.

Trust comment: Randomized, double-blind, placebo-controlled multicenter trial with adequate sample size and clear clinically relevant outcomes.

Study Details

PMID:26075752
Participants:165
Impact:less decline: -1.36% (vit D3+Ca) vs -3.22% (placebo) at 48 weeks (P = 0.004)
Trust score:5/5

high‑sensitivity CRP (Hs‑CRP)

1 evidences

Double‑blind placebo‑controlled trial in middle‑aged healthy adults: calcium fructoborate for 30 days reduced several lipids and inflammatory markers vs placebo.

Trust comment: Double‑blind, placebo‑controlled randomized trial but small sample (78 completers) limits generalizability despite randomized design.

Study Details

PMID:25433580
Participants:78
Impact:significant decrease with higher‑dose CFB (112 mg) versus placebo (p<0.05)
Trust score:4/5

function (ODI)

1 evidences

After PKP surgery, patients given calcium plus calcitriol showed improved short-term pain and function and increased BMD versus preoperative; adding calcitonin and exercise improved longer-term outcomes.

Trust comment: Randomized study (138 randomized, 114 completers) with clinical and BMD outcomes reported; limited methodological detail in excerpt but plausible internal validity.

Study Details

PMID:26255474
Participants:114
Impact:decreased (improved) at 3 days, 2 weeks and 1 month vs preoperative
Trust score:3/5

60‑day all‑cause mortality (ITT)

1 evidences

Multicenter RCT of SCD+CRRT vs CRRT alone in AKI was terminated early due to a national shortage of injectable calcium that altered circuit ionized calcium; ITT showed no mortality benefit, but a post-hoc subset with circuit iCa maintained in target (<0.4 mmol/L) plus SCD had lower 60‑day mortality.

Trust comment: Human RCT but early termination and wide protocol non‑adherence due to national calcium shortage limit confidence; post‑hoc subset findings are hypothesis‑generating.

Study Details

PMID:26244978
Participants:134
Impact:no significant difference (39% CRRT+SCD vs 36% CRRT alone)
Trust score:3/5

60‑day mortality (riCa subset)

1 evidences

Multicenter RCT of SCD+CRRT vs CRRT alone in AKI was terminated early due to a national shortage of injectable calcium that altered circuit ionized calcium; ITT showed no mortality benefit, but a post-hoc subset with circuit iCa maintained in target (<0.4 mmol/L) plus SCD had lower 60‑day mortality.

Trust comment: Human RCT but early termination and wide protocol non‑adherence due to national calcium shortage limit confidence; post‑hoc subset findings are hypothesis‑generating.

Study Details

PMID:26244978
Participants:134
Impact:reduced from 41% (control) to 16% (SCD+riCa) in post‑hoc subset
Trust score:3/5

dialysis dependency / composite outcome (riCa subset)

1 evidences

Multicenter RCT of SCD+CRRT vs CRRT alone in AKI was terminated early due to a national shortage of injectable calcium that altered circuit ionized calcium; ITT showed no mortality benefit, but a post-hoc subset with circuit iCa maintained in target (<0.4 mmol/L) plus SCD had lower 60‑day mortality.

Trust comment: Human RCT but early termination and wide protocol non‑adherence due to national calcium shortage limit confidence; post‑hoc subset findings are hypothesis‑generating.

Study Details

PMID:26244978
Participants:134
Impact:lower composite death or dialysis‑dependency at Day 60 in riCa SCD group (post‑hoc, p≈0.01)
Trust score:3/5

adhesion severity

1 evidences

Using calcium alginate nasal packing after sinus surgery reduced swelling and adhesions versus carboxymethyl cellulose but did not change pain or discharge-related discomfort.

Trust comment: Randomized, within-patient controlled single-blind trial with appropriate outcome measures but small sample size (27 patients).

Study Details

PMID:26212693
Participants:27
Impact:decrease (significant at 4 weeks)
Trust score:4/5

oedema severity

1 evidences

Using calcium alginate nasal packing after sinus surgery reduced swelling and adhesions versus carboxymethyl cellulose but did not change pain or discharge-related discomfort.

Trust comment: Randomized, within-patient controlled single-blind trial with appropriate outcome measures but small sample size (27 patients).

Study Details

PMID:26212693
Participants:27
Impact:decrease (significant at 4 weeks)
Trust score:4/5

dentinal hypersensitivity

1 evidences

A single topical application of NovaMin (contains calcium phosphosilicate) reduced tooth sensitivity over 30 days, but ProArgin was more effective.

Trust comment: Randomized, parallel-group trial with moderate sample size and validated sensitivity scales, though product comparisons limit generalizability to calcium per se.

Study Details

PMID:26211687
Participants:56
Impact:decrease (significant vs baseline at all time points; NovaMin less effective than ProArgin at 30 days)
Trust score:4/5

serum PINP increase

1 evidences

In Japanese osteoporosis patients receiving teriparatide (with daily calcium/vitamin D), PINP rose rapidly but corrected serum calcium stayed within normal range and calcium-related AEs were rare.

Trust comment: Phase III randomized double‑blind study and systematic lab monitoring support reliability; post hoc analysis limits causal inference.

Study Details

PMID:26185429
Participants:180
Impact:+rapid increase by 1 month; sustained through 12–24 months; 28/195 subjects exceeded 200 μg/L
Trust score:4/5

Defect fill

1 evidences

Adding a biphasic calcium phosphate bone graft to enamel matrix derivative did not improve periodontal healing versus enamel matrix alone over 3 years.

Trust comment: Randomized, multicenter, 36-month follow-up but small sample (n=30) limits precision.

Study Details

PMID:26174080
Participants:30
Impact:EMD+SBG: +2.6 mm vs EMD: +2.3 mm; no significant difference
Trust score:4/5

tooth sensitivity (control 35% HP)

1 evidences

Some in‑office bioactive glass pastes prevented tooth sensitivity from strong in‑office bleaching, while an experimental bioactive glass dentifrice did not; effects of commercial calcium-containing dentifrices/pastes were not clearly reported.

Trust comment: Large randomized controlled trial (n=140) with objective VAS assessments, but subgroup reporting for specific commercial calcium agents was limited/unclear.

Study Details

PMID:26159384
Participants:140
Impact:increased on early assessments (points 1 and 2) in control group
Trust score:4/5

tooth sensitivity reduction — in‑office bioactive glass pastes (D4, D5)

1 evidences

Some in‑office bioactive glass pastes prevented tooth sensitivity from strong in‑office bleaching, while an experimental bioactive glass dentifrice did not; effects of commercial calcium-containing dentifrices/pastes were not clearly reported.

Trust comment: Large randomized controlled trial (n=140) with objective VAS assessments, but subgroup reporting for specific commercial calcium agents was limited/unclear.

Study Details

PMID:26159384
Participants:140
Impact:prevented/controlled sensitivity caused by 35% hydrogen peroxide (no reported TS increase)
Trust score:4/5

experimental bioactive glass dentifrice (D1)

1 evidences

Some in‑office bioactive glass pastes prevented tooth sensitivity from strong in‑office bleaching, while an experimental bioactive glass dentifrice did not; effects of commercial calcium-containing dentifrices/pastes were not clearly reported.

Trust comment: Large randomized controlled trial (n=140) with objective VAS assessments, but subgroup reporting for specific commercial calcium agents was limited/unclear.

Study Details

PMID:26159384
Participants:140
Impact:did not control sensitivity
Trust score:4/5

Plasma ADH

1 evidences

Prospective study comparing children with SDB and enuresis vs SDB alone and before/after adenotonsillectomy; surgery normalized BNP/ADH and reduced urinary sodium and calcium excretion.

Trust comment: Prospective, controlled study with moderate sample size and clear before/after changes linking urinary calcium excretion to clinical hormonal changes; limited follow-up and moderate sample sizes reduce certainty.

Study Details

PMID:26142600
Participants:68
Impact:Lower in SDB+enuresis group vs SDB-only (p=0.04)
Trust score:3/5

Plasma BNP

1 evidences

Prospective study comparing children with SDB and enuresis vs SDB alone and before/after adenotonsillectomy; surgery normalized BNP/ADH and reduced urinary sodium and calcium excretion.

Trust comment: Prospective, controlled study with moderate sample size and clear before/after changes linking urinary calcium excretion to clinical hormonal changes; limited follow-up and moderate sample sizes reduce certainty.

Study Details

PMID:26142600
Participants:68
Impact:Higher in SDB+enuresis group (p=0.009) and decreased after T&A (p=0.018)
Trust score:3/5

Urinary calcium-to-creatinine ratio

1 evidences

Prospective study comparing children with SDB and enuresis vs SDB alone and before/after adenotonsillectomy; surgery normalized BNP/ADH and reduced urinary sodium and calcium excretion.

Trust comment: Prospective, controlled study with moderate sample size and clear before/after changes linking urinary calcium excretion to clinical hormonal changes; limited follow-up and moderate sample sizes reduce certainty.

Study Details

PMID:26142600
Participants:68
Impact:Decreased after T&A (p=0.007) and change correlated with sodium excretion and BNP changes
Trust score:3/5

24-h proteinuria

1 evidences

Randomized study in children with severe HSPN showing that adding low-molecular-weight heparin calcium to conventional therapy improved proteinuria and overall clinical outcomes over 8 weeks.

Trust comment: Randomized trial in children (n=89) showing clinical and laboratory benefit of adding heparin-calcium; moderate sample size and clear endpoints give moderate-to-high confidence though reporting detail is limited.

Study Details

PMID:26133741
Participants:89
Impact:Improved in heparin-calcium group vs control after 8 weeks (p<0.05)
Trust score:4/5

Clinical outcome (HSPN)

1 evidences

Randomized study in children with severe HSPN showing that adding low-molecular-weight heparin calcium to conventional therapy improved proteinuria and overall clinical outcomes over 8 weeks.

Trust comment: Randomized trial in children (n=89) showing clinical and laboratory benefit of adding heparin-calcium; moderate sample size and clear endpoints give moderate-to-high confidence though reporting detail is limited.

Study Details

PMID:26133741
Participants:89
Impact:Overall clinical outcomes better in treatment group after 8 weeks (p<0.05)
Trust score:4/5

Fibrinolysis markers (Fg, D-dimer, FDP)

1 evidences

Randomized study in children with severe HSPN showing that adding low-molecular-weight heparin calcium to conventional therapy improved proteinuria and overall clinical outcomes over 8 weeks.

Trust comment: Randomized trial in children (n=89) showing clinical and laboratory benefit of adding heparin-calcium; moderate sample size and clear endpoints give moderate-to-high confidence though reporting detail is limited.

Study Details

PMID:26133741
Participants:89
Impact:Markers corrected toward normal in treatment group, indicating inhibited hyperfibrinolysis
Trust score:4/5

dense calcium volume in coronary plaques

1 evidences

Randomized AMI trial: intensive statin therapy increased dense calcium content in coronary plaques over 12 months.

Trust comment: Randomized blinded-endpoint trial with serial CTA and clear significant finding for dense calcium increase; moderate-high quality.

Study Details

PMID:26115069
Participants:96
Impact:+23% (Δ+11.1 mm^3 in intensive vs Δ−0.4 mm^3 in usual care; p<0.001)
Trust score:4/5

necrotic core volume

1 evidences

Randomized AMI trial: intensive statin therapy increased dense calcium content in coronary plaques over 12 months.

Trust comment: Randomized blinded-endpoint trial with serial CTA and clear significant finding for dense calcium increase; moderate-high quality.

Study Details

PMID:26115069
Participants:96
Impact:no between-group difference (p=0.94)
Trust score:4/5

Lumbar (L2–L4) BMD

1 evidences

Randomized 12-month trial in postmenopausal women: exercise (MESE) improved BMD and balance; calcium+vitamin D produced small lumbar BMD gain but less effect than exercise.

Trust comment: Randomized controlled trial in humans with high completion and objective DXA outcomes; exercise rather than calcium drove most effects.

Study Details

PMID:26107684
Participants:184
Impact:+1.0% within-group increase in Ca alone group after 12 months
Trust score:4/5

Left femoral neck BMD

1 evidences

Randomized 12-month trial in postmenopausal women: exercise (MESE) improved BMD and balance; calcium+vitamin D produced small lumbar BMD gain but less effect than exercise.

Trust comment: Randomized controlled trial in humans with high completion and objective DXA outcomes; exercise rather than calcium drove most effects.

Study Details

PMID:26107684
Participants:184
Impact:no significant increase with Ca alone (exercise groups showed ~1.9–2.3% increases; Ca group smaller/non-significant)
Trust score:4/5

treatment-related adverse events (gastrointestinal)

1 evidences

100 adults ≥50 y in a randomized cross-over trial: monthly vitamin D alone produced higher compliance than daily vitamin D+calcium, with similar changes in 25(OH)D.

Trust comment: Randomized cross-over human study with objective compliance and biochemical endpoints; appropriate design and sample size for compliance outcome.

Study Details

PMID:26100413
Participants:100
Impact:more frequent with daily vitamin D+calcium (higher treatment-related AEs and withdrawals)
Trust score:4/5

malondialdehyde (MDA)

1 evidences

In 104 overweight, vitamin D–deficient women with PCOS, 8 weeks of calcium plus vitamin D improved several inflammation and oxidative-stress biomarkers compared with placebo.

Trust comment: Randomized double-blind placebo-controlled trial with adequate sample size and clear biomarker changes, though short duration (8 weeks).

Study Details

PMID:26119844
Participants:104
Impact:decrease −0.6 μmol/L (P=0.009)
Trust score:4/5

glutathione (GSH)

1 evidences

In 104 overweight, vitamin D–deficient women with PCOS, 8 weeks of calcium plus vitamin D improved several inflammation and oxidative-stress biomarkers compared with placebo.

Trust comment: Randomized double-blind placebo-controlled trial with adequate sample size and clear biomarker changes, though short duration (8 weeks).

Study Details

PMID:26119844
Participants:104
Impact:increase +216.0 μmol/L (P=0.001)
Trust score:4/5

serum copper

1 evidences

Serum copper, iron, and calcium levels were lower during pulmonary exacerbation and rose by 3 months after recovery in adults with cystic fibrosis.

Trust comment: Small ancillary study with clear repeated measures showing significant changes, but limited sample size and context (ancillary to vitamin D trial).

Study Details

PMID:26078287
Participants:24
Impact:+0.1 µg/mL (1.5 ± 0.6 → 1.6 ± 0.6 µg/mL; P = .027)
Trust score:3/5

serum iron

1 evidences

Serum copper, iron, and calcium levels were lower during pulmonary exacerbation and rose by 3 months after recovery in adults with cystic fibrosis.

Trust comment: Small ancillary study with clear repeated measures showing significant changes, but limited sample size and context (ancillary to vitamin D trial).

Study Details

PMID:26078287
Participants:24
Impact:+0.5 µg/mL (0.8 ± 0.3 → 1.3 ± 1.1 µg/mL; P = .026)
Trust score:3/5

number of menopause-related symptoms

1 evidences

Daily 1000 mg calcium + 400 IU vitamin D did not change menopause-related symptoms over ~5.7 years.

Trust comment: Large, randomized WHI trial with long follow-up and robust methods directly testing calcium + vitamin D supplementation.

Study Details

PMID:26044075
Participants:34157
Impact:No significant difference vs placebo (p=0.702)
Trust score:5/5

sleep disturbance

1 evidences

Daily 1000 mg calcium + 400 IU vitamin D did not change menopause-related symptoms over ~5.7 years.

Trust comment: Large, randomized WHI trial with long follow-up and robust methods directly testing calcium + vitamin D supplementation.

Study Details

PMID:26044075
Participants:34157
Impact:No significant difference vs placebo
Trust score:5/5

emotional well-being / energy-fatique

1 evidences

Daily 1000 mg calcium + 400 IU vitamin D did not change menopause-related symptoms over ~5.7 years.

Trust comment: Large, randomized WHI trial with long follow-up and robust methods directly testing calcium + vitamin D supplementation.

Study Details

PMID:26044075
Participants:34157
Impact:No significant difference vs placebo
Trust score:5/5

24-hour average pain score

1 evidences

Phase 2 randomized double-blind trial in patients with diabetic neuropathic pain found ABT-639 did not reduce pain more than placebo over 6 weeks.

Trust comment: Well-designed multicenter randomized double-blind phase 2 trial (n=194) with appropriate controls; primary endpoint negative.

Study Details

PMID:26067585
Participants:194
Impact:Mean change −2.28 (ABT-639) vs −2.36 (placebo); no significant difference (P = 0.582)
Trust score:4/5

Responder rates (≥30% or ≥50% pain reduction)

1 evidences

Phase 2 randomized double-blind trial in patients with diabetic neuropathic pain found ABT-639 did not reduce pain more than placebo over 6 weeks.

Trust comment: Well-designed multicenter randomized double-blind phase 2 trial (n=194) with appropriate controls; primary endpoint negative.

Study Details

PMID:26067585
Participants:194
Impact:No significant difference for ABT-639 or pregabalin versus placebo at week 6
Trust score:4/5

Visit-to-visit SD of SBP

1 evidences

Subanalysis of a large trial showed olmesartan plus a calcium channel blocker reduced visit-to-visit SBP variability versus olmesartan plus diuretic in very elderly patients, linked to fewer cardiovascular events.

Trust comment: Large randomized trial subanalysis (n=4876) with long follow-up and blinded endpoint adjudication; open-label allocation is a limitation.

Study Details

PMID:26066644
Participants:4876
Impact:Significantly smaller with olmesartan+CCB vs olmesartan+diuretic (P = 0.006 overall; P = 0.018 in very elderly)
Trust score:4/5

Association of SD of SBP with cardiovascular events

1 evidences

Subanalysis of a large trial showed olmesartan plus a calcium channel blocker reduced visit-to-visit SBP variability versus olmesartan plus diuretic in very elderly patients, linked to fewer cardiovascular events.

Trust comment: Large randomized trial subanalysis (n=4876) with long follow-up and blinded endpoint adjudication; open-label allocation is a limitation.

Study Details

PMID:26066644
Participants:4876
Impact:Higher SD quartiles associated with increased primary endpoint incidence (P for trend < 0.001)
Trust score:4/5

30-month treatment success rate

1 evidences

Randomized double-blind trial in children found three root-filling materials (including a calcium-hydroxide product) had similar clinical and radiographic success at 30 months.

Trust comment: Single-center double-blind RCT (129 treated teeth) with 30-month follow-up; outcomes assessed by blinded evaluators.

Study Details

PMID:26059708
Participants:129
Impact:RC Fill 94%, Vitapex (calcium hydroxide + iodoform) 90%, Pulpdent 97%; differences not significant (P = 0.137)
Trust score:4/5

≥30% reduction in FGF23

1 evidences

Secondary analysis of a large RCT in hemodialysis patients showed cinacalcet markedly reduced FGF23; patients with ≥30% FGF23 reduction had lower rates of cardiovascular death and events.

Trust comment: Large randomized trial secondary analysis (thousands of patients); treatment effect on FGF23 is randomized but outcome associations are observational within trial.

Study Details

PMID:26059012
Participants:2985
Impact:Observed in 68% with cinacalcet vs 28% with placebo
Trust score:4/5

Primary composite endpoint (death or first nonfatal CV event)

1 evidences

Secondary analysis of a large RCT in hemodialysis patients showed cinacalcet markedly reduced FGF23; patients with ≥30% FGF23 reduction had lower rates of cardiovascular death and events.

Trust comment: Large randomized trial secondary analysis (thousands of patients); treatment effect on FGF23 is randomized but outcome associations are observational within trial.

Study Details

PMID:26059012
Participants:2985
Impact:Among cinacalcet-treated, ≥30% FGF23 reduction associated with relative hazard 0.82 (95% CI 0.69–0.98)
Trust score:4/5

Sclerostin and DKK1

1 evidences

In 60-day bed-rest, resistive exercise increased markers of bone formation but did not significantly prevent rises in sclerostin or DKK1 compared with control.

Trust comment: Small controlled human bed-rest study (n=24) with repeated measures; limited sample size and male-only cohort reduce generalizability.

Study Details

PMID:26056021
Participants:24
Impact:No statistically significant attenuation by exercise (no clear impact)
Trust score:3/5

DMFT increment at 2 years

1 evidences

Large double-blind randomized trial in children found dentifrices containing arginine plus an insoluble calcium compound and fluoride reduced new caries increments by ~20% versus a fluoride-only control after two years.

Trust comment: Large double-blind randomized trial (>5,500 children) with 2-year follow-up and calibrated examiners; robust evidence for topical calcium-containing formulation benefit.

Study Details

PMID:26054185
Participants:5500
Impact:20.5% reduction vs control
Trust score:4/5

DMFS increment at 2 years

1 evidences

Large double-blind randomized trial in children found dentifrices containing arginine plus an insoluble calcium compound and fluoride reduced new caries increments by ~20% versus a fluoride-only control after two years.

Trust comment: Large double-blind randomized trial (>5,500 children) with 2-year follow-up and calibrated examiners; robust evidence for topical calcium-containing formulation benefit.

Study Details

PMID:26054185
Participants:5500
Impact:19.6% reduction vs control
Trust score:4/5

fetal body weight at 36 wk

1 evidences

In pregnant adolescents with low calcium intake, calcium+vitamin D increased fetal weight at 36 weeks but did not change infant bone mass at 5 weeks postpartum.

Trust comment: Randomized controlled trial in humans with clear endpoints and moderate sample size (n=56).

Study Details

PMID:26019245
Participants:56
Impact:+6.8%
Trust score:4/5

fetal weight increment (23→36 wk)

1 evidences

In pregnant adolescents with low calcium intake, calcium+vitamin D increased fetal weight at 36 weeks but did not change infant bone mass at 5 weeks postpartum.

Trust comment: Randomized controlled trial in humans with clear endpoints and moderate sample size (n=56).

Study Details

PMID:26019245
Participants:56
Impact:+10.5% (P=0.07)
Trust score:4/5

infant BMC/BA/BMD at 5 wk

1 evidences

In pregnant adolescents with low calcium intake, calcium+vitamin D increased fetal weight at 36 weeks but did not change infant bone mass at 5 weeks postpartum.

Trust comment: Randomized controlled trial in humans with clear endpoints and moderate sample size (n=56).

Study Details

PMID:26019245
Participants:56
Impact:no significant change
Trust score:4/5

amount of bone regeneration

1 evidences

In adults needing alveolar ridge augmentation, rhPDGF-BB in a β-TCP/HA carrier produced similar bone regeneration to autogenous bone block grafts.

Trust comment: Human clinical study (n=30) showing comparable outcomes, but sample size is small and methodological details limited.

Study Details

PMID:26009922
Participants:30
Impact:no significant difference
Trust score:3/5

need for additional grafting

1 evidences

In adults needing alveolar ridge augmentation, rhPDGF-BB in a β-TCP/HA carrier produced similar bone regeneration to autogenous bone block grafts.

Trust comment: Human clinical study (n=30) showing comparable outcomes, but sample size is small and methodological details limited.

Study Details

PMID:26009922
Participants:30
Impact:no significant difference
Trust score:3/5

growth rate in girls

1 evidences

In schoolchildren over 8 months, a sorghum-enriched diet improved several micronutrient markers and increased serum calcium in boys; growth effects varied by sex.

Trust comment: Randomized 8-month trial with a large sample (≈320) showing biochemical improvements, though methodological details are limited in the abstract.

Study Details

PMID:26001905
Participants:320
Impact:increase (p<0.01)
Trust score:3/5

hemoglobin, ferritin, albumin, RBP, iron

1 evidences

In schoolchildren over 8 months, a sorghum-enriched diet improved several micronutrient markers and increased serum calcium in boys; growth effects varied by sex.

Trust comment: Randomized 8-month trial with a large sample (≈320) showing biochemical improvements, though methodological details are limited in the abstract.

Study Details

PMID:26001905
Participants:320
Impact:increase (p<0.05)
Trust score:3/5

serum calcium (boys)

1 evidences

In schoolchildren over 8 months, a sorghum-enriched diet improved several micronutrient markers and increased serum calcium in boys; growth effects varied by sex.

Trust comment: Randomized 8-month trial with a large sample (≈320) showing biochemical improvements, though methodological details are limited in the abstract.

Study Details

PMID:26001905
Participants:320
Impact:increase
Trust score:3/5

reparative dentin bridge thickness

1 evidences

In human third molars with mechanical pulp exposure, calcium hydroxide produced thicker and larger reparative dentin bridges than a dentin bonding system over a 6-week period.

Trust comment: Small controlled human tooth study with objective imaging but limited sample size and short follow-up, limiting clinical generalizability.

Study Details

PMID:26031301
Participants:44
Impact:greater vs Single Bond Universal (statistically significant)
Trust score:3/5

reparative dentin bridge volume

1 evidences

In human third molars with mechanical pulp exposure, calcium hydroxide produced thicker and larger reparative dentin bridges than a dentin bonding system over a 6-week period.

Trust comment: Small controlled human tooth study with objective imaging but limited sample size and short follow-up, limiting clinical generalizability.

Study Details

PMID:26031301
Participants:44
Impact:greater vs Single Bond Universal; Biodentine showed the highest average and maximum volumes
Trust score:3/5

reparative dentin bridge density

1 evidences

In human third molars with mechanical pulp exposure, calcium hydroxide produced thicker and larger reparative dentin bridges than a dentin bonding system over a 6-week period.

Trust comment: Small controlled human tooth study with objective imaging but limited sample size and short follow-up, limiting clinical generalizability.

Study Details

PMID:26031301
Participants:44
Impact:mean density highest in MTA; Single Bond Universal lowest (calcium hydroxide not highest)
Trust score:3/5

composite diabetes control (HbA1c<7%, LDL<2.59 mmol/L, SBP<130 mmHg)

1 evidences

Adding Roux-en-Y gastric bypass to intensive medical/lifestyle care improved diabetes control markedly at 2 years but increased adverse events and nutritional deficiencies, including calcium and vitamin D deficiencies.

Trust comment: Randomized controlled trial (n=120) with clear reporting; indirectly reports increased calcium deficiency after gastric bypass—relevant to calcium status.

Study Details

PMID:25979364
Participants:120
Impact:43% (gastric bypass) vs 14% (medical)
Trust score:4/5

HbA1c <7% attainment

1 evidences

Adding Roux-en-Y gastric bypass to intensive medical/lifestyle care improved diabetes control markedly at 2 years but increased adverse events and nutritional deficiencies, including calcium and vitamin D deficiencies.

Trust comment: Randomized controlled trial (n=120) with clear reporting; indirectly reports increased calcium deficiency after gastric bypass—relevant to calcium status.

Study Details

PMID:25979364
Participants:120
Impact:75% vs 24%; treatment difference −1.9% (improved glycemic control)
Trust score:4/5

nutritional deficiencies (including calcium)

1 evidences

Adding Roux-en-Y gastric bypass to intensive medical/lifestyle care improved diabetes control markedly at 2 years but increased adverse events and nutritional deficiencies, including calcium and vitamin D deficiencies.

Trust comment: Randomized controlled trial (n=120) with clear reporting; indirectly reports increased calcium deficiency after gastric bypass—relevant to calcium status.

Study Details

PMID:25979364
Participants:120
Impact:more frequent in gastric bypass group (increased incidence)
Trust score:4/5

serum ionized calcium (iCa)

1 evidences

A high-calcium dairy breakfast before cycling kept blood ionized calcium steadier and reduced markers of bone resorption compared with a low-calcium meal.

Trust comment: Randomized crossover trial in 32 elite female cyclists with appropriate biomarkers and analysis; unblinded meal and short-term outcomes limit some generalizability.

Study Details

PMID:25970439
Participants:32
Impact:+~0.04 mmol/L (higher in calcium meal vs control at pre- and immediate post-exercise timepoints)
Trust score:4/5

β-CTX-I (bone resorption marker)

1 evidences

A high-calcium dairy breakfast before cycling kept blood ionized calcium steadier and reduced markers of bone resorption compared with a low-calcium meal.

Trust comment: Randomized crossover trial in 32 elite female cyclists with appropriate biomarkers and analysis; unblinded meal and short-term outcomes limit some generalizability.

Study Details

PMID:25970439
Participants:32
Impact:reduced vs control (median CTX-I ~1.20–1.40 times higher in control at post-exercise timepoints; ~22–40% relative reduction with calcium)
Trust score:4/5

WOMAC total score (pain/function)

1 evidences

Monthly knee injections of sodium bicarbonate plus calcium gluconate improved pain and function; the higher calcium dose prevented joint-space narrowing over 12 months.

Trust comment: Randomized double-blind clinical trial with clinical and radiographic outcomes, but no placebo arm and all patients received active formulations.

Study Details

PMID:25963758
Participants:51
Impact:large reduction vs baseline (~−14.6 to −14.8 points at 12 months; ≈80% improvement)
Trust score:4/5

Lequesne functional index

1 evidences

Monthly knee injections of sodium bicarbonate plus calcium gluconate improved pain and function; the higher calcium dose prevented joint-space narrowing over 12 months.

Trust comment: Randomized double-blind clinical trial with clinical and radiographic outcomes, but no placebo arm and all patients received active formulations.

Study Details

PMID:25963758
Participants:51
Impact:substantial improvement (≈64–70% reduction vs baseline at 12 months)
Trust score:4/5

joint space width

1 evidences

Monthly knee injections of sodium bicarbonate plus calcium gluconate improved pain and function; the higher calcium dose prevented joint-space narrowing over 12 months.

Trust comment: Randomized double-blind clinical trial with clinical and radiographic outcomes, but no placebo arm and all patients received active formulations.

Study Details

PMID:25963758
Participants:51
Impact:SBCG1: −0.37 mm narrowing; SBCG2 (higher calcium): no significant narrowing (≈+0.15 mm), SBCG2 > SBCG1
Trust score:4/5

cumulative success (direct pulp capping)

1 evidences

Randomized trial comparing two pulp capping materials in teeth; both materials showed similar 1-year success rates.

Trust comment: Prospective randomized controlled trial with small sample (46 allocated, 41 followed to 1 year), moderate quality.

Study Details

PMID:25933707
Participants:41
Impact:no significant difference between ProRoot MTA and Endocem
Trust score:3/5

cavity type effect

1 evidences

Randomized trial comparing two pulp capping materials in teeth; both materials showed similar 1-year success rates.

Trust comment: Prospective randomized controlled trial with small sample (46 allocated, 41 followed to 1 year), moderate quality.

Study Details

PMID:25933707
Participants:41
Impact:class V cavities: lower cumulative success
Trust score:3/5

probing parameters

1 evidences

Small randomized comparison of single vs double flap surgical approaches with rhPDGF-BB + β-TCP grafts; similar clinical outcomes but less early pain with single flap.

Trust comment: Randomized defect-level comparison with small sample; applicable to surgical approach rather than systemic calcium intake.

Study Details

PMID:25924545
Participants:28
Impact:no significant difference between SFA and DFA
Trust score:3/5

Radiographic defect fill

1 evidences

Small randomized comparison of single vs double flap surgical approaches with rhPDGF-BB + β-TCP grafts; similar clinical outcomes but less early pain with single flap.

Trust comment: Randomized defect-level comparison with small sample; applicable to surgical approach rather than systemic calcium intake.

Study Details

PMID:25924545
Participants:28
Impact:no significant difference
Trust score:3/5

early postoperative pain (VAS)

1 evidences

Small randomized comparison of single vs double flap surgical approaches with rhPDGF-BB + β-TCP grafts; similar clinical outcomes but less early pain with single flap.

Trust comment: Randomized defect-level comparison with small sample; applicable to surgical approach rather than systemic calcium intake.

Study Details

PMID:25924545
Participants:28
Impact:lower in Single Flap Approach (days 1,2,6)
Trust score:3/5

TRAP5b (bone resorption marker)

2 evidences

Randomized double-blind trial in women >60: yogurt fortified with vitamin D3 (400 IU) and additional calcium increased 25OHD and decreased PTH and bone resorption markers over 12 weeks.

Trust comment: Randomized double-blind trial with good adherence and clear biochemical endpoints, moderate sample size.

Study Details

PMID:25923487
Participants:48
Impact:−0.17 U/L (D84-D0) in fortified group vs +0.25 U/L in control
Trust score:4/5

Postmenopausal osteopenic women taking a calcium-collagen chelate supplement had less whole-body bone loss and favorable bone turnover marker changes vs control over 12 months.

Trust comment: Randomized controlled trial in humans with intent-to-treat analysis but small sample (n=39) limits generalizability.

Study Details

PMID:25314004
Participants:39
Impact:Decreased at 6 months (P<.05)
Trust score:4/5

parathyroid hormone (PTH) percentage change

1 evidences

In hemodialysis patients, both cinacalcet and vitamin D analogs produced modest PTH reductions; cinacalcet caused more low calcium while vitamin D analogs caused more high calcium/phosphate.

Trust comment: Large randomized multicenter phase 4 trial with clear outcomes, open-label design and regional interaction limit some generalizability.

Study Details

PMID:25904755
Participants:312
Impact:cinacalcet -12.1%; vitamin D analogs -7.0%; between-group difference -5.0% (P=0.35)
Trust score:4/5

hypocalcemia frequency

1 evidences

In hemodialysis patients, both cinacalcet and vitamin D analogs produced modest PTH reductions; cinacalcet caused more low calcium while vitamin D analogs caused more high calcium/phosphate.

Trust comment: Large randomized multicenter phase 4 trial with clear outcomes, open-label design and regional interaction limit some generalizability.

Study Details

PMID:25904755
Participants:312
Impact:increased with cinacalcet (more common)
Trust score:4/5

hypercalcemia and hyperphosphatemia frequency

1 evidences

In hemodialysis patients, both cinacalcet and vitamin D analogs produced modest PTH reductions; cinacalcet caused more low calcium while vitamin D analogs caused more high calcium/phosphate.

Trust comment: Large randomized multicenter phase 4 trial with clear outcomes, open-label design and regional interaction limit some generalizability.

Study Details

PMID:25904755
Participants:312
Impact:increased with vitamin D analogs (more common)
Trust score:4/5

25-hydroxyvitamin D normalization (>75 nmol/L)

1 evidences

An individualized high loading dose of cholecalciferol rapidly normalized vitamin D levels in nursing home patients without causing hypercalcemia.

Trust comment: Small randomized trial with clear biochemical endpoints; limited sample size reduces precision for safety outcomes.

Study Details

PMID:25899914
Participants:30
Impact:loading dose: 79% reached >75 nmol/L at T5 (and 83% at T26); daily 800 IU: 0% at T5 (30% at T26)
Trust score:3/5

hypercalcemia (safety)

1 evidences

An individualized high loading dose of cholecalciferol rapidly normalized vitamin D levels in nursing home patients without causing hypercalcemia.

Trust comment: Small randomized trial with clear biochemical endpoints; limited sample size reduces precision for safety outcomes.

Study Details

PMID:25899914
Participants:30
Impact:no hypercalcemia observed
Trust score:3/5

white spot lesion (WSL) area change

1 evidences

In young children, topical CPP-ACP (tooth mousse) and fluoride varnish plus oral hygiene reduced white spot lesion area and prevented rise in dmft compared with control; CPP-ACP performed at least as well as fluoride varnish.

Trust comment: Well-conducted randomized double-blind trial in children with objective measures and adequate sample size and follow-up.

Study Details

PMID:25895964
Participants:122
Impact:after 12 months: control +115%; oral hygiene +10%; fluoride varnish -51%; CPP-ACP -63%
Trust score:4/5

dmft index

1 evidences

In young children, topical CPP-ACP (tooth mousse) and fluoride varnish plus oral hygiene reduced white spot lesion area and prevented rise in dmft compared with control; CPP-ACP performed at least as well as fluoride varnish.

Trust comment: Well-conducted randomized double-blind trial in children with objective measures and adequate sample size and follow-up.

Study Details

PMID:25895964
Participants:122
Impact:lowest after 12 months in CPP-ACP group (prevented increase compared with control)
Trust score:4/5

total cholesterol, LDL-C, HDL-C, LDL/HDL ratio

1 evidences

One-year supplementation with vitamin D with or without 600 mg calcium did not change TC, LDL-C, HDL-C or LDL/HDL ratio; small increases in VLDL-C and triglycerides were observed.

Trust comment: Randomized placebo-controlled trial with moderate sample size and objective lipid measures, but not powered specifically for lipid endpoints.

Study Details

PMID:25895202
Participants:153
Impact:no significant change after 12 months (no effect)
Trust score:4/5

VLDL-C

1 evidences

One-year supplementation with vitamin D with or without 600 mg calcium did not change TC, LDL-C, HDL-C or LDL/HDL ratio; small increases in VLDL-C and triglycerides were observed.

Trust comment: Randomized placebo-controlled trial with moderate sample size and objective lipid measures, but not powered specifically for lipid endpoints.

Study Details

PMID:25895202
Participants:153
Impact:small increase with supplementation (mean change up to +0.02 mmol/L; p=0.039)
Trust score:4/5

Triglycerides (TAG)

1 evidences

One-year supplementation with vitamin D with or without 600 mg calcium did not change TC, LDL-C, HDL-C or LDL/HDL ratio; small increases in VLDL-C and triglycerides were observed.

Trust comment: Randomized placebo-controlled trial with moderate sample size and objective lipid measures, but not powered specifically for lipid endpoints.

Study Details

PMID:25895202
Participants:153
Impact:small increase with supplementation (mean change up to +0.04 mmol/L; p=0.048)
Trust score:4/5

insertion-torque-value (ITV)

1 evidences

Moldable self‑hardening calcium phosphate grafts (with/without aPRF) used in subperiosteal tunnel augmentations increased implant insertion torque and produced adequate buccal bone gain with minimal complications.

Trust comment: Checklist: 1) Confirm relevance to Calcium biomaterials; 2) extract up to 3 main outcomes (ITV, bone gain, complications); 3) record participant count; 4) rate trust and summarize — Randomized clinical study in humans with clear quantitative ITV outcomes and adequate sample (82), randomized assignment of biomaterials; results reported with means and SDs (good internal validity).

Study Details

PMID:25954758
Participants:82
Impact:BiSHB mean 52.5 Ncm; MoSHB + aPRF 46.89 Ncm; MoSHB 42.51 Ncm; control (native anterior maxilla) 27.87 Ncm (BiSHB >> control)
Trust score:4/5

buccal bone gain (radiographic)

1 evidences

Moldable self‑hardening calcium phosphate grafts (with/without aPRF) used in subperiosteal tunnel augmentations increased implant insertion torque and produced adequate buccal bone gain with minimal complications.

Trust comment: Checklist: 1) Confirm relevance to Calcium biomaterials; 2) extract up to 3 main outcomes (ITV, bone gain, complications); 3) record participant count; 4) rate trust and summarize — Randomized clinical study in humans with clear quantitative ITV outcomes and adequate sample (82), randomized assignment of biomaterials; results reported with means and SDs (good internal validity).

Study Details

PMID:25954758
Participants:82
Impact:sufficient even buccal bone gain reported at all augmentation sites (qualitative)
Trust score:4/5

postoperative complications / pain

1 evidences

Moldable self‑hardening calcium phosphate grafts (with/without aPRF) used in subperiosteal tunnel augmentations increased implant insertion torque and produced adequate buccal bone gain with minimal complications.

Trust comment: Checklist: 1) Confirm relevance to Calcium biomaterials; 2) extract up to 3 main outcomes (ITV, bone gain, complications); 3) record participant count; 4) rate trust and summarize — Randomized clinical study in humans with clear quantitative ITV outcomes and adequate sample (82), randomized assignment of biomaterials; results reported with means and SDs (good internal validity).

Study Details

PMID:25954758
Participants:82
Impact:no surgical complications; minor swelling; low analgesic use (mean ibuprofen 3.2 tablets)
Trust score:4/5

sealant retention

1 evidences

Split-mouth randomized trial in children comparing sealants (including an ACP-containing resin): retention and caries rates were similar across sealants, with a significant difference detected only for marginal discoloration.

Trust comment: Checklist: 1) Confirm relevance (ACP = calcium compound in sealant); 2) extract main outcomes (retention, caries, discoloration); 3) record participants; 4) rate trust — Split-mouth randomized clinical design in 75 children with 24-month follow-up; methods appropriate though limited detail on direction/magnitude of discoloration effect.

Study Details

PMID:25951308
Participants:75
Impact:no significant difference between sealants over 24 months (p > 0.05)
Trust score:4/5

presence of caries

1 evidences

Split-mouth randomized trial in children comparing sealants (including an ACP-containing resin): retention and caries rates were similar across sealants, with a significant difference detected only for marginal discoloration.

Trust comment: Checklist: 1) Confirm relevance (ACP = calcium compound in sealant); 2) extract main outcomes (retention, caries, discoloration); 3) record participants; 4) rate trust — Split-mouth randomized clinical design in 75 children with 24-month follow-up; methods appropriate though limited detail on direction/magnitude of discoloration effect.

Study Details

PMID:25951308
Participants:75
Impact:no significant difference between sealants over 24 months (p > 0.05)
Trust score:4/5

marginal discoloration

1 evidences

Split-mouth randomized trial in children comparing sealants (including an ACP-containing resin): retention and caries rates were similar across sealants, with a significant difference detected only for marginal discoloration.

Trust comment: Checklist: 1) Confirm relevance (ACP = calcium compound in sealant); 2) extract main outcomes (retention, caries, discoloration); 3) record participants; 4) rate trust — Split-mouth randomized clinical design in 75 children with 24-month follow-up; methods appropriate though limited detail on direction/magnitude of discoloration effect.

Study Details

PMID:25951308
Participants:75
Impact:statistically significant difference between sealants in Group 1 (p < 0.05)
Trust score:4/5

plasma ionized calcium

1 evidences

Randomized double-blind trial: IV calcium chloride raised ionized calcium but did not prevent oxytocin-associated blood pressure drop and had no effect on uterine tone, vasopressor use, or blood loss at the doses tested.

Trust comment: Checklist: 1) Confirm relevance to Calcium (IV calcium chloride administration); 2) extract main outcomes (ionized calcium, BP, uterine tone/blood loss); 3) record participants (60); 4) rate trust — double‑blind randomized placebo‑controlled trial in humans with direct calcium administration and clear null/positive findings; moderate sample size.

Study Details

PMID:25935422
Participants:60
Impact:elevated in calcium groups compared with placebo (P = 0.001)
Trust score:4/5

uterine tone / blood loss

1 evidences

Randomized double-blind trial: IV calcium chloride raised ionized calcium but did not prevent oxytocin-associated blood pressure drop and had no effect on uterine tone, vasopressor use, or blood loss at the doses tested.

Trust comment: Checklist: 1) Confirm relevance to Calcium (IV calcium chloride administration); 2) extract main outcomes (ionized calcium, BP, uterine tone/blood loss); 3) record participants (60); 4) rate trust — double‑blind randomized placebo‑controlled trial in humans with direct calcium administration and clear null/positive findings; moderate sample size.

Study Details

PMID:25935422
Participants:60
Impact:no differences between groups in uterine tone, estimated blood loss, or vasopressor use
Trust score:4/5

dentin hypersensitivity (VAS) immediate

1 evidences

Double-blind randomized study in patients with dentin hypersensitivity: an in-office/home-use system containing 8% arginine and calcium carbonate produced greater short-term reduction in sensitivity than control.

Trust comment: Randomized, double-blind RCT (n=50) showing superiority of an arginine + calcium carbonate system for early reductions in dentin hypersensitivity; modest sample size and short follow-up.

Study Details

PMID:25864242
Participants:50
Impact:-26.2% vs baseline
Trust score:4/5

dentin hypersensitivity (Schiff) immediate

1 evidences

Double-blind randomized study in patients with dentin hypersensitivity: an in-office/home-use system containing 8% arginine and calcium carbonate produced greater short-term reduction in sensitivity than control.

Trust comment: Randomized, double-blind RCT (n=50) showing superiority of an arginine + calcium carbonate system for early reductions in dentin hypersensitivity; modest sample size and short follow-up.

Study Details

PMID:25864242
Participants:50
Impact:-29.1% vs baseline
Trust score:4/5

dentin hypersensitivity (Schiff) at 2 and 4 weeks

1 evidences

Double-blind randomized study in patients with dentin hypersensitivity: an in-office/home-use system containing 8% arginine and calcium carbonate produced greater short-term reduction in sensitivity than control.

Trust comment: Randomized, double-blind RCT (n=50) showing superiority of an arginine + calcium carbonate system for early reductions in dentin hypersensitivity; modest sample size and short follow-up.

Study Details

PMID:25864242
Participants:50
Impact:-44.5% (2 wk) and -55.2% (4 wk) for Test versus -27.7% and -40.5% for Control
Trust score:4/5

24h urine calcium concentration

1 evidences

Randomized placebo-controlled trial (secondary analysis) of 500 mg/day calcium supplementation in postmenopausal women: calcium increased 24-hour urine calcium concentration, and higher urine volume mitigated increased stone-risk.

Trust comment: Randomized placebo-controlled trial with n=240 and clear 24h urine outcomes; secondary analysis but statistically robust and directly evaluates oral calcium supplementation effects.

Study Details

PMID:25856469
Participants:240
Impact:Increased with 500 mg/day calcium supplementation (p < 0.001)
Trust score:4/5

renal stone risk (based on urine calcium concentration)

1 evidences

Randomized placebo-controlled trial (secondary analysis) of 500 mg/day calcium supplementation in postmenopausal women: calcium increased 24-hour urine calcium concentration, and higher urine volume mitigated increased stone-risk.

Trust comment: Randomized placebo-controlled trial with n=240 and clear 24h urine outcomes; secondary analysis but statistically robust and directly evaluates oral calcium supplementation effects.

Study Details

PMID:25856469
Participants:240
Impact:Higher in calcium-supplemented women with urine volume <2 L (lowest-risk proportion <35% vs >50% in placebo)
Trust score:4/5

effect of hydration

1 evidences

Randomized placebo-controlled trial (secondary analysis) of 500 mg/day calcium supplementation in postmenopausal women: calcium increased 24-hour urine calcium concentration, and higher urine volume mitigated increased stone-risk.

Trust comment: Randomized placebo-controlled trial with n=240 and clear 24h urine outcomes; secondary analysis but statistically robust and directly evaluates oral calcium supplementation effects.

Study Details

PMID:25856469
Participants:240
Impact:Adequate urine volume (≥2 L/24 h) largely eliminated the increased stone-risk from calcium supplementation (>80% of supplemented women at lowest risk when volume high)
Trust score:4/5

tooth sensitivity (VAS)

1 evidences

Chewing gum containing CPP-ACP (a calcium-containing preparation) before in-office tooth whitening did not reduce whitening-associated tooth sensitivity.

Trust comment: Small randomized study (n=30) with objective shade measures but limited power to detect small differences in sensitivity.

Study Details

PMID:25828296
Participants:30
Impact:+14.7 mm overall (from 5.12 to 19.81); CPP-ACP gum did not reduce sensitivity versus control
Trust score:3/5

tooth shade change

1 evidences

Chewing gum containing CPP-ACP (a calcium-containing preparation) before in-office tooth whitening did not reduce whitening-associated tooth sensitivity.

Trust comment: Small randomized study (n=30) with objective shade measures but limited power to detect small differences in sensitivity.

Study Details

PMID:25828296
Participants:30
Impact:-2.27 (mean Δ shade)
Trust score:3/5

truncal lean mass

1 evidences

In a double-blind RCT of 208 older adults, daily whey protein for 18 months increased lean mass but did not change lumbar spine bone mineral density.

Trust comment: Well-designed double-blind RCT with adequate sample size; study addresses calcium metabolism indirectly (protein effect on Ca absorption) but does not assess calcium supplementation.

Study Details

PMID:25844619
Participants:208
Impact:increase (significantly higher in protein group at 18 months, P=0.048)
Trust score:3/5

C-terminal telopeptide (bone turnover)

1 evidences

In a double-blind RCT of 208 older adults, daily whey protein for 18 months increased lean mass but did not change lumbar spine bone mineral density.

Trust comment: Well-designed double-blind RCT with adequate sample size; study addresses calcium metabolism indirectly (protein effect on Ca absorption) but does not assess calcium supplementation.

Study Details

PMID:25844619
Participants:208
Impact:increase in protein group (P=0.0414)
Trust score:3/5

Back pain (VAS)

1 evidences

Ossein-hydroxyapatite complex (OHC) reduced back and knee pain and improved physical quality of life more than calcium carbonate over 6 months.

Trust comment: Randomized, controlled trial with modest sample size and objective pain and QoL measures, but open-label design limits blinding.

Study Details

PMID:25819354
Participants:74
Impact:Significant decrease with OHC after 5–6 months versus calcium carbonate (reported as statistically significant; exact magnitude not provided)
Trust score:3/5

knee pain (VRS)

1 evidences

Ossein-hydroxyapatite complex (OHC) reduced back and knee pain and improved physical quality of life more than calcium carbonate over 6 months.

Trust comment: Randomized, controlled trial with modest sample size and objective pain and QoL measures, but open-label design limits blinding.

Study Details

PMID:25819354
Participants:74
Impact:Significant decrease with OHC after 5–6 months versus calcium carbonate (reported as statistically significant; exact magnitude not provided)
Trust score:3/5

physical component of quality of life (SF-36)

1 evidences

Ossein-hydroxyapatite complex (OHC) reduced back and knee pain and improved physical quality of life more than calcium carbonate over 6 months.

Trust comment: Randomized, controlled trial with modest sample size and objective pain and QoL measures, but open-label design limits blinding.

Study Details

PMID:25819354
Participants:74
Impact:Significant improvement with OHC; no change with calcium carbonate
Trust score:3/5

dentin hypersensitivity (pain VAS)

1 evidences

A desensitizing paste containing 8% arginine-calcium carbonate reduced tooth sensitivity pain substantially; combining with low-level laser did not add benefit.

Trust comment: Randomized split-mouth trial (n=21) with subjective VAS outcomes; small sample but randomized and relevant to calcium-containing topical product.

Study Details

PMID:25764483
Participants:21
Impact:decreased by 65.4% with 8% arginine-calcium carbonate paste at day 90 (placebo +7.8%)
Trust score:3/5

combination therapy efficacy

1 evidences

A desensitizing paste containing 8% arginine-calcium carbonate reduced tooth sensitivity pain substantially; combining with low-level laser did not add benefit.

Trust comment: Randomized split-mouth trial (n=21) with subjective VAS outcomes; small sample but randomized and relevant to calcium-containing topical product.

Study Details

PMID:25764483
Participants:21
Impact:LLL + DP not superior to either treatment alone
Trust score:3/5

plaque pH

1 evidences

Pastes containing CPP-ACP or CPP-ACFP increased plaque pH and enhanced enamel remineralisation compared with NaF in patients with Sjögren's syndrome over 28 days.

Trust comment: Randomized small trial (n=30) with in situ and imaging endpoints; short duration but directly tests calcium-containing remineralisation agents.

Study Details

PMID:25762499
Participants:30
Impact:significant rise with CPP-ACP and CPP-ACFP versus control
Trust score:3/5

enamel remineralisation (enamel defects)

1 evidences

Pastes containing CPP-ACP or CPP-ACFP increased plaque pH and enhanced enamel remineralisation compared with NaF in patients with Sjögren's syndrome over 28 days.

Trust comment: Randomized small trial (n=30) with in situ and imaging endpoints; short duration but directly tests calcium-containing remineralisation agents.

Study Details

PMID:25762499
Participants:30
Impact:reduction in defect dimensions and decrease in number of defects with CPP-ACP/CPP-ACFP
Trust score:3/5

total neuropathy score (TNS)

1 evidences

Randomized study comparing IV glutamine versus calcium/magnesium infusions during platinum chemotherapy; neither prevented neuropathy, but glutamine reduced severity in symptomatic patients.

Trust comment: Prospective randomized design but small sample size limiting power; direct measures reported.

Study Details

PMID:25800685
Participants:55
Impact:increased in both groups (no prevention of worsening)
Trust score:3/5

IV glutamine effect in symptomatic patients

1 evidences

Randomized study comparing IV glutamine versus calcium/magnesium infusions during platinum chemotherapy; neither prevented neuropathy, but glutamine reduced severity in symptomatic patients.

Trust comment: Prospective randomized design but small sample size limiting power; direct measures reported.

Study Details

PMID:25800685
Participants:55
Impact:reduced severity in patients symptomatic at baseline (P=0.045)
Trust score:3/5

calcium/magnesium infusion

1 evidences

Randomized study comparing IV glutamine versus calcium/magnesium infusions during platinum chemotherapy; neither prevented neuropathy, but glutamine reduced severity in symptomatic patients.

Trust comment: Prospective randomized design but small sample size limiting power; direct measures reported.

Study Details

PMID:25800685
Participants:55
Impact:did not prevent platinum-induced neuropathy (no significant benefit)
Trust score:3/5

radiographic healing (score ≤1.5)

1 evidences

Randomized trial in children with calcium-deficiency rickets comparing limestone versus ground fish as calcium sources; both treatments healed rickets in most children with no difference between sources.

Trust comment: Randomized trial with good completion rate (88 completers) and direct clinically relevant outcomes.

Study Details

PMID:25799193
Participants:88
Impact:ground fish 66% vs limestone 55% achieved healing within 6 months (P=0.39, no significant difference)
Trust score:4/5

radiographic score improvement

1 evidences

Randomized trial in children with calcium-deficiency rickets comparing limestone versus ground fish as calcium sources; both treatments healed rickets in most children with no difference between sources.

Trust comment: Randomized trial with good completion rate (88 completers) and direct clinically relevant outcomes.

Study Details

PMID:25799193
Participants:88
Impact:ground fish: 6.2±2.4 → 1.8±2.2; limestone: 6.3±2.2 → 2.1±2.4 (no group difference)
Trust score:4/5

biochemical and BMD changes

1 evidences

Randomized trial in children with calcium-deficiency rickets comparing limestone versus ground fish as calcium sources; both treatments healed rickets in most children with no difference between sources.

Trust comment: Randomized trial with good completion rate (88 completers) and direct clinically relevant outcomes.

Study Details

PMID:25799193
Participants:88
Impact:alkaline phosphatase decreased; serum calcium, 25‑OH vitamin D, and BMD increased in both groups
Trust score:4/5

caesarean section rate

1 evidences

Double-blind RCT in women with gestational diabetes showing that calcium plus high-dose vitamin D for 6 weeks reduced C-section rate, maternal hospitalization, and several adverse newborn outcomes.

Trust comment: Randomized double-blind placebo-controlled trial with clear, significant effects but modest sample size (n=60).

Study Details

PMID:25790761
Participants:60
Impact:23.3% (Ca+vitD) vs 63.3% (placebo), P=0.002
Trust score:4/5

maternal hospitalization

1 evidences

Double-blind RCT in women with gestational diabetes showing that calcium plus high-dose vitamin D for 6 weeks reduced C-section rate, maternal hospitalization, and several adverse newborn outcomes.

Trust comment: Randomized double-blind placebo-controlled trial with clear, significant effects but modest sample size (n=60).

Study Details

PMID:25790761
Participants:60
Impact:0% (Ca+vitD) vs 13.3% (placebo), P=0.03
Trust score:4/5

newborn adverse outcomes (macrosomia, hyperbilirubinaemia, hospitalization)

1 evidences

Double-blind RCT in women with gestational diabetes showing that calcium plus high-dose vitamin D for 6 weeks reduced C-section rate, maternal hospitalization, and several adverse newborn outcomes.

Trust comment: Randomized double-blind placebo-controlled trial with clear, significant effects but modest sample size (n=60).

Study Details

PMID:25790761
Participants:60
Impact:macrosomia 0% vs 13.3% (P=0.03); hyperbilirubinaemia 20.0% vs 56.7% (P=0.03); neonatal hospitalization 20.0% vs 56.7% (P=0.03)
Trust score:4/5

incidental parathyroidectomy

1 evidences

Using carbon nanoparticles in endoscopic thyroid surgery reduced accidental removal of parathyroids and sped recovery of parathyroid hormone; serum calcium was slightly higher but not significantly different.

Trust comment: Randomized human surgical trial with clear outcomes but small sample size limits precision.

Study Details

PMID:25761552
Participants:55
Impact:reduced in CN group (control had 5 cases in specimens vs 0 in CN group; P=0.023)
Trust score:4/5

breast milk other minerals (Zn, Cu, Fe, Mg)

1 evidences

In this pilot RCT, synbiotic supplementation in lactating mothers prevented declines in breast milk minerals including calcium and was associated with slight improvements in infant weight-for-age Z-score.

Trust comment: Randomized, double-blind pilot trial in humans but small sample size limits confidence.

Study Details

PMID:25744506
Participants:57
Impact:maintained or slightly increased in synbiotic group vs significant decreases in placebo (between-group P<0.05)
Trust score:3/5

infant weight-for-age Z-score (WAZ)

1 evidences

In this pilot RCT, synbiotic supplementation in lactating mothers prevented declines in breast milk minerals including calcium and was associated with slight improvements in infant weight-for-age Z-score.

Trust comment: Randomized, double-blind pilot trial in humans but small sample size limits confidence.

Study Details

PMID:25744506
Participants:57
Impact:WAZ slightly increased in supplemented group (1.19±0.79 → 1.20±0.69) and decreased in placebo (decrease significant for placebo; between-group difference for WAZ reported significant P=0.01)
Trust score:3/5

Hip circumference

1 evidences

In vitamin D–insufficient adults with type 2 diabetes, 8 weeks of calcium plus vitamin D reduced BMI, hip circumference, and systolic blood pressure versus placebo.

Trust comment: Randomized placebo-controlled trial with moderate sample size but short (8-week) duration.

Study Details

PMID:25738212
Participants:118
Impact:Significant reduction with calcium supplementation vs other groups (p < 0.001)
Trust score:4/5

Child calcium intake (nutrient density)

1 evidences

A community feeding intervention increased mothers' knowledge and improved children's intakes of calcium, iron, niacin, and zinc, though calcium intake/density remained below desired levels.

Trust comment: Quasi-experimental community intervention with good sample size and positive program effects, but non-randomized design and remaining intakes below recommendations limit strength.

Study Details

PMID:25733629
Participants:455
Impact:Endline median 23 mg/100 kcal in intervention group (below desired 63 mg/100 kcal); intake increased vs control (significant)
Trust score:3/5

Maternal nutrition knowledge

1 evidences

A community feeding intervention increased mothers' knowledge and improved children's intakes of calcium, iron, niacin, and zinc, though calcium intake/density remained below desired levels.

Trust comment: Quasi-experimental community intervention with good sample size and positive program effects, but non-randomized design and remaining intakes below recommendations limit strength.

Study Details

PMID:25733629
Participants:455
Impact:Improved after the complementary feeding recommendations intervention
Trust score:3/5

Child feeding practices

1 evidences

A community feeding intervention increased mothers' knowledge and improved children's intakes of calcium, iron, niacin, and zinc, though calcium intake/density remained below desired levels.

Trust comment: Quasi-experimental community intervention with good sample size and positive program effects, but non-randomized design and remaining intakes below recommendations limit strength.

Study Details

PMID:25733629
Participants:455
Impact:Improved in intervention group (behavioral uptake of CFRs)
Trust score:3/5

CBCT detection of periapical radiolucency

1 evidences

Randomized trial in patients needing indirect pulp capping showed similar 12-month clinical success for calcium-silicate cement and glass ionomer, though CBCT revealed more healed lesions with the calcium-silicate material.

Trust comment: Randomized clinical trial with 53 patients and 12-month follow-up; moderate sample and objective imaging outcomes support moderate confidence.

Study Details

PMID:25710953
Participants:53
Impact:CBCT more effective than periapical radiographs (P=0.0069)
Trust score:3/5

healing rates on CBCT

1 evidences

Randomized trial in patients needing indirect pulp capping showed similar 12-month clinical success for calcium-silicate cement and glass ionomer, though CBCT revealed more healed lesions with the calcium-silicate material.

Trust comment: Randomized clinical trial with 53 patients and 12-month follow-up; moderate sample and objective imaging outcomes support moderate confidence.

Study Details

PMID:25710953
Participants:53
Impact:majority of healed CBCT lesions received Biodentine (71%); more new/progressed lesions with GIC
Trust score:3/5

ACS occurrence with CAC=0

1 evidences

Prespecified subanalysis of 473 ED patients found coronary artery calcium scoring did not add diagnostic value beyond coronary CT angiography for acute coronary syndrome.

Trust comment: Large prespecified subanalysis (n=473) from a multicenter trial with clear diagnostic endpoints; strong quality for imaging evidence.

Study Details

PMID:25710925
Participants:473
Impact:0.8% developed ACS among patients with CAC=0
Trust score:4/5

ACS occurrence with CAC>400

1 evidences

Prespecified subanalysis of 473 ED patients found coronary artery calcium scoring did not add diagnostic value beyond coronary CT angiography for acute coronary syndrome.

Trust comment: Large prespecified subanalysis (n=473) from a multicenter trial with clear diagnostic endpoints; strong quality for imaging evidence.

Study Details

PMID:25710925
Participants:473
Impact:49% developed ACS among patients with CAC>400
Trust score:4/5

diagnostic performance (c-statistic)

1 evidences

Prespecified subanalysis of 473 ED patients found coronary artery calcium scoring did not add diagnostic value beyond coronary CT angiography for acute coronary syndrome.

Trust comment: Large prespecified subanalysis (n=473) from a multicenter trial with clear diagnostic endpoints; strong quality for imaging evidence.

Study Details

PMID:25710925
Participants:473
Impact:CAC c-statistic 0.86 vs CCTA 0.92; CAC adds no incremental value beyond CCTA
Trust score:4/5

serum methylglyoxal

1 evidences

Randomized study comparing sevelamer to calcium carbonate in T2DM with DKD found sevelamer reduced circulating and intracellular AGEs and increased antioxidant markers; calcium carbonate did not lower AGEs overall.

Trust comment: Randomized open-label trial with 117 patients; adequate size but open-label design and subgroup findings reduce certainty regarding calcium comparator effects.

Study Details

PMID:25710801
Participants:117
Impact:decreased with sevelamer vs calcium carbonate (95% CI -0.72 to -0.29)
Trust score:3/5

serum and intracellular CML

1 evidences

Randomized study comparing sevelamer to calcium carbonate in T2DM with DKD found sevelamer reduced circulating and intracellular AGEs and increased antioxidant markers; calcium carbonate did not lower AGEs overall.

Trust comment: Randomized open-label trial with 117 patients; adequate size but open-label design and subgroup findings reduce certainty regarding calcium comparator effects.

Study Details

PMID:25710801
Participants:117
Impact:decreased with sevelamer vs calcium carbonate (serum 95% CI -5.08 to -1.35; intracellular 95% CI -1.63 to -0.28)
Trust score:3/5

venous thromboembolism (overall)

1 evidences

Daily calcium (1,000 mg) plus vitamin D (400 IU) for ~7 years did not change overall venous clot risk but reduced idiopathic clots.

Trust comment: Large randomized double-blind placebo-controlled trial with long follow-up and robust methodology—high-quality evidence.

Study Details

PMID:25672892
Participants:36282
Impact:no significant difference (320 vs 348 events; HR 0.92)
Trust score:5/5

idiopathic venous thromboembolism

1 evidences

Daily calcium (1,000 mg) plus vitamin D (400 IU) for ~7 years did not change overall venous clot risk but reduced idiopathic clots.

Trust comment: Large randomized double-blind placebo-controlled trial with long follow-up and robust methodology—high-quality evidence.

Study Details

PMID:25672892
Participants:36282
Impact:reduced (40 vs 65 events; HR 0.62)
Trust score:5/5

Proportion achieving normal corrected serum calcium (≤10.3 mg/dl)

1 evidences

In PHPT patients unable to undergo surgery, cinacalcet markedly lowered serum calcium and PTH and normalized calcium in most treated subjects.

Trust comment: Phase 3 double‑blind randomized controlled trial with clear endpoints but modest sample size.

Study Details

PMID:25637076
Participants:67
Impact:75.8% cinacalcet vs 0% placebo (P<0.001)
Trust score:4/5

Decrease in corrected serum calcium ≥1.0 mg/dl

1 evidences

In PHPT patients unable to undergo surgery, cinacalcet markedly lowered serum calcium and PTH and normalized calcium in most treated subjects.

Trust comment: Phase 3 double‑blind randomized controlled trial with clear endpoints but modest sample size.

Study Details

PMID:25637076
Participants:67
Impact:84.8% cinacalcet vs 5.9% placebo (P<0.001)
Trust score:4/5

25-hydroxyvitamin D (25OHD) level

1 evidences

In this Macau population survey, taking calcium supplements was modestly associated with slightly higher vitamin D levels and slightly lower PTH.

Trust comment: Well‑characterized cross‑sectional household survey with adjusted analyses; observational design limits causal inference.

Study Details

PMID:25636721
Participants:566
Impact:Positive association with calcium supplement intake (β=0.06; adjusted)
Trust score:3/5

Bone mineral density (BMD) Z‑scores — lumbar spine and femoral neck

1 evidences

Over 5 years, parathyroidectomy for mild PHPT normalized calcium/PTH and increased bone mineral density compared with observation.

Trust comment: Randomized controlled multicenter trial with 5‑year follow‑up; some loss to follow‑up but strong design for clinical outcomes.

Study Details

PMID:25636048
Participants:145
Impact:Significant increases after surgery (P<.02 for both); treatment effect P<.001 versus observation
Trust score:4/5

New radiographic vertebral fractures

1 evidences

Over 5 years, parathyroidectomy for mild PHPT normalized calcium/PTH and increased bone mineral density compared with observation.

Trust comment: Randomized controlled multicenter trial with 5‑year follow‑up; some loss to follow‑up but strong design for clinical outcomes.

Study Details

PMID:25636048
Participants:145
Impact:5 fractures observed only in observation group (P=0.058; not statistically significant)
Trust score:4/5

Bronchial smooth muscle (BSM) area

1 evidences

In severe asthma, the calcium‑channel blocker gallopamil reduced bronchial smooth muscle thickness and was associated with fewer exacerbations during follow‑up.

Trust comment: Small double‑blind RCT with objective morphometric endpoints; proof‑of‑concept study limited by sample size.

Study Details

PMID:25633090
Participants:31
Impact:Reduced within gallopamil group (between-group difference not significant)
Trust score:3/5

Normalized BSM thickness

1 evidences

In severe asthma, the calcium‑channel blocker gallopamil reduced bronchial smooth muscle thickness and was associated with fewer exacerbations during follow‑up.

Trust comment: Small double‑blind RCT with objective morphometric endpoints; proof‑of‑concept study limited by sample size.

Study Details

PMID:25633090
Participants:31
Impact:Significant between-group decrease with gallopamil
Trust score:3/5

Asthma exacerbations (follow-up)

1 evidences

In severe asthma, the calcium‑channel blocker gallopamil reduced bronchial smooth muscle thickness and was associated with fewer exacerbations during follow‑up.

Trust comment: Small double‑blind RCT with objective morphometric endpoints; proof‑of‑concept study limited by sample size.

Study Details

PMID:25633090
Participants:31
Impact:Fewer exacerbations in patients previously treated with gallopamil during follow-up
Trust score:3/5

lumbar spine bone mineral density (BMD) loss

1 evidences

High-calcium milk powder (450 mg elemental Ca twice daily plus vitamin D) reduced lumbar spine bone loss in postmenopausal women over 24 months and reduced height loss.

Trust comment: Randomized controlled trial with 24-month follow-up and CACE analysis improves causal inference; moderate sample size limits generalizability.

Study Details

PMID:25626413
Participants:141
Impact:Calcium supplementation significantly reduced lumbar spine bone loss at 24 months (effect size 1.170; 95% CI 0.376–1.964; P = 0.004)
Trust score:4/5

height loss

1 evidences

High-calcium milk powder (450 mg elemental Ca twice daily plus vitamin D) reduced lumbar spine bone loss in postmenopausal women over 24 months and reduced height loss.

Trust comment: Randomized controlled trial with 24-month follow-up and CACE analysis improves causal inference; moderate sample size limits generalizability.

Study Details

PMID:25626413
Participants:141
Impact:Less height loss at 24 months in calcium group (effect size 1.040; 95% CI 0.012–2.066; P = 0.047)
Trust score:4/5

operative time

1 evidences

Compared two thyroid surgery techniques; LSJ shortened operation time and reduced intraoperative blood loss; postoperative calcium and parathyroid hormone changes were similar between groups.

Trust comment: Prospective randomized single-center trial with 190 patients and clear outcome reporting; surgical focus but calcium-related measures reported and not different between groups.

Study Details

PMID:25582310
Participants:190
Impact:-13.7 min (73.90 ± 23.35 min CT vs 60.20 ± 22.36 min LSJ; p = 0.002)
Trust score:4/5

postoperative serum calcium / iPTH

1 evidences

Compared two thyroid surgery techniques; LSJ shortened operation time and reduced intraoperative blood loss; postoperative calcium and parathyroid hormone changes were similar between groups.

Trust comment: Prospective randomized single-center trial with 190 patients and clear outcome reporting; surgical focus but calcium-related measures reported and not different between groups.

Study Details

PMID:25582310
Participants:190
Impact:no significant difference between groups (day1-3 Ca means ~8.12-7.92 mg/dL CT vs 8.26-8.22 mg/dL LSJ; iPTH Δ ~49.15% vs 45.69%; p > 0.05)
Trust score:4/5

femoral trabecular volumetric BMD

1 evidences

Older adults received daily low-magnitude vibration or placebo while all received calcium (1000 mg) and vitamin D; no clear benefit on hip or spine volumetric bone density or bone turnover markers.

Trust comment: Randomized, placebo-controlled trial with protocolized calcium/vitamin D supplementation and objective primary outcomes; adequately designed though variability limited power.

Study Details

PMID:25581217
Participants:174
Impact:median % change active 2.2% [-0.8,5.2] vs placebo 0.4% [-4.8,5.0]; no significant difference (p > 0.1)
Trust score:4/5

mid-vertebral (L1-L2) trabecular vBMD

1 evidences

Older adults received daily low-magnitude vibration or placebo while all received calcium (1000 mg) and vitamin D; no clear benefit on hip or spine volumetric bone density or bone turnover markers.

Trust comment: Randomized, placebo-controlled trial with protocolized calcium/vitamin D supplementation and objective primary outcomes; adequately designed though variability limited power.

Study Details

PMID:25581217
Participants:174
Impact:median % change active 5.3% [-6.9,13.3] vs placebo 2.4% [-4.4,11.1]; no significant difference (p > 0.1)
Trust score:4/5

bone turnover markers (P1NP, sCTX)

1 evidences

Older adults received daily low-magnitude vibration or placebo while all received calcium (1000 mg) and vitamin D; no clear benefit on hip or spine volumetric bone density or bone turnover markers.

Trust comment: Randomized, placebo-controlled trial with protocolized calcium/vitamin D supplementation and objective primary outcomes; adequately designed though variability limited power.

Study Details

PMID:25581217
Participants:174
Impact:no difference between groups (p = 0.19 and p = 0.97)
Trust score:4/5

white spot lesion (DIAGNOdent)

1 evidences

Children with white spot tooth lesions used CPP-ACP cream or fluoride toothpaste for 3 months; CPP-ACP showed only slight remineralization and both groups had reduced S. mutans counts.

Trust comment: Small randomized study with short follow-up; objective measures used but limited sample and duration reduce strength of evidence.

Study Details

PMID:25571679
Participants:60
Impact:no significant improvement in CPP-ACP group over 3 months (p = 0.217); control group DIAGNOdent increased over time (p = 0.002)
Trust score:3/5

Streptococcus mutans counts

1 evidences

Children with white spot tooth lesions used CPP-ACP cream or fluoride toothpaste for 3 months; CPP-ACP showed only slight remineralization and both groups had reduced S. mutans counts.

Trust comment: Small randomized study with short follow-up; objective measures used but limited sample and duration reduce strength of evidence.

Study Details

PMID:25571679
Participants:60
Impact:decreased in both groups during the 3-month period
Trust score:3/5

all-cause stroke risk

1 evidences

In a case-cohort within REGARDS, higher FGF23 (linked to higher calcium/phosphorus) was not associated with all-cause stroke but was associated with higher risk of cardioembolic stroke.

Trust comment: Large case-cohort analysis within a well-characterized cohort with multivariable adjustment and prespecified stroke subtype analyses.

Study Details

PMID:25563643
Participants:1551
Impact:no significant association with FGF23 (HR Q4 vs Q1 = 1.19; 95% CI 0.78-1.82)
Trust score:4/5

cardioembolic stroke risk

1 evidences

In a case-cohort within REGARDS, higher FGF23 (linked to higher calcium/phosphorus) was not associated with all-cause stroke but was associated with higher risk of cardioembolic stroke.

Trust comment: Large case-cohort analysis within a well-characterized cohort with multivariable adjustment and prespecified stroke subtype analyses.

Study Details

PMID:25563643
Participants:1551
Impact:graded positive association with FGF23 (Q4 vs Q1 HR = 2.52; 95% CI 1.08-5.91)
Trust score:4/5

association of calcium/phosphorus with FGF23

1 evidences

In a case-cohort within REGARDS, higher FGF23 (linked to higher calcium/phosphorus) was not associated with all-cause stroke but was associated with higher risk of cardioembolic stroke.

Trust comment: Large case-cohort analysis within a well-characterized cohort with multivariable adjustment and prespecified stroke subtype analyses.

Study Details

PMID:25563643
Participants:1551
Impact:higher calcium and phosphorus concentrations independently associated with higher FGF23
Trust score:4/5

incidence of OHSS

1 evidences

In women at high risk for OHSS undergoing IVF/ICSI, intravenous calcium gluconate given around egg retrieval markedly reduced incidence and severity of OHSS without lowering pregnancy rates.

Trust comment: Double-blind randomized controlled trial with 200 participants and clear, clinically significant outcome differences favoring calcium infusion.

Study Details

PMID:25552412
Participants:200
Impact:7% in calcium group vs 23% in placebo (absolute reduction 16 percentage points)
Trust score:5/5

moderate OHSS

1 evidences

In women at high risk for OHSS undergoing IVF/ICSI, intravenous calcium gluconate given around egg retrieval markedly reduced incidence and severity of OHSS without lowering pregnancy rates.

Trust comment: Double-blind randomized controlled trial with 200 participants and clear, clinically significant outcome differences favoring calcium infusion.

Study Details

PMID:25552412
Participants:200
Impact:1% in calcium group vs 8% in placebo
Trust score:5/5

severe OHSS

1 evidences

In women at high risk for OHSS undergoing IVF/ICSI, intravenous calcium gluconate given around egg retrieval markedly reduced incidence and severity of OHSS without lowering pregnancy rates.

Trust comment: Double-blind randomized controlled trial with 200 participants and clear, clinically significant outcome differences favoring calcium infusion.

Study Details

PMID:25552412
Participants:200
Impact:0% in calcium group vs 4% in placebo
Trust score:5/5

Progressively motile sperm count per ejaculate

1 evidences

Randomized trial of vitamin D plus calcium versus vitamins E/C in men with idiopathic oligoasthenozoospermia found improved progressive motile sperm count and higher pregnancy rate in the vitamin D + calcium group.

Trust comment: Randomized human trial (n=86) where calcium was co-administered with vitamin D, so observed effects may reflect vitamin D, calcium, or their combination; moderate sample size.

Study Details

PMID:25597173
Participants:86
Impact:increased by +11.65×10^6 (from 9.82 to 21.47×10^6) after treatment
Trust score:3/5

proportion progressively motile sperm

1 evidences

Randomized trial of vitamin D plus calcium versus vitamins E/C in men with idiopathic oligoasthenozoospermia found improved progressive motile sperm count and higher pregnancy rate in the vitamin D + calcium group.

Trust comment: Randomized human trial (n=86) where calcium was co-administered with vitamin D, so observed effects may reflect vitamin D, calcium, or their combination; moderate sample size.

Study Details

PMID:25597173
Participants:86
Impact:small/non-significant increase (from 17.79% to 21.35%)
Trust score:3/5

pregnancy rate

1 evidences

Randomized trial of vitamin D plus calcium versus vitamins E/C in men with idiopathic oligoasthenozoospermia found improved progressive motile sperm count and higher pregnancy rate in the vitamin D + calcium group.

Trust comment: Randomized human trial (n=86) where calcium was co-administered with vitamin D, so observed effects may reflect vitamin D, calcium, or their combination; moderate sample size.

Study Details

PMID:25597173
Participants:86
Impact:VD+calcium 16.3% vs control 2.3% (absolute +14.0%; P<0.05)
Trust score:3/5

24-h urinary calcium (proxy for intestinal absorption)

1 evidences

Randomized double-blind crossover in 125 healthy adults testing chymosin added to milk; evaluated effects on calcium absorption proxies and calciotropic hormones.

Trust comment: Well-designed randomized double-blind crossover with objective urinary and hormonal measures, moderate sample size (N=125).

Study Details

PMID:25515208
Participants:125
Impact:No overall change compared with placebo
Trust score:4/5

early post-meal urinary calcium excretion (urine Ca/creatinine ratio first 4 h)

1 evidences

Randomized double-blind crossover in 125 healthy adults testing chymosin added to milk; evaluated effects on calcium absorption proxies and calciotropic hormones.

Trust comment: Well-designed randomized double-blind crossover with objective urinary and hormonal measures, moderate sample size (N=125).

Study Details

PMID:25515208
Participants:125
Impact:+17% increase vs placebo during first 4 hours after milk with chymosin
Trust score:4/5

urinary calcium in high habitual calcium intake subgroup

1 evidences

Randomized double-blind crossover in 125 healthy adults testing chymosin added to milk; evaluated effects on calcium absorption proxies and calciotropic hormones.

Trust comment: Well-designed randomized double-blind crossover with objective urinary and hormonal measures, moderate sample size (N=125).

Study Details

PMID:25515208
Participants:125
Impact:Significant increase in urinary calcium and urine Ca/creatinine ratio versus placebo in participants with habitual intake >1050 mg/day
Trust score:4/5

urinary N-telopeptides (NTx) — bone resorption marker

1 evidences

Large double-blind randomized placebo-controlled trial (completed follow-up N=563) showing daily 1,200 mg calcium carbonate during pregnancy reduced markers of bone resorption and had dose-dependent effects.

Trust comment: Large, double-blind RCT with intent-to-treat analysis, objective biochemical endpoints, and clear dose–response by compliance.

Study Details

PMID:25511814
Participants:563
Impact:↓ Adjusted overall average reduction ~15.8% vs placebo (visit-specific adjusted reductions: 2nd trimester −13.8%, 3rd −15.6%, 1-month postpartum −19.2%; all P≤0.001)
Trust score:5/5

NTx by compliance (dose–response)

1 evidences

Large double-blind randomized placebo-controlled trial (completed follow-up N=563) showing daily 1,200 mg calcium carbonate during pregnancy reduced markers of bone resorption and had dose-dependent effects.

Trust comment: Large, double-blind RCT with intent-to-treat analysis, objective biochemical endpoints, and clear dose–response by compliance.

Study Details

PMID:25511814
Participants:563
Impact:↓ Reduction increased with compliance: ≥50% pills −17.3%; ≥67% −21.3%; ≥75% −22.1% (all P<0.001)
Trust score:5/5

NTx/BAP ratio (resorption:formation) at 1 month postpartum

1 evidences

Large double-blind randomized placebo-controlled trial (completed follow-up N=563) showing daily 1,200 mg calcium carbonate during pregnancy reduced markers of bone resorption and had dose-dependent effects.

Trust comment: Large, double-blind RCT with intent-to-treat analysis, objective biochemical endpoints, and clear dose–response by compliance.

Study Details

PMID:25511814
Participants:563
Impact:↓ −21.5% vs placebo (P=0.04)
Trust score:5/5

radial speed of sound (SOS) — bone quality

1 evidences

Large double-blind randomized placebo-controlled trial (completed follow-up N=563) showing daily 1,200 mg calcium carbonate during pregnancy reduced markers of bone resorption and had dose-dependent effects.

Trust comment: Large, double-blind RCT with intent-to-treat analysis, objective biochemical endpoints, and clear dose–response by compliance.

Study Details

PMID:25511814
Participants:563
Impact:Overall non-significant +9.05 m/s vs placebo; significant increases in higher compliance groups (≥50% +26.3 m/s, P=0.03; ≥75% +59.0 m/s, P=0.009)
Trust score:5/5

Modified Agatston score strata (risk)

1 evidences

Large prospective cohort of male smokers: higher coronary artery calcium scores strongly predicted future cardiovascular events.

Trust comment: Large cohort study with robust outcomes and follow-up; nongated CT modality and single-sex sample limit some generalizability.

Study Details

PMID:25533223
Participants:3559
Impact:HRs for cardiovascular events by strata: 1–10 HR 3.39; 11–100 HR 6.52; 101–400 HR 6.58; >400 HR 12.58 (95% CI 5.42–29.16)
Trust score:4/5

Number of calcifications

1 evidences

Large prospective cohort of male smokers: higher coronary artery calcium scores strongly predicted future cardiovascular events.

Trust comment: Large cohort study with robust outcomes and follow-up; nongated CT modality and single-sex sample limit some generalizability.

Study Details

PMID:25533223
Participants:3559
Impact:HR 1.13 per 10 calcifications (95% CI 1.05–1.21); small but independent prognostic value
Trust score:4/5

Net reclassification improvement (NRI) adding Agatston strata

1 evidences

Large prospective cohort of male smokers: higher coronary artery calcium scores strongly predicted future cardiovascular events.

Trust comment: Large cohort study with robust outcomes and follow-up; nongated CT modality and single-sex sample limit some generalizability.

Study Details

PMID:25533223
Participants:3559
Impact:NRI 27.3% (P<0.0001) versus model with age/pack-years/smoking
Trust score:4/5

Serum calcium (post-op day 7)

1 evidences

In CKD patients after parathyroidectomy, a loading calcitriol regimen reduced the early postoperative drop in serum calcium more than a titrated regimen; other clinical outcomes similar.

Trust comment: Randomized controlled trial but open-label and small (n=25); biochemical endpoints measured reliably though sample size limits robustness.

Study Details

PMID:25509696
Participants:25
Impact:Smaller mean decrease with loaded calcitriol (~−0.33 mg/dL) vs titrated (~−2.68 mg/dL); p=0.036
Trust score:3/5

IV calcium gluconate use

1 evidences

In CKD patients after parathyroidectomy, a loading calcitriol regimen reduced the early postoperative drop in serum calcium more than a titrated regimen; other clinical outcomes similar.

Trust comment: Randomized controlled trial but open-label and small (n=25); biochemical endpoints measured reliably though sample size limits robustness.

Study Details

PMID:25509696
Participants:25
Impact:No significant difference between regimens (p=0.160)
Trust score:3/5

Hypocalcemia incidence / hospital stay duration

1 evidences

In CKD patients after parathyroidectomy, a loading calcitriol regimen reduced the early postoperative drop in serum calcium more than a titrated regimen; other clinical outcomes similar.

Trust comment: Randomized controlled trial but open-label and small (n=25); biochemical endpoints measured reliably though sample size limits robustness.

Study Details

PMID:25509696
Participants:25
Impact:No significant differences (p=0.645 and p=0.460)
Trust score:3/5

Fat‑soluble vitamins

1 evidences

8-week randomized double-blind dietary study: EPG altered some fat‑soluble vitamins but did not change serum calcium or other measured minerals.

Trust comment: Well-powered double‑blind randomized study (n=139) with comprehensive nutrient measures; EPG (not calcium) was the intervention and calcium was a measured endpoint.

Study Details

PMID:25497998
Participants:139
Impact:β‑carotene and phylloquinone decreased; 25‑OH D3 increased less than control
Trust score:4/5

Collum femoris BMD

1 evidences

In postmenopausal women (all given calcium 1000 mg and vitamin D3 800 IU), strontium ranelate plus alfacalcidol improved BMD, functional tests, and bone markers more than strontium alone or calcium/vitamin D alone.

Trust comment: Randomized study but open‑label and small (n=48); all groups received calcium/vitamin D so calcium effects cannot be isolated.

Study Details

PMID:25480348
Participants:48
Impact:↑ 8.17% (SrRan+alfacalcidol) vs ↑3.20% (SrRan) and ↑0.06% control; significant
Trust score:3/5

functional ability ("up and go" test)

1 evidences

In postmenopausal women (all given calcium 1000 mg and vitamin D3 800 IU), strontium ranelate plus alfacalcidol improved BMD, functional tests, and bone markers more than strontium alone or calcium/vitamin D alone.

Trust comment: Randomized study but open‑label and small (n=48); all groups received calcium/vitamin D so calcium effects cannot be isolated.

Study Details

PMID:25480348
Participants:48
Impact:↓14.26% time with SrRan+alfacalcidol vs no change in others (P=0.01)
Trust score:3/5

apical (calcified) barrier presence at 12 months

1 evidences

In children with non-vital immature incisors, MTA achieved higher rates of apical barrier formation at 12 months than calcium hydroxide.

Trust comment: Randomized clinical trial in children with clear clinical endpoints but small sample size limits precision.

Study Details

PMID:25467231
Participants:30
Impact:Ca(OH)2: 50% vs MTA: 82.4% (Ca(OH)2 −32.4 percentage points vs MTA)
Trust score:3/5

coronal/radicular fracture incidence (Ca(OH)2 group)

1 evidences

In children with non-vital immature incisors, MTA achieved higher rates of apical barrier formation at 12 months than calcium hydroxide.

Trust comment: Randomized clinical trial in children with clear clinical endpoints but small sample size limits precision.

Study Details

PMID:25467231
Participants:30
Impact:4/15 teeth (26.7%) after 12 months
Trust score:3/5

proinflammatory cytokines (IL‑1β, IL‑6, MCP‑1)

1 evidences

Double‑blind placebo‑controlled trial in middle‑aged healthy adults: calcium fructoborate for 30 days reduced several lipids and inflammatory markers vs placebo.

Trust comment: Double‑blind, placebo‑controlled randomized trial but small sample (78 completers) limits generalizability despite randomized design.

Study Details

PMID:25433580
Participants:78
Impact:significant reductions in IL‑1β (CFB‑1 vs placebo) and reductions in IL‑6 and MCP‑1 for both CFB doses versus placebo (p values reported <0.05)
Trust score:4/5

bone formation (%)

1 evidences

Sixty subjects had extraction sockets grafted with NanoGen (nanocrystalline calcium sulfate) or DentoGen; both yielded similar bone formation at 4 months, with minor differences in graft remnants and soft tissue.

Trust comment: Randomized assignment with clinical, histomorphometric and radiographic endpoints in 60 subjects; moderate sample size and follow-up.

Study Details

PMID:25454818
Participants:60
Impact:NanoGen 51.19 ± 9.53% vs DentoGen 50.67 ± 16.16% at 4 months (no significant difference)
Trust score:3/5

graft remnants (%)

1 evidences

Sixty subjects had extraction sockets grafted with NanoGen (nanocrystalline calcium sulfate) or DentoGen; both yielded similar bone formation at 4 months, with minor differences in graft remnants and soft tissue.

Trust comment: Randomized assignment with clinical, histomorphometric and radiographic endpoints in 60 subjects; moderate sample size and follow-up.

Study Details

PMID:25454818
Participants:60
Impact:NanoGen mean remnants ~6.8% (maxilla) and ~7.4% (mandible) at 4 months; DentoGen remnants not detected at 4 months
Trust score:3/5

radiographic socket fill (%) at 4 months

1 evidences

Sixty subjects had extraction sockets grafted with NanoGen (nanocrystalline calcium sulfate) or DentoGen; both yielded similar bone formation at 4 months, with minor differences in graft remnants and soft tissue.

Trust comment: Randomized assignment with clinical, histomorphometric and radiographic endpoints in 60 subjects; moderate sample size and follow-up.

Study Details

PMID:25454818
Participants:60
Impact:DentoGen 76.7 ± 11% vs NanoGen 76.47 ± 12.43% (similar)
Trust score:3/5

dolutegravir AUC(0–∞)

1 evidences

In a randomized crossover PK study, co-administration of calcium carbonate 1,200 mg (fasted) reduced dolutegravir exposure (~37–39%); taking dolutegravir with a meal or separating doses by 2 hours prevented the reduction.

Trust comment: Well-designed randomized 4-period crossover PK study in healthy adults with clear quantitative PK endpoints and predefined no-effect criteria.

Study Details

PMID:25449994
Participants:21
Impact:-39% when co-administered with calcium carbonate 1,200 mg under fasted conditions
Trust score:5/5

dolutegravir Cmax

1 evidences

In a randomized crossover PK study, co-administration of calcium carbonate 1,200 mg (fasted) reduced dolutegravir exposure (~37–39%); taking dolutegravir with a meal or separating doses by 2 hours prevented the reduction.

Trust comment: Well-designed randomized 4-period crossover PK study in healthy adults with clear quantitative PK endpoints and predefined no-effect criteria.

Study Details

PMID:25449994
Participants:21
Impact:-37% when co-administered with calcium carbonate 1,200 mg under fasted conditions
Trust score:5/5

dolutegravir C24

1 evidences

In a randomized crossover PK study, co-administration of calcium carbonate 1,200 mg (fasted) reduced dolutegravir exposure (~37–39%); taking dolutegravir with a meal or separating doses by 2 hours prevented the reduction.

Trust comment: Well-designed randomized 4-period crossover PK study in healthy adults with clear quantitative PK endpoints and predefined no-effect criteria.

Study Details

PMID:25449994
Participants:21
Impact:-39% when co-administered with calcium carbonate 1,200 mg under fasted conditions
Trust score:5/5

ionized calcium level

1 evidences

In liver surgery patients, Plasmalyte-148 led to lower ionized calcium, lower clotting times, less blood loss and fewer postoperative hemoglobin drops compared with Hartmann's solution.

Trust comment: Multicentre double-blind RCT measuring calcium-related labs but not testing calcium supplementation; moderate sample size and direct biochemical measurements.

Study Details

PMID:25407026
Participants:60
Impact:decreased (PL vs HS)
Trust score:3/5

prothrombin time and aPTT

1 evidences

In liver surgery patients, Plasmalyte-148 led to lower ionized calcium, lower clotting times, less blood loss and fewer postoperative hemoglobin drops compared with Hartmann's solution.

Trust comment: Multicentre double-blind RCT measuring calcium-related labs but not testing calcium supplementation; moderate sample size and direct biochemical measurements.

Study Details

PMID:25407026
Participants:60
Impact:decreased (PL vs HS immediately after surgery)
Trust score:3/5

heart failure incidence (overall)

1 evidences

Randomized trial of calcium (1000 mg/day) plus vitamin D3 showed no reduction in heart failure overall but a 37% lower HF risk in women without major HF precursors.

Trust comment: Large randomized double-blind trial (secondary analysis) with long follow-up; high sample size but subgroup findings require confirmation.

Study Details

PMID:25398967
Participants:35983
Impact:HR 0.95 (no significant change)
Trust score:4/5

heart failure incidence (low-risk subgroup)

1 evidences

Randomized trial of calcium (1000 mg/day) plus vitamin D3 showed no reduction in heart failure overall but a 37% lower HF risk in women without major HF precursors.

Trust comment: Large randomized double-blind trial (secondary analysis) with long follow-up; high sample size but subgroup findings require confirmation.

Study Details

PMID:25398967
Participants:35983
Impact:−37% risk (HR 0.63; significant reduction)
Trust score:4/5

heart failure incidence (high-risk subgroup)

1 evidences

Randomized trial of calcium (1000 mg/day) plus vitamin D3 showed no reduction in heart failure overall but a 37% lower HF risk in women without major HF precursors.

Trust comment: Large randomized double-blind trial (secondary analysis) with long follow-up; high sample size but subgroup findings require confirmation.

Study Details

PMID:25398967
Participants:35983
Impact:HR 1.06 (no benefit)
Trust score:4/5

Growth parameters

1 evidences

Very low birth weight preterm infants fed human milk fortified with either standard human milk fortifier or post-discharge formula showed similar growth and blood biochemical markers over the study period.

Trust comment: Randomized pilot RCT on human infants but small sample and pilot design limit generalizability.

Study Details

PMID:25391190
Participants:33
Impact:no significant change between fortifier groups
Trust score:3/5

serum calcium (and other electrolytes)

1 evidences

Very low birth weight preterm infants fed human milk fortified with either standard human milk fortifier or post-discharge formula showed similar growth and blood biochemical markers over the study period.

Trust comment: Randomized pilot RCT on human infants but small sample and pilot design limit generalizability.

Study Details

PMID:25391190
Participants:33
Impact:no significant change between fortifier groups
Trust score:3/5

osteopenia of prematurity / complications

1 evidences

Very low birth weight preterm infants fed human milk fortified with either standard human milk fortifier or post-discharge formula showed similar growth and blood biochemical markers over the study period.

Trust comment: Randomized pilot RCT on human infants but small sample and pilot design limit generalizability.

Study Details

PMID:25391190
Participants:33
Impact:no significant difference between groups
Trust score:3/5

stool palmitate soaps

1 evidences

In term infants, formula with high sn-2 palmitate plus oligofructose reduced stool palmitate soaps and stool calcium and produced softer stools versus control formula; all formulas were well tolerated.

Trust comment: Large randomized, double-blind multicenter trial with objective stool biochemistry outcomes; suitable for assessing effects on stool calcium excretion.

Study Details

PMID:25373935
Participants:230
Impact:Control 186.9→ sn-2 159.3 mg/g (−27.6 mg/g; p=0.0028); sn-2+OF 113.3 mg/g (−73.6 mg/g vs control; p<0.0001)
Trust score:4/5

stool calcium

1 evidences

In term infants, formula with high sn-2 palmitate plus oligofructose reduced stool palmitate soaps and stool calcium and produced softer stools versus control formula; all formulas were well tolerated.

Trust comment: Large randomized, double-blind multicenter trial with objective stool biochemistry outcomes; suitable for assessing effects on stool calcium excretion.

Study Details

PMID:25373935
Participants:230
Impact:reduced in sn-2+OF (28.5 mg/g) vs Control (38.0) and sn-2 (39.4); p<0.0001
Trust score:4/5

stool consistency (softness)

1 evidences

In term infants, formula with high sn-2 palmitate plus oligofructose reduced stool palmitate soaps and stool calcium and produced softer stools versus control formula; all formulas were well tolerated.

Trust comment: Large randomized, double-blind multicenter trial with objective stool biochemistry outcomes; suitable for assessing effects on stool calcium excretion.

Study Details

PMID:25373935
Participants:230
Impact:sn-2+OF mean score 2.7 (runny–mushy) vs Control 3.1 and sn-2 3.2 (mushy-soft); p<0.0001
Trust score:4/5

operative blood loss

1 evidences

PEEK cages filled with calcium sulphate/DBM performed similarly to autograft for cervical fusion, with less blood loss and fewer donor-site complications.

Trust comment: Prospective randomized clinical trial with 2-year follow-up and objective radiologic/clinical outcomes; moderate sample size.

Study Details

PMID:25432324
Participants:68
Impact:-25 ml (-25%) (75 ± 18.5 ml vs 100 ± 19.6 ml)
Trust score:4/5

JOA score recovery / neck and arm pain

1 evidences

PEEK cages filled with calcium sulphate/DBM performed similarly to autograft for cervical fusion, with less blood loss and fewer donor-site complications.

Trust comment: Prospective randomized clinical trial with 2-year follow-up and objective radiologic/clinical outcomes; moderate sample size.

Study Details

PMID:25432324
Participants:68
Impact:no difference between groups
Trust score:4/5

fractional calcium absorption (FCA) — formulation effect

1 evidences

Enteric-coated microencapsulated calcium showed markedly lower fractional calcium absorption than non-coated calcium in pregnant women; higher elemental doses provided little additional absorbable calcium.

Trust comment: Rigorous randomized crossover design with dual stable-isotope measurement of absorption and adequate primary-sample size for analyses.

Study Details

PMID:25411294
Participants:49
Impact:Enteric-coated calcium cumulative 48-h FCA 85% lower than non-EC calcium (P < 0.001); EC FCA ≈ 1.2–3.3% vs non-EC 9.2–21.8% depending on dose
Trust score:5/5

dose-response of FCA

1 evidences

Enteric-coated microencapsulated calcium showed markedly lower fractional calcium absorption than non-coated calcium in pregnant women; higher elemental doses provided little additional absorbable calcium.

Trust comment: Rigorous randomized crossover design with dual stable-isotope measurement of absorption and adequate primary-sample size for analyses.

Study Details

PMID:25411294
Participants:49
Impact:FCA 61% lower at 1000 mg vs 500 mg and 42% lower at 1500 mg vs 500 mg (adjusted comparisons)
Trust score:5/5

intact parathyroid hormone (iPTH) control

1 evidences

In 255 hemodialysis patients with SHPT, both paricalcitol and maxacalcitol reduced iPTH and had similar safety; paricalcitol failed to demonstrate non-inferiority to maxacalcitol for the primary endpoint.

Trust comment: Phase 3, double-blind randomized trial with adequate sample size and clinically relevant endpoints; non-inferiority not met.

Study Details

PMID:25363733
Participants:255
Impact:reduced; 27.7% (paricalcitol) vs 30.5% (maxacalcitol) achieved target iPTH without hypercalcemia
Trust score:4/5

hypercalcemia incidence / calcium control

1 evidences

In 255 hemodialysis patients with SHPT, both paricalcitol and maxacalcitol reduced iPTH and had similar safety; paricalcitol failed to demonstrate non-inferiority to maxacalcitol for the primary endpoint.

Trust comment: Phase 3, double-blind randomized trial with adequate sample size and clinically relevant endpoints; non-inferiority not met.

Study Details

PMID:25363733
Participants:255
Impact:similar safety profiles between treatments (no clear advantage)
Trust score:4/5

bone mineral density (lumbar spine and femoral neck)

1 evidences

In 60 postmenopausal women with CKD stage 5, raloxifene increased lumbar spine BMD (~+2%) but did not differ from placebo in reducing intact PTH.

Trust comment: Randomized study but small sample and mixed dialysis status limits generalizability.

Study Details

PMID:25362221
Participants:60
Impact:increased ~+2% in raloxifene group vs −1.9% in control (lumbar spine change significant, P = .01)
Trust score:3/5

eCS vs nCACS correlation

1 evidences

In 141 patients, an echocardiographic calcium score (eCS) moderately-to-strongly correlated with CT non-coronary cardiac calcium and with coronary artery calcium and helped predict severe coronary calcification.

Trust comment: Well-characterized single-center study with appropriate imaging comparisons and solid statistical correlations, though retrospective.

Study Details

PMID:25352208
Participants:141
Impact:rho = 0.64, p < 0.0001
Trust score:4/5

eCS vs CACS correlation

1 evidences

In 141 patients, an echocardiographic calcium score (eCS) moderately-to-strongly correlated with CT non-coronary cardiac calcium and with coronary artery calcium and helped predict severe coronary calcification.

Trust comment: Well-characterized single-center study with appropriate imaging comparisons and solid statistical correlations, though retrospective.

Study Details

PMID:25352208
Participants:141
Impact:rho = 0.43, p < 0.0001
Trust score:4/5

prediction of severe coronary calcification (CACS ≥400)

1 evidences

In 141 patients, an echocardiographic calcium score (eCS) moderately-to-strongly correlated with CT non-coronary cardiac calcium and with coronary artery calcium and helped predict severe coronary calcification.

Trust comment: Well-characterized single-center study with appropriate imaging comparisons and solid statistical correlations, though retrospective.

Study Details

PMID:25352208
Participants:141
Impact:eCS AUC ≈ 0.77 for CACS ≥400
Trust score:4/5

iron absorption

1 evidences

In schoolchildren, added calcium (100–200 mg/meal) reduced iron absorption by ~18–27%, while ascorbic acid (vitamin C) increased absorption 2–4-fold and overcame the calcium inhibition.

Trust comment: Randomized crossover human study using stable isotopes in children with reasonable methodology but modest sample size.

Study Details

PMID:25332469
Participants:30
Impact:-18% to -27% (with added calcium)
Trust score:4/5

effect of ascorbic acid on iron absorption

1 evidences

In schoolchildren, added calcium (100–200 mg/meal) reduced iron absorption by ~18–27%, while ascorbic acid (vitamin C) increased absorption 2–4-fold and overcame the calcium inhibition.

Trust comment: Randomized crossover human study using stable isotopes in children with reasonable methodology but modest sample size.

Study Details

PMID:25332469
Participants:30
Impact:+200% to +400% (2–4× increase; dose-dependent, overcompensated calcium inhibition)
Trust score:4/5

blood creatinine concentration

1 evidences

Daily calcium supplements (1200 mg) caused a very small rise in blood creatinine and a small increase in blood total calcium after one year; effects were larger in people with reduced baseline kidney function.

Trust comment: Large, multicenter, double-blind randomized controlled trial with high follow-up and pre-specified safety measurements.

Study Details

PMID:25329821
Participants:1675
Impact:+0.013 mg/dL (adjusted mean difference at 1 year; calcium vs control)
Trust score:5/5

blood total calcium concentration

1 evidences

Daily calcium supplements (1200 mg) caused a very small rise in blood creatinine and a small increase in blood total calcium after one year; effects were larger in people with reduced baseline kidney function.

Trust comment: Large, multicenter, double-blind randomized controlled trial with high follow-up and pre-specified safety measurements.

Study Details

PMID:25329821
Participants:1675
Impact:+0.046 mg/dL (mean change at 1 year in calcium group)
Trust score:5/5

eGFR (kidney function) in participants with baseline eGFR <60

1 evidences

Daily calcium supplements (1200 mg) caused a very small rise in blood creatinine and a small increase in blood total calcium after one year; effects were larger in people with reduced baseline kidney function.

Trust comment: Large, multicenter, double-blind randomized controlled trial with high follow-up and pre-specified safety measurements.

Study Details

PMID:25329821
Participants:1675
Impact:−4.9 ml/min/1.73 m² (adjusted mean difference, subgroup; suggestive)
Trust score:5/5

nemonoxacin exposure (AUC0-∞)

1 evidences

Concomitant calcium carbonate (600 mg Ca2+) mildly reduced nemonoxacin absorption (exposure and peak concentration) compared with nemonoxacin alone in healthy men.

Trust comment: Two single‑dose, randomized, crossover pharmacokinetic studies in healthy volunteers; small sample but appropriate crossover design for drug–calcium interaction.

Study Details

PMID:25327812
Participants:24
Impact:−17.8% AUC0-∞ (concomitant calcium carbonate 600 mg)
Trust score:4/5

nemonoxacin peak concentration (Cmax)

1 evidences

Concomitant calcium carbonate (600 mg Ca2+) mildly reduced nemonoxacin absorption (exposure and peak concentration) compared with nemonoxacin alone in healthy men.

Trust comment: Two single‑dose, randomized, crossover pharmacokinetic studies in healthy volunteers; small sample but appropriate crossover design for drug–calcium interaction.

Study Details

PMID:25327812
Participants:24
Impact:−14.3% Cmax (concomitant calcium carbonate 600 mg)
Trust score:4/5

whole-body BMD loss

1 evidences

Postmenopausal osteopenic women taking a calcium-collagen chelate supplement had less whole-body bone loss and favorable bone turnover marker changes vs control over 12 months.

Trust comment: Randomized controlled trial in humans with intent-to-treat analysis but small sample (n=39) limits generalizability.

Study Details

PMID:25314004
Participants:39
Impact:CC completers: −1.33% vs control −3.75% at 12 mo (difference 2.42 percentage points); ITT: −0.33% vs −2.17% (difference 1.84pp); P=.026/.035
Trust score:4/5

Sclerostin level

1 evidences

Postmenopausal osteopenic women taking a calcium-collagen chelate supplement had less whole-body bone loss and favorable bone turnover marker changes vs control over 12 months.

Trust comment: Randomized controlled trial in humans with intent-to-treat analysis but small sample (n=39) limits generalizability.

Study Details

PMID:25314004
Participants:39
Impact:Decreased at 6 months (P<.05)
Trust score:4/5

Bone-specific alkaline phosphatase / TRAP5b ratio

1 evidences

Postmenopausal osteopenic women taking a calcium-collagen chelate supplement had less whole-body bone loss and favorable bone turnover marker changes vs control over 12 months.

Trust comment: Randomized controlled trial in humans with intent-to-treat analysis but small sample (n=39) limits generalizability.

Study Details

PMID:25314004
Participants:39
Impact:Increased at 6 months (P<.05)
Trust score:4/5

QUICKI (insulin sensitivity)

1 evidences

8-week randomized trial in vitamin D–deficient overweight/obese women with PCOS tested calcium, vitamin D, both, or placebo; co-supplementation improved some insulin and triglyceride measures.

Trust comment: Randomized double-blind placebo-controlled RCT with clear reported outcomes and adequate sample size per arm (n=26 groups), supporting moderate–high trust.

Study Details

PMID:25300649
Participants:104
Impact:increased (P=0.001)
Trust score:4/5

insulin sensitivity (overall)

1 evidences

6-month randomized placebo-controlled trial of combined calcium+vitamin D in vitamin D–deficient adults at risk for type 2 diabetes found no overall improvement in insulin secretion/sensitivity, though a prediabetes subgroup showed improved insulin sensitivity.

Trust comment: Randomized double-blind placebo-controlled trial with objective measures and clear reporting; limited by smaller than planned sample size and some baseline imbalances.

Study Details

PMID:25299668
Participants:80
Impact:no significant change between groups (no effect)
Trust score:4/5

insulin sensitivity (prediabetes subgroup)

1 evidences

6-month randomized placebo-controlled trial of combined calcium+vitamin D in vitamin D–deficient adults at risk for type 2 diabetes found no overall improvement in insulin secretion/sensitivity, though a prediabetes subgroup showed improved insulin sensitivity.

Trust comment: Randomized double-blind placebo-controlled trial with objective measures and clear reporting; limited by smaller than planned sample size and some baseline imbalances.

Study Details

PMID:25299668
Participants:80
Impact:improved (HOMA%S and Matsuda indices; post hoc significant)
Trust score:4/5

acute ionized and total serum calcium (citrate/carbonate)

1 evidences

Randomized trial in postmenopausal women comparing calcium formulations vs placebo showed acute rises in serum calcium after conventional calcium salts, smaller ionized Ca rise after microcrystalline hydroxyapatite (MCH), and comparable suppression of bone resorption at 8 h and after 3 months.

Trust comment: Randomized controlled trial in relevant population with biochemical outcomes and 3-month follow-up; moderate–high trust for effects of calcium formulations.

Study Details

PMID:25274192
Participants:100
Impact:increased for up to 8 h after dose (sustained effect)
Trust score:4/5

acute ionized serum calcium (MCH)

1 evidences

Randomized trial in postmenopausal women comparing calcium formulations vs placebo showed acute rises in serum calcium after conventional calcium salts, smaller ionized Ca rise after microcrystalline hydroxyapatite (MCH), and comparable suppression of bone resorption at 8 h and after 3 months.

Trust comment: Randomized controlled trial in relevant population with biochemical outcomes and 3-month follow-up; moderate–high trust for effects of calcium formulations.

Study Details

PMID:25274192
Participants:100
Impact:increased less than citrate/carbonate (smaller acute rise)
Trust score:4/5

Bone resorption (serum CTX)

1 evidences

Randomized trial in postmenopausal women comparing calcium formulations vs placebo showed acute rises in serum calcium after conventional calcium salts, smaller ionized Ca rise after microcrystalline hydroxyapatite (MCH), and comparable suppression of bone resorption at 8 h and after 3 months.

Trust comment: Randomized controlled trial in relevant population with biochemical outcomes and 3-month follow-up; moderate–high trust for effects of calcium formulations.

Study Details

PMID:25274192
Participants:100
Impact:decreased comparably after citrate/carbonate and MCH over 8 h and at 3 months (CTX↓)
Trust score:4/5

new caries lesions (all surfaces)

1 evidences

In irradiated nasopharyngeal cancer patients, adding CPP-ACP crème to stannous fluoride produced fewer new caries lesions over 3 months, but the difference was not statistically significant.

Trust comment: Small randomized controlled trial with short (3-month) follow-up and non-significant primary comparisons, but directly tests a calcium-containing topical preparation in humans.

Study Details

PMID:25261399
Participants:22
Impact:test 32 vs control 59 new lesions; OR 0.51 (95% CI 0.17–1.59), not significant
Trust score:3/5

new occlusal caries

1 evidences

In irradiated nasopharyngeal cancer patients, adding CPP-ACP crème to stannous fluoride produced fewer new caries lesions over 3 months, but the difference was not statistically significant.

Trust comment: Small randomized controlled trial with short (3-month) follow-up and non-significant primary comparisons, but directly tests a calcium-containing topical preparation in humans.

Study Details

PMID:25261399
Participants:22
Impact:OR 0.20 (95% CI 0.03–1.29), not significant
Trust score:3/5

salivary/ plaque changes post-radiotherapy

1 evidences

In irradiated nasopharyngeal cancer patients, adding CPP-ACP crème to stannous fluoride produced fewer new caries lesions over 3 months, but the difference was not statistically significant.

Trust comment: Small randomized controlled trial with short (3-month) follow-up and non-significant primary comparisons, but directly tests a calcium-containing topical preparation in humans.

Study Details

PMID:25261399
Participants:22
Impact:reduced plaque pH, salivary flow, pH and buffering capacity in both groups at 3 months
Trust score:3/5